Details of Disease

General Information of Disease (ID: DIS7DPX1)

• Disease Name: Breast cancer
• Synonyms: mammary neoplasm; primary breast cancer; breast tumour; breast tumor; mammary tumour; mammary tumor; mammary cancer; malignant tumour of breast; malignant tumor of the breast; cancer of breast; malignant breast neoplasm; malignant breast tumor; malignant neoplasm of breast; malignant tumor of breast; malignant neoplasm of the breast; malignant tumour of the breast; breast cancer; malignant breast tumour
• Disease Class: 2C60-2C6Y: Breast cancer
• Definition: A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.
• Disease Hierarchy:
  DIS4GB9P: Thymic cancer
  DIS0QDLG: Mammary tumour
  DISAT1Z9: Advanced cancer
  DIS7DPX1: Breast cancer
• ICD Code:
  ICD-11: ICD-11: 2C60-2C65
  ICD-10: ICD-10: C50, C79.51
  Expand ICD-9: 174175198.5
• Disease Identifiers:
  MONDO ID: MONDO_0007254
  MESH ID: D001943
  UMLS CUI: C0006142
  OMIM ID: 114480
  MedGen ID: 651
  SNOMED CT ID: 254837009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 60 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
99mTc-sestamibi	DMVZO01	Approved	Small molecular drug	[1]
99mTc-tetrofosmin	DM89JEQ	Approved	NA	[1]
Alpelisib	DMEXMYK	Approved	Small molecular drug	[2]
Anastrozole	DMNP60F	Approved	Small molecular drug	[3]
Arcitumomab	DM9GH25	Approved	Antibody	[4]
ARZOXIFENE	DMOKCVI	Approved	Small molecular drug	[5]
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[6]
Bavencio	DMU9C8F	Approved	Monoclonal antibody	[6]
Bosutinib	DMTI8YE	Approved	Small molecular drug	[7]
Cabazitaxel	DMPAZHC	Approved	Small molecular drug	[8]
Capecitabine	DMTS85L	Approved	Small molecular drug	[9]
Capivasertib	DM9SKW8	Approved	Small molecular drug	[10]
Danazol	DML8KTN	Approved	Small molecular drug	[11]
Dexrazoxane	DMD7X1O	Approved	Small molecular drug	[12]
Dostarlimab	DM78NWP	Approved	Antibody	[13]
Doxorubicin	DMVP5YE	Approved	Small molecular drug	[14]
Eflapegrastim	DMACVEI	Approved	NA	[15]
Elacestrant	DM8RLJ5	Approved	NA	[16]
Eribulin	DM1DX4Q	Approved	Small molecular drug	[17]
Esterified estrogens	DM9KZDO	Approved	NA	[1]
Estradiol	DMUNTE3	Approved	Small molecular drug	[18]
FADROZOLE	DM3C5GZ	Approved	Small molecular drug	[19]
Fluoxymesterone	DMUHCF1	Approved	Small molecular drug	[20]
Fulvestrant	DM0YZC6	Approved	Small molecular drug	[21]
Gestrinone	DMP0OVQ	Approved	Small molecular drug	[1]
Goserelin	DMAT8CG	Approved	Small molecular drug	[22]
Halaven	DM7JNTV	Approved	NA	[23]
Ixabepilone	DM2OZ3G	Approved	Small molecular drug	[24]
Lapatinib	DM3BH1Y	Approved	Small molecular drug	[25]
Levormeloxifene	DM2XVNI	Approved	Small molecular drug	[26]
Lobaplatin	DM3UWDA	Approved	Small molecular drug	[1]
LY2835219	DM93VBZ	Approved	Small molecular drug	[27]
Megesterol acetate	DMQ1Q37	Approved	NA	[1]
Megestrol	DMDH9KX	Approved	Small molecular drug	[28]
Merimepodib	DM0HS92	Approved	Small molecular drug	[29]
Mitomycin	DMH0ZJE	Approved	Small molecular drug	[30]
Nomegestrol acetate	DMRJ7D1	Approved	Small molecular drug	[31]
Oxidized glutathione	DM9EQC0	Approved	Small molecular drug	[1]
Palbociclib	DMD7L94	Approved	Small molecular drug	[32]
Pembrolizumab	DMFQEA6	Approved	Monoclonal antibody	[6]
Peplomycin	DMN6SDD	Approved	Small molecular drug	[1]
Pertuzumab	DMHJV0X	Approved	Monoclonal antibody	[33]
Pirarubicin	DMGTW1I	Approved	Small molecular drug	[1]
Pralatrexate	DMAO80I	Approved	Small molecular drug	[34]
Prosorba	DML0EUS	Approved	NA	[1]
Quinestrol	DMJ6H1Z	Approved	Small molecular drug	[35]
Radium-223 chloride	DMG21CZ	Approved	NA	[6]
Ribociclib Succinate	DM9CIUW	Approved	Small molecular drug	[27]
Sacituzumab govitecan	DMUWFD8	Approved	Antibody drug conjugate	[36]
Satumomab Pendetide	DMRSKMZ	Approved	Monoclonal antibody	[37]
Talaporfin	DMCB7ZZ	Approved	Small molecular drug	[1]
Talazoparib	DM1KS78	Approved	Small molecular drug	[38]
Tamoxifen	DMLB0EZ	Approved	Small molecular drug	[39]
Taxol	DMUOT9V	Approved	Small molecular drug	[40]
Testolactone	DMVY4GN	Approved	Small molecular drug	[41]
Thiotepa	DMIZKOP	Approved	Small molecular drug	[42]
Toremifene	DMQYUWG	Approved	Small molecular drug	[43]
Trastuzumab	DMZQOUX	Approved	Antibody	[44]
Virulizin	DM0REZS	Approved	NA	[45]
YN-968D1	DMMP3Y2	Approved	Small molecular drug	[46]

This Disease is Treated as An Indication in 235 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Abexinostat	DM91LGU	Phase 3	Small molecular drug	[6]
ABP 980	DMEH3LA	Phase 3	NA	[47]
ABT-888	DM4HYMS	Phase 3	Small molecular drug	[48]
Acolbifene	DM3UQ9K	Phase 3	Small molecular drug	[49]
Adagloxad simolenin	DMICKCQ	Phase 3	Vaccine	[50]
AMG 386	DMQJXL4	Phase 3	Small molecular drug	[51]
Amonafide	DMAH59S	Phase 3	Small molecular drug	[52]
Brivanib	DM942HP	Phase 3	Small molecular drug	[53]
Buparlisib	DM1WEHC	Phase 3	Small molecular drug	[54]
Cotellic	DMF9M57	Phase 3	Small molecular drug	[6]
Custirsen	DMIQ31Y	Phase 3	Small molecular drug	[55]
Datopotamab deruxtecan	DMO4GTC	Phase 3	Antibody drug conjugate	[56]
Dendritic cell therapy	DMFGZIV	Phase 3	NA	[57]
EG12014	DMLFYI7	Phase 3	NA	[58]
Etirinotecan pegol	DMQHX1Y	Phase 3	Small molecular drug	[59]
GDC-0032	DMT4QHD	Phase 3	Small molecular drug	[6]
GDC-0068	DMWBZJD	Phase 3	Small molecular drug	[6]
Gilotrif	DM6NIZD	Phase 3	NA	[6]
Giredestrant	DMBSFFK	Phase 3	Small molecule	[60]
GM3 ganglioside vaccine	DM7Z4K1	Phase 3	NA	[61]
GTx-024	DMZXF05	Phase 3	Small molecular drug	[6]
HKI-272	DM6QOVN	Phase 3	Small molecular drug	[62]
I3C	DMIGFOR	Phase 3	Small molecular drug	[63]
Imlunestrant	DMYBWL9	Phase 3	Small molecule	[64]
Kadcyla	DM6W717	Phase 3	NA	[6]
LEE011	DMMX75K	Phase 3	Small molecular drug	[6]
MK-4827	DMLYGH4	Phase 3	Small molecular drug	[6]
Nelipepimut S	DMDBY30	Phase 3	Small molecular drug	[50]
NeuVax	DMYTC4I	Phase 3	Vaccine	[65]
Onzeald	DM4P72R	Phase 3	NA	[6]
OPT-822/OPT-821	DM8EJ3S	Phase 3	NA	[66]
Oraxol	DMNDH3J	Phase 3	NA	[6]
OSE2101	DM4ORRQ	Phase 3	NA	[67]
PF-05280014	DM23BUP	Phase 3	NA	[68]
Rostaporfin	DM7SAKN	Phase 3	Small molecular drug	[69]
Sapacitabine	DM704AN	Phase 3	Small molecular drug	[6]
SBG	DMG57EV	Phase 3	NA	[70]
SNDX-275	DMH7W9X	Phase 3	Small molecular drug	[71]
SYD985	DM0JC9L	Phase 3	Antibody drug conjugate	[72]
Taxol/Paraplatin/Herceptin	DML6GAN	Phase 3	NA	[73]
Tesetaxel	DM9LFYN	Phase 3	Small molecular drug	[6]
Trastuzumab duocarmazine	DM6GBKI	Phase 3	Antibody drug conjugate	[6]
Trastuzumab-DM1	DMLB3I4	Phase 3	Antibody drug conjugate	[74]
TRC105	DM1874J	Phase 3	Monoclonal antibody	[47]
Tusamitamab ravtansine	DMMPSA1	Phase 3	Antibody drug conjugate	[75]
Imetelstat	DMONWJ4	Phase 2/3	Small molecular drug	[76]
Imprime PGG	DMIUA3M	Phase 2/3	NA	[6]
MGCD516	DM752PU	Phase 2/3	NA	[77]
Varlitinib	DMDG8Q3	Phase 2/3	Small molecular drug	[78]
18F-fluorothymidine	DM1X1QZ	Phase 2	Small molecular drug	[79]
2X-121	DMX9MSL	Phase 2	NA	[6]
AE-37	DMMRSK1	Phase 2	Small molecular drug	[80]
AE37 peptide vaccine	DME1WNB	Phase 2	NA	[81]
AE37/GP2 peptide vaccine	DM15QZ4	Phase 2	NA	[6]
Afimoxifene	DMFORDT	Phase 2	Small molecular drug	[82]
AFP464	DM1FJ2B	Phase 2	Small molecular drug	[83]
Alovudine	DMJPV5X	Phase 2	Small molecular drug	[84]
AMG 479	DM0DRAZ	Phase 2	NA	[85]
ANG1005	DMV5ENT	Phase 2	NA	[86]
Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells	DMPRIHK	Phase 2	Antibody	[87]
Apristor	DMWFD3K	Phase 2	NA	[6]
ARC-100	DMF6GK1	Phase 2	Small molecular drug	[88]
ARN-810	DML3PJF	Phase 2	NA	[89]
AS-1402	DMMX1EJ	Phase 2	Antibody	[90]
AZD8931	DMFLCW4	Phase 2	Small molecular drug	[91]
BAY 86-5044	DMRZLU4	Phase 2	Small molecular drug	[92]
BGB-324	DMDI43Y	Phase 2	siRNA drug	[6]
BIIB 2024	DM44Z9R	Phase 2	NA	[93]
BIIB-021	DMPAJ41	Phase 2	Small molecular drug	[94]
BMS-906024	DMEYR4K	Phase 2	Small molecular drug	[95]
Breast cancer vaccine	DMLAOTB	Phase 2	NA	[96]
Brostallicin	DMUI5PA	Phase 2	Small molecular drug	[97]
BZL-101	DMTRONK	Phase 2	NA	[98]
CB-103	DMLW115	Phase 2	Small molecular drug	[99]
CB-839	DM094UH	Phase 2	NA	[6]
CFI-400945	DM3BN4W	Phase 2	Small molecular drug	[100]
Coumate	DMVKW0N	Phase 2	Small molecular drug	[101]
CV-301	DMSJZB9	Phase 2	NA	[102]
Dalotuzumab	DMHEQQL	Phase 2	Monoclonal antibody	[103]
Debio 1347	DMZW50O	Phase 2	NA	[6]
DS-8201	DMYCAN7	Phase 2	NA	[6]
Dusigitumab	DM1ZJYS	Phase 2	NA	[47]
Efungumab	DMBHP56	Phase 2	Antibody	[104]
Endoxifen	DMTX8IZ	Phase 2	Small molecular drug	[105]
EP-101	DM69NF1	Phase 2	Small molecular drug	[6]
EP-302	DM3UHGF	Phase 2	Small molecular drug	[6]
Ertumaxomab	DM5Z3VP	Phase 2	Antibody	[106]
FANG vaccine	DM0OV22	Phase 2	Vaccine	[47]
G1T38	DMQO2IT	Phase 2	NA	[6]
GDC-0077	DMY6WUV	Phase 2	NA	[6]
GDC0941	DM1YAK6	Phase 2	Small molecular drug	[107]
Gimatecan	DMSKMET	Phase 2	Small molecular drug	[108]
GPI-0100	DMB6BGT	Phase 2	Small molecular drug	[109]
GPX-150D	DMHNIGB	Phase 2	NA	[110]
GSK3326595	DMJRD7A	Phase 2	NA	[111]
HE3235	DMV50R1	Phase 2	Small molecular drug	[112]
HER-2 Protein AutoVac	DM8TOS0	Phase 2	NA	[113]
HER2 antigen-specific cancer immunotherapeutic	DMZAYYD	Phase 2	NA	[114]
HER2/neu peptide vaccine	DMISETH	Phase 2	Vaccine	[115]
ICARITIN	DMGHQ37	Phase 2	Small molecular drug	[116]
ICO-25	DMC13BQ	Phase 2	Antibody	[117]
ImmunoPulse IL-12	DM0W3B4	Phase 2	NA	[47]
INK128	DMGO7QT	Phase 2	Small molecular drug	[6]
IPI-549	DMG5Q7F	Phase 2	NA	[6]
IRX-2	DMODLN7	Phase 2	NA	[47]
KN026	DMNLH9W	Phase 2	Antibody	[118]
Ladiratuzumab vedotin	DM00R2I	Phase 2	NA	[6]
LADIRUBICIN	DM7063I	Phase 2	Small molecular drug	[119]
LCL161	DMTM4QA	Phase 2	NA	[6]
LOR-2040	DMX2TEM	Phase 2	NA	[120]
LY2784544	DMZASMP	Phase 2	Small molecular drug	[121]
Maraciclatide	DMLZJSJ	Phase 2	Small molecular drug	[122]
MCLA-128	DM0W3R7	Phase 2	NA	[6]
MCS-110	DM0CL4I	Phase 2	NA	[47]
MM-111	DMO7MBS	Phase 2	Monoclonal antibody	[123]
MM-121	DMDJRU1	Phase 2	NA	[124]
NSC-645809	DMPJQZG	Phase 2	Small molecular drug	[125]
OGX-427	DMJTU8D	Phase 2	Antisense drug	[126]
ONAPRISTONE	DMT6E5N	Phase 2	Small molecular drug	[127]
P-276	DMMJUHD	Phase 2	Small molecular drug	[128]
Patritumab deruxtecan	DMNIAWS	Phase 2	Antibody drug conjugate	[129]
PD-0325901	DM27D4J	Phase 2	Small molecular drug	[130]
PEG-SN38	DMX9ZM4	Phase 2	Small molecular drug	[131]
POL-6326	DM4OT29	Phase 2	NA	[6]
Polyamine	DMUXEBQ	Phase 2	NA	[132]
PTX-200	DM0ZIT2	Phase 2	NA	[6]
Racotumomab	DM79YAS	Phase 2	Monoclonal antibody	[133]
REM-001	DMYA0T8	Phase 2	NA	[6]
RO-4929097	DMXA6B3	Phase 2	Small molecular drug	[134]
Sagopilone	DM6JXWL	Phase 2	Small molecular drug	[135]
SAR439859	DMR5CSZ	Phase 2	Small molecular drug	[136]
Seviteronel	DM9IMEZ	Phase 2	NA	[6]
SFV IL-12 gene therapy	DMVIWNK	Phase 2	NA	[137]
SFX-01	DMAQW9M	Phase 2	NA	[138]
SR 16234	DMRFO34	Phase 2	Small molecular drug	[139]
Tanespimycin	DMNLQHK	Phase 2	Small molecular drug	[140]
TgDCC-E1A	DMPU168	Phase 2	NA	[141]
Tigatuzumab	DMKYJJC	Phase 2	Monoclonal antibody	[142]
TPI-287	DMC5TV6	Phase 2	Small molecular drug	[143]
TPIV200	DM4UZRE	Phase 2	NA	[50]
Trastuzumab emtansine	DMU1LXS	Phase 2	Antibody drug conjugate	[47]
Upamostat	DMFZULI	Phase 2	Small molecular drug	[144]
VER 50589	DMFLZPC	Phase 2	Small molecular drug	[145]
Vx-001	DMDKWA3	Phase 2	Vaccine	[146]
Xentuzumab	DM4ZIDH	Phase 2	NA	[147]
XL880	DMHJTR2	Phase 2	Small molecular drug	[148]
YM155	DM5Q1W4	Phase 2	Small molecular drug	[149]
ZW25	DMRLZA1	Phase 2	Antibody	[150]
Aderbasib	DMYOMSC	Phase 1/2	Small molecular drug	[151]
ADXS-HER2	DMW8C1D	Phase 1/2	NA	[152]
Anti-MUC1 CAR T Cells	DM0C1IX	Phase 1/2	CAR T Cell Therapy	[153]
ARV-471	DM276Y8	Phase 1/2	Small molecular drug	[154]
AVX901	DM7O29W	Phase 1/2	NA	[155]
Bria-IMT	DMX7NQF	Phase 1/2	NA	[6]
BriaVax	DM0M0N8	Phase 1/2	NA	[47]
CT84.66	DM6078F	Phase 1/2	NA	[156]
DCC-2036	DMJKFNU	Phase 1/2	Small molecular drug	[6]
FCN-437	DMQ8VUW	Phase 1/2	NA	[157]
H3B-6545	DMIFCY2	Phase 1/2	NA	[158]
HER-2-targeting CAR T Cells	DM1U6VX	Phase 1/2	CAR T Cell Therapy	[159]
LJM716	DMGTB5N	Phase 1/2	Antibody	[160]
ME-344	DM6JN19	Phase 1/2	Small molecular drug	[6]
NB1011	DM5O4GR	Phase 1/2	Small molecular drug	[161]
OBP-301	DM9MF08	Phase 1/2	NA	[162]
OP-1250	DMIU26T	Phase 1/2	Small interfering RNA	[163]
P10s-Padre/Montanide ISA 51 vaccine	DMCSXHW	Phase 1/2	NA	[164]
Samuraciclib	DM54FQA	Phase 1/2	Small molecule	[165]
SV-BR-1-GM cancer vaccine	DM70TX5	Phase 1/2	Vaccine	[166]
TC-510	DMSPG60	Phase 1/2	Cell therapy	[167]
ZN-c5	DMVG4OC	Phase 1/2	Small molecular drug	[168]
177Lu-AMBA	DMFG1YA	Phase 1	NA	[169]
AC0682	DM49FVF	Phase 1	PROTAC	[170]
Ad.hIL-12	DM40OOG	Phase 1	NA	[171]
ADPT01	DMS6DPF	Phase 1	Antibody	[172]
Afeletecan	DMNF3GW	Phase 1	Small molecular drug	[173]
AIP-303	DMHCBI0	Phase 1	Radiopharmaceutical therapy agent	[174]
ARX788	DMQ9VJW	Phase 1	NA	[47]
Autologous T Cells Expressing MET scFv CAR	DMZ763A	Phase 1	CAR T Cell Therapy	[175]
AZD9496	DMPMDTH	Phase 1	NA	[6]
BP-C1	DMSG08M	Phase 1	NA	[176]
BTSCAN	DM4R2YC	Phase 1	NA	[177]
CAR-T cells recognizing EpCAM	DMC7Y5F	Phase 1	CAR T Cell Therapy	[178]
CT-P6	DM1L7OU	Phase 1	NA	[47]
D-0502	DMGA1DS	Phase 1	Small molecular drug	[179]
DAN-222	DMJD93K	Phase 1	NA	[180]
Demobesin	DMPXLMB	Phase 1	NA	[181]
DHES0815A	DM4OKDB	Phase 1	NA	[6]
DPX-0907	DM2XVCE	Phase 1	NA	[182]
EP-301	DMVLI4R	Phase 1	Vaccine	[183]
ETBX-021	DM4XL4C	Phase 1	NA	[6]
G1T-48	DMRGP72	Phase 1	NA	[184]
GDC-9545	DMDIU0M	Phase 1	NA	[6]
GMI-1359	DML1KSA	Phase 1	Small molecular drug	[185]
HC-5404	DMKFZW5	Phase 1	Small molecule	[186]
HHCYH33	DMRQ4L6	Phase 1	Small molecular drug	[187]
HuMNC2-CAR44 T cells	DMVGBA1	Phase 1	CAR T Cell Therapy	[188]
IMT-1012 immunotherapeutic vaccine	DM3JYBZ	Phase 1	NA	[6]
IMT1012	DMG5PF0	Phase 1	Vaccine	[189]
INO-1400	DMLN5E4	Phase 1	NA	[50]
IRX4204	DM9SCME	Phase 1	Small molecular drug	[6]
JCAR024	DMQ1TK0	Phase 1	NA	[47]
LSZ102	DMS1DMA	Phase 1	NA	[6]
LV305	DMP0TQA	Phase 1	NA	[190]
LY3484356	DMY8W3S	Phase 1	NA	[191]
LY3849524	DM8I68X	Phase 1	NA	[192]
Mesothelin-targeted T cells	DMHXA79	Phase 1	CAR T Cell Therapy	[193]
MM-302	DMYSJTR	Phase 1	NA	[194]
MVA HER-2 AutoVac	DM3JUXW	Phase 1	Vaccine	[195]
OBT076	DMW4JRY	Phase 1	Antibody drug conjugate	[196]
Odetiglucan	DMH8IO5	Phase 1	Antibody	[197]
OTSSP167	DMF5KNO	Phase 1	Small molecular drug	[6]
pbi-shRNA STMN1	DM529QO	Phase 1	Short hairpin RNA	[132]
PCA062	DM1GNEH	Phase 1	NA	[6]
PEV-6A	DMN2SF8	Phase 1	NA	[198]
PF-06873600	DMRZHV6	Phase 1	NA	[6]
PF-07248144	DM5P0PC	Phase 1	Small molecule	[199]
PF-07260437	DMU7LYP	Phase 1	Antibody	[200]
PU-H71	DMIYHAW	Phase 1	Small molecular drug	[6]
Quinazoline derivative 9	DMP3QSA	Phase 1	Small molecular drug	[201]
RAD-140	DMNVDI2	Phase 1	Small molecular drug	[6]
RGT-419B	DMD2MND	Phase 1	Small molecule	[202]
Runimotamab	DML6BK5	Phase 1	Bispecific antibody	[203]
Sch-58500	DMHE7R4	Phase 1	NA	[204]
SCO-120	DMB1MZS	Phase 1	NA	[205]
SGN LIV1A	DMVBQ2L	Phase 1	Antibody	[206]
Sialyl Lea-KLH conjugate vaccine	DMCU3Z2	Phase 1	NA	[207]
TPIV 100/110 vaccine	DM4K0KW	Phase 1	NA	[50]
TPIV 110	DMIO289	Phase 1	NA	[47]
Trodusquemine	DMQ7UN6	Phase 1	Small molecular drug	[6]
TTC-352	DM7CHZ2	Phase 1	NA	[6]
VIMO-001	DMY4LTE	Phase 1	Small molecular drug	[208]
XmAb20717	DMJIH83	Phase 1	Antibody	[209]
XMT-1522	DMPVP4D	Phase 1	NA	[6]
KH064	DMR1NYF	Clinical trial	Small molecular drug	[210]
Methylselenocysteine	DMAAB9A	Clinical Trial	Small molecular drug	[211]

This Disease is Treated as An Indication in 1 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID28460551-Compound-1	DMHV75N	Patented	Small molecular drug	[212]

This Disease is Treated as An Indication in 38 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
FORMESTANE	DMWIDJK	Withdrawn from market	Small molecular drug	[1]
Nomifensine	DMCP2TS	Withdrawn from market	Small molecular drug	[213]
Idoxifene	DMRXUY7	Discontinued in Phase 3	Small molecular drug	[214]
99mTc-RP-527	DM6QRLF	Discontinued in Phase 2	NA	[215]
AVE-1642	DMUQ6IL	Discontinued in Phase 2	Antibody	[216]
Droloxifene	DM9JPUD	Discontinued in Phase 2	Small molecular drug	[217]
Epothilone D	DM1WGUT	Discontinued in Phase 2	Small molecular drug	[218]
ERA-923	DM6NTAS	Discontinued in Phase 2	Small molecular drug	[219]
Her-2-Bi-armed ATC	DM5JZW2	Discontinued in Phase 2	Antibody	[220]
KW-2170	DM5YHJ2	Discontinued in Phase 2	Small molecular drug	[221]
LOSOXANTRONE	DMM843E	Discontinued in Phase 2	Small molecular drug	[222]
Mirostipen	DMKI8AC	Discontinued in Phase 2	NA	[223]
Recombinant pox virus vaccine	DM5NCIK	Discontinued in Phase 2	NA	[224]
RHIZOXIN	DMQ4IKZ	Discontinued in Phase 2	Small molecular drug	[225]
SMART ABL-364	DMY87J3	Discontinued in Phase 2	NA	[226]
SU-14813	DMNRW68	Discontinued in Phase 2	Small molecular drug	[227]
Tesmilifene	DMPB36I	Discontinued in Phase 2	Small molecular drug	[228]
YM-511	DM7WDAG	Discontinued in Phase 2	Small molecular drug	[229]
KW-2450	DM7QGSX	Discontinued in Phase 1/2	NA	[230]
SF-1	DMAZXN5	Discontinued in Phase 1/2	NA	[231]
AS-1403	DMSI81F	Discontinued in Phase 1	NA	[232]
AZD-4992	DMNI7BA	Discontinued in Phase 1	NA	[233]
GSK1059615	DMI6KQM	Discontinued in Phase 1	Small molecular drug	[234]
HER-2VAX	DMXLQE6	Discontinued in Phase 1	NA	[235]
NRLU-10	DMLIMQ5	Discontinued in Phase 1	NA	[236]
Anatumomab mafenatox	DMMLDG8	Terminated	Antibody	[245]
CMB-401	DMN1KKT	Terminated	NA	[246]
Datelliptium chloride	DMR80AL	Terminated	Small molecular drug	[247]
Doxorubicin-CEA conjugate	DM4BPFV	Terminated	NA	[248]
GW-974	DMPLYHU	Terminated	NA	[249]
Herzyme	DMMUBT3	Terminated	NA	[250]
ICI-164384	DMYN3WG	Terminated	Small molecular drug	[251]
MB-300	DM8BQAY	Terminated	NA	[252]
MX-6162	DMV1SGP	Terminated	NA	[253]
MX-781	DMNZ356	Terminated	NA	[254]
Rogletimide	DM6JO30	Terminated	Small molecular drug	[255]
VT-1	DMU30D6	Terminated	Small molecular drug	[256]
Zindoxifene	DM81DJV	Terminated	Small molecular drug	[257]

This Disease is Treated as An Indication in 12 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Kanjinti	DM3YJNL	Application submitted	NA	[6]
SB3	DM90HIN	Application submitted	NA	[6]
(R)-PFI-2	DMIUZEX	Preclinical	Small molecular drug	[237]
111In-hEGF	DM9TQDE	Preclinical	NA	[238]
2-Amino-4-[3-hydroxyphenyl]-4-hydroxybutanoic acid	DM1R3VC	Preclinical	Small molecular drug	[239]
2-Ethoxypropanoic acid	DMAM4FE	Preclinical	Small molecular drug	[240]
AA-102	DM0N111	Preclinical	NA	[241]
BIX-01294	DM5CBNY	Preclinical	Small molecular drug	[237]
Cu-anti-hAXL	DMKVW25	Preclinical	Antibody	[242]
EDD7H9	DMELPJM	Preclinical	Antibody	[243]
SP-MET-1	DMO2UKI	Preclinical	NA	[244]
YW327.6S2	DMH0I9N	Preclinical	Antibody	[242]

This Disease is Treated as An Indication in 41 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
76Br-16alpha,17alpha-dioxolane progestin	DMNQK9Y	Investigative	NA	[132]
AFPep	DMC5ZSR	Investigative	NA	[132]
AntiHer2-XTEN-Docetaxel	DM8QOBV	Investigative	NA	[132]
ARX-AHD	DM15KLR	Investigative	Antibody	[258]
ASP4131	DM9B6WH	Investigative	NA	[132]
Beta 1-6 glucan-conjugated trastuzumab	DMUGJY3	Investigative	Monoclonal antibody	[132]
BreMel/rGel	DMUSJNA	Investigative	NA	[132]
BreMel/TNF alpha	DMW6JJN	Investigative	NA	[132]
BW-42	DMSBVGB	Investigative	NA	[132]
Crodox	DMJ5X3T	Investigative	NA	[132]
Cu64-CNND1-B	DM902DU	Investigative	NA	[132]
EGF-SLiP fusion protein	DMCFQRZ	Investigative	NA	[132]
ETP-45658	DM79XSF	Investigative	Small molecular drug	[259]
Foxy-5	DM8NIEE	Investigative	NA	[132]
Fsn-1006	DM8W096	Investigative	NA	[132]
GBP-1a	DMGKZ1I	Investigative	NA	[132]
GSK-2302024A	DM3733M	Investigative	NA	[132]
Hedgehog labelled stem cells	DMATT2T	Investigative	NA	[132]
HM-2002	DM5CXKR	Investigative	NA	[132]
HMAG-1 targeting GRSA	DM4MEVL	Investigative	NA	[132]
HTERT-VISA-BikDD nanoparticles	DMZ121A	Investigative	NA	[132]
ITL-1636	DMBH3L7	Investigative	NA	[132]
IVVS-1001	DMS69AB	Investigative	NA	[132]
KW-2581	DM1P5DP	Investigative	Small molecular drug	[132]
mabionHER2	DMJX2CS	Investigative	Antibody	[258]
MAGE-101	DMMJEEG	Investigative	NA	[132]
MS1943	DMTPGQ3	Investigative	Small molecular drug	[237]
ON-04	DMRNE3B	Investigative	NA	[132]
PINS	DM9Y198	Investigative	NA	[132]
Plant-based oncology candidate	DMY5Z5D	Investigative	NA	[132]
RG6046	DMGYWIK	Investigative	NA	[1]
RL-6A	DMPT1YA	Investigative	NA	[132]
ScFv23/rGel	DM02XLI	Investigative	NA	[132]
SLX-1016	DMN7HEK	Investigative	NA	[132]
SNG-8023	DM6O9DQ	Investigative	Antibody	[261]
SR-13654	DMZN18C	Investigative	NA	[132]
TB-010	DMUY0EY	Investigative	NA	[132]
Tc99-labeled 14F7 humanized mab	DM45HCT	Investigative	Monoclonal antibody	[132]
Tetanolic acid	DMI2JHN	Investigative	NA	[132]
VM-505	DMXSY75	Investigative	NA	[132]
Zn-DPA-B	DMB98OG	Investigative	NA	[132]

This Disease is Treated as An Indication in 1 Investigative Agents

Drug Name	Drug ID	Highest Status	Drug Type	REF
Sapanisertib	DMYZFNH	Investigative	Small molecular drug	[260]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 3128 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
XRCC2	OTJB2PV4	Disputed	Autosomal dominant	[265]
AAMP	OTZXBSS4	Limited	Altered Expression	[1785]
AATF	OT1QOKLD	Limited	Biomarker	[1786]
ACOX2	OT3VH359	Limited	Biomarker	[1787]
ACSL1	OTB06ESI	Limited	Biomarker	[1788]
ACTN1	OTUCLNXH	Limited	Altered Expression	[1789]
ADAM22	OT452ZDC	Limited	Biomarker	[1790]
ADAM23	OTVWT6JZ	Limited	Biomarker	[1791]
ADAMTS12	OTG7HEA2	Limited	Biomarker	[1792]
ADGRE2	OTUYJVYG	Limited	Biomarker	[1793]
ADGRF5	OTWU7AOO	Limited	Biomarker	[1794]
ADSL	OTSNJALL	Limited	Biomarker	[1795]
AGBL2	OTCX9987	Limited	Altered Expression	[1796]
AIF1L	OTDEOB80	Limited	Altered Expression	[1797]
AK6	OT84OHHP	Limited	Biomarker	[1798]
AKAP4	OTL4Z99V	Limited	Altered Expression	[1799]
ALDH3A1	OTAYZZE6	Limited	Biomarker	[356]
ALPP	OTZU4G9W	Limited	Biomarker	[700]
AMPD1	OTU17BCI	Limited	Genetic Variation	[1800]
ANAPC4	OTVW4DW1	Limited	Altered Expression	[1801]
ANK3	OTJ3IRBP	Limited	Biomarker	[1802]
ANKHD1	OTVYQ7ZL	Limited	Altered Expression	[1803]
ANKRD36B	OT3MW415	Limited	Biomarker	[1804]
ANKRD6	OTM86B04	Limited	Biomarker	[1805]
AP1S2	OTZHJFYI	Limited	Biomarker	[1806]
API5	OTYX9YCZ	Limited	Altered Expression	[1807]
AQP10	OT8Q5UWS	Limited	Altered Expression	[279]
ARHGAP8	OT19H5Q9	Limited	Altered Expression	[1808]
ARHGEF28	OT3F32IU	Limited	Biomarker	[1809]
ARL6IP5	OTYZ6BEQ	Limited	Biomarker	[1810]
ARRDC3	OTAKW7R9	Limited	Biomarker	[1811]
ASAH1	OT1DNGXL	Limited	Biomarker	[1812]
ASH2L	OT3HG324	Limited	Altered Expression	[1813]
ATG5	OT4T5SMS	Limited	Genetic Variation	[698]
ATOX1	OT05LF59	Limited	Altered Expression	[1814]
ATP2B4	OTMWFDAC	Limited	Altered Expression	[1815]
ATP6V1C1	OT2LI8ZG	Limited	Altered Expression	[1816]
AURKA	OTMX0HYT	Limited	Autosomal dominant	[265]
AZIN2	OT8OB7CG	Limited	Biomarker	[1817]
B3GAT1	OTXFP98E	Limited	Biomarker	[296]
BCCIP	OTFFKG79	Limited	Altered Expression	[1818]
BCL10	OT47MCLI	Limited	Genetic Variation	[392]
BCL2L10	OTYXQJ3I	Limited	Biomarker	[1105]
BCL3	OT1M5B95	Limited	Altered Expression	[1819]
BRCC3	OTK0ZN7Y	Limited	Biomarker	[1820]
BRI3	OT1RWIH7	Limited	Biomarker	[1821]
BRINP1	OTEUVSCP	Limited	Biomarker	[1822]
BTN3A3	OTKMSJRA	Limited	Biomarker	[1823]
BVES	OT4GT1WC	Limited	Biomarker	[1824]
CAP2	OTC1WFNO	Limited	Altered Expression	[1825]
CAPG	OTJ86KI6	Limited	Altered Expression	[1826]
CAPRIN1	OTEJAMS3	Limited	Altered Expression	[1827]
CARMIL3	OT4ZN0K3	Limited	Altered Expression	[1828]
CARTPT	OTTE4V9S	Limited	Biomarker	[1829]
CAV2	OT1FGRQX	Limited	Altered Expression	[1830]
CBX2	OTOQ5WS4	Limited	Biomarker	[1831]
CBX3	OTOP9RLD	Limited	Altered Expression	[293]
CCDC106	OTWUTA1W	Limited	Biomarker	[1832]
CCDC170	OTNQOJ6S	Limited	Biomarker	[1833]
CCDC85A	OT2GLF5Z	Limited	Genetic Variation	[1834]
CCL27	OTUZYC61	Limited	Biomarker	[700]
CCL4L2	OTDBSXOU	Limited	Altered Expression	[1835]
CCL7	OTDIS99H	Limited	Altered Expression	[756]
CCN3	OTOW5YL4	Limited	Biomarker	[1836]
CCNA1	OTX4HD45	Limited	Biomarker	[1837]
CCNB2	OTIEXTDK	Limited	Altered Expression	[1656]
CCNG2	OTII38K2	Limited	Biomarker	[1838]
CCS	OTXHT3QO	Limited	Altered Expression	[1839]
CD177	OTS79FNF	Limited	Biomarker	[1840]
CD1D	OT3ROU4J	Limited	Biomarker	[1841]
CDC6	OTX93FE7	Limited	Biomarker	[1842]
CDCP1	OTD7RRWK	Limited	Altered Expression	[1843]
CDH4	OT8LH3HN	Limited	Genetic Variation	[1844]
CEP135	OT1O9XYJ	Limited	Biomarker	[1845]
CEP70	OTMY5KAE	Limited	Biomarker	[1846]
CFAP97	OT0RSQO4	Limited	Biomarker	[1847]
CHAC1	OTJGE772	Limited	Altered Expression	[1848]
CHD1	OT9R9G0H	Limited	Posttranslational Modification	[1849]
CHI3L2	OT26R3HQ	Limited	Altered Expression	[1850]
CHL1	OT6E6E8P	Limited	Posttranslational Modification	[1851]
CHSY1	OTB1XSSF	Limited	Biomarker	[720]
CHSY3	OT8ERGMH	Limited	Biomarker	[720]
CISD1	OT0MTVGF	Limited	Biomarker	[1852]
CITED2	OT812TV7	Limited	Biomarker	[1853]
CKS2	OTPTMHIV	Limited	Altered Expression	[1854]
CLCA2	OTF191LZ	Limited	Biomarker	[1855]
CLDN2	OTRF3D6Y	Limited	Biomarker	[1856]
CLDN3	OT71MN9S	Limited	Altered Expression	[1857]
CLEC4G	OTUGTR0H	Limited	Biomarker	[1823]
CLGN	OTEWVFQV	Limited	Biomarker	[1858]
CLIC3	OT5KUZ3A	Limited	Biomarker	[1859]
CMTM1	OTKN7E89	Limited	Biomarker	[1860]
COPS2	OTDSCPVV	Limited	Genetic Variation	[1861]
CORO1B	OT7C4BMQ	Limited	Altered Expression	[363]
CORO1C	OTXDF9T3	Limited	Biomarker	[1862]
COX3	OTNNGBYJ	Limited	Genetic Variation	[1863]
COX4I1	OTU0FC24	Limited	Biomarker	[1864]
CPQ	OTTNZNLD	Limited	Altered Expression	[1386]
CPSF4	OT53UK5L	Limited	Biomarker	[1865]
CREB3L4	OTSGQGT2	Limited	Biomarker	[1866]
CRIP1	OT0EICG3	Limited	Biomarker	[1867]
CRISPLD2	OTVSFHTL	Limited	Biomarker	[1868]
CSPP1	OTNX7GD4	Limited	Altered Expression	[1869]
CSRP2	OT4SW0HI	Limited	Biomarker	[1870]
CSTA	OT1K68KE	Limited	Biomarker	[1871]
CT62	OTV9N4KM	Limited	Biomarker	[1872]
CT83	OTQEGHAB	Limited	Altered Expression	[1873]
CYBA	OT16N9ZO	Limited	Genetic Variation	[1874]
CYLD	OT37FKH0	Limited	Biomarker	[1875]
DAB1	OTPL9MA3	Limited	Biomarker	[1876]
DACT1	OT19Z704	Limited	Altered Expression	[1877]
DBT	OT4KZ5R9	Limited	Biomarker	[1878]
DCDC2	OTSUFH1H	Limited	Biomarker	[1879]
DDT	OTF5HTYL	Limited	Biomarker	[1880]
DDX56	OTGURA53	Limited	Biomarker	[1881]
DEF6	OTIRBYVK	Limited	Altered Expression	[1882]
DENR	OTXP9HOY	Limited	Biomarker	[490]
DESI1	OTFNIW98	Limited	Genetic Variation	[1883]
DHRS11	OTU3J0ZL	Limited	Biomarker	[362]
DHX9	OT5AAOQI	Limited	Altered Expression	[1884]
DIAPH3	OTPOT23F	Limited	Altered Expression	[1885]
DMXL2	OTB4JWN3	Limited	Altered Expression	[1886]
DNAJC15	OTNDUKAA	Limited	Biomarker	[1887]
DOCK4	OTH3XY8B	Limited	Biomarker	[1888]
DOK5	OT2XWUPN	Limited	Altered Expression	[1519]
DOK7	OTR2V7HO	Limited	Altered Expression	[1889]
DSE	OTQ108VJ	Limited	Biomarker	[720]
DST	OTHZBM4X	Limited	Biomarker	[1890]
E2F6	OT2PN28R	Limited	Biomarker	[1891]
E2F7	OTWW358N	Limited	Altered Expression	[1892]
E2F8	OTQKZGFP	Limited	Altered Expression	[1892]
ECRG4	OTHZYUXX	Limited	Posttranslational Modification	[753]
ECT2	OTQDUCT6	Limited	Biomarker	[1893]
EFEMP2	OT0I2B4J	Limited	Altered Expression	[1894]
EHF	OTY6TPWD	Limited	Altered Expression	[1895]
EIF2B5	OTV3R4RB	Limited	Biomarker	[1896]
EIF3E	OTI0WG98	Limited	Biomarker	[1897]
EIF3H	OT61RBF5	Limited	Genetic Variation	[1898]
EIF4A2	OT08H03R	Limited	Altered Expression	[1899]
EIPR1	OTNQKNL3	Limited	Biomarker	[1900]
ELK4	OTVSSEOE	Limited	Altered Expression	[1901]
EMB	OT67E3Q1	Limited	Biomarker	[1902]
EN2	OT7EZCM2	Limited	Biomarker	[1903]
EPB41L5	OTPPQPLU	Limited	Biomarker	[1904]
EPS15	OT7NPP8U	Limited	Altered Expression	[1905]
ESRP1	OTNCS4SL	Limited	Biomarker	[1906]
ETV3	OTEN03BM	Limited	Altered Expression	[1901]
ETV6	OTCZMG61	Limited	Genetic Variation	[1907]
FANCC	OTTIDM3P	Limited	Autosomal dominant	[265]
FBH1	OTDJBKO1	Limited	Genetic Variation	[1908]
FBLIM1	OTFHXMON	Limited	Genetic Variation	[1909]
FBXO28	OTKTMVC4	Limited	Genetic Variation	[1910]
FBXO39	OTPRR6SK	Limited	Biomarker	[1911]
FERMT3	OTFQOT3C	Limited	Altered Expression	[1912]
FGFRL1	OT8HZ3ZL	Limited	Biomarker	[1913]
FIG4	OT501PY9	Limited	Biomarker	[422]
FKBPL	OTR9ND6K	Limited	Biomarker	[1914]
FLI1	OT0EV3LX	Limited	Altered Expression	[1915]
FLNB	OTPCOYL6	Limited	Biomarker	[1916]
FLVCR1	OT9XCFOC	Limited	Biomarker	[1917]
FMR1	OTWEV0T5	Limited	Biomarker	[1918]
FOXA2	OTJOCVOY	Limited	Altered Expression	[1342]
FOXF2	OTV20NGX	Limited	Biomarker	[1919]
FOXN4	OTE3MWYJ	Limited	Altered Expression	[1920]
FOXP2	OTVX6A59	Limited	Biomarker	[1921]
FSIP1	OTYLL6GM	Limited	Biomarker	[1922]
FTL	OTYQA8A6	Limited	Biomarker	[1923]
FUNDC1	OTA6IVKQ	Limited	Biomarker	[1924]
GAB1	OTQKE6V4	Limited	Altered Expression	[1925]
GADL1	OTJM4A0R	Limited	Biomarker	[1817]
GALNT14	OT9BSDDQ	Limited	Biomarker	[1926]
GATAD2B	OTJL128N	Limited	Biomarker	[1881]
GBP1	OTUM7RPJ	Limited	Biomarker	[1927]
GC	OTWS63BY	Limited	Genetic Variation	[1928]
GFPT1	OTQBDO45	Limited	Biomarker	[1929]
GLRX3	OTUPAU1N	Limited	Biomarker	[1930]
GLYR1	OTY0VAVL	Limited	Altered Expression	[1931]
GMPR2	OTKZSZPE	Limited	Altered Expression	[1932]
GNA12	OT3IRZH3	Limited	Biomarker	[1933]
GNB1	OTLL7L74	Limited	Biomarker	[308]
GNL3	OTILGYO4	Limited	Altered Expression	[1934]
GNMT	OT0O2OQO	Limited	Biomarker	[1935]
GOT2	OT6XBWN0	Limited	Altered Expression	[1936]
GPAT2	OTZ8VP2Y	Limited	Altered Expression	[1937]
GPAT3	OTJUGPK0	Limited	Biomarker	[1938]
GPHN	OTAKK1SV	Limited	Biomarker	[1939]
GPM6B	OT8Q1582	Limited	Biomarker	[1940]
GPR151	OT7EACU6	Limited	Biomarker	[399]
GPX2	OTXI2NTI	Limited	Biomarker	[1941]
GTF2H2	OTK72L9I	Limited	Genetic Variation	[1942]
H1-0	OTRLJK4Z	Limited	Biomarker	[1943]
H2AZ1	OT3KJJNQ	Limited	Biomarker	[764]
H2BC10	OTLQH0D6	Limited	Altered Expression	[1944]
H2BC5	OTXDTDHN	Limited	Altered Expression	[1944]
H6PD	OTO7TNDD	Limited	Altered Expression	[1945]
HADHA	OTO557N2	Limited	Altered Expression	[1946]
HAS1	OTJIAG1W	Limited	Genetic Variation	[1947]
HAVCR1	OT184CRZ	Limited	Altered Expression	[1948]
HDDC3	OTIX7RRB	Limited	Genetic Variation	[1949]
HERC4	OTU4DSDE	Limited	Biomarker	[1950]
HES6	OTWO5SCF	Limited	Biomarker	[1951]
HGS	OTCYYCAC	Limited	Biomarker	[1952]
HIP1	OT7AKCFQ	Limited	Altered Expression	[1953]
HLA-DOB	OTKADDUB	Limited	Genetic Variation	[1954]
HLA-E	OTX1CTFB	Limited	Genetic Variation	[1040]
HMGB4	OT28OBR2	Limited	Altered Expression	[1955]
HOXA1	OTMSOJ7D	Limited	Altered Expression	[1956]
HOXA6	OTHJP8M2	Limited	Biomarker	[1957]
HOXB5	OTU74TB8	Limited	Altered Expression	[1958]
HPX	OT14T7Q1	Limited	Biomarker	[1959]
HSD17B6	OTSB55D2	Limited	Genetic Variation	[1960]
HSPH1	OTVRR73T	Limited	Biomarker	[1961]
HTR3C	OT65ZLIJ	Limited	Biomarker	[1962]
HUS1	OTY1XON9	Limited	Biomarker	[1963]
ID4	OTPMJ39I	Limited	Altered Expression	[1964]
IFI30	OT9DERT1	Limited	Biomarker	[1965]
IFI6	OTWOOAM4	Limited	Biomarker	[1966]
IFITM1	OTECO1G8	Limited	Altered Expression	[1967]
IFITM10	OTU2YGKP	Limited	Altered Expression	[1968]
IGBP1	OTTHH4YE	Limited	Biomarker	[1969]
IGFBP4	OT2HZRBD	Limited	Biomarker	[979]
IKBKG	OTNWJWSD	Limited	Altered Expression	[1970]
IL20RA	OTSIVBVS	Limited	Altered Expression	[1971]
ILF3	OTKMZ5K5	Limited	Altered Expression	[1972]
ING5	OTRNNSFM	Limited	Altered Expression	[1973]
ISG20	OTCWRJJW	Limited	Biomarker	[1087]
ISYNA1	OT49ONSE	Limited	Altered Expression	[1262]
ITGAX	OTOGIMHE	Limited	Biomarker	[1974]
ITGB4	OT28UK84	Limited	Altered Expression	[1975]
KAT5	OTL7257A	Limited	Biomarker	[1976]
KDM3B	OTZU5J5S	Limited	Altered Expression	[1977]
KDM8	OTCN5ST8	Limited	Biomarker	[1978]
KHDRBS3	OTUG02U7	Limited	Altered Expression	[1979]
KIF1A	OT3JVEGV	Limited	Posttranslational Modification	[1980]
KIF2A	OT2WQ6QD	Limited	Biomarker	[1981]
KIF4A	OT3UWL7D	Limited	Altered Expression	[1982]
KLF17	OT5NWVP7	Limited	Altered Expression	[1983]
KLHL1	OTAX6SAD	Limited	Biomarker	[645]
KMT2D	OTTVHCLY	Limited	Posttranslational Modification	[1984]
KPNA2	OTU7FOE6	Limited	Biomarker	[1893]
LAMA5	OTIIXE4M	Limited	Altered Expression	[1985]
LARP7	OTLLOZTL	Limited	Altered Expression	[1986]
LCOR	OT1K7DKB	Limited	Biomarker	[1987]
LDHB	OT9B1CT3	Limited	Altered Expression	[1044]
LGR6	OTPZ1PWR	Limited	Biomarker	[399]
LHX2	OTK61NP8	Limited	Biomarker	[1988]
LHX6	OT47UQZ5	Limited	Altered Expression	[1989]
LIG3	OT48SKET	Limited	Genetic Variation	[1990]
LINGO2	OT3N88Q1	Limited	Genetic Variation	[365]
LOXL4	OT6XY2JL	Limited	Altered Expression	[1991]
LRPPRC	OTXSK5LP	Limited	Biomarker	[1992]
LRRC75B	OTAHOBSS	Limited	Altered Expression	[1993]
LXN	OTZQ2M6Y	Limited	Altered Expression	[1796]
MACIR	OTPSW8Y8	Limited	Biomarker	[1015]
MACROH2A1	OTV2DQDD	Limited	Altered Expression	[1994]
MAGEA12	OT8ULELL	Limited	Biomarker	[1995]
MAP1S	OT5WUD4C	Limited	Biomarker	[1996]
MAP2K3	OTI2OREX	Limited	Biomarker	[1997]
MAP3K12	OT5HODDD	Limited	Biomarker	[1998]
MARK4	OT6Z2TGV	Limited	Biomarker	[1999]
MB	OTYWYL2D	Limited	Altered Expression	[2000]
MCCC2	OTQDHSMI	Limited	Biomarker	[2001]
MCM2	OTGGORIQ	Limited	Biomarker	[2002]
MCU	OTQZAYWQ	Limited	Altered Expression	[2003]
MED19	OTT9RT5N	Limited	Biomarker	[2004]
MEF2A	OTV2SF6E	Limited	Biomarker	[2005]
MFAP4	OT5W64QY	Limited	Altered Expression	[2006]
MFN2	OTPYN8A3	Limited	Biomarker	[2007]
MIP	OTEBLU3E	Limited	Biomarker	[2008]
MLC1	OTCNZLSP	Limited	Biomarker	[1401]
MLF2	OTU3B4WU	Limited	Biomarker	[2009]
MLIP	OTMT7AII	Limited	Biomarker	[1798]
MLLT11	OTG5RVHC	Limited	Altered Expression	[2010]
MMS22L	OTJI0HM9	Limited	Biomarker	[2011]
MOSPD2	OTTN4NR7	Limited	Biomarker	[2012]
MRGPRX3	OTRKCCDS	Limited	Biomarker	[399]
MRGPRX4	OTOBHZVA	Limited	Biomarker	[399]
MRPL58	OTPTWLZY	Limited	Biomarker	[2013]
MSH6	OT46FP09	Limited	Autosomal dominant	[265]
MT1G	OTAV1OCR	Limited	Biomarker	[1233]
MT1M	OTVT8PLU	Limited	Biomarker	[1233]
MT1X	OT9AKFVS	Limited	Biomarker	[1233]
MTBP	OTWLCW9C	Limited	Altered Expression	[2014]
MTO1	OT7HCZ1D	Limited	Biomarker	[2015]
MTUS1	OTBPALMU	Limited	Biomarker	[2016]
MUSTN1	OTKO05K3	Limited	Genetic Variation	[1949]
MYH10	OTXN2WXS	Limited	Altered Expression	[2017]
MYO5A	OTMWLP3E	Limited	Biomarker	[2018]
MYOD1	OTV2S79X	Limited	Biomarker	[2019]
NAIP	OTLA925F	Limited	Altered Expression	[2020]
NCR3LG1	OT15YWU7	Limited	Biomarker	[2021]
NCS1	OT6JHAWM	Limited	Biomarker	[2022]
NDC80	OTS7D306	Limited	Biomarker	[2023]
NDST1	OT9E10W2	Limited	Altered Expression	[2024]
NECTIN1	OTTE5ZR6	Limited	Biomarker	[2025]
NEIL2	OTV6JEON	Limited	Genetic Variation	[2026]
NFAT5	OTKIE59S	Limited	Biomarker	[2027]
NFIL3	OTQH9HM3	Limited	Altered Expression	[2028]
NGB	OTW0SIUY	Limited	Altered Expression	[2029]
NKD1	OTY3MO97	Limited	Biomarker	[2030]
NKD2	OTCYT3I6	Limited	Biomarker	[2031]
NMI	OTYVG3NM	Limited	Biomarker	[441]
NMT1	OT42GQ3D	Limited	Altered Expression	[2032]
NR2F6	OTNVO2B6	Limited	Altered Expression	[2033]
NRARP	OTMYHUV2	Limited	Biomarker	[2034]
NRF1	OTOXWNV8	Limited	Biomarker	[2035]
NUCB2	OTHO6JWN	Limited	Altered Expression	[2036]
NUCKS1	OTL4VJC5	Limited	Altered Expression	[2037]
NUS1	OT4DQ82L	Limited	Altered Expression	[2038]
NXF1	OTEFHXG6	Limited	Biomarker	[2039]
OPN1LW	OTFNUZ7O	Limited	Biomarker	[917]
OXA1L	OTS0BFRD	Limited	Genetic Variation	[2040]
OXT	OT48M72Z	Limited	Biomarker	[2041]
P3H3	OTRC8QCM	Limited	Altered Expression	[2042]
PADI1	OT13WAQX	Limited	Biomarker	[2043]
PAG1	OTFOJUIQ	Limited	Biomarker	[917]
PARVA	OTLKEWRY	Limited	Biomarker	[2044]
PC	OT6O0V51	Limited	Altered Expression	[2045]
PCP4	OTM1XXYX	Limited	Altered Expression	[2046]
PDIA2	OTC2WMXS	Limited	Biomarker	[2043]
PDLIM2	OTEURRPD	Limited	Altered Expression	[2047]
PDLIM4	OT23LZYY	Limited	Biomarker	[2048]
PDLIM7	OTAZVODU	Limited	Genetic Variation	[2049]
PEBP4	OTKDCVC6	Limited	Biomarker	[2050]
PHLPP2	OTXB1OUI	Limited	Biomarker	[2051]
PI4K2A	OTL9L6MX	Limited	Biomarker	[2052]
PIAS3	OT3TWH9R	Limited	Biomarker	[2053]
PIH1D1	OTDKEDUA	Limited	Biomarker	[2054]
PIPOX	OTWTCOTN	Limited	Biomarker	[1935]
PLA2G10	OTRZ2L5A	Limited	Biomarker	[2055]
PLA2G15	OT6VJTPA	Limited	Biomarker	[1705]
PLA2G2D	OTU604XM	Limited	Biomarker	[2056]
PLAC8	OT3SYRUJ	Limited	Biomarker	[2057]
PLPP4	OTH5EXZC	Limited	Altered Expression	[2058]
PLS3	OTYBM4PK	Limited	Biomarker	[2059]
PMS2	OTNLWTMI	Limited	Autosomal dominant	[265]
PNPLA2	OTR3ERMR	Limited	Altered Expression	[2060]
POC1A	OTXAG4PL	Limited	Biomarker	[2061]
POLD3	OTEQEFQ2	Limited	Biomarker	[1881]
POTEE	OTSQ6J24	Limited	Biomarker	[1959]
PPBP	OT1FHGQS	Limited	Biomarker	[2062]
PPP1R12C	OT9Q86JO	Limited	Biomarker	[2063]
PPP1R13L	OTNCPLWE	Limited	Biomarker	[2064]
PPP1R15B	OTL5RWA8	Limited	Biomarker	[2065]
PRIM1	OTWWP8Y6	Limited	Altered Expression	[2066]
PRIMA1	OT9ITT3P	Limited	Biomarker	[2067]
PRKAG2	OTHTAM54	Limited	Genetic Variation	[2068]
PRM1	OT6HWA11	Limited	Altered Expression	[1946]
PROSER2	OT1SX3LS	Limited	Altered Expression	[1993]
PRPF38B	OTQLH551	Limited	Biomarker	[2069]
PTPN12	OT5WA666	Limited	Genetic Variation	[2070]
PTPN23	OT5WDPXB	Limited	Altered Expression	[2071]
PTPRK	OTAP5AT3	Limited	Altered Expression	[2072]
PTX3	OTPXHRKU	Limited	Biomarker	[2073]
PUF60	OTG90DYF	Limited	Altered Expression	[2074]
PUM2	OT2H7NXV	Limited	Biomarker	[1276]
RAB21	OTH3WGLG	Limited	Altered Expression	[2075]
RAB31	OTMLXQZ0	Limited	Genetic Variation	[2076]
RAD1	OT886MA8	Limited	Biomarker	[1963]
RAD21	OTQS84ZF	Limited	Biomarker	[2077]
RAD52	OT0OTDHI	Limited	Biomarker	[2078]
RAG2	OTG9UYTW	Limited	Biomarker	[2079]
RAI1	OTKLQU00	Limited	Genetic Variation	[2080]
RAI2	OTR8LX4J	Limited	Altered Expression	[2081]
RANBP9	OTM8COM5	Limited	Altered Expression	[2082]
RASAL1	OTAHUNN7	Limited	Autosomal dominant	[265]
RASD1	OT2BAJHK	Limited	Biomarker	[2083]
RASGRP3	OTEMEV3P	Limited	Biomarker	[2084]
RBMS3	OTFSC9MR	Limited	Altered Expression	[2085]
RCOR1	OTREADPC	Limited	Biomarker	[2086]
RECQL5	OTVZMP1Q	Limited	Autosomal dominant	[265]
RFX1	OTZUDMPR	Limited	Altered Expression	[2087]
RGCC	OTYJMLWM	Limited	Biomarker	[2088]
RGS11	OTIAZ36F	Limited	Biomarker	[1806]
RHBDF1	OTCQ7UDS	Limited	Biomarker	[1247]
RNF17	OTKOEPRW	Limited	Biomarker	[1911]
RNF8	OTRR43PZ	Limited	Biomarker	[2089]
ROBO3	OTPVG40S	Limited	Biomarker	[314]
ROPN1L	OTRWZJ68	Limited	Genetic Variation	[698]
ROS1	OTDSKUGE	Limited	Autosomal dominant	[265]
RPAP1	OTL31TWE	Limited	Genetic Variation	[2090]
RPL5	OTM8EBRI	Limited	Biomarker	[2091]
RPS27	OTFXKY7P	Limited	Altered Expression	[1069]
RPS6	OTT4D1LN	Limited	Biomarker	[2092]
RTCA	OTSJRVTD	Limited	Biomarker	[2093]
RTP4	OTPHXVTY	Limited	Altered Expression	[2094]
SARNP	OTE0OVK5	Limited	Altered Expression	[2095]
SARS1	OTFKXQ1O	Limited	Biomarker	[2096]
SARS2	OTU4T99W	Limited	Biomarker	[2096]
SASH1	OTQA8BD4	Limited	Biomarker	[2097]
SCN1B	OTGD78J3	Limited	Altered Expression	[2098]
SCNN1A	OTE2KVZV	Limited	Biomarker	[1968]
SDCBP	OTS3NCC5	Limited	Biomarker	[2099]
SEC62	OTCWEL5F	Limited	Altered Expression	[2100]
SEMA4A	OT8901H3	Limited	Biomarker	[2101]
SENP7	OTQJ05ZS	Limited	Genetic Variation	[2102]
SERPINB1	OT5RDUFO	Limited	Altered Expression	[2103]
SETDB1	OTWVUA1B	Limited	Biomarker	[2104]
SFTPC	OTIZJD09	Limited	Biomarker	[1975]
SGMS2	OT3NHO99	Limited	Altered Expression	[2105]
SGTA	OTKOJ3JB	Limited	Biomarker	[2106]
SHARPIN	OTU1J2KH	Limited	Biomarker	[2107]
SHC1	OT1J5IRN	Limited	Biomarker	[1254]
SHMT2	OT5NCAZN	Limited	Biomarker	[2108]
SIGLEC1	OTNWSQA9	Limited	Biomarker	[2109]
SIL1	OTDI85I5	Limited	Biomarker	[2110]
SLC16A4	OT1YXBKC	Limited	Biomarker	[1247]
SLC25A41	OTVFKZXV	Limited	Altered Expression	[1801]
SLC2A4RG	OTW3LX8D	Limited	Altered Expression	[2111]
SLC35G1	OTKZUA8O	Limited	Genetic Variation	[1883]
SLFN5	OTT1AESL	Limited	Altered Expression	[2112]
SLX4	OTF6236I	Limited	Biomarker	[2113]
SMARCAD1	OT90AZTX	Limited	Biomarker	[2114]
SMARCC1	OTUOMBE7	Limited	Biomarker	[2115]
SMIM10L2B	OT04IG2N	Limited	Biomarker	[2116]
SMR3B	OTL5HNM8	Limited	Altered Expression	[2117]
SND1	OTT734JN	Limited	Biomarker	[2118]
SOCS7	OT503VJG	Limited	Biomarker	[2119]
SOHLH2	OTB9EM6C	Limited	Biomarker	[2120]
SOS1	OTTCWXC3	Limited	Altered Expression	[2111]
SOX7	OTOZOFAG	Limited	Biomarker	[2121]
SOX8	OTEJXYZM	Limited	Altered Expression	[2122]
SPARCL1	OT74DWMV	Limited	Biomarker	[2123]
SPATA2	OTOA45GL	Limited	Altered Expression	[2124]
SPRR1A	OTJMI34A	Limited	Altered Expression	[2125]
SPRR2A	OT62ZU6B	Limited	Biomarker	[2126]
SRI	OT4R3EAC	Limited	Biomarker	[2127]
SRSF3	OTOFT707	Limited	Altered Expression	[2128]
SRSF6	OTGLOSYE	Limited	Biomarker	[2129]
SRY	OT516T6D	Limited	Biomarker	[1490]
ST7L	OT0I8XNI	Limited	Biomarker	[2130]
ST8SIA1	OTGND2YZ	Limited	Altered Expression	[2131]
STAT2	OTO9G2RZ	Limited	Biomarker	[2132]
STOML1	OTSIO2QA	Limited	Altered Expression	[1993]
SUMF1	OTALXO2A	Limited	Altered Expression	[2133]
SUN1	OTIU8V4U	Limited	Altered Expression	[2134]
SYCE1L	OTXU44F3	Limited	Biomarker	[645]
SYNJ2BP	OT2Q677P	Limited	Biomarker	[2135]
SYNPO2	OTC3U0YH	Limited	Genetic Variation	[588]
TACC2	OTW4M7HI	Limited	Biomarker	[2136]
TAF7L	OTPDZ6XV	Limited	Biomarker	[2137]
TANC2	OTDXY7PX	Limited	Biomarker	[2138]
TAP2	OTWSYFI7	Limited	Altered Expression	[2139]
TAS2R38	OTX5MM36	Limited	Biomarker	[335]
TBX1	OTQLBPRA	Limited	Biomarker	[2140]
TDRD10	OT5WIRLE	Limited	Biomarker	[2141]
TENM2	OTPLUYEF	Limited	Altered Expression	[2142]
TENM4	OT91K3FC	Limited	Altered Expression	[2142]
TES	OTL8PP6V	Limited	Biomarker	[809]
TET3	OT76U3YF	Limited	Altered Expression	[2143]
TFDP3	OTI4K6MN	Limited	Biomarker	[2144]
THEMIS2	OTI1OBLN	Limited	Biomarker	[2145]
THOC1	OTVABJ4Z	Limited	Biomarker	[2146]
THY1	OTVONVTB	Limited	Biomarker	[2147]
TINAGL1	OTZZO56M	Limited	Biomarker	[2148]
TM6SF1	OTQR4I2N	Limited	Biomarker	[2149]
TMED3	OTNOPHHC	Limited	Biomarker	[2150]
TMEM126A	OTLP76WE	Limited	Altered Expression	[2151]
TMEM132C	OT3297S6	Limited	Biomarker	[2141]
TMEM43	OTM9RS9G	Limited	Biomarker	[2152]
TMEM54	OTPQEFR0	Limited	Biomarker	[2153]
TMPRSS7	OTW938I4	Limited	Genetic Variation	[2154]
TMX1	OTX4FHYQ	Limited	Biomarker	[2155]
TMX2	OTM9O21K	Limited	Biomarker	[2156]
TNFAIP8	OT1G9297	Limited	Altered Expression	[2157]
TNFAIP8L2	OTII0RM0	Limited	Biomarker	[2158]
TNP1	OTKQH7E5	Limited	Biomarker	[2159]
TNRC6A	OT493IOM	Limited	Biomarker	[2160]
TP53I11	OTFPDYZU	Limited	Biomarker	[2161]
TP53INP1	OT2363Z9	Limited	Altered Expression	[2162]
TPD52L2	OTTOG0NK	Limited	Biomarker	[2163]
TRAF1	OTTLM5RU	Limited	Biomarker	[2164]
TRAF7	OTW8Q5TF	Limited	Biomarker	[2165]
TRAP1	OTNG0L8J	Limited	Biomarker	[2166]
TRAPPC9	OTF0CVMC	Limited	Altered Expression	[1882]
TRIM21	OTA4UJCF	Limited	Genetic Variation	[2167]
TRIM25	OT35SG1R	Limited	Altered Expression	[2168]
TRIM33	OT0KS4J7	Limited	Altered Expression	[2169]
TRIM56	OTFGU8E3	Limited	Altered Expression	[2170]
TRIP4	OTA8OASA	Limited	Biomarker	[1659]
TRMT11	OTRK0IOR	Limited	Biomarker	[1015]
ACYP2	OTRB4S6X	Disputed	Genetic Variation	[2171]
ADAMTS9	OTV3Q0DS	Disputed	Posttranslational Modification	[2172]
AP2B1	OTL6LZJ4	Disputed	Biomarker	[2173]
APIP	OT8ZABOU	Disputed	Biomarker	[500]
ARHGAP31	OTUYTF4I	Disputed	Biomarker	[2174]
ATG4D	OTSWUO4R	Disputed	Altered Expression	[2175]
BLM	OTEJOAJX	Disputed	Autosomal dominant	[265]
CCL16	OTOOQI1F	Disputed	Biomarker	[2176]
CDK15	OT8S67QS	Disputed	Altered Expression	[495]
CDK16	OTUBXIIT	Disputed	Altered Expression	[495]
CILK1	OTWOYEYP	Disputed	Altered Expression	[495]
CLTC	OTBFASMA	Disputed	Biomarker	[500]
COL15A1	OTTFKK18	Disputed	Altered Expression	[2177]
CREM	OTJIJ5AL	Disputed	Biomarker	[500]
DNAH8	OTGES2OU	Disputed	Altered Expression	[2178]
FAM133B	OTQH2A95	Disputed	Biomarker	[500]
FANCM	OTNJG99Z	Disputed	Autosomal dominant	[265]
FH	OTEQWU6Q	Disputed	Biomarker	[501]
LPXN	OTUNV3CK	Disputed	Altered Expression	[2179]
MAGEH1	OTVE05K7	Disputed	Altered Expression	[2177]
MAP1LC3C	OTM4ECDK	Disputed	Biomarker	[2175]
MEPE	OTXJRUW0	Disputed	Genetic Variation	[2180]
MINDY4	OTBZ2SZB	Disputed	Altered Expression	[693]
MLH1	OTG5XDD8	Disputed	Autosomal dominant	[265]
MORC2	OT52A8BJ	Disputed	Altered Expression	[2181]
MSH2	OT10H1AB	Disputed	Autosomal dominant	[265]
NEFH	OTMSCW5I	Disputed	Biomarker	[2182]
NEFM	OT8VCBNF	Disputed	Biomarker	[2182]
NOP14	OTKPM0Z5	Disputed	Biomarker	[2183]
PIBF1	OTCBT1A1	Disputed	Genetic Variation	[2184]
PRKACG	OTKOQYF8	Disputed	Altered Expression	[495]
PTBP3	OTVVYKIF	Disputed	Altered Expression	[2185]
RBFOX2	OTXY1WVH	Disputed	Genetic Variation	[2186]
RECQL	OTPCH3JH	Disputed	Autosomal dominant	[265]
RFC3	OT1MS7AO	Disputed	Biomarker	[2187]
RINT1	OTMO19ZD	Disputed	Autosomal dominant	[265]
RTN1	OTCX1SMK	Disputed	Biomarker	[499]
SPECC1	OTPEML48	Disputed	Biomarker	[499]
TADA3	OTNUAIO9	Disputed	Altered Expression	[2188]
TFAP2B	OTR1T8E9	Disputed	Biomarker	[2173]
TLK1	OTICTXI8	Disputed	Altered Expression	[495]
TMEM88	OTA96YEL	Disputed	Altered Expression	[2189]
ABI2	OT8GIIS5	moderate	Genetic Variation	[519]
ACP1	OTJ9CKLU	moderate	Altered Expression	[2190]
ACSM3	OT0AE1IV	moderate	Biomarker	[2191]
ACTL8	OTUDD0QT	moderate	Biomarker	[2192]
ACTN4	OTCNZAJ5	moderate	Altered Expression	[2193]
ACTRT1	OTHFKSIZ	moderate	Genetic Variation	[519]
ADAM11	OTPTVW5W	moderate	Biomarker	[2194]
ADAM15	OTZ7VLTP	moderate	Altered Expression	[2195]
ADCY4	OTHBLJA7	moderate	Biomarker	[2196]
AFDN	OTTRU341	moderate	Biomarker	[1856]
AKAP3	OT42QOFG	moderate	Biomarker	[2197]
AMBP	OTLU8GU8	moderate	Biomarker	[2198]
AMELX	OTIN26MM	moderate	Altered Expression	[2199]
ANGPTL2	OTB6JG41	moderate	Biomarker	[274]
ANKRD11	OTV0V70M	moderate	Biomarker	[2200]
ANLN	OTXJY54C	moderate	Altered Expression	[2201]
APAF1	OTJWIVY0	moderate	Altered Expression	[2202]
APBB1	OTZPVSSC	moderate	Biomarker	[2203]
AQP5	OT77GBY8	moderate	Biomarker	[511]
ARF4	OT3GMDHA	moderate	Biomarker	[2204]
ARHGEF7	OT9BPJCL	moderate	Altered Expression	[2205]
ARID4B	OTYLPILE	moderate	Biomarker	[2206]
ARL13B	OT9PYPV1	moderate	Biomarker	[2207]
ARL6IP1	OT536XAV	moderate	Genetic Variation	[519]
ARNT	OTMSIEZY	moderate	Altered Expression	[2208]
ARPP21	OTWXZN5I	moderate	Biomarker	[2209]
ARSF	OTC0L12N	moderate	Biomarker	[2210]
ARSI	OTIANNWW	moderate	Genetic Variation	[2211]
ASAP1	OT4DLRYY	moderate	Biomarker	[2212]
ASXL1	OTX931AW	moderate	Genetic Variation	[2213]
ASXL2	OTNG4E2M	moderate	Biomarker	[2214]
ASXL3	OTNDJWEZ	moderate	Biomarker	[2213]
ATAD3B	OTL508AF	moderate	Biomarker	[2215]
ATG12	OTJRO09Y	moderate	Altered Expression	[2216]
ATG4A	OTDHXAPG	moderate	Biomarker	[2217]
ATP1B1	OTTO6ZP4	moderate	Biomarker	[2218]
ATP8	OTYQQR53	moderate	Biomarker	[2219]
B4GALT1	OTBCXEK7	moderate	Altered Expression	[2220]
BCL9L	OTTWI90E	moderate	Biomarker	[2221]
BDH1	OT62RL5P	moderate	Altered Expression	[574]
BID	OTOSHSHU	moderate	Biomarker	[2222]
BMP5	OTC0Y6E0	moderate	Biomarker	[2223]
BRI3BP	OTWCFPRM	moderate	Biomarker	[2224]
BRWD3	OT3BM9B0	moderate	Altered Expression	[2225]
BTRC	OT2EZDGR	moderate	Genetic Variation	[2226]
C4orf3	OT6TFN1O	moderate	Altered Expression	[2227]
CALM2	OTNYA92F	moderate	Biomarker	[2228]
CAMK1	OTRN55RE	moderate	Biomarker	[2229]
CAMK2B	OTS9YK3E	moderate	Altered Expression	[2230]
CANX	OTYP1F6J	moderate	Altered Expression	[2231]
CAPNS1	OT95EBBD	moderate	Altered Expression	[2232]
CAVIN2	OTFHHDRU	moderate	Altered Expression	[2233]
CAVIN3	OTOLBK79	moderate	Altered Expression	[2234]
CBX1	OT2L4XZX	moderate	Biomarker	[2235]
CBX6	OTO1I9W0	moderate	Biomarker	[2236]
CCL8	OTCTWYN8	moderate	Biomarker	[2237]
CCN4	OT69BER9	moderate	Biomarker	[2238]
CCNJ	OTCR4WVV	moderate	Biomarker	[2239]
CCT2	OTW1VV4E	moderate	Biomarker	[1302]
CD200R1	OT65Q9M6	moderate	Biomarker	[2240]
CDC42BPB	OTO6NT7Q	moderate	Altered Expression	[526]
CDH23	OTOJGQ7S	moderate	Altered Expression	[2241]
CDK2AP2	OTR99SJ8	moderate	Genetic Variation	[1416]
CEMIP	OTK80FYN	moderate	Biomarker	[2242]
CENPA	OT0NEJ4X	moderate	Altered Expression	[2243]
CERS6	OTOP4GV1	moderate	Altered Expression	[2244]
CFHR1	OT72R16T	moderate	Biomarker	[2245]
CHPT1	OT4FJ0K3	moderate	Biomarker	[2246]
CKAP2	OTCLTC0J	moderate	Altered Expression	[2247]
CLCA4	OTCRR1M9	moderate	Altered Expression	[2248]
CLIP2	OTSCIQIY	moderate	Biomarker	[2249]
CNTROB	OTR7C7NR	moderate	Genetic Variation	[2250]
COL12A1	OTHLTV53	moderate	Altered Expression	[2251]
CPSF7	OT4WE5J7	moderate	Altered Expression	[2251]
CRABP2	OTY01V9G	moderate	Biomarker	[2252]
CSHL1	OTQKU2F5	moderate	Biomarker	[619]
CTHRC1	OTV88X2G	moderate	Altered Expression	[2253]
CTR9	OTP151PZ	moderate	Biomarker	[2254]
CYP2U1	OT6RXLXS	moderate	Biomarker	[2255]
DAAM1	OT0VHIYZ	moderate	Altered Expression	[2256]
DAB2IP	OTF456VC	moderate	Genetic Variation	[519]
DCAF6	OT3EYK1J	moderate	Altered Expression	[2257]
DDIAS	OTTGG2PM	moderate	Biomarker	[2258]
DGCR8	OT62LXE4	moderate	Genetic Variation	[2259]
DLGAP1	OTF2PUUI	moderate	Biomarker	[2260]
DNALI1	OTTB3L8N	moderate	Altered Expression	[2261]
DOK6	OTX55OIF	moderate	Biomarker	[2262]
DRAM1	OTIJTXEN	moderate	Genetic Variation	[2263]
DROSHA	OTCE68KZ	moderate	Genetic Variation	[2264]
DZIP1	OTBVPO66	moderate	Biomarker	[2265]
EBAG9	OTTQLQCP	moderate	Biomarker	[2266]
ECHS1	OTS0593S	moderate	Altered Expression	[2267]
ECM1	OT1K65VW	moderate	Biomarker	[2268]
EEF1E1	OTRA6XOB	moderate	Biomarker	[515]
EIF4E3	OTTWVS2R	moderate	Altered Expression	[2269]
ENY2	OTTNU8RK	moderate	Biomarker	[2270]
EPHA10	OT1XJGFG	moderate	Biomarker	[2271]
FAM107B	OT5RG4J0	moderate	Biomarker	[2249]
FAM171A1	OT33BHEP	moderate	Biomarker	[2272]
FAM83A	OTBI16V7	moderate	Altered Expression	[2273]
FANCL	OTJC7QPQ	moderate	Genetic Variation	[2274]
FBLN2	OTEHR7N7	moderate	Altered Expression	[2275]
FBP1	OTQBANEP	moderate	Altered Expression	[2276]
FBRS	OTUVH446	moderate	Biomarker	[2277]
FBXL17	OT8R6KYN	moderate	Biomarker	[2278]
FBXO10	OTAGWV4B	moderate	Genetic Variation	[2279]
FGF9	OT2SKDGM	moderate	Biomarker	[2280]
FOXE1	OT5IR5IT	moderate	Biomarker	[2281]
FOXG1	OTAW57J4	moderate	Altered Expression	[2282]
FOXN2	OTBPLTCM	moderate	Biomarker	[2283]
FZD1	OTZATHVS	moderate	Altered Expression	[2284]
GABARAP	OTAQUX6E	moderate	Altered Expression	[2285]
GABARAPL1	OT4U7SBG	moderate	Biomarker	[2286]
GALNT6	OTOQQVH1	moderate	Altered Expression	[2287]
GATA2	OTBP2QQ2	moderate	Altered Expression	[2288]
GDPD5	OTUM65JL	moderate	Altered Expression	[2289]
GEMIN4	OTX7402E	moderate	Genetic Variation	[2259]
GFRA1	OT3WBVYB	moderate	Biomarker	[2290]
GINS2	OT974IYI	moderate	Altered Expression	[2291]
GLS2	OT08MSHL	moderate	Altered Expression	[2292]
GOLGA2	OT5S9KYM	moderate	Biomarker	[2293]
GOSR1	OTX8TMVU	moderate	Altered Expression	[2261]
GPN3	OTZ4584O	moderate	Biomarker	[2294]
GPRC5A	OTPOCWR7	moderate	Biomarker	[2295]
HACE1	OTEZULKD	moderate	Biomarker	[2296]
HAP1	OT6SG0JQ	moderate	Biomarker	[2297]
HLA-C	OTV38BUJ	moderate	Genetic Variation	[2298]
HLA-DOA	OTZE5Q7R	moderate	Genetic Variation	[2299]
HNRNPDL	OTB3BFCV	moderate	Altered Expression	[2300]
HOXA10	OTB6GQ09	moderate	Genetic Variation	[2301]
HOXB1	OTGC0EKI	moderate	Biomarker	[2302]
HOXD1	OTN4V9ZF	moderate	Biomarker	[2303]
HTRA4	OT58M21J	moderate	Biomarker	[2304]
HVCN1	OT4ALYU4	moderate	Altered Expression	[2305]
HYAL1	OT2SJN0X	moderate	Biomarker	[2306]
HYLS1	OT3SW5UC	moderate	Genetic Variation	[2307]
IARS1	OT9WXH5N	moderate	Biomarker	[2308]
IFNE	OTXO5MHZ	moderate	Biomarker	[2309]
IFNGR1	OTCTQBWW	moderate	Biomarker	[2310]
IGF2BP3	OTB97VIK	moderate	Biomarker	[2244]
INPPL1	OTCDAVBQ	moderate	Altered Expression	[2311]
IQCC	OTVNC81X	moderate	Biomarker	[2312]
ITM2A	OT590V63	moderate	Biomarker	[2313]
ITSN1	OT8YF3S5	moderate	Biomarker	[2314]
KBTBD11	OTBOY3WH	moderate	Biomarker	[2315]
KDM2B	OTDMCVW7	moderate	Altered Expression	[2316]
KIF1B	OTI1XQTO	moderate	Biomarker	[2317]
KIFC1	OTNQDS00	moderate	Altered Expression	[2318]
KRT13	OTTYSKGX	moderate	Altered Expression	[2319]
KRT2	OTG2EZEN	moderate	Altered Expression	[2320]
L3MBTL1	OT8M52QY	moderate	Altered Expression	[2321]
LAMTOR1	OTIBJBW9	moderate	Biomarker	[515]
LETMD1	OTZTZ4RD	moderate	Biomarker	[2224]
LIMS1	OT729S0T	moderate	Biomarker	[2322]
LMNB1	OT100T3P	moderate	Biomarker	[2323]
LOXL3	OTLLY1QI	moderate	Altered Expression	[2324]
LRIG1	OTY5HZN5	moderate	Altered Expression	[2325]
LRMDA	OTIPNKTU	moderate	Genetic Variation	[2326]
LRP1B	OT4YZG2N	moderate	Altered Expression	[2327]
LRRC26	OTXEFL76	moderate	Biomarker	[2328]
LTBP4	OTC8WL2V	moderate	Altered Expression	[2329]
LYPD5	OTGP7UKA	moderate	Biomarker	[2330]
MAD2L2	OT24ZO59	moderate	Biomarker	[2331]
MAFK	OTZJUE4P	moderate	Biomarker	[515]
MAGEF1	OTUU40U3	moderate	Biomarker	[1804]
MAGI2	OTXDDKZS	moderate	Genetic Variation	[519]
MAML1	OTQA4DDN	moderate	Altered Expression	[2332]
MAP1LC3B	OTUYHB84	moderate	Biomarker	[2333]
MAP3K7CL	OT9J7RLC	moderate	Genetic Variation	[2334]
MARCHF5	OTBK6BBM	moderate	Biomarker	[2335]
MAVS	OTTQ0J64	moderate	Biomarker	[2336]
MCM3AP	OT895FEC	moderate	Genetic Variation	[2337]
MDC1	OTEUQH4J	moderate	Biomarker	[1274]
MEGF9	OTDQWTY4	moderate	Biomarker	[2239]
MICAL3	OTD229X7	moderate	Biomarker	[2338]
MICB	OTS2DVDW	moderate	Biomarker	[2339]
MICU1	OTS7N0LE	moderate	Altered Expression	[2340]
MIEN1	OTCQ8DAD	moderate	Biomarker	[2341]
MORC4	OTJBEHNE	moderate	Altered Expression	[2342]
MPRIP	OT5FV5NS	moderate	Altered Expression	[2343]
MR1	OTZU3XX7	moderate	Altered Expression	[2344]
MRPL41	OTG5URO4	moderate	Altered Expression	[2345]
MUC4	OTLT11V1	moderate	Biomarker	[2346]
MUC5B	OTPW6K5C	moderate	Biomarker	[2347]
MXD1	OTS5CTHX	moderate	Altered Expression	[2348]
MYO1D	OTP2RGPN	moderate	Biomarker	[2349]
MYOCD	OTSJNHTH	moderate	Biomarker	[2350]
NAP1L1	OTI7WBZV	moderate	Biomarker	[2351]
ND2	OTG9OHOX	moderate	Genetic Variation	[2352]
NDN	OTYBYJ82	moderate	Altered Expression	[2353]
NECTIN3	OTS8N7MK	moderate	Altered Expression	[2354]
NEK3	OTKWD5FY	moderate	Altered Expression	[2355]
NEK5	OTHDXCYZ	moderate	Biomarker	[762]
NEO1	OTGJ1997	moderate	Biomarker	[2356]
NEUROD1	OTZQ7QJ2	moderate	Altered Expression	[2357]
NGDN	OTBXTCN5	moderate	Altered Expression	[2358]
NINL	OTWIK6HT	moderate	Biomarker	[2359]
NLK	OT2LETFS	moderate	Altered Expression	[2360]
NMU	OTW9X7BQ	moderate	Biomarker	[1259]
NOB1	OTW0YNSL	moderate	Biomarker	[2361]
NOC2L	OTNT7R33	moderate	Biomarker	[2362]
NONO	OTN36Q6U	moderate	Biomarker	[2363]
NOS1AP	OTDFOBRU	moderate	Biomarker	[641]
NPNT	OTFZAO1G	moderate	Altered Expression	[2364]
NRSN1	OT1KKXC8	moderate	Biomarker	[2365]
NRXN3	OTJ0I7HJ	moderate	Genetic Variation	[2366]
NSD3	OT3677ZG	moderate	Biomarker	[2367]
NUMB	OTMB586Q	moderate	Altered Expression	[2368]
ODAM	OTT666SJ	moderate	Biomarker	[2369]
OGA	OT7ZBWT1	moderate	Biomarker	[2370]
OPTN	OT2UXWH9	moderate	Biomarker	[2351]
OR2AG1	OTEITRP4	moderate	Biomarker	[2371]
ORMDL3	OTAB7MZF	moderate	Genetic Variation	[2372]
OTP	OTS0JN6Y	moderate	Posttranslational Modification	[2373]
PA2G4	OT7IG7HT	moderate	Biomarker	[2374]
PAK5	OT32WQGL	moderate	Biomarker	[894]
PAQR3	OTTKJ9Y4	moderate	Posttranslational Modification	[2375]
PBLD	OTI3A8RS	moderate	Biomarker	[2376]
PCLAF	OTMVIOUU	moderate	Biomarker	[2377]
PCSK1N	OT7ZRW2F	moderate	Biomarker	[2378]
PDC	OT1UUVYY	moderate	Biomarker	[2379]
PDCD5	OT6T2DDL	moderate	Biomarker	[2380]
PDLIM1	OT4EGCPG	moderate	Biomarker	[2381]
PDS5B	OT3U3X8Z	moderate	Altered Expression	[2382]
PENK	OT8P3HMP	moderate	Biomarker	[2383]
PINK1	OT50NR57	moderate	Genetic Variation	[2384]
PIR	OT8ALXHU	moderate	Biomarker	[2385]
PLAAT4	OTI66SAJ	moderate	Biomarker	[314]
PLCG2	OTGVC9MY	moderate	Genetic Variation	[2386]
PLEK	OTB73XXA	moderate	Biomarker	[2387]
PMP22	OTXWYWCZ	moderate	Biomarker	[2388]
PPP1R1A	OTGTAGCV	moderate	Biomarker	[2389]
PPP1R7	OTY5IE69	moderate	Biomarker	[2390]
PPP2R2A	OT9297OG	moderate	Altered Expression	[2391]
PPP4C	OT4B0TNV	moderate	Biomarker	[2392]
PRDM14	OTWZKY4L	moderate	Biomarker	[2393]
PRDM2	OT8L7CGX	moderate	Posttranslational Modification	[2394]
PREX2	OTYT1J6J	moderate	Biomarker	[2395]
PRMT2	OT63JZCI	moderate	Biomarker	[2396]
PRPF4	OTK0XRQN	moderate	Altered Expression	[2397]
PRRX2	OT8UR4AU	moderate	Biomarker	[2398]
PRSS23	OT6DQAM1	moderate	Biomarker	[2399]
PSD4	OTEFB87Z	moderate	Biomarker	[2400]
PSMC3	OTSKT0JI	moderate	Biomarker	[2401]
PTPRA	OTZA82J1	moderate	Biomarker	[497]
PTPRM	OTCEL6PN	moderate	Biomarker	[2402]
PTPRO	OTFLKWOY	moderate	Biomarker	[2403]
PUM3	OTN1IPNS	moderate	Biomarker	[2378]
PYCR1	OTQHB52T	moderate	Biomarker	[2404]
PYGB	OT2ZTJT0	moderate	Biomarker	[2405]
QSOX1	OT4ZPK4P	moderate	Biomarker	[2406]
RAB1B	OTAFCUAS	moderate	Altered Expression	[2407]
RAB2A	OT6SK83U	moderate	Biomarker	[2408]
RASGRF1	OTNWJ7EN	moderate	Altered Expression	[2111]
RBM10	OTES2MES	moderate	Biomarker	[2409]
RCAN3	OTTS3CQA	moderate	Altered Expression	[2410]
RCHY1	OTAE7504	moderate	Altered Expression	[2411]
RECQL4	OT59LSW7	moderate	Genetic Variation	[2412]
REV1	OTHIKICX	moderate	Biomarker	[947]
REV3L	OT0OP8EJ	moderate	Altered Expression	[2413]
RFTN1	OT8875JE	moderate	Altered Expression	[2414]
RHOC	OTOLE1FT	moderate	Altered Expression	[2415]
RHOXF1	OT3SC14T	moderate	Altered Expression	[2416]
RILPL2	OTL2KPRO	moderate	Biomarker	[2417]
RMDN3	OTKO7AUM	moderate	Biomarker	[2418]
RNF144A	OTCG27CT	moderate	Biomarker	[2419]
ROM1	OTE7H0YV	moderate	Biomarker	[2420]
RPP14	OT4OYFSK	moderate	Genetic Variation	[1416]
RPTOR	OT4TQZ9F	moderate	Biomarker	[2421]
RRS1	OTTNCZN6	moderate	Altered Expression	[2422]
RSU1	OTO5GHT1	moderate	Biomarker	[2423]
RUNX1T1	OT30DED5	moderate	Genetic Variation	[1717]
RUSC1	OTYB8ZMT	moderate	Biomarker	[2424]
S100A16	OT3ERKQI	moderate	Genetic Variation	[2425]
SALL4	OTC08PR5	moderate	Biomarker	[2426]
SCAI	OTAK3TMO	moderate	Biomarker	[2427]
SDF4	OTQ7WFYW	moderate	Genetic Variation	[2428]
SEC14L2	OTJST64D	moderate	Biomarker	[2039]
SELENOF	OT2JFB3S	moderate	Genetic Variation	[2429]
SELENON	OTSGKO5M	moderate	Genetic Variation	[2430]
SELENOS	OTUEWIU9	moderate	Genetic Variation	[2430]
SEMA6B	OT3VVVUO	moderate	Altered Expression	[2431]
SENP2	OTPQJXIR	moderate	Genetic Variation	[2102]
SEPTIN4	OTD16B30	moderate	Biomarker	[2432]
SF3B6	OTPRKS6S	moderate	Genetic Variation	[1416]
SFR1	OTSRFFUV	moderate	Biomarker	[2433]
SIN3A	OTM8OZWV	moderate	Genetic Variation	[2434]
SIN3B	OTFB59FK	moderate	Altered Expression	[2435]
SIRT7	OT5M4OT4	moderate	Biomarker	[2436]
SKA3	OTLHEVJD	moderate	Biomarker	[2437]
SLC25A52	OT5DI4DL	moderate	Genetic Variation	[1678]
SMARCA1	OT0Y6PTU	moderate	Biomarker	[2438]
SMARCA5	OT5GR4Z2	moderate	Altered Expression	[2439]
SMC4	OTEJE6AG	moderate	Biomarker	[2328]
SMG1	OTTS3SXE	moderate	Biomarker	[543]
SMN2	OT54RLO1	moderate	Altered Expression	[2440]
SMPX	OTLSHGBF	moderate	Biomarker	[619]
SMURF1	OT5UIZR8	moderate	Altered Expression	[2441]
SNRPD1	OTWKZV4E	moderate	Biomarker	[2442]
SNW1	OTKWG3PS	moderate	Biomarker	[2443]
SPACA9	OTVRFX49	moderate	Genetic Variation	[2444]
SPAG9	OT45AHMB	moderate	Altered Expression	[2445]
SPC25	OTCAS0OH	moderate	Biomarker	[2446]
SPG21	OTMKJSYS	moderate	Genetic Variation	[2444]
SRXN1	OTYDBO4L	moderate	Genetic Variation	[2447]
SYN1	OTMNPWC1	moderate	Biomarker	[2448]
SYNPO	OTICDJAB	moderate	Biomarker	[2449]
TACC1	OTGX20TE	moderate	Biomarker	[2450]
TBATA	OTGDMAAL	moderate	Biomarker	[2451]
TDRD9	OTS4UBI8	moderate	Genetic Variation	[2307]
TFAM	OTXXV5V7	moderate	Biomarker	[2035]
TFF2	OTRXB19X	moderate	Biomarker	[2452]
THBS4	OTA1T9KK	moderate	Altered Expression	[2453]
THRSP	OTKYE01L	moderate	Altered Expression	[2454]
THSD7A	OT7249HH	moderate	Altered Expression	[2455]
TMED5	OT70W1J8	moderate	Altered Expression	[2261]
TMEM132E	OTHCX3RI	moderate	Genetic Variation	[1678]
TMEM45A	OT54KJG6	moderate	Altered Expression	[2456]
TMOD4	OTXLGJ4R	moderate	Biomarker	[2457]
TMPO	OTL68EL4	moderate	Biomarker	[2458]
TNFRSF10D	OTOSRDJT	moderate	Biomarker	[2459]
TNFSF9	OTV9L89D	moderate	Biomarker	[492]
TNS3	OTPG2D8Z	moderate	Biomarker	[2460]
TPPP2	OTI3WA6X	moderate	Biomarker	[515]
TRDMT1	OTAYQ8ZF	moderate	Genetic Variation	[539]
TRIM14	OTLQKUG0	moderate	Altered Expression	[2461]
TRIM16	OTLRXYOZ	moderate	Biomarker	[2462]
TRIM22	OTJBLG5R	moderate	Altered Expression	[2463]
TRIM63	OTUSWA74	moderate	Biomarker	[2464]
TRO	OTRZQMU8	moderate	Biomarker	[1804]
TSPAN33	OTH6C0WU	moderate	Biomarker	[2378]
A1CF	OTJBKFA1	Strong	Altered Expression	[2465]
A2ML1	OTWNUXIS	Strong	Altered Expression	[2466]
AADAC	OT8VACT2	Strong	Posttranslational Modification	[2467]
AANAT	OTUBJ7SX	Strong	Genetic Variation	[1234]
ABCB10	OT1C44F9	Strong	Biomarker	[2468]
ABCC12	OTYB58S2	Strong	Altered Expression	[2469]
ABCE1	OTH19LOA	Strong	Biomarker	[2470]
ABHD14B	OTFIYC6Y	Strong	Biomarker	[1464]
ABHD8	OT736H1Q	Strong	Genetic Variation	[743]
ABI1	OT5H4M62	Strong	Altered Expression	[2471]
ABR	OTZQK8JF	Strong	Biomarker	[2472]
ACACA	OT5CQPZY	Strong	Biomarker	[1273]
ACAD8	OT3JI5GB	Strong	Genetic Variation	[2473]
ACADM	OTA4P0FC	Strong	Altered Expression	[2474]
ACADSB	OTDO6HBG	Strong	Genetic Variation	[2475]
ACAT2	OTZ092ZJ	Strong	Altered Expression	[2476]
ACBD3	OTMYNY7A	Strong	Biomarker	[2477]
ACCS	OTHIHI9D	Strong	Biomarker	[1705]
ACKR2	OTWYY14H	Strong	Biomarker	[2478]
ACKR4	OTZPWT2N	Strong	Genetic Variation	[2479]
ACOT7	OT7C68YV	Strong	Genetic Variation	[651]
ACSBG1	OTM040MW	Strong	Altered Expression	[2480]
ACSL5	OT3L9XO3	Strong	Biomarker	[2481]
ACTA1	OTOVGLPG	Strong	Altered Expression	[2482]
ACTA2	OTEDLG8E	Strong	Biomarker	[2483]
ACTB	OT1MCP2F	Strong	Biomarker	[2484]
ACTBL2	OTD6B81U	Strong	Genetic Variation	[651]
ACTC1	OTJU04B1	Strong	Biomarker	[2485]
ACTG2	OTRDWUO0	Strong	Genetic Variation	[651]
ACTR1B	OTGBCKLO	Strong	Biomarker	[1300]
ACTR2	OT3C8U5T	Strong	Biomarker	[274]
ACVR1C	OTOTYERF	Strong	Biomarker	[2486]
ADAM12	OTZKOTDB	Strong	Altered Expression	[2487]
ADAM29	OTGLTTKU	Strong	Biomarker	[2488]
ADAMTS17	OTCFITM9	Strong	Biomarker	[2489]
ADAMTS18	OTRMFI04	Strong	Biomarker	[2490]
ADAMTS2	OTTK22NO	Strong	Biomarker	[2491]
ADAMTS3	OT2U6VF5	Strong	Biomarker	[659]
ADAMTS6	OTSZE6L4	Strong	Biomarker	[2492]
ADAMTS8	OT2KFY1S	Strong	Biomarker	[2493]
ADAR	OTQNOHR8	Strong	Biomarker	[2494]
ADARB1	OTGKSZEV	Strong	Altered Expression	[2495]
ADGRE5	OTTSB84Q	Strong	Biomarker	[1793]
ADGRL2	OTCXD2YR	Strong	Altered Expression	[2496]
ADIPOR1	OT65ZFZN	Strong	Biomarker	[2497]
ADIPOR2	OT2HDTL8	Strong	Biomarker	[2498]
ADPRS	OTI1KPN6	Strong	Biomarker	[2499]
ADRM1	OTOU4EY6	Strong	Altered Expression	[2500]
AEBP1	OTBI1RZ6	Strong	Biomarker	[2501]
AFAP1	OTR473H8	Strong	Biomarker	[2502]
AFF3	OTR0705Z	Strong	Altered Expression	[2503]
AFM	OTPOR8IO	Strong	Biomarker	[2504]
AGFG1	OTI8ZKC4	Strong	Biomarker	[2505]
AGO3	OTNQGROH	Strong	Biomarker	[2506]
AGO4	OTKXQD70	Strong	Biomarker	[2506]
AHNAK	OT6KH1WG	Strong	Biomarker	[2507]
AHRR	OTSJ12W6	Strong	Altered Expression	[2508]
AHSA1	OTC7AFHT	Strong	Altered Expression	[370]
AIFM1	OTKPWB7Q	Strong	Altered Expression	[2509]
AIFM3	OTSWKCAO	Strong	Altered Expression	[2510]
AIM2	OT86QUI8	Strong	Biomarker	[1542]
AIRE	OTA7G1Y1	Strong	Altered Expression	[2511]
AK4	OTA0T02Q	Strong	Biomarker	[2512]
AKAP1	OTIIB2JB	Strong	Altered Expression	[2513]
AKAP10	OTPNFTOU	Strong	Genetic Variation	[2514]
AKAP12	OTCVRDDX	Strong	Altered Expression	[2515]
AKAP13	OTOZAR14	Strong	Biomarker	[2516]
AKAP8	OTK3EQAI	Strong	Biomarker	[1307]
AKAP9	OT7Z2YRP	Strong	Biomarker	[453]
AKIP1	OT7XPG27	Strong	Biomarker	[2517]
AKT1S1	OT4JHN4Y	Strong	Posttranslational Modification	[2518]
ALDH1A3	OT1C9NKQ	Strong	Altered Expression	[1156]
ALDOA	OTWRFTIB	Strong	Biomarker	[817]
ALG2	OT77B384	Strong	Biomarker	[2519]
ALG3	OTPOL1QW	Strong	Biomarker	[2520]
ALKBH2	OTSQW0BG	Strong	Posttranslational Modification	[2521]
ALKBH3	OTS1CD9Z	Strong	Biomarker	[2521]
ALKBH8	OTXN70DV	Strong	Biomarker	[2522]
ALPK1	OTBW6SGD	Strong	Biomarker	[2523]
ALX1	OTZVARA5	Strong	Biomarker	[2524]
ALX3	OTXZ25PZ	Strong	Biomarker	[2525]
ALX4	OTNS9A29	Strong	Posttranslational Modification	[2526]
AMBRA1	OTY0YGT9	Strong	Biomarker	[2527]
AMFR	OTQRX7LC	Strong	Biomarker	[2528]
AMH	OT5FH4BD	Strong	Altered Expression	[2529]
AMIGO2	OTPAIT1O	Strong	Altered Expression	[2530]
AMOTL1	OT40G45S	Strong	Altered Expression	[2531]
ANAPC11	OTK2SJXR	Strong	Altered Expression	[2532]
ANGPTL1	OTXIN6V5	Strong	Biomarker	[2533]
ANKK1	OT0OM1O0	Strong	Genetic Variation	[2534]
ANKLE1	OTQ7WN9J	Strong	Biomarker	[2535]
ANKLE2	OTHCYR6Y	Strong	Biomarker	[2536]
ANKRD12	OTK16BL9	Strong	Biomarker	[2200]
ANKRD30A	OTJXYAE5	Strong	Biomarker	[2537]
ANKRD34A	OTI00ROL	Strong	Biomarker	[674]
ANKRD46	OTG8X76U	Strong	Altered Expression	[2538]
ANO8	OT07SRRX	Strong	Genetic Variation	[743]
ANP32A	OTRHPFO2	Strong	Altered Expression	[2539]
ANP32B	OT3SQMLU	Strong	Biomarker	[484]
ANTXR1	OT5W1GPC	Strong	Biomarker	[2540]
ANXA13	OTM33P73	Strong	Biomarker	[2541]
ANXA3	OTDD8OI7	Strong	Altered Expression	[2542]
ANXA4	OTUCRYXL	Strong	Biomarker	[2271]
ANXA6	OT9KIQ0Y	Strong	Biomarker	[1235]
ANXA7	OTLMD0TK	Strong	Altered Expression	[2543]
AP2A1	OTEFZB21	Strong	Biomarker	[2544]
AP2A2	OTD1UGUN	Strong	Biomarker	[2545]
AP3B1	OTYTIH5Q	Strong	Biomarker	[2546]
APBA3	OTAAATXF	Strong	Biomarker	[2547]
APBB3	OTNUTR0N	Strong	Biomarker	[2548]
APCDD1	OTV9AD0L	Strong	Biomarker	[2549]
APOBEC3A	OTYO6F5P	Strong	Genetic Variation	[2550]
APPBP2	OTLNFV4J	Strong	Biomarker	[2551]
APPL1	OT8VR95S	Strong	Biomarker	[2552]
AQP4	OTA9MYD5	Strong	Biomarker	[2553]
AQP8	OT99JKME	Strong	Altered Expression	[2554]
ARAP3	OTUWZTH7	Strong	Biomarker	[2555]
ARF3	OTYYQX85	Strong	Biomarker	[2556]
ARF6	OTVV7KJO	Strong	Altered Expression	[2557]
ARFGEF1	OTPAU0L4	Strong	Biomarker	[2558]
ARFGEF2	OTM3CQZT	Strong	Biomarker	[2558]
ARFGEF3	OTGQV0CU	Strong	Biomarker	[491]
ARGLU1	OTRVRZ4Z	Strong	Altered Expression	[2559]
ARHGAP1	OT0H2ZBZ	Strong	Biomarker	[2560]
ARHGAP10	OT84ATF5	Strong	Altered Expression	[2561]
ARHGAP11A	OTVQCFVP	Strong	Altered Expression	[2562]
ARHGAP17	OTEABPLV	Strong	Biomarker	[2563]
ARHGAP18	OTYMJP6H	Strong	Altered Expression	[2564]
ARHGAP26	OTNGQU7A	Strong	Biomarker	[816]
ARHGAP5	OTOQELUN	Strong	Altered Expression	[2565]
ARHGAP9	OTJNHX96	Strong	Biomarker	[2566]
ARHGDIA	OTEXWJDO	Strong	Biomarker	[2567]
ARHGDIB	OT9PD6CS	Strong	Altered Expression	[363]
ARHGDIG	OT07JK0M	Strong	Biomarker	[2568]
ARHGEF1	OTXU4HBW	Strong	Biomarker	[1323]
ARHGEF11	OTDOMEH6	Strong	Biomarker	[2569]
ARHGEF12	OTM2D3LT	Strong	Biomarker	[2570]
ARHGEF2	OTBQTFRT	Strong	Altered Expression	[2111]
ARID3B	OTUP9MS4	Strong	Altered Expression	[2571]
ARID4A	OT1XKBZ0	Strong	Genetic Variation	[2572]
ARL11	OTF6UDDB	Strong	Genetic Variation	[2573]
ARMH1	OTTJC0D6	Strong	Altered Expression	[1148]
ARNT2	OTAQD3YV	Strong	Altered Expression	[2574]
ARPC1B	OTYE3DN2	Strong	Altered Expression	[2575]
ARPC2	OTSOKOMY	Strong	Biomarker	[2576]
ARPIN	OTNNYP9A	Strong	Biomarker	[2577]
ARSD	OTAHW9M8	Strong	Biomarker	[2578]
ARTN	OTWIWGL6	Strong	Biomarker	[2579]
ASAH2B	OT2M9WWQ	Strong	Biomarker	[2580]
ASB6	OTFAJPSF	Strong	Altered Expression	[2581]
ASCC1	OTH4VAP9	Strong	Altered Expression	[2205]
ASCC2	OT3B204T	Strong	Biomarker	[1337]
ASCL1	OTI4X44G	Strong	Altered Expression	[2582]
ASCL2	OT3D62WB	Strong	Biomarker	[2583]
ASF1B	OTKXX12I	Strong	Biomarker	[2584]
ASL	OTI2NGQR	Strong	Altered Expression	[2585]
ASPG	OT5E2EKR	Strong	Altered Expression	[2586]
ASPM	OTKXQMNA	Strong	Genetic Variation	[698]
ASS1	OT4ZMG0Q	Strong	Altered Expression	[289]
ATAD1	OTJ02XFL	Strong	Genetic Variation	[2587]
ATAD3A	OTWF6HBP	Strong	Altered Expression	[2588]
ATF5	OT03QCLM	Strong	Biomarker	[2589]
ATF6	OTAFHAVI	Strong	Altered Expression	[2590]
ATG10	OTVRPC5X	Strong	Biomarker	[674]
ATG3	OT28VBVK	Strong	Biomarker	[2591]
ATG4C	OTD9HN3X	Strong	Biomarker	[2592]
ATN1	OTNZFLKY	Strong	Biomarker	[2593]
ATP1B2	OTYTBYVU	Strong	Biomarker	[2594]
ATP2A3	OTFYDEES	Strong	Altered Expression	[2595]
ATP2B3	OT9DIEOP	Strong	Biomarker	[2596]
ATP2C2	OTGIHTYQ	Strong	Biomarker	[2597]
ATP6	OTPHOGLX	Strong	Genetic Variation	[2598]
ATP6AP2	OT0IABVV	Strong	Altered Expression	[2599]
ATP6V0A2	OTJBDX0Y	Strong	Biomarker	[2600]
ATRNL1	OTY5JUX2	Strong	Biomarker	[700]
ATRX	OT77RSQW	Strong	Genetic Variation	[2601]
ATXN1	OTQF0HNR	Strong	Altered Expression	[2602]
ATXN7	OTL3YF1H	Strong	Biomarker	[2603]
ATXN7L3B	OTUYOYAR	Strong	Biomarker	[2604]
AXIN1	OTRGZGZ5	Strong	Biomarker	[2605]
AZIN1	OTX5W77I	Strong	Biomarker	[1343]
AZU1	OTHXU264	Strong	Altered Expression	[2606]
B3GALNT2	OTOF6O2B	Strong	Altered Expression	[2607]
B3GALT4	OTLKSMQE	Strong	Altered Expression	[2608]
B4GAT1	OT5NH9TD	Strong	Biomarker	[674]
BABAM1	OTCFPER6	Strong	Genetic Variation	[2609]
BABAM2	OTOY7FNT	Strong	Biomarker	[2610]
BAD	OT63ERYM	Strong	Posttranslational Modification	[383]
BAG1	OTRQNIA4	Strong	Altered Expression	[2611]
BAG3	OTVXYUDQ	Strong	Biomarker	[2612]
BANP	OT1JMTBD	Strong	Biomarker	[2613]
BARHL1	OTIUTWBD	Strong	Altered Expression	[2614]
BARX2	OT0R3QD3	Strong	Biomarker	[2615]
BASP1	OTF4VS5G	Strong	Altered Expression	[2616]
BATF3	OTI61WXQ	Strong	Altered Expression	[889]
BAZ1B	OTD5KR2J	Strong	Biomarker	[2617]
BCAP31	OTKSACR4	Strong	Biomarker	[2618]
BCAS1	OTQKJR81	Strong	Biomarker	[2619]
BCAS4	OT596N5E	Strong	Altered Expression	[2620]
BCDIN3D	OTLO1EOO	Strong	Altered Expression	[2621]
BCL2L11	OTNQQWFJ	Strong	Biomarker	[2622]
BCL2L12	OTS6IFZY	Strong	Altered Expression	[2623]
BCL7A	OTYFUJTP	Strong	Altered Expression	[2624]
BCORL1	OTPTFQN5	Strong	Biomarker	[2625]
BCS1L	OT5PY5CY	Strong	Biomarker	[2626]
BEST1	OTWHE1ZC	Strong	Biomarker	[888]
BEX2	OT4G5SIC	Strong	Biomarker	[2627]
BGLAP	OTK1YLWQ	Strong	Altered Expression	[1262]
BHLHA15	OTY7IER8	Strong	Altered Expression	[2628]
BHLHE22	OTZUQY5L	Strong	Biomarker	[2629]
BHLHE40	OTITX14U	Strong	Biomarker	[2630]
BHLHE41	OTY9GJ1Y	Strong	Biomarker	[2631]
BIK	OTTH1T3D	Strong	Altered Expression	[2632]
BIN1	OTK8O0X8	Strong	Biomarker	[2633]
BIRC6	OTCQJAB0	Strong	Biomarker	[2634]
BLCAP	OTGJVU0C	Strong	Altered Expression	[2635]
BLID	OT479VJV	Strong	Biomarker	[2636]
BMF	OT90NSLI	Strong	Biomarker	[2637]
BMP8B	OTJC3AB9	Strong	Altered Expression	[652]
BMPR1A	OTQOA4ZH	Strong	Biomarker	[2638]
BMPR1B	OTGFN0OD	Strong	Altered Expression	[867]
BNC1	OTGJ5WUF	Strong	Biomarker	[2639]
BNIP1	OT7USYCY	Strong	Altered Expression	[2640]
BNIP3	OT4SO7J4	Strong	Altered Expression	[2641]
BNIP3L	OTJKOMXE	Strong	Altered Expression	[2642]
BOD1	OTQL6F4R	Strong	Altered Expression	[2643]
BOK	OTDQPDIX	Strong	Biomarker	[2644]
BPY2	OT2WQPNQ	Strong	Biomarker	[2645]
BRAP	OTB7BAFQ	Strong	Biomarker	[2646]
BRF1	OTQC6DMG	Strong	Altered Expression	[2647]
BRF2	OT2C6TH2	Strong	Biomarker	[2648]
BRMS1L	OTJIW47U	Strong	Biomarker	[2649]
BTC	OTW4B2O0	Strong	Biomarker	[2650]
BTD	OTJYTQ69	Strong	Biomarker	[2651]
BTF3	OT5ZZFJL	Strong	Altered Expression	[2652]
BTG2	OTZF6K1H	Strong	Biomarker	[2653]
BTG4	OTT3TKPI	Strong	Biomarker	[288]
BTN3A2	OT3DIBU3	Strong	Biomarker	[2654]
BUB1B	OT8KME51	Strong	Genetic Variation	[2655]
BYSL	OTPTLZJT	Strong	Altered Expression	[2656]
C10orf88	OT5KV1OA	Strong	Genetic Variation	[2475]
C10orf90	OT6DNZC4	Strong	Altered Expression	[2657]
C1GALT1	OT2ZSZ6P	Strong	Biomarker	[2658]
C1orf52	OT8RQW3W	Strong	Altered Expression	[2659]
C1QL1	OTNQ0G3E	Strong	Biomarker	[534]
C1QL3	OT4TZH3J	Strong	Biomarker	[2660]
C4BPA	OTHNH6Y8	Strong	Biomarker	[2661]
CA10	OTC3N1F6	Strong	Genetic Variation	[2662]
CABIN1	OT4G5CIK	Strong	Genetic Variation	[2663]
CACUL1	OT6P1ZVP	Strong	Biomarker	[2664]
CACYBP	OTJMZD2T	Strong	Biomarker	[2665]
CALD1	OTNJKJ6Q	Strong	Biomarker	[2618]
CALML3	OTM8DNQU	Strong	Altered Expression	[2666]
CALML6	OTHVPDSD	Strong	Biomarker	[2667]
CALU	OTSYQN71	Strong	Biomarker	[2271]
CAMK1D	OTU24HAU	Strong	Biomarker	[2668]
CAMKMT	OTLJBRUW	Strong	Biomarker	[2228]
CAMLG	OTTSRY39	Strong	Biomarker	[2669]
CAMTA1	OTAN1S5B	Strong	Biomarker	[2670]
CAP1	OTYM8A2N	Strong	Biomarker	[1162]
CAPN5	OTQ8QM7K	Strong	Genetic Variation	[2671]
CARD10	OT2RPM4I	Strong	Biomarker	[2672]
CARD16	OT4NUHWB	Strong	Biomarker	[2673]
CARD8	OTXXZYWU	Strong	Altered Expression	[2674]
CASC3	OTLK3K4U	Strong	Biomarker	[2675]
CASD1	OT1YB54Z	Strong	Biomarker	[1671]
CASP14	OTKY93H9	Strong	Altered Expression	[2676]
CAST	OTBXZZGF	Strong	Biomarker	[2677]
CBFA2T2	OTNOIB23	Strong	Biomarker	[2063]
CBFA2T3	OTOJ10S1	Strong	Altered Expression	[2678]
CBFB	OTIAC6W4	Strong	Biomarker	[2679]
CBLC	OT3RKZI9	Strong	Biomarker	[2680]
CBLL1	OTZUQBYX	Strong	Altered Expression	[2681]
CBX4	OT4XVRRF	Strong	Biomarker	[2682]
CBX5	OT8VYY84	Strong	Posttranslational Modification	[2683]
CBX8	OT4U5V1T	Strong	Biomarker	[2684]
CCAR2	OTLUDG5T	Strong	Biomarker	[1822]
CCBE1	OTO4UIDB	Strong	Altered Expression	[2685]
CCDC116	OTYMNP3C	Strong	Genetic Variation	[2686]
CCDC181	OTPE3H8B	Strong	Biomarker	[2687]
CCDC54	OTW5WCX9	Strong	Altered Expression	[2688]
CCDC8	OTO295IH	Strong	Altered Expression	[2231]
CCDC88A	OT3SSYYC	Strong	Biomarker	[2689]
CCDC88C	OTIU02BS	Strong	Genetic Variation	[2609]
CCL1	OT23NON8	Strong	Biomarker	[2690]
CCL14	OT8QETQU	Strong	Biomarker	[2691]
CCL18	OT7JYSK9	Strong	Altered Expression	[2692]
CCL19	OTQ2UJMH	Strong	Biomarker	[2693]
CCL25	OTLWJ8CJ	Strong	Biomarker	[771]
CCL28	OTY6XNQ7	Strong	Biomarker	[2694]
CCL4	OT6B8P25	Strong	Altered Expression	[1835]
CCN5	OTADU8JJ	Strong	Biomarker	[2695]
CCN6	OTRFHQ2Z	Strong	Biomarker	[2696]
CCND2	OTDULQF9	Strong	Biomarker	[2697]
CCNF	OTJFVU43	Strong	Biomarker	[2698]
CCNH	OTKDU3SR	Strong	Biomarker	[1015]
CCNL1	OTAJSS3D	Strong	Biomarker	[2699]
CCR10	OT7ZWSSD	Strong	Biomarker	[2700]
CCT3	OTL6EOS1	Strong	Biomarker	[2701]
CCT4	OT5D452X	Strong	Altered Expression	[2702]
CCT5	OTPZ38BT	Strong	Biomarker	[2703]
CCT6A	OTCYWL5F	Strong	Biomarker	[2704]
CD109	OTDADBM4	Strong	Biomarker	[827]
CD226	OT4UG0KB	Strong	Altered Expression	[2705]
CD3D	OTRBLP0R	Strong	Biomarker	[2706]
CD5L	OTPY4WQR	Strong	Biomarker	[2707]
CD63	OT2UGZA9	Strong	Biomarker	[2708]
CD68	OTOYEY3J	Strong	Biomarker	[2709]
CD8A	OTDWQJXK	Strong	Altered Expression	[2710]
CD99	OTPUZ5DE	Strong	Biomarker	[2711]
CDC14A	OTL10OY6	Strong	Biomarker	[2712]
CDC27	OTDT45XJ	Strong	Altered Expression	[2713]
CDC42	OT5QBC5M	Strong	Biomarker	[2714]
CDC42EP3	OTUZ3U9Z	Strong	Biomarker	[2715]
CDC5L	OTTPFUU5	Strong	Altered Expression	[2716]
CDCA4	OT0AAXAC	Strong	Biomarker	[2717]
CDCA5	OTZLCQ5U	Strong	Altered Expression	[2718]
CDCA7	OT12HDZY	Strong	Altered Expression	[2719]
CDH13	OTD2CYM5	Strong	Posttranslational Modification	[2720]
CDH15	OTJ1TO02	Strong	Genetic Variation	[2721]
CDH17	OT9EV2XK	Strong	Biomarker	[2722]
CDH22	OTQEUWQN	Strong	Altered Expression	[2723]
CDK10	OTKP7TTR	Strong	Biomarker	[2724]
CDK14	OT385ZH1	Strong	Altered Expression	[2725]
CDK2AP1	OTNFOHDJ	Strong	Altered Expression	[2726]
CDKAL1	OTA0SGNE	Strong	Genetic Variation	[2727]
CDKN2B	OTAG24N1	Strong	Posttranslational Modification	[1416]
CDKN3	OTBE3H07	Strong	Biomarker	[2728]
CDO1	OTLG1P77	Strong	Altered Expression	[2729]
CDT1	OTVY53VG	Strong	Altered Expression	[1842]
CDYL2	OTGUD2XL	Strong	Genetic Variation	[2730]
CEACAM19	OTMECF5R	Strong	Altered Expression	[2731]
CEACAM7	OTKFDTZY	Strong	Biomarker	[803]
CEACAM8	OTLL9WWO	Strong	Altered Expression	[530]
CEBPD	OTNBIPMY	Strong	Altered Expression	[2732]
CELF2	OTLJJ4VT	Strong	Posttranslational Modification	[2672]
CEMIP2	OT9I1XUO	Strong	Altered Expression	[2733]
CENPF	OT7AG0SW	Strong	Altered Expression	[2734]
CENPH	OTPOO9LK	Strong	Biomarker	[2735]
CENPI	OTWRIMZ3	Strong	Biomarker	[2736]
CENPK	OTKPUF8K	Strong	Altered Expression	[2737]
CENPU	OTQ4TZRS	Strong	Biomarker	[2738]
CEP131	OT6PF80T	Strong	Biomarker	[2739]
CEP55	OTGSG2PA	Strong	Biomarker	[2740]
CEP57	OTPOHLIX	Strong	Genetic Variation	[2741]
CEP85L	OTSHJFOT	Strong	Biomarker	[500]
CERS2	OTRAHYYP	Strong	Biomarker	[2742]
CERS4	OTV5ENAX	Strong	Biomarker	[2743]
CERT1	OTNUCNHX	Strong	Altered Expression	[2744]
CETN1	OTGQ8JOZ	Strong	Biomarker	[2667]
CFAP20	OTIG8TR5	Strong	Altered Expression	[2745]
CFAP54	OTS4SW4H	Strong	Genetic Variation	[743]
CFL1	OTT6D5MH	Strong	Biomarker	[2746]
CFL2	OTE2W0DH	Strong	Altered Expression	[2747]
CGRRF1	OTLMNRCL	Strong	Biomarker	[2748]
CHAF1A	OTXSSY4H	Strong	Biomarker	[376]
CHAF1B	OTOMK4KH	Strong	Biomarker	[2749]
CHCHD2	OTL5PA3Y	Strong	Altered Expression	[2750]
CHD1L	OT7CZK7C	Strong	Biomarker	[2751]
CHD3	OTDBU4F3	Strong	Biomarker	[1738]
CHD4	OTBDEHDP	Strong	Biomarker	[2752]
CHD5	OTS5EVHH	Strong	Altered Expression	[2753]
CHD8	OTS7A6AF	Strong	Genetic Variation	[2754]
CHFR	OTRAD2TT	Strong	Altered Expression	[2755]
CHGB	OT7SAQT2	Strong	Biomarker	[2756]
CHMP3	OT0963JJ	Strong	Altered Expression	[2757]
CHORDC1	OT3W6F1U	Strong	Biomarker	[2758]
CHP2	OT4UMKUR	Strong	Biomarker	[2759]
CHRAC1	OTBXN4YZ	Strong	Genetic Variation	[2760]
CHRDL1	OTGMWVVA	Strong	Biomarker	[2761]
CHST11	OTNJJ5Q1	Strong	Biomarker	[2762]
CHST9	OT1DEZRM	Strong	Genetic Variation	[2730]
CIAPIN1	OTWS90F9	Strong	Altered Expression	[2763]
CIB1	OT4BVCRU	Strong	Biomarker	[1798]
CIB2	OT9ZJX1I	Strong	Altered Expression	[1798]
CIC	OTFXCHNZ	Strong	Biomarker	[2764]
CIP2A	OTVS2GXA	Strong	Biomarker	[2765]
CIRBP	OTXWTPBL	Strong	Biomarker	[2766]
CISD2	OTVS7S2H	Strong	Biomarker	[2064]
CISH	OT8T5NYL	Strong	Biomarker	[1486]
CITED1	OTUJQ3VL	Strong	Altered Expression	[2767]
CITED4	OTR6NHI2	Strong	Altered Expression	[2768]
CKAP4	OTDUC9ME	Strong	Biomarker	[1174]
CKB	OTUCKOTT	Strong	Biomarker	[2769]
CKS1B	OTNUPLUJ	Strong	Biomarker	[2770]
CLDN10	OT2CVAKY	Strong	Genetic Variation	[2771]
CLDN12	OTO55YZI	Strong	Biomarker	[2772]
CLDN16	OTTHAIKR	Strong	Altered Expression	[2773]
CLDN5	OTUX60YO	Strong	Altered Expression	[2774]
CLDN7	OTNE0XHQ	Strong	Altered Expression	[1217]
CLEC14A	OT0UJQ4O	Strong	Biomarker	[2775]
CLEC3A	OTTOAEGT	Strong	Biomarker	[2776]
CLEC4D	OTT7X1UC	Strong	Biomarker	[872]
CLIC4	OT6KTPKD	Strong	Altered Expression	[2777]
CLIP1	OTTGAEJE	Strong	Altered Expression	[2177]
CLPTM1L	OTDJWQXI	Strong	Genetic Variation	[2778]
CLTA	OTLHOXMQ	Strong	Genetic Variation	[1026]
CLUL1	OTYIXQ36	Strong	Biomarker	[1293]
CMC2	OTRYIO1J	Strong	Biomarker	[2703]
CMTR1	OTG0N8GA	Strong	Biomarker	[1572]
CMTR2	OT82FBWS	Strong	Biomarker	[2779]
CNBP	OTTGM9NK	Strong	Altered Expression	[2780]
CNGB1	OTA5DE38	Strong	Biomarker	[1169]
CNKSR1	OTSNAEQ9	Strong	Biomarker	[2781]
CNKSR2	OTAGERJ2	Strong	Altered Expression	[2782]
CNOT3	OT4D5Z9L	Strong	Genetic Variation	[2783]
CNOT7	OTJBKCPI	Strong	Biomarker	[2749]
CNOT8	OT6CMCS0	Strong	Biomarker	[2749]
CNOT9	OT1NIIQD	Strong	Biomarker	[2784]
CNTN3	OTC1274J	Strong	Biomarker	[2558]
CNTN4	OTULXVE0	Strong	Biomarker	[2558]
COIL	OTP4I4DL	Strong	Altered Expression	[2785]
COL10A1	OTC4G2YC	Strong	Biomarker	[2786]
COL11A1	OTB0DRMS	Strong	Altered Expression	[2787]
COL11A2	OT3BQUBH	Strong	Genetic Variation	[2788]
COL4A2	OTJK1LKN	Strong	Biomarker	[2789]
COL4A5	OTHG60RE	Strong	Genetic Variation	[2790]
COL5A1	OT24078H	Strong	Altered Expression	[2791]
COP1	OT6J2K12	Strong	Biomarker	[2792]
COPS6	OTG9AAG0	Strong	Altered Expression	[2793]
COPS8	OTNAD2S4	Strong	Genetic Variation	[2794]
CORT	OTX3GUHB	Strong	Biomarker	[2795]
COTL1	OT6YCNLF	Strong	Altered Expression	[2666]
COX1	OTG3O9BN	Strong	Altered Expression	[2796]
COX11	OT0N3WL9	Strong	Genetic Variation	[2797]
COX5A	OTP0961M	Strong	Biomarker	[2798]
COX5B	OTDP94F3	Strong	Biomarker	[2799]
COX6C	OT3V7JE5	Strong	Genetic Variation	[2800]
COX7A2L	OTY21FKV	Strong	Altered Expression	[2801]
COX8A	OTU0NR39	Strong	Biomarker	[2798]
CP	OTM8JE4Y	Strong	Biomarker	[2802]
CPD	OT2CS64Y	Strong	Altered Expression	[395]
CPEB1	OTLCXC6H	Strong	Biomarker	[2803]
CPEB2	OTKES4YR	Strong	Altered Expression	[2804]
CPEB4	OTW1SCZW	Strong	Biomarker	[2805]
CPED1	OTJJPZOZ	Strong	Biomarker	[1833]
CPNE3	OTCR3WG2	Strong	Biomarker	[2806]
CPOX	OTIAY121	Strong	Biomarker	[2798]
CPSF6	OTM6QYNQ	Strong	Altered Expression	[2807]
CPT1A	OTI862QH	Strong	Altered Expression	[2808]
CPT1C	OT8F1MBF	Strong	Altered Expression	[2809]
CPT2	OTIN6G20	Strong	Altered Expression	[2810]
CPXM1	OTRCSQPG	Strong	Biomarker	[2811]
CRB3	OTQKPTMU	Strong	Altered Expression	[2812]
CRCP	OT4K9BT7	Strong	Biomarker	[2813]
CREB3L1	OT2JHIHM	Strong	Altered Expression	[2814]
CREBZF	OTO3TOEU	Strong	Biomarker	[2815]
CRIP2	OTVVJSYX	Strong	Biomarker	[1867]
CRLS1	OT7XNL0K	Strong	Genetic Variation	[2816]
CROCC	OTVNOZSM	Strong	Biomarker	[2817]
CRYL1	OT0SJSJM	Strong	Biomarker	[1713]
CSGALNACT1	OTBML9D9	Strong	Altered Expression	[2818]
CSH1	OT33HTRR	Strong	Altered Expression	[2819]
CSH2	OTW8JVAN	Strong	Biomarker	[2819]
CSMD1	OTIVDSC4	Strong	Altered Expression	[2820]
CSN1S1	OTXOW6XJ	Strong	Biomarker	[2821]
CSNK2B	OT2WW7R1	Strong	Biomarker	[796]
CSRP3	OTECBJMV	Strong	Altered Expression	[2666]
CST6	OTZVHJTF	Strong	Altered Expression	[2822]
CSTF1	OTYSXAX6	Strong	Genetic Variation	[2823]
CT45A1	OT80VTZO	Strong	Altered Expression	[2824]
CT47A11	OTQHGP0S	Strong	Altered Expression	[2825]
CT55	OTQC0H27	Strong	Biomarker	[2382]
CTAG1B	OTIQGW6U	Strong	Genetic Variation	[845]
CTBP1	OTVYH2DH	Strong	Altered Expression	[2826]
CTBP2	OTGZGT87	Strong	Altered Expression	[2827]
CTNNA1	OTFC725Z	Strong	Genetic Variation	[2828]
CTNNBIP1	OTX9SBJG	Strong	Biomarker	[2829]
CTNND2	OTYKE30Y	Strong	Altered Expression	[2830]
CTRL	OTB6NA5O	Strong	Altered Expression	[2831]
CTSO	OTFL6VRO	Strong	Genetic Variation	[2832]
CTSZ	OTSCX2LL	Strong	Biomarker	[2833]
CTTN	OTJRG4ES	Strong	Biomarker	[479]
CTU1	OTNTM9D1	Strong	Biomarker	[2834]
CTU2	OT323X9J	Strong	Biomarker	[2522]
CUEDC1	OTQ7V4FF	Strong	Biomarker	[2835]
CUEDC2	OTWMOLAJ	Strong	Altered Expression	[2836]
CUL1	OTXPE1UZ	Strong	Biomarker	[2837]
CUL2	OTPF83PG	Strong	Altered Expression	[2664]
CUL4A	OTTBV70J	Strong	Altered Expression	[2664]
CUL4B	OT2QX4DO	Strong	Altered Expression	[2664]
CUL5	OTMTZD47	Strong	Biomarker	[2664]
CUL9	OTPUCLZT	Strong	Altered Expression	[2664]
CUX1	OTU1LCNJ	Strong	Biomarker	[1337]
CXCL14	OTM189TA	Strong	Biomarker	[2478]
CXCL16	OTD49T9R	Strong	Altered Expression	[1310]
CXCL3	OTSL94KH	Strong	Biomarker	[2838]
CYB5D2	OTX10KKR	Strong	Biomarker	[2839]
CYBRD1	OTUTVBES	Strong	Biomarker	[2840]
CYCS	OTBFALJD	Strong	Biomarker	[2841]
CYFIP1	OTOBEH24	Strong	Biomarker	[2842]
CYFIP2	OTCAY35T	Strong	Genetic Variation	[2843]
CYGB	OTX153DQ	Strong	Altered Expression	[2844]
CYP2A7	OTRJ3P2Z	Strong	Genetic Variation	[1942]
CYP2D7	OTYJTL3S	Strong	Biomarker	[2845]
CYP2W1	OTXSB1AE	Strong	Altered Expression	[1721]
CYP4Z1	OTKRGJBG	Strong	Biomarker	[2846]
DAB2	OTRMQTMZ	Strong	Biomarker	[2847]
DACH1	OTMKNAGG	Strong	Biomarker	[2848]
DACT2	OTNLCC0K	Strong	Posttranslational Modification	[2849]
DAP	OT5YLL7E	Strong	Biomarker	[2850]
DAP3	OTNPEZYM	Strong	Biomarker	[2851]
DAPK1	OTNCNUCO	Strong	Genetic Variation	[2852]
DAPK2	OTWODUQG	Strong	Biomarker	[490]
DBR1	OTLTWLTE	Strong	Genetic Variation	[2853]
DCAF1	OT3ZDVOE	Strong	Biomarker	[2854]
DCC	OT2C1SHW	Strong	Genetic Variation	[2855]
DCD	OTV5PBGJ	Strong	Biomarker	[2856]
DCLRE1B	OT2LFW7A	Strong	Genetic Variation	[2857]
DCLRE1C	OTW3KB1I	Strong	Biomarker	[2858]
DCTN4	OTM7C943	Strong	Biomarker	[2859]
DCX	OTISR7K3	Strong	Genetic Variation	[2860]
DDA1	OTAZIAIH	Strong	Genetic Variation	[743]
DDB2	OTO8HVVB	Strong	Biomarker	[540]
DDHD2	OTUP0WHF	Strong	Biomarker	[2861]
DDIT3	OTI8YKKE	Strong	Biomarker	[2862]
DDX1	OT3U8FD0	Strong	Genetic Variation	[2863]
DDX10	OTH48438	Strong	Biomarker	[2864]
DDX17	OTXRMMBP	Strong	Altered Expression	[2865]
DDX20	OT6G8YF3	Strong	Biomarker	[2866]
DDX21	OTV73GMZ	Strong	Altered Expression	[2867]
DDX3X	OTDO4TRX	Strong	Biomarker	[2868]
DDX53	OTHK3EGZ	Strong	Biomarker	[2869]
DDX54	OTVOJU6G	Strong	Biomarker	[2870]
DEFA1	OT5N1B9B	Strong	Altered Expression	[2871]
DEPDC1B	OTMVFOT1	Strong	Biomarker	[2872]
DEPP1	OTB36PHJ	Strong	Altered Expression	[2873]
DERL1	OTJUS74N	Strong	Altered Expression	[514]
DERL2	OTI3TUUZ	Strong	Genetic Variation	[2874]
DERL3	OTRZRT6Q	Strong	Altered Expression	[2875]
DES	OTI09KBW	Strong	Biomarker	[2483]
DHDDS	OTVLYBUS	Strong	Biomarker	[2246]
DHRS2	OTFHWIY8	Strong	Biomarker	[2876]
DHX32	OTDYB66V	Strong	Altered Expression	[2877]
DIP2A	OTXPTR8R	Strong	Biomarker	[2645]
DIP2C	OTVNSS2T	Strong	Altered Expression	[2878]
DIRAS3	OT3XHLQA	Strong	Altered Expression	[2879]
DKC1	OTX7DJR6	Strong	Altered Expression	[2880]
DLAT	OT9LBJVN	Strong	Genetic Variation	[2881]
DLD	OT378CU9	Strong	Biomarker	[1103]
DLG3	OTH591WK	Strong	Biomarker	[2882]
DLG5	OTU9Z17K	Strong	Altered Expression	[2883]
DLK2	OT56Y83S	Strong	Biomarker	[2884]
DLX2	OTKC2DQ0	Strong	Biomarker	[2885]
DLX4	OTLWVCN4	Strong	Biomarker	[2886]
DLX5	OTEEFBEU	Strong	Biomarker	[2885]
DMBT1	OTVNU9D9	Strong	Genetic Variation	[2887]
DMP1	OTBWBWW7	Strong	Biomarker	[2888]
DNAAF4	OTVDYBJE	Strong	Altered Expression	[2889]
DNAJA3	OT61924T	Strong	Altered Expression	[2890]
DNAJB6	OTMHIIAN	Strong	Altered Expression	[2891]
DNAJC10	OTD2EG0R	Strong	Genetic Variation	[2892]
DNAJC12	OTNU59PT	Strong	Altered Expression	[889]
DNAJC13	OTYAVVJ6	Strong	Biomarker	[2893]
DNAJC2	OT3JDA0R	Strong	Biomarker	[2894]
DNAJC27	OTJRPCUR	Strong	Altered Expression	[2895]
DNAJC3	OT7ROIJF	Strong	Altered Expression	[2896]
DND1	OTHLC8TA	Strong	Biomarker	[2897]
DNER	OT2GH2E5	Strong	Biomarker	[730]
DNM1L	OTXK1Q1G	Strong	Biomarker	[490]
DOCK1	OTCFV3ON	Strong	Altered Expression	[2898]
DOCK11	OTFSTN6A	Strong	Genetic Variation	[2899]
DOCK3	OTF3YS2W	Strong	Biomarker	[2900]
DOCK8	OTNQLL21	Strong	Genetic Variation	[2901]
DOK1	OTGVRLW6	Strong	Altered Expression	[1500]
DOK2	OTIJ38UF	Strong	Altered Expression	[2902]
DOP1A	OTBKLQH5	Strong	Biomarker	[2903]
DPF3	OTEWLMNB	Strong	Biomarker	[2904]
DPP3	OTUIVL1C	Strong	Biomarker	[2905]
DPT	OTINRFC7	Strong	Biomarker	[2906]
DPYS	OTLTUIVL	Strong	Biomarker	[2775]
DPYSL3	OTINJV20	Strong	Biomarker	[2907]
DRG1	OTIFYMI3	Strong	Biomarker	[2908]
DSC1	OTNII6GZ	Strong	Biomarker	[2909]
DSC2	OTODVH8K	Strong	Altered Expression	[2910]
DSC3	OTYG47F8	Strong	Biomarker	[2911]
DSPP	OT1TYNDN	Strong	Altered Expression	[2912]
DTX3	OTSUUV9N	Strong	Biomarker	[1685]
DUOX1	OTQ2AEW0	Strong	Posttranslational Modification	[2913]
DUOXA1	OTNG3HH4	Strong	Altered Expression	[2640]
DUSP16	OTK7S078	Strong	Altered Expression	[903]
DUSP2	OTH54FMR	Strong	Biomarker	[2594]
DUSP22	OTEZ3U85	Strong	Biomarker	[2914]
DUSP23	OTE2PG54	Strong	Altered Expression	[2915]
DUSP4	OT6WAO12	Strong	Biomarker	[2916]
DUSP6	OT4H6RKW	Strong	Biomarker	[2917]
DUSP7	OT6Z5AHP	Strong	Altered Expression	[2918]
DVL1	OTD67RF1	Strong	Biomarker	[2919]
DVL3	OTPRROHJ	Strong	Biomarker	[2920]
DYM	OTQ670WI	Strong	Biomarker	[2921]
DYNC2H1	OTLC8K6B	Strong	Biomarker	[2483]
DYNLL2	OTLIT58K	Strong	Biomarker	[1395]
E2F4	OTB3JFH4	Strong	Biomarker	[2922]
E2F5	OT1XWING	Strong	Altered Expression	[1892]
EBF1	OTZ61YYH	Strong	Biomarker	[2923]
EBNA1BP2	OTBRVMZH	Strong	Altered Expression	[1148]
ECPAS	OT1C0KOI	Strong	Altered Expression	[2924]
EDA	OTAKS5WS	Strong	Posttranslational Modification	[2925]
EDA2R	OTJLAIIH	Strong	Posttranslational Modification	[2925]
EDAR	OT3W2UQS	Strong	Altered Expression	[2925]
EDC4	OTBBNIUJ	Strong	Genetic Variation	[2926]
EDIL3	OTDVVNS0	Strong	Biomarker	[2927]
EDN3	OTN7Q9BE	Strong	Altered Expression	[2928]
EEF1A1	OT00THXS	Strong	Altered Expression	[2929]
EEF1A2	OT9Z23K5	Strong	Altered Expression	[2930]
EEF1B2	OTW64NPU	Strong	Biomarker	[817]
EEF2	OTZ7SZ39	Strong	Biomarker	[817]
EEPD1	OTTOGO05	Strong	Biomarker	[2931]
EFEMP1	OTZVUOOB	Strong	Altered Expression	[2932]
EFNA2	OTEAUKRX	Strong	Biomarker	[2933]
EFNA3	OTJGOUMZ	Strong	Biomarker	[2934]
EFNA5	OTOH4DRR	Strong	Biomarker	[2935]
EFNB2	OT0DCUOM	Strong	Altered Expression	[2936]
EGR3	OTGPJIRA	Strong	Altered Expression	[2937]
EHD2	OTTX391J	Strong	Altered Expression	[2938]
EI24	OTD4NOYS	Strong	Biomarker	[2939]
EID3	OTAND0C7	Strong	Altered Expression	[2940]
EIF1	OTB4GZ0V	Strong	Biomarker	[967]
EIF2A	OTWXELQP	Strong	Biomarker	[2941]
EIF2B1	OT4NCVY1	Strong	Biomarker	[1266]
EIF2B2	OTQQMHM1	Strong	Biomarker	[1266]
EIF2B4	OTTM5SX1	Strong	Biomarker	[1266]
EIF2S1	OTM0GDTP	Strong	Posttranslational Modification	[1126]
EIF2S2	OTXF0B09	Strong	Biomarker	[1266]
EIF2S3	OTARRES9	Strong	Posttranslational Modification	[1126]
EIF3C	OTR8RF9X	Strong	Biomarker	[2942]
EIF3G	OT5L1SRY	Strong	Biomarker	[2943]
EIF4A1	OTMTBX6N	Strong	Biomarker	[2944]
EIF4B	OTE8TXA8	Strong	Altered Expression	[2945]
EIF4G1	OT2CF1E6	Strong	Altered Expression	[1899]
EIF4G2	OTEO98CR	Strong	Altered Expression	[1462]
EIF5B	OTZTT22W	Strong	Genetic Variation	[2946]
EIF6	OTEXMUED	Strong	Biomarker	[1685]
ELAVL2	OT6EJ8MQ	Strong	Altered Expression	[2404]
ELF1	OTV5LKIA	Strong	Biomarker	[2933]
ELF3	OTUTLEQO	Strong	Biomarker	[2947]
ELF4	OT167PR5	Strong	Biomarker	[2948]
ELF5	OTLRU8YF	Strong	Altered Expression	[2949]
ELK1	OTH9MXD6	Strong	Altered Expression	[2950]
ELL	OTCBN5LF	Strong	Genetic Variation	[1861]
ELOC	OT0XHHWP	Strong	Biomarker	[2951]
ELOF1	OT8BXS5U	Strong	Biomarker	[2933]
ELP1	OTYEWBF7	Strong	Biomarker	[2522]
ELP3	OTT5UKSZ	Strong	Biomarker	[2522]
EMD	OTR8ZANE	Strong	Biomarker	[2952]
EMID1	OTJ27FQ1	Strong	Genetic Variation	[2730]
EMILIN2	OTOYK5A8	Strong	Biomarker	[2953]
EMP1	OTSZHUHQ	Strong	Altered Expression	[2954]
EMP2	OTPS2H0L	Strong	Biomarker	[449]
EMP3	OTODMJ1D	Strong	Altered Expression	[2955]
EMSY	OTBQ3KQE	Strong	Biomarker	[2956]
ENGASE	OTKXNR5B	Strong	Biomarker	[2957]
ENHO	OT91QASK	Strong	Biomarker	[2958]
ENO1	OTB1KWJS	Strong	Biomarker	[2959]
ENO2	OTRODL0T	Strong	Biomarker	[2960]
ENTPD5	OTFH05B9	Strong	Altered Expression	[2961]
EPB41	OTGCFPV8	Strong	Altered Expression	[2962]
EPB41L2	OT6UABPM	Strong	Altered Expression	[2962]
EPB41L3	OTS6CHG2	Strong	Biomarker	[2963]
EPB41L4B	OT2K30P7	Strong	Biomarker	[2964]
EPG5	OT3P5HQD	Strong	Genetic Variation	[2965]
EPRS1	OTXK0FLB	Strong	Biomarker	[2966]
EPS8	OTZ6ES6V	Strong	Biomarker	[2967]
EPSTI1	OT75I1UH	Strong	Biomarker	[2968]
ERAL1	OTSH78HD	Strong	Biomarker	[2969]
ERAS	OT528IZO	Strong	Biomarker	[2970]
ERCC1	OTNPYQHI	Strong	Biomarker	[2971]
ERCC3	OTVAW3P1	Strong	Biomarker	[2972]
ERCC6	OT2QZKSF	Strong	Biomarker	[2973]
ERCC6L	OTE9V7D9	Strong	Altered Expression	[2974]
ERG	OTOTX9VU	Strong	Altered Expression	[2975]
ERLIN2	OT551BVG	Strong	Altered Expression	[2976]
ERO1A	OTVKOQWM	Strong	Altered Expression	[2977]
ERP29	OTNKANMH	Strong	Altered Expression	[2978]
ERRFI1	OT7VZ2IZ	Strong	Altered Expression	[2979]
ERV3-1	OT4CW64T	Strong	Genetic Variation	[2980]
ESPL1	OTMGEVOK	Strong	Altered Expression	[2981]
ESRP2	OTVTKJ4I	Strong	Altered Expression	[2982]
ESS2	OTZ08VCZ	Strong	Biomarker	[2983]
ETF1	OTH8C5U5	Strong	Biomarker	[2984]
ETFA	OTXX61VZ	Strong	Biomarker	[2985]
ETV1	OT6PMJIK	Strong	Biomarker	[2986]
ETV4	OT8C98UZ	Strong	Altered Expression	[2987]
ETV5	OTE2OBM4	Strong	Biomarker	[2988]
ETV7	OTIAADPA	Strong	Biomarker	[1887]
EVL	OTZ8ZDNY	Strong	Biomarker	[827]
EXO1	OTI87RS5	Strong	Altered Expression	[764]
EXOSC6	OTAC10N6	Strong	Biomarker	[2989]
EXT1	OTRPALJK	Strong	Biomarker	[2990]
EXTL3	OT2BRUBN	Strong	Biomarker	[2991]
FA2H	OT8HA13U	Strong	Biomarker	[2992]
FABP7	OTRE2H4G	Strong	Altered Expression	[2993]
FADD	OTV7GFHH	Strong	Biomarker	[835]
FAH	OTGZA1YR	Strong	Genetic Variation	[2994]
FAM124B	OTL2A8O8	Strong	Altered Expression	[2995]
FAM13A	OTZ6GN0Q	Strong	Genetic Variation	[2996]
FAM3C	OTBR6U9G	Strong	Biomarker	[2997]
FAM53A	OT92WJE6	Strong	Biomarker	[2998]
FAN1	OT1LM1HZ	Strong	Biomarker	[2999]
FANCD2	OTVEB5LF	Strong	Biomarker	[3000]
FANCI	OTW8E3SC	Strong	Biomarker	[3001]
FASTK	OTTHFZMP	Strong	Biomarker	[3002]
FASTKD2	OTD635WX	Strong	Altered Expression	[3003]
FAT4	OT7QONNV	Strong	Altered Expression	[3004]
FBL	OTRODIE5	Strong	Altered Expression	[3005]
FBLN1	OT5MHHOP	Strong	Altered Expression	[3006]
FBXL14	OTBTN6WS	Strong	Biomarker	[3007]
FBXL7	OTNUK1DJ	Strong	Biomarker	[3008]
FBXO22	OTEJ5MO0	Strong	Altered Expression	[3009]
FBXO31	OTF96IC2	Strong	Altered Expression	[3010]
FBXO32	OTUE978R	Strong	Biomarker	[3011]
FBXO5	OTTR957W	Strong	Biomarker	[3012]
FBXO8	OTZNGJGW	Strong	Biomarker	[2277]
FBXW4	OTEGSZOX	Strong	Posttranslational Modification	[2467]
FBXW8	OTJG15EO	Strong	Genetic Variation	[3013]
FCER1A	OTIRUOHF	Strong	Genetic Variation	[3014]
FCGR3B	OTSLSPZG	Strong	Biomarker	[3015]
FEN1	OT6QGG7O	Strong	Biomarker	[3016]
FERMT1	OT626PBA	Strong	Biomarker	[3017]
FERMT2	OTZNPWWX	Strong	Biomarker	[3018]
FEZ1	OTWCXPRE	Strong	Genetic Variation	[3019]
FGA	OTMIHY80	Strong	Biomarker	[3020]
FGD1	OTV3T64P	Strong	Altered Expression	[3021]
FGD3	OTIH6283	Strong	Biomarker	[3022]
FGD4	OTYXJQCW	Strong	Biomarker	[3023]
FGD5	OT5VIRP2	Strong	Altered Expression	[3024]
FGF13	OTHNNVSG	Strong	Biomarker	[907]
FGF17	OTAQSFZ2	Strong	Altered Expression	[3025]
FGF5	OTQXGHBY	Strong	Biomarker	[3026]
FGL1	OTT0QHQ1	Strong	Biomarker	[2546]
FHL2	OT0OAYWT	Strong	Altered Expression	[3027]
FHL3	OTMPRLZ5	Strong	Biomarker	[3028]
FHL5	OT6C00Z1	Strong	Genetic Variation	[651]
FHOD1	OTROM7N3	Strong	Biomarker	[3029]
FLACC1	OTZN9TZV	Strong	Biomarker	[674]
FLCN	OTVM78XM	Strong	Genetic Variation	[3030]
FLG	OTE9QDV6	Strong	Biomarker	[3031]
FLII	OT7G9JG6	Strong	Biomarker	[3032]
FLOT1	OT0JPPJZ	Strong	Altered Expression	[3033]
FLT3LG	OTU0YGC4	Strong	Biomarker	[3034]
FMN1	OT9CID5R	Strong	Genetic Variation	[743]
FMOD	OT9EJ5H8	Strong	Biomarker	[3035]
FNBP1L	OTH1S2P2	Strong	Altered Expression	[3036]
FOSB	OTW6C05J	Strong	Biomarker	[1616]
FOXD1	OT80PRHS	Strong	Altered Expression	[3037]
FOXD3	OTXYV6GO	Strong	Biomarker	[3038]
FOXF1	OT2CJZ5K	Strong	Biomarker	[3039]
FOXJ1	OT7LLBZ7	Strong	Biomarker	[3040]
FOXK1	OTLZGS7J	Strong	Altered Expression	[3041]
FOXK2	OTFXDZ3R	Strong	Altered Expression	[3042]
FOXL1	OT89XFPN	Strong	Biomarker	[3043]
FOXP4	OTHCGIEZ	Strong	Altered Expression	[3044]
FOXS1	OTPM9TZ5	Strong	Altered Expression	[3045]
FRAT1	OT1PS84E	Strong	Altered Expression	[3046]
FRK	OTEKV1SC	Strong	Biomarker	[3047]
FRS2	OTDMD800	Strong	Biomarker	[3048]
FRY	OT74IAG2	Strong	Altered Expression	[3049]
FRZB	OTTO3DPY	Strong	Genetic Variation	[3050]
FSD1	OT8P6PT3	Strong	Altered Expression	[3051]
FSD1L	OTBQ48RF	Strong	Altered Expression	[3051]
FUBP1	OT77SC9N	Strong	Altered Expression	[3052]
FUCA1	OTW71IK4	Strong	Biomarker	[3053]
FUT1	OTODG57A	Strong	Biomarker	[3054]
FUT2	OTLXM6WI	Strong	Biomarker	[3054]
FUT6	OTBZUQ7F	Strong	Altered Expression	[3055]
FXYD3	OT9PPRHE	Strong	Biomarker	[3056]
FXYD5	OT81DIOD	Strong	Biomarker	[3057]
FYB1	OT6345CH	Strong	Altered Expression	[3058]
FZD3	OTIWDN78	Strong	Biomarker	[3059]
FZD4	OTGLZIE0	Strong	Biomarker	[399]
FZD5	OTXFFY56	Strong	Altered Expression	[2284]
FZD6	OTBCPII8	Strong	Genetic Variation	[3060]
FZR1	OT0WGWZS	Strong	Altered Expression	[3061]
G0S2	OT8FL49L	Strong	Biomarker	[3062]
G3BP2	OTAWW3KI	Strong	Biomarker	[3063]
GAB2	OTBFN705	Strong	Biomarker	[3064]
GADD45A	OTDRV63V	Strong	Altered Expression	[3065]
GADD45G	OT8V1J4M	Strong	Biomarker	[3066]
GAL3ST1	OTSFFZRD	Strong	Altered Expression	[3067]
GALNT16	OTUBTPGE	Strong	Genetic Variation	[3068]
GALNT4	OT6WKC13	Strong	Biomarker	[3069]
GALNT9	OTFRD9RI	Strong	Biomarker	[502]
GAS1	OTKJXG52	Strong	Biomarker	[3070]
GAS7	OT0M5TNY	Strong	Biomarker	[2842]
GAS8	OT8KT2AK	Strong	Genetic Variation	[3071]
GATA1	OTX1R7O1	Strong	Biomarker	[3072]
GATA5	OTO81B63	Strong	Altered Expression	[3073]
GATA6	OTO2BC0F	Strong	Altered Expression	[3073]
GBP2	OTVU4G07	Strong	Biomarker	[3074]
GBX2	OTW0ZI4D	Strong	Biomarker	[3075]
GCM2	OTSKNPTI	Strong	Biomarker	[3076]
GCNT2	OTRUIMC4	Strong	Biomarker	[3077]
GCSH	OTNC1OKA	Strong	Biomarker	[3078]
GDF1	OTZ1VRBH	Strong	Genetic Variation	[3079]
GDF10	OTEVXGJ7	Strong	Biomarker	[3080]
GDF11	OTOSNMND	Strong	Biomarker	[1301]
GDF3	OTD3KGJK	Strong	Altered Expression	[3081]
GDPD2	OTKEPVWI	Strong	Altered Expression	[3082]
GEMIN2	OT4L6TLL	Strong	Biomarker	[3083]
GEN1	OT1XFQXF	Strong	Biomarker	[3084]
GFM1	OTUN4V3N	Strong	Biomarker	[3085]
GGN	OTKPYNWP	Strong	Genetic Variation	[3086]
GGNBP2	OT7K9YZV	Strong	Altered Expression	[3086]
GIGYF2	OTFNVEJ4	Strong	Posttranslational Modification	[2784]
GINS1	OTVQZMMQ	Strong	Altered Expression	[3087]
GIPC1	OTXLVCPJ	Strong	Biomarker	[3088]
GIPC2	OT68YFO1	Strong	Altered Expression	[3089]
GIT1	OTHO92S5	Strong	Altered Expression	[3090]
GLCE	OTPRSHX5	Strong	Genetic Variation	[3091]
GLI3	OTKDOE94	Strong	Biomarker	[3092]
GLUD1	OTXKOCUH	Strong	Altered Expression	[3093]
GNA13	OTVDL515	Strong	Altered Expression	[3094]
GNAI2	OTTLGRGH	Strong	Biomarker	[3095]
GNLY	OTZJKA8C	Strong	Biomarker	[3096]
GOLGA1	OTBBPBG0	Strong	Altered Expression	[3097]
GOLM1	OTOZSV6O	Strong	Altered Expression	[3098]
GOLPH3	OTDLGYM3	Strong	Biomarker	[3099]
GOPC	OTRBGH71	Strong	Genetic Variation	[1909]
GORASP1	OTQS91S7	Strong	Biomarker	[1605]
GPAA1	OTWVRR35	Strong	Altered Expression	[3100]
GPATCH2	OT09TY4W	Strong	Biomarker	[3101]
GPC1	OTQKRSSV	Strong	Altered Expression	[3102]
GPC2	OT3WSQE1	Strong	Altered Expression	[3103]
GPC6	OTNJBESF	Strong	Biomarker	[3104]
GPLD1	OTUUQOVY	Strong	Biomarker	[3105]
GPR161	OT80FYA3	Strong	Biomarker	[3106]
GPR19	OTR7MUS5	Strong	Altered Expression	[3107]
GPR42	OTEB0ROY	Strong	Biomarker	[399]
GPR50	OT0EJBM4	Strong	Altered Expression	[3108]
GPSM2	OT6RPMRM	Strong	Biomarker	[3109]
GPT2	OTS5VF7N	Strong	Biomarker	[3110]
GPX4	OTRAFFX2	Strong	Biomarker	[3111]
GPX7	OTINT9Z4	Strong	Altered Expression	[3112]
GRAMD1B	OTCG1GX2	Strong	Biomarker	[3113]
GRAP2	OTS5NIZ3	Strong	Altered Expression	[370]
GRB14	OTFET2YM	Strong	Biomarker	[3114]
GRB7	OTF8Y9XY	Strong	Altered Expression	[3115]
GRID1	OTJ3WIKC	Strong	Genetic Variation	[743]
GRID2	OTJ3R10R	Strong	Genetic Variation	[743]
GRIN3B	OT7T1OJP	Strong	Biomarker	[935]
GRK4	OTUU8V2S	Strong	Biomarker	[3116]
GSDMB	OTWA7P10	Strong	Altered Expression	[3117]
GSDME	OT1ZWY32	Strong	Biomarker	[3118]
GSE1	OT3J7CJB	Strong	Biomarker	[3119]
GSPT1	OT18H1B0	Strong	Genetic Variation	[3120]
GSTM5	OTMMBFY8	Strong	Genetic Variation	[1753]
GTF2H1	OTCRXC6B	Strong	Biomarker	[2859]
GTF2H4	OTPD1DIU	Strong	Genetic Variation	[1861]
GTF2I	OTUYL1TQ	Strong	Biomarker	[3121]
GTF3A	OTVROUVQ	Strong	Biomarker	[3122]
GTSE1	OTPP742Z	Strong	Altered Expression	[3123]
GUCY1A2	OTR6DVAA	Strong	Biomarker	[827]
GYPA	OTABU4YV	Strong	Biomarker	[3124]
GYPB	OTESHUIX	Strong	Biomarker	[3125]
GYPE	OTBHAG6A	Strong	Biomarker	[3125]
GZMM	OTEC5CWT	Strong	Altered Expression	[3126]
H1-2	OT0AVI4M	Strong	Biomarker	[2703]
H2AC20	OTEIVLM1	Strong	Altered Expression	[3127]
H2AJ	OTVA4XTW	Strong	Biomarker	[3128]
H2AX	OT18UX57	Strong	Altered Expression	[3129]
H2BC12	OTQ8V0KG	Strong	Biomarker	[2703]
H2BC21	OT0FDCUC	Strong	Altered Expression	[3130]
H4C1	OTB71W46	Strong	Genetic Variation	[3131]
HACD1	OTEC7EP7	Strong	Biomarker	[1162]
HADHB	OT4Y1I62	Strong	Biomarker	[1293]
HAPLN3	OTB853Z1	Strong	Biomarker	[3132]
HAPLN4	OTZQOG9A	Strong	Biomarker	[674]
HAS2	OTTD3PAL	Strong	Biomarker	[3133]
HAT1	OT307KEN	Strong	Altered Expression	[3134]
HAVCR2	OTOL603T	Strong	Biomarker	[3135]
HBP1	OTDPGGDV	Strong	Biomarker	[3136]
HCLS1	OTX7WGYN	Strong	Altered Expression	[1088]
HDLBP	OTKDEEYX	Strong	Biomarker	[3137]
HEATR6	OTD3MYS0	Strong	Altered Expression	[3138]
HEBP1	OTR9MPDX	Strong	Altered Expression	[2606]
HECW1	OT1PVAZA	Strong	Biomarker	[3139]
HELLS	OTVVV668	Strong	Biomarker	[1672]
HELQ	OTL1STJT	Strong	Genetic Variation	[3140]
HEPH	OTZ2F15Z	Strong	Altered Expression	[3141]
HERC2	OTNQYKOB	Strong	Altered Expression	[3142]
HES1	OT8P19W2	Strong	Altered Expression	[3143]
HEY1	OTJQL0I3	Strong	Biomarker	[3144]
HEY2	OTU4J3ZI	Strong	Biomarker	[3144]
HEYL	OTN7BH79	Strong	Genetic Variation	[3145]
HFM1	OTHV3EFE	Strong	Biomarker	[3146]
HHEX	OTLIUVYX	Strong	Genetic Variation	[1094]
HHIP	OT77RQYS	Strong	Genetic Variation	[1385]
HIC1	OTI9TWY4	Strong	Biomarker	[3147]
HIVEP2	OTVOMCW4	Strong	Biomarker	[3148]
HIVEP3	OTM3QT3L	Strong	Altered Expression	[3149]
HJURP	OTWMV16B	Strong	Altered Expression	[3150]
HJV	OT4235J2	Strong	Altered Expression	[1389]
HLA-DRA	OT7KZMP2	Strong	Altered Expression	[3058]
HLA-DRB3	OT5PM9N7	Strong	Genetic Variation	[3151]
HLA-DRB5	OTUX5TWM	Strong	Genetic Variation	[3152]
HLCS	OTPDUX30	Strong	Biomarker	[2841]
HM13	OTGEO1LP	Strong	Altered Expression	[3153]
HMGB3	OTCJ2EZY	Strong	Biomarker	[3154]
HMGN2	OTN20MEF	Strong	Biomarker	[3155]
HMGN5	OTUUAHVQ	Strong	Biomarker	[3156]
HNF4G	OTTSIHJP	Strong	Genetic Variation	[2730]
HNRNPC	OT47AK4C	Strong	Biomarker	[3157]
HNRNPF	OTSMBXMF	Strong	Biomarker	[3158]
HNRNPK	OTNPRM8U	Strong	Biomarker	[1293]
HNRNPL	OT0DJX74	Strong	Genetic Variation	[3159]
HNRNPM	OTFU3OEZ	Strong	Altered Expression	[3160]
HNRNPR	OT3FITK2	Strong	Biomarker	[1293]
HOPX	OTBSR6C9	Strong	Biomarker	[3161]
HOXA4	OTNVTQDT	Strong	Posttranslational Modification	[3162]
HOXA9	OTKNK5H0	Strong	Biomarker	[2301]
HOXB2	OTTD6HMV	Strong	Biomarker	[3163]
HOXB4	OTH1HRW5	Strong	Biomarker	[3164]
HOXB7	OTC7WYU8	Strong	Altered Expression	[3165]
HOXB8	OTKHOD17	Strong	Biomarker	[3166]
HOXB9	OTMVHQOU	Strong	Biomarker	[3167]
HOXC10	OT5WF17M	Strong	Biomarker	[3168]
HOXC11	OT8NMHM6	Strong	Biomarker	[3169]
HOXC6	OTBCRAZV	Strong	Altered Expression	[3170]
HOXC8	OTJUYU8J	Strong	Biomarker	[3171]
HOXD10	OT0NOWU2	Strong	Altered Expression	[3172]
HOXD11	OT9XGA4G	Strong	Biomarker	[3173]
HOXD3	OTBUZ35T	Strong	Altered Expression	[3174]
HPR	OTXSC9UB	Strong	Biomarker	[2146]
HPS1	OTKS5I7T	Strong	Biomarker	[2546]
HPS5	OTLO2374	Strong	Biomarker	[1879]
HPSE2	OTGEPP8V	Strong	Genetic Variation	[3175]
HRG	OTPLUFOG	Strong	Biomarker	[3176]
HRNR	OT560QR5	Strong	Altered Expression	[3177]
HS3ST2	OTWFA0GJ	Strong	Altered Expression	[3178]
HS3ST3A1	OTUOM1GV	Strong	Biomarker	[3179]
HS3ST3B1	OTK53GUD	Strong	Biomarker	[3178]
HS6ST3	OTTW9PDL	Strong	Biomarker	[3180]
HSDL2	OT4IN0MV	Strong	Biomarker	[3181]
HSPA2	OTSDET7B	Strong	Altered Expression	[2419]
HSPA4	OT5HR0AR	Strong	Biomarker	[3182]
HSPB2	OTS01646	Strong	Biomarker	[1060]
HTN3	OTEUXA81	Strong	Biomarker	[3183]
HTRA2	OTC7616F	Strong	Altered Expression	[3184]
HUWE1	OTFH6BJS	Strong	Biomarker	[3185]
HYAL2	OTTVINXW	Strong	Posttranslational Modification	[3186]
HYOU1	OTBGBSOV	Strong	Altered Expression	[3187]
IBSP	OT29944Y	Strong	Biomarker	[3188]
ICAM4	OT1BI27E	Strong	Genetic Variation	[3189]
ICAM5	OTDGGAFH	Strong	Genetic Variation	[3190]
IFI16	OT4SPU0U	Strong	Altered Expression	[3191]
IFI44	OTOKSZVA	Strong	Altered Expression	[3192]
IFIT5	OTYTSO77	Strong	Altered Expression	[1126]
IFITM3	OT2QP8D3	Strong	Biomarker	[3193]
IFNA1	OTPMKY0L	Strong	Biomarker	[1505]
IFNLR1	OTWWWK45	Strong	Altered Expression	[3194]
IGDCC3	OTGR1KA4	Strong	Biomarker	[3195]
IGF2BP1	OT9G360P	Strong	Altered Expression	[3196]
IGF2BP2	OT4ZSEEE	Strong	Biomarker	[3197]
IGFBPL1	OTY4HVN8	Strong	Posttranslational Modification	[3198]
IGHMBP2	OTAZFPF5	Strong	Genetic Variation	[1294]
IKBKE	OT5VYOSM	Strong	Biomarker	[3199]
IL17B	OTS86H50	Strong	Biomarker	[3200]
IL17RB	OT0KDNSF	Strong	Altered Expression	[3201]
IL18BP	OTW0LRYZ	Strong	Biomarker	[1835]
IL18R1	OT83XMPQ	Strong	Altered Expression	[3202]
IL27	OTIS3OF8	Strong	Genetic Variation	[3203]
IL3	OT0CQ35N	Strong	Genetic Variation	[3204]
IL6R	OTCQL07Z	Strong	Biomarker	[3205]
IL6ST	OT1N9C70	Strong	Biomarker	[3206]
ILF2	OTWWVM9X	Strong	Altered Expression	[3207]
ILKAP	OT2A6FSA	Strong	Altered Expression	[3208]
ILRUN	OTE8FHQD	Strong	Altered Expression	[3209]
IMMP1L	OTA6LOLR	Strong	Altered Expression	[3196]
IMPACT	OTQ923OB	Strong	Biomarker	[3210]
INAVA	OTGXNB86	Strong	Biomarker	[3211]
INCENP	OT9HFRYK	Strong	Genetic Variation	[3212]
ING1	OTEZBRKW	Strong	Altered Expression	[3213]
ING2	OT6H0EWF	Strong	Altered Expression	[3214]
ING4	OT0VVG4V	Strong	Biomarker	[3215]
INHBB	OT2QLD11	Strong	Genetic Variation	[3216]
INPP4B	OTLROA7G	Strong	Biomarker	[3217]
INPP5F	OTPKUY50	Strong	Biomarker	[3218]
INSRR	OT3F75WA	Strong	Genetic Variation	[3219]
INTS6	OT6GDV46	Strong	Biomarker	[2867]
INTU	OTXB13E6	Strong	Altered Expression	[3220]
IPO13	OT887N3O	Strong	Biomarker	[3221]
IPO9	OT1DGLQE	Strong	Altered Expression	[3222]
IQGAP1	OTZRWTGA	Strong	Biomarker	[3223]
IQGAP3	OT4RZV2M	Strong	Altered Expression	[3224]
IQSEC1	OTK1PBFD	Strong	Biomarker	[3225]
IQUB	OTT1VKEF	Strong	Altered Expression	[3226]
IRF5	OT8SIIAP	Strong	Altered Expression	[3227]
IRF6	OTKJ44EV	Strong	Genetic Variation	[3228]
IRF7	OTC1A2PQ	Strong	Altered Expression	[579]
IRF9	OTK4MYQJ	Strong	Altered Expression	[3229]
IRS4	OTTOL40K	Strong	Biomarker	[3230]
IRX3	OTLJ48FG	Strong	Genetic Variation	[3231]
ISCU	OTSW6DQP	Strong	Biomarker	[3232]
ISL1	OTVNVKAX	Strong	Biomarker	[3233]
ISOC1	OTAO7Z87	Strong	Altered Expression	[3234]
IST1	OTSFEZ2O	Strong	Altered Expression	[3235]
ITFG1	OTX0PCR3	Strong	Biomarker	[3236]
ITGA2B	OT4Y17PY	Strong	Biomarker	[3237]
ITGA7	OTTBTAYW	Strong	Altered Expression	[3238]
ITGB3BP	OT6Q7GR3	Strong	Altered Expression	[3239]
ITGB5	OT21MF51	Strong	Biomarker	[3240]
ITIH2	OTG3WBBE	Strong	Altered Expression	[829]
ITIH4	OT460OO1	Strong	Biomarker	[3020]
ITIH5	OTP46PZM	Strong	Biomarker	[922]
ITM2B	OTMXEPXB	Strong	Biomarker	[3241]
ITPKA	OTX5ERUD	Strong	Altered Expression	[3242]
ITSN2	OT8S0OO8	Strong	Biomarker	[3095]
JMJD6	OTILR7E4	Strong	Biomarker	[3243]
JMJD7	OT8EJRD8	Strong	Biomarker	[3244]
JPH1	OTCAILYU	Strong	Altered Expression	[1373]
JPT1	OT6CRZEU	Strong	Altered Expression	[3245]
JPT2	OTJGPA4T	Strong	Biomarker	[3246]
JTB	OT314JB6	Strong	Altered Expression	[3247]
JUNB	OTG2JXV5	Strong	Biomarker	[3248]
JUND	OTNKACJD	Strong	Biomarker	[3249]
KANK1	OT2E7A6W	Strong	Altered Expression	[3250]
KANK2	OT3SZIWM	Strong	Biomarker	[2665]
KAT2A	OTN0W2SW	Strong	Biomarker	[3251]
KAT7	OTUN98IC	Strong	Biomarker	[3252]
KCNH4	OTHJ8WTU	Strong	Altered Expression	[2950]
KCNH8	OT3I5FLB	Strong	Altered Expression	[2950]
KCNIP3	OTCQPEM4	Strong	Biomarker	[3253]
KCNK1	OTBXPTKX	Strong	Genetic Variation	[3254]
KCNK5	OT68V64E	Strong	Biomarker	[3255]
KDM4B	OT5P1UPY	Strong	Altered Expression	[3256]
KDM6A	OTZM3MJJ	Strong	Biomarker	[3257]
KHSRP	OTDHZARB	Strong	Altered Expression	[1088]
KIDINS220	OTLBH2MA	Strong	Genetic Variation	[3258]
KIF12	OTTALNDD	Strong	Altered Expression	[3259]
KIF14	OTXHT4JM	Strong	Altered Expression	[3260]
KIF15	OTJRJEXL	Strong	Biomarker	[3261]
KIF17	OTHASX9G	Strong	Biomarker	[3262]
KIF20A	OTXOQHE0	Strong	Altered Expression	[3263]
KIF22	OTY6X6BL	Strong	Biomarker	[3264]
KIF23	OTY850JC	Strong	Biomarker	[3261]
KIF2C	OTJ8G3NP	Strong	Altered Expression	[3265]
KIF5B	OTT34MT8	Strong	Altered Expression	[3266]
KIN	OTB2DNQU	Strong	Biomarker	[3267]
KIR2DL5B	OTSV0JL9	Strong	Biomarker	[3268]
KIR3DL1	OTPOSXFX	Strong	Genetic Variation	[384]
KL	OTD4VWU6	Strong	Altered Expression	[3269]
KLC1	OTSTTTW7	Strong	Altered Expression	[3266]
KLF10	OT4F4UGS	Strong	Altered Expression	[3270]
KLF11	OTKVQDJD	Strong	Biomarker	[3271]
KLF15	OTGMQMVR	Strong	Altered Expression	[3272]
KLF5	OT1ABI9N	Strong	Biomarker	[3273]
KLF6	OTQY9S7F	Strong	Altered Expression	[3274]
KLF8	OTUC5CDB	Strong	Altered Expression	[3275]
KLHDC10	OTLDF1OX	Strong	Biomarker	[674]
KLHDC7A	OTZAAF38	Strong	Biomarker	[674]
KLHDC7B	OT2H5BNX	Strong	Altered Expression	[3276]
KLHL22	OTNRE2DW	Strong	Altered Expression	[3277]
KLHL7	OT2OF1O8	Strong	Altered Expression	[3278]
KLK10	OTD573EL	Strong	Biomarker	[3279]
KLK11	OT5PKX7Y	Strong	Altered Expression	[3280]
KLK12	OTNYK59J	Strong	Altered Expression	[3281]
KLK13	OT8LOD2U	Strong	Altered Expression	[3282]
KLK15	OT7BVG17	Strong	Biomarker	[3283]
KLK9	OTGJWBIF	Strong	Biomarker	[3284]
KMT2B	OTMMAZQX	Strong	Biomarker	[3285]
KRIT1	OT58AP1I	Strong	Biomarker	[2228]
KRR1	OTCMJ3K3	Strong	Biomarker	[3286]
KRT1	OTIOJWA4	Strong	Biomarker	[3287]
KRT14	OTUVZ1DW	Strong	Altered Expression	[2530]
KRT18	OTVLQFIP	Strong	Altered Expression	[3288]
KRT20	OT4RB40L	Strong	Biomarker	[3289]
KRT5	OTVGI9HT	Strong	Genetic Variation	[1857]
KRT80	OTAU54U3	Strong	Biomarker	[3290]
KRT81	OTMKIK2S	Strong	Altered Expression	[3291]
L3MBTL4	OTERBGKR	Strong	Biomarker	[3292]
LACTB	OTRWGNBF	Strong	Biomarker	[3293]
LAD1	OT6YGTVX	Strong	Biomarker	[1103]
LAMA3	OTFME7HT	Strong	Posttranslational Modification	[3294]
LAMP3	OTN0XL3W	Strong	Altered Expression	[3295]
LAMTOR5	OTER0U8L	Strong	Biomarker	[3296]
LARP6	OTUQ9QS9	Strong	Biomarker	[3297]
LATS1	OTOOCG4R	Strong	Biomarker	[1950]
LBR	OT1HG3HG	Strong	Altered Expression	[2323]
LBX1	OTQJHICM	Strong	Biomarker	[3298]
LCN1	OT8BWXTV	Strong	Biomarker	[3299]
LDB1	OT20EAPR	Strong	Altered Expression	[3300]
LDHAL6B	OT3T9D1S	Strong	Biomarker	[817]
LDLRAD1	OTG1GL9H	Strong	Genetic Variation	[2671]
LEF1	OTWS5I5H	Strong	Altered Expression	[3301]
LEPROT	OT2EENVA	Strong	Biomarker	[2497]
LGALS3BP	OT9AGQKH	Strong	Biomarker	[3302]
LGALS4	OTKQCG0H	Strong	Altered Expression	[398]
LGALS7	OTMSVI7R	Strong	Altered Expression	[3303]
LGALS8	OT71LJ8T	Strong	Biomarker	[673]
LGALSL	OTC983KJ	Strong	Biomarker	[3304]
LHB	OT5GBOVJ	Strong	Biomarker	[3305]
LIG1	OTEEQS43	Strong	Altered Expression	[3306]
LIMA1	OTONPC9R	Strong	Altered Expression	[3307]
LIMD2	OTSIFTD8	Strong	Biomarker	[3308]
LIN28B	OTVWP0FN	Strong	Biomarker	[3309]
LIN9	OTLHW00C	Strong	Altered Expression	[3310]
LLGL1	OTAIQSXZ	Strong	Biomarker	[856]
LLGL2	OTU8ZDC4	Strong	Biomarker	[1471]
LMLN	OTQF0JPY	Strong	Biomarker	[3311]
LMO4	OT5NDCT9	Strong	Biomarker	[3121]
LOXL1	OTA0NEJU	Strong	Altered Expression	[2324]
LPIN1	OTQ75KF2	Strong	Altered Expression	[3312]
LPP	OT6TU8SE	Strong	Posttranslational Modification	[3313]
LRATD2	OTEZBUUL	Strong	Biomarker	[3314]
LRG1	OTLD0KWA	Strong	Altered Expression	[3315]
LRP8	OTZ71YV2	Strong	Altered Expression	[3316]
LRRC1	OTSVD30Q	Strong	Biomarker	[3317]
LRRC37A	OT41U0KO	Strong	Biomarker	[674]
LRRC37A2	OT9UI93T	Strong	Biomarker	[674]
LRRC3B	OT9VDGPR	Strong	Biomarker	[674]
LRRC4	OT7XJ70N	Strong	Altered Expression	[2659]
LRRC49	OT9SOV66	Strong	Posttranslational Modification	[3318]
LRRC59	OT6BQJ5E	Strong	Biomarker	[3319]
LRTOMT	OTMLESUJ	Strong	Genetic Variation	[3320]
LSM2	OTHL77NY	Strong	Biomarker	[3321]
LSP1	OTSPSIFO	Strong	Genetic Variation	[3322]
LSR	OTR8Y32X	Strong	Biomarker	[3323]
LUM	OTSRC874	Strong	Biomarker	[3324]
LY6E	OTMG16BZ	Strong	Altered Expression	[3325]
LYPD4	OTYNO8BS	Strong	Biomarker	[3326]
LZTFL1	OTIEIOEW	Strong	Altered Expression	[3327]
LZTS1	OTXXL864	Strong	Biomarker	[3328]
MACC1	OTV3DLX0	Strong	Genetic Variation	[3329]
MACF1	OTVIHD77	Strong	Altered Expression	[3330]
MACROD1	OTWFEVRW	Strong	Altered Expression	[3331]
MADD	OTUFYVGG	Strong	Altered Expression	[3332]
MAEA	OTPA2FDE	Strong	Altered Expression	[3333]
MAEL	OTZ2VU30	Strong	Altered Expression	[3334]
MAGED2	OTMEWNSE	Strong	Biomarker	[1804]
MAGED4B	OTO37U7W	Strong	Genetic Variation	[1179]
MAGEE2	OTL3E0G7	Strong	Biomarker	[567]
MAGI3	OTDJ5QUH	Strong	Biomarker	[3335]
MAGT1	OTQSAV5C	Strong	Biomarker	[676]
MAK16	OTD546E5	Strong	Biomarker	[3336]
MAL	OTBM30SW	Strong	Biomarker	[1980]
MAL2	OTVPEI80	Strong	Biomarker	[3337]
MAN1A1	OT6LIGJP	Strong	Biomarker	[3338]
MAN2C1	OT17VT8D	Strong	Biomarker	[674]
MANEA	OTV7L8I6	Strong	Altered Expression	[3339]
MAP1LC3A	OTPMGIU4	Strong	Altered Expression	[3340]
MAP2	OT6UYT3X	Strong	Biomarker	[3341]
MAP2K4	OTZPZX11	Strong	Altered Expression	[3342]
MAP3K13	OTS93BTX	Strong	Biomarker	[1998]
MAP9	OTZD5099	Strong	Biomarker	[3343]
MAPK13	OT0W9GE7	Strong	Biomarker	[3344]
MAPK15	OT8SW0L7	Strong	Biomarker	[3345]
MAPK6	OTDDNF3Q	Strong	Biomarker	[3346]
MAPRE1	OTCVQD60	Strong	Biomarker	[3347]
MARCHF8	OTH7PNN2	Strong	Genetic Variation	[3348]
MARCKSL1	OT13J2FM	Strong	Altered Expression	[1200]
MARVELD1	OT5CPOJE	Strong	Altered Expression	[3349]
MASTL	OTQ7YKK5	Strong	Altered Expression	[3350]
MATK	OTVOJJLJ	Strong	Biomarker	[3351]
MATN1	OTBRTCTQ	Strong	Biomarker	[3352]
MAX	OTKZ0YKM	Strong	Biomarker	[3353]
MBD1	OTD19VO6	Strong	Genetic Variation	[1746]
MBD4	OTWR9YXE	Strong	Posttranslational Modification	[3354]
MCAT	OTH07FIW	Strong	Biomarker	[1449]
MCC	OTQVI1EM	Strong	Genetic Variation	[3355]
MCF2L	OTEURA8N	Strong	Biomarker	[3356]
MCF2L2	OTOGFMIH	Strong	Biomarker	[3357]
MCM10	OTV0O3JN	Strong	Biomarker	[3358]
MCM8	OTC93H3S	Strong	Genetic Variation	[3359]
MCPH1	OTYT3TT5	Strong	Biomarker	[1449]
MCTS1	OT7SAOJP	Strong	Altered Expression	[821]
ME3	OT3XMLYG	Strong	Biomarker	[3360]
MECOM	OTP983W8	Strong	Biomarker	[770]
MED1	OTOO24C4	Strong	Altered Expression	[3361]
MED12	OTQZ4D2X	Strong	Genetic Variation	[3362]
MED18	OT6M6CQ8	Strong	Genetic Variation	[3363]
MED23	OTKZQT0R	Strong	Biomarker	[3364]
MED25	OTDBY87B	Strong	Biomarker	[3365]
MED28	OTEDM1L5	Strong	Biomarker	[3366]
MED7	OTGF64SM	Strong	Altered Expression	[3367]
MEF2B	OT880SE6	Strong	Altered Expression	[1185]
MEIS1	OTH9DKAD	Strong	Altered Expression	[3368]
MEN1	OTN6U6V0	Strong	Altered Expression	[3369]
MEOX1	OTJEMT2D	Strong	Biomarker	[3370]
MEST	OT8Q4U8Y	Strong	Biomarker	[3371]
METTL3	OTSXP1M3	Strong	Biomarker	[3372]
METTL6	OTYAOD1Q	Strong	Biomarker	[1685]
MFAP1	OTZN4FT3	Strong	Biomarker	[1734]
MFAP5	OT46VXSG	Strong	Altered Expression	[778]
MGA	OTTLB216	Strong	Altered Expression	[3373]
MGAT3	OTXI5X4T	Strong	Altered Expression	[3374]
MGAT5	OTU4DD4G	Strong	Biomarker	[3375]
MGP	OTZWU3FU	Strong	Biomarker	[3376]
MGRN1	OTFZC41K	Strong	Biomarker	[2421]
MIB1	OT5C404P	Strong	Biomarker	[3377]
MIB2	OTJCC3HS	Strong	Biomarker	[3378]
MICAL1	OTJEDVWA	Strong	Biomarker	[3379]
MICAL2	OT04OQQJ	Strong	Biomarker	[3380]
MIER3	OTL5BGOB	Strong	Genetic Variation	[3381]
MIIP	OT79EXZ7	Strong	Altered Expression	[3382]
MINAR1	OTV1X2R0	Strong	Altered Expression	[3383]
MLH3	OT91PPBI	Strong	Genetic Variation	[3384]
MLKL	OTDSLC81	Strong	Altered Expression	[3385]
MLN	OTBZ5SE5	Strong	Biomarker	[2524]
MLXIP	OT30UNI7	Strong	Genetic Variation	[3348]
MMD	OTB5I4OC	Strong	Biomarker	[3386]
MMP26	OT9O89KU	Strong	Biomarker	[3387]
MMRN1	OT7ZNYHT	Strong	Biomarker	[3388]
MMUT	OTBBBV70	Strong	Biomarker	[3389]
MNAT1	OTXLOYCB	Strong	Altered Expression	[3390]
MNT	OTPC4ANL	Strong	Biomarker	[3391]
MNX1	OTXP9FH1	Strong	Biomarker	[3392]
MPC1	OT6DYFUO	Strong	Altered Expression	[3393]
MPEG1	OT7DAO0F	Strong	Altered Expression	[1069]
MPG	OTAHW80B	Strong	Altered Expression	[3394]
MPHOSPH10	OT8DJTO7	Strong	Biomarker	[3395]
MPST	OTCDPH5D	Strong	Altered Expression	[1186]
MPZL2	OTKFNDUI	Strong	Genetic Variation	[3396]
MRE11	OTGU8TZM	Strong	Biomarker	[3397]
MRPL13	OT6D8Y9G	Strong	Biomarker	[1293]
MRPL19	OTRBKF6R	Strong	Biomarker	[1293]
MRPL28	OT4LUTZU	Strong	Posttranslational Modification	[1416]
MRPL34	OTOR0EVV	Strong	Genetic Variation	[743]
MRPL36	OTZ9QV3U	Strong	Genetic Variation	[3398]
MRPL9	OT3I6W77	Strong	Biomarker	[1293]
MRPS18A	OTFCBPX2	Strong	Altered Expression	[3399]
MRPS18C	OTL868QS	Strong	Genetic Variation	[3140]
MRPS22	OTIVNAJL	Strong	Biomarker	[1293]
MRPS23	OTDVWT5V	Strong	Biomarker	[3400]
MRPS28	OT8CLJ6M	Strong	Biomarker	[1293]
MRPS30	OTDXIAGG	Strong	Genetic Variation	[3401]
MRPS7	OT57AX7G	Strong	Biomarker	[1293]
MSH4	OTJZMG1Z	Strong	Genetic Variation	[3402]
MSN	OTZJ4J6G	Strong	Altered Expression	[3403]
MSRB3	OT4UZXMN	Strong	Biomarker	[3404]
MST1	OTOC4UNG	Strong	Altered Expression	[490]
MSTO1	OT37XCNP	Strong	Altered Expression	[1186]
MSX2	OT1WDKE1	Strong	Altered Expression	[3405]
MT1B	OTUA4FFH	Strong	Biomarker	[1233]
MT1E	OTXJKU4Y	Strong	Biomarker	[1233]
MT1F	OTZVUYG1	Strong	Biomarker	[1233]
MT1H	OT0MVBM6	Strong	Biomarker	[1233]
MT3	OTVCZ7HI	Strong	Altered Expression	[3406]
MTA2	OTCCYIQJ	Strong	Biomarker	[3407]
MTA3	OTIA6C79	Strong	Biomarker	[3408]
MTFR2	OTLOR68D	Strong	Altered Expression	[3409]
MTHFD1	OTMKHVWC	Strong	Genetic Variation	[3410]
MTHFD2	OT1LQSGX	Strong	Biomarker	[3411]
MTMR3	OTBIT23O	Strong	Altered Expression	[3412]
MTPN	OT5N60RU	Strong	Altered Expression	[3413]
MTSS1	OT5DTDO2	Strong	Biomarker	[3414]
MTX1	OTLSDNZO	Strong	Biomarker	[3415]
MUC19	OTM06UGV	Strong	Altered Expression	[3416]
MUC2	OT3X4QVX	Strong	Biomarker	[3417]
MUC3A	OTI4XUDY	Strong	Biomarker	[1237]
MUC6	OTPVL723	Strong	Biomarker	[3418]
MUCL1	OT9QUFL3	Strong	Biomarker	[3419]
MUS81	OTVZ4E60	Strong	Genetic Variation	[3420]
MVP	OTJGHJRB	Strong	Biomarker	[3421]
MXI1	OTUQ9E0D	Strong	Altered Expression	[3422]
MYBBP1A	OTIVEMIU	Strong	Biomarker	[3287]
MYBL2	OTZ3JX8Q	Strong	Biomarker	[3423]
MYCBPAP	OT3W21WR	Strong	Biomarker	[2212]
MYCL	OT1MFQ5U	Strong	Genetic Variation	[1949]
MYDGF	OT9HRPL6	Strong	Biomarker	[3424]
MYEOV	OTDC7UHL	Strong	Biomarker	[3425]
MYH11	OTVNVWY3	Strong	Genetic Variation	[3426]
MYH9	OT94Z706	Strong	Altered Expression	[3427]
MYL4	OTURFCSE	Strong	Altered Expression	[2755]
MYLIP	OTL0PFGV	Strong	Genetic Variation	[3348]
MYO10	OTHB78ZQ	Strong	Biomarker	[3428]
MYO1C	OT69L39Y	Strong	Altered Expression	[3429]
MYO9B	OTQ94R5K	Strong	Genetic Variation	[743]
MYOF	OTRFC3IJ	Strong	Altered Expression	[2322]
MYT1L	OTV45MAS	Strong	Altered Expression	[3430]
MZF1	OTMVZCPW	Strong	Altered Expression	[3431]
NAA10	OTYB9R6I	Strong	Biomarker	[3432]
NAA16	OTWMA7LK	Strong	Biomarker	[1460]
NABP1	OTFTNFHW	Strong	Biomarker	[3433]
NAF1	OTMJKJAK	Strong	Biomarker	[2064]
NANOS1	OT3UNZZY	Strong	Altered Expression	[3434]
NANS	OTMQ2FUH	Strong	Biomarker	[3435]
NAV1	OT667KTL	Strong	Biomarker	[2995]
NBPF1	OTAZ55UQ	Strong	Posttranslational Modification	[3436]
NBR1	OTVRL7J9	Strong	Biomarker	[3437]
NCAM2	OT8LBJN8	Strong	Biomarker	[3438]
NCAPG2	OTZYENKO	Strong	Biomarker	[3439]
NCBP2	OTQNZTE4	Strong	Altered Expression	[2640]
NCKAP1	OTEZQXXJ	Strong	Altered Expression	[3440]
NCKIPSD	OT24UORN	Strong	Biomarker	[968]
NCOA1	OTLIUJQD	Strong	Biomarker	[3441]
NCOA5	OTOGWTWB	Strong	Biomarker	[3442]
NCOA6	OTOMIGTV	Strong	Altered Expression	[3443]
NCOA7	OT2CNBOG	Strong	Genetic Variation	[3444]
NCOR1	OT04XNOU	Strong	Biomarker	[3445]
NCOR2	OTY917X0	Strong	Genetic Variation	[3446]
NCR2	OT2H13BX	Strong	Altered Expression	[3447]
NCSTN	OT5QBTA4	Strong	Biomarker	[3448]
ND3	OT1OC3K3	Strong	Genetic Variation	[2598]
ND4	OT4RQVAA	Strong	Genetic Variation	[3449]
ND5	OT45LW1K	Strong	Genetic Variation	[3450]
NDP	OTGDJ4US	Strong	Altered Expression	[3451]
NDRG1	OTVO66BO	Strong	Biomarker	[835]
NDRG2	OT5L6KD7	Strong	Biomarker	[3452]
NDRG3	OTJTJCHD	Strong	Altered Expression	[3453]
NDUFB3	OTDV12IF	Strong	Genetic Variation	[3454]
NECAB3	OTRASC9G	Strong	Altered Expression	[2640]
NECTIN2	OTIE0W6O	Strong	Therapeutic	[3455]
NEDD4L	OT1B19RU	Strong	Altered Expression	[3456]
NEFL	OTQESJV4	Strong	Biomarker	[2182]
NEK10	OTN0JAYL	Strong	Genetic Variation	[3457]
NELFB	OTCFH88S	Strong	Biomarker	[3458]
NEMP1	OTWN3S47	Strong	Altered Expression	[3459]
NET1	OTZHNMJV	Strong	Altered Expression	[3460]
NEUROG3	OT6DIPWC	Strong	Biomarker	[3461]
NF1	OTC29NHH	Strong	Genetic Variation	[3462]
NFATC1	OT4TMERS	Strong	Altered Expression	[3463]
NFATC4	OTTDCUAO	Strong	Altered Expression	[3464]
NFE2L1	OT1QHOS2	Strong	Biomarker	[3465]
NFE2L3	OT1MGXT0	Strong	Altered Expression	[3466]
NFIB	OTX94PD0	Strong	Biomarker	[3467]
NFIC	OTLMCUIB	Strong	Biomarker	[1453]
NFYA	OTWFFOVH	Strong	Biomarker	[3468]
NHS	OTKE8QAT	Strong	Biomarker	[3469]
NIBAN2	OTVDQSPI	Strong	Biomarker	[3470]
NID1	OTKLBLS6	Strong	Biomarker	[3471]
NIN	OTVH3M4Z	Strong	Genetic Variation	[3472]
NIPBL	OTF6OOLU	Strong	Altered Expression	[3473]
NKAP	OT7K7I8Q	Strong	Altered Expression	[3474]
NKX2-1	OTCMEJTA	Strong	Altered Expression	[3475]
NLGN4X	OTDJGBK8	Strong	Altered Expression	[3476]
NMBR	OTBJEGPN	Strong	Altered Expression	[3477]
NME2	OTCYGLHV	Strong	Biomarker	[1782]
NOG	OTGRHHPG	Strong	Biomarker	[3478]
NOL3	OT1K0L0D	Strong	Biomarker	[3479]
NOL9	OTCCIJ8I	Strong	Biomarker	[3480]
NOP16	OT2829ZC	Strong	Altered Expression	[2093]
NOP9	OTA3O9QW	Strong	Biomarker	[827]
NOVA1	OT6A9KHY	Strong	Altered Expression	[3481]
NOVA2	OTQ2X3Q4	Strong	Biomarker	[3482]
NOX3	OT0FFJH8	Strong	Altered Expression	[1266]
NOX5	OTHTH59G	Strong	Biomarker	[3483]
NPAS2	OTMRT2TS	Strong	Biomarker	[310]
NPAS4	OTA3HH6W	Strong	Altered Expression	[3484]
NPC2	OTE9UEJC	Strong	Biomarker	[3485]
NPPA	OTMQNTNX	Strong	Altered Expression	[1088]
NPS	OTEG25A2	Strong	Biomarker	[3486]
NPTN	OTAQKSAU	Strong	Genetic Variation	[3487]
NR1D2	OT9CVF41	Strong	Biomarker	[310]
NR2E1	OTW47GKM	Strong	Biomarker	[783]
NR2E3	OTO3GBHQ	Strong	Biomarker	[3488]
NR2F1	OTGWZWYL	Strong	Biomarker	[3489]
NR2F2	OTJFS67N	Strong	Altered Expression	[3490]
NRBF2	OTXSUYCD	Strong	Genetic Variation	[3491]
NRCAM	OT80HHQ2	Strong	Genetic Variation	[3492]
NRDC	OTWBBCXO	Strong	Biomarker	[3493]
NRG2	OTMDE844	Strong	Altered Expression	[3494]
NRG3	OTIFZ5CT	Strong	Biomarker	[3495]
NRIP1	OTIZOJQV	Strong	Altered Expression	[3496]
NRM	OTK7F9XZ	Strong	Genetic Variation	[1990]
NSD2	OTQ6SW4R	Strong	Biomarker	[3497]
NSMCE2	OTJXLDC9	Strong	Biomarker	[3498]
NSUN2	OTZCNM33	Strong	Biomarker	[3499]
NSUN6	OTPBRUH6	Strong	Biomarker	[3500]
NT5C3A	OT67KZJA	Strong	Biomarker	[3501]
NTMT1	OTLRH78U	Strong	Biomarker	[3502]
NTN4	OTDRRMP3	Strong	Biomarker	[1464]
NTS	OTPGDNQS	Strong	Altered Expression	[1282]
NUDT1	OTZSES3W	Strong	Biomarker	[3503]
NUDT17	OTE8FOEW	Strong	Biomarker	[674]
NUDT2	OTMHM1DH	Strong	Biomarker	[3504]
NUDT5	OTHYCBA6	Strong	Biomarker	[3505]
NUMA1	OTTKAVG4	Strong	Genetic Variation	[3506]
NUP214	OTWEA19O	Strong	Biomarker	[3507]
NUP43	OTDF5K8Y	Strong	Biomarker	[3508]
NUP62	OTMN63DH	Strong	Biomarker	[2859]
NUP88	OT647WOR	Strong	Altered Expression	[3509]
NUP98	OTNT12G2	Strong	Altered Expression	[3510]
NUPR1	OT4FU8C0	Strong	Altered Expression	[3511]
NUSAP1	OT85HIJ5	Strong	Biomarker	[1081]
NXT1	OT0VO6AY	Strong	Posttranslational Modification	[1416]
OAS3	OT6E5FYS	Strong	Biomarker	[1337]
OAZ1	OTPT0PKZ	Strong	Biomarker	[3512]
OBP2A	OTBIJ5TI	Strong	Biomarker	[3264]
OCA2	OTDWIGBF	Strong	Genetic Variation	[3513]
OCLN	OTSUTVWL	Strong	Altered Expression	[3514]
OGDHL	OT1AZK6R	Strong	Genetic Variation	[3515]
OGN	OTKP5S4L	Strong	Altered Expression	[3516]
OGT	OT1Z1ZXE	Strong	Altered Expression	[3517]
OIP5	OTI5C2DE	Strong	Biomarker	[3518]
OMA1	OT0JRVY7	Strong	Altered Expression	[3519]
OPCML	OT93PQ6Y	Strong	Altered Expression	[3520]
OPN5	OTCYGHDA	Strong	Genetic Variation	[3521]
OPRPN	OT6K1ZD6	Strong	Biomarker	[3522]
OR10A4	OTYYB8SY	Strong	Genetic Variation	[3523]
OR2T6	OTJNNJ0M	Strong	Altered Expression	[3524]
ORC4	OT3ACTST	Strong	Genetic Variation	[2946]
OSCP1	OTZ4IFGJ	Strong	Altered Expression	[3525]
OSGIN1	OT9KIVZW	Strong	Biomarker	[3526]
OTUB1	OT8WWM9O	Strong	Biomarker	[3527]
OTUD1	OTE6O5XB	Strong	Biomarker	[3528]
OTUD3	OTHUWQHP	Strong	Genetic Variation	[3529]
OTUD4	OT7U62SW	Strong	Biomarker	[3530]
OTX1	OTRGSGH9	Strong	Altered Expression	[3531]
OTX2	OTTV05B1	Strong	Altered Expression	[3532]
P2RX5	OTLBR20R	Strong	Biomarker	[3533]
P4HB	OTTYNYPF	Strong	Biomarker	[2043]
PADI2	OTT40K94	Strong	Altered Expression	[3534]
PAF1	OTDDGUBQ	Strong	Genetic Variation	[3535]
PAGR1	OTXR5PQ8	Strong	Biomarker	[3536]
PAICS	OTMZN747	Strong	Biomarker	[3537]
PAIP1	OTL2F5T5	Strong	Altered Expression	[3538]
PAK6	OTAHPZTT	Strong	Altered Expression	[3539]
PALD1	OTLGUM8H	Strong	Biomarker	[3540]
PALLD	OTZ2MUJZ	Strong	Biomarker	[3540]
PAMR1	OT83ZH5U	Strong	Posttranslational Modification	[3541]
PANX1	OTXPEDOK	Strong	Altered Expression	[3542]
PAPOLG	OTIV69YA	Strong	Biomarker	[3543]
PAPPA	OTTTG9PG	Strong	Biomarker	[3544]
PARD3	OTH5BPLO	Strong	Altered Expression	[943]
PARN	OTTG4PE3	Strong	Altered Expression	[430]
PARP6	OTWSXW4O	Strong	Biomarker	[3545]
PARP9	OT7K4494	Strong	Biomarker	[3546]
PARVB	OT9OGVWX	Strong	Biomarker	[3547]
PAX2	OTKP1N8F	Strong	Biomarker	[3548]
PAX8	OTRPD9MI	Strong	Biomarker	[3549]
PAX9	OT25J0F7	Strong	Genetic Variation	[2730]
PAXIP1	OTRHTKG3	Strong	Altered Expression	[3550]
PBOV1	OT67PERT	Strong	Altered Expression	[3551]
PBX1	OTORABGO	Strong	Biomarker	[3552]
PBXIP1	OTEAAUBY	Strong	Biomarker	[3553]
PCARE	OTUSRSB5	Strong	Biomarker	[3554]
PCBP1	OTHN0TD7	Strong	Altered Expression	[2713]
PCBP4	OTDLL4NB	Strong	Biomarker	[917]
PCDH10	OT2GIT0E	Strong	Posttranslational Modification	[3555]
PCDH17	OTRK0M05	Strong	Altered Expression	[3556]
PCDH7	OTP091X8	Strong	Altered Expression	[3557]
PCDH8	OTDDOQM2	Strong	Biomarker	[3558]
PCDHGB6	OT1Y20JS	Strong	Biomarker	[3173]
PCGF2	OTIY1J5L	Strong	Biomarker	[3559]
PCNT	OTW4Z65J	Strong	Biomarker	[3560]
PDCD10	OTCHJTSF	Strong	Biomarker	[3561]
PDCD4	OTZ6NXUX	Strong	Biomarker	[1446]
PDCD6	OT2YA5M8	Strong	Altered Expression	[3562]
PDCD6IP	OTS8T6A7	Strong	Biomarker	[3563]
PDHB	OT2NHE5E	Strong	Biomarker	[1146]
PDHX	OTG7O271	Strong	Biomarker	[3564]
PDIA3	OTHPQ0Q3	Strong	Altered Expression	[3565]
PDIA6	OT8YBR17	Strong	Altered Expression	[3566]
PDIK1L	OTISF4KG	Strong	Biomarker	[3567]
PDK4	OTCMHMBZ	Strong	Biomarker	[3568]
PDLIM3	OTVXQC81	Strong	Biomarker	[700]
PDLIM5	OTLQVV22	Strong	Altered Expression	[1158]
PDPN	OTBUV19I	Strong	Altered Expression	[3569]
PDS5A	OT34P56Z	Strong	Biomarker	[3570]
PEAK1	OTVVM637	Strong	Biomarker	[538]
PEG10	OTWD2278	Strong	Biomarker	[3571]
PEG3	OTHQW98S	Strong	Biomarker	[3572]
PER2	OTU2B1DJ	Strong	Biomarker	[3573]
PER3	OTVKYVJA	Strong	Biomarker	[310]
PERP	OTP0YL53	Strong	Altered Expression	[2666]
PES1	OTMZK7XE	Strong	Altered Expression	[3574]
PEX14	OT98BZHE	Strong	Genetic Variation	[3575]
PFDN4	OT5NRHER	Strong	Altered Expression	[3576]
PFKFB4	OTQYEXL2	Strong	Biomarker	[3577]
PFKM	OT1QY9JM	Strong	Genetic Variation	[3578]
PFKP	OTFP7AA8	Strong	Altered Expression	[3579]
PFN1	OTHTGA1H	Strong	Biomarker	[3580]
PFN2	OT5SSSA7	Strong	Biomarker	[3581]
PGAM1	OTZ5DB06	Strong	Biomarker	[3582]
PGAP3	OTH9A75E	Strong	Biomarker	[1338]
PGK1	OT6V1ICH	Strong	Altered Expression	[3583]
PHB2	OTCAX3AW	Strong	Biomarker	[1800]
PHF2	OTJCIQR2	Strong	Biomarker	[3584]
PHF20	OTCBVH5P	Strong	Biomarker	[3378]
PHF20L1	OTCLYOCL	Strong	Biomarker	[3585]
PHF5A	OTS94JFM	Strong	Biomarker	[3586]
PHLDA1	OTFTWMIQ	Strong	Biomarker	[3587]
PHLDA3	OTXFUDO2	Strong	Altered Expression	[3588]
PHLDB1	OTIRCB6I	Strong	Biomarker	[2996]
PHPT1	OTFYWNFX	Strong	Biomarker	[3589]
PHRF1	OT21KEGX	Strong	Biomarker	[3590]
PI3	OT47MTC3	Strong	Altered Expression	[3591]
PIAS1	OTZVAHZI	Strong	Biomarker	[3592]
PIEZO1	OTBG1FU4	Strong	Biomarker	[3593]
PIEZO2	OTQ7AT38	Strong	Altered Expression	[3594]
PIGT	OTWA8819	Strong	Biomarker	[3595]
PIGX	OTUN0WC4	Strong	Biomarker	[3596]
PIK3C2A	OTFBU4GD	Strong	Biomarker	[3597]
PIK3C2B	OTY2PROB	Strong	Biomarker	[3598]
PIK3C3	OTLUM9L7	Strong	Biomarker	[3599]
PIK3IP1	OTWE5G4T	Strong	Biomarker	[3600]
PIK3R1	OT5BZ1J9	Strong	Biomarker	[764]
PIK3R2	OTZSUQK5	Strong	Biomarker	[3601]
PIK3R3	OTXGJ8N1	Strong	Altered Expression	[3602]
PIMREG	OTKC8T3E	Strong	Biomarker	[3603]
PIP4K2C	OTHRWR93	Strong	Biomarker	[425]
PIP5K1C	OT3LPG1R	Strong	Biomarker	[3604]
PITPNM1	OTIUYAG5	Strong	Biomarker	[3605]
PITPNM3	OTHLZY8D	Strong	Biomarker	[3606]
PITX1	OTA0UN4C	Strong	Altered Expression	[3607]
PKD1	OT5ALRZ5	Strong	Altered Expression	[920]
PKD2	OTIXBU8H	Strong	Biomarker	[920]
PKIB	OT7C8GFN	Strong	Biomarker	[3608]
PLAAT3	OTVXXJ5K	Strong	Biomarker	[3609]
PLAGL1	OTZAO900	Strong	Altered Expression	[3610]
PLAGL2	OT6AP4V2	Strong	Biomarker	[3611]
PLB1	OTZ6TTYV	Strong	Biomarker	[1325]
PLCB4	OTPA0QHW	Strong	Biomarker	[2485]
PLCD1	OT6WFVXZ	Strong	Altered Expression	[3612]
PLCD4	OT14EZVB	Strong	Altered Expression	[3613]
PLEKHB1	OTC7TNAX	Strong	Biomarker	[3614]
PLEKHD1	OTGYUZKM	Strong	Biomarker	[674]
PLEKHG6	OTZWA27A	Strong	Biomarker	[3615]
PLIN2	OTRXJ9UN	Strong	Biomarker	[3616]
PLK3	OT19CT2Z	Strong	Altered Expression	[3617]
PLPP5	OTHT51D6	Strong	Biomarker	[3618]
PLPPR5	OTVL01TR	Strong	Biomarker	[3543]
PLVAP	OTAQGWYA	Strong	Genetic Variation	[743]
PLXNA1	OTN0BING	Strong	Biomarker	[1836]
PLXNA3	OTMZIBVG	Strong	Biomarker	[3619]
PLXNB1	OTCA7JIT	Strong	Biomarker	[3620]
PMAIP1	OTXEE550	Strong	Altered Expression	[3621]
PMEPA1	OTY8Z9UF	Strong	Biomarker	[3622]
PNCK	OT35ZL74	Strong	Altered Expression	[3623]
PNKD	OT6G9UXN	Strong	Altered Expression	[3624]
PNO1	OT010GIS	Strong	Biomarker	[3336]
PODXL	OTPNQXF3	Strong	Altered Expression	[3625]
POFUT1	OTOBJZIT	Strong	Altered Expression	[3626]
POLDIP2	OT8SZSJ6	Strong	Altered Expression	[370]
POLE	OTFM3MMU	Strong	Genetic Variation	[3627]
POLI	OTBA4DCE	Strong	Biomarker	[3628]
POLK	OTKZ38JH	Strong	Genetic Variation	[1528]
POLL	OTZ24QGM	Strong	Genetic Variation	[1528]
POLQ	OTBHK0E6	Strong	Altered Expression	[3629]
POMP	OTMPM1P5	Strong	Altered Expression	[3630]
POT1	OTNBXJCQ	Strong	Posttranslational Modification	[3631]
POTED	OTAUSTUK	Strong	Altered Expression	[3632]
POTEF	OTV3WXYE	Strong	Altered Expression	[3633]
POTEM	OT7L2HGH	Strong	Genetic Variation	[651]
POU1F1	OTXT8A5C	Strong	Biomarker	[1677]
POU2F1	OTK7ELJ0	Strong	Biomarker	[1453]
POU2F3	OTIOOJWD	Strong	Biomarker	[3634]
POU5F1	OTDHHN7O	Strong	Biomarker	[3635]
POU5F1B	OT0FKQ51	Strong	Genetic Variation	[2730]
PPA1	OTHZK1QB	Strong	Biomarker	[3636]
PPARGC1A	OTHCDQ22	Strong	Biomarker	[3637]
PPFIA1	OTYYFA9C	Strong	Altered Expression	[3638]
PPIG	OTZ8BTTM	Strong	Genetic Variation	[3639]
PPIL2	OTL9Y4IO	Strong	Altered Expression	[3640]
PPM1E	OTXRH3YA	Strong	Posttranslational Modification	[3641]
PPP1R12B	OTONIS87	Strong	Biomarker	[3642]
PPP1R13B	OTC88VQO	Strong	Biomarker	[2063]
PPP1R14C	OTZ3F6D2	Strong	Altered Expression	[3643]
PPP1R1B	OTSIJMQ9	Strong	Altered Expression	[3644]
PPP1R2	OTNLOUQR	Strong	Altered Expression	[3645]
PPP1R26	OTAKR0DQ	Strong	Altered Expression	[3646]
PPP1R3B	OTVCRXEZ	Strong	Biomarker	[3647]
PPP1R3C	OTEU05TX	Strong	Biomarker	[3647]
PPP1R8	OTH5KB2P	Strong	Altered Expression	[3432]
PPP1R9B	OTDCTHTT	Strong	Altered Expression	[3648]
PPP2R1A	OTYA3GB4	Strong	Genetic Variation	[3649]
PPP2R1B	OTFIHQGD	Strong	Genetic Variation	[3650]
PPP2R2B	OTSFVC82	Strong	Biomarker	[2068]
PPP2R5E	OT8GPFT5	Strong	Biomarker	[3649]
PPP3R1	OTGQNFJQ	Strong	Biomarker	[3651]
PRAC2	OT56IBFQ	Strong	Biomarker	[2141]
PRAP1	OT48QD82	Strong	Biomarker	[497]
PRB2	OTAD4JZ0	Strong	Altered Expression	[3652]
PRC1	OTHD0XS0	Strong	Altered Expression	[3653]
PRDM1	OTQLSVBS	Strong	Biomarker	[3654]
PRDX1	OTZ3BEC4	Strong	Biomarker	[3655]
PRDX2	OTLWCY9T	Strong	Biomarker	[3656]
PRDX3	OTLB2WEU	Strong	Biomarker	[3657]
PRDX6	OTS8KC8A	Strong	Biomarker	[3658]
PRICKLE4	OT19NLJR	Strong	Altered Expression	[3659]
PRIM2	OTGT0KTF	Strong	Altered Expression	[1126]
PRKAA1	OT7TNF0L	Strong	Altered Expression	[3660]
PRKAA2	OTU1KZPV	Strong	Altered Expression	[3660]
PRKAB1	OT1OG4QZ	Strong	Altered Expression	[3660]
PRKAG3	OTS1A2VE	Strong	Genetic Variation	[3661]
PRKD2	OTIFSVI8	Strong	Altered Expression	[3662]
PRKD3	OT987HJI	Strong	Altered Expression	[3662]
PRKRA	OTUTVZZU	Strong	Biomarker	[3663]
PRLH	OTJBP360	Strong	Biomarker	[3664]
PRMT6	OT5V3XIN	Strong	Biomarker	[3665]
PROCR	OTRHED17	Strong	Biomarker	[3666]
PROK2	OT70IFEZ	Strong	Biomarker	[3667]
PROX1	OT68R6IO	Strong	Altered Expression	[3668]
PRPF3	OTUA4OLZ	Strong	Genetic Variation	[3669]
PRPF31	OTSJ0Z1Y	Strong	Biomarker	[3670]
PRPF8	OTU39JZI	Strong	Biomarker	[462]
PRPS1	OTN3A6CN	Strong	Biomarker	[3671]
PRR11	OT2JJ08Z	Strong	Altered Expression	[3672]
PRR5	OTYHSGJL	Strong	Biomarker	[3673]
PRR5L	OTQ1Z0OU	Strong	Genetic Variation	[2727]
PRRT1	OTN0YIS3	Strong	Biomarker	[3674]
PRRT2	OTCJUBDO	Strong	Altered Expression	[765]
PRRX1	OTTZK5G8	Strong	Genetic Variation	[3675]
PRSS3	OTN3S5YB	Strong	Biomarker	[3676]
PRSS50	OTC5JAVO	Strong	Altered Expression	[3677]
PRUNE1	OTQ3UHWQ	Strong	Biomarker	[3678]
PSAP	OTUOEKY7	Strong	Biomarker	[3679]
PSG2	OT2EIXAI	Strong	Biomarker	[803]
PSMB4	OTOJ9OHA	Strong	Biomarker	[3680]
PSMC3IP	OT9UB5UO	Strong	Biomarker	[2401]
PSMD1	OTW258OV	Strong	Biomarker	[3681]
PSMD14	OTJWHMZ5	Strong	Altered Expression	[3682]
PSMD2	OT6HZHN7	Strong	Biomarker	[3683]
PSMD3	OT585WY8	Strong	Biomarker	[3684]
PSMD4	OTH1VZTM	Strong	Biomarker	[3685]
PSMD7	OT7PZZ4K	Strong	Altered Expression	[1148]
PSMD8	OTY6X27P	Strong	Altered Expression	[2454]
PSME3	OTSTC4YY	Strong	Altered Expression	[3686]
PSMG1	OTZ5I6UM	Strong	Altered Expression	[660]
PSORS1C2	OTK43GE4	Strong	Altered Expression	[3687]
PTBP2	OTF4S7NE	Strong	Biomarker	[1365]
PTGES3	OTPPQWI0	Strong	Biomarker	[799]
PTMA	OT2W4T1M	Strong	Altered Expression	[3688]
PTOV1	OT94WT5X	Strong	Biomarker	[3689]
PTPA	OTRGFOI7	Strong	Biomarker	[435]
PTPN22	OTDCNTC3	Strong	Biomarker	[3690]
PTPN3	OTSLZBVY	Strong	Posttranslational Modification	[3691]
PTPN5	OT2H1KDK	Strong	Biomarker	[3692]
PTPN9	OTNAR1I2	Strong	Biomarker	[3693]
PTPRD	OTZPJ3GX	Strong	Biomarker	[3694]
PTPRF	OTH5KF2D	Strong	Genetic Variation	[3695]
PTPRG	OT9N2WOF	Strong	Genetic Variation	[3696]
PTPRN2	OTL6SH28	Strong	Biomarker	[3697]
PTPRU	OTHDO0QG	Strong	Biomarker	[1679]
PTRH2	OTBU39Q1	Strong	Biomarker	[3698]
PTTG1	OTIMYS4W	Strong	Biomarker	[3699]
PTTG1IP	OTX21QTE	Strong	Genetic Variation	[3700]
PVR	OT3N91T7	Strong	Altered Expression	[3701]
PXDNL	OT52SSS5	Strong	Biomarker	[3702]
PXN	OTVMMUOF	Strong	Altered Expression	[3703]
PYCARD	OT67RON3	Strong	Biomarker	[3704]
PYGO2	OTZHB2OI	Strong	Biomarker	[3705]
PYHIN1	OT30GD05	Strong	Biomarker	[3706]
QRSL1	OTJDU2UG	Strong	Biomarker	[3707]
QTRT1	OTC33MCV	Strong	Biomarker	[3708]
RAB11A	OTC4FW0J	Strong	Biomarker	[3709]
RAB11FIP1	OT0T71OW	Strong	Altered Expression	[3710]
RAB11FIP3	OTDFFCZA	Strong	Altered Expression	[1905]
RAB1A	OTKPHRD0	Strong	Biomarker	[3711]
RAB25	OTW0W6NP	Strong	Biomarker	[3712]
RAB27A	OT9SQRWY	Strong	Biomarker	[3713]
RAB27B	OTPF9D0K	Strong	Altered Expression	[3714]
RAB34	OTHKTSA0	Strong	Biomarker	[3715]
RAB3A	OT2GIUO5	Strong	Altered Expression	[3716]
RAB3D	OTGKRR3C	Strong	Biomarker	[3717]
RAB5A	OTFR2KM4	Strong	Biomarker	[3718]
RAB5B	OT06PN42	Strong	Biomarker	[3719]
RAB6B	OT5N57RK	Strong	Altered Expression	[3720]
RAB6C	OTA66R5E	Strong	Posttranslational Modification	[3721]
RABEPK	OTCZSREH	Strong	Altered Expression	[1148]
RABGEF1	OTWC3Z3R	Strong	Biomarker	[3722]
RABL6	OTJLVIQ1	Strong	Altered Expression	[3723]
RACGAP1	OTQE8IEH	Strong	Biomarker	[3724]
RAD17	OT1I93DT	Strong	Biomarker	[3725]
RAD23B	OT0PGOG3	Strong	Genetic Variation	[3726]
RAD54B	OTMWB2P2	Strong	Biomarker	[3727]
RAD9A	OTJ3AJQU	Strong	Altered Expression	[1963]
RAE1	OT54OKC3	Strong	Biomarker	[3728]
RAI14	OT6USGBK	Strong	Biomarker	[3729]
RALGAPB	OTY8CGA3	Strong	Altered Expression	[2466]
RALY	OT78NNWY	Strong	Genetic Variation	[3730]
RALYL	OT232N7Q	Strong	Biomarker	[1293]
RAN	OT2TER5M	Strong	Biomarker	[3731]
RAP1A	OT5RH6TI	Strong	Biomarker	[3722]
RAP1B	OTHEIIMM	Strong	Altered Expression	[3720]
RAP1GDS1	OTH70UHD	Strong	Biomarker	[3732]
RAP2A	OT0JB5S4	Strong	Biomarker	[3733]
RAP2B	OTD2NDQP	Strong	Altered Expression	[3720]
RAPGEF6	OTR1QQA3	Strong	Biomarker	[3734]
RAPH1	OTMQXW7S	Strong	Biomarker	[3735]
RAPSN	OTGMSWDQ	Strong	Biomarker	[2421]
RARRES1	OTETUPP5	Strong	Altered Expression	[3736]
RASA2	OTL06RG2	Strong	Biomarker	[3737]
RASAL2	OTGMMX6W	Strong	Biomarker	[3738]
RASGRP1	OTX9WN2E	Strong	Biomarker	[3739]
RASGRP2	OTABVLVQ	Strong	Altered Expression	[2359]
RASSF3	OT4V9SRK	Strong	Altered Expression	[3740]
RASSF6	OT25GVWY	Strong	Biomarker	[3741]
RASSF8	OTXKGIB3	Strong	Altered Expression	[3742]
RASSF9	OTCY4KST	Strong	Altered Expression	[3743]
RB1CC1	OTZK8PFX	Strong	Biomarker	[3744]
RBBP6	OTTVG4HU	Strong	Biomarker	[3663]
RBBP7	OTLB56HX	Strong	Altered Expression	[3745]
RBL1	OTDEBFYC	Strong	Posttranslational Modification	[3746]
RBM14	OTO9GMBD	Strong	Biomarker	[2665]
RBM3	OTAJ7R31	Strong	Biomarker	[2576]
RBM38	OTPO8EXU	Strong	Biomarker	[3172]
RBM39	OTCMPTF9	Strong	Altered Expression	[2599]
RBM4	OT5SFQA3	Strong	Biomarker	[3747]
RBM5	OTCBWHHV	Strong	Altered Expression	[3748]
RBMS2	OTTX6071	Strong	Biomarker	[3749]
RBMY1A1	OTM2F25H	Strong	Biomarker	[3750]
RBP1	OTRP1MFC	Strong	Altered Expression	[3751]
RCC1	OT25AGMB	Strong	Biomarker	[3752]
RCC2	OTUJVTLS	Strong	Biomarker	[3753]
RCCD1	OT60N06L	Strong	Biomarker	[674]
RDM1	OTBSJEAG	Strong	Biomarker	[3754]
REG1A	OTMHUH1D	Strong	Biomarker	[1679]
RELA	OTUJP9CN	Strong	Biomarker	[1605]
RELB	OTU3QYEF	Strong	Biomarker	[3755]
RELN	OTLKMW1O	Strong	Altered Expression	[3756]
REM1	OTUXL0HC	Strong	Biomarker	[3757]
REPIN1	OTVTPXNX	Strong	Biomarker	[3758]
REPS2	OTSE3TRP	Strong	Biomarker	[3759]
REST	OTLL92LQ	Strong	Biomarker	[3760]
RETN	OTW5Z1NH	Strong	Altered Expression	[3761]
REXO4	OT2NNFKZ	Strong	Altered Expression	[3762]
RFC2	OTJ9N6BD	Strong	Biomarker	[3763]
RGMB	OT2DROYU	Strong	Biomarker	[3764]
RGN	OTD04KB1	Strong	Biomarker	[3765]
RGS17	OT5RVUDS	Strong	Biomarker	[3766]
RGS20	OT6CGYHW	Strong	Altered Expression	[3767]
RGS3	OTYG5OXI	Strong	Altered Expression	[3768]
RGSL1	OTNNYLGW	Strong	Genetic Variation	[1392]
RHBDD1	OTL5J132	Strong	Biomarker	[3769]
RHEB	OTFLTSEC	Strong	Altered Expression	[3770]
RHNO1	OTYKRRGE	Strong	Genetic Variation	[3771]
RHOBTB1	OTGE8K45	Strong	Altered Expression	[3772]
RHOBTB2	OT2DATFX	Strong	Biomarker	[3773]
RHOD	OTALMEIN	Strong	Biomarker	[3774]
RHOJ	OTWI65OA	Strong	Biomarker	[3775]
RHOQ	OTUBTU57	Strong	Biomarker	[3776]
RHPN1	OTYZ1NV8	Strong	Biomarker	[3777]
RIBC2	OTDB4FM2	Strong	Biomarker	[1293]
RIN2	OTCY73U9	Strong	Biomarker	[1595]
RIOK1	OT1OS3H3	Strong	Altered Expression	[3778]
RIOX1	OTN41QXP	Strong	Genetic Variation	[3779]
RIOX2	OT2YFPI2	Strong	Genetic Variation	[3779]
RMC1	OT7K8MTJ	Strong	Altered Expression	[3780]
RMDN1	OTE1NB6U	Strong	Altered Expression	[3781]
RMDN2	OTK5WSFI	Strong	Altered Expression	[3781]
RMND1	OT7I6RBT	Strong	Biomarker	[674]
RNASE3	OTVE2XD1	Strong	Biomarker	[3782]
RNASEH1	OTT7L25X	Strong	Altered Expression	[3783]
RNASEH2C	OTJL9ZRN	Strong	Biomarker	[3784]
RNF11	OTFBJSKQ	Strong	Altered Expression	[3785]
RNF115	OT35B6L5	Strong	Biomarker	[3786]
RNF126	OTTECSYY	Strong	Biomarker	[3787]
RNF169	OTLS6875	Strong	Altered Expression	[3788]
RNF182	OT08FLHZ	Strong	Biomarker	[827]
RNF19A	OTKWCV80	Strong	Altered Expression	[370]
RNF2	OTFPLOIN	Strong	Biomarker	[3653]
RNF20	OT9NK6ZT	Strong	Biomarker	[3789]
RNF31	OT4BZONL	Strong	Biomarker	[3790]
RNF5	OTDQGI37	Strong	Biomarker	[3791]
RNH1	OT6EC79B	Strong	Genetic Variation	[3079]
RO60	OTLGM5A8	Strong	Altered Expression	[3792]
RPA2	OTZ54WAF	Strong	Altered Expression	[3793]
RPAIN	OTBMXAYK	Strong	Biomarker	[2854]
RPH3AL	OT9VFJEL	Strong	Genetic Variation	[3794]
RPL10	OTBHOZGC	Strong	Biomarker	[1836]
RPL13	OTFKNTD6	Strong	Biomarker	[3795]
RPL17	OTTYMPS6	Strong	Altered Expression	[3796]
RPL23	OTXI1YLM	Strong	Altered Expression	[3796]
RPL23A	OTPYLCCX	Strong	Biomarker	[1293]
RPL24	OTCY9DEB	Strong	Altered Expression	[3797]
RPL29	OTUFIBJL	Strong	Genetic Variation	[1385]
RPL31	OTV9E1OE	Strong	Biomarker	[1293]
RPL36A	OT1LYV85	Strong	Altered Expression	[2979]
RPL39	OTL8TZHQ	Strong	Genetic Variation	[3798]
RPL7A	OT6E6UKF	Strong	Altered Expression	[3799]
RPLP2	OT2YBK3W	Strong	Biomarker	[674]
RPN2	OTJ1SKOA	Strong	Biomarker	[3800]
RPRD1A	OTXTV6FU	Strong	Altered Expression	[3801]
RPRD1B	OTB41D5K	Strong	Biomarker	[3802]
RPS14	OTB90KV5	Strong	Altered Expression	[2454]
RPS15A	OT0BUA12	Strong	Altered Expression	[1196]
RPS16	OTVGZOB5	Strong	Altered Expression	[3803]
RPS19	OTBKGP48	Strong	Biomarker	[737]
RPS27A	OTIIGGZ2	Strong	Altered Expression	[3804]
RPS27L	OTZWHU0N	Strong	Biomarker	[3805]
RPS4X	OTIH80EK	Strong	Altered Expression	[1322]
RPS6KA4	OTTK8MUO	Strong	Biomarker	[3806]
RPS7	OTIK25WI	Strong	Biomarker	[1293]
RPS8	OTEBS4HZ	Strong	Biomarker	[1293]
RPS9	OTPV69Q0	Strong	Biomarker	[3807]
RRAD	OTW2O4GD	Strong	Biomarker	[3808]
RRAS	OTBBF28C	Strong	Biomarker	[2970]
RRAS2	OT83NCEB	Strong	Genetic Variation	[3809]
RRM2B	OTE8GBUR	Strong	Genetic Variation	[1345]
RRN3	OTKGOZ49	Strong	Altered Expression	[3810]
RRP1B	OTHDRVML	Strong	Genetic Variation	[3488]
RSPO2	OT3HHXU0	Strong	Altered Expression	[456]
RSPO4	OTFX5N3G	Strong	Altered Expression	[456]
RTCB	OTUED31V	Strong	Altered Expression	[3811]
RTKN	OTSS8XR6	Strong	Biomarker	[3812]
RTL1	OTOT33IM	Strong	Biomarker	[1220]
RTL10	OTHGB81W	Strong	Biomarker	[3813]
RTRAF	OTJ6NVMW	Strong	Biomarker	[1896]
RUVBL1	OTWV19L7	Strong	Altered Expression	[3236]
RUVBL2	OTGWJ4T4	Strong	Biomarker	[3814]
RYBP	OTZZ4P2Z	Strong	Altered Expression	[3815]
RYR3	OT4EHIP4	Strong	Genetic Variation	[3816]
S100A1	OT1F2G4J	Strong	Biomarker	[3817]
S100A10	OTI71243	Strong	Altered Expression	[3818]
S100A11	OTI57KDN	Strong	Altered Expression	[3819]
S100A14	OTVFJJ91	Strong	Altered Expression	[3820]
S100A2	OTTGHJ1H	Strong	Biomarker	[3821]
S100A7A	OTNM8DCP	Strong	Biomarker	[3822]
SACM1L	OT6ORKTD	Strong	Altered Expression	[3823]
SAE1	OT18HFX5	Strong	Biomarker	[3824]
SAFB	OTGRV2LW	Strong	Biomarker	[3825]
SAFB2	OTQ1IH80	Strong	Biomarker	[3826]
SAGE1	OT4H6FFA	Strong	Biomarker	[3827]
SALL1	OTYYZGLH	Strong	Biomarker	[3828]
SALL2	OTQWI68Q	Strong	Biomarker	[3829]
SARDH	OTQ49Q27	Strong	Biomarker	[3830]
SART1	OTHMOGO1	Strong	Genetic Variation	[3831]
SART3	OTC1AM7S	Strong	Biomarker	[1337]
SAT2	OT28QL7H	Strong	Genetic Variation	[3832]
SATB2	OT2W80XC	Strong	Biomarker	[3833]
SCAF1	OT16TM3N	Strong	Biomarker	[3834]
SCAF11	OTX59D0X	Strong	Biomarker	[3083]
SCAMP1	OTFS4IKJ	Strong	Biomarker	[3414]
SCARA3	OT46I38Y	Strong	Altered Expression	[3835]
SCARA5	OTOVA96E	Strong	Altered Expression	[3836]
SCD5	OTSSUQ3Z	Strong	Biomarker	[1419]
SCGB2A1	OT9L87U9	Strong	Altered Expression	[3837]
SCGB3A1	OTIR98RB	Strong	Genetic Variation	[3838]
SCIN	OT6U09OL	Strong	Altered Expression	[3839]
SCN4B	OT3JSUWO	Strong	Altered Expression	[3840]
SCO2	OTJQQDRS	Strong	Altered Expression	[1582]
SCP2	OTPAFCPQ	Strong	Biomarker	[3841]
SCPEP1	OT43LYEZ	Strong	Genetic Variation	[3842]
SDC4	OTKUVUGZ	Strong	Biomarker	[3843]
SDF2	OTSLRFRF	Strong	Altered Expression	[3844]
SDHA	OTOJ8QFF	Strong	Altered Expression	[3845]
SDHAF2	OT0UG9H5	Strong	Biomarker	[3846]
SDHB	OTRE1M1T	Strong	Biomarker	[3847]
SDS	OT5WTJ2M	Strong	Biomarker	[1488]
SEC14L1	OTA75FET	Strong	Altered Expression	[3848]
SEC16A	OTFNQ1ZU	Strong	Biomarker	[3849]
SEC16B	OT244C1N	Strong	Genetic Variation	[3850]
SEL1L	OTC0FB7T	Strong	Biomarker	[3851]
SELENOP	OT02B8IR	Strong	Biomarker	[1760]
SELENOW	OTVSKPAN	Strong	Altered Expression	[3852]
SEM1	OTASLBM1	Strong	Biomarker	[3853]
SEMA3B	OTCZCPMS	Strong	Biomarker	[1158]
SEMA3C	OTEGUY7F	Strong	Biomarker	[3854]
SEMA3F	OTQFMS8S	Strong	Altered Expression	[3855]
SEMA4C	OTF5JHQ0	Strong	Altered Expression	[3856]
SEMA4F	OTVP97ZV	Strong	Biomarker	[3619]
SEMA6A	OTDQ7QAW	Strong	Biomarker	[3857]
SEMA7A	OT0ZJK64	Strong	Biomarker	[3858]
SEPHS2	OTTFXROR	Strong	Biomarker	[3859]
SEPTIN2	OT3G33TM	Strong	Altered Expression	[1428]
SEPTIN7	OTJI08YX	Strong	Biomarker	[3860]
SEPTIN9	OT1VMRFQ	Strong	Biomarker	[3861]
SERPINA3	OT9BP2S0	Strong	Genetic Variation	[651]
SERPINA5	OTTZXPGD	Strong	Genetic Variation	[3862]
SERPINB6	OT7G55IK	Strong	Biomarker	[1162]
SERPINE2	OTYF5340	Strong	Biomarker	[3863]
SERTAD1	OTBHKZQP	Strong	Biomarker	[2697]
SESN2	OT889IXY	Strong	Altered Expression	[740]
SETBP1	OTKGCOSR	Strong	Biomarker	[1317]
SETD4	OTBMCZQA	Strong	Biomarker	[3864]
SETD6	OTH5APN1	Strong	Posttranslational Modification	[3865]
SETD9	OT4961W1	Strong	Genetic Variation	[3866]
SF3B3	OTAC9LZT	Strong	Biomarker	[2648]
SFN	OTLJCZ1U	Strong	Biomarker	[1121]
SFRP1	OT0U9G41	Strong	Altered Expression	[3801]
SFRP5	OTLCVVSH	Strong	Biomarker	[3867]
SFXN1	OTL66767	Strong	Genetic Variation	[3868]
SGK3	OTQ6QO99	Strong	Biomarker	[3869]
SGSM3	OTIB1P8A	Strong	Biomarker	[3870]
SH2D1A	OTLU49I5	Strong	Biomarker	[688]
SH2D3C	OTAGXO0N	Strong	Altered Expression	[3142]
SH3BP4	OTVIRKW7	Strong	Biomarker	[3871]
SH3GL2	OTOE443G	Strong	Altered Expression	[3872]
SH3GLB1	OTAZ5OP8	Strong	Biomarker	[3873]
SH3KBP1	OTIUA60B	Strong	Biomarker	[3874]
SHC2	OTTWMRNQ	Strong	Biomarker	[540]
SHC3	OT305NPA	Strong	Genetic Variation	[3079]
SHLD1	OTPKJQ0D	Strong	Altered Expression	[3875]
SHOC1	OTP51XIP	Strong	Altered Expression	[1695]
SHOX2	OTLCZZJW	Strong	Biomarker	[3876]
SHROOM4	OT33GO6E	Strong	Genetic Variation	[743]
SIAH1	OT29A838	Strong	Altered Expression	[3877]
SIAH2	OTKED2XN	Strong	Altered Expression	[3878]
SIGIRR	OTNC3XFD	Strong	Altered Expression	[3879]
SIGLEC7	OTNDLURR	Strong	Altered Expression	[1088]
SIM1	OTYKFPKZ	Strong	Biomarker	[2687]
SIM2	OT0QWHK4	Strong	Biomarker	[3880]
SIX1	OT70YYWM	Strong	Biomarker	[3881]
SIX2	OTYOVGSC	Strong	Altered Expression	[3882]
SIX6	OTD1RD9D	Strong	Biomarker	[3883]
SKA2	OTVYF4XT	Strong	Altered Expression	[3672]
SKI	OT4KJ8F6	Strong	Biomarker	[3884]
SLAMF1	OTBTT3ZQ	Strong	Genetic Variation	[2760]
SLBP	OTVYYQRT	Strong	Altered Expression	[2606]
SLC22A18	OT9C3KR4	Strong	Biomarker	[3885]
SLC25A43	OTY6MWVD	Strong	Biomarker	[3886]
SLFN11	OTJWFPMY	Strong	Biomarker	[3887]
SLIT3	OTU8MKEU	Strong	Posttranslational Modification	[3888]
SLN	OTERIU75	Strong	Biomarker	[3889]
SLURP1	OT89YD2E	Strong	Genetic Variation	[536]
SMAD2	OTC6VB4K	Strong	Altered Expression	[3890]
SMAD5	OTQNSVCQ	Strong	Biomarker	[3891]
SMARCE1	OTAX4ITH	Strong	Biomarker	[3892]
SMC6	OT3IBHQD	Strong	Biomarker	[2712]
SMIM22	OTTX8AH1	Strong	Biomarker	[1497]
SMPD3	OTHQBETH	Strong	Altered Expression	[1483]
SMS	OT8JYKNH	Strong	Biomarker	[2018]
SMUG1	OT2YIOCQ	Strong	Biomarker	[3893]
SMURF2	OT3TRVL7	Strong	Biomarker	[3894]
SMYD4	OTT349CJ	Strong	Altered Expression	[3895]
SMYD5	OTE5VET6	Strong	Biomarker	[3896]
SNAI1	OTDPYAMC	Strong	Biomarker	[3897]
SNAI2	OT7Y8EJ2	Strong	Biomarker	[3898]
SNAPC1	OTAPN1NI	Strong	Biomarker	[3899]
SNCB	OTELSEK6	Strong	Biomarker	[3900]
SNRPN	OTQB1ID1	Strong	Posttranslational Modification	[3901]
SNTA1	OTUICTGZ	Strong	Altered Expression	[3902]
SNX27	OTVPS7S0	Strong	Biomarker	[1224]
SNX32	OTIXXIHF	Strong	Biomarker	[674]
SOAT1	OTB4Y5RJ	Strong	Biomarker	[3903]
SOCS2	OTBPNKJQ	Strong	Biomarker	[3904]
SOCS5	OTN1ABYR	Strong	Altered Expression	[1486]
SOD3	OTIOZQAB	Strong	Posttranslational Modification	[3905]
SORBS1	OTWH8762	Strong	Altered Expression	[3906]
SOSTDC1	OTAKDNSM	Strong	Altered Expression	[2028]
SOX10	OTF25ULQ	Strong	Altered Expression	[3907]
SOX11	OT4LG7LA	Strong	Biomarker	[3908]
SOX12	OT93P8C9	Strong	Biomarker	[3909]
SOX17	OT9H4WWE	Strong	Altered Expression	[3910]
SOX18	OTPUMHWA	Strong	Altered Expression	[3911]
SOX3	OT1CRCOB	Strong	Biomarker	[3912]
SOX4	OTSS40SS	Strong	Biomarker	[3913]
SOX9	OTVDJFGN	Strong	Altered Expression	[3914]
SPA17	OT8J7T7U	Strong	Altered Expression	[3915]
SPAG5	OTCLJ56M	Strong	Biomarker	[3916]
SPAG8	OTZC5XP9	Strong	Altered Expression	[3917]
SPAM1	OTMPOB4E	Strong	Biomarker	[3918]
SPATA18	OTOEHTHU	Strong	Altered Expression	[3919]
SPC24	OT1HVYV4	Strong	Biomarker	[3920]
SPIN1	OT69VAOX	Strong	Biomarker	[3921]
SPINK1	OTSUVAL2	Strong	Biomarker	[3922]
SPINT1	OT1CLR5L	Strong	Genetic Variation	[3923]
SPINT2	OTQV7BKQ	Strong	Biomarker	[3924]
SPRED1	OTKX7P8G	Strong	Biomarker	[3925]
SPRY2	OTH0CRCZ	Strong	Altered Expression	[3926]
SPRY4	OT2VK9N0	Strong	Biomarker	[3927]
SPSB1	OTGY26U4	Strong	Biomarker	[3928]
SPSB2	OT7ZVT8R	Strong	Biomarker	[3433]
SRA1	OTYOGMTG	Strong	Altered Expression	[3929]
SRARP	OTR3TNTJ	Strong	Altered Expression	[3930]
SRF	OTW18FQN	Strong	Biomarker	[3931]
SRGAP2	OTUWFMCQ	Strong	Genetic Variation	[3932]
SRL	OT7IEBWZ	Strong	Biomarker	[3830]
SRRM2	OTSIMMC9	Strong	Biomarker	[3336]
SRSF1	OTF61HOV	Strong	Biomarker	[3933]
SRSF2	OTVDHO6U	Strong	Genetic Variation	[3934]
SRSF5	OTC5WP98	Strong	Altered Expression	[3935]
SSH1	OT4BE2M4	Strong	Altered Expression	[3936]
SSR1	OTQ6GDL2	Strong	Biomarker	[3937]
SSX2	OT2Z6RLL	Strong	Altered Expression	[3938]
ST13	OTNML6UP	Strong	Biomarker	[3161]
ST18	OTPRIMTA	Strong	Biomarker	[3430]
ST3GAL1	OTFCO8QX	Strong	Altered Expression	[3939]
ST3GAL3	OTOORKUE	Strong	Biomarker	[3940]
ST6GAL1	OT7US3NO	Strong	Altered Expression	[3941]
ST6GAL2	OTXIBF4D	Strong	Altered Expression	[3941]
ST6GALNAC1	OT3JQD99	Strong	Altered Expression	[3942]
ST6GALNAC2	OT9PBQVT	Strong	Biomarker	[3943]
ST6GALNAC5	OTH91ETM	Strong	Altered Expression	[3944]
ST7	OTZG8RC6	Strong	Genetic Variation	[3945]
ST8SIA2	OTRBBBD8	Strong	Altered Expression	[631]
STAC2	OTRJ9PG0	Strong	Biomarker	[3946]
STAG1	OT564IX4	Strong	Altered Expression	[3947]
STAM2	OT9OBWPH	Strong	Altered Expression	[2606]
STAP2	OTEB1VVI	Strong	Posttranslational Modification	[3948]
STARD10	OTWVNFV4	Strong	Altered Expression	[3949]
STARD13	OTB4U1HY	Strong	Biomarker	[1395]
STARD3	OTSTC5B5	Strong	Altered Expression	[3950]
STARD8	OTY9IAKW	Strong	Biomarker	[827]
STIM1	OT8CLQ1W	Strong	Altered Expression	[3951]
STIM2	OTYNXAW0	Strong	Biomarker	[3952]
STK24	OTGUHOIL	Strong	Altered Expression	[1187]
STK25	OT4YPNTF	Strong	Biomarker	[1478]
STK3	OTLNSCQD	Strong	Biomarker	[3953]
STN1	OT8UWRA3	Strong	Genetic Variation	[3359]
STPG4	OT5K4UFL	Strong	Genetic Variation	[3954]
STUB1	OTSUYI9A	Strong	Altered Expression	[3955]
STX18	OTW4GF3X	Strong	Biomarker	[3956]
STX1A	OTSBUZB4	Strong	Biomarker	[3827]
STX3	OT4CIWLJ	Strong	Biomarker	[3957]
STYX	OT8W6Y1J	Strong	Altered Expression	[3958]
SUB1	OTK71JYU	Strong	Biomarker	[3959]
SULF1	OTJCNCO0	Strong	Biomarker	[3960]
SULT4A1	OT7AL3KJ	Strong	Biomarker	[3961]
SUMO1	OTJFD4P5	Strong	Biomarker	[2260]
SUN2	OT2IQJUC	Strong	Altered Expression	[2134]
SUPT20H	OTTMC0LH	Strong	Altered Expression	[1690]
SUSD3	OTERJTUL	Strong	Biomarker	[3962]
SUV39H2	OTU0F4LL	Strong	Altered Expression	[3963]
SYBU	OT3FQV7N	Strong	Altered Expression	[3781]
SYCP2	OTBH622S	Strong	Biomarker	[3964]
SYF2	OTY2ZW1H	Strong	Biomarker	[3965]
SYNE1	OTSBSLUH	Strong	Biomarker	[827]
SYNJ2	OTLRHXP1	Strong	Biomarker	[3966]
SYNM	OTOI8TRJ	Strong	Altered Expression	[3967]
SYNPR	OTNCJ9L0	Strong	Genetic Variation	[743]
SYP	OTFJKMO4	Strong	Biomarker	[3968]
SYT1	OTVTPOI6	Strong	Biomarker	[1605]
TAB2	OTPZK76F	Strong	Biomarker	[3969]
TAC1	OTM842YW	Strong	Biomarker	[474]
TAF7	OT43QHS3	Strong	Altered Expression	[3970]
TAF8	OTWWGCHV	Strong	Altered Expression	[3899]
TAFA4	OT0RHMNG	Strong	Biomarker	[3173]
TAL1	OTX4K6QZ	Strong	Altered Expression	[3971]
TALDO1	OTDKV2S2	Strong	Altered Expression	[3972]
TANK	OTZSGFIK	Strong	Biomarker	[856]
TAS2R13	OTSTOX5G	Strong	Biomarker	[3973]
TATDN1	OTQ3S9AL	Strong	Altered Expression	[3481]
TAX1BP3	OTQ6IB4T	Strong	Biomarker	[3974]
TBC1D10A	OTR2CI46	Strong	Genetic Variation	[3975]
TBC1D24	OTKZUSMD	Strong	Biomarker	[3976]
TBC1D3	OT1GW0K2	Strong	Biomarker	[3977]
TBL1Y	OTA0F7TM	Strong	Biomarker	[3978]
TBP	OT6C0S52	Strong	Altered Expression	[3899]
TBPL1	OT4I143E	Strong	Altered Expression	[1530]
TBX2	OTTOT7A9	Strong	Altered Expression	[3979]
TCAP	OTQQMJ94	Strong	Biomarker	[1338]
TCEA1	OTBFO594	Strong	Biomarker	[3980]
TCEA2	OT1OS9TY	Strong	Biomarker	[3980]
TCEA3	OTLTRSK4	Strong	Biomarker	[3980]
TCF12	OTZVONNU	Strong	Biomarker	[2678]
TCF21	OT393IMA	Strong	Genetic Variation	[3981]
TCF4	OTB9ASTK	Strong	Biomarker	[3982]
TCF7	OT1ID822	Strong	Altered Expression	[2010]
TCHP	OTVDMHSY	Strong	Biomarker	[3983]
TCIM	OTARUXQF	Strong	Biomarker	[3984]
TCL1B	OT4CSO39	Strong	Genetic Variation	[477]
TCN1	OTW6A49Y	Strong	Altered Expression	[3985]
TCP1	OT1MGUX9	Strong	Biomarker	[1302]
TDRD3	OTG83E2C	Strong	Biomarker	[3986]
TEAD1	OTK6971C	Strong	Biomarker	[3987]
TEKT4	OT1GMBOX	Strong	Genetic Variation	[3988]
TENM1	OTSKSU4V	Strong	Biomarker	[3989]
TENM3	OTWY13GR	Strong	Genetic Variation	[3924]
TENT5A	OTSYF511	Strong	Genetic Variation	[2609]
TET1	OTZDHT1D	Strong	Altered Expression	[3990]
TET2	OTKKT03T	Strong	Altered Expression	[3991]
TEX14	OTBL9LPZ	Strong	Genetic Variation	[3992]
TFCP2	OTA246TE	Strong	Altered Expression	[1993]
TFDP1	OT6RZ7VT	Strong	Altered Expression	[3993]
TFE3	OTM99ZWH	Strong	Altered Expression	[3994]
TFEB	OTJUJJQY	Strong	Biomarker	[3995]
TFG	OT2KJENI	Strong	Altered Expression	[3996]
TFPI2	OTZCRWOR	Strong	Biomarker	[3427]
TGFBI	OTR443C5	Strong	Biomarker	[3898]
TGFBR3	OTQOOUC4	Strong	Biomarker	[3997]
THAP10	OTCMT4L7	Strong	Posttranslational Modification	[3318]
THBS2	OTXET551	Strong	Altered Expression	[1429]
THEM4	OTSIZU8Y	Strong	Biomarker	[3998]
THUMPD1	OTKU8KWH	Strong	Biomarker	[3999]
TIMELESS	OTD8DCBJ	Strong	Biomarker	[4000]
TIMM17A	OTVFRL8G	Strong	Altered Expression	[4001]
TIMM44	OTXP7MXN	Strong	Biomarker	[4002]
TIMM50	OTWJNUQL	Strong	Biomarker	[4003]
TIMM8A	OTDX9687	Strong	Biomarker	[828]
TIMP2	OT8S1RRP	Strong	Biomarker	[4004]
TIMP3	OTDGQAD1	Strong	Posttranslational Modification	[4005]
TIMP4	OT8A68SW	Strong	Biomarker	[4006]
TJP1	OTBDCUPK	Strong	Altered Expression	[4007]
TLCD3B	OTM6EPUS	Strong	Biomarker	[4008]
TLE1	OT50MRZ1	Strong	Altered Expression	[4009]
TLE3	OTR9PH95	Strong	Biomarker	[4010]
TLE4	OT4QEH6T	Strong	Biomarker	[4011]
TLK2	OTZ09CG8	Strong	Biomarker	[4012]
TLR10	OTQ1KVJO	Strong	Altered Expression	[4013]
TM4SF1	OTY0ECQN	Strong	Altered Expression	[4014]
TM7SF2	OTILU5S7	Strong	Biomarker	[1202]
TM9SF4	OT85D4H9	Strong	Biomarker	[4015]
TMC4	OT8FX82D	Strong	Biomarker	[1464]
TMED10	OTUXSHH7	Strong	Biomarker	[799]
TMED2	OTBLO7RW	Strong	Posttranslational Modification	[4016]
TMEFF1	OTH6M3CH	Strong	Altered Expression	[4017]
TMEFF2	OT1WZ2QO	Strong	Biomarker	[2149]
TMEM131L	OT7MO7XU	Strong	Biomarker	[4018]
TMEM158	OT0KUBBI	Strong	Biomarker	[4019]
TMEM17	OTEU00OH	Strong	Altered Expression	[4020]
TMEM170B	OT4AS8RJ	Strong	Biomarker	[4021]
TMEM199	OTU1GZOY	Strong	Altered Expression	[4022]
TMEM25	OTIMMWZ6	Strong	Biomarker	[3368]
TMEM26	OTHZCXYB	Strong	Biomarker	[4023]
TMEM70	OTLTKYXG	Strong	Biomarker	[2951]
TMEM8B	OTJZWPS6	Strong	Biomarker	[4024]
TMOD1	OTTRYF9Y	Strong	Altered Expression	[4025]
TMPRSS13	OTMAOAP3	Strong	Biomarker	[3311]
TMPRSS3	OT0GTO1Z	Strong	Biomarker	[4026]
TMPRSS4	OTCCGY2K	Strong	Biomarker	[4027]
TMSB10	OTLVZ13T	Strong	Altered Expression	[4028]
TMTC3	OTMTTDYG	Strong	Biomarker	[2815]
TNFAIP1	OT37EWR0	Strong	Altered Expression	[4022]
TNFAIP2	OTRZH80H	Strong	Biomarker	[4029]
TNFAIP6	OT1SLUZH	Strong	Altered Expression	[4030]
TNFAIP8L1	OTVVKOTV	Strong	Biomarker	[4031]
TNFAIP8L3	OTHSBS1B	Strong	Biomarker	[4032]
TNFRSF10C	OTVHOL9B	Strong	Biomarker	[2453]
TNFRSF6B	OTKAN9G7	Strong	Biomarker	[4033]
TNFSF18	OT3ANRX1	Strong	Altered Expression	[4034]
TNIP1	OTRAOTEW	Strong	Biomarker	[2064]
TNIP3	OTSAE5UE	Strong	Genetic Variation	[4035]
TNN	OTQK2AMX	Strong	Biomarker	[678]
TNNT1	OT8PBOAR	Strong	Biomarker	[4036]
TNNT3	OT4C498E	Strong	Genetic Variation	[4037]
TOB1	OTNW949D	Strong	Biomarker	[288]
TOP1MT	OT2H77ID	Strong	Genetic Variation	[4038]
TOP3A	OT3CKUI9	Strong	Genetic Variation	[4039]
TOPBP1	OT6UPZPD	Strong	Genetic Variation	[487]
TOX	OTE8BL5Z	Strong	Posttranslational Modification	[4040]
TOX4	OTSOXQFN	Strong	Biomarker	[3334]
TP53AIP1	OT1XVNDP	Strong	Altered Expression	[4041]
TP53BP2	OTOWJ2Y4	Strong	Altered Expression	[4042]
TP53I3	OTSCM68G	Strong	Altered Expression	[2345]
TP53INP2	OT0GTBXO	Strong	Biomarker	[3100]
TPI1	OT14KP4B	Strong	Altered Expression	[1948]
TPK1	OTCHPUD0	Strong	Genetic Variation	[4043]
TPM1	OTD73X6R	Strong	Altered Expression	[1384]
TPM3	OT5RU5G6	Strong	Biomarker	[4044]
TRA2A	OT5NHOO3	Strong	Biomarker	[4045]
TRA2B	OTZYQW52	Strong	Altered Expression	[4046]
TRADD	OTBOSJHO	Strong	Altered Expression	[4047]
TRAF2	OT1MEZZN	Strong	Biomarker	[4048]
TRAF3	OT5TQBGV	Strong	Biomarker	[4049]
TRAF4	OTJLRVMC	Strong	Biomarker	[4050]
TRAM1	OT3I0H8E	Strong	Biomarker	[4051]
TRARG1	OTQ1R3JD	Strong	Biomarker	[4052]
TRAT1	OTMPUNPD	Strong	Genetic Variation	[4053]
TRERF1	OTA7UQF1	Strong	Biomarker	[4010]
TREX1	OTQG7K12	Strong	Altered Expression	[4054]
TRIB1	OTPEO17G	Strong	Altered Expression	[4055]
TRIM11	OTMD6IM2	Strong	Biomarker	[4056]
TRIM23	OTVIGJ4T	Strong	Altered Expression	[3432]
TRIM29	OT2DNESG	Strong	Biomarker	[4057]
TRIM3	OT704FQ0	Strong	Altered Expression	[4058]
TRIM32	OTJOV0PG	Strong	Biomarker	[676]
TRIM44	OT0B1T2B	Strong	Biomarker	[4059]
TRIM46	OTFE7WZW	Strong	Biomarker	[4060]
TRIM62	OT15YO6N	Strong	Biomarker	[4061]
TRIP13	OTFM3TI9	Strong	Biomarker	[4062]
TRIT1	OTCU9FS5	Strong	Biomarker	[1268]
TRMT12	OTCN4IQZ	Strong	Altered Expression	[4063]
TROAP	OTC8CE0R	Strong	Biomarker	[4064]
TRPS1	OT7XPPEL	Strong	Biomarker	[4065]
TSACC	OT3QW6PH	Strong	Biomarker	[2665]
TSGA10	OTIF1O1T	Strong	Genetic Variation	[4066]
TSHZ1	OTYQ9ECW	Strong	Genetic Variation	[4067]
TSHZ2	OTZWBXXY	Strong	Biomarker	[4068]
TSHZ3	OTAN7RY5	Strong	Posttranslational Modification	[4069]
TSPAN1	OTZQPIYK	Strong	Biomarker	[4070]
TSPAN12	OTF9I3CX	Strong	Altered Expression	[4071]
TSPAN13	OTCS9BZY	Strong	Biomarker	[4072]
TSPAN31	OT8WQ83R	Strong	Biomarker	[3435]
TSPAN8	OT1F68WQ	Strong	Biomarker	[4073]
TSPY1	OTPY57X4	Strong	Biomarker	[4074]
TSPY3	OTQK3AKI	Strong	Biomarker	[4074]
TSPYL5	OT7QEI2X	Strong	Biomarker	[4075]
TSPYL6	OTQFY184	Strong	Genetic Variation	[4076]
TTC36	OT90ZLHE	Strong	Altered Expression	[4077]
TTF1	OT4K90WD	Strong	Altered Expression	[4078]
AARS1	OTW8D813	Definitive	Genetic Variation	[536]
AFAP1L2	OTJBI0VN	Definitive	Biomarker	[4079]
AGR3	OTONJPDP	Definitive	Biomarker	[4080]
ALDH1L1	OT15HOJX	Definitive	Altered Expression	[1781]
ALG1	OTVXPA9E	Definitive	Biomarker	[1233]
AMPH	OTWPGWZX	Definitive	Biomarker	[4081]
ANKRD44	OTUI0WOO	Definitive	Genetic Variation	[4082]
ANP32E	OTTWELUQ	Definitive	Altered Expression	[4083]
ARMC8	OTNAXGM7	Definitive	Biomarker	[4084]
ARMCX1	OTOGL58Z	Definitive	Biomarker	[4085]
ATF7IP	OTU6ZA7F	Definitive	Biomarker	[4086]
ATP2B2	OT1NPZ9T	Definitive	Altered Expression	[4087]
ATXN3L	OTZV3BG4	Definitive	Biomarker	[4088]
BCAM	OTHZOPSD	Definitive	Biomarker	[4089]
BCAS2	OTRMF2WY	Definitive	Genetic Variation	[4090]
BDH2	OTDD7G8S	Definitive	Altered Expression	[4091]
CCAR1	OTUXLQZZ	Definitive	Biomarker	[953]
CCNC	OTMVK4K4	Definitive	Biomarker	[4092]
CCNG1	OT17IA9L	Definitive	Altered Expression	[4093]
CCRL2	OT5PX0RX	Definitive	Biomarker	[4094]
CD81	OTQFXNAZ	Definitive	Biomarker	[4095]
CELSR2	OTON6JSZ	Definitive	Biomarker	[3215]
CLDND1	OTGECYGG	Definitive	Biomarker	[4096]
CMPK2	OTOG90R0	Definitive	Biomarker	[1782]
CNMD	OTHND8EL	Definitive	Biomarker	[4097]
CST1	OTE4I83Q	Definitive	Altered Expression	[4098]
CXCL5	OTZOUPCA	Definitive	Biomarker	[4099]
CYC1	OT0962IM	Definitive	Biomarker	[4100]
DNA2	OT4DJFFU	Definitive	Genetic Variation	[4101]
DNAJB4	OTUD01BK	Definitive	Biomarker	[4095]
EIF3D	OTDOMP80	Definitive	Biomarker	[4102]
FANCE	OTKRPBW1	Definitive	Altered Expression	[4103]
FBLN5	OTLVNZ8U	Definitive	Biomarker	[4104]
FLRT2	OTGD8TID	Definitive	Biomarker	[4105]
FOXN3	OTOJYJZP	Definitive	Biomarker	[4106]
FUT8	OTJJCVG1	Definitive	Biomarker	[4107]
GOLT1A	OTY8H2OF	Definitive	Altered Expression	[4108]
HABP2	OTAUIPW0	Definitive	Genetic Variation	[3216]
HARS1	OTHOEOTS	Definitive	Genetic Variation	[536]
HHLA2	OTYBTVQS	Definitive	Biomarker	[4109]
HIVEP1	OT7CAG4A	Definitive	Biomarker	[4110]
HOXB3	OT9UC5PE	Definitive	Biomarker	[4111]
IMMP2L	OT9WGAFD	Definitive	Biomarker	[4112]
IMMT	OTBDSLE7	Definitive	Altered Expression	[4113]
INPP5J	OT8M7KWA	Definitive	Biomarker	[4114]
IRX2	OTBHXXQ2	Definitive	Altered Expression	[4115]
ITGBL1	OTJDHE17	Definitive	Altered Expression	[4116]
KAT8	OT5LPQTR	Definitive	Biomarker	[4117]
KIF18A	OTSMBJ24	Definitive	Biomarker	[4118]
KIF3C	OTTXKIWA	Definitive	Altered Expression	[4113]
KLF2	OTIP1UFX	Definitive	Biomarker	[4119]
LGALS9	OT7MF91K	Definitive	Biomarker	[4120]
LTBP3	OTME98V7	Definitive	Biomarker	[4121]
MCM5	OTAHLB62	Definitive	Altered Expression	[4122]
MED13	OTP5LEJE	Definitive	Biomarker	[3362]
MPZ	OTAR2YXH	Definitive	Biomarker	[2388]
MRTFA	OTCVXASM	Definitive	Biomarker	[4123]
MSX1	OT5U41ZP	Definitive	Posttranslational Modification	[4124]
MYH6	OT3YNCH1	Definitive	Biomarker	[4125]
MYO6	OTJQYRC7	Definitive	Biomarker	[4125]
NDUFAF4	OTWJ5B9M	Definitive	Biomarker	[4126]
NDUFS4	OTJKUYEE	Definitive	Genetic Variation	[4127]
NNAT	OTNRLO7G	Definitive	Altered Expression	[4128]
NPRL2	OTOB10MO	Definitive	Biomarker	[4129]
NR2C2	OTDZWVOJ	Definitive	Biomarker	[1191]
NRL	OT65MFKQ	Definitive	Biomarker	[4130]
OGFOD1	OTTUQ5O3	Definitive	Biomarker	[4131]
ORAI3	OTUP3OH3	Definitive	Altered Expression	[1287]
PAQR4	OTNO659U	Definitive	Biomarker	[4132]
PARP4	OTXBK59G	Definitive	Biomarker	[4133]
PCDHGB7	OTBNJN7B	Definitive	Biomarker	[4134]
PDZK1IP1	OTWA6M5K	Definitive	Altered Expression	[4135]
PEA15	OTKCKTSX	Definitive	Altered Expression	[3390]
PGLS	OTO6C0IQ	Definitive	Altered Expression	[1945]
PIWIL2	OT1PXQIF	Definitive	Altered Expression	[4136]
PLCB2	OTPAHDGO	Definitive	Biomarker	[2485]
POU4F2	OT6SW5H0	Definitive	Biomarker	[4137]
PPM1B	OTZMH6V3	Definitive	Biomarker	[4138]
PRG2	OT0BCPQG	Definitive	Biomarker	[4110]
RAB23	OTBAKFBR	Definitive	Biomarker	[4139]
RARRES2	OT1BJE8K	Definitive	Biomarker	[4140]
RARS1	OTHPZ6JN	Definitive	Genetic Variation	[536]
RASSF10	OTGB7EBG	Definitive	Posttranslational Modification	[4141]
RBBP8	OTRHJ3GI	Definitive	Biomarker	[4142]
RBL2	OTBQSOE6	Definitive	Biomarker	[4143]
RBP2	OTR8QG5V	Definitive	Biomarker	[4144]
RIPK3	OTL1D484	Definitive	Biomarker	[1998]
RND1	OTOC223Z	Definitive	Genetic Variation	[4145]
SERPINB9	OTJ811IF	Definitive	Biomarker	[4146]
SETD1A	OTVVWRIC	Definitive	Altered Expression	[4147]
SIRT4	OT5S0J23	Definitive	Biomarker	[4148]
SIX3	OTP5E3VU	Definitive	Biomarker	[3408]
SNX9	OTLNQ0ZM	Definitive	Biomarker	[4149]
SPDYA	OTYKC1AJ	Definitive	Altered Expression	[4150]
SPPL3	OT2HLJF6	Definitive	Biomarker	[4112]
STING1	OTDAP4G0	Definitive	Biomarker	[925]
SUSD4	OTWCJTT3	Definitive	Altered Expression	[4151]
SUZ12	OT655XF8	Definitive	Biomarker	[4065]
TARBP2	OT1QQ8H3	Definitive	Biomarker	[4152]
TBC1D16	OTPR3C6A	Definitive	Biomarker	[4153]
TBX5	OT70PISV	Definitive	Genetic Variation	[4154]
TC2N	OT6482WN	Definitive	Altered Expression	[4155]
TEAD4	OTJS0T2B	Definitive	Biomarker	[4156]
TERF2IP	OT3M5P3G	Definitive	Biomarker	[3722]
TEX101	OTNO747E	Definitive	Biomarker	[4157]
TIAL1	OTV2KFZH	Definitive	Biomarker	[4158]
TIPIN	OT9PZHXV	Definitive	Biomarker	[4159]
TMEM132D	OTV6I4Z0	Definitive	Genetic Variation	[4160]
TMEM14C	OTHYTMLC	Definitive	Biomarker	[4161]
TP53	OTIE1VH3	Definitive	Autosomal dominant	[265]
TPM2	OTA1L0P8	Definitive	Altered Expression	[4162]
TRIAP1	OTEAUJXN	Definitive	Altered Expression	[4163]

This Disease Is Related to 1510 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABL2	TT1A6HL	Limited	Biomarker	[266]
ACE2	TTUI5H7	Limited	Altered Expression	[267]
ACHE	TT1RS9F	Limited	Biomarker	[268]
ACLY	TT0Z6Y2	Limited	Biomarker	[269]
ADAMTS1	TTS2TEI	Limited	Biomarker	[270]
ADORA2B	TTNE7KG	Limited	Biomarker	[271]
ADRB1	TTR6W5O	Limited	Altered Expression	[272]
ADRB3	TTMXGCW	Limited	Altered Expression	[272]
AGK	TTJETQC	Limited	Altered Expression	[273]
AICDA	TTKRTP6	Limited	Biomarker	[274]
ALKBH5	TTOHB1M	Limited	Biomarker	[275]
ALOX5	TTSJ6Q4	Limited	Biomarker	[276]
AMHR2	TTZDCPK	Limited	Biomarker	[277]
ANTXR2	TTOD34I	Limited	Altered Expression	[278]
AQP7	TTNGCRK	Limited	Altered Expression	[279]
AQP9	TTQEI32	Limited	Biomarker	[279]
ASAP3	TTB4ZEN	Limited	Biomarker	[280]
ATF4	TTQCKWT	Limited	Biomarker	[281]
ATP2A2	TTE6THL	Limited	Altered Expression	[282]
AURKA	TTPS3C0	Limited	Autosomal dominant	[265]
AURKC	TTLYXIT	Limited	Biomarker	[283]
B2M	TTY7FKA	Limited	Biomarker	[284]
BCHE	TT3MSAO	Limited	Biomarker	[285]
BDKRB1	TTG5QIA	Limited	Biomarker	[286]
BRD1	TTT09OB	Limited	Biomarker	[287]
BTG1	TTL7N2W	Limited	Biomarker	[288]
CA5A	TT75WPO	Limited	Biomarker	[289]
CACNA1G	TT729IR	Limited	Biomarker	[290]
CALCA	TTVSFJW	Limited	Biomarker	[274]
CBR1	TTVG0SN	Limited	Altered Expression	[291]
CBS	TTVZJ7G	Limited	Altered Expression	[292]
CBX7	TTBN3HC	Limited	Altered Expression	[293]
CCL22	TTBTWI1	Limited	Biomarker	[294]
CD14	TT6I7DC	Limited	Biomarker	[295]
CD160	TTOFEAS	Limited	Biomarker	[296]
CD22	TTM6QSK	Limited	Biomarker	[297]
CD33	TTJVYO3	Limited	Biomarker	[297]
CD40LG	TTIJP3Q	Limited	Biomarker	[298]
CD69	TTPQE9F	Limited	Biomarker	[299]
CD80	TT89Z17	Limited	Biomarker	[300]
CDH1	TTLAWO6	Limited	Altered Expression	[301]
CDH11	TTRGWZC	Limited	Biomarker	[302]
CDK12	TTJ21A9	Limited	Altered Expression	[303]
CEBPA	TT5LWG1	Limited	Posttranslational Modification	[304]
CENPE	TTZD5QR	Limited	Biomarker	[305]
CHIT1	TTDYX6T	Limited	Altered Expression	[306]
CHUK	TT1F8OQ	Limited	Altered Expression	[307]
COASY	TT4YO0Z	Limited	Biomarker	[308]
CSNK1D	TTH30UI	Limited	Biomarker	[309]
CSNK1E	TTA8PLI	Limited	Biomarker	[310]
CTSK	TTDZN01	Limited	Altered Expression	[311]
CX3CL1	TT1OFBQ	Limited	Biomarker	[312]
CYP11B1	TTIQUX7	Limited	Biomarker	[313]
DDX58	TTVB0O3	Limited	Biomarker	[314]
DEK	TT1NMGV	Limited	Altered Expression	[315]
DGKA	TTGL8F0	Limited	Biomarker	[316]
DKK2	TTST5KX	Limited	Altered Expression	[317]
DLK1	TTF4AVB	Limited	Biomarker	[318]
DPP4	TTDIGC1	Limited	Biomarker	[319]
DPYD	TTZPS91	Limited	Biomarker	[320]
DPYSL2	TTZCW3T	Limited	Biomarker	[321]
DRD1	TTZFYLI	Limited	Altered Expression	[322]
DRD5	TTS2PH3	Limited	Altered Expression	[322]
DUSP5	TTZN92A	Limited	Altered Expression	[323]
E2F2	TT5FYX0	Limited	Biomarker	[324]
EEF2K	TT1QFLA	Limited	Biomarker	[325]
EGFL6	TTXJGAR	Limited	Biomarker	[326]
EGFL7	TT7WD0H	Limited	Altered Expression	[327]
EGR1	TTE8LGD	Limited	Altered Expression	[328]
ELANE	TTPLTSQ	Limited	Biomarker	[329]
ELK3	TT5OJMV	Limited	Biomarker	[330]
ENTPD3	TT7ES5I	Limited	Biomarker	[331]
EP300	TTGH73N	Limited	Altered Expression	[332]
EPX	TTCIO0M	Limited	Altered Expression	[333]
EYA2	TTUY9C6	Limited	Biomarker	[334]
F9	TTFEZ5Q	Limited	Biomarker	[335]
FAF1	TTSKL3G	Limited	Posttranslational Modification	[336]
FAM83B	TT1Q347	Limited	Altered Expression	[337]
FAP	TTGPQ0F	Limited	Altered Expression	[338]
FAT1	TTGUJYV	Limited	Genetic Variation	[339]
FFAR4	TT08JVB	Limited	Biomarker	[340]
FGF19	TTGCH11	Limited	Altered Expression	[341]
FKBP4	TTHY0FT	Limited	Altered Expression	[342]
FOXC2	TTLBAP1	Limited	Altered Expression	[343]
FOXQ1	TTEJZOL	Limited	Biomarker	[344]
FYN	TT2B9KF	Limited	Biomarker	[345]
GAD2	TT7UY6K	Limited	Biomarker	[346]
GATA4	TT1VDN2	Limited	Posttranslational Modification	[347]
GGH	TTZJRL0	Limited	Biomarker	[348]
GHSR	TTWDC17	Limited	Biomarker	[349]
GJA8	TTJ7ATH	Limited	Biomarker	[350]
GJB6	TTAU8SJ	Limited	Altered Expression	[351]
GLP1R	TTVIMDE	Limited	Altered Expression	[352]
GNA11	TTSRXJW	Limited	Biomarker	[353]
GZMB	TTKEPHX	Limited	Biomarker	[354]
HCAR2	TTWNV8U	Limited	Genetic Variation	[355]
HCN1	TTNB6UQ	Limited	Biomarker	[356]
HDGF	TTKGV26	Limited	Biomarker	[357]
HEXIM1	TTFOKAH	Limited	Altered Expression	[358]
HNRNPA2B1	TT8UPW6	Limited	Altered Expression	[359]
HRH3	TT9JNIC	Limited	Genetic Variation	[360]
HSD11B2	TT9H85R	Limited	Altered Expression	[361]
HSD17B13	TTDJYZR	Limited	Biomarker	[362]
HSPE1	TTWYMFE	Limited	Altered Expression	[363]
IFNGR2	TT13TL0	Limited	Genetic Variation	[364]
IFNW1	TTS2TGF	Limited	Genetic Variation	[365]
IKZF2	TTKT5NV	Limited	Biomarker	[366]
IL16	TTW4R0B	Limited	Biomarker	[367]
IL19	TT87RWS	Limited	Genetic Variation	[368]
IL22	TTLDX4N	Limited	Biomarker	[369]
IL32	TTD4G7L	Limited	Biomarker	[370]
IL33	TT5MD4P	Limited	Biomarker	[371]
IL4R	TTDWHC3	Limited	Biomarker	[372]
IRAK1	TTXAJWN	Limited	Altered Expression	[373]
ISG15	TTVOH3T	Limited	Biomarker	[374]
ITK	TT3C80U	Limited	Biomarker	[375]
KAT2B	TTVK7SB	Limited	Biomarker	[376]
KAT6A	TT6O1J0	Limited	Altered Expression	[377]
KCNN3	TT9JH25	Limited	Biomarker	[378]
KDM1B	TT8VP2T	Limited	Biomarker	[379]
KDM2A	TT8XTY2	Limited	Biomarker	[380]
KDM5C	TT94UCF	Limited	Biomarker	[381]
KDM6B	TTDIJUQ	Limited	Altered Expression	[382]
KDM7A	TT0NYMP	Limited	Biomarker	[383]
KIR2DS1	TTVWAGF	Limited	Genetic Variation	[384]
KIR2DS2	TTV3CFI	Limited	Biomarker	[384]
KIR3DL2	TTQH3N0	Limited	Genetic Variation	[384]
KLB	TTARBVH	Limited	Biomarker	[385]
KLRG1	TT299E6	Limited	Biomarker	[386]
LBP	TTVQJLY	Limited	Altered Expression	[387]
LGMN	TTPTWV5	Limited	Biomarker	[388]
LILRB2	TTHC6XU	Limited	Altered Expression	[389]
LTB4R2	TTVJX54	Limited	Biomarker	[390]
LY6K	TT5GKHN	Limited	Biomarker	[391]
MALT1	TTCI81G	Limited	Genetic Variation	[392]
MAP3K20	TTTUZ3O	Limited	Biomarker	[393]
MAPK11	TT73U6C	Limited	Biomarker	[394]
MAPKAP1	TTWDKCL	Limited	Biomarker	[395]
MERTK	TTO7LKR	Limited	Altered Expression	[396]
MGAM	TTXWASR	Limited	Biomarker	[397]
MGAT1	TTYJRN5	Limited	Biomarker	[398]
MRGPRX1	TTIX6PK	Limited	Biomarker	[399]
MST1R	TTBQ3OC	Limited	Biomarker	[400]
MUC15	TTGQ6MI	Limited	Biomarker	[401]
MYLK2	TTHLGB2	Limited	Genetic Variation	[402]
NLRP1	TTQX29T	Limited	Biomarker	[403]
NLRX1	TTKT026	Limited	Altered Expression	[404]
NR0B1	TTTK36V	Limited	Biomarker	[405]
NR1H2	TTXA6PH	Limited	Biomarker	[406]
NR4A1	TTMXE2Q	Limited	Biomarker	[407]
NR4A2	TT9HKN3	Limited	Altered Expression	[408]
NR4A3	TTJQB49	Limited	Altered Expression	[409]
NTN1	TT0AH4L	Limited	Biomarker	[410]
P2RY12	TTZ1DT0	Limited	Biomarker	[411]
P2RY2	TTOZHQC	Limited	Altered Expression	[412]
P4HA1	TTNH25W	Limited	Altered Expression	[413]
PAK2	TT279WO	Limited	Biomarker	[414]
PBK	TTMY6BZ	Limited	Biomarker	[415]
PBRM1	TTH8ZRL	Limited	Biomarker	[416]
PDGFB	TTQA6SX	Limited	Altered Expression	[417]
PDGFC	TTOABM9	Limited	Altered Expression	[418]
PDGFRA	TT8FYO9	Limited	Altered Expression	[419]
PEMT	TT735V2	Limited	Posttranslational Modification	[420]
PHF8	TT81PFE	Limited	Altered Expression	[421]
PIKFYVE	TTA4M1N	Limited	Biomarker	[422]
PIM2	TT69J2Z	Limited	Posttranslational Modification	[423]
PIM3	TTCGOIN	Limited	Biomarker	[424]
PIP5K1A	TTA7DU1	Limited	Biomarker	[425]
PKLR	TT31N4S	Limited	Biomarker	[426]
PKMYT1	TTB4PAZ	Limited	Altered Expression	[427]
PKN3	TTW3P4R	Limited	Biomarker	[428]
PLD1	TT3T17P	Limited	Altered Expression	[429]
PLD2	TTRLMKF	Limited	Altered Expression	[430]
PLK4	TTGPNZQ	Limited	Biomarker	[431]
PLP2	TTK5OG6	Limited	Altered Expression	[432]
PPARD	TT2JWF6	Limited	Biomarker	[433]
PPIA	TTL2ADK	Limited	Biomarker	[434]
PPP2CA	TTHTKNY	Limited	Altered Expression	[435]
PRDX5	TTLPJWH	Limited	Biomarker	[436]
PREP	TTNGKET	Limited	Biomarker	[437]
PRKCD	TT7A1BO	Limited	Altered Expression	[438]
PRKCE	TT57MT2	Limited	Altered Expression	[439]
PSMB8	TTEAD9J	Limited	Altered Expression	[440]
PSMB9	TTOUSTQ	Limited	Biomarker	[441]
PSMD10	TT2H4LN	Limited	Biomarker	[442]
PTGER4	TT79WV3	Limited	Altered Expression	[443]
PTH1R	TTFPD47	Limited	Biomarker	[444]
PTK7	TTXH2ZN	Limited	Altered Expression	[445]
PTN	TTA9EJK	Limited	Altered Expression	[446]
PTP4A2	TT1MHKD	Limited	Biomarker	[447]
PTPN13	TT405FP	Limited	Biomarker	[448]
PTPRC	TTUS45N	Limited	Biomarker	[449]
RAB9A	TT958S6	Limited	Biomarker	[450]
RACK1	TTJ10AL	Limited	Altered Expression	[451]
RALBP1	TTVSRUA	Limited	Altered Expression	[452]
RAPGEF3	TTOE7I0	Limited	Biomarker	[453]
RHOB	TT6LPFO	Limited	Altered Expression	[454]
RIPK1	TTVJHX8	Limited	Biomarker	[455]
ROS1	TTSZ6Y3	Limited	Autosomal dominant	[265]
RSPO1	TTI9HL4	Limited	Biomarker	[456]
S1PR1	TT9JZCK	Limited	Altered Expression	[457]
S1PR2	TTVSMOH	Limited	Biomarker	[458]
SCAP	TTL6U2P	Limited	Biomarker	[459]
SCN3A	TTAXZ0K	Limited	Altered Expression	[460]
SERPINF1	TTR59S1	Limited	Biomarker	[461]
SF3B1	TTL2WUI	Limited	Biomarker	[462]
SGK1	TTTV8EJ	Limited	Genetic Variation	[463]
SLC5A2	TTF8JAT	Limited	Biomarker	[464]
SLC5A6	TT61XTV	Limited	Altered Expression	[465]
SLC8A1	TTCF82X	Limited	Altered Expression	[466]
SLCO2A1	TTKVTQO	Limited	Biomarker	[467]
SORT1	TTRX9AV	Limited	Biomarker	[468]
SPN	TTOZAX0	Limited	Biomarker	[469]
SREBF1	TTER0UB	Limited	Biomarker	[470]
SSRP1	TTETDKQ	Limited	Altered Expression	[471]
STEAP2	TTOXF5J	Limited	Altered Expression	[472]
STXBP4	TTKS60G	Limited	Biomarker	[473]
TACR1	TTZPO1L	Limited	Biomarker	[474]
TAGLN2	TTP6BIJ	Limited	Altered Expression	[475]
TBL1XR1	TTYXT16	Limited	Altered Expression	[476]
TCL1A	TTUKRDV	Limited	Genetic Variation	[477]
TDGF1	TTN7HMG	Limited	Posttranslational Modification	[478]
TGFB2	TTI0KH6	Limited	Biomarker	[479]
TLN1	TTQSMFG	Limited	Genetic Variation	[480]
TNFRSF14	TTWGTC1	Limited	Genetic Variation	[481]
TNFRSF25	TTDV6BQ	Limited	Biomarker	[482]
TNFSF12	TTBTDM1	Limited	Altered Expression	[483]
TNFSF13B	TTWMIDN	Limited	Biomarker	[484]
TNFSF15	TTEST6I	Limited	Altered Expression	[485]
TNIK	TTPB1W3	Limited	Biomarker	[486]
TOP2B	TT4NVEM	Limited	Genetic Variation	[487]
TRPV6	TTBK14N	Limited	Biomarker	[488]
UCP2	TTSC2YM	Limited	Biomarker	[489]
UTRN	TTNO1VA	Limited	Biomarker	[490]
WDR5	TT7OFWB	Limited	Biomarker	[491]
WEE1	TTJFOAL	Limited	Biomarker	[492]
CD6	TTMF6KC	Disputed	Genetic Variation	[493]
CDK3	TTMYWL7	Disputed	Biomarker	[494]
CDKL1	TTBTI6P	Disputed	Biomarker	[495]
GAL	TTXZAJ5	Disputed	Biomarker	[496]
LRP5	TT7VMG4	Disputed	Biomarker	[497]
MLH1	TTISG27	Disputed	Autosomal dominant	[265]
MSH2	TTCAWRT	Disputed	Autosomal dominant	[265]
PKD2L1	TTAHD89	Disputed	Biomarker	[498]
RTN4	TT7GXMU	Disputed	Biomarker	[499]
SLC1A2	TT2F078	Disputed	Biomarker	[500]
TKT	TT04R7I	Disputed	Biomarker	[501]
TLR6	TTWRI8V	Disputed	Biomarker	[502]
TRPM2	TTEBMN7	Disputed	Biomarker	[503]
ABCG1	TTMWDGU	moderate	Biomarker	[504]
ACKR1	TTKY2NS	moderate	Genetic Variation	[505]
ADGRL3	TTQST3U	moderate	Altered Expression	[506]
AGTR2	TTQVOEI	moderate	Altered Expression	[507]
AKR1C3	TT5ZWB6	moderate	Biomarker	[508]
APOA4	TTNC3WS	moderate	Altered Expression	[509]
APOB	TTN1IE2	moderate	Altered Expression	[510]
AQP3	TTLDNMQ	moderate	Biomarker	[511]
ARF1	TT70KXY	moderate	Biomarker	[512]
ARRB2	TT8SO2I	moderate	Biomarker	[513]
ATAD2	TT9A0HI	moderate	Altered Expression	[514]
ATRAID	TTFLIKM	moderate	Biomarker	[515]
ATXN3	TT6A17J	moderate	Altered Expression	[516]
AVP	TTJ8EWH	moderate	Genetic Variation	[517]
AZGP1	TTUPYLV	moderate	Biomarker	[518]
BIRC3	TTAIWZN	moderate	Genetic Variation	[519]
BRD2	TTDP48B	moderate	Biomarker	[520]
BRSK2	TTHZN4X	moderate	Biomarker	[521]
CACNA1E	TTYRP0M	moderate	Biomarker	[522]
CACNA1I	TTQZFTH	moderate	Altered Expression	[523]
CACNA2D3	TTN7T29	moderate	Posttranslational Modification	[524]
CD27	TTDO1MV	moderate	Genetic Variation	[525]
CDC42BPA	TT5Z0EF	moderate	Altered Expression	[526]
CDC7	TTSMTDI	moderate	Genetic Variation	[527]
CDK19	TTNABU9	moderate	Biomarker	[528]
CDK8	TTBJR4L	moderate	Biomarker	[529]
CEACAM6	TTIGH2W	moderate	Altered Expression	[530]
CEL	TTTRNQW	moderate	Altered Expression	[531]
CIT	TT3BKTU	moderate	Altered Expression	[532]
CLCN3	TT8XNZ7	moderate	Biomarker	[533]
CRH	TTA7YIZ	moderate	Biomarker	[534]
DAPK3	TTERVQN	moderate	Altered Expression	[535]
DCPS	TTLSW9V	moderate	Genetic Variation	[536]
DFFA	TTYVQ9C	moderate	Biomarker	[537]
DHPS	TTBO2A9	moderate	Biomarker	[538]
DNMT3L	TT3FDAV	moderate	Genetic Variation	[539]
E2F3	TTWIJYH	moderate	Biomarker	[540]
EED	TTFNJ4R	moderate	Biomarker	[541]
EML4	TT92GY4	moderate	Genetic Variation	[542]
ENPP2	TTSCIM2	moderate	Biomarker	[543]
ENSA	TTQD0YT	moderate	Biomarker	[544]
EPHA5	TTV9KOD	moderate	Biomarker	[545]
EPHB6	TTZEMUY	moderate	Biomarker	[546]
EZH1	TTNJA0C	moderate	Biomarker	[547]
F2RL3	TTD0652	moderate	Biomarker	[548]
F5	TT1O264	moderate	Genetic Variation	[549]
F7	TTF0EGX	moderate	Biomarker	[550]
FABP3	TT3TGLR	moderate	Biomarker	[551]
FAM83D	TTFIW7J	moderate	Altered Expression	[552]
FANCA	TTV5HJS	moderate	Genetic Variation	[553]
FHL1	TTI7ENL	moderate	Biomarker	[554]
FSHR	TTZFDBT	moderate	Altered Expression	[555]
GDF5	TT37XV9	moderate	Altered Expression	[556]
GJC2	TTPOCAL	moderate	Genetic Variation	[557]
GLA	TTIS03D	moderate	Biomarker	[558]
GLB1	TTNGJPH	moderate	Biomarker	[559]
GPC3	TTJTSX4	moderate	Biomarker	[560]
GPD1	TTKTEAH	moderate	Biomarker	[561]
GREM1	TTOUZN5	moderate	Altered Expression	[562]
GRK2	TTAZ3MN	moderate	Altered Expression	[563]
GRM4	TTICZ1O	moderate	Altered Expression	[564]
GUCY1B1	TTLBYH1	moderate	Altered Expression	[565]
HAMP	TTRV5YJ	moderate	Biomarker	[566]
HCAR3	TT8WFXV	moderate	Biomarker	[567]
HDAC11	TT8K17W	moderate	Biomarker	[568]
HDAC2	TTSHTOI	moderate	Altered Expression	[569]
HDAC5	TTUELN5	moderate	Altered Expression	[570]
HDAC8	TTT6LFV	moderate	Altered Expression	[571]
HDC	TTV9GOF	moderate	Altered Expression	[572]
HIPK2	TTOB49C	moderate	Biomarker	[573]
HMGCS2	TTS0EZJ	moderate	Biomarker	[574]
HNMT	TT2B6EV	moderate	Genetic Variation	[575]
HPN	TT25MVL	moderate	Altered Expression	[576]
HSD17B2	TT0PT1R	moderate	Altered Expression	[577]
IDS	TTNY2AP	moderate	Biomarker	[578]
IFNAR1	TTSYFMA	moderate	Altered Expression	[579]
IL17F	TT2B6PS	moderate	Genetic Variation	[580]
IL1R1	TTWOTEA	moderate	Altered Expression	[581]
IL25	TTVMO5W	moderate	Biomarker	[582]
ITCH	TT5SEWD	moderate	Biomarker	[583]
ITGA2	TTSJ542	moderate	Biomarker	[584]
KCNA1	TTS3DIK	moderate	Altered Expression	[585]
KDM4C	TTV8CRH	moderate	Biomarker	[586]
LAMP2	TTULDG7	moderate	Altered Expression	[587]
LATS2	TTML7FG	moderate	Genetic Variation	[588]
LRP2	TTPH1AJ	moderate	Biomarker	[589]
LRRK2	TTK0FEA	moderate	Genetic Variation	[590]
MAP3K21	TTSW9YL	moderate	Altered Expression	[591]
MAP3K5	TTOQCD8	moderate	Biomarker	[592]
MAP3K9	TTUNSIX	moderate	Biomarker	[593]
MECP2	TTTAU9R	moderate	Altered Expression	[594]
MS4A1	TTUE541	moderate	Biomarker	[595]
MSI2	TTTXQF6	moderate	Biomarker	[596]
MTAP	TTDBX7N	moderate	Altered Expression	[597]
MYH2	TTBIL13	moderate	Biomarker	[598]
NDUFA13	TTRU1NG	moderate	Altered Expression	[599]
NPR1	TTM9IYA	moderate	Biomarker	[600]
NSD1	TTTSJ3H	moderate	Biomarker	[601]
NUAK1	TT65FL0	moderate	Biomarker	[602]
PADI4	TTQHAXM	moderate	Biomarker	[603]
PARP2	TTQ4V96	moderate	Genetic Variation	[604]
PAX5	TTA4REJ	moderate	Biomarker	[605]
PCSK6	TT75LN9	moderate	Biomarker	[606]
PCSK7	TTD30LY	moderate	Biomarker	[607]
PDXP	TT9UYG4	moderate	Altered Expression	[608]
PGF	TT48I1Y	moderate	Altered Expression	[609]
PINX1	TT4FJ3A	moderate	Altered Expression	[610]
PLA2R1	TTHKW7D	moderate	Altered Expression	[611]
PLCG1	TT6T4JI	moderate	Biomarker	[612]
PNP	TTMCF1Y	moderate	Biomarker	[613]
PRAME	TTPH7T0	moderate	Altered Expression	[614]
PRKCH	TTONI0R	moderate	Biomarker	[615]
PRSS8	TTT4N0Q	moderate	Altered Expression	[616]
PTGER2	TT1ZAVI	moderate	Biomarker	[617]
PTPRJ	TTWMKXP	moderate	Genetic Variation	[618]
RBPJ	TT72D4Z	moderate	Biomarker	[619]
RGS6	TTJ96M8	moderate	Genetic Variation	[620]
RORA	TT1TYN7	moderate	Genetic Variation	[621]
RXRB	TTKLV96	moderate	Biomarker	[622]
RXRG	TTH029C	moderate	Biomarker	[623]
SCUBE2	TTWREQP	moderate	Altered Expression	[624]
SIRT2	TTLKF5M	moderate	Altered Expression	[625]
SLC25A4	TTU5A6Q	moderate	Altered Expression	[626]
SLC26A4	TT7X02I	moderate	Biomarker	[627]
SLC3A2	TT5CZSM	moderate	Biomarker	[628]
SLC6A2	TTAWNKZ	moderate	Biomarker	[330]
SLCO1A2	TTUGD21	moderate	Altered Expression	[629]
SRD5A1	TTTU72V	moderate	Genetic Variation	[630]
ST8SIA4	TTDP8YM	moderate	Altered Expression	[631]
TACSTD2	TTP2HE5	moderate	Altered Expression	[632]
TBXA2R	TT2O84V	moderate	Biomarker	[633]
TEP1	TTQGAVX	moderate	Genetic Variation	[634]
THRA	TTTSEPU	moderate	Biomarker	[635]
TLR5	TTCXP8J	moderate	Altered Expression	[636]
TPX2	TT0PHL4	moderate	Biomarker	[637]
USP13	TTVJIO2	moderate	Biomarker	[638]
USP14	TTVSYP9	moderate	Biomarker	[639]
UTS2	TTERU0T	moderate	Genetic Variation	[640]
VANGL1	TT18WJB	moderate	Biomarker	[641]
VDAC1	TTAMKGB	moderate	Biomarker	[642]
ABCA1	TTJW1GN	Strong	Genetic Variation	[504]
ABCA4	TTLB52K	Strong	Genetic Variation	[504]
ABCB11	TTUXCAF	Strong	Genetic Variation	[643]
ABCB4	TTJUXV6	Strong	Altered Expression	[644]
ABCC2	TTFLHJV	Strong	Biomarker	[645]
ABCC3	TTVLG21	Strong	Biomarker	[646]
ABCC4	TTUEAFL	Strong	Altered Expression	[647]
ABCC8	TTP835K	Strong	Genetic Variation	[648]
ABL1	TT6B75U	Strong	Posttranslational Modification	[649]
ACKR3	TTRQJTC	Strong	Biomarker	[399]
ACR	TTAHE2N	Strong	Biomarker	[650]
ACTG1	TTGAZF9	Strong	Genetic Variation	[651]
ACVR2A	TTX2DRI	Strong	Altered Expression	[652]
ACVR2B	TTLFRKS	Strong	Altered Expression	[652]
ADA	TTLP57V	Strong	Biomarker	[653]
ADAM10	TTVXEGU	Strong	Biomarker	[654]
ADAM17	TT6AZXG	Strong	Biomarker	[655]
ADAM33	TTQICM2	Strong	Genetic Variation	[656]
ADAM8	TTQWYMD	Strong	Biomarker	[657]
ADAM9	TTTYQNS	Strong	Biomarker	[658]
ADAMTS4	TTYG6BU	Strong	Biomarker	[659]
ADAMTS5	TTXSU2Y	Strong	Biomarker	[659]
ADCYAP1R1	TT5OREU	Strong	Altered Expression	[660]
ADM	TTV14YH	Strong	Biomarker	[661]
ADORA1	TTK25J1	Strong	Biomarker	[662]
ADRA1A	TTNGILX	Strong	Biomarker	[399]
ADRA1D	TT34BHT	Strong	Biomarker	[663]
ADRA2A	TTWG9A4	Strong	Biomarker	[664]
ADRA2B	TTWM4TY	Strong	Biomarker	[399]
ADRA2C	TT2NUT5	Strong	Biomarker	[664]
ADRB2	TTG8ZWP	Strong	Genetic Variation	[665]
AFP	TTCFEA1	Strong	Therapeutic	[666]
AGR2	TT9K86S	Strong	Altered Expression	[667]
AHCY	TTE2KUJ	Strong	Biomarker	[668]
AHSG	TTKF4WV	Strong	Biomarker	[669]
AIF1	TT12MEP	Strong	Biomarker	[670]
AIMP2	TTXWHGF	Strong	Altered Expression	[370]
AKR1B1	TTFBNVI	Strong	Altered Expression	[434]
AKT2	TTH24WI	Strong	Biomarker	[671]
AKT3	TTO6SGY	Strong	Biomarker	[671]
ALAD	TTJHKYD	Strong	Altered Expression	[672]
ALCAM	TT2AFT6	Strong	Biomarker	[673]
ALK	TTPMQSO	Strong	Biomarker	[674]
ALOX12	TT12ABZ	Strong	Biomarker	[675]
ALPI	TTHYMUV	Strong	Biomarker	[676]
ALPL	TTMR5UV	Strong	Biomarker	[677]
AMACR	TTLN1AP	Strong	Genetic Variation	[678]
AMD1	TTBFROQ	Strong	Biomarker	[679]
ANGPT2	TTKLQTJ	Strong	Altered Expression	[680]
ANGPTL4	TTWALY5	Strong	Biomarker	[681]
ANO1	TTOJI4S	Strong	Biomarker	[682]
ANO7	TT2X79I	Strong	Biomarker	[683]
ANXA2	TT4YANI	Strong	Altered Expression	[684]
AOC1	TTM3B5R	Strong	Biomarker	[685]
AOC3	TT7HC21	Strong	Biomarker	[686]
APC2	TTSMK36	Strong	Altered Expression	[687]
APCS	TTB7VAT	Strong	Biomarker	[688]
APLN	TT87D3J	Strong	Biomarker	[689]
APOA1	TT5S8DR	Strong	Biomarker	[690]
APOC3	TTXOZQ1	Strong	Genetic Variation	[691]
APP	TTE4KHA	Strong	Biomarker	[692]
AQP1	TTSF1KH	Strong	Biomarker	[693]
ARAF	TT5TURO	Strong	Therapeutic	[694]
AREG	TT76B3W	Strong	Biomarker	[695]
ARL2	TTIDSFT	Strong	Altered Expression	[696]
ARRB1	TTMVD4A	Strong	Biomarker	[697]
ASPA	TT6TLZP	Strong	Genetic Variation	[698]
ASPH	TT2KHP7	Strong	Biomarker	[699]
ASRGL1	TT4WT91	Strong	Biomarker	[700]
ATF3	TTCE793	Strong	Altered Expression	[701]
ATG7	TTLVB9Z	Strong	Biomarker	[702]
ATIC	TT9NVXQ	Strong	Biomarker	[703]
ATP7B	TTOPO51	Strong	Biomarker	[704]
ATR	TT8ZYBQ	Strong	Posttranslational Modification	[705]
AXL	TTZPY6J	Strong	Altered Expression	[706]
BACE2	TT69DB8	Strong	Biomarker	[707]
BACH1	TT2ME4S	Strong	Biomarker	[708]
BAGE	TTS5GLJ	Strong	Altered Expression	[709]
BAK1	TTFM7V0	Strong	Altered Expression	[710]
BAP1	TT47RXJ	Strong	Biomarker	[711]
BAX	TTQ57WJ	Strong	Altered Expression	[712]
BBC3	TT7JUKC	Strong	Biomarker	[713]
BCAT1	TTES57P	Strong	Biomarker	[714]
BCAT2	TTF9OQ6	Strong	Biomarker	[715]
BCL11A	TTR61MW	Strong	Biomarker	[716]
BCL2A1	TTGT9C7	Strong	Altered Expression	[407]
BCL2L2	TTQ79W8	Strong	Biomarker	[717]
BCL6	TTC9YX5	Strong	Altered Expression	[718]
BDNF	TTSMLOH	Strong	Genetic Variation	[719]
BGN	TT0JPVF	Strong	Biomarker	[720]
BIRC2	TTQ5LRD	Strong	Biomarker	[721]
BIRC5	TTTPU1G	Strong	Biomarker	[722]
BMP1	TT0L58T	Strong	Altered Expression	[723]
BMP10	TTTG6H1	Strong	Biomarker	[724]
BMP2	TTP3IGX	Strong	Altered Expression	[725]
BMP7	TTKOBRA	Strong	Biomarker	[726]
BMPR2	TTGKF90	Strong	Biomarker	[727]
BPHL	TTTZ3EU	Strong	Biomarker	[728]
BRAF	TT0EOB8	Strong	Biomarker	[729]
BRD3	TTHE657	Strong	Biomarker	[730]
BRD4	TTSRAOU	Strong	Altered Expression	[731]
BRD7	TT07ZS1	Strong	Biomarker	[732]
BRS3	TTKYEPM	Strong	Biomarker	[399]
BRSK1	TTV6WMQ	Strong	Biomarker	[521]
BST2	TT90BJT	Strong	Biomarker	[733]
BTK	TTGM6VW	Strong	Biomarker	[734]
BTLA	TTER58P	Strong	Genetic Variation	[735]
C1QBP	TTWTD7F	Strong	Altered Expression	[736]
C5	TTKANGO	Strong	Biomarker	[737]
C5AR1	TTHXFA1	Strong	Biomarker	[737]
CA12	TTSYM0R	Strong	Biomarker	[738]
CA2	TTANPDJ	Strong	Biomarker	[739]
CA9	TT2LVK8	Strong	Biomarker	[740]
CACNA2D2	TTU8P3M	Strong	Genetic Variation	[741]
CAD	TT2YT1K	Strong	Biomarker	[742]
CALCB	TTUZ9GV	Strong	Genetic Variation	[743]
CAMKK2	TTV298Y	Strong	Biomarker	[744]
CAMP	TTULOB6	Strong	Altered Expression	[745]
CAPN1	TT1WBIJ	Strong	Biomarker	[746]
CAPN2	TTG5QB7	Strong	Altered Expression	[747]
CARM1	TTIZQFJ	Strong	Biomarker	[748]
CASP10	TTX5HEK	Strong	Altered Expression	[749]
CASP2	TT12VNG	Strong	Biomarker	[750]
CASP6	TTKW4ML	Strong	Genetic Variation	[751]
CASP7	TTM7Y45	Strong	Biomarker	[752]
CASP9	TTB6T7O	Strong	Biomarker	[753]
CBL	TT7QT13	Strong	Biomarker	[754]
CCKBR	TTVFO0U	Strong	Biomarker	[755]
CCL11	TTCF05Y	Strong	Altered Expression	[756]
CCL17	TTMPHAE	Strong	Altered Expression	[757]
CCL20	TT2XAZY	Strong	Biomarker	[758]
CCL5	TT9DWLC	Strong	Altered Expression	[759]
CCN1	TTPK79J	Strong	Biomarker	[760]
CCN2	TTIL516	Strong	Biomarker	[761]
CCNA2	TTAMQ62	Strong	Altered Expression	[762]
CCND3	TT1JXNR	Strong	Biomarker	[763]
CCNE2	TTLDRGX	Strong	Biomarker	[764]
CCR2	TTFZYTO	Strong	Biomarker	[765]
CCR3	TTD3XFU	Strong	Altered Expression	[766]
CCR4	TT7HQD0	Strong	Biomarker	[767]
CCR5	TTJIH8Q	Strong	Biomarker	[768]
CCR6	TTFDB30	Strong	Biomarker	[769]
CCR7	TT2GIDQ	Strong	Biomarker	[770]
CCR9	TTIPS8B	Strong	Biomarker	[771]
CD163	TTTZ9DE	Strong	Biomarker	[772]
CD1A	TTBGTFN	Strong	Biomarker	[773]
CD200	TT0BE68	Strong	Biomarker	[774]
CD276	TT6CQUM	Strong	Biomarker	[775]
CD28	TTQ13FT	Strong	Altered Expression	[776]
CD320	TT0KV32	Strong	Biomarker	[777]
CD34	TTZAVYN	Strong	Biomarker	[778]
CD36	TTPJMCU	Strong	Altered Expression	[779]
CD38	TTPURFN	Strong	Biomarker	[780]
CD3E	TTZAT79	Strong	Biomarker	[781]
CD40	TT1ERKL	Strong	Altered Expression	[782]
CD46	TTMS7DF	Strong	Biomarker	[783]
CD47	TT28S46	Strong	Biomarker	[784]
CD55	TT5Z9WY	Strong	Altered Expression	[785]
CD70	TTNCIE0	Strong	Biomarker	[786]
CD83	TTT9MRQ	Strong	Genetic Variation	[787]
CDA	TTQ12RK	Strong	Biomarker	[788]
CDC25A	TTLZS4Q	Strong	Biomarker	[789]
CDC25B	TTR0SWN	Strong	Altered Expression	[790]
CDC25C	TTESBNC	Strong	Biomarker	[791]
CDCA8	TT04YCM	Strong	Biomarker	[792]
CDH2	TT1WS0T	Strong	Biomarker	[793]
CDH3	TTARMD9	Strong	Biomarker	[794]
CDH5	TTXLCFO	Strong	Biomarker	[795]
CDK11B	TT5Q79O	Strong	Altered Expression	[796]
CDK18	TTUMFAR	Strong	Altered Expression	[797]
CDK5	TTL4Q97	Strong	Altered Expression	[798]
CDK5R1	TTBYM6V	Strong	Biomarker	[799]
CDK7	TTQYF7G	Strong	Biomarker	[800]
CDK9	TT1LVF2	Strong	Biomarker	[801]
CEACAM1	TTA9CK4	Strong	Biomarker	[802]
CEACAM3	TTPX7I5	Strong	Biomarker	[803]
CEACAM5	TTY6DTE	Strong	Biomarker	[803]
CEBPB	TTUI35N	Strong	Biomarker	[804]
CERK	TT9XRNV	Strong	Biomarker	[805]
CETP	TTFQAYR	Strong	Biomarker	[806]
CFB	TTA0P7K	Strong	Genetic Variation	[807]
CFLAR	TTJZQYH	Strong	Genetic Variation	[808]
CFP	TTLA0VS	Strong	Biomarker	[809]
CHEK1	TTTU902	Strong	Biomarker	[810]
CHKA	TT10AWB	Strong	Biomarker	[811]
CHM	TTOA18V	Strong	Altered Expression	[812]
CHRNA5	TTH2QRX	Strong	Altered Expression	[813]
CHST15	TTFK7E1	Strong	Biomarker	[814]
CLCA1	TT3AF4R	Strong	Biomarker	[815]
CLDN18	TT6PKBX	Strong	Biomarker	[816]
CLDN4	TTMTS9H	Strong	Biomarker	[804]
CLIC1	TT8KZG6	Strong	Biomarker	[817]
CLK2	TT85TPS	Strong	Biomarker	[818]
CLN3	TTORF9W	Strong	Biomarker	[819]
CLU	TTRL76H	Strong	Biomarker	[820]
CMA1	TT8VUE0	Strong	Altered Expression	[821]
CMKLR1	TT4UGZL	Strong	Biomarker	[822]
CNP	TT71P0H	Strong	Biomarker	[823]
CNR2	TTMSFAW	Strong	Biomarker	[824]
CNTN1	TTPR8FK	Strong	Biomarker	[825]
COL18A1	TT63DI9	Strong	Biomarker	[826]
COL7A1	TTBCOKN	Strong	Biomarker	[827]
COPS5	TTSTNJR	Strong	Biomarker	[828]
CPA1	TT3LJ6G	Strong	Biomarker	[829]
CPB1	TT4UJX5	Strong	Biomarker	[830]
CPB2	TTP18AY	Strong	Altered Expression	[831]
CR1	TTEA8OW	Strong	Biomarker	[832]
CRAT	TTC8M31	Strong	Biomarker	[833]
CREB1	TTH4AN3	Strong	Altered Expression	[745]
CRHR1	TT7EFHR	Strong	Biomarker	[674]
CRK	TTFEUYR	Strong	Altered Expression	[370]
CRTC2	TTFWETR	Strong	Biomarker	[834]
CRY1	TT5MLZR	Strong	Biomarker	[310]
CRY2	TTAO58M	Strong	Genetic Variation	[621]
CRYAB	TT7RUHB	Strong	Biomarker	[835]
CSE1L	TTTRULD	Strong	Altered Expression	[836]
CSF1	TT0IQER	Strong	Biomarker	[837]
CSF1R	TT7MRDV	Strong	Biomarker	[838]
CSF2	TTNYZG2	Strong	Biomarker	[839]
CSF3	TT5TQ2W	Strong	Altered Expression	[840]
CSK	TTX6F0Q	Strong	Altered Expression	[841]
CSNK2A1	TTER6YH	Strong	Biomarker	[842]
CSNK2A2	TT7GR5W	Strong	Altered Expression	[843]
CSPG4	TT7MYXI	Strong	Biomarker	[844]
CTAG1A	TTE5ITK	Strong	Genetic Variation	[845]
CTCFL	TTY0RZT	Strong	Altered Expression	[846]
CTDSP1	TTHZAF0	Strong	Altered Expression	[847]
CTH	TTLQUZS	Strong	Altered Expression	[848]
CTLA4	TTI2S1D	Strong	Biomarker	[849]
CTSB	TTF2LRI	Strong	Biomarker	[850]
CTSG	TTQAJF1	Strong	Biomarker	[851]
CTSL	TT36ETB	Strong	Altered Expression	[852]
CTSS	TTUMQVO	Strong	Biomarker	[853]
CUL3	TTPCU0Q	Strong	Altered Expression	[395]
CXCL1	TTLK1RW	Strong	Biomarker	[854]
CXCL10	TTQOVYA	Strong	Biomarker	[855]
CXCL2	TTZF0K2	Strong	Biomarker	[856]
CXCL9	TTWE5PB	Strong	Genetic Variation	[857]
CXCR1	TTMWT8Z	Strong	Biomarker	[858]
CXCR2	TT30C9G	Strong	Biomarker	[859]
CXCR3	TT1UCIJ	Strong	Altered Expression	[860]
CXCR6	TT2BVUA	Strong	Biomarker	[399]
CXXC5	TTVS4C3	Strong	Biomarker	[861]
CYP11A1	TTSYVO6	Strong	Genetic Variation	[862]
CYP26A1	TTD7Q0R	Strong	Biomarker	[863]
CYP2A6	TTAQ6ZW	Strong	Genetic Variation	[864]
CYP2C9	TTR40YJ	Strong	Genetic Variation	[865]
CYP2E1	TTWVHQ5	Strong	Genetic Variation	[866]
CYP2J2	TTNE1C7	Strong	Altered Expression	[867]
CYSLTR1	TTGKOY9	Strong	Altered Expression	[868]
CYSLTR2	TT0PZR5	Strong	Altered Expression	[868]
DAG1	TT4X7PG	Strong	Altered Expression	[869]
DCK	TTJOCE4	Strong	Altered Expression	[870]
DCLK1	TTOHTCY	Strong	Altered Expression	[871]
DCLK3	TTMYK4Z	Strong	Biomarker	[872]
DCN	TTB3XAN	Strong	Biomarker	[720]
DDC	TTN451K	Strong	Biomarker	[873]
DDR1	TTI1FPZ	Strong	Biomarker	[874]
DDR2	TTU98HG	Strong	Biomarker	[875]
DDX5	TTZKPVC	Strong	Biomarker	[876]
DEPDC1	TT8S9CM	Strong	Altered Expression	[877]
DEPTOR	TTLYP6D	Strong	Altered Expression	[878]
DHCR24	TTTK0NH	Strong	Biomarker	[879]
DHODH	TTLVP78	Strong	Altered Expression	[880]
DIABLO	TTN74LE	Strong	Biomarker	[881]
DICER1	TTTEOPU	Strong	Biomarker	[882]
DKK1	TTE3RAC	Strong	Biomarker	[883]
DKK3	TTY2ZV6	Strong	Altered Expression	[884]
DLL1	TT9CFQD	Strong	Biomarker	[885]
DLL3	TT1C9K6	Strong	Altered Expression	[886]
DLL4	TTV23LH	Strong	Altered Expression	[887]
DMD	TTWLFXU	Strong	Biomarker	[888]
DNAJB1	TTPXAWS	Strong	Altered Expression	[889]
DNASE1	TTYWGOJ	Strong	Genetic Variation	[890]
DNM1	TTE3JW9	Strong	Biomarker	[891]
DNM2	TTVRA5G	Strong	Biomarker	[892]
DNMT3A	TTJUALD	Strong	Biomarker	[893]
DNPEP	TTGMFY7	Strong	Altered Expression	[894]
DOT1L	TTSZ8T1	Strong	Biomarker	[895]
DPEP1	TTYUENF	Strong	Biomarker	[896]
DRD3	TT4C8EA	Strong	Genetic Variation	[897]
DRD4	TTE0A2F	Strong	Biomarker	[898]
DSG3	TTEO4P8	Strong	Biomarker	[899]
DTL	TT8396I	Strong	Biomarker	[900]
DUSP1	TTG8HIM	Strong	Altered Expression	[901]
DUSP10	TTF3RJ0	Strong	Altered Expression	[902]
DUSP9	TT1GV6C	Strong	Altered Expression	[903]
DYRK1A	TTSBVFO	Strong	Biomarker	[904]
DYRK1B	TTYGQ8A	Strong	Biomarker	[905]
DYRK2	TT84OS6	Strong	Biomarker	[906]
E2F1	TTASI04	Strong	Biomarker	[907]
EBI3	TTJF68X	Strong	Biomarker	[908]
EBP	TT4VQZX	Strong	Biomarker	[909]
ECE1	TTQ9RYT	Strong	Biomarker	[910]
EDNRA	TTKRD0G	Strong	Biomarker	[399]
EDNRB	TT3ZTGU	Strong	Biomarker	[911]
EGLN1	TT9ISBX	Strong	Altered Expression	[912]
EGLN2	TTMHFRY	Strong	Genetic Variation	[913]
EHMT1	TTOFXD7	Strong	Biomarker	[352]
EHMT2	TTS6RZT	Strong	Biomarker	[914]
EIF2AK2	TTXEZJ4	Strong	Biomarker	[915]
EIF2AK3	TT79U1M	Strong	Altered Expression	[916]
EIF4E	TTZGCP6	Strong	Biomarker	[917]
EIF4EBP1	TTKGEBL	Strong	Biomarker	[918]
EIF5A2	TTH53G9	Strong	Altered Expression	[919]
ELAVL1	TTPC9D0	Strong	Biomarker	[920]
ENAH	TTY36UA	Strong	Altered Expression	[921]
ENG	TTB30LE	Strong	Biomarker	[922]
ENOX2	TTUJZRL	Strong	Genetic Variation	[923]
ENPEP	TT9PBIL	Strong	Altered Expression	[924]
ENPP1	TTZTIWS	Strong	Biomarker	[925]
EPAS1	TTWPA54	Strong	Altered Expression	[926]
EPHA3	TTHS2LR	Strong	Altered Expression	[927]
EPHA4	TTG84D3	Strong	Biomarker	[928]
EPHA6	TTFAHWI	Strong	Altered Expression	[929]
EPHB2	TTKPV6O	Strong	Biomarker	[930]
EPHB3	TT5LM7U	Strong	Altered Expression	[546]
EPHB4	TTI4ZX2	Strong	Biomarker	[546]
ERBB4	TTWALCO	Strong	Biomarker	[931]
EREG	TTYSB89	Strong	Altered Expression	[932]
ERN1	TTKIAT3	Strong	Biomarker	[933]
ESRRB	TTKF0XS	Strong	Altered Expression	[934]
ESRRG	TT9ZRHB	Strong	Biomarker	[935]
ETS1	TTTGPSD	Strong	Altered Expression	[936]
ETS2	TT9AH0M	Strong	Biomarker	[937]
EZR	TTE47YC	Strong	Biomarker	[938]
F10	TTCIHJA	Strong	Biomarker	[939]
F11	TTDM4ZU	Strong	Biomarker	[940]
F11R	TT3C8EG	Strong	Genetic Variation	[941]
F2RL1	TTQR74A	Strong	Biomarker	[942]
F2RL2	TTVSEBF	Strong	Altered Expression	[943]
F8	TT1290U	Strong	Biomarker	[944]
FABP5	TTNT2S6	Strong	Altered Expression	[945]
FADS2	TTT2VDU	Strong	Altered Expression	[946]
FANCF	TTNZKFJ	Strong	Biomarker	[947]
FASLG	TTO7014	Strong	Genetic Variation	[948]
FBXO11	TT6G10V	Strong	Altered Expression	[949]
FBXW7	TT29KY7	Strong	Biomarker	[950]
FCGR2A	TTXT21W	Strong	Genetic Variation	[951]
FDXR	TT3W4IX	Strong	Altered Expression	[434]
FECH	TTQ6VF4	Strong	Altered Expression	[952]
FES	TTLBY21	Strong	Biomarker	[953]
FFAR1	TTB8FUC	Strong	Altered Expression	[954]
FGF1	TTMY81X	Strong	Biomarker	[955]
FGF10	TTNPEFX	Strong	Genetic Variation	[956]
FGF18	TT6ICRA	Strong	Biomarker	[957]
FGF2	TTGKIED	Strong	Biomarker	[958]
FGF21	TTQ916P	Strong	Biomarker	[959]
FGF4	TTCEKVZ	Strong	Biomarker	[960]
FGF7	TTFY134	Strong	Biomarker	[961]
FGF8	TTIUF3J	Strong	Biomarker	[962]
FGFBP1	TTV1YFT	Strong	Altered Expression	[963]
FHIT	TTMS54D	Strong	Biomarker	[964]
FKBP1A	TTMW94E	Strong	Biomarker	[965]
FLNA	TTSTRZY	Strong	Altered Expression	[966]
FLT1	TT1VAUK	Strong	Biomarker	[967]
FN1	TTPJ921	Strong	Altered Expression	[968]
FOLH1	TT9G4N0	Strong	Biomarker	[969]
FOS	TTOM5AU	Strong	Altered Expression	[970]
FOSL1	TTY8LZG	Strong	Altered Expression	[971]
FOSL2	TT689IR	Strong	Altered Expression	[972]
FOXC1	TTNT3YA	Strong	Biomarker	[973]
FOXJ2	TTV1FDA	Strong	Biomarker	[974]
FOXM1	TTD3KOX	Strong	Altered Expression	[975]
FPR1	TT5Y4EM	Strong	Biomarker	[976]
FSCN1	TTTRS9B	Strong	Altered Expression	[977]
FST	TTDNM9W	Strong	Biomarker	[978]
FSTL3	TTWRPM8	Strong	Biomarker	[979]
FTH1	TT975ZT	Strong	Biomarker	[980]
FTO	TTFW3BT	Strong	Biomarker	[275]
FUS	TTKGYZ9	Strong	Biomarker	[981]
FUT3	TTUPAD7	Strong	Biomarker	[982]
FUT4	TTNV1KZ	Strong	Altered Expression	[983]
FZD7	TTUQMO5	Strong	Biomarker	[984]
G3BP1	TTG0R8Z	Strong	Altered Expression	[985]
G6PC2	TT7EV4P	Strong	Genetic Variation	[986]
GABRA3	TT37EDJ	Strong	Biomarker	[987]
GABRP	TT3E0DI	Strong	Biomarker	[988]
GALNS	TTT9YPO	Strong	Altered Expression	[989]
GAPDH	TTUGSWA	Strong	Altered Expression	[990]
GAS6	TT69QD2	Strong	Biomarker	[991]
GAST	TT4LRVO	Strong	Biomarker	[755]
GCG	TT6Y4PN	Strong	Biomarker	[352]
GDF15	TT4MXVG	Strong	Biomarker	[992]
GDF2	TTAP4T1	Strong	Biomarker	[993]
GDNF	TTF23ML	Strong	Altered Expression	[994]
GEM	TTAZF9M	Strong	Genetic Variation	[384]
GHR	TTHJWYD	Strong	Biomarker	[995]
GHRHR	TTG4R8V	Strong	Biomarker	[996]
GIP	TT40HS5	Strong	Altered Expression	[997]
GJA1	TT4F7SL	Strong	Biomarker	[998]
GJA3	TTFZRG0	Strong	Biomarker	[351]
GJB2	TTRGZX3	Strong	Altered Expression	[999]
GLI2	TT045OH	Strong	Altered Expression	[1000]
GLUL	TTURQ2G	Strong	Altered Expression	[1001]
GM2A	TTGOFW6	Strong	Biomarker	[1002]
GMNN	TT390KA	Strong	Biomarker	[1003]
GNAQ	TTL1SRG	Strong	Genetic Variation	[353]
GOT1	TTU507L	Strong	Altered Expression	[1004]
GPBAR1	TTSDVTR	Strong	Biomarker	[1005]
GPI	TT19JIZ	Strong	Biomarker	[1006]
GPNMB	TT7315J	Strong	Biomarker	[1007]
GPR119	TT7QNVC	Strong	Altered Expression	[1008]
GPR132	TTNBW4F	Strong	Biomarker	[1009]
GPR17	TTMPART	Strong	Genetic Variation	[1010]
GPR55	TTNET8J	Strong	Biomarker	[1011]
GPRC6A	TTI1PRE	Strong	Biomarker	[1012]
GRB2	TTEYRJ9	Strong	Biomarker	[1013]
GRHL2	TTUGH4C	Strong	Biomarker	[1014]
GRIK2	TT0K5RG	Strong	Genetic Variation	[1015]
GRIK3	TTNP6O2	Strong	Biomarker	[1016]
GRIN1	TTLD29N	Strong	Altered Expression	[1017]
GRK3	TT5A4DX	Strong	Altered Expression	[1018]
GRK5	TTTCXO0	Strong	Altered Expression	[1019]
GRM1	TTVBPDM	Strong	Biomarker	[1020]
GRN	TT0LWE3	Strong	Altered Expression	[1021]
GRPR	TTC1MVT	Strong	Biomarker	[1022]
GSK3B	TTRSMW9	Strong	Altered Expression	[1023]
GSN	TTUH7OM	Strong	Altered Expression	[1024]
GSR	TTEP6RV	Strong	Biomarker	[1025]
GUCY2D	TTWNFC2	Strong	Genetic Variation	[1026]
GUSB	TTHS7CM	Strong	Altered Expression	[1027]
HAX1	TT21BYA	Strong	Biomarker	[1028]
HBB	TTM6HK1	Strong	Biomarker	[1029]
HBEGF	TT15SL0	Strong	Altered Expression	[1030]
HCAR1	TTVK4ZO	Strong	Biomarker	[1031]
HDAC3	TT4YWTO	Strong	Biomarker	[1032]
HDAC4	TTTQGH8	Strong	Biomarker	[1033]
HDAC6	TT5ZKDI	Strong	Biomarker	[1034]
HDAC7	TTMUEK1	Strong	Biomarker	[1035]
HDAC9	TT8M4E1	Strong	Biomarker	[1036]
HHAT	TT1VNCG	Strong	Altered Expression	[1037]
HK2	TTK02H8	Strong	Biomarker	[423]
HKDC1	TTVUI8G	Strong	Altered Expression	[1038]
HLA-A	TTHONFT	Strong	Altered Expression	[1039]
HLA-G	TTLKFB3	Strong	Biomarker	[1040]
HMBS	TTT0HW3	Strong	Biomarker	[1041]
HMGA1	TTBA219	Strong	Altered Expression	[1042]
HMGA2	TTSTVM0	Strong	Biomarker	[1043]
HMGB2	TTA78JQ	Strong	Biomarker	[1044]
HMOX1	TTI6V2A	Strong	Biomarker	[1045]
HNF4A	TT2F3CD	Strong	Altered Expression	[1046]
HNRNPA1	TTPJ9XK	Strong	Biomarker	[1047]
HOXA5	TTXSVQP	Strong	Altered Expression	[1048]
HOXA7	TTMRE4Q	Strong	Biomarker	[1049]
HP	TTLC8E1	Strong	Biomarker	[1050]
HPSE	TTR7GJO	Strong	Biomarker	[1051]
HRH1	TTTIBOJ	Strong	Biomarker	[1052]
HRH4	TTXJ178	Strong	Biomarker	[1053]
HSD11B1	TTN7BL9	Strong	Altered Expression	[361]
HSD17B4	TTL1WGS	Strong	Biomarker	[1054]
HSF1	TTN6STZ	Strong	Biomarker	[1055]
HSP90AA1	TT78R5H	Strong	Biomarker	[1056]
HSP90AB1	TTH5YN2	Strong	Biomarker	[1057]
HSP90B1	TTFPKXQ	Strong	Biomarker	[1058]
HSPA5	TTW26OG	Strong	Biomarker	[1034]
HSPA9	TTMTPG3	Strong	Altered Expression	[1059]
HSPB1	TT9AZWY	Strong	Biomarker	[1060]
HSPB3	TTLH8WG	Strong	Biomarker	[1060]
HSPB8	TTY0OJN	Strong	Altered Expression	[1061]
HSPG2	TT5UM29	Strong	Altered Expression	[1062]
HTR1B	TTK8CXU	Strong	Biomarker	[1063]
HTR2A	TTJQOD7	Strong	Genetic Variation	[1064]
HTRA1	TT8POQR	Strong	Altered Expression	[1065]
HTT	TTIWZ0O	Strong	Genetic Variation	[1066]
IAPP	TTHN8EM	Strong	Biomarker	[676]
ID2	TTW8A5N	Strong	Altered Expression	[1067]
IDO1	TTZJYKH	Strong	Biomarker	[1068]
IDUA	TT0IUKX	Strong	Altered Expression	[1069]
IFNA2	TTSIUJ9	Strong	Biomarker	[1070]
IFNB1	TT4TZ8J	Strong	Biomarker	[1071]
IFNG	TT93WF5	Strong	Biomarker	[1072]
IGF1R	TTQFBMY	Strong	Biomarker	[1073]
IGFBP2	TTU4QSN	Strong	Altered Expression	[1074]
IGFBP7	TTUQ01B	Strong	Posttranslational Modification	[1075]
IKBKB	TTJ3E9X	Strong	Biomarker	[1076]
IKZF3	TTCZVFZ	Strong	Genetic Variation	[1077]
IL11	TTGUYTR	Strong	Biomarker	[1078]
IL13RA2	TTMPZ7V	Strong	Altered Expression	[1079]
IL15	TTJFA35	Strong	Altered Expression	[1080]
IL15RA	TTGN89I	Strong	Biomarker	[1081]
IL17A	TTG0MT6	Strong	Biomarker	[859]
IL18	TTRICUF	Strong	Altered Expression	[1082]
IL1A	TTPM6HI	Strong	Genetic Variation	[1083]
IL20	TTNZMY2	Strong	Altered Expression	[1084]
IL23R	TT6H4QR	Strong	Altered Expression	[1085]
IL24	TT1EPXZ	Strong	Biomarker	[1086]
IL2RA	TT10Y9E	Strong	Biomarker	[1087]
IL2RB	TT9721Y	Strong	Altered Expression	[1088]
IL9	TT0JTFD	Strong	Biomarker	[1089]
ILK	TT7ALZG	Strong	Biomarker	[1090]
IMP3	TTEJA2R	Strong	Altered Expression	[1091]
IMPDH2	TTTB4UP	Strong	Altered Expression	[1092]
INPP5D	TTTP2Z1	Strong	Altered Expression	[1093]
INSR	TTCBFJO	Strong	Genetic Variation	[1094]
IRF1	TT4TU3L	Strong	Biomarker	[721]
IRF3	TTYR7OH	Strong	Biomarker	[1095]
IRS1	TTAJSQ0	Strong	Biomarker	[1096]
ITGA1	TTPERWV	Strong	Altered Expression	[1097]
ITGA11	TTANXZ7	Strong	Biomarker	[1098]
ITGA4	TTJMF9P	Strong	Altered Expression	[1099]
ITGA5	TTHIZP9	Strong	Biomarker	[1097]
ITGA6	TT165T3	Strong	Biomarker	[1100]
ITGAV	TTT1R2L	Strong	Biomarker	[1101]
ITGB1	TTBVIQC	Strong	Biomarker	[1102]
ITGB2	TTIJWR7	Strong	Biomarker	[1103]
ITGB6	TTKQSXZ	Strong	Biomarker	[1104]
ITPR1	TT5HWAT	Strong	Biomarker	[466]
ITPR3	TTH1769	Strong	Biomarker	[1105]
JAG2	TTOJY1B	Strong	Altered Expression	[1106]
JMJD1C	TTBISK4	Strong	Altered Expression	[1107]
JUN	TTS7IR5	Strong	Altered Expression	[1108]
JUP	TTREN0G	Strong	Biomarker	[1109]
KAT6B	TTH4VJL	Strong	Genetic Variation	[1110]
KCNA5	TTW0CMT	Strong	Altered Expression	[1111]
KCNH1	TT9XKUC	Strong	Genetic Variation	[1112]
KCNH2	TTQ6VDM	Strong	Altered Expression	[1113]
KCNJ3	TTGM19J	Strong	Biomarker	[1114]
KCNK9	TTL4FMB	Strong	Biomarker	[1115]
KCNMA1	TTE87WJ	Strong	Altered Expression	[1116]
KDM1A	TTNR0UQ	Strong	Biomarker	[1117]
KDM4A	TTZHPB8	Strong	Biomarker	[1118]
KDM5A	TTIG67W	Strong	Biomarker	[1119]
KDM5B	TTCLI75	Strong	Biomarker	[1120]
KEAP1	TT3Z6Y9	Strong	Biomarker	[1121]
KHDRBS1	TTAT6C7	Strong	Biomarker	[927]
KIF11	TTBGTCW	Strong	Biomarker	[1122]
KIF20B	TTQECT2	Strong	Biomarker	[1123]
KIF26B	TTQWICZ	Strong	Altered Expression	[1124]
KIF5A	TTCJPAH	Strong	Altered Expression	[1125]
KIR2DL3	TTEX3SI	Strong	Altered Expression	[1126]
KISS1R	TT3KBZY	Strong	Biomarker	[1127]
KIT	TTX41N9	Strong	Biomarker	[1128]
KITLG	TTDJ51N	Strong	Genetic Variation	[1129]
KLK1	TT5T3P6	Strong	Biomarker	[1130]
KLK2	TTJLNAW	Strong	Altered Expression	[1131]
KLK4	TT4319X	Strong	Biomarker	[1132]
KLK5	TTULSEW	Strong	Biomarker	[1133]
KLK6	TTLPF4X	Strong	Biomarker	[1134]
KLK7	TTE6GTB	Strong	Altered Expression	[1135]
KMT2A	TT1GNDM	Strong	Biomarker	[1136]
KMT5A	TTGC95K	Strong	Biomarker	[1137]
KMT5C	TT7H3YM	Strong	Biomarker	[1138]
KNG1	TTDJ4MY	Strong	Biomarker	[1139]
KRT17	TTKV0EC	Strong	Biomarker	[1140]
KRT6A	TT2FX8W	Strong	Genetic Variation	[1141]
KSR1	TTHL1TV	Strong	Genetic Variation	[1142]
KYNU	TTWQM3J	Strong	Biomarker	[1143]
L1CAM	TTC9D3K	Strong	Altered Expression	[1144]
L3MBTL3	TTQDMJN	Strong	Biomarker	[674]
LALBA	TTBRLU3	Strong	Biomarker	[1145]
LAMB3	TT2WOUQ	Strong	Biomarker	[1146]
LAMP1	TTC214J	Strong	Altered Expression	[1147]
LANCL1	TTZW8NS	Strong	Altered Expression	[1148]
LCN2	TTKTLAI	Strong	Altered Expression	[1149]
LDHA	TTW76JE	Strong	Biomarker	[1150]
LDLR	TTH0DUS	Strong	Biomarker	[1151]
LGALS1	TTO3NYT	Strong	Biomarker	[1152]
LGR4	TTY6C71	Strong	Biomarker	[1153]
LGR5	TTTSGRH	Strong	Altered Expression	[1154]
LIFR	TTID542	Strong	Biomarker	[1155]
LILRB1	TTC0QRJ	Strong	Biomarker	[1156]
LIMK1	TTWL9TY	Strong	Biomarker	[1157]
LIMK2	TTASMD8	Strong	Biomarker	[1158]
LIPE	TTLUQ8E	Strong	Biomarker	[1159]
LIPG	TTHSZXO	Strong	Altered Expression	[1160]
LMO2	TTFX379	Strong	Biomarker	[1161]
LNPEP	TTY2KP7	Strong	Biomarker	[1162]
LONP1	TTM1VPZ	Strong	Biomarker	[1163]
LOXL2	TTFSUHX	Strong	Biomarker	[1164]
LPA	TTU9LGY	Strong	Biomarker	[1165]
LPAR1	TTQ6S1K	Strong	Biomarker	[1166]
LPAR2	TTB7Y8I	Strong	Biomarker	[399]
LPAR6	TTZDAGB	Strong	Altered Expression	[1167]
LRP1	TTF2V7I	Strong	Biomarker	[497]
LRP6	TTSXOWE	Strong	Biomarker	[1168]
LRRC32	TT0FAYT	Strong	Biomarker	[1169]
LSM1	TT2KHSC	Strong	Altered Expression	[1170]
LSS	TT7O8ZA	Strong	Biomarker	[1171]
LTA	TTP73TM	Strong	Genetic Variation	[1172]
LTB	TTHQ6US	Strong	Genetic Variation	[368]
LTF	TTSZDQU	Strong	Biomarker	[1173]
LY75	TTG180Q	Strong	Altered Expression	[1174]
LYN	TT1RWNJ	Strong	Altered Expression	[1175]
LYVE1	TTG8DNU	Strong	Biomarker	[1176]
LYZ	TTAOZBW	Strong	Biomarker	[1177]
MAD1L1	TTNE9U7	Strong	Biomarker	[1178]
MAGEA1	TT63M7Q	Strong	Genetic Variation	[1179]
MAGEA2	TTOZT28	Strong	Biomarker	[1180]
MAGEA4	TT9EQUY	Strong	Genetic Variation	[1181]
MAGEC2	TTKGUEB	Strong	Biomarker	[1182]
MAOA	TT3WG5C	Strong	Altered Expression	[1183]
MAP2K1	TTIDAPM	Strong	Biomarker	[1184]
MAP2K5	TTV3O87	Strong	Altered Expression	[1185]
MAP2K7	TT6QY3J	Strong	Biomarker	[729]
MAP3K10	TT9FN4J	Strong	Altered Expression	[1186]
MAP3K11	TTETX6Q	Strong	Altered Expression	[1187]
MAP3K14	TT4LIAC	Strong	Altered Expression	[1188]
MAP3K2	TTIX0ZU	Strong	Genetic Variation	[593]
MAP3K3	TTJZNIG	Strong	Biomarker	[1189]
MAP3K4	TT1RSX7	Strong	Biomarker	[1190]
MAP3K7	TTJQT60	Strong	Biomarker	[1191]
MAP3K8	TTGECUM	Strong	Altered Expression	[1192]
MAP4K4	TT6NI13	Strong	Altered Expression	[1193]
MAPK1	TT4TQBX	Strong	Biomarker	[930]
MAPK10	TT056SO	Strong	Altered Expression	[1194]
MAPK12	TTYT93M	Strong	Biomarker	[1195]
MAPK14	TTQBR95	Strong	Altered Expression	[370]
MAPK3	TT1MG9E	Strong	Biomarker	[1196]
MAPK7	TTU6FSC	Strong	Altered Expression	[1197]
MAPK8	TT0K6EO	Strong	Biomarker	[490]
MAPK9	TT3IVG2	Strong	Posttranslational Modification	[1198]
MAPT	TTS87KH	Strong	Altered Expression	[1199]
MARCKS	TTHRM39	Strong	Altered Expression	[1200]
MARK2	TTAJ45Y	Strong	Biomarker	[1201]
MAS1	TTOISYB	Strong	Biomarker	[1202]
MAZ	TT059DA	Strong	Biomarker	[1203]
MBL2	TTMQDZ5	Strong	Genetic Variation	[1204]
MBNL2	TTH9OLG	Strong	Altered Expression	[1205]
MBOAT4	TTSYOWR	Strong	Altered Expression	[1206]
MBTPS1	TTNSM2I	Strong	Biomarker	[1207]
MC1R	TT0MV2T	Strong	Genetic Variation	[1208]
MCAM	TTHRE05	Strong	Altered Expression	[1209]
MCM6	TTQGKSD	Strong	Biomarker	[1210]
MCM7	TT1RM3F	Strong	Biomarker	[1211]
MDK	TTV8UE7	Strong	Altered Expression	[1212]
MFGE8	TT1GLAJ	Strong	Biomarker	[1213]
MGLL	TTZ963I	Strong	Biomarker	[561]
MGMT	TTJ8DV7	Strong	Posttranslational Modification	[1214]
MIA	TT5HNVS	Strong	Biomarker	[1215]
MIF	TT6804T	Strong	Genetic Variation	[1216]
MKI67	TTB4UNG	Strong	Biomarker	[1217]
MKNK1	TTEZAUX	Strong	Altered Expression	[1218]
MKNK2	TTRECN3	Strong	Biomarker	[1219]
MLANA	TT362RB	Strong	Biomarker	[1220]
MME	TT5TKPM	Strong	Biomarker	[1174]
MMP10	TTXLEG7	Strong	Altered Expression	[1221]
MMP11	TTZW4MV	Strong	Biomarker	[1222]
MMP13	TTHY57M	Strong	Biomarker	[1223]
MMP14	TTJ4QE7	Strong	Biomarker	[1224]
MMP17	TTVSZKN	Strong	Biomarker	[1225]
MMP7	TTMTWOS	Strong	Altered Expression	[1226]
MMP9	TT6X50U	Strong	Biomarker	[1227]
MRC2	TTYVR8M	Strong	Altered Expression	[1228]
MSI1	TTSM4BA	Strong	Altered Expression	[1229]
MSLN	TT4RXME	Strong	Altered Expression	[1230]
MSR1	TT2TDH9	Strong	Altered Expression	[1231]
MSTN	TTM8I2X	Strong	Biomarker	[978]
MTM1	TTY2TCU	Strong	Biomarker	[1232]
MTNR1A	TT0WAIE	Strong	Biomarker	[1233]
MTNR1B	TT32JK8	Strong	Biomarker	[1234]
MTOR	TTCJG29	Strong	Biomarker	[1235]
MTTP	TTUS1RD	Strong	Biomarker	[1236]
MUC16	TTC1PS3	Strong	Biomarker	[803]
MUC17	TTVO0JU	Strong	Biomarker	[1237]
MVD	TTE5J6X	Strong	Biomarker	[1238]
MYB	TT8V13P	Strong	Biomarker	[1239]
MYD88	TTB6Q2O	Strong	Altered Expression	[1240]
MYLK	TT18ETS	Strong	Biomarker	[1241]
NAMPT	TTD1WIG	Strong	Altered Expression	[1242]
NCAM1	TTVXPHT	Strong	Altered Expression	[1243]
NCL	TTK1V5Q	Strong	Biomarker	[822]
NCOA4	TT8OY02	Strong	Genetic Variation	[1244]
NECTIN4	TTPO9EG	Strong	Biomarker	[1245]
NEDD8	TTNDC4K	Strong	Biomarker	[1246]
NEDD9	TT1UREA	Strong	Biomarker	[1247]
NEK2	TT3VZ24	Strong	Altered Expression	[1248]
NEK6	TT8I2M7	Strong	Altered Expression	[1249]
NELL1	TT7H4BF	Strong	Biomarker	[1250]
NES	TTHZ752	Strong	Altered Expression	[1251]
NF2	TTZIK7P	Strong	Biomarker	[1252]
NFKB1	TTUIZKC	Strong	Biomarker	[1253]
NFKB2	TTKLNRV	Strong	Biomarker	[1254]
NFKBIA	TTSHAEB	Strong	Genetic Variation	[368]
NGFR	TTEDJN4	Strong	Biomarker	[1255]
NISCH	TT789FN	Strong	Biomarker	[1256]
NKX3-1	TT1E0JK	Strong	Biomarker	[1257]
NME1	TTDY8JH	Strong	Biomarker	[1258]
NMUR2	TT2L6C5	Strong	Altered Expression	[1259]
NNT	TTKIH76	Strong	Biomarker	[1260]
NODAL	TTK2O1Q	Strong	Biomarker	[1261]
NOS2	TTF10I9	Strong	Altered Expression	[1262]
NOTCH1	TTB1STW	Strong	Biomarker	[1263]
NOTCH2	TT82FVD	Strong	Biomarker	[1264]
NOTCH3	TTVX7IA	Strong	Biomarker	[1265]
NOX4	TTQRBSJ	Strong	Altered Expression	[1266]
NPPB	TTY63XT	Strong	Biomarker	[1267]
NPY4R	TTW4N16	Strong	Genetic Variation	[1268]
NPY5R	TTY6EWA	Strong	Biomarker	[1269]
NQO2	TTJLP0R	Strong	Genetic Variation	[1270]
NR0B2	TT25A9Q	Strong	Biomarker	[1271]
NR1D1	TTAD1O8	Strong	Altered Expression	[1272]
NR1H4	TTS4UGC	Strong	Altered Expression	[1273]
NR5A2	TTAU3SY	Strong	Altered Expression	[1274]
NRG1	TTEH395	Strong	Biomarker	[992]
NRG4	TTWAGKJ	Strong	Altered Expression	[1275]
NRP1	TTIPJCB	Strong	Biomarker	[1276]
NRP2	TTRXUVC	Strong	Biomarker	[1277]
NT5E	TTK0O6Y	Strong	Biomarker	[1278]
NTF4	TTIM2WO	Strong	Biomarker	[1279]
NTRK1	TTTDVOJ	Strong	Altered Expression	[1280]
NTRK3	TTXABCW	Strong	Genetic Variation	[1281]
NTSR1	TTTUMEP	Strong	Altered Expression	[1282]
NUF2	TTIXBFP	Strong	Biomarker	[1283]
ODC1	TTUMGNO	Strong	Altered Expression	[653]
OGDH	TTH8T6I	Strong	Biomarker	[1284]
OLR1	TTKSND3	Strong	Biomarker	[1285]
OPRM1	TTKWM86	Strong	Genetic Variation	[1286]
ORAI1	TTE76YK	Strong	Biomarker	[1287]
OSM	TTIVXSE	Strong	Biomarker	[1288]
OSMR	TTAH0KM	Strong	Biomarker	[1289]
OXER1	TT7WBSV	Strong	Biomarker	[1012]
OXTR	TTSCIUP	Strong	Biomarker	[1290]
P2RX7	TT473XN	Strong	Biomarker	[1291]
P2RY6	TTNVSKA	Strong	Altered Expression	[1292]
PABPC1	TTHC8EF	Strong	Biomarker	[1293]
PAH	TTGSVH2	Strong	Genetic Variation	[1294]
PAK1	TTFN95D	Strong	Biomarker	[1295]
PAM	TTF4ZPC	Strong	Genetic Variation	[1296]
PAOX	TTNQ760	Strong	Altered Expression	[1297]
PARG	TT39J16	Strong	Altered Expression	[1298]
PARP3	TTD8MEH	Strong	Biomarker	[1299]
PAWR	TT3I4WV	Strong	Biomarker	[548]
PCSK1	TTED9LZ	Strong	Biomarker	[1300]
PCSK5	TTPFWHU	Strong	Biomarker	[1301]
PCYT1B	TTUAIKM	Strong	Biomarker	[1302]
PDCD1	TTNBFWK	Strong	Biomarker	[1303]
PDCD1LG2	TTW14O3	Strong	Biomarker	[1304]
PDCD2	TTYOVWN	Strong	Altered Expression	[1305]
PDE2A	TTJGW1Z	Strong	Biomarker	[1306]
PDE4A	TTZ97H5	Strong	Biomarker	[1307]
PDE4B	TTVIAT9	Strong	Genetic Variation	[1308]
PDE4D	TTSKMI8	Strong	Altered Expression	[1309]
PDE5A	TTJ0IQB	Strong	Altered Expression	[1310]
PDE7B	TTWIEY9	Strong	Altered Expression	[1311]
PDGFA	TTSM78N	Strong	Altered Expression	[1312]
PDGFD	TTSN0GA	Strong	Altered Expression	[1313]
PDK1	TTCZOF2	Strong	Altered Expression	[1314]
PDPK1	TTYMGWX	Strong	Biomarker	[1315]
PDX1	TT8SGZK	Strong	Biomarker	[1316]
PDZK1	TTDTBLM	Strong	Biomarker	[1317]
PEBP1	TT1BGU8	Strong	Altered Expression	[1318]
PECAM1	TT4EZB2	Strong	Biomarker	[1176]
PF4	TTSG7Q5	Strong	Altered Expression	[860]
PFKFB2	TTQYVKD	Strong	Biomarker	[1319]
PGC	TT7K6AD	Strong	Biomarker	[1320]
PGD	TTZ3IFB	Strong	Biomarker	[1321]
PHKG2	TTI5WS6	Strong	Altered Expression	[1322]
PIGU	TT2LHI6	Strong	Biomarker	[1323]
PIM1	TTTN5QW	Strong	Altered Expression	[1324]
PLA2G1B	TT9V5JH	Strong	Biomarker	[1325]
PLA2G4A	TTT1JVS	Strong	Altered Expression	[1326]
PLA2G4C	TTBYG4O	Strong	Biomarker	[1327]
PLAC1	TTM18HX	Strong	Biomarker	[1328]
PLAT	TTXAGYU	Strong	Biomarker	[1329]
PLAU	TTGY7WI	Strong	Biomarker	[1330]
PLAUR	TTNOSTX	Strong	Biomarker	[1331]
PLCB1	TTLPGU7	Strong	Altered Expression	[1332]
PLK1	TTH4IP0	Strong	Biomarker	[1333]
PLK2	TT976FS	Strong	Biomarker	[1334]
PLOD2	TT8MEUD	Strong	Altered Expression	[1335]
PLTP	TTZF6SN	Strong	Altered Expression	[1336]
PMEL	TT8MK59	Strong	Biomarker	[1337]
PML	TTLH9NY	Strong	Biomarker	[1324]
PNMT	TT0NZIC	Strong	Biomarker	[1338]
POLB	TTA0XPV	Strong	Biomarker	[1339]
POR	TTOQ9GZ	Strong	Genetic Variation	[1340]
PPARA	TTJ584C	Strong	Altered Expression	[1341]
PPARGC1B	TTKSQ3W	Strong	Altered Expression	[1342]
PPAT	TTZFTY4	Strong	Biomarker	[1343]
PPIB	TT6ZFQ4	Strong	Altered Expression	[1344]
PPID	TTNAFOU	Strong	Altered Expression	[1345]
PPIF	TTRFQTB	Strong	Altered Expression	[1345]
PPP1CA	TTFLH0E	Strong	Altered Expression	[1346]
PPP3CA	TTA4LDE	Strong	Biomarker	[1347]
PPP5C	TTTW7FJ	Strong	Biomarker	[1348]
PPT1	TTSQC14	Strong	Altered Expression	[1349]
PRCP	TTTJZ4M	Strong	Altered Expression	[723]
PRG4	TTSKF4V	Strong	Biomarker	[1350]
PRKACA	TT5U49F	Strong	Altered Expression	[1351]
PRKCA	TTFJ8Q1	Strong	Altered Expression	[765]
PRKCB	TTYPXQF	Strong	Altered Expression	[765]
PRKCQ	TT1MS7X	Strong	Biomarker	[1352]
PRKDC	TTK3PY9	Strong	Biomarker	[1353]
PRLR	TTBPXMA	Strong	Altered Expression	[1354]
PRMT1	TTVOJAI	Strong	Biomarker	[1355]
PRMT5	TTR1D7X	Strong	Altered Expression	[1356]
PRMT7	TTAR2P0	Strong	Biomarker	[1357]
PRNP	TTY5F9C	Strong	Altered Expression	[1358]
PROC	TTZUXYS	Strong	Biomarker	[1359]
PROM1	TTXMZ81	Strong	Biomarker	[1360]
PSCA	TT9T4AV	Strong	Biomarker	[1361]
PSEN2	TTWN3F4	Strong	Biomarker	[1362]
PSIP1	TTH9LDP	Strong	Biomarker	[1254]
PSMB5	TT68GPI	Strong	Altered Expression	[1363]
PSMB7	TT49BVC	Strong	Altered Expression	[1364]
PTBP1	TTWMX0U	Strong	Biomarker	[1365]
PTGER3	TTPNGDE	Strong	Biomarker	[1366]
PTGES	TTYLQ8V	Strong	Altered Expression	[1367]
PTGFR	TTT2ZAR	Strong	Altered Expression	[1368]
PTH	TT6F7GZ	Strong	Altered Expression	[1369]
PTK2B	TTTEFBV	Strong	Biomarker	[1370]
PTK6	TT6TH8V	Strong	Altered Expression	[1371]
PTP4A1	TTA8GFO	Strong	Biomarker	[1372]
PTP4A3	TT7YM8D	Strong	Altered Expression	[1373]
PTPN14	TTNIR6C	Strong	Biomarker	[1374]
PTPN2	TTY8PUS	Strong	Genetic Variation	[1375]
PTPN6	TT369M5	Strong	Altered Expression	[1280]
PVRIG	TTOGCNT	Strong	Biomarker	[1376]
PYGM	TTZHY6R	Strong	Genetic Variation	[1377]
PYY	TTVFJLX	Strong	Altered Expression	[997]
QPCT	TTJ7YTV	Strong	Biomarker	[1378]
RAB22A	TTAJ746	Strong	Biomarker	[1379]
RAC1	TT2M9CG	Strong	Altered Expression	[1046]
RAC3	TT9BQ50	Strong	Biomarker	[1380]
RAF1	TTAN5W2	Strong	Altered Expression	[1381]
RARG	TT1Q3IE	Strong	Altered Expression	[1382]
RBCK1	TTIKUVC	Strong	Biomarker	[1383]
RECK	TTRZBW7	Strong	Biomarker	[1384]
REG3A	TTL4H8N	Strong	Genetic Variation	[1385]
REN	TTB2MXP	Strong	Biomarker	[1386]
RENBP	TTZCG0Q	Strong	Genetic Variation	[1387]
RET	TT4DXQT	Strong	Altered Expression	[1388]
RGMA	TTURJV4	Strong	Altered Expression	[1389]
RGS2	TTKB7T3	Strong	Biomarker	[1390]
RGS4	TTGTKX9	Strong	Altered Expression	[1391]
RGS8	TTWME23	Strong	Biomarker	[1392]
RHAG	TTVHFE8	Strong	Biomarker	[1393]
RHBDF2	TTH1ZOP	Strong	Genetic Variation	[1394]
RHOA	TTP2U16	Strong	Altered Expression	[1395]
RIC8A	TTDFTJG	Strong	Altered Expression	[1396]
RNF6	TT4S09X	Strong	Biomarker	[1397]
RNMT	TTG45HY	Strong	Biomarker	[1398]
ROBO1	TTND1YP	Strong	Altered Expression	[1399]
ROCK1	TTZN7RP	Strong	Biomarker	[1400]
ROCK2	TTGWKQJ	Strong	Biomarker	[1401]
ROR1	TTDEJAU	Strong	Biomarker	[1402]
ROR2	TTUDPCI	Strong	Biomarker	[1403]
RORC	TTGV6LY	Strong	Genetic Variation	[310]
RPE65	TTBOH16	Strong	Biomarker	[1174]
RPS6KA2	TT0ZW9O	Strong	Altered Expression	[1404]
RPS6KA3	TTUM2ZR	Strong	Biomarker	[1405]
RPS6KA5	TTYXEPL	Strong	Biomarker	[1406]
RPS6KA6	TT3KYWB	Strong	Altered Expression	[1407]
RPS6KB1	TTG0U4H	Strong	Altered Expression	[1408]
RPS6KB2	TTMVQXO	Strong	Biomarker	[540]
RPSA	TTLUW5B	Strong	Biomarker	[497]
RRM2	TT1S4LJ	Strong	Biomarker	[1409]
RSF1	TTMP86V	Strong	Biomarker	[1410]
RSPO3	TT7HJTF	Strong	Biomarker	[1411]
RUNX1	TTWIN3H	Strong	Biomarker	[1412]
RUNX2	TTD6SZ8	Strong	Biomarker	[1247]
RUNX3	TTKCVO7	Strong	Biomarker	[1413]
S100A12	TTQ4ESF	Strong	Biomarker	[1414]
S100A8	TT4AF6N	Strong	Biomarker	[1415]
S100A9	TT0TMQG	Strong	Genetic Variation	[1416]
S100B	TTQ0V86	Strong	Altered Expression	[1417]
S1PR3	TTDYP7I	Strong	Biomarker	[1418]
S1PR4	TTZ8C5Q	Strong	Biomarker	[458]
SCD	TT6RIOV	Strong	Biomarker	[1419]
SCGB1A1	TTONPVW	Strong	Biomarker	[1420]
SCGB1D2	TT5D314	Strong	Altered Expression	[1421]
SCN2A	TTLJTUF	Strong	Biomarker	[1422]
SCN5A	TTZOVE0	Strong	Biomarker	[1423]
SDC1	TTYDSVG	Strong	Altered Expression	[1424]
SDC2	TT5H2F0	Strong	Altered Expression	[1425]
SELE	TT1PL7M	Strong	Biomarker	[1426]
SELP	TTE5VG0	Strong	Genetic Variation	[683]
SEMA3A	TTVKD3S	Strong	Altered Expression	[1427]
SEPTIN6	TTAGE7U	Strong	Altered Expression	[1428]
SERPINB5	TT1KW50	Strong	Biomarker	[1429]
SERPINH1	TTPSWQG	Strong	Biomarker	[1430]
SETD7	TTJ0FSU	Strong	Biomarker	[1431]
SFTPD	TTGLMU7	Strong	Altered Expression	[1432]
SGCG	TTSMT9W	Strong	Altered Expression	[1433]
SGPL1	TT618Q2	Strong	Altered Expression	[1434]
SH3GL1	TTTYNAM	Strong	Biomarker	[1435]
SHCBP1	TTZ9WGL	Strong	Biomarker	[1436]
SHH	TTIENCJ	Strong	Altered Expression	[1437]
SIGMAR1	TT5TPI6	Strong	Altered Expression	[1438]
SIK1	TT1H6LC	Strong	Altered Expression	[1439]
SIK2	TTCUGZR	Strong	Biomarker	[1440]
SIK3	TTW6L4V	Strong	Biomarker	[1441]
SIRPA	TTBRJS9	Strong	Altered Expression	[1442]
SIRT3	TTVZLIJ	Strong	Altered Expression	[1443]
SIRT5	TTH0IOD	Strong	Biomarker	[1444]
SIRT6	TTUXYWF	Strong	Altered Expression	[1445]
SKP2	TT5B2EO	Strong	Biomarker	[1446]
SLC11A2	TT2IS7P	Strong	Biomarker	[1447]
SLC12A6	TT8DFHE	Strong	Biomarker	[1448]
SLC12A7	TTU2PCD	Strong	Biomarker	[1448]
SLC16A1	TTN1J82	Strong	Biomarker	[1449]
SLC16A3	TTG6VD5	Strong	Biomarker	[1247]
SLC19A2	TT2A1DZ	Strong	Biomarker	[1450]
SLC19A3	TT9BTWM	Strong	Altered Expression	[1451]
SLC1A5	TTF7WRM	Strong	Biomarker	[1452]
SLC22A1	TTM5Q4V	Strong	Biomarker	[1453]
SLC22A16	TTITAVR	Strong	Genetic Variation	[1454]
SLC22A3	TTG2UMS	Strong	Biomarker	[375]
SLC23A2	TTOP832	Strong	Altered Expression	[1455]
SLC27A4	TT20AYF	Strong	Altered Expression	[1456]
SLC2A12	TTZO36H	Strong	Biomarker	[1457]
SLC2A4	TTP6MT5	Strong	Biomarker	[1457]
SLC34A2	TTQPZTM	Strong	Biomarker	[1458]
SLC36A1	TTUYIZW	Strong	Biomarker	[1459]
SLC38A1	TT1YE9Z	Strong	Biomarker	[1460]
SLC38A2	TTUSC27	Strong	Biomarker	[1461]
SLC38A3	TTMAVJQ	Strong	Altered Expression	[1462]
SLC39A6	TTZN1CF	Strong	Biomarker	[1463]
SLC40A1	TT6Y1PG	Strong	Biomarker	[1464]
SLC5A1	TT2UE56	Strong	Biomarker	[1465]
SLC5A5	TTW7HI9	Strong	Biomarker	[1466]
SLC6A14	TTB6H2S	Strong	Biomarker	[1467]
SLC6A3	TTVBI8W	Strong	Biomarker	[1468]
SLC6A5	TTI0138	Strong	Biomarker	[1469]
SLC7A1	TT4S150	Strong	Biomarker	[833]
SLC7A11	TTBZMIO	Strong	Altered Expression	[1470]
SLC7A5	TTPH2JB	Strong	Biomarker	[1471]
SLC9A1	TTGSEFH	Strong	Altered Expression	[1472]
SLCO1B1	TTFGXEB	Strong	Biomarker	[1473]
SLCO1B3	TTU86P0	Strong	Genetic Variation	[1474]
SLCO2B1	TTDL3UZ	Strong	Biomarker	[1475]
SLCO3A1	TT5CE6L	Strong	Altered Expression	[1476]
SLCO4A1	TTV1YIE	Strong	Biomarker	[1477]
SLIT2	TTDWK85	Strong	Biomarker	[1399]
SLK	TT8K4DE	Strong	Biomarker	[1478]
SMAD3	TTHQZV7	Strong	Altered Expression	[1479]
SMAD6	TTON5JB	Strong	Biomarker	[1480]
SMAD7	TT0J32Z	Strong	Altered Expression	[1481]
SMARCA4	TTVQEZS	Strong	Biomarker	[1482]
SMPD2	TTE5VI6	Strong	Altered Expression	[1483]
SMYD2	TT7YJFO	Strong	Biomarker	[1484]
SMYD3	TTKLJYX	Strong	Genetic Variation	[1485]
SOCS1	TT8COJM	Strong	Altered Expression	[1486]
SOCS3	TTI0ME6	Strong	Biomarker	[1487]
SORD	TTLSRBZ	Strong	Biomarker	[1488]
SOST	TTYRO4F	Strong	Biomarker	[1489]
SOX5	TTXHSZK	Strong	Biomarker	[1490]
SP1	TTZEP6S	Strong	Genetic Variation	[1491]
SPAG6	TTDAKTW	Strong	Altered Expression	[1492]
SPARC	TTBQFM7	Strong	Genetic Variation	[1493]
SPHK1	TTOHFIY	Strong	Biomarker	[1494]
SPOCK1	TTF23RE	Strong	Biomarker	[1495]
SPRY1	TT0PSN6	Strong	Biomarker	[1496]
SQLE	TTE14XG	Strong	Biomarker	[1497]
SRC	TT6PKBN	Strong	Biomarker	[1498]
SREBF2	TTRQ4AP	Strong	Biomarker	[459]
SRGN	TTCHB06	Strong	Altered Expression	[1499]
SRMS	TT7YMXZ	Strong	Altered Expression	[1500]
SRPK1	TTU3WV6	Strong	Biomarker	[1501]
SRR	TTZFUY6	Strong	Biomarker	[967]
SST	TTWF7UG	Strong	Biomarker	[1502]
SSTR4	TTAE1BR	Strong	Biomarker	[399]
SSTR5	TT2BC4G	Strong	Altered Expression	[1503]
ST14	TTPRO7W	Strong	Biomarker	[1504]
STAB1	TTJFEOC	Strong	Biomarker	[1176]
STAT1	TTN7R6K	Strong	Biomarker	[1505]
STAT6	TTWOE1T	Strong	Biomarker	[1506]
STC1	TTDLUER	Strong	Biomarker	[1507]
STC2	TT4EFTR	Strong	Biomarker	[1508]
STEAP1	TT9E64S	Strong	Altered Expression	[1509]
STK39	TTYQTIU	Strong	Biomarker	[1510]
STK4	TTCPLVN	Strong	Biomarker	[1511]
STMN1	TT7W5OT	Strong	Biomarker	[1512]
STRAP	TT165DP	Strong	Altered Expression	[1513]
STS	TTHM0R1	Strong	Biomarker	[1514]
STYK1	TTRMCYJ	Strong	Biomarker	[1515]
SULF2	TTLQTHB	Strong	Biomarker	[418]
SUV39H1	TTUWQTK	Strong	Biomarker	[1516]
SYK	TT2HUPM	Strong	Biomarker	[1517]
SYVN1	TT8XKYM	Strong	Altered Expression	[1518]
TAAR1	TTIU98M	Strong	Altered Expression	[1519]
TAAR5	TTCO25G	Strong	Altered Expression	[1520]
TAOK3	TTO7L0V	Strong	Biomarker	[1478]
TAP1	TT7JZI8	Strong	Biomarker	[1521]
TBL1X	TTAL6S1	Strong	Biomarker	[1522]
TCF3	TTULOD8	Strong	Biomarker	[1523]
TDG	TTEXRQD	Strong	Biomarker	[1524]
TDO2	TTXNCBV	Strong	Altered Expression	[1525]
TDP1	TT64IHJ	Strong	Altered Expression	[1526]
TEC	TT1ZV49	Strong	Biomarker	[1527]
TEK	TT9VGXW	Strong	Altered Expression	[680]
TENT4A	TT0XZ4Q	Strong	Genetic Variation	[1528]
TERF1	TT1Y6J2	Strong	Altered Expression	[1529]
TERF2	TT5XSLT	Strong	Altered Expression	[1530]
TF	TT8WXAV	Strong	Altered Expression	[1531]
TFRC	TT8MG4S	Strong	Biomarker	[1532]
TGM2	TT2F4OL	Strong	Biomarker	[1533]
THPO	TTCG5PE	Strong	Biomarker	[1534]
TICAM1	TT2GQT6	Strong	Biomarker	[1535]
TIE1	TTT4236	Strong	Biomarker	[1536]
TIPARP	TT2FRAN	Strong	Biomarker	[1537]
TK1	TTP3QRF	Strong	Biomarker	[1538]
TLR1	TTW14D0	Strong	Genetic Variation	[1539]
TLR2	TTY7ZHS	Strong	Genetic Variation	[1540]
TLR3	TTD24Y0	Strong	Genetic Variation	[1541]
TLR8	TT8CWFK	Strong	Altered Expression	[636]
TLR9	TTSHG0T	Strong	Biomarker	[1542]
TMBIM6	TT7QSMG	Strong	Altered Expression	[1543]
TMEM219	TTY078U	Strong	Biomarker	[1544]
TMEM97	TT9NXW4	Strong	Biomarker	[1545]
TMPRSS11D	TTWHYC8	Strong	Genetic Variation	[1546]
TMPRSS6	TTL9KE7	Strong	Genetic Variation	[1547]
TNC	TTUCPMY	Strong	Altered Expression	[1548]
TNFRSF10A	TT5WLRX	Strong	Genetic Variation	[1549]
TNFRSF10B	TTW20TU	Strong	Biomarker	[1550]
TNFRSF11A	TT3K9S2	Strong	Biomarker	[1551]
TNFRSF17	TTZ3P4W	Strong	Biomarker	[484]
TNFRSF1B	TT63WSF	Strong	Altered Expression	[1552]
TNFRSF8	TT2GM5R	Strong	Biomarker	[297]
TNFSF10	TTA5MS9	Strong	Biomarker	[1553]
TNFSF13	TTOI1RM	Strong	Biomarker	[484]
TNFSF4	TTBW580	Strong	Biomarker	[1554]
TNK2	TTIET93	Strong	Biomarker	[1555]
TNKS	TTVUSO7	Strong	Biomarker	[1556]
TNKS2	TTFQI4H	Strong	Genetic Variation	[1557]
TNNC1	TT8RDXP	Strong	Altered Expression	[1558]
TOP1	TTGTQHC	Strong	Altered Expression	[1526]
TP53BP1	TTX4UE9	Strong	Biomarker	[1015]
TPH1	TTZSJHV	Strong	Altered Expression	[1559]
TPO	TT52XDZ	Strong	Altered Expression	[1560]
TPT1	TT3PTB6	Strong	Altered Expression	[1561]
TRAF6	TTCDR6M	Strong	Altered Expression	[1562]
TREM1	TTHZQP0	Strong	Altered Expression	[1563]
TRH	TT2Z39D	Strong	Biomarker	[1564]
TRIM24	TT9Q7AE	Strong	Biomarker	[1565]
TRIM28	TTQ2BKV	Strong	Altered Expression	[1566]
TRIM37	TTAMCSL	Strong	Biomarker	[1117]
TRIM59	TT613U4	Strong	Biomarker	[1567]
TRIP10	TTKHTGE	Strong	Altered Expression	[1568]
TRPC1	TTA76X0	Strong	Altered Expression	[1569]
TRPC3	TTNVC34	Strong	Biomarker	[1570]
TRPC5	TT32NQ1	Strong	Altered Expression	[1571]
TRPM5	TT1N8F3	Strong	Biomarker	[1572]
TRPM7	TTFPVZO	Strong	Altered Expression	[1573]
TRPM8	TTXDKTO	Strong	Altered Expression	[1574]
TRPV1	TTMI6F5	Strong	Altered Expression	[1575]
TRPV4	TTKP2SU	Strong	Biomarker	[1576]
TSG101	TTHU7JA	Strong	Genetic Variation	[1577]
TSPO	TTPTXIN	Strong	Altered Expression	[1578]
TTK	TTP7EGM	Strong	Altered Expression	[1069]
TUSC2	TTJ8O14	Strong	Biomarker	[981]
TXN	TTZJ5U9	Strong	Biomarker	[1136]
TXNIP	TTTLDZK	Strong	Biomarker	[1579]
TXNRD1	TTR7UJ3	Strong	Biomarker	[1580]
TYK2	TTBYWP2	Strong	Biomarker	[1581]
TYMP	TTO0IB8	Strong	Altered Expression	[1582]
TYR	TTULVH8	Strong	Genetic Variation	[1583]
TYRO3	TTIEMFN	Strong	Altered Expression	[1584]
TYRP1	TTFRV98	Strong	Genetic Variation	[1585]
UBC	TTBP3XA	Strong	Biomarker	[1586]
UBE2E2	TTXJEOF	Strong	Biomarker	[1587]
UBE3A	TTUZX6V	Strong	Biomarker	[1588]
UCHL3	TT23UD6	Strong	Altered Expression	[1589]
UGCG	TTPHEX3	Strong	Posttranslational Modification	[1590]
UMPS	TTAFJUD	Strong	Genetic Variation	[1591]
USP1	TTG9MT5	Strong	Biomarker	[1592]
USP2	TTUEQ1W	Strong	Altered Expression	[1593]
USP33	TT4E85Q	Strong	Biomarker	[1594]
USP37	TTJDELN	Strong	Altered Expression	[1595]
USP7	TTXU3EQ	Strong	Biomarker	[748]
USP8	TT1J07C	Strong	Biomarker	[1263]
UTS2R	TTW5UDX	Strong	Genetic Variation	[1596]
VEGFB	TTPJQHE	Strong	Biomarker	[1597]
VEGFD	TTOM5H4	Strong	Biomarker	[1598]
VIP	TTGTWLF	Strong	Genetic Variation	[1599]
VIPR1	TTCL30I	Strong	Biomarker	[1600]
VIPR2	TT4O5P0	Strong	Biomarker	[1601]
VTCN1	TTCK85E	Strong	Biomarker	[1602]
VWF	TT3SZBT	Strong	Biomarker	[1603]
WAS	TTE8T73	Strong	Biomarker	[1604]
WNK1	TTJ9UMX	Strong	Biomarker	[1605]
WNT5A	TTKG7F8	Strong	Biomarker	[1606]
WNT7A	TT8NARC	Strong	Altered Expression	[1607]
WRN	TT2H5WQ	Strong	Genetic Variation	[1608]
WT1	TTZ8UT4	Strong	Altered Expression	[1609]
XDH	TT7RJY8	Strong	Altered Expression	[1610]
XIAP	TTK3WBU	Strong	Altered Expression	[1611]
XPA	TTGT87E	Strong	Genetic Variation	[1612]
XPO1	TTCJUR4	Strong	Altered Expression	[1613]
XRCC5	TTCB9KW	Strong	Genetic Variation	[1614]
YES1	TT0SQ8J	Strong	Biomarker	[1615]
ZAP70	TTUMHT8	Strong	Biomarker	[1616]
ZEB2	TTT2WK4	Strong	Biomarker	[1617]
ZFP36L1	TT8QVJO	Strong	Biomarker	[1618]
ZNF224	TT1CDXL	Strong	Biomarker	[1619]
ZUP1	TTZC0KV	Strong	Biomarker	[1620]
ZWINT	TTWY768	Strong	Biomarker	[1621]
CA1	TTHQPL7	Definitive	Biomarker	[1622]
CACNA1H	TTZPWGN	Definitive	Biomarker	[1623]
CFI	TT6ATLX	Definitive	Altered Expression	[1624]
CHRNA4	TT4H1MQ	Definitive	Biomarker	[1625]
CHRNA9	TTQACP9	Definitive	Biomarker	[1626]
DFFB	TT2SRE0	Definitive	Altered Expression	[1627]
GPR39	TTTPCNU	Definitive	Biomarker	[1628]
HOXA11	TTEX4ZA	Definitive	Altered Expression	[1629]
HPD	TT8DSFC	Definitive	Altered Expression	[1630]
ICOS	TTE5VP6	Definitive	Biomarker	[1631]
LTB4R	TTN53ZF	Definitive	Altered Expression	[1632]
LTBR	TTFO0PM	Definitive	Genetic Variation	[1633]
NDUFB9	TTBYJ39	Definitive	Biomarker	[1634]
NOD1	TTYSRXM	Definitive	Altered Expression	[1635]
OLFM4	TTK1CX7	Definitive	Biomarker	[1636]
PCSK9	TTNIZ2B	Definitive	Biomarker	[1637]
PDE8A	TTIS4OW	Definitive	Altered Expression	[1638]
PFKFB3	TTTHMQJ	Definitive	Altered Expression	[1639]
PRDX4	TTPBL9I	Definitive	Altered Expression	[1640]
PRKCZ	TTBSN0L	Definitive	Biomarker	[1641]
RIPK2	TTCQ2E5	Definitive	Biomarker	[1642]
RORB	TTGB2LZ	Definitive	Biomarker	[310]
SLC25A1	TTTD730	Definitive	Biomarker	[1643]
STAR	TTEI40H	Definitive	Altered Expression	[1644]
TCF7L2	TT80QAL	Definitive	Biomarker	[1645]
TKTL1	TTNQ1J3	Definitive	Biomarker	[1646]
TNFAIP3	TT5W0IO	Definitive	Biomarker	[1647]
TNFRSF13C	TT7NJSE	Definitive	Genetic Variation	[1633]
TNFRSF9	TTPW9LJ	Definitive	Biomarker	[1648]
TP53	TT7SBF5	Definitive	Autosomal dominant	[265]
UCHL1	TTX9IFP	Definitive	Biomarker	[1649]
USP44	TTJLTNM	Definitive	Biomarker	[1650]
VCAM1	TTHCEF6	Definitive	Biomarker	[1651]

This Disease Is Related to 64 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCB5	DTKVEXO	Limited	Biomarker	[1652]
ABCC10	DTPS120	Limited	Altered Expression	[1653]
CACNG2	DTRL7OG	Limited	Genetic Variation	[1654]
KCNH7	DT3WXPI	Limited	Biomarker	[1655]
SLC24A3	DTO18LP	Limited	Biomarker	[466]
SLC27A2	DTXK9WA	Limited	Biomarker	[1656]
SLC39A8	DTLPQGT	Limited	Altered Expression	[1657]
SLC39A9	DTJH79E	Limited	Genetic Variation	[1012]
SLC50A1	DTI9CQU	Limited	Altered Expression	[1658]
SLC7A10	DTVL2JY	Limited	Biomarker	[1659]
SLC14A2	DT8QC7K	moderate	Genetic Variation	[1596]
SLC22A5	DT3HUVD	moderate	Altered Expression	[1660]
SLC25A20	DTQOUM4	moderate	Biomarker	[739]
SLC25A37	DTLBGTZ	moderate	Biomarker	[1661]
SLC25A6	DTLMGFJ	moderate	Altered Expression	[626]
SLC27A1	DTKDTML	moderate	Biomarker	[1662]
SLC4A1	DTB0Q3P	moderate	Altered Expression	[1663]
SLC6A6	DTHWCVA	moderate	Altered Expression	[1664]
SLC9A7	DTQPK6R	moderate	Altered Expression	[1665]
ABCB6	DTF9Y2V	Strong	Biomarker	[1666]
ABCB7	DT2IMBW	Strong	Biomarker	[1667]
ABCC11	DTWN7FC	Strong	Genetic Variation	[1668]
ATP2B1	DTJWQ1L	Strong	Altered Expression	[1669]
ATP7A	DT0LT17	Strong	Biomarker	[1670]
SLC10A6	DT5A9X2	Strong	Biomarker	[1671]
SLC11A1	DT650XW	Strong	Biomarker	[1672]
SLC12A8	DT0OA2B	Strong	Biomarker	[1673]
SLC16A2	DTQ8MP1	Strong	Biomarker	[1674]
SLC16A6	DT8ZFIO	Strong	Biomarker	[1674]
SLC16A7	DTLT3UG	Strong	Altered Expression	[1675]
SLC18A1	DTM953D	Strong	Altered Expression	[1676]
SLC20A1	DTMULXV	Strong	Biomarker	[1677]
SLC25A16	DTNU9EW	Strong	Genetic Variation	[1603]
SLC25A21	DT2UQYR	Strong	Genetic Variation	[1678]
SLC25A3	DTCRIWV	Strong	Biomarker	[1679]
SLC25A5	DTL1TRY	Strong	Altered Expression	[1680]
SLC26A2	DTFSLX5	Strong	Biomarker	[1681]
SLC26A3	DTN1FMD	Strong	Genetic Variation	[1682]
SLC27A6	DTG4CWJ	Strong	Altered Expression	[1683]
SLC28A1	DT0EQPW	Strong	Biomarker	[1684]
SLC2A10	DT3BI6S	Strong	Biomarker	[1685]
SLC2A2	DTUJPOL	Strong	Biomarker	[1686]
SLC2A3	DT9SQ3L	Strong	Altered Expression	[1687]
SLC2A5	DTOR02F	Strong	Biomarker	[1688]
SLC30A1	DT1BO38	Strong	Altered Expression	[1657]
SLC35A2	DT0567K	Strong	Biomarker	[1689]
SLC35A4	DT2OPRB	Strong	Altered Expression	[1690]
SLC35B2	DT81RKJ	Strong	Biomarker	[1691]
SLC37A1	DTH9SQJ	Strong	Altered Expression	[1692]
SLC37A2	DTU58HL	Strong	Biomarker	[1693]
SLC38A6	DTZUHR9	Strong	Altered Expression	[1462]
SLC39A10	DTK02RZ	Strong	Biomarker	[1694]
SLC39A2	DTL8VXO	Strong	Altered Expression	[1695]
SLC39A7	DTDQSAM	Strong	Biomarker	[1696]
SLC3A1	DTBCKVM	Strong	Biomarker	[1697]
SLC45A2	DTNCJAT	Strong	Genetic Variation	[1698]
SLC48A1	DTZFHNT	Strong	Altered Expression	[1699]
SLC4A11	DTH2J1G	Strong	Altered Expression	[1700]
SLC52A1	DT7NOKR	Strong	Altered Expression	[1701]
SLC5A8	DTE3TAW	Strong	Altered Expression	[1702]
SLC7A2	DTWY9RT	Strong	Biomarker	[1703]
SLCO5A1	DTYVQ5M	Strong	Biomarker	[1476]
ABCD2	DT4MBHD	Definitive	Genetic Variation	[648]
SLC4A7	DT03V27	Definitive	Altered Expression	[1704]

This Disease Is Related to 98 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ACSS2	DEE76VW	Limited	Biomarker	[1705]
ASNS	DEXISVQ	Limited	Biomarker	[1706]
BCO1	DE6BOK3	Limited	Genetic Variation	[1707]
CRMP1	DE0EUXB	Limited	Biomarker	[490]
CYB5A	DE9A2LB	Limited	Genetic Variation	[1708]
CYP2C8	DES5XRU	Limited	Genetic Variation	[1474]
EPHX1	DELB4KP	Limited	Biomarker	[1709]
GCLC	DESYL1F	Limited	Biomarker	[1710]
GPX6	DEOS3FD	Limited	Genetic Variation	[1711]
LAP3	DENZF0O	Limited	Altered Expression	[977]
LDHC	DEQG7F9	Limited	Altered Expression	[1712]
NAT10	DEZV4AP	Limited	Biomarker	[700]
P4HA2	DE5EGK0	Limited	Altered Expression	[413]
UBASH3B	DE10BJ5	Limited	Biomarker	[1235]
UGDH	DE48Q2Z	Limited	Biomarker	[1713]
UGT1A8	DE2GB8N	Limited	Altered Expression	[1714]
ACP5	DESITDW	Disputed	Biomarker	[1715]
AKR1C1	DE7P2FB	Disputed	Biomarker	[1716]
AKR1C4	DEAJN47	moderate	Genetic Variation	[1717]
CHST3	DEQIZP2	moderate	Altered Expression	[1718]
CYB5R3	DE4A3BL	moderate	Altered Expression	[1719]
CYP27A1	DEBS639	moderate	Altered Expression	[1720]
CYP2S1	DE6NMGO	moderate	Altered Expression	[1721]
LPO	DEHX1DZ	moderate	Biomarker	[1722]
MSRA	DEU2ZBY	moderate	Biomarker	[1723]
UGT1A4	DELOY3P	moderate	Genetic Variation	[1724]
UGT1A6	DESD26P	moderate	Altered Expression	[1725]
UGT2B4	DENUPDX	moderate	Biomarker	[1726]
UPRT	DE20ETR	moderate	Biomarker	[1727]
ABO	DESIA7R	Strong	Biomarker	[1728]
ACP3	DEDW5H6	Strong	Altered Expression	[1729]
ADH5	DEIOH6A	Strong	Genetic Variation	[1730]
ADHFE1	DE8RJ3F	Strong	Biomarker	[1731]
AKR1A1	DED2FW3	Strong	Genetic Variation	[517]
AKR1B10	DEP6GT1	Strong	Posttranslational Modification	[1732]
AKR1C2	DEOY5ZM	Strong	Genetic Variation	[1733]
APRT	DE2MV1R	Strong	Biomarker	[1734]
BAAT	DERA3OF	Strong	Genetic Variation	[1735]
CBR3	DEIVKZ8	Strong	Genetic Variation	[1736]
CES2	DETHCPD	Strong	Biomarker	[1737]
CHDH	DEAHED0	Strong	Biomarker	[1738]
CPA4	DEXKD7J	Strong	Biomarker	[1739]
CYP27B1	DE3FYEM	Strong	Biomarker	[1740]
CYP2C18	DEZMWRE	Strong	Altered Expression	[1741]
CYP3A7	DERD86B	Strong	Genetic Variation	[1742]
CYP4B1	DEMF740	Strong	Altered Expression	[1743]
CYP4F3	DEFCMPI	Strong	Biomarker	[1744]
CYP7B1	DE36TMY	Strong	Posttranslational Modification	[1745]
DCTD	DEXL3P2	Strong	Genetic Variation	[1746]
DDAH1	DEY0TQC	Strong	Biomarker	[1747]
DIO3	DET89OV	Strong	Biomarker	[318]
EGLN3	DEMQTKH	Strong	Biomarker	[1748]
FAAH	DEUM1EX	Strong	Altered Expression	[1749]
FADS1	DE05S8C	Strong	Biomarker	[1750]
FMO5	DEBMX7C	Strong	Biomarker	[1751]
GGCT	DEKW6PB	Strong	Genetic Variation	[1752]
GSTM4	DERQ52Z	Strong	Genetic Variation	[1753]
HIF1AN	DEY1CBW	Strong	Biomarker	[1754]
HK1	DEDMAGE	Strong	Biomarker	[1755]
HPGD	DEHKSC6	Strong	Posttranslational Modification	[1756]
HPRT1	DEVXTP5	Strong	Genetic Variation	[1757]
HSD17B7	DEDMWFX	Strong	Biomarker	[362]
HSD3B1	DERDQWN	Strong	Biomarker	[1758]
MAT1A	DEQ6NC9	Strong	Genetic Variation	[1759]
MMEL1	DEYCUQ2	Strong	Biomarker	[1760]
MT1A	DE5ME8A	Strong	Biomarker	[1233]
MT2A	DEFKGT7	Strong	Genetic Variation	[1761]
NDUFS3	DE741FI	Strong	Biomarker	[1762]
NDUFS7	DEIW03B	Strong	Biomarker	[1763]
NT5C2	DE1DOKJ	Strong	Biomarker	[1764]
P3H1	DEW527E	Strong	Altered Expression	[1765]
P3H2	DELB5PA	Strong	Posttranslational Modification	[1765]
PARK7	DEPOVCH	Strong	Altered Expression	[992]
PER1	DE9HF0I	Strong	Genetic Variation	[310]
PGM3	DER0EN5	Strong	Biomarker	[1766]
PGPEP1	DEVDR46	Strong	Altered Expression	[723]
PLPP1	DE6WXTH	Strong	Biomarker	[1767]
PNPO	DE3Z1RA	Strong	Biomarker	[1768]
PON2	DEHJU7E	Strong	Genetic Variation	[1769]
PRKCSH	DE073GW	Strong	Biomarker	[1770]
PRODH	DEVJIHS	Strong	Biomarker	[1771]
PTGR1	DE4Q2OE	Strong	Altered Expression	[1772]
SAT1	DEMWO83	Strong	Biomarker	[1773]
SULT1A2	DERUZL7	Strong	Altered Expression	[1774]
SULT1C2	DEYMAD4	Strong	Altered Expression	[1774]
SULT1E1	DESTKG6	Strong	Altered Expression	[1775]
SULT2A1	DE0P6LK	Strong	Biomarker	[1776]
TGM7	DERWDYE	Strong	Biomarker	[1777]
THOP1	DE95LJC	Strong	Genetic Variation	[1716]
UCK2	DETN1O0	Strong	Biomarker	[1778]
UGT2B15	DENZ6B1	Strong	Genetic Variation	[1454]
UGT2B7	DEB3CV1	Strong	Genetic Variation	[1779]
UPP1	DEFZWAX	Strong	Altered Expression	[1780]
WARS1	DEPVE0M	Strong	Genetic Variation	[536]
ALDH1A2	DEKN1H4	Definitive	Altered Expression	[1781]
CMPK1	DEMPH4I	Definitive	Biomarker	[1782]
NNMT	DECVGJ3	Definitive	Altered Expression	[1783]
UGT2B17	DEAZDL8	Definitive	Biomarker	[1784]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5137).
• [4] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (BLA) 103425.
• [5] Clinical pipeline report, company report or official report of Lilly.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5710).
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6798).
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6799).
• [10] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 218197
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6942).
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7330).
• [13] ClinicalTrials.gov (NCT04837209) Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR). U.S. National Institutes of Health.
• [14] Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst. 1990 Nov 7;82(21):1706-10.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031953)
• [16] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217639.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6813).
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1013).
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8311).
• [20] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2861).
• [21] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1015).
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3879).
• [23] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2010
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6824).
• [25] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5692).
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009670)
• [27] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [28] Hormonal therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther. 2006 Jan;6(1):43-7.
• [29] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
• [30] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7089).
• [31] Regulation of rat uterine steroid receptors by nomegestrol acetate, a new 19-nor-progesterone derivative. J Pharmacol Exp Ther. 1989 Feb;248(2):758-61.
• [32] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
• [33] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5046).
• [34] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6840).
• [35] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7097).
• [36] FDA Approved Drug Products from FDA Official Website.
• [37] Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging. J Nucl Med Technol. 1998 Sep;26(3):155-63; quiz 170-1.
• [38] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [39] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1016).
• [40] Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
• [41] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7303).
• [42] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7622).
• [43] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4325).
• [44] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5082).
• [45] Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages. Cancer Immunol Immunother. 2005 Nov;54(11):1115-26.
• [46] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7648).
• [47] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [48] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7417).
• [49] ClinicalTrials.gov (NCT01452373) Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women. U.S. National Institutes of Health.
• [50] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [51] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8414).
• [52] ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
• [53] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5671).
• [54] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7878).
• [55] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016680)
• [56] ClinicalTrials.gov (NCT05374512) A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02). U.S.National Institutes of Health.
• [57] The cryopreservation of high concentrated PBMC for dendritic cell (DC)-based cancer immunotherapy. Cryobiology. 2009 Apr;58(2):203-9.
• [58] ClinicalTrials.gov (NCT03433313) A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 With Herceptin as Neoadjuvant Treatment in Combination With Anthracycline/Paclitaxel Systemic Therapy in HER2-Positive Early Breast Cancer. U.S.National Institutes of Health.
• [59] ClinicalTrials.gov (NCT01492101) The BEACON Study (Breast Cancer Outcomes With NKTR-102). U.S. National Institutes of Health.
• [60] ClinicalTrials.gov (NCT04961996) A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer. U.S.National Institutes of Health.
• [61] A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo. Melanoma Res. 2001 Jun;11(3):219-27.
• [62] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021154)
• [63] ClinicalTrials.gov (NCT02525159) Effectiveness of DIM Supplements to Increase 2-OHE1/16 Ratio (EDIMI216OHE1). U.S. National Institutes of Health.
• [64] ClinicalTrials.gov (NCT04975308) EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy. U.S.National Institutes of Health.
• [65] ClinicalTrials.gov (NCT01479244) Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence. U.S. National Institutes of Health.
• [66] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017925)
• [67] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017699)
• [68] ClinicalTrials.gov (NCT02187744) A Study Of PF-05280014 Or Trastuzumab Plus Taxotere And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04). U.S. National Institutes of Health.
• [69] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [70] ClinicalTrials.gov (NCT00632008) Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers. U.S. National Institutes of Health.
• [71] ClinicalTrials.gov (NCT03538171) Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer. U.S. National Institutes of Health.
• [72] ClinicalTrials.gov (NCT03262935) A Multi-centre, Open-label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-drug Conjugate SYD985 to Physician's Choice in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer. U.S.National Institutes of Health.
• [73] Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2786-92.
• [74] Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer. 2014 Mar 1;120(5):642-51.
• [75] ClinicalTrials.gov (NCT04659603) Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors. U.S.National Institutes of Health.
• [76] ClinicalTrials.gov (NCT02426086) Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor. U.S. National Institutes of Health.
• [77] ClinicalTrials.gov (NCT04123704) Sitravatinib in Metastatic Breast Cancer. U.S. National Institutes of Health.
• [78] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7645).
• [79] ClinicalTrials.gov (NCT00572728) 3'-Deoxy-3'-18F Fluorothymidine PET/CT in Predicting Response To Chemotherapy Before Surgery in Patients With Locally Advanced Breast Cancer. U.S. National Institutesof Health.
• [80] ClinicalTrials.gov (NCT00524277) Vaccine Therapy in Treating Patients With Breast Cancer. U.S. National Institutes of Health.
• [81] Clinical pipeline report, company report or official report of Generex.
• [82] ClinicalTrials.gov (NCT00272714) Study of Afimoxifene Gel to Treat Cyclic Mastalgia in Premenopausal Women. U.S. National Institutes of Health.
• [83] Clinical pipeline report, company report or official report of AFP464.
• [84] ClinicalTrials.gov (NCT02232581) Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure. U.S. National Institutes of Health.
• [85] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024318)
• [86] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [87] Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 26, No 15S (May 20 Supplement), 2008: 3034.
• [88] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019429)
• [89] ClinicalTrials.gov (NCT01823835) A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer. U.S. National Institutes of Health.
• [90] Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11(5):R73.
• [91] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7717).
• [92] ClinicalTrials.gov (NCT00555919) ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer. U.S. National Institutes of Health.
• [93] ClinicalTrials.gov (NCT00574236) Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer. U.S. National Institutes of Health.
• [94] ClinicalTrials.gov (NCT00618319) An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST). U.S. National Institutes of Health.
• [95] ClinicalTrials.gov (NCT03691207) A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY). U.S. National Institutes of Health.
• [96] Clinical pipeline report, company report or official report of Aduro BioTech.
• [97] ClinicalTrials.gov (NCT00633165) Brostallicin Clinical Trial for Myxoid Liposarcoma. U.S. National Institutes of Health.
• [98] ClinicalTrials.gov (NCT00907959) A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer. U.S. National Institutes of Health.
• [99] ClinicalTrials.gov (NCT04714619) CB-103 Plus NSAI In Luminal Advanced Breast Cancer (CAILA). U.S. National Institutes of Health.
• [100] ClinicalTrials.gov (NCT04176848) CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer. U.S. National Institutes of Health.
• [101] Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer. Expert Rev Anticancer Ther. 2011 Feb;11(2):179-83.
• [102] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019475)
• [103] ClinicalTrials.gov (NCT01605396) A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064). U.S. National Institutes of Health.
• [104] ClinicalTrials.gov (NCT00847678) Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS. U.S. National Institutes of Health.
• [105] ClinicalTrials.gov (NCT02311933) Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer. U.S.National Institutes of Health.
• [106] Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
• [107] Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in P... J Clin Oncol. 2016 Jun 10;34(17):1987-94.
• [108] A phase II trial of oral gimatecan for recurrent glioblastoma. J Neurooncol. 2013 Feb;111(3):347-53.
• [109] ClinicalTrials.gov (NCT00485563) A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma. U.S. National Institutes of Health.
• [110] ClinicalTrials.gov (NCT02267083) Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma. U.S. National Institutes of Health.
• [111] ClinicalTrials.gov (NCT04676516) A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer (OTT-19-06). U.S. National Institutes of Health.
• [112] 17alpha-alkynyl 3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs. 2012 Feb;30(1):59-78.
• [113] Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32.
• [114] ClinicalTrials.gov (NCT01220128) Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer. U.S. National Institutes of Health.
• [115] ClinicalTrials.gov (NCT01729884) Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer. U.S. National Institutes of Health.
• [116] ClinicalTrials.gov (NCT01972672) The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma. U.S. National Institutes of Health.
• [117] Atemonate and Imuteran: novel Russian monoclonal antibody-based therapeutic agents. Biotechnol J. 2007 Jul;2(7):863-70.
• [118] ClinicalTrials.gov (NCT04881929) Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer. U.S. National Institutes of Health.
• [119] Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. Eur J Cancer. 2002 Dec;38(18):2407-15.
• [120] ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
• [121] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7909).
• [122] ClinicalTrials.gov (NCT01440517) Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction. U.S. National Institutes of Health.
• [123] ClinicalTrials.gov (NCT01774851) A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach. U.S. National Institutes of Health.
• [124] ClinicalTrials.gov (NCT01447706) A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers. U.S. National Institutes of Health.
• [125] Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10. Drug Metab Dispos. 2012 Sep;40(9):1736-43.
• [126] ClinicalTrials.gov (NCT02423590) Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers. U.S. National Institutes of Health.
• [127] Clinical pipeline report, company report or official report of Context Therapeutics.
• [128] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7934).
• [129] ClinicalTrials.gov (NCT05865990) Multicenter, Single-arm, 3 Cohort, Phase II Trial of HER3-DXd in Patients With Active Brain Metastases From Metastatic Breast Cancer and Non-small Cell Lung Cancer, and in Patients With Leptomeningeal Disease From Advanced Solid Tumors. U.S.National Institutes of Health.
• [130] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7935).
• [131] ClinicalTrials.gov (NCT01036113) A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer. U.S. National Institutes of Health.
• [132] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [133] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7995).
• [134] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7338).
• [135] ClinicalTrials.gov (NCT00598507) Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma. U.S. National Institutes of Health.
• [136] ClinicalTrials.gov (NCT04191382) Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer (AMEERA-4) (AMEERA-4). U.S. National Institutes of Health.
• [137] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036273)
• [138] ClinicalTrials.gov (NCT02970682) SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer (STEM). U.S. National Institutes of Health.
• [139] Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer. Cancer. 2012 Jul 1;118(13):3244-53.
• [140] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7751).
• [141] ClinicalTrials.gov (NCT02157870) A Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer. U.S. National Institutes of Health.
• [142] ClinicalTrials.gov (NCT01307891) Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer. U.S. National Institutes of Health.
• [143] ClinicalTrials.gov (NCT01332630) TPI 287 in Breast Cancer Metastatic to the Brain. U.S. National Institutes of Health.
• [144] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6497).
• [145] The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther. 2013 Jun;12(6):890-900.
• [146] ClinicalTrials.gov (NCT01935154) Efficacy Study of Vx001 Vaccine in NSCLC Patients. U.S. National Institutes of Health.
• [147] ClinicalTrials.gov (NCT03659136) The XENERA 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread. U.S. National Institutes of Health.
• [148] ClinicalTrials.gov (NCT01147484) A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer (IND197). U.S. National Institutes of Health.
• [149] ClinicalTrials.gov (NCT00818480) An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155. U.S. National Institutes of Health.
• [150] ClinicalTrials.gov (NCT04224272) A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer. U.S. National Institutes of Health.
• [151] ClinicalTrials.gov (NCT02141451) INCB7839 With Rituximab After Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
• [152] ClinicalTrials.gov (NCT02386501) Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors. U.S. National Institutes of Health.
• [153] ClinicalTrials.gov (NCT02587689) Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
• [154] ClinicalTrials.gov (NCT04072952) A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (mBC). U.S. National Institutes of Health.
• [155] ClinicalTrials.gov (NCT01526473) A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901. U.S. National Institutes of Health.
• [156] ClinicalTrials.gov (NCT00645710) Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery. U.S. National Institutes of Health.
• [157] ClinicalTrials.gov (NCT04488107) Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c. U.S. National Institutes of Health.
• [158] ClinicalTrials.gov (NCT03250676) Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer. U.S. National Institutes of Health.
• [159] ClinicalTrials.gov (NCT02547961) Chimeric Antigen Receptor-Modified T Cells for Breast Cancer
• [160] ClinicalTrials.gov (NCT02143622) Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients. U.S. National Institutes of Health.
• [161] ClinicalTrials.gov (NCT00248404) NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS). U.S. National Institutes of Health.
• [162] ClinicalTrials.gov (NCT02293850) Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma. U.S. National Institutes of Health.
• [163] ClinicalTrials.gov (NCT04505826) A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer. U.S. National Institutes of Health.
• [164] ClinicalTrials.gov (NCT02229084) Vaccination of High Risk Breast Cancer Patients. U.S. National Institutes of Health.
• [165] ClinicalTrials.gov (NCT04802759) A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER). U.S.National Institutes of Health.
• [166] ClinicalTrials.gov (NCT03066947) SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer. U.S. National Institutes of Health.
• [167] ClinicalTrials.gov (NCT05451849) A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer. U.S.National Institutes of Health.
• [168] ClinicalTrials.gov (NCT03560531) A Study of ZN-c5 in Subjects With Breast Cancer. U.S. National Institutes of Health.
• [169] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029232)
• [170] ClinicalTrials.gov (NCT05489679) A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer. U.S.National Institutes of Health.
• [171] ClinicalTrials.gov (NCT00110526) Gene Therapy for Prostate Cancer That Returns After Radiation Therapy. U.S. National Institutes of Health.
• [172] Clinical pipeline report, company report or official report of Novartis.
• [173] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013469)
• [174] ClinicalTrials.gov (NCT04469127) A Study of AIP-303 in HER2 Positive Breast Cancer and/or Metastatic Breast Cancer Patients (Heroine01). U.S. National Institutes of Health.
• [175] ClinicalTrials.gov (NCT03060356) Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)
• [176] ClinicalTrials.gov (NCT01861509) BP-C1 in Metastatic Breast Cancer Patients. U.S. National Institutes of Health.
• [177] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015939)
• [178] ClinicalTrials.gov (NCT02915445) EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer
• [179] ClinicalTrials.gov (NCT03471663) A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer. U.S. National Institutes of Health.
• [180] ClinicalTrials.gov (NCT05261269) A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer. U.S.National Institutes of Health.
• [181] ClinicalTrials.gov (NCT00989105) Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer. U.S. National Institutes of Health.
• [182] ClinicalTrials.gov (NCT01095848) A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer. U.S. National Institutes of Health.
• [183] Clinical pipeline report, company report or official report of EpiThany.
• [184] ClinicalTrials.gov (NCT03455270) G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer. U.S. National Institutes of Health.
• [185] ClinicalTrials.gov (NCT04197999) A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer. U.S. National Institutes of Health.
• [186] ClinicalTrials.gov (NCT04834778) A Multicenter, Open-label, Phase 1a Study of HC-5404-FU in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
• [187] ClinicalTrials.gov (NCT04856371) Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer. U.S. National Institutes of Health.
• [188] ClinicalTrials.gov (NCT04020575) Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*). U.S. National Institutes of Health.
• [189] Clinical pipeline report, company report or official report of Immunotope.
• [190] ClinicalTrials.gov (NCT02122861) A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1. U.S. National Institutes of Health.
• [191] ClinicalTrials.gov (NCT04647487) A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (EMBER-2). U.S. National Institutes of Health.
• [192] ClinicalTrials.gov (NCT05307705) A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation. U.S.National Institutes of Health.
• [193] ClinicalTrials.gov (NCT02792114) T-Cell Therapy for Advanced Breast Cancer
• [194] ClinicalTrials.gov (NCT01304797) Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer. U.S. National Institutes of Health.
• [195] ClinicalTrials.gov (NCT01152398) A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy. U.S. National Institutes of Health.
• [196] ClinicalTrials.gov (NCT04064359) Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors and HER2-neg Breast Cancer. U.S. National Institutes of Health.
• [197] ClinicalTrials.gov (NCT05484011) P1b, Open-Label, Safety, Tolerability, Efficacy Study of a Soluble Beta-glucan Odetiglucan in Combination w/ a CD40 Agonist (CDX-1140) in Patients w/ Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During 1st-Line Chemo. U.S.National Institutes of Health.
• [198] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022229)
• [199] ClinicalTrials.gov (NCT04606446) A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
• [200] ClinicalTrials.gov (NCT05067972) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07260437 IN ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.
• [201] ClinicalTrials.gov (NCT03065010) Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer. U.S. National Institutes of Health.
• [202] ClinicalTrials.gov (NCT05304962) First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer. U.S.National Institutes of Health.
• [203] ClinicalTrials.gov (NCT03448042) A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers. U.S. National Institutes of Health.
• [204] ClinicalTrials.gov (NCT00002960) SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084). U.S. National Institutes of Health.
• [205] ClinicalTrials.gov (NCT04242953) Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects. U.S. National Institutes of Health.
• [206] ClinicalTrials.gov (NCT01969643) A Safety Study of SGN-LIV1A in Breast Cancer Patients. U.S. National Institutes of Health.
• [207] Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine. Cancer Immunol Immunother. 2009 Sep;58(9):1397-405.
• [208] Clinical pipeline report, company report or official report of Veana Therapeutics.
• [209] ClinicalTrials.gov (NCT03517488) A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2). U.S. National Institutes of Health.
• [210] D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem. 2003 Mar 3;4(2-3):181-5.
• [211] ClinicalTrials.gov (NCT01611038) Methylselenocysteine Effects on Circadian Rhythm. U.S. National Institutes of Health.
• [212] Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
• [213] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4792).
• [214] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003448)
• [215] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011762)
• [216] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021953)
• [217] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000847)
• [218] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015773)
• [219] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011640)
• [220] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028450)
• [221] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004178)
• [222] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000754)
• [223] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009932)
• [224] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008156)
• [225] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001808)
• [226] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003856)
• [227] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5712).
• [228] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005041)
• [229] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002721)
• [230] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030562)
• [231] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028912)
• [232] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011217)
• [233] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025155)
• [234] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028447)
• [235] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015029)
• [236] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015872)
• [237] Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
• [238] A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive br... Nucl Med Biol. 2015 Dec;42(12):931-8.
• [239] 2-Amino-4-[3'-hydroxyphenyl]-4-hydroxybutanoic acid; a potent inhibitor of rat and recombinant human kynureninase. Bioorg Med Chem Lett. 2002 Feb 11;12(3):361-3.
• [240] Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
• [241] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023898)
• [242] AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.
• [243] Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017 Sep;16(9):787-810.
• [244] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022727)
• [245] A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74.
• [246] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003836)
• [247] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001278)
• [248] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007194)
• [249] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010108)
• [250] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013096)
• [251] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000792)
• [252] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008316)
• [253] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017949)
• [254] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011240)
• [255] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001207)
• [256] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005862)
• [257] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000885)
• [258] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [259] A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes. Breast Cancer Res. 2014 Dec 9;16(6):482.
• [260] ClinicalTrials.gov (NCT02049957) Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer. U.S. National Institutes of Health.
• [261] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
• [262] ClinicalTrials.gov (NCT00044291) Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer. U.S. National Institutes of Health.
• [263] AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013 May 10;31(14):1719-25.
• [264] Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
• [265] Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
• [266] Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo.Oncogene. 2013 May 23;32(21):2622-30. doi: 10.1038/onc.2012.284. Epub 2012 Jul 9.
• [267] ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway.J Exp Clin Cancer Res. 2019 Apr 25;38(1):173. doi: 10.1186/s13046-019-1156-5.
• [268] Spatial memory deficits in mice induced by chemotherapeutic agents are prevented by acetylcholinesterase inhibitors.Cancer Chemother Pharmacol. 2019 Sep;84(3):579-589. doi: 10.1007/s00280-019-03881-8. Epub 2019 Jul 13.
• [269] ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis.Tumour Biol. 2017 Apr;39(4):1010428317698338. doi: 10.1177/1010428317698338.
• [270] ADAMTS1 Promotes Adhesion to Extracellular Matrix Proteins and Predicts Prognosis in Early Stage Breast Cancer Patients.Cell Physiol Biochem. 2019;52(6):1553-1568. doi: 10.33594/000000108.
• [271] Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis.Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5139-44. doi: 10.1073/pnas.1222085110. Epub 2013 Mar 12.
• [272] Use of non-selective -blockers is associated with decreased tumor proliferative indices in early stage breast cancer.Oncotarget. 2017 Jan 24;8(4):6446-6460. doi: 10.18632/oncotarget.14119.
• [273] Acylglycerol kinase promotes cell proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor.Mol Cancer. 2014 May 8;13:106. doi: 10.1186/1476-4598-13-106.
• [274] Breast cancer induced nociceptor aberrant growth and collateral sensory axonal branching.Oncotarget. 2017 Sep 1;8(44):76606-76621. doi: 10.18632/oncotarget.20609. eCollection 2017 Sep 29.
• [275] Changes of N6-methyladenosine modulators promote breast cancer progression.BMC Cancer. 2019 Apr 5;19(1):326. doi: 10.1186/s12885-019-5538-z.
• [276] Human cytomegalovirus infection is correlated with enhanced cyclooxygenase-2 and 5-lipoxygenase protein expression in breast cancer.J Cancer Res Clin Oncol. 2019 Aug;145(8):2083-2095. doi: 10.1007/s00432-019-02946-8. Epub 2019 Jun 15.
• [277] Expression of AMHR2 and C-KIT in cervical lesions in Uyghur Women of Xinjiang, China.Medicine (Baltimore). 2018 Jun;97(22):e10793. doi: 10.1097/MD.0000000000010793.
• [278] Capillary morphogenesis gene 2 inhibits growth of breast cancer cells and is inversely correlated with the disease progression and prognosis.J Cancer Res Clin Oncol. 2014 Jun;140(6):957-67. doi: 10.1007/s00432-014-1650-2. Epub 2014 Mar 26.
• [279] Significant prognostic values of aquaporin mRNA expression in breast cancer.Cancer Manag Res. 2019 Feb 14;11:1503-1515. doi: 10.2147/CMAR.S193396. eCollection 2019.
• [280] Acetylation of ACAP4 regulates CCL18-elicited breast cancer cell migration and invasion.J Mol Cell Biol. 2018 Dec 1;10(6):559-572. doi: 10.1093/jmcb/mjy058.
• [281] HER2 Upregulates ATF4 to Promote Cell Migration via Activation of ZEB1 and Downregulation of E-Cadherin.Int J Mol Sci. 2019 May 6;20(9):2223. doi: 10.3390/ijms20092223.
• [282] ATP2A3 gene as an important player for resveratrol anticancer activity in breast cancer cells.Mol Carcinog. 2017 Jul;56(7):1703-1711. doi: 10.1002/mc.22625. Epub 2017 Feb 15.
• [283] A small-molecule inhibitor targeting the AURKC-IB interaction decreases transformed growth of MDA-MB-231 breast cancer cells.Oncotarget. 2017 Jun 29;8(41):69691-69708. doi: 10.18632/oncotarget.18883. eCollection 2017 Sep 19.
• [284] 2-microglobulin has a different regulatory molecular mechanism between ER(+) and ER(-) breast cancer with HER2().BMC Cancer. 2019 Mar 12;19(1):223. doi: 10.1186/s12885-019-5410-1.
• [285] Serum butyrylcholinesterase and zinc in breast cancer.J Cancer Res Ther. 2017 Apr-Jun;13(2):367-370. doi: 10.4103/0973-1482.165869.
• [286] ATP/pH Dual Responsive Nanoparticle with d-[des-Arg(10) ]Kallidin Mediated Efficient In Vivo Targeting Drug Delivery.Small. 2017 Jan;13(3). doi: 10.1002/smll.201602494. Epub 2016 Oct 24.
• [287] A strategy to apply quantitative epistasis analysis on developmental traits.BMC Genet. 2017 May 15;18(1):42. doi: 10.1186/s12863-017-0508-4.
• [288] Expression and prognosis analyses of the Tob/BTG antiproliferative (APRO) protein family in human cancers.PLoS One. 2017 Sep 18;12(9):e0184902. doi: 10.1371/journal.pone.0184902. eCollection 2017.
• [289] L-Canavanine Potentiates Cytotoxicity of Chemotherapeutic Drugs in Human Breast Cancer Cells.Anticancer Agents Med Chem. 2017;17(2):206-211. doi: 10.2174/1871520616666160223111551.
• [290] Meta-Analysis of Public Microarray Datasets Reveals Voltage-Gated Calcium Gene Signatures in Clinical Cancer Patients.PLoS One. 2015 Jul 6;10(7):e0125766. doi: 10.1371/journal.pone.0125766. eCollection 2015.
• [291] Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.Antioxid Redox Signal. 2017 Jan 10;26(2):70-83. doi: 10.1089/ars.2015.6457. Epub 2016 Aug 5.
• [292] Attenuation of Antioxidant Capacity in Human Breast Cancer Cells by Carbon Monoxide through Inhibition of Cystathionine -Synthase Activity: Implications in Chemotherapeutic Drug Sensitivity.J Med Chem. 2017 Oct 12;60(19):8000-8010. doi: 10.1021/acs.jmedchem.7b00476. Epub 2017 Sep 20.
• [293] Prognostic values of distinct CBX family members in breast cancer.Oncotarget. 2017 Sep 28;8(54):92375-92387. doi: 10.18632/oncotarget.21325. eCollection 2017 Nov 3.
• [294] The Anti-tumoral Effect of -D-Mannuronic Acid (M2000) as a Novel NSAID on Treg Cells Frequency and MMP-2, MMP-9, CCL22 and TGF1 Gene Expression in Pre-surgical Breast Cancer Patients.Iran J Allergy Asthma Immunol. 2019 Feb;18(1):80-90.
• [295] High expression of CCL2 in tumor cells and abundant infiltration with CD14 positive macrophages predict early relapse in breast cancer.Virchows Arch. 2019 Jan;474(1):3-12. doi: 10.1007/s00428-018-2461-7. Epub 2018 Oct 27.
• [296] The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.Int J Oncol. 2014 Oct;45(4):1658-72. doi: 10.3892/ijo.2014.2565. Epub 2014 Jul 28.
• [297] Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.Clin Cancer Res. 2019 Sep 15;25(18):5441-5448. doi: 10.1158/1078-0432.CCR-19-0272. Epub 2019 Apr 12.
• [298] Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer.Curr Gene Ther. 2019;19(1):54-65. doi: 10.2174/1566523219666190307094713.
• [299] Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells.Int Immunol. 2018 Nov 14;30(12):559-567. doi: 10.1093/intimm/dxy050.
• [300] The Overexpression of CD80 and ISG15 Are Associated with the Progression and Metastasis of Breast Cancer by a Meta-Analysis Integrating Three Microarray Datasets.Pathol Oncol Res. 2020 Jan;26(1):443-452. doi: 10.1007/s12253-018-0478-5. Epub 2018 Nov 9.
• [301] Epigenetic silencing of genes enhanced by collective role of reactive oxygen species and MAPK signaling downstream ERK/Snail axis: Ectopic application of hydrogen peroxide repress CDH1 gene by enhanced DNA methyltransferase activity in human breast cancer.Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1651-1665. doi: 10.1016/j.bbadis.2019.04.002. Epub 2019 Apr 4.
• [302] Cadherin 11 Inhibition Downregulates -catenin, Deactivates the Canonical WNT Signalling Pathway and Suppresses the Cancer Stem Cell-Like Phenotype of Triple Negative Breast Cancer.J Clin Med. 2019 Jan 27;8(2):148. doi: 10.3390/jcm8020148.
• [303] CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/ -catenin Signaling.Curr Cancer Drug Targets. 2020;20(2):156-165. doi: 10.2174/1568009619666191118113220.
• [304] Methylation of C/EBP by PRMT1 Inhibits Its Tumor-Suppressive Function in Breast Cancer.Cancer Res. 2019 Jun 1;79(11):2865-2877. doi: 10.1158/0008-5472.CAN-18-3211. Epub 2019 Apr 23.
• [305] Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer.Mol Cancer Ther. 2014 Aug;13(8):2104-15. doi: 10.1158/1535-7163.MCT-14-0083-T. Epub 2014 Jun 13.
• [306] Chitotriosidase, a marker of innate immunity, is elevated in patients with primary breast cancer.Cancer Biomark. 2017 Jul 4;19(4):383-391. doi: 10.3233/CBM-160101.
• [307] High IKK expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer.Int J Cancer. 2017 Apr 1;140(7):1633-1644. doi: 10.1002/ijc.30578. Epub 2017 Jan 6.
• [308] Guanine nucleotide binding protein 1: a novel transduction protein with a possible role in human breast cancer.Cancer Genomics Proteomics. 2013 Mar-Apr;10(2):69-73.
• [309] Development of dual casein kinase 1/1 (CK1/) inhibitors for treatment of breast cancer.Bioorg Med Chem. 2018 Feb 1;26(3):590-602. doi: 10.1016/j.bmc.2017.12.020. Epub 2017 Dec 15.
• [310] Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies.BMC Med. 2018 Feb 19;16(1):20. doi: 10.1186/s12916-018-1010-1.
• [311] A novel derivative of artemisinin inhibits cell proliferation and metastasis via down-regulation of cathepsin K in breast cancer.Eur J Pharmacol. 2019 Sep 5;858:172382. doi: 10.1016/j.ejphar.2019.05.011. Epub 2019 May 18.
• [312] CX3CL1 involves in breast cancer metastasizing to the spine via the Src/FAK signaling pathway.J Cancer. 2018 Sep 8;9(19):3603-3612. doi: 10.7150/jca.26497. eCollection 2018.
• [313] Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design.J Biol Chem. 2019 Jan 11;294(2):453-460. doi: 10.1074/jbc.RA118.006214. Epub 2018 Nov 13.
• [314] Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers.Cancer Res. 2018 Nov 1;78(21):6183-6195. doi: 10.1158/0008-5472.CAN-18-0730. Epub 2018 Sep 17.
• [315] Optical Redox Imaging Detects the Effects of DEK Oncogene Knockdown on the Redox State of MDA-MB-231 Breast Cancer Cells.Mol Imaging Biol. 2019 Jun;21(3):410-416. doi: 10.1007/s11307-019-01321-w.
• [316] Diacylglycerol kinase promotes 3D cancer cell growth and limits drug sensitivity through functional interaction with Src.Oncotarget. 2014 Oct 30;5(20):9710-26. doi: 10.18632/oncotarget.2344.
• [317] Prognostic value of DKK2 from the Dickkopf family in human breast cancer. Int J Oncol. 2018 Dec;53(6):2555-2565.
• [318] Network analysis of EMT and MET micro-RNA regulation in breast cancer.Sci Rep. 2017 Oct 19;7(1):13534. doi: 10.1038/s41598-017-13903-1.
• [319] Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.Cancer Res. 2019 Feb 15;79(4):735-746. doi: 10.1158/0008-5472.CAN-18-0620. Epub 2018 Dec 24.
• [320] Effect of dihydropyrimidine dehydrogenase single nucleotide polymorphisms on prognosis of breast cancer patients with chemotherapy.Oncotarget. 2017 Dec 8;8(67):112060-112075. doi: 10.18632/oncotarget.23033. eCollection 2017 Dec 19.
• [321] Collapsin response mediator protein 2 is involved in regulating breast cancer progression.Breast Cancer. 2014 Nov;21(6):715-23. doi: 10.1007/s12282-013-0447-5. Epub 2013 Feb 5.
• [322] Dopamine receptor gene (DRD1-DRD5) expression changes as stress factors associated with breast cancer.Asian Pac J Cancer Prev. 2014;15(23):10339-43. doi: 10.7314/apjcp.2014.15.23.10339.
• [323] Modelling the role of dual specificity phosphatases in herceptin resistant breast cancer cell lines.Comput Biol Chem. 2019 Jun;80:138-146. doi: 10.1016/j.compbiolchem.2019.03.018. Epub 2019 Mar 25.
• [324] miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2.Breast Cancer. 2020 Jan;27(1):147-158. doi: 10.1007/s12282-019-01002-0. Epub 2019 Aug 13.
• [325] Design, synthesis and structure-activity relationship of a focused library of -phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer.Eur J Med Chem. 2018 Jan 1;143:402-418. doi: 10.1016/j.ejmech.2017.11.065. Epub 2017 Dec 1.
• [326] EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis.Oncogene. 2019 Mar;38(12):2123-2134. doi: 10.1038/s41388-018-0565-9. Epub 2018 Nov 19.
• [327] Expression of Egfl7 correlates with low-grade invasive lesions in human breast cancer.Int J Oncol. 2013 Apr;42(4):1367-75. doi: 10.3892/ijo.2013.1820. Epub 2013 Feb 8.
• [328] TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells.Oncogene. 2019 Aug;38(31):5971-5986. doi: 10.1038/s41388-019-0853-z. Epub 2019 Jun 28.
• [329] Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells.J Biol Chem. 2017 Jun 16;292(24):10295-10305. doi: 10.1074/jbc.M116.773051. Epub 2017 May 3.
• [330] Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors.Haematologica. 2020 Jan;105(1):218-225. doi: 10.3324/haematol.2019.217083. Epub 2019 May 2.
• [331] GATA Binding Protein 3 Boosts Extracellular ATP Hydrolysis and Inhibits Metastasis of Breast Cancer by Up-regulating Ectonucleoside Triphosphate Diphosphohydrolase 3.Int J Biol Sci. 2019 Sep 7;15(12):2522-2537. doi: 10.7150/ijbs.35563. eCollection 2019.
• [332] Antitumoral potential of microvesicles extracted from human adipose-derived mesenchymal stem cells on human breast cancer cells.J Cancer Res Ther. 2019 Jul-Sep;15(5):1114-1119. doi: 10.4103/jcrt.JCRT_147_18.
• [333] Inflammatory peroxidases promote breast cancer progression in mice via regulation of the tumour microenvironment.Int J Oncol. 2017 Apr;50(4):1191-1200. doi: 10.3892/ijo.2017.3883. Epub 2017 Feb 20.
• [334] EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival.Front Oncol. 2019 Jan 29;9:26. doi: 10.3389/fonc.2019.00026. eCollection 2019.
• [335] Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation.Oncotarget. 2017 Jun 13;8(24):38731-38742. doi: 10.18632/oncotarget.16317.
• [336] FAF1 phosphorylation by AKT accumulates TGF- type II receptor and drives breast cancer metastasis.Nat Commun. 2017 Apr 26;8:15021. doi: 10.1038/ncomms15021.
• [337] Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B.Oncogene. 2014 Jun 19;33(25):3298-306. doi: 10.1038/onc.2013.293. Epub 2013 Aug 5.
• [338] Tumor-targeting efficacy of a BF211 prodrug through hydrolysis by fibroblast activation protein-.Acta Pharmacol Sin. 2018 Mar;39(3):415-424. doi: 10.1038/aps.2017.121. Epub 2017 Nov 9.
• [339] Endogenously Synthesized n-3 Polyunsaturated Fatty Acids in Pregnant fat-1 Mice Decreases Mammary Cancer Risk of Female Offspring by Regulating Expression of Long Noncoding RNAs.Mol Nutr Food Res. 2019 Mar;63(6):e1801150. doi: 10.1002/mnfr.201801150. Epub 2019 Jan 27.
• [340] Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer.J Exp Clin Cancer Res. 2019 Feb 22;38(1):100. doi: 10.1186/s13046-019-1040-3.
• [341] FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression.Mol Carcinog. 2018 Nov;57(11):1616-1625. doi: 10.1002/mc.22884. Epub 2018 Aug 22.
• [342] FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer.Theranostics. 2019 Sep 21;9(23):7003-7015. doi: 10.7150/thno.35561. eCollection 2019.
• [343] MicroRNA Let-7g Directly Targets Forkhead Box C2 (FOXC2) to Modulate Bone Metastasis in Breast Cancer.Open Med (Wars). 2017 Sep 6;12:157-162. doi: 10.1515/med-2017-0023. eCollection 2017.
• [344] MicroRNA-937 inhibits the malignant phenotypes of breast cancer by directly targeting and downregulating forkhead box Q1.Onco Targets Ther. 2019 Jun 20;12:4813-4824. doi: 10.2147/OTT.S207593. eCollection 2019.
• [345] Ampelopsins A and C Induce Apoptosis and Metastasis through Downregulating AxL, TYRO3, and FYN Expressions in MDA-MB-231 Breast Cancer Cells.J Agric Food Chem. 2019 Mar 13;67(10):2818-2830. doi: 10.1021/acs.jafc.8b06444. Epub 2019 Mar 4.
• [346] Allelic loss at chromosome 11q13 alters FGF3 gene expression in a human breast cancer progression model.Oncol Rep. 2014 Dec;32(6):2445-52. doi: 10.3892/or.2014.3502. Epub 2014 Sep 19.
• [347] Restoration of GATA4 expression impedes breast cancer progression by transcriptional repression of ReLA and inhibition of NF-B signaling.J Cell Biochem. 2019 Jan;120(1):917-927. doi: 10.1002/jcb.27455. Epub 2018 Sep 6.
• [348] High levels of -glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.BMC Cancer. 2013 Feb 1;13:47. doi: 10.1186/1471-2407-13-47.
• [349] The long non-coding RNA GHSROS facilitates breast cancer cell migration and orthotopic xenograft tumour growth.Int J Oncol. 2019 Dec;55(6):1223-1236. doi: 10.3892/ijo.2019.4891. Epub 2019 Oct 4.
• [350] Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study.Breast. 2017 Aug;34:53-57. doi: 10.1016/j.breast.2017.05.005. Epub 2017 May 12.
• [351] Correlations of differentially expressed gap junction connexins Cx26, Cx30, Cx32, Cx43 and Cx46 with breast cancer progression and prognosis.PLoS One. 2014 Nov 10;9(11):e112541. doi: 10.1371/journal.pone.0112541. eCollection 2014.
• [352] Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-B Activation.Endocrinology. 2017 Dec 1;158(12):4218-4232. doi: 10.1210/en.2017-00461.
• [353] Novel therapeutic strategies and targets in advanced uveal melanoma.Curr Opin Oncol. 2018 Mar;30(2):134-141. doi: 10.1097/CCO.0000000000000425.
• [354] Synergistic effect of granzyme B-azurin fusion protein on breast cancer cells.Mol Biol Rep. 2019 Jun;46(3):3129-3140. doi: 10.1007/s11033-019-04767-x. Epub 2019 Apr 1.
• [355] The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival.Cancer Res. 2014 Feb 15;74(4):1166-78. doi: 10.1158/0008-5472.CAN-13-1451. Epub 2013 Dec 26.
• [356] Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.Oncotarget. 2017 Mar 28;8(13):20925-20938. doi: 10.18632/oncotarget.14995.
• [357] LncRNA SNHG3 promotes cell proliferation and invasion through the miR-384/hepatoma-derived growth factor axis in breast cancer.Hum Cell. 2020 Jan;33(1):232-242. doi: 10.1007/s13577-019-00287-9. Epub 2019 Oct 4.
• [358] HMBA is a putative HSP70 activator stimulating HEXIM1 expression that is down-regulated by estrogen.J Steroid Biochem Mol Biol. 2017 Apr;168:91-101. doi: 10.1016/j.jsbmb.2017.02.008. Epub 2017 Feb 14.
• [359] Splicing factor hnRNPA2B1 contributes to tumorigenic potential of breast cancer cells through STAT3 and ERK1/2 signaling pathway.Tumour Biol. 2017 Mar;39(3):1010428317694318. doi: 10.1177/1010428317694318.
• [360] Associations of polymorphisms in histidine decarboxylase, histamine N-methyltransferase and histamine receptor H3 genes with breast cancer.PLoS One. 2014 May 16;9(5):e97728. doi: 10.1371/journal.pone.0097728. eCollection 2014.
• [361] Steroid enzyme and receptor expression and regulations in breast tumor samples - A statistical evaluation of public data.J Steroid Biochem Mol Biol. 2020 Feb;196:105494. doi: 10.1016/j.jsbmb.2019.105494. Epub 2019 Oct 11.
• [362] Estrogen and androgen-converting enzymes 17-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.Oncotarget. 2017 May 2;8(18):30552-30562. doi: 10.18632/oncotarget.15547.
• [363] Profilin-1 overexpression in MDA-MB-231 breast cancer cells is associated with alterations in proteomics biomarkers of cell proliferation, survival, and motility as revealed by global proteomics analyses.OMICS. 2014 Dec;18(12):778-91. doi: 10.1089/omi.2014.0075.
• [364] Cytokine and cytokine receptor genes of the adaptive immune response are differentially associated with breast cancer risk in American women of African and European ancestry.Int J Cancer. 2014 Mar 15;134(6):1408-21. doi: 10.1002/ijc.28458. Epub 2013 Oct 8.
• [365] Genetic polymorphisms in the 9p21 region associated with risk of multiple cancers.Carcinogenesis. 2014 Dec;35(12):2698-705. doi: 10.1093/carcin/bgu203. Epub 2014 Sep 19.
• [366] Integration of genomic data enables selective discovery of breast cancer drivers.Cell. 2014 Dec 4;159(6):1461-75. doi: 10.1016/j.cell.2014.10.048. Epub 2014 Nov 26.
• [367] Regulation of cellular processes by interleukin-16 in homeostasis and cancer.J Cell Physiol. 2014 Feb;229(2):139-47. doi: 10.1002/jcp.24441.
• [368] Genetic polymorphisms in inflammatory response genes and their associations with breast cancer risk.Croat Med J. 2014 Dec;55(6):638-46. doi: 10.3325/cmj.2014.55.638.
• [369] Interleukin-22 promotes development of malignant lesions in a mouse model of spontaneous breast cancer.Mol Oncol. 2020 Jan;14(1):211-224. doi: 10.1002/1878-0261.12598. Epub 2019 Dec 4.
• [370] Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin 3-p38 MAPK signalling.Cancer Lett. 2019 Feb 1;442:320-332. doi: 10.1016/j.canlet.2018.10.015. Epub 2018 Oct 27.
• [371] Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development.Int J Cancer. 2020 Mar 1;146(5):1421-1434. doi: 10.1002/ijc.32779. Epub 2019 Dec 5.
• [372] Blocking Interleukin-4 Receptor Using Polyethylene Glycol Functionalized Superparamagnetic Iron Oxide Nanocarriers to Inhibit Breast Cancer Cell Proliferation.Cancer Res Treat. 2017 Apr;49(2):322-329. doi: 10.4143/crt.2016.091. Epub 2016 Jul 12.
• [373] The role of IRAK1 in breast cancer patients treated with neoadjuvant chemotherapy.Onco Targets Ther. 2019 Mar 25;12:2171-2180. doi: 10.2147/OTT.S185662. eCollection 2019.
• [374] Interplay between interferon-stimulated gene 15/ISGylation and interferon gamma signaling in breast cancer cells.Cell Signal. 2019 Feb;54:91-101. doi: 10.1016/j.cellsig.2018.11.021. Epub 2018 Nov 27.
• [375] EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.J Immunother Cancer. 2019 Jan 8;7(1):5. doi: 10.1186/s40425-018-0470-3.
• [376] Calendula arvensis L. as an anti-cancer agent against breast cancer cell lines.Mol Biol Rep. 2019 Apr;46(2):2187-2196. doi: 10.1007/s11033-019-04672-3. Epub 2019 Feb 11.
• [377] Identification of MYST3 as a novel epigenetic activator of ER frequently amplified in breast cancer.Oncogene. 2017 May 18;36(20):2910-2918. doi: 10.1038/onc.2016.433. Epub 2016 Nov 28.
• [378] The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells.Tumour Biol. 2016 May;37(5):6275-83. doi: 10.1007/s13277-015-4509-5. Epub 2015 Nov 30.
• [379] Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression.Oncotarget. 2017 Jul 19;8(47):81737-81753. doi: 10.18632/oncotarget.19387. eCollection 2017 Oct 10.
• [380] SF-KDM2A binds to ribosomal RNA gene promoter, reduces H4K20me3 level, and elevates ribosomal RNA transcription in breast cancer cells.Int J Oncol. 2017 Apr;50(4):1372-1382. doi: 10.3892/ijo.2017.3908. Epub 2017 Mar 10.
• [381] Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.Biochem Biophys Res Commun. 2015 Aug 21;464(2):659-66. doi: 10.1016/j.bbrc.2015.07.049. Epub 2015 Jul 13.
• [382] KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer.Mol Cancer Ther. 2018 Sep;17(9):1973-1983. doi: 10.1158/1535-7163.MCT-17-0802. Epub 2018 Jun 20.
• [383] Histone demethylase KDM7A is required for stem cell maintenance and apoptosis inhibition in breast cancer.J Cell Physiol. 2020 Feb;235(2):932-943. doi: 10.1002/jcp.29008. Epub 2019 Jun 24.
• [384] Association of the genetic diversity of killer cell immunoglobulin-like receptor genes and HLA-C ligand in Saudi women with breast cancer.Immunogenetics. 2017 Feb;69(2):69-76. doi: 10.1007/s00251-016-0950-x. Epub 2016 Sep 15.
• [385] Downregulation of klotho is associated with invasive ductal carcinoma progression.Oncol Lett. 2017 Dec;14(6):7443-7448. doi: 10.3892/ol.2017.7110. Epub 2017 Sep 29.
• [386] Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models.Oncotarget. 2019 Feb 15;10(14):1399-1406. doi: 10.18632/oncotarget.26659. eCollection 2019 Feb 15.
• [387] Lipopolysaccharide-Binding Protein Is an Early Biomarker of Cardiac Function After Radiation Therapy for Breast Cancer.Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1074-1083. doi: 10.1016/j.ijrobp.2019.04.002. Epub 2019 Apr 13.
• [388] USP17 Suppresses Tumorigenesis and Tumor Growth through Deubiquitinating AEP.Int J Biol Sci. 2019 Jan 29;15(4):738-748. doi: 10.7150/ijbs.30106. eCollection 2019.
• [389] Inhibitory receptor immunoglobulin-like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10.Diagn Pathol. 2014 Apr 24;9:85. doi: 10.1186/1746-1596-9-85.
• [390] Wogonin suppresses the LPSenhanced invasiveness of MDAMB?31 breast cancer cells by inhibiting the 5LO/BLT2 cascade.Int J Mol Med. 2018 Oct;42(4):1899-1908. doi: 10.3892/ijmm.2018.3776. Epub 2018 Jul 12.
• [391] Transgenic overexpression of human LY6K in mice suppresses mature T cell development in the thymus.Oncol Lett. 2019 Jan;17(1):379-387. doi: 10.3892/ol.2018.9548. Epub 2018 Oct 4.
• [392] The CARMA3-Bcl10-MALT1 Signalosome Drives NFB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer.Cancer Res. 2018 Mar 1;78(5):1225-1240. doi: 10.1158/0008-5472.CAN-17-1089. Epub 2017 Dec 19.
• [393] Mixed lineage kinase ZAK promotes epithelial-mesenchymal transition in cancer progression.Cell Death Dis. 2018 Feb 2;9(2):143. doi: 10.1038/s41419-017-0161-x.
• [394] Topological alternate centrality measure capturing drug targets in the network of MAPK pathways.IET Syst Biol. 2018 Oct;12(5):226-232. doi: 10.1049/iet-syb.2017.0058.
• [395] Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro.Breast Cancer Res Treat. 2017 Jul;164(1):27-40. doi: 10.1007/s10549-017-4223-7. Epub 2017 Mar 31.
• [396] Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.J Biol Chem. 2014 Sep 12;289(37):25737-49. doi: 10.1074/jbc.M114.570838. Epub 2014 Jul 29.
• [397] Proteins with Evolutionarily Hypervariable Domains are Associated with Immune Response and Better Survival of Basal-like Breast Cancer Patients.Comput Struct Biotechnol J. 2019 Mar 19;17:430-440. doi: 10.1016/j.csbj.2019.03.008. eCollection 2019.
• [398] Bisected, complex N-glycans and galectins in mouse mammary tumor progression and human breast cancer.Glycobiology. 2013 Dec;23(12):1477-90. doi: 10.1093/glycob/cwt075. Epub 2013 Sep 13.
• [399] Human G protein-coupled receptor 30 is N-glycosylated and N-terminal domain asparagine 44 is required for receptor structure and activity.Biosci Rep. 2019 Feb 26;39(2):BSR20182436. doi: 10.1042/BSR20182436. Print 2019 Feb 28.
• [400] Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth.Oncoimmunology. 2018 Jul 11;7(9):e1480286. doi: 10.1080/2162402X.2018.1480286. eCollection 2018.
• [401] Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays.Breast Cancer Res. 2014 Nov 8;16(6):470. doi: 10.1186/s13058-014-0470-2.
• [402] Mutational analysis of the kinase domain of MYLK2 gene in common human cancers.Pathol Res Pract. 2006;202(3):137-40. doi: 10.1016/j.prp.2005.12.003. Epub 2006 Jan 31.
• [403] Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients.Cancer Biol Ther. 2020;21(2):189-196. doi: 10.1080/15384047.2019.1680057. Epub 2019 Nov 4.
• [404] NLRX1 regulates TNF--induced mitochondria-lysosomal crosstalk to maintain the invasive and metastatic potential of breast cancer cells.Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1460-1476. doi: 10.1016/j.bbadis.2019.02.018. Epub 2019 Feb 23.
• [405] MiRNA-106a promotes breast cancer progression by regulating DAX-1.Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1574-1583. doi: 10.26355/eurrev_201902_17116.
• [406] Variability in DNA Repair Capacity Levels among Molecular Breast Cancer Subtypes: Triple Negative Breast Cancer Shows Lowest Repair.Int J Mol Sci. 2017 Jul 12;18(7):1505. doi: 10.3390/ijms18071505.
• [407] Alterations of the interactome of Bcl-2 proteins in breast cancer at the transcriptional, mutational and structural level.PLoS Comput Biol. 2019 Dec 11;15(12):e1007485. doi: 10.1371/journal.pcbi.1007485. eCollection 2019 Dec.
• [408] Dichotomous roles for the orphan nuclear receptor NURR1 in breast cancer.BMC Cancer. 2013 Mar 21;13:139. doi: 10.1186/1471-2407-13-139.
• [409] Learning common and specific patterns from data of multiple interrelated biological scenarios with matrix factorization.Nucleic Acids Res. 2019 Jul 26;47(13):6606-6617. doi: 10.1093/nar/gkz488.
• [410] Ultrasound molecular imaging as a non-invasive companion diagnostic for netrin-1 interference therapy in breast cancer.Theranostics. 2018 Oct 6;8(18):5126-5142. doi: 10.7150/thno.27221. eCollection 2018.
• [411] Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.Clin Exp Metastasis. 2018 Feb;35(1-2):25-35. doi: 10.1007/s10585-018-9874-1. Epub 2018 Jan 11.
• [412] P2Y2 receptor promotes the migration and invasion of breast cancer cells via EMT-related genes Snail and E-cadherin.Oncol Rep. 2018 Jan;39(1):138-150. doi: 10.3892/or.2017.6081. Epub 2017 Nov 7.
• [413] Prolyl-4-hydroxylase subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition.BMC Cancer. 2014 Jan 2;14:1. doi: 10.1186/1471-2407-14-1.
• [414] MiR-216a-5p act as a tumor suppressor, regulating the cell proliferation and metastasis by targeting PAK2 in breast cancer.Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2469-2475. doi: 10.26355/eurrev_201903_17394.
• [415] TOPK promotes epithelial-mesenchymal transition and invasion of breast cancer cells through upregulation of TBX3 in TGF-1/Smad signaling.Biochem Biophys Res Commun. 2020 Jan 29;522(1):270-277. doi: 10.1016/j.bbrc.2019.11.104. Epub 2019 Nov 20.
• [416] BAF180: Its Roles in DNA Repair and Consequences in Cancer.ACS Chem Biol. 2017 Oct 20;12(10):2482-2490. doi: 10.1021/acschembio.7b00541. Epub 2017 Sep 28.
• [417] The oncoprotein HBXIP upregulates PDGFB via activating transcription factor Sp1 to promote the proliferation of breast cancer cells.Biochem Biophys Res Commun. 2013 May 3;434(2):305-10. doi: 10.1016/j.bbrc.2013.02.123. Epub 2013 Mar 26.
• [418] Sulfatase 2 promotes breast cancer progression through regulating some tumor-related factors.Oncol Rep. 2016 Mar;35(3):1318-28. doi: 10.3892/or.2015.4525. Epub 2015 Dec 28.
• [419] The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence.Breast Cancer Res Treat. 2018 Jun;169(2):231-241. doi: 10.1007/s10549-018-4664-7. Epub 2018 Jan 29.
• [420] Epigenetic repression of phosphatidylethanolamine N-methyltransferase (PEMT) in BRCA1-mutated breast cancer.Oncotarget. 2014 Mar 15;5(5):1315-25. doi: 10.18632/oncotarget.1800.
• [421] Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis.Nucleic Acids Res. 2017 Feb 28;45(4):1687-1702. doi: 10.1093/nar/gkw1093.
• [422] The PIKfyve-ArPIKfyve-Sac3 triad in human breast cancer: Functional link between elevated Sac3 phosphatase and enhanced proliferation of triple negative cell lines.Biochem Biophys Res Commun. 2013 Oct 18;440(2):342-7. doi: 10.1016/j.bbrc.2013.09.080. Epub 2013 Sep 23.
• [423] Correction: PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer.Oncogene. 2020 Jan;39(3):720-721. doi: 10.1038/s41388-019-0982-4.
• [424] Gene expression correlation for cancer diagnosis: a pilot study.Biomed Res Int. 2014;2014:253804. doi: 10.1155/2014/253804. Epub 2014 Apr 9.
• [425] The role of PIP5K1/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1 inhibitor.Oncogene. 2019 Jan;38(3):375-389. doi: 10.1038/s41388-018-0438-2. Epub 2018 Aug 13.
• [426] The NQO1/PKLR axis promotes lymph node metastasis and breast cancer progression by modulating glycolytic reprogramming.Cancer Lett. 2019 Jul 1;453:170-183. doi: 10.1016/j.canlet.2019.03.054. Epub 2019 Apr 4.
• [427] Systematic expression analysis of WEE family kinases reveals the importance of PKMYT1 in breast carcinogenesis.Cell Prolif. 2020 Feb;53(2):e12741. doi: 10.1111/cpr.12741. Epub 2019 Dec 14.
• [428] The interaction of p130Cas with PKN3 promotes malignant growth.Mol Oncol. 2019 Feb;13(2):264-289. doi: 10.1002/1878-0261.12401. Epub 2018 Dec 3.
• [429] Regulation of the Hippo Pathway by Phosphatidic Acid-Mediated Lipid-Protein Interaction.Mol Cell. 2018 Oct 18;72(2):328-340.e8. doi: 10.1016/j.molcel.2018.08.038. Epub 2018 Oct 4.
• [430] A feedback mechanism between PLD and deadenylase PARN for the shortening of eukaryotic poly(A) mRNA tails that is deregulated in cancer cells.Biol Open. 2017 Feb 15;6(2):176-186. doi: 10.1242/bio.021261.
• [431] YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.Cell Death Dis. 2018 Oct 18;9(11):1066. doi: 10.1038/s41419-018-1071-2.
• [432] MiR-422a weakened breast cancer stem cells properties by targeting PLP2. Cancer Biol Ther. 2018 May 4;19(5):436-444.
• [433] Ligand-activated interaction of PPAR with c-Myc governs the tumorigenicity of breast cancer.Int J Cancer. 2018 Dec 1;143(11):2985-2996. doi: 10.1002/ijc.31864. Epub 2018 Oct 4.
• [434] miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A.Kaohsiung J Med Sci. 2019 Jan;35(1):17-23. doi: 10.1002/kjm2.12004.
• [435] Dephosphorylation of Girdin by PP2A inhibits breast cancer metastasis.Biochem Biophys Res Commun. 2019 May 21;513(1):28-34. doi: 10.1016/j.bbrc.2019.03.167. Epub 2019 Mar 29.
• [436] Inhibition of Thioredoxin Reductase by Targeted Selenopolymeric Nanocarriers Synergizes the Therapeutic Efficacy of Doxorubicin in MCF7 Human Breast Cancer Cells.ACS Appl Mater Interfaces. 2017 Oct 25;9(42):36493-36512. doi: 10.1021/acsami.7b07056. Epub 2017 Oct 10.
• [437] The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.Breast Cancer. 2017 Sep;24(5):658-666. doi: 10.1007/s12282-017-0752-5. Epub 2017 Jan 9.
• [438] Interleukin-32 inhibits tumor-promoting effects of macrophage-secreted CCL18 in breast cancer.Cell Commun Signal. 2019 May 24;17(1):53. doi: 10.1186/s12964-019-0374-y.
• [439] Transcriptional regulation of oncogenic protein kinase C (PKC) by STAT1 and Sp1 proteins.J Biol Chem. 2014 Jul 11;289(28):19823-38. doi: 10.1074/jbc.M114.548446. Epub 2014 May 13.
• [440] Expression of Immunoproteasome Subunit LMP7 in Breast Cancer and Its Association with Immune-Related Markers.Cancer Res Treat. 2019 Jan;51(1):80-89. doi: 10.4143/crt.2017.500. Epub 2018 Feb 26.
• [441] Regulatory network reconstruction of five essential microRNAs for survival analysis in breast cancer by integrating miRNA and mRNA expression datasets.Funct Integr Genomics. 2019 Jul;19(4):645-658. doi: 10.1007/s10142-019-00670-7. Epub 2019 Mar 12.
• [442] Multifunctional superparamagnetic nanoparticles conjugated with fluorescein-labeled designed ankyrin repeat protein as an efficient HER2-targeted probe in breast cancer.Biomaterials. 2017 Dec;147:86-98. doi: 10.1016/j.biomaterials.2017.09.010. Epub 2017 Sep 8.
• [443] The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells.Breast Cancer Res. 2019 Apr 24;21(1):53. doi: 10.1186/s13058-019-1131-2.
• [444] PTH1R-CaSR Cross Talk: New Treatment Options for Breast Cancer Osteolytic Bone Metastases.Int J Endocrinol. 2018 Jul 29;2018:7120979. doi: 10.1155/2018/7120979. eCollection 2018.
• [445] PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement.PLoS One. 2014 Jan 7;9(1):e84472. doi: 10.1371/journal.pone.0084472. eCollection 2014.
• [446] Pleiotrophin as a potential biomarker in breast cancer patients.Clin Chim Acta. 2017 Mar;466:6-12. doi: 10.1016/j.cca.2016.12.030. Epub 2016 Dec 29.
• [447] Inhibition of PRL-2CNNM3 Protein Complex Formation Decreases Breast Cancer Proliferation and Tumor Growth.J Biol Chem. 2016 May 13;291(20):10716-25. doi: 10.1074/jbc.M115.705863. Epub 2016 Mar 11.
• [448] Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.Cell Death Dis. 2018 Feb 27;9(3):326. doi: 10.1038/s41419-018-0347-x.
• [449] Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer.Clin Transl Oncol. 2019 Apr;21(4):433-442. doi: 10.1007/s12094-018-1941-1. Epub 2018 Sep 14.
• [450] The overexpression of Rab9 promotes tumor progression regulated by XBP1 in breast cancer.Onco Targets Ther. 2019 Mar 4;12:1815-1824. doi: 10.2147/OTT.S183748. eCollection 2019.
• [451] RACK1 stabilises the activity of PP2A to regulate the transformed phenotype in mammary epithelial cells.Cell Signal. 2017 Jul;35:290-300. doi: 10.1016/j.cellsig.2016.09.001. Epub 2016 Sep 4.
• [452] 2'-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer.Oncotarget. 2018 Apr 6;9(26):18053-18068. doi: 10.18632/oncotarget.24720. eCollection 2018 Apr 6.
• [453] Role of exchange protein directly activated by cAMP (EPAC1) in breast cancer cell migration and apoptosis.Mol Cell Biochem. 2017 Jun;430(1-2):115-125. doi: 10.1007/s11010-017-2959-3. Epub 2017 Feb 16.
• [454] Atorvastatin Inhibits Breast Cancer Cells by Downregulating PTEN/AKT Pathway via Promoting Ras Homolog Family Member B (RhoB).Biomed Res Int. 2019 Mar 18;2019:3235021. doi: 10.1155/2019/3235021. eCollection 2019.
• [455] Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.Sci Transl Med. 2017 Apr 12;9(385):eaak9679. doi: 10.1126/scitranslmed.aak9679.
• [456] Clinical value of R-spondins in triple-negative and metaplastic breast cancers.Br J Cancer. 2017 Jun 6;116(12):1595-1603. doi: 10.1038/bjc.2017.131. Epub 2017 May 4.
• [457] S1PR1 regulates the switch of two angiogenic modes by VE-cadherin phosphorylation in breast cancer.Cell Death Dis. 2019 Feb 27;10(3):200. doi: 10.1038/s41419-019-1411-x.
• [458] Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 phosphorylated c-Src and increases estrogen receptor negative MDA-MB-231 breast cancer cell growth: The role of sphingosine 1-phosphate receptor-4.Cell Signal. 2014 May;26(5):1040-7. doi: 10.1016/j.cellsig.2014.01.023. Epub 2014 Jan 29.
• [459] SREBP-2 aggravates breast cancer associated osteolysis by promoting osteoclastogenesis and breast cancer metastasis.Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):115-125. doi: 10.1016/j.bbadis.2018.10.026. Epub 2018 Oct 28.
• [460] Long noncoding RNA HOXA-AS2 regulates the expression of SCN3A by sponging miR-106a in breast cancer.J Cell Biochem. 2019 Sep;120(9):14465-14475. doi: 10.1002/jcb.28706. Epub 2019 Apr 16.
• [461] Stem-like tumor cells involved in heterogeneous vasculogenesis in breast cancer.Endocr Relat Cancer. 2020 Jan;27(1):23-39. doi: 10.1530/ERC-19-0054.
• [462] Mutational landscape of RNA-binding proteins in human cancers.RNA Biol. 2018 Jan 2;15(1):115-129. doi: 10.1080/15476286.2017.1391436. Epub 2017 Nov 14.
• [463] Serum- and Glucocorticoid-inducible Kinase 1 is Essential for Osteoclastogenesis and Promotes Breast Cancer Bone Metastasis.Mol Cancer Ther. 2020 Feb;19(2):650-660. doi: 10.1158/1535-7163.MCT-18-0783. Epub 2019 Nov 6.
• [464] SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.Endocr J. 2020 Jan 28;67(1):99-106. doi: 10.1507/endocrj.EJ19-0428. Epub 2019 Nov 27.
• [465] Biotin uptake by T47D breast cancer cells: functional and molecular evidence of sodium-dependent multivitamin transporter (SMVT).Int J Pharm. 2013 Jan 30;441(1-2):535-43. doi: 10.1016/j.ijpharm.2012.10.047. Epub 2012 Nov 8.
• [466] Calcium signaling affects migration and proliferation differently in individual cancer cells due to nifedipine treatment.Biochem Pharmacol. 2020 Jan;171:113695. doi: 10.1016/j.bcp.2019.113695. Epub 2019 Nov 9.
• [467] Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.Oncotarget. 2017 Jan 24;8(4):6540-6554. doi: 10.18632/oncotarget.14145.
• [468] ProNGF increases breast tumor aggressiveness through functional association of TrkA with EphA2.Cancer Lett. 2019 May 1;449:196-206. doi: 10.1016/j.canlet.2019.02.019. Epub 2019 Feb 13.
• [469] Intracellular patterns of sialophorin expression define a new molecular classification of breast cancer and represent new targets for therapy.Br J Cancer. 2014 Jan 7;110(1):146-55. doi: 10.1038/bjc.2013.526. Epub 2013 Nov 26.
• [470] SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2.Cell Death Differ. 2019 May;26(5):843-859. doi: 10.1038/s41418-018-0158-8. Epub 2018 Jul 9.
• [471] Prognostic value of histone chaperone FACT subunits expression in breast cancer.Breast Cancer (Dove Med Press). 2017 May 3;9:301-311. doi: 10.2147/BCTT.S126390. eCollection 2017.
• [472] STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo.Cancer Biol Ther. 2020;21(3):278-291. doi: 10.1080/15384047.2019.1685290. Epub 2019 Nov 7.
• [473] Long noncoding RNA LINC00511 involves in breast cancer recurrence and radioresistance by regulating STXBP4 expression via miR-185.Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7457-7468. doi: 10.26355/eurrev_201909_18855.
• [474] MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis.Cell Prolif. 2019 Jan;52(1):e12527. doi: 10.1111/cpr.12527. Epub 2018 Oct 17.
• [475] Transgelin 2 Promotes Paclitaxel Resistance, Migration, and Invasion of Breast Cancer by Directly Interacting with PTEN and Activating PI3K/Akt/GSK-3 Pathway.Mol Cancer Ther. 2019 Dec;18(12):2457-2468. doi: 10.1158/1535-7163.MCT-19-0261. Epub 2019 Sep 5.
• [476] Transducin ()-like 1 X-linked receptor 1 promotes proliferation and tumorigenicity in human breast cancer via activation of beta-catenin signaling.Breast Cancer Res. 2014 Oct 24;16(5):465. doi: 10.1186/s13058-014-0465-z.
• [477] Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth.Nat Med. 2017 Jan;23(1):120-127. doi: 10.1038/nm.4232. Epub 2016 Nov 21.
• [478] Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells.J Cell Physiol. 2013 Jun;228(6):1174-88. doi: 10.1002/jcp.24271.
• [479] Novel CD44-downstream signaling pathways mediating breast tumor invasion.Int J Biol Sci. 2018 Oct 5;14(13):1782-1790. doi: 10.7150/ijbs.23586. eCollection 2018.
• [480] A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.Clin Cancer Res. 2013 Apr 15;19(8):2061-70. doi: 10.1158/1078-0432.CCR-13-0082. Epub 2013 Mar 11.
• [481] HVEM gene polymorphisms are associated with sporadic breast cancer in Chinese women.PLoS One. 2013 Aug 16;8(8):e71040. doi: 10.1371/journal.pone.0071040. eCollection 2013.
• [482] Expression of death receptor-3 in human breast cancer and its functional effects on breast cancer cells in vitro.Oncol Rep. 2013 Apr;29(4):1356-64. doi: 10.3892/or.2013.2259. Epub 2013 Jan 30.
• [483] Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol. 2013 Feb;139(2):315-25.
• [484] BCMA (TNFRSF17) Induces APRIL and BAFF Mediated Breast Cancer Cell Stemness.Front Oncol. 2018 Aug 7;8:301. doi: 10.3389/fonc.2018.00301. eCollection 2018.
• [485] Vascular endothelial growth inhibitor affects the invasion, apoptosis and vascularisation in breast cancer cell line MDA-MB-231.Chin Med J (Engl). 2014;127(10):1947-53.
• [486] Gene rearrangements in hormone receptor negative breast cancers revealed by mate pair sequencing.BMC Genomics. 2013 Mar 12;14:165. doi: 10.1186/1471-2164-14-165.
• [487] Association between the c.*229C>T polymorphism of the topoisomerase II binding protein 1 (TopBP1) gene and breast cancer.Mol Biol Rep. 2013 May;40(5):3493-502. doi: 10.1007/s11033-012-2424-z. Epub 2013 Jan 1.
• [488] Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model.J Cancer. 2018 Aug 6;9(17):3196-3207. doi: 10.7150/jca.20639. eCollection 2018.
• [489] Identification of differentially expressed genes and typical fusion genes associated with three subtypes of breast cancer.Breast Cancer. 2019 May;26(3):305-316. doi: 10.1007/s12282-018-0924-y. Epub 2018 Nov 16.
• [490] Mst1-Hippo pathway triggers breast cancer apoptosis via inducing mitochondrial fragmentation in a manner dependent on JNK-Drp1 axis.Onco Targets Ther. 2019 Feb 11;12:1147-1159. doi: 10.2147/OTT.S193787. eCollection 2019.
• [491] Biophysical characterization of the breast cancer-related BIG3-PHB2 interaction: Effect of non-conserved loop region of BIG3 on the structure and the interaction.Biochem Biophys Res Commun. 2019 Oct 8;518(1):183-189. doi: 10.1016/j.bbrc.2019.08.028. Epub 2019 Aug 14.
• [492] Tumor suppressive effects of WEE1 gene silencing could not enhance immunopotentiation effects of CD80 and 4-1BBL co-stimulation in human T cells.J Cancer Res Ther. 2015 Oct-Dec;11(4):708-16. doi: 10.4103/0973-1482.147746.
• [493] Male secretory breast cancer: case in a 6-year-old boy with a peculiar gene duplication and review of the literature.Breast Cancer Res Treat. 2018 Aug;170(3):445-454. doi: 10.1007/s10549-018-4772-4. Epub 2018 Apr 3.
• [494] miR-125a-3p inhibits ER transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer.FASEB J. 2018 Feb;32(2):588-600. doi: 10.1096/fj.201700461RR. Epub 2018 Jan 4.
• [495] RNAi-mediated downregulation of CDKL1 inhibits growth and colony-formation ability, promotes apoptosis of human melanoma cells.J Dermatol Sci. 2015 Jul;79(1):57-63. doi: 10.1016/j.jdermsci.2015.03.020. Epub 2015 Apr 9.
• [496] Nuclear galectin-1-FOXP3 interaction dampens the tumor-suppressive properties of FOXP3 in breast cancer.Cell Death Dis. 2018 Apr 1;9(4):416. doi: 10.1038/s41419-018-0448-6.
• [497] Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.Biomaterials. 2018 Jan;152:47-62. doi: 10.1016/j.biomaterials.2017.10.035. Epub 2017 Oct 21.
• [498] -Lipoic acid stabilized DTX/IR780 micelles for photoacoustic/fluorescence imaging guided photothermal therapy/chemotherapy of breast cancer.Biomater Sci. 2018 May 1;6(5):1201-1216. doi: 10.1039/c8bm00096d.
• [499] AND-34/BCAR3 differs from other NSP homologs in induction of anti-estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphology.J Cell Physiol. 2007 Sep;212(3):655-65. doi: 10.1002/jcp.21059.
• [500] Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.PLoS Genet. 2013 Apr;9(4):e1003464. doi: 10.1371/journal.pgen.1003464. Epub 2013 Apr 25.
• [501] Transketolase Regulates the Metabolic Switch to Control Breast Cancer Cell Metastasis via the -Ketoglutarate Signaling Pathway.Cancer Res. 2018 Jun 1;78(11):2799-2812. doi: 10.1158/0008-5472.CAN-17-2906. Epub 2018 Mar 29.
• [502] Body mass index, diet, and exercise: testing possible linkages to breast cancer risk via DNA methylation.Breast Cancer Res Treat. 2018 Feb;168(1):241-248. doi: 10.1007/s10549-017-4573-1. Epub 2017 Nov 10.
• [503] Enhanced cytotoxicity in triple-negative and estrogen receptorpositive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel.Oncol Rep. 2015 Sep;34(3):1589-98. doi: 10.3892/or.2015.4131. Epub 2015 Jul 14.
• [504] Expression of LXR? ABCA1 and ABCG1 in human triplenegative breast cancer tissues.Oncol Rep. 2019 Nov;42(5):1869-1877. doi: 10.3892/or.2019.7279. Epub 2019 Aug 14.
• [505] Host genotype and tumor phenotype of chemokine decoy receptors integrally affect breast cancer relapse.Oncotarget. 2015 Sep 22;6(28):26519-27. doi: 10.18632/oncotarget.4470.
• [506] Quantitative real-time RT-PCR of ITGA7, SVEP1, TNS1, LPHN3, SEMA3G, KLB and MMP13 mRNA expression in breast cancer.Asian Pac J Cancer Prev. 2012;13(11):5879-82. doi: 10.7314/apjcp.2012.13.11.5879.
• [507] Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer.Tumour Biol. 2015 Jul;36(7):5627-34. doi: 10.1007/s13277-015-3235-3. Epub 2015 Feb 15.
• [508] AKR1C3 (type 5 17-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.Mol Cell Endocrinol. 2019 Jun 1;489:82-91. doi: 10.1016/j.mce.2018.07.002. Epub 2018 Sep 19.
• [509] Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.J Cancer Res Clin Oncol. 2012 May;138(5):867-75. doi: 10.1007/s00432-012-1161-y. Epub 2012 Feb 7.
• [510] Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPIC-Heidelberg cohort.BMC Med. 2017 Dec 19;15(1):218. doi: 10.1186/s12916-017-0976-4.
• [511] Human Aquaporin-5 Facilitates Hydrogen Peroxide Permeation Affecting Adaption to Oxidative Stress and Cancer Cell Migration.Cancers (Basel). 2019 Jul 3;11(7):932. doi: 10.3390/cancers11070932.
• [512] Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1. Oncotarget. 2016 Sep 6;7(36):58111-58120.
• [513] -arrestin 2 is associated with multidrug resistance in breast cancer cells through regulating MDR1 gene expression.Int J Clin Exp Pathol. 2015 Feb 1;8(2):1354-63. eCollection 2015.
• [514] Derlin-1 functions as a growth promoter in breast cancer.Biol Chem. 2020 Feb 25;401(3):377-387. doi: 10.1515/hsz-2018-0442.
• [515] Indolo-pyrido-isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation ofp53-miR34a axis.Mol Oncol. 2016 Aug;10(7):1118-32. doi: 10.1016/j.molonc.2016.04.003. Epub 2016 May 20.
• [516] ATXN3 promotes breast cancer metastasis by deubiquitinating KLF4.Cancer Lett. 2019 Dec 28;467:19-28. doi: 10.1016/j.canlet.2019.09.012. Epub 2019 Sep 26.
• [517] The alcohol dehydrogenase 1C(rs698) genotype and breast cancer: a meta-analysis.Asia Pac J Public Health. 2015 Mar;27(2):NP36-46. doi: 10.1177/1010539512446962. Epub 2012 May 31.
• [518] Exosome secretome and mediated signaling in breast cancer patients with nontuberculous mycobacterial disease.Oncotarget. 2017 Mar 14;8(11):18070-18081. doi: 10.18632/oncotarget.14964.
• [519] AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis.Cancer Res. 2015 Sep 1;75(17):3492-504. doi: 10.1158/0008-5472.CAN-15-0088. Epub 2015 Jul 2.
• [520] Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin's lymphoma when compared with breast cancer candidates for fertility preservation.J Assist Reprod Genet. 2018 Jan;35(1):91-97. doi: 10.1007/s10815-017-1059-3. Epub 2017 Oct 6.
• [521] SUN2: A potential therapeutic target in cancer.Oncol Lett. 2019 Feb;17(2):1401-1408. doi: 10.3892/ol.2018.9764. Epub 2018 Nov 27.
• [522] Baihe Zhimu formula attenuates the efficacy of tamoxifen against breast cancer in mice through modulation of CYP450 enzymes.BMC Complement Altern Med. 2019 Sep 4;19(1):240. doi: 10.1186/s12906-019-2651-0.
• [523] Voltage-gated calcium channels: Novel targets for cancer therapy.Oncol Lett. 2017 Aug;14(2):2059-2074. doi: 10.3892/ol.2017.6457. Epub 2017 Jun 22.
• [524] Methylation of the calcium channel regulatory subunit 2-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas.Br J Cancer. 2012 Jul 10;107(2):375-81. doi: 10.1038/bjc.2012.231. Epub 2012 May 29.
• [525] Association of CD27 and CD70 gene polymorphisms with risk of sporadic breast cancer in Chinese women in Heilongjiang Province.Breast Cancer Res Treat. 2012 Jun;133(3):1105-13. doi: 10.1007/s10549-012-1987-7. Epub 2012 Mar 8.
• [526] ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression.Mol Cell. 2012 Mar 30;45(6):764-76. doi: 10.1016/j.molcel.2012.01.029.
• [527] Functional Analysis of Promoter Variants in Genes Involved in Sex Steroid Action, DNA Repair and Cell Cycle Control.Genes (Basel). 2019 Feb 28;10(3):186. doi: 10.3390/genes10030186.
• [528] Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.Histochem Cell Biol. 2019 Oct;152(4):281-291. doi: 10.1007/s00418-019-01794-4. Epub 2019 Jul 27.
• [529] Identifying Cancers Impacted by CDK8/19.Cells. 2019 Aug 3;8(8):821. doi: 10.3390/cells8080821.
• [530] Co-expression of carcinoembryonic antigen-related cell adhesion molecule 6 and 8 inhibits proliferation and invasiveness of breast carcinoma cells.Clin Exp Metastasis. 2019 Oct;36(5):423-432. doi: 10.1007/s10585-019-09981-2. Epub 2019 Jun 20.
• [531] A new prognostic factor of breast cancer: High carboxyl ester lipase expression related to poor survival.Cancer Genet. 2019 Nov;239:54-61. doi: 10.1016/j.cancergen.2019.09.005. Epub 2019 Sep 18.
• [532] Citron kinase (CIT-K) promotes aggressiveness and tumorigenesis of breast cancer cells in vitro and in vivo: preliminary study of the underlying mechanism.Clin Transl Oncol. 2019 Jul;21(7):910-923. doi: 10.1007/s12094-018-02003-9. Epub 2018 Dec 18.
• [533] Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression.J Cell Physiol. 2019 May;234(5):6611-6623. doi: 10.1002/jcp.27402. Epub 2018 Sep 19.
• [534] Yoga has a solid effect on cancer-related fatigue in patients with breast cancer: a meta-analysis.Breast Cancer Res Treat. 2019 Aug;177(1):5-16. doi: 10.1007/s10549-019-05278-w. Epub 2019 May 24.
• [535] DAPK3 suppresses acini morphogenesis and is required for mouse development.Mol Cancer Res. 2015 Feb;13(2):358-67. doi: 10.1158/1541-7786.MCR-14-0333. Epub 2014 Oct 10.
• [536] Potentially functional polymorphisms in aminoacyl-tRNA synthetases genes are associated with breast cancer risk in a Chinese population.Mol Carcinog. 2015 Jul;54(7):577-83. doi: 10.1002/mc.22128. Epub 2014 Feb 9.
• [537] siRNA-mediated knock-down of DFF45 amplifies doxorubicin therapeutic effects in breast cancer cells.Cell Oncol (Dordr). 2013 Dec;36(6):515-26. doi: 10.1007/s13402-013-0157-1. Epub 2013 Nov 26.
• [538] DHPS-dependent hypusination of eIF5A1/2 is necessary for TGF/fibronectin-induced breast cancer metastasis and associates with prognostically unfavorable genomic alterations in TP53.Biochem Biophys Res Commun. 2019 Nov 19;519(4):838-845. doi: 10.1016/j.bbrc.2019.09.075. Epub 2019 Sep 24.
• [539] Association of DNMT1 and DNMT3B polymorphisms with breast cancer risk in Han Chinese women from South China.Genet Mol Res. 2012 Dec 17;11(4):4330-41. doi: 10.4238/2012.September.26.1.
• [540] NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.Breast Cancer Res Treat. 2018 Nov;172(2):469-485. doi: 10.1007/s10549-018-4905-9. Epub 2018 Aug 20.
• [541] PRC2/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ.PLoS One. 2012;7(12):e51239. doi: 10.1371/journal.pone.0051239. Epub 2012 Dec 10.
• [542] Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.Expert Rev Mol Diagn. 2012 Jul;12(6):593-602. doi: 10.1586/erm.12.59.
• [543] Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer.Mol Cancer Ther. 2020 Jan;19(1):63-74. doi: 10.1158/1535-7163.MCT-19-0386. Epub 2019 Sep 23.
• [544] ENSA expression correlates with attenuated tumor propagation in liver cancer.Biochem Biophys Res Commun. 2013 Dec 6;442(1-2):56-61. doi: 10.1016/j.bbrc.2013.10.165. Epub 2013 Nov 8.
• [545] EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.FASEB J. 2019 Apr;33(4):4851-4865. doi: 10.1096/fj.201701561RRRR. Epub 2019 Jan 8.
• [546] Prognostic value of ephrin B receptors in breast cancer: An online survival analysis using the microarray data of 3,554 patients.Oncol Lett. 2019 Jul;18(1):742-750. doi: 10.3892/ol.2019.10363. Epub 2019 May 17.
• [547] MicroRNA-765 alleviates the malignant progression of breast cancer via interacting with EZH1.Am J Transl Res. 2019 Jul 15;11(7):4500-4507. eCollection 2019.
• [548] PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1.Sci Rep. 2019 Jun 19;9(1):8755. doi: 10.1038/s41598-019-45209-9.
• [549] Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study.J Thromb Haemost. 2018 Jul;16(7):1347-1356. doi: 10.1111/jth.14151. Epub 2018 Jun 12.
• [550] Coagulation factor VII is regulated by androgen receptor in breast cancer.Exp Cell Res. 2015 Feb 1;331(1):239-250. doi: 10.1016/j.yexcr.2014.10.002. Epub 2014 Oct 14.
• [551] Suppression subtractive hybridization to identify gene expressions in variant and classic small cell lung cancer cell lines.J Surg Res. 2000 Sep;93(1):108-19. doi: 10.1006/jsre.2000.5957.
• [552] Prognostic significance of FAM83D gene expression across human cancer types.Oncotarget. 2016 Jan 19;7(3):3332-40. doi: 10.18632/oncotarget.6620.
• [553] A rare FANCA gene variation as a breast cancer susceptibility allele in an Iranian population.Mol Med Rep. 2017 Jun;15(6):3983-3988. doi: 10.3892/mmr.2017.6489. Epub 2017 Apr 20.
• [554] Four-and-a-half-LIM protein 1 down-regulates estrogen receptor activity through repression of AKT phosphorylation in human breast cancer cell.Int J Biochem Cell Biol. 2012 Feb;44(2):320-6. doi: 10.1016/j.biocel.2011.11.002. Epub 2011 Nov 10.
• [555] Endothelial follicle-stimulating hormone receptor expression in invasive breast cancer and vascular remodeling at tumor periphery.J Exp Clin Cancer Res. 2015 Feb 5;34(1):12. doi: 10.1186/s13046-015-0128-7.
• [556] GDF5 regulates TGF-dependent angiogenesis in breast carcinoma MCF-7 cells: in vitro and in vivo control by anti-TGF peptides.PLoS One. 2012;7(11):e50342. doi: 10.1371/journal.pone.0050342. Epub 2012 Nov 30.
• [557] Connexin 47 mutations increase risk for secondary lymphedema following breast cancer treatment.Clin Cancer Res. 2012 Apr 15;18(8):2382-90. doi: 10.1158/1078-0432.CCR-11-2303. Epub 2012 Feb 20.
• [558] Glaucocalyxin A activates FasL and induces apoptosis through activation of the JNK pathway in human breast cancer cells.Asian Pac J Cancer Prev. 2013;14(10):5805-10. doi: 10.7314/apjcp.2013.14.10.5805.
• [559] Purification and characterization of -galactosidase from newly isolated Aspergillus terreus (KUBCF1306) and evaluating its efficacy on breast cancer cell line (MCF-7).Bioorg Chem. 2020 Jan;94:103442. doi: 10.1016/j.bioorg.2019.103442. Epub 2019 Nov 15.
• [560] Signaling network involved in the GPC3-induced inhibition of breast cancer progression: role of canonical Wnt pathway.J Cancer Res Clin Oncol. 2018 Dec;144(12):2399-2418. doi: 10.1007/s00432-018-2751-0. Epub 2018 Sep 28.
• [561] Comparative Proteome Analysis of Breast Cancer Tissues Highlights the Importance of Glycerol-3-phosphate Dehydrogenase 1 and Monoacylglycerol Lipase in Breast Cancer Metabolism.Cancer Genomics Proteomics. 2019 Sep-Oct;16(5):377-397. doi: 10.21873/cgp.20143.
• [562] Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression.Breast Cancer Res. 2019 Sep 18;21(1):109. doi: 10.1186/s13058-019-1194-0.
• [563] G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis.EBioMedicine. 2016 Nov;13:132-145. doi: 10.1016/j.ebiom.2016.09.030. Epub 2016 Oct 1.
• [564] Glutamate metabotropic receptor 4 (GRM4) inhibits cell proliferation, migration and invasion in breast cancer and is regulated by miR-328-3p and miR-370-3p.BMC Cancer. 2019 Sep 6;19(1):891. doi: 10.1186/s12885-019-6068-4.
• [565] Differential expression of alternative transcripts of soluble guanylyl cyclase, GYCY1a3 and GUCY1b3 genes, in the malignant and benign breast tumors.Nitric Oxide. 2019 Feb 1;83:65-71. doi: 10.1016/j.niox.2018.12.009. Epub 2018 Dec 28.
• [566] Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer.Oncogene. 2018 Jul;37(29):4013-4032. doi: 10.1038/s41388-018-0243-y. Epub 2018 Apr 26.
• [567] Hydroxycarboxylic acid receptors are essential for breast cancer cells to control their lipid/fatty acid metabolism.Oncotarget. 2015 Aug 14;6(23):19706-20. doi: 10.18632/oncotarget.3565.
• [568] Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes.Nat Commun. 2019 Sep 13;10(1):4192. doi: 10.1038/s41467-019-12222-5.
• [569] Tricho-rhino-phalangeal syndrome 1 protein functions as a scaffold required for ubiquitin-specific protease 4-directed histone deacetylase 2 de-ubiquitination and tumor growth.Breast Cancer Res. 2018 Aug 2;20(1):83. doi: 10.1186/s13058-018-1018-7.
• [570] HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer.Br J Cancer. 2019 Dec;121(12):1039-1049. doi: 10.1038/s41416-019-0625-0. Epub 2019 Nov 6.
• [571] miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8>oncogene.J Cell Physiol. 2020 Mar;235(3):2631-2642. doi: 10.1002/jcp.29167. Epub 2019 Sep 11.
• [572] Study of the antitumour effects and the modulation of immune response by histamine in breast cancer.Br J Cancer. 2020 Feb;122(3):348-360. doi: 10.1038/s41416-019-0636-x. Epub 2019 Nov 21.
• [573] HIPK2 downregulates vimentin and inhibits breast cancer cell invasion.Cancer Biol Ther. 2012 Feb 15;13(4):198-205. doi: 10.4161/cbt.13.4.18694. Epub 2012 Feb 15.
• [574] Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells.Cell Cycle. 2012 Nov 1;11(21):3956-63. doi: 10.4161/cc.22136. Epub 2012 Sep 19.
• [575] Genetic alterations of histone lysine methyltransferases and their significance in breast cancer.Oncotarget. 2015 Feb 10;6(4):2466-82. doi: 10.18632/oncotarget.2967.
• [576] Cathepsin D enhances breast cancer invasion and metastasis through promoting hepsin ubiquitin-proteasome degradation.Cancer Lett. 2018 Dec 1;438:105-115. doi: 10.1016/j.canlet.2018.09.021. Epub 2018 Sep 15.
• [577] The regulation of hydroxysteroid 17-dehydrogenase type 1 and 2 gene expression in breast cancer cell lines by estradiol, dihydrotestosterone, microRNAs, and genes related to breast cancer.Oncotarget. 2017 Jul 10;8(37):62183-62194. doi: 10.18632/oncotarget.19136. eCollection 2017 Sep 22.
• [578] Iduronate-2-Sulfatase-Regulated Dermatan Sulfate Levels Potentiate the Invasion of Breast Cancer Epithelia through Collagen Matrix.J Clin Med. 2019 Sep 30;8(10):1562. doi: 10.3390/jcm8101562.
• [579] Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer.Oncogene. 2019 Apr;38(15):2814-2829. doi: 10.1038/s41388-018-0624-2. Epub 2018 Dec 13.
• [580] Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer.PLoS One. 2012;7(3):e34400. doi: 10.1371/journal.pone.0034400. Epub 2012 Mar 26.
• [581] Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.Clin Cancer Res. 2019 May 1;25(9):2769-2782. doi: 10.1158/1078-0432.CCR-18-2202. Epub 2019 Jan 22.
• [582] Circulating soluble levels of MIF in women with breast cancer in the molecular subtypes: relationship with Th17 cytokine profile.Clin Exp Med. 2019 Aug;19(3):385-391. doi: 10.1007/s10238-019-00559-6. Epub 2019 May 18.
• [583] Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer.Oncotarget. 2016 Jan 12;7(2):1477-85. doi: 10.18632/oncotarget.6395.
• [584] C-reactive protein binds to integrin 2 and Fc receptor I, leading to breast cell adhesion and breast cancer progression.Oncogene. 2018 Jan 4;37(1):28-38. doi: 10.1038/onc.2017.298. Epub 2017 Aug 28.
• [585] Potassium channel KCNA1 modulates oncogene-induced senescence and transformation.Cancer Res. 2013 Aug 15;73(16):5253-65. doi: 10.1158/0008-5472.CAN-12-3690. Epub 2013 Jun 17.
• [586] Kdm4c is Recruited to Mitotic Chromosomes and Is Relevant for Chromosomal Stability, Cell Migration and Invasion of Triple Negative Breast Cancer Cells.Breast Cancer (Auckl). 2018 Jul 27;12:1178223418773075. doi: 10.1177/1178223418773075. eCollection 2018.
• [587] CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction.J Pathol. 2012 Feb;226(3):482-94. doi: 10.1002/path.2998. Epub 2011 Oct 19.
• [588] Synaptopodin-2 suppresses metastasis of triple-negative breast cancer via inhibition of YAP/TAZ activity.J Pathol. 2018 Jan;244(1):71-83. doi: 10.1002/path.4995.
• [589] Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer.Eur J Pharm Biopharm. 2012 May;81(1):24-32. doi: 10.1016/j.ejpb.2012.02.005. Epub 2012 Feb 18.
• [590] Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.JAMA Neurol. 2015 Jan;72(1):58-65. doi: 10.1001/jamaneurol.2014.1973.
• [591] Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells.Oncogene. 2019 Apr;38(15):2860-2875. doi: 10.1038/s41388-018-0618-0. Epub 2018 Dec 14.
• [592] Expression of apoptosis signal-regulating kinase 1 is associated with tight junction protein claudin-6 in cervical carcinoma.Int J Clin Exp Pathol. 2015 May 1;8(5):5535-41. eCollection 2015.
• [593] MAPK genes interact with diet and lifestyle factors to alter risk of breast cancer: the Breast Cancer Health Disparities Study.Nutr Cancer. 2015;67(2):292-304. doi: 10.1080/01635581.2015.990568. Epub 2015 Jan 28.
• [594] Epigenetic regulation by Z-DNA silencer function controls cancer-associated ADAM-12 expression in breast cancer: cross-talk between MeCP2 and NF1 transcription factor family.Cancer Res. 2013 Jan 15;73(2):736-44. doi: 10.1158/0008-5472.CAN-12-2601. Epub 2012 Nov 7.
• [595] Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells.Hum Pathol. 2018 Oct;80:170-178. doi: 10.1016/j.humpath.2018.06.008. Epub 2018 Jun 22.
• [596] Correction: Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer.Oncogene. 2019 May;38(22):4427-4428. doi: 10.1038/s41388-019-0721-x.
• [597] Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.PLoS One. 2016 Jan 11;11(1):e0145647. doi: 10.1371/journal.pone.0145647. eCollection 2016.
• [598] Non-Muscle Myosin II Isoforms Have Different Functions in Matrix Rearrangement by MDA-MB-231 Cells.PLoS One. 2015 Jul 2;10(7):e0131920. doi: 10.1371/journal.pone.0131920. eCollection 2015.
• [599] Additive effects of eukaryotic coexpression plasmid carrying GRIM?9 and LKB1 genes on breast cancer in vitro and in vivo.Mol Med Rep. 2015 Nov;12(5):7665-72. doi: 10.3892/mmr.2015.4393. Epub 2015 Sep 30.
• [600] Natriuretic peptide receptor a promotes breast cancer development by upregulating MMP9.Am J Cancer Res. 2019 Jul 1;9(7):1415-1428. eCollection 2019.
• [601] Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.Breast Cancer Res Treat. 2017 Nov;166(2):593-601. doi: 10.1007/s10549-017-4428-9. Epub 2017 Aug 4.
• [602] ARK5 is associated with the invasive and metastatic potential of human breast cancer cells.J Cancer Res Clin Oncol. 2012 Feb;138(2):247-54. doi: 10.1007/s00432-011-1102-1. Epub 2011 Nov 22.
• [603] Peptidylarginine deiminase 4 overexpression resensitizes MCF-7/ADR breast cancer cells to adriamycin via GSK3/p53 activation.Cancer Manag Res. 2019 Jan 10;11:625-636. doi: 10.2147/CMAR.S191353. eCollection 2019.
• [604] A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.BMC Cancer. 2015 Dec 16;15:978. doi: 10.1186/s12885-015-1957-7.
• [605] Pax-5 Inhibits Breast Cancer Proliferation Through MiR-215 Up-regulation.Anticancer Res. 2018 Sep;38(9):5013-5026. doi: 10.21873/anticanres.12820.
• [606] Proprotein convertase subtilisin/kexin type 6 activates the extracellular signal-regulated kinase 1/2 and Wnt family member 3A pathways and promotes in vitro proliferation, migration and invasion of breast cancer MDA-MB-231 cells.Oncol Lett. 2018 Jul;16(1):145-150. doi: 10.3892/ol.2018.8654. Epub 2018 May 7.
• [607] Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer.Eur J Pharm Sci. 2016 Sep 20;92:39-48. doi: 10.1016/j.ejps.2016.06.020. Epub 2016 Jun 26.
• [608] A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials.Oncotarget. 2015 Oct 13;6(31):31693-701. doi: 10.18632/oncotarget.5562.
• [609] PlGF signaling and macrophage repolarization contribute to the anti-neoplastic effect of metformin.Eur J Pharmacol. 2019 Nov 15;863:172696. doi: 10.1016/j.ejphar.2019.172696. Epub 2019 Sep 25.
• [610] Low expression of PinX1 is associated with malignant behavior in basal-like breast cancer.Oncol Rep. 2017 Jul;38(1):109-119. doi: 10.3892/or.2017.5696. Epub 2017 Jun 2.
• [611] Epigenetic control of phospholipase A2 receptor expression in mammary cancer cells.BMC Cancer. 2015 Dec 16;15:971. doi: 10.1186/s12885-015-1937-y.
• [612] PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes.BMC Cancer. 2019 Jul 30;19(1):747. doi: 10.1186/s12885-019-5949-x.
• [613] Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy.PLoS One. 2013 Oct 3;8(10):e76403. doi: 10.1371/journal.pone.0076403. eCollection 2013.
• [614] Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?.Breast. 2018 Dec;42:68-73. doi: 10.1016/j.breast.2018.08.106. Epub 2018 Aug 29.
• [615] Differential effects of protein kinase C-eta on apoptosis versus senescence.Cell Signal. 2019 Mar;55:1-7. doi: 10.1016/j.cellsig.2018.12.003. Epub 2018 Dec 15.
• [616] Strong expression association between matriptase and its substrate prostasin in breast cancer.J Cell Physiol. 2012 Apr;227(4):1604-9. doi: 10.1002/jcp.22877.
• [617] Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer.J Steroid Biochem Mol Biol. 2012 Nov;132(3-5):331-8. doi: 10.1016/j.jsbmb.2012.07.007. Epub 2012 Aug 19.
• [618] Tumor Suppressor PTPRJ Is a Target of miR-155 in Colorectal Cancer.J Cell Biochem. 2017 Oct;118(10):3391-3400. doi: 10.1002/jcb.25995. Epub 2017 May 3.
• [619] Loss of CSL Unlocks a Hypoxic Response and Enhanced Tumor Growth Potential in Breast Cancer Cells.Stem Cell Reports. 2016 May 10;6(5):643-651. doi: 10.1016/j.stemcr.2016.03.004. Epub 2016 Apr 7.
• [620] Standing in the GAP : To formulate a novel radioimmunotherapy regime to improve the long-term outcome in breast cancer.Immunotherapy. 2018 Feb 1;10(4):255-263. doi: 10.2217/imt-2017-0080.
• [621] Night-shift work, circadian and melatonin pathway related genes and their interaction on breast cancer risk: evidence from a case-control study in Korean women.Sci Rep. 2019 Jul 29;9(1):10982. doi: 10.1038/s41598-019-47480-2.
• [622] A fatty acid-binding protein 7/RXR pathway enhances survival and proliferation in triple-negative breast cancer. J Pathol. 2012 Nov;228(3):310-21. doi: 10.1002/path.4001. Epub 2012 Apr 18.
• [623] Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.Br J Cancer. 2019 Oct;121(9):776-785. doi: 10.1038/s41416-019-0589-0. Epub 2019 Sep 27.
• [624] Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.Exp Cell Res. 2018 Sep 15;370(2):444-453. doi: 10.1016/j.yexcr.2018.07.008. Epub 2018 Jul 5.
• [625] Upregulated tumor sirtuin 2 expression correlates with reduced TNM stage and better overall survival in surgical breast cancer patients.Ir J Med Sci. 2020 Feb;189(1):83-89. doi: 10.1007/s11845-019-02071-y. Epub 2019 Aug 15.
• [626] MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients.Asian Pac J Cancer Prev. 2012;13(2):591-8. doi: 10.7314/apjcp.2012.13.2.591.
• [627] Iodide transport and breast cancer.J Endocrinol. 2015 Oct;227(1):R1-R12. doi: 10.1530/JOE-15-0234. Epub 2015 Aug 18.
• [628] Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer.Br J Cancer. 2020 Jan;122(1):94-101. doi: 10.1038/s41416-019-0626-z. Epub 2019 Dec 10.
• [629] Effect of Carbon-Ion Radiation on Drug Transporters Organic Anion Transporting Polypeptides in Breast Cancer Cells.Radiat Res. 2017 Jun;187(6):689-700. doi: 10.1667/RR14603.1. Epub 2017 Apr 7.
• [630] Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.Breast Cancer Res Treat. 2012 Jan;131(2):653-61. doi: 10.1007/s10549-011-1772-z. Epub 2011 Sep 23.
• [631] Enhanced expression of polysialic acid correlates with malignant phenotype in breast cancer cell lines and clinical tissue samples.Int J Mol Med. 2016 Jan;37(1):197-206. doi: 10.3892/ijmm.2015.2395. Epub 2015 Oct 27.
• [632] Trop2 is a potential biomarker for the promotion of EMT in human breast cancer.Oncol Rep. 2018 Aug;40(2):759-766. doi: 10.3892/or.2018.6496. Epub 2018 Jun 14.
• [633] Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs).Oncotarget. 2016 Aug 23;7(34):55458-55472. doi: 10.18632/oncotarget.10969.
• [634] Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study.Genes Chromosomes Cancer. 2013 Jul;52(7):595-609. doi: 10.1002/gcc.22056. Epub 2013 Apr 30.
• [635] The Antiarrhythmic Drug, Dronedarone, Demonstrates Cytotoxic Effects in Breast Cancer Independent of Thyroid Hormone Receptor Alpha 1 (THR1) Antagonism.Sci Rep. 2018 Nov 8;8(1):16562. doi: 10.1038/s41598-018-34348-0.
• [636] Expression profile of Tolllike receptors in human breast cancer.Mol Med Rep. 2020 Feb;21(2):786-794. doi: 10.3892/mmr.2019.10853. Epub 2019 Nov 26.
• [637] MiR-491 suppresses migration and invasion via directly targeting TPX2 in breast cancer.Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9996-10004. doi: 10.26355/eurrev_201911_19566.
• [638] Deubiquitylation and stabilization of PTEN by USP13.Nat Cell Biol. 2013 Dec;15(12):1486-1494. doi: 10.1038/ncb2874. Epub 2013 Nov 24.
• [639] CyclinB1 deubiquitination by USP14 regulates cell cycle progression in breast cancer.Pathol Res Pract. 2019 Oct;215(10):152592. doi: 10.1016/j.prp.2019.152592. Epub 2019 Aug 17.
• [640] The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer.Tumour Biol. 2015 Jun;36(6):4427-32. doi: 10.1007/s13277-015-3082-2. Epub 2015 Jan 22.
• [641] A protein complex of SCRIB, NOS1AP and VANGL1 regulates cell polarity and migration, and is associated with breast cancer progression.Oncogene. 2012 Aug 9;31(32):3696-708. doi: 10.1038/onc.2011.528. Epub 2011 Dec 19.
• [642] VDAC1 is regulated by BRD4 and contributes to JQ1 resistance in breast cancer.Oncol Lett. 2019 Sep;18(3):2340-2347. doi: 10.3892/ol.2019.10534. Epub 2019 Jun 27.
• [643] The earwax-associated SNP c.538G>A (G180R) in ABCC11 is not associated with breast cancer risk in Europeans.Breast Cancer Res Treat. 2011 Oct;129(3):993-9. doi: 10.1007/s10549-011-1613-0. Epub 2011 Jun 8.
• [644] Overexpression of ABCB4 contributes to acquired doxorubicin resistance in breast cancer cells in vitro. Cancer Chemother Pharmacol. 2018 Aug;82(2):199-210.
• [645] The phytoestrogens daidzein and equol inhibit the drug transporter BCRP/ABCG2 in breast cancer cells: potential chemosensitizing effect.Eur J Nutr. 2019 Feb;58(1):139-150. doi: 10.1007/s00394-017-1578-9. Epub 2017 Nov 3.
• [646] Role of the Drug Transporter ABCC3 in Breast Cancer Chemoresistance.PLoS One. 2016 May 12;11(5):e0155013. doi: 10.1371/journal.pone.0155013. eCollection 2016.
• [647] Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells.Genet Test Mol Biomarkers. 2019 Mar;23(3):156-165. doi: 10.1089/gtmb.2018.0259. Epub 2019 Feb 26.
• [648] Whole exome sequencing analysis of ABCC8 and ABCD2 genes associating with clinical course of breast carcinoma.Physiol Res. 2015;64(Suppl 4):S549-57. doi: 10.33549/physiolres.933212.
• [649] Combined inhibition of EGFR and c-ABL suppresses the growth of fulvestrant-resistant breast cancer cells through miR-375-autophagy axis.Biochem Biophys Res Commun. 2018 Apr 6;498(3):559-565. doi: 10.1016/j.bbrc.2018.03.019. Epub 2018 Mar 6.
• [650] Breast Cancer Screening in Women atHigher-Than-Average Risk: Recommendations From the ACR.J Am Coll Radiol. 2018 Mar;15(3 Pt A):408-414. doi: 10.1016/j.jacr.2017.11.034. Epub 2018 Jan 19.
• [651] Association of vitamin D receptor gene polymorphisms with breast cancer risk in an Egyptian population.Tumour Biol. 2017 Oct;39(10):1010428317727738. doi: 10.1177/1010428317727738.
• [652] A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7.Breast Cancer Res Treat. 2007 Jun;103(2):239-46. doi: 10.1007/s10549-006-9362-1. Epub 2006 Sep 21.
• [653] Urtica dioica inhibits cell growth and induces apoptosis by targeting Ornithine decarboxylase and Adenosine deaminase as key regulatory enzymes in adenosine and polyamines homeostasis in human breast cancer cell lines.Cell Mol Biol (Noisy-le-grand). 2018 Feb 28;64(3):97-102. doi: 10.14715/cmb/2018.64.3.16.
• [654] miR-365 inhibits cell invasion and migration of triple negative breast cancer through ADAM10.J BUON. 2019 Sep-Oct;24(5):1905-1912.
• [655] The xenoestrogens biphenol-A and nonylphenol differentially regulate metalloprotease-mediated shedding of EGFR ligands.J Cell Physiol. 2018 Mar;233(3):2247-2256. doi: 10.1002/jcp.26097. Epub 2017 Aug 25.
• [656] Breast cancer is associated with methylation and expression of the a disintegrin and metalloproteinase domain33 (ADAM33) gene affected by endocrinedisrupting chemicals.Oncol Rep. 2018 Nov;40(5):2766-2777. doi: 10.3892/or.2018.6675. Epub 2018 Aug 30.
• [657] ADAM8 expression in breast cancer derived brain metastases: Functional implications on MMP-9 expression and transendothelial migration in breast cancer cells.Int J Cancer. 2018 Feb 15;142(4):779-791. doi: 10.1002/ijc.31090. Epub 2017 Oct 31.
• [658] MicroRNA-154/ADAM9 axis inhibits the proliferation, migration and invasion of breast cancer cells.Oncol Lett. 2017 Dec;14(6):6969-6975. doi: 10.3892/ol.2017.7021. Epub 2017 Sep 21.
• [659] Cleavage of Fibulin-2 by the aggrecanases ADAMTS-4 and ADAMTS-5 contributes to the tumorigenic potential of breast cancer cells.Oncotarget. 2017 Feb 21;8(8):13716-13729. doi: 10.18632/oncotarget.14627.
• [660] Differential coupling of the PAC1 SV1 splice variant on human colonic tumors to the activation of intracellular cAMP but not intracellular Ca2+ does not activate tumor proliferation.J Mol Neurosci. 2004;22(1-2):83-92. doi: 10.1385/JMN:22:1-2:83.
• [661] A vascular disrupting agent overcomes tumor multidrug resistance by skewing macrophage polarity toward the M1 phenotype.Cancer Lett. 2018 Apr 1;418:239-249. doi: 10.1016/j.canlet.2018.01.016. Epub 2018 Jan 11.
• [662] Adenosine A1 receptor, a target and regulator of estrogen receptoralpha action, mediates the proliferative effects of estradiol in breast cancer.Oncogene. 2010 Feb 25;29(8):1114-22. doi: 10.1038/onc.2009.409. Epub 2009 Nov 23.
• [663] Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells.Gene Ther. 2002 Jul;9(13):867-78. doi: 10.1038/sj.gt.3301703.
• [664] Prognostic significance of - and 2-adrenoceptor gene expression in breast cancer patients.Br J Clin Pharmacol. 2019 Sep;85(9):2143-2154. doi: 10.1111/bcp.14030. Epub 2019 Jul 31.
• [665] Single nucleotide polymorphisms of let-7-related genes increase susceptibility to breast cancer.Am J Transl Res. 2019 Mar 15;11(3):1748-1759. eCollection 2019.
• [666] Hormones of pregnancy, alpha-feto protein, and reduction of breast cancer risk. Adv Exp Med Biol. 2008;617:477-84. doi: 10.1007/978-0-387-69080-3_47.
• [667] miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2.J Exp Clin Cancer Res. 2019 Jan 21;38(1):26. doi: 10.1186/s13046-019-1024-3.
• [668] The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy.J Hematol Oncol. 2019 Jul 24;12(1):81. doi: 10.1186/s13045-019-0747-0.
• [669] Lack of fetuin-A (alpha2-HS-glycoprotein) reduces mammary tumor incidence and prolongs tumor latency via the transforming growth factor-beta signaling pathway in a mouse model of breast cancer.Am J Pathol. 2010 Nov;177(5):2635-44. doi: 10.2353/ajpath.2010.100177. Epub 2010 Sep 16.
• [670] Effects of AIF-1 inflammatory factors on the regulation of proliferation of breast cancer cells.J Biol Regul Homeost Agents. 2019 Jul-Aug;33(4):1085-1095.
• [671] Distinct functions of AKT isoforms in breast cancer: a comprehensive review.Cell Commun Signal. 2019 Nov 21;17(1):154. doi: 10.1186/s12964-019-0450-3.
• [672] Downregulation of delta-aminolevulinate dehydratase is associated with poor prognosis inpatients with breast cancer.Cancer Sci. 2017 Apr;108(4):604-611. doi: 10.1111/cas.13180. Epub 2017 Apr 12.
• [673] Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth.Biochim Biophys Acta Mol Cell Res. 2019 Aug;1866(8):1338-1352. doi: 10.1016/j.bbamcr.2019.03.010. Epub 2019 Mar 21.
• [674] A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer.Nat Genet. 2018 Jul;50(7):968-978. doi: 10.1038/s41588-018-0132-x. Epub 2018 Jun 18.
• [675] ALOX12 inhibition sensitizes breast cancer to chemotherapy via AMPK activation and inhibition of lipid synthesis.Biochem Biophys Res Commun. 2019 Jun 18;514(1):24-30. doi: 10.1016/j.bbrc.2019.04.101. Epub 2019 Apr 20.
• [676] TRIM32 promotes proliferation and confers chemoresistance to breast cancer cells through activation of the NF-B pathway.J Cancer. 2018 Apr 5;9(8):1349-1356. doi: 10.7150/jca.22390. eCollection 2018.
• [677] Progesterone induced expression of alkaline phosphatase is associated with a secretory phenotype in T47D breast cancer cells.Biochem Biophys Res Commun. 1993 May 14;192(3):1066-72. doi: 10.1006/bbrc.1993.1525.
• [678] Transcriptional regulation of tenascin-W by TGF-beta signaling in the bone metastatic niche of breast cancer cells.Int J Cancer. 2015 Oct 15;137(8):1842-54. doi: 10.1002/ijc.29565. Epub 2015 Apr 29.
• [679] The Effect of Counseling on Breast Cancer Awareness in Rural Iranian Women: a Randomized Controlled Clinical Trial.J Cancer Educ. 2019 Dec;34(6):1083-1091. doi: 10.1007/s13187-018-1411-z.
• [680] Complementary actions of melatonin on angiogenic factors, the angiopoietin/Tie2 axis and VEGF, in cocultures of human endothelial and breast cancer cells.Oncol Rep. 2018 Jan;39(1):433-441. doi: 10.3892/or.2017.6070. Epub 2017 Nov 2.
• [681] Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4.Oncogene. 2019 Mar;38(13):2351-2363. doi: 10.1038/s41388-018-0592-6. Epub 2018 Dec 5.
• [682] A mutual activation loop between the Ca(2+)-activated chloride channel TMEM16A and EGFR/STAT3 signaling promotes breast cancer tumorigenesis.Cancer Lett. 2019 Jul 28;455:48-59. doi: 10.1016/j.canlet.2019.04.027. Epub 2019 Apr 28.
• [683] Exome analysis reveals differentially mutated gene signatures of stage, grade and subtype in breast cancers.PLoS One. 2015 Mar 24;10(3):e0119383. doi: 10.1371/journal.pone.0119383. eCollection 2015.
• [684] ANXA2 expression in African American triple-negative breast cancer patients.Breast Cancer Res Treat. 2019 Feb;174(1):113-120. doi: 10.1007/s10549-018-5030-5. Epub 2018 Nov 26.
• [685] ABP 980: A Trastuzumab Biosimilar.BioDrugs. 2018 Oct;32(5):511-514. doi: 10.1007/s40259-018-0305-2.
• [686] Vascular adhesion protein-1 as indicator of breast cancer tumor aggressiveness and invasiveness.APMIS. 2018 Sep;126(9):755-761. doi: 10.1111/apm.12885.
• [687] Panobinostat (LBH589) inhibits Wnt/-catenin signaling pathway via upregulating APCL expression in breast cancer.Cell Signal. 2019 Jul;59:62-75. doi: 10.1016/j.cellsig.2019.03.014. Epub 2019 Mar 14.
• [688] Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.Oncotarget. 2017 Jun 6;8(23):37250-37262. doi: 10.18632/oncotarget.16763.
• [689] What is normal? Apelin and VEGFA, drivers of tumor vessel abnormality.EMBO Mol Med. 2019 Aug;11(8):e10892. doi: 10.15252/emmm.201910892. Epub 2019 Jul 18.
• [690] HDL and LDL: Potential New Players in Breast Cancer Development.J Clin Med. 2019 Jun 14;8(6):853. doi: 10.3390/jcm8060853.
• [691] European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables. Breast Cancer Somatic Genetics Consortium.Br J Cancer. 1999 May;80(5-6):879-82. doi: 10.1038/sj.bjc.6690435.
• [692] Amyloid precursor protein promotes the migration and invasion of breast cancer cells by regulating the MAPK signaling pathway.Int J Mol Med. 2020 Jan;45(1):162-174. doi: 10.3892/ijmm.2019.4404. Epub 2019 Nov 13.
• [693] Decreased miR-320 expression is associated with breast cancer progression, cell migration, and invasiveness via targeting Aquaporin 1.Acta Biochim Biophys Sin (Shanghai). 2018 May 1;50(5):473-480. doi: 10.1093/abbs/gmy023.
• [694] The effects of beta-estradiol on Raf activity, cell cycle progression and growth factor synthesis in the MCF-7 breast cancer cell line. Cancer Biol Ther. 2002 May-Jun;1(3):256-62. doi: 10.4161/cbt.77.
• [695] Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice.Breast Cancer Res Treat. 2020 Feb;179(3):653-660. doi: 10.1007/s10549-019-05507-2. Epub 2019 Dec 14.
• [696] Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line.Cell Cycle. 2008 Oct;7(19):3074-82. doi: 10.4161/cc.7.19.6777. Epub 2008 Oct 12.
• [697] miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer.Cancer Lett. 2019 Jul 10;454:224-233. doi: 10.1016/j.canlet.2019.04.006. Epub 2019 Apr 17.
• [698] ErbB4 receptor polymorphism 2368A>C and risk of breast cancer.Breast. 2018 Dec;42:157-163. doi: 10.1016/j.breast.2018.10.002. Epub 2018 Oct 9.
• [699] ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis.Mol Cancer. 2019 Nov 7;18(1):156. doi: 10.1186/s12943-019-1077-0.
• [700] Three gold indicators for breast cancer prognosis: a case-control study with ROC analysis for novel ratios related to CBC with (ALP and LDH).Mol Biol Rep. 2019 Apr;46(2):2013-2027. doi: 10.1007/s11033-019-04650-9. Epub 2019 Jan 31.
• [701] Stimulation of ATF3 interaction with Smad4 via TGF-1 for matrix metalloproteinase 13 gene activation in human breast cancer cells.Int J Biol Macromol. 2019 Aug 1;134:954-961. doi: 10.1016/j.ijbiomac.2019.05.062. Epub 2019 May 10.
• [702] Autophagy-related 7 modulates tumor progression in triple-negative breast cancer.Lab Invest. 2019 Sep;99(9):1266-1274. doi: 10.1038/s41374-019-0249-2. Epub 2019 Apr 15.
• [703] PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.Invest New Drugs. 2018 Oct;36(5):763-772. doi: 10.1007/s10637-018-0563-3. Epub 2018 Mar 5.
• [704] Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma.Jpn J Cancer Res. 2002 Jan;93(1):70-7. doi: 10.1111/j.1349-7006.2002.tb01202.x.
• [705] Withaferin A inhibits expression of ataxia telangiectasia and Rad3-related kinase and enhances sensitivity of human breast cancer cells to cisplatin.Mol Carcinog. 2019 Nov;58(11):2139-2148. doi: 10.1002/mc.23104. Epub 2019 Aug 22.
• [706] AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer.Oncotarget. 2019 Mar 12;10(21):2055-2067. doi: 10.18632/oncotarget.26725. eCollection 2019 Mar 12.
• [707] A novel aspartic protease gene, ALP56, is up-regulated in human breast cancer independently from the cathepsin D gene.Breast Cancer Res Treat. 2003 Mar;78(1):37-44. doi: 10.1023/a:1022149226430.
• [708] Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism.Nature. 2019 Apr;568(7751):254-258. doi: 10.1038/s41586-019-1005-x. Epub 2019 Mar 6.
• [709] Expression of MAGE and BAGE genes in Japanese breast cancers.Ann Oncol. 1997 Apr;8(4):369-72. doi: 10.1023/a:1008255630202.
• [710] Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.Sci Transl Med. 2017 Aug 2;9(401):eaam7049. doi: 10.1126/scitranslmed.aam7049.
• [711] BAP1 expression is prognostic in breast and uveal melanoma but not colon cancer and is highly positively correlated with RBM15B and USP19.PLoS One. 2019 Feb 4;14(2):e0211507. doi: 10.1371/journal.pone.0211507. eCollection 2019.
• [712] In vitro and in silico anticancer activity of amygdalin on the SK-BR-3 human breast cancer cell line.Mol Biol Rep. 2019 Dec;46(6):6361-6370. doi: 10.1007/s11033-019-05080-3. Epub 2019 Oct 3.
• [713] Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis.J Clin Invest. 2018 Jan 2;128(1):531-544. doi: 10.1172/JCI93707. Epub 2017 Dec 11.
• [714] Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function.Biochem Biophys Res Commun. 2017 Apr 29;486(2):224-231. doi: 10.1016/j.bbrc.2017.02.101. Epub 2017 Feb 22.
• [715] Transcriptional hallmarks of cancer cell lines reveal an emerging role of branched chain amino acid catabolism.Sci Rep. 2017 Aug 10;7(1):7820. doi: 10.1038/s41598-017-08329-8.
• [716] BCL11A enhances stemness and promotes progression by activating Wnt/-catenin signaling in breast cancer.Cancer Manag Res. 2019 Apr 11;11:2997-3007. doi: 10.2147/CMAR.S199368. eCollection 2019.
• [717] Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis.PLoS One. 2010 Jan 6;5(1):e8604. doi: 10.1371/journal.pone.0008604.
• [718] Bcl6/p53 expression, macrophages/mast cells infiltration and microvascular density in invasive breast carcinoma.Oncotarget. 2018 Apr 27;9(32):22727-22740. doi: 10.18632/oncotarget.25220. eCollection 2018 Apr 27.
• [719] Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy.Mol Neurobiol. 2019 Jul;56(7):4741-4750. doi: 10.1007/s12035-018-1410-4. Epub 2018 Oct 31.
• [720] Tumor-dependent Effects of Proteoglycans and Various Glycosaminoglycan Synthesizing Enzymes and Sulfotransferases on Patients' Outcome.Curr Cancer Drug Targets. 2019;19(3):210-221. doi: 10.2174/1568009618666180706165845.
• [721] IRF-1 inhibits NF-B activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.Cancer Biol Ther. 2015;16(7):1029-41. doi: 10.1080/15384047.2015.1046646.
• [722] BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.Breast Cancer Res Treat. 2016 Oct;159(3):499-511. doi: 10.1007/s10549-016-3961-2. Epub 2016 Sep 3.
• [723] Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer.Nat Commun. 2016 Jan 12;7:10318. doi: 10.1038/ncomms10318.
• [724] Expression of bone morphogenetic protein-10 (BMP10) in human urothelial cancer of the bladder and its effects on the aggressiveness of bladder cancer cells in vitro.Anticancer Res. 2013 May;33(5):1917-25.
• [725] Microcalcification and BMP-2 in breast cancer: correlation with clinicopathological features and outcomes.Onco Targets Ther. 2019 Mar 15;12:2023-2033. doi: 10.2147/OTT.S187835. eCollection 2019.
• [726] Biological effects of BMP7 on small-cell lung cancer cells and its bone metastasis.Int J Oncol. 2018 Sep;53(3):1354-1362. doi: 10.3892/ijo.2018.4469. Epub 2018 Jul 4.
• [727] BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation.Mol Oncol. 2015 Jan;9(1):179-91. doi: 10.1016/j.molonc.2014.08.004. Epub 2014 Aug 23.
• [728] Silencing of Apoptosis-Inducing factor and poly(ADP-ribose) glycohydrolase reveals novel roles in breast cancer cell death after chemotherapy.Mol Cancer. 2012 Jul 29;11:48. doi: 10.1186/1476-4598-11-48.
• [729] BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.Clin Breast Cancer. 2020 Feb;20(1):41-50.e8. doi: 10.1016/j.clbc.2019.08.005. Epub 2019 Aug 29.
• [730] Distinct Roles for BET Family Members in Estrogen Receptor Enhancer Function and Gene Regulation in Breast Cancer Cells.Mol Cancer Res. 2019 Dec;17(12):2356-2368. doi: 10.1158/1541-7786.MCR-19-0393. Epub 2019 Sep 24.
• [731] Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail.Cell Death Differ. 2020 Jan;27(1):255-268. doi: 10.1038/s41418-019-0353-2. Epub 2019 May 21.
• [732] Bromodomaincontaining protein7 sensitizes breast cancer cells to paclitaxel by activating Bcl2antagonist/killer protein.Oncol Rep. 2019 Mar;41(3):1487-1496. doi: 10.3892/or.2018.6951. Epub 2018 Dec 21.
• [733] B49, a BST-2-based peptide, inhibits adhesion and growth of breast cancer cells.Sci Rep. 2018 Mar 9;8(1):4305. doi: 10.1038/s41598-018-22364-z.
• [734] Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.Mol Cancer Ther. 2016 Sep;15(9):2198-208. doi: 10.1158/1535-7163.MCT-15-0813. Epub 2016 Jun 2.
• [735] Association of BTLA gene polymorphisms with the risk of malignant breast cancer in Chinese women of Heilongjiang Province.Breast Cancer Res Treat. 2010 Feb;120(1):195-202. doi: 10.1007/s10549-009-0462-6. Epub 2009 Jul 8.
• [736] C1QBP Promotes Homologous Recombination by Stabilizing MRE11 and Controlling the Assembly and Activation of MRE11/RAD50/NBS1 Complex.Mol Cell. 2019 Sep 19;75(6):1299-1314.e6. doi: 10.1016/j.molcel.2019.06.023. Epub 2019 Jul 25.
• [737] The Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1.J Immunol. 2017 Apr 1;198(7):2989-2999. doi: 10.4049/jimmunol.1602057. Epub 2017 Feb 22.
• [738] TFAP2C regulates carbonic anhydrase XII in human breast cancer.Oncogene. 2020 Feb;39(6):1290-1301. doi: 10.1038/s41388-019-1062-5. Epub 2019 Oct 21.
• [739] Comparison of Framingham risk score and chest-CT identified coronary artery calcification in breast cancer patients to predict cardiovascular events.Int J Cardiol. 2019 Aug 15;289:138-143. doi: 10.1016/j.ijcard.2019.01.056. Epub 2019 Jan 23.
• [740] Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells.Oncol Rep. 2019 Apr;41(4):2585-2594. doi: 10.3892/or.2019.7001. Epub 2019 Feb 5.
• [741] Assessing the value of CAN-gene mutations using MALDI-TOF MS.J Cancer Res Clin Oncol. 2011 Aug;137(8):1239-44. doi: 10.1007/s00432-011-0990-4. Epub 2011 Jun 21.
• [742] Applying a new computer-aided detection scheme generated imaging marker to predict short-term breast cancer risk.Phys Med Biol. 2018 May 15;63(10):105005. doi: 10.1088/1361-6560/aabefe.
• [743] A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.Nat Genet. 2010 Oct;42(10):885-92. doi: 10.1038/ng.669. Epub 2010 Sep 19.
• [744] CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer.Nat Commun. 2019 Jun 4;10(1):2450. doi: 10.1038/s41467-019-10424-5.
• [745] LINC01585 functions as a regulator of gene expression by the CAMP/CREB signaling pathway in breast cancer.Gene. 2019 Feb 5;684:139-148. doi: 10.1016/j.gene.2018.10.063. Epub 2018 Oct 23.
• [746] Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib.Oncotarget. 2018 Sep 7;9(70):33382-33395. doi: 10.18632/oncotarget.26078. eCollection 2018 Sep 7.
• [747] Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer.Diagn Pathol. 2018 May 30;13(1):36. doi: 10.1186/s13000-018-0715-y.
• [748] Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer.EMBO Rep. 2020 Feb 5;21(2):e48597. doi: 10.15252/embr.201948597. Epub 2019 Dec 12.
• [749] MicroRNA-421 inhibits caspase-10 expression and promotes breast cancer progression.Neoplasma. 2018;65(1):49-54. doi: 10.4149/neo_2018_170306N159.
• [750] Importance of transcript levels of caspase-2 isoforms S and L for breast carcinoma progression.Future Oncol. 2013 Mar;9(3):427-38. doi: 10.2217/fon.12.200.
• [751] A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.Anticancer Res. 2004 Jan-Feb;24(1):123-31.
• [752] Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers.J Mol Med (Berl). 2018 Oct;96(10):1025-1037. doi: 10.1007/s00109-018-1675-0. Epub 2018 Aug 1.
• [753] ECRG4 acts as a tumor suppressor gene frequently hypermethylated in human breast cancer.Biosci Rep. 2019 May 10;39(5):BSR20190087. doi: 10.1042/BSR20190087. Print 2019 May 31.
• [754] miR-124-3p functions as a tumor suppressor in breast cancer by targeting CBL.BMC Cancer. 2016 Nov 15;16(1):826. doi: 10.1186/s12885-016-2862-4.
• [755] Low serum gastrin associated with ER(+) breast cancer development via inactivation of CCKBR/ERK/P65 signaling.BMC Cancer. 2018 Aug 16;18(1):824. doi: 10.1186/s12885-018-4717-7.
• [756] Induction of the MCP chemokine cluster cascade in the periphery by cancer cell-derived Ccl3.Cancer Lett. 2017 Mar 28;389:49-58. doi: 10.1016/j.canlet.2016.12.028. Epub 2016 Dec 29.
• [757] Down-regulation of CCL17 in cancer-associated fibroblasts inhibits cell migration and invasion of breast cancer through ERK1/2 pathway.Cancer Manag Res. 2019 Aug 7;11:7439-7453. doi: 10.2147/CMAR.S211651. eCollection 2019.
• [758] Effects of Notch signalling on the expression of SEMA3C, HMGA2, CXCL14, CXCR7, and CCL20 in breast cancer.Turk J Biol. 2019 Feb 7;43(1):70-76. doi: 10.3906/biy-1808-58. eCollection 2019.
• [759] Significant association between high serum CCL5 levels and better disease-free survival of patients with early breast cancer.Cancer Sci. 2020 Jan;111(1):209-218. doi: 10.1111/cas.14234. Epub 2019 Dec 16.
• [760] Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion.Front Oncol. 2019 Oct 23;9:1074. doi: 10.3389/fonc.2019.01074. eCollection 2019.
• [761] In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors.J Mammary Gland Biol Neoplasia. 2017 Sep;22(3):203-214. doi: 10.1007/s10911-017-9384-9. Epub 2017 Aug 18.
• [762] NEK5 promotes breast cancer cell proliferation through up-regulation of Cyclin A2.Mol Carcinog. 2019 Jun;58(6):933-943. doi: 10.1002/mc.22982. Epub 2019 Feb 22.
• [763] Prognostic role of cyclin D2/D3 in multiple human malignant neoplasms: A systematic review and meta-analysis.Cancer Med. 2019 Jun;8(6):2717-2729. doi: 10.1002/cam4.2152. Epub 2019 Apr 5.
• [764] Significant prognostic values of differentially expressed-aberrantly methylated hub genes in breast cancer.J Cancer. 2019 Oct 21;10(26):6618-6634. doi: 10.7150/jca.33433. eCollection 2019.
• [765] CCR2 Chemokine Receptors Enhance Growth and Cell-Cycle Progression of Breast Cancer Cells through SRC and PKC Activation.Mol Cancer Res. 2019 Feb;17(2):604-617. doi: 10.1158/1541-7786.MCR-18-0750. Epub 2018 Nov 16.
• [766] Intratumoral expression of CCR3 in breast cancer is associated with improved relapse-free survival in luminal-like disease.Oncotarget. 2016 May 10;7(19):28570-8. doi: 10.18632/oncotarget.8680.
• [767] HIC1 deletion promotes breast cancer progression by activating tumor cell/fibroblast crosstalk.J Clin Invest. 2018 Dec 3;128(12):5235-5250. doi: 10.1172/JCI99974. Epub 2018 Oct 22.
• [768] Association analysis and allelic distribution of deletion in CC chemokine receptor 5 gene (CCR532) among breast cancer patients of Pakistan.Mol Biol Rep. 2019 Apr;46(2):2387-2394. doi: 10.1007/s11033-019-04699-6. Epub 2019 Mar 8.
• [769] MiR-21 controls in situ expansion of CCR6?regulatory T cells through PTEN/AKT pathway in breast cancer.Immunol Cell Biol. 2015 Sep;93(8):753-64. doi: 10.1038/icb.2015.37. Epub 2015 Mar 4.
• [770] EVI? acts as an oncogene and positively regulates calreticulin in breast cancer.Mol Med Rep. 2019 Mar;19(3):1645-1653. doi: 10.3892/mmr.2018.9796. Epub 2018 Dec 24.
• [771] 4T1 Mammary Carcinoma Colonization of Metastatic Niches Is Accelerated by Obesity.Front Oncol. 2019 Sep 20;9:685. doi: 10.3389/fonc.2019.00685. eCollection 2019.
• [772] PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.Hum Pathol. 2019 Apr;86:108-114. doi: 10.1016/j.humpath.2018.12.007. Epub 2019 Jan 8.
• [773] CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome.Histopathology. 2008 Jan;52(2):203-12. doi: 10.1111/j.1365-2559.2007.02919.x.
• [774] Antibody-based cell-surface proteome profiling of metastatic breast cancer primary explants and cell lines.Cytometry A. 2018 Apr;93(4):448-457. doi: 10.1002/cyto.a.23300. Epub 2018 Mar 2.
• [775] Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation.Oncogene. 2019 Jan;38(1):88-102. doi: 10.1038/s41388-018-0407-9. Epub 2018 Aug 6.
• [776] Expression of ICOSL is associated with decreased survival in invasive breast cancer.PeerJ. 2019 May 16;7:e6903. doi: 10.7717/peerj.6903. eCollection 2019.
• [777] (89)Zr-Cobalamin PET Tracer: Synthesis, Cellular Uptake, and Use for Tumor Imaging.ACS Omega. 2017 Oct 31;2(10):6314-6320. doi: 10.1021/acsomega.7b01180. Epub 2017 Oct 2.
• [778] Immunohistochemical Expression of Microfibrillar-associated Protein 5 (MFAP5) in Invasive Breast Carcinoma of No Special Type.Appl Immunohistochem Mol Morphol. 2019 Oct;27(9):649-657. doi: 10.1097/PAI.0000000000000686.
• [779] Endocytosis of very low-density lipoproteins: an unexpected mechanism for lipid acquisition by breast cancer cells.J Lipid Res. 2020 Feb;61(2):205-218. doi: 10.1194/jlr.RA119000327. Epub 2019 Dec 5.
• [780] BRCA2-positive spinal intramedullary ovarian metastatic disease: case report.Spine J. 2016 Mar;16(3):e201-7. doi: 10.1016/j.spinee.2015.10.053. Epub 2015 Nov 10.
• [781] T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants.Ann Oncol. 2019 Jun 1;30(6):934-944. doi: 10.1093/annonc/mdz112.
• [782] A replication-incompetent CD154/40L recombinant vaccinia virus induces direct and macrophage-mediated antitumor effects in vitro and in vivo.Oncoimmunology. 2019 Feb 14;8(5):e1568162. doi: 10.1080/2162402X.2019.1568162. eCollection 2019.
• [783] Computer-Aided Discovery of Small Molecule Inhibitors of Transcriptional Activity of TLX (NR2E1) Nuclear Receptor.Molecules. 2018 Nov 14;23(11):2967. doi: 10.3390/molecules23112967.
• [784] Anticancer effects of anti-CD47 immunotherapy in vivo.Oncoimmunology. 2018 Dec 11;8(3):1550619. doi: 10.1080/2162402X.2018.1550619. eCollection 2019.
• [785] CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity.Oncol Lett. 2017 Sep;14(3):2961-2969. doi: 10.3892/ol.2017.6555. Epub 2017 Jul 8.
• [786] Breast cancer stem cells characterized by CD70 expression preferentially metastasize to the lungs.Breast Cancer. 2018 Nov;25(6):706-716. doi: 10.1007/s12282-018-0880-6. Epub 2018 Jun 14.
• [787] Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.Cancer Res. 2010 Aug 1;70(15):6150-60. doi: 10.1158/0008-5472.CAN-09-2758. Epub 2010 Jul 14.
• [788] Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer.Cancer Res. 2015 Apr 1;75(7):1504-15. doi: 10.1158/0008-5472.CAN-14-2341. Epub 2015 Feb 2.
• [789] CDC25A pathway toward tumorigenesis: Molecular targets of CDC25A in cell-cycle regulation.J Cell Biochem. 2019 Mar;120(3):2919-2928. doi: 10.1002/jcb.26838. Epub 2018 Nov 15.
• [790] CDC25 phosphatases as potential human oncogenes.Science. 1995 Sep 15;269(5230):1575-7. doi: 10.1126/science.7667636.
• [791] Association and clinicopathologic significance of p38MAPK-ERK-JNK-CDC25C with polyploid giant cancer cell formation.Med Oncol. 2019 Nov 16;37(1):6. doi: 10.1007/s12032-019-1330-9.
• [792] CDCA8 is a key mediator of estrogen-stimulated cell proliferation in breast cancer cells.Gene. 2019 Jun 30;703:1-6. doi: 10.1016/j.gene.2019.04.006. Epub 2019 Apr 3.
• [793] Cadherins: The Superfamily Critically Involved in Breast Cancer.Curr Pharm Des. 2016;22(5):616-38. doi: 10.2174/138161282205160127095338.
• [794] Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.Oncotarget. 2016 Sep 27;7(39):63537-63548. doi: 10.18632/oncotarget.11535.
• [795] The expression of VE-cadherin in breast cancer cells modulates cell dynamics as a function of tumor differentiation and promotes tumor-endothelial cell interactions.Histochem Cell Biol. 2018 Jan;149(1):15-30. doi: 10.1007/s00418-017-1619-8. Epub 2017 Nov 15.
• [796] Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.Breast Cancer Res. 2015;17:19. doi: 10.1186/s13058-015-0524-0. Epub 2015 Feb 11.
• [797] The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response.Oncotarget. 2018 Jun 29;9(50):29508-29524. doi: 10.18632/oncotarget.25686. eCollection 2018 Jun 29.
• [798] Loss of Cdk5 in breast cancer cells promotes ROS-mediated cell death through dysregulation of the mitochondrial permeability transition pore.Oncogene. 2018 Mar;37(13):1788-1804. doi: 10.1038/s41388-017-0103-1. Epub 2018 Jan 19.
• [799] Identification of stage-specific breast markers using quantitative proteomics.J Proteome Res. 2013 Dec 6;12(12):5696-708. doi: 10.1021/pr400662k. Epub 2013 Oct 29.
• [800] Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.Oncogene. 2020 Jan;39(1):50-63. doi: 10.1038/s41388-019-0953-9. Epub 2019 Aug 28.
• [801] The anticancer effect of the TLR4 inhibition using TAK-242 (resatorvid) either as a single agent or in combination with chemotherapy: A novel therapeutic potential for breast cancer.J Cell Biochem. 2020 Feb;121(2):1623-1634. doi: 10.1002/jcb.29397. Epub 2019 Sep 18.
• [802] The adaptor SASH1 acts through NOTCH1 and its inhibitor DLK1 in a 3D model of lumenogenesis involving CEACAM1.Exp Cell Res. 2017 Oct 15;359(2):384-393. doi: 10.1016/j.yexcr.2017.08.022. Epub 2017 Aug 18.
• [803] The association of five preoperative serum tumor markers and pathological features in patients with breast cancer.J Clin Lab Anal. 2019 Jun;33(5):e22875. doi: 10.1002/jcla.22875. Epub 2019 Mar 6.
• [804] A novel PAK4-CEBPB-CLDN4 axis involving in breast cancer cell migration and invasion.Biochem Biophys Res Commun. 2019 Apr 2;511(2):404-408. doi: 10.1016/j.bbrc.2019.02.070. Epub 2019 Feb 23.
• [805] Ceramide kinase promotes tumor cell survival and mammary tumor recurrence.Cancer Res. 2014 Nov 1;74(21):6352-63. doi: 10.1158/0008-5472.CAN-14-1292. Epub 2014 Aug 27.
• [806] A Mendelian randomization study of the effects of blood lipids on breast cancer risk.Nat Commun. 2018 Sep 27;9(1):3957. doi: 10.1038/s41467-018-06467-9.
• [807] Intense dose-dense epirubicin, paclitaxel, cyclophosphamideversus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.Eur J Cancer. 2019 Jan;106:181-192. doi: 10.1016/j.ejca.2018.10.015. Epub 2018 Dec 5.
• [808] Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium.Int J Cancer. 2017 Nov 1;141(9):1830-1840. doi: 10.1002/ijc.30859. Epub 2017 Aug 11.
• [809] CFP suppresses breast cancer cell growth by TES-mediated upregulation of the transcription factor DDIT3.Oncogene. 2019 Jun;38(23):4560-4573. doi: 10.1038/s41388-019-0739-0. Epub 2019 Feb 12.
• [810] lncRNA CASC9 positively regulates CHK1 to promote breast cancer cell proliferation and survival through sponging the miR?95/497 cluster.Int J Oncol. 2019 May;54(5):1665-1675. doi: 10.3892/ijo.2019.4734. Epub 2019 Feb 28.
• [811] Efficacy and safety of compound Kushen injection combined with chemotherapy on postoperative Patients with breast cancer: A meta-analysis of randomized controlled trials.Medicine (Baltimore). 2019 Jan;98(3):e14024. doi: 10.1097/MD.0000000000014024.
• [812] In silico design, synthesis and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents.Comput Biol Chem. 2019 Dec;83:107156. doi: 10.1016/j.compbiolchem.2019.107156. Epub 2019 Nov 1.
• [813] Cholinergic Receptor Nicotinic Alpha 5 (CHRNA5) RNAi is associated with cell cycle inhibition, apoptosis, DNA damage response and drug sensitivity in breast cancer.PLoS One. 2018 Dec 13;13(12):e0208982. doi: 10.1371/journal.pone.0208982. eCollection 2018.
• [814] Long noncoding RNA HOTAIR promotes invasion of breast cancer cells through chondroitin sulfotransferase CHST15.Int J Cancer. 2019 Nov 1;145(9):2478-2487. doi: 10.1002/ijc.32319. Epub 2019 Apr 26.
• [815] Expression of the Ca2+-activated chloride channel genes CLCA1 and CLCA2 is downregulated in human colorectal cancer.DNA Cell Biol. 2001 Jun;20(6):331-8. doi: 10.1089/10445490152122442.
• [816] Dichotomous roles of claudins as tumor promoters or suppressors: lessons from knockout mice.Cell Mol Life Sci. 2019 Dec;76(23):4663-4672. doi: 10.1007/s00018-019-03238-7. Epub 2019 Jul 23.
• [817] Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling.Cell Cycle. 2010 Jun 15;9(12):2412-22. doi: 10.4161/cc.9.12.11989. Epub 2010 Jun 15.
• [818] CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer.Cancer Res. 2015 Apr 1;75(7):1516-26. doi: 10.1158/0008-5472.CAN-14-2443. Epub 2015 Feb 10.
• [819] A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells.Cell Death Dis. 2015 Mar 12;6(3):e1686. doi: 10.1038/cddis.2015.25.
• [820] Aberrant fucosylation enables breast cancer clusterin to interact with dendritic cell-specific ICAM-grabbing non-integrin (DC-SIGN).Oncoimmunology. 2019 Jun 24;8(9):e1629257. doi: 10.1080/2162402X.2019.1629257. eCollection 2019.
• [821] MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.Mol Cancer. 2019 Mar 18;18(1):42. doi: 10.1186/s12943-019-0988-0.
• [822] Engineering a Nanostructured Nucleolin-Binding Peptide for Intracellular Drug Delivery in Triple-Negative Breast Cancer Stem Cells.ACS Appl Mater Interfaces. 2020 Feb 5;12(5):5381-5388. doi: 10.1021/acsami.9b15803. Epub 2020 Jan 21.
• [823] Cationic Polymeric Nanoparticle Delivering CCR2 siRNA to Inflammatory Monocytes for Tumor Microenvironment Modification and Cancer Therapy.Mol Pharm. 2018 Sep 4;15(9):3642-3653. doi: 10.1021/acs.molpharmaceut.7b00997. Epub 2018 Jan 26.
• [824] Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer.Oncotarget. 2017 May 2;8(18):29668-29678. doi: 10.18632/oncotarget.9408.
• [825] Overexpression of Contactin 1 promotes growth, migration and invasion in Hs578T breast cancer cells.BMC Cell Biol. 2018 Apr 19;19(1):5. doi: 10.1186/s12860-018-0154-3.
• [826] A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first-line therapy for patients with breast cancer (CBCRT01).Int J Cancer. 2018 May 15;142(10):2130-2138. doi: 10.1002/ijc.31217. Epub 2017 Dec 23.
• [827] Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis.PLoS Med. 2008 May 27;5(5):e114. doi: 10.1371/journal.pmed.0050114.
• [828] The novel Jab1 inhibitor CSN5i-3 suppresses cell proliferation and induces apoptosis in human breast cancer cells.Neoplasma. 2019 May 23;66(3):481-486. doi: 10.4149/neo_2018_181016N772. Epub 2019 Mar 7.
• [829] Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis.BMC Cancer. 2008 Jan 28;8:25. doi: 10.1186/1471-2407-8-25.
• [830] Combined Proteomics and Transcriptomics Identifies Carboxypeptidase B1 and Nuclear Factor B (NF-B) Associated Proteins as Putative Biomarkers of Metastasis in Low Grade Breast Cancer.Mol Cell Proteomics. 2015 Jul;14(7):1814-30. doi: 10.1074/mcp.M114.041335. Epub 2015 Apr 22.
• [831] IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages.Curr Probl Cancer. 2018 Mar-Apr;42(2):215-230. doi: 10.1016/j.currproblcancer.2018.01.009. Epub 2018 Jan 10.
• [832] Inhibition of CX(3)CR1 reduces cell motility and viability in pancreatic adenocarcinoma epithelial cells.Biochem Biophys Res Commun. 2018 Jan 15;495(3):2264-2269. doi: 10.1016/j.bbrc.2017.12.116. Epub 2017 Dec 21.
• [833] CAT-1-mediated arginine uptake and regulation of nitric oxide synthases for the survival of human breast cancer cell lines.J Cell Biochem. 2011 Apr;112(4):1084-92. doi: 10.1002/jcb.23022.
• [834] Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women.Cancer Res. 2009 Jul 1;69(13):5392-9. doi: 10.1158/0008-5472.CAN-09-0108. Epub 2009 Jun 9.
• [835] Prognostic value of biomarkers EpCAM and B-crystallin associated with lymphatic metastasis in breast cancer by iTRAQ analysis.BMC Cancer. 2019 Aug 23;19(1):831. doi: 10.1186/s12885-019-6016-3.
• [836] Expression of cellular apoptosis susceptibility (CAS) in the human testis and testicular germ cell tumors.Med Oncol. 2019 May 29;36(7):61. doi: 10.1007/s12032-019-1281-1.
• [837] Human ALKBH3-induced m(1)A demethylation increases the CSF-1 mRNA stability in breast and ovarian cancer cells.Biochim Biophys Acta Gene Regul Mech. 2019 Jan;1862(1):35-46. doi: 10.1016/j.bbagrm.2018.10.008. Epub 2018 Oct 17.
• [838] Imaging endogenous macrophage iron deposits reveals a metabolic biomarker of polarized tumor macrophage infiltration and response to CSF1R breast cancer immunotherapy.Sci Rep. 2019 Jan 29;9(1):857. doi: 10.1038/s41598-018-37408-7.
• [839] The Relationship Between Cytokine Production, CSF2RA, and IL1R2 Expression in Mammary Adenocarcinoma, Tumor Histopathological Parameters, and Lymph Node Metastasis.Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819883626. doi: 10.1177/1533033819883626.
• [840] A high-risk luminal A dominant breast cancer subtype with increased mobility.Breast Cancer Res Treat. 2019 Jun;175(2):459-472. doi: 10.1007/s10549-019-05135-w. Epub 2019 Feb 19.
• [841] Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):7869-7878. doi: 10.1073/pnas.1722617115. Epub 2018 Jul 9.
• [842] Molecular Pathways: Emergence of Protein Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage Response and Repair Pathways in Cancer Cells.Clin Cancer Res. 2016 Jun 15;22(12):2840-7. doi: 10.1158/1078-0432.CCR-15-1314.
• [843] Protein kinase CK2 in mammary gland tumorigenesis.Oncogene. 2001 May 31;20(25):3247-57. doi: 10.1038/sj.onc.1204411.
• [844] Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors.PLoS One. 2019 Jan 9;14(1):e0210608. doi: 10.1371/journal.pone.0210608. eCollection 2019.
• [845] Association of rs2234693 and rs9340799 polymorphisms of ESR1 gene in breast cancer of Mexican population.J BUON. 2019 Sep-Oct;24(5):1927-1933.
• [846] MAGEA1 inhibits the expression of BORIS via increased promoter methylation.J Cell Sci. 2019 Jan 2;132(1):jcs218628. doi: 10.1242/jcs.218628.
• [847] The Small C-terminal Domain Phosphatase 1 Inhibits Cancer Cell Migration and Invasion by Dephosphorylating Ser(P)68-Twist1 to Accelerate Twist1 Protein Degradation.J Biol Chem. 2016 May 27;291(22):11518-28. doi: 10.1074/jbc.M116.721795. Epub 2016 Mar 14.
• [848] I157172, a novel inhibitor of cystathionine -lyase, inhibits growth and migration of breast cancer cells via SIRT1-mediated deacetylation of STAT3.Oncol Rep. 2019 Jan;41(1):427-436. doi: 10.3892/or.2018.6798. Epub 2018 Oct 16.
• [849] Improving cancer-specific outcomes in solid organ transplant recipients: Where to begin?.Cancer. 2019 Mar 15;125(6):838-842. doi: 10.1002/cncr.31963. Epub 2019 Jan 9.
• [850] Targeting the lysosome by an aminomethylated Riccardin D triggers DNA damage through cathepsin B-mediated degradation of BRCA1.J Cell Mol Med. 2019 Mar;23(3):1798-1812. doi: 10.1111/jcmm.14077. Epub 2018 Dec 18.
• [851] Insulin-like growth factor-1 signaling is responsible for cathepsin G-induced aggregation of breast cancer MCF-7 cells.Cancer Sci. 2017 Aug;108(8):1574-1583. doi: 10.1111/cas.13286. Epub 2017 Jun 21.
• [852] CCAAT-displacement protein/cut homeobox transcription factor (CUX1) represses estrogen receptor-alpha (ER-) in triple-negative breast cancer cells and can be antagonized by muscadine grape skin extract (MSKE).PLoS One. 2019 Apr 9;14(4):e0214844. doi: 10.1371/journal.pone.0214844. eCollection 2019.
• [853] Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradation.Cell Death Differ. 2019 May;26(5):812-825. doi: 10.1038/s41418-018-0153-0. Epub 2018 Jul 13.
• [854] XIAOPI Formula Inhibits Breast Cancer Stem Cells via Suppressing Tumor-Associated Macrophages/C-X-C Motif Chemokine Ligand 1 Pathway.Front Pharmacol. 2019 Nov 15;10:1371. doi: 10.3389/fphar.2019.01371. eCollection 2019.
• [855] Long Non-Coding RNA (LncRNA) UFC1/miR-34a Contributes to Proliferation and Migration in Breast Cancer.Med Sci Monit. 2019 Sep 23;25:7149-7157. doi: 10.12659/MSM.917562.
• [856] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [857] The Role of CXCL13 and CXCL9 in Early Breast Cancer.Clin Breast Cancer. 2020 Feb;20(1):e36-e53. doi: 10.1016/j.clbc.2019.08.008. Epub 2019 Sep 5.
• [858] The evaluation of the distribution of CD133, CXCR1 and the tumor associated macrophages in different molecular subtypes of breast cancer.Histol Histopathol. 2020 Jan;35(1):83-96. doi: 10.14670/HH-18-139. Epub 2019 Jun 28.
• [859] IL-17-CXC Chemokine Receptor 2 Axis Facilitates Breast Cancer Progression by Up-Regulating Neutrophil Recruitment.Am J Pathol. 2020 Jan;190(1):222-233. doi: 10.1016/j.ajpath.2019.09.016. Epub 2019 Oct 22.
• [860] The role of CXC chemokine ligand 4/CXC chemokine receptor 3-B in breast cancer progression.Biotech Histochem. 2019 Jan;94(1):53-59. doi: 10.1080/10520295.2018.1497201. Epub 2018 Sep 28.
• [861] Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.Oncoimmunology. 2018 Jul 30;7(10):e1490854. doi: 10.1080/2162402X.2018.1490854. eCollection 2018.
• [862] Interaction between dietary acrylamide intake and genetic variants for estrogen receptor-positive breast cancer risk.Eur J Nutr. 2019 Apr;58(3):1033-1045. doi: 10.1007/s00394-018-1619-z. Epub 2018 Feb 14.
• [863] The retinoic acid-metabolizing enzyme CYP26A1 upregulates fascin and promotes the malignant behavior of breast carcinoma cells.Oncol Rep. 2015 Aug;34(2):850-8. doi: 10.3892/or.2015.4042. Epub 2015 Jun 8.
• [864] Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. Breast Cancer Res Treat. 2018 Nov;172(2):371-379.
• [865] Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.BMC Med Genet. 2012 Jun 15;13:45. doi: 10.1186/1471-2350-13-45.
• [866] Role of CYP2E1 polymorphisms in breast cancer: a systematic review and meta-analysis.Cancer Cell Int. 2017 Jan 7;17:11. doi: 10.1186/s12935-016-0371-9. eCollection 2017.
• [867] Activation of the pro-migratory bone morphogenetic protein receptor 1B gene in human MDA-MB-468 triple-negative breast cancer cells that over-express CYP2J2.Int J Biochem Cell Biol. 2016 Nov;80:173-178. doi: 10.1016/j.biocel.2016.10.004. Epub 2016 Oct 5.
• [868] Cysteinyl leukotriene receptor expression pattern affects migration of breast cancer cells and survival of breast cancer patients.Int J Cancer. 2011 Jul 1;129(1):9-22. doi: 10.1002/ijc.25648. Epub 2010 Nov 9.
• [869] Increased expression of dystroglycan inhibits the growth and tumorigenicity of human mammary epithelial cells.Cancer Biol Ther. 2004 Oct;3(10):967-75. doi: 10.4161/cbt.3.10.1132. Epub 2004 Oct 2.
• [870] Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs.Breast Cancer Res Treat. 2012 Feb;131(3):809-18. doi: 10.1007/s10549-011-1477-3. Epub 2011 Apr 5.
• [871] DCLK1 promotes malignant progression of breast cancer by regulating Wnt/-Catenin signaling pathway.Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9489-9498. doi: 10.26355/eurrev_201911_19443.
• [872] Activation of B-1 Cells Promotes Tumor Cell Killing in the Peritoneal Cavity.Cancer Res. 2019 Jan 1;79(1):159-170. doi: 10.1158/0008-5472.CAN-18-0981. Epub 2018 Sep 17.
• [873] Carbidopa Alters Tryptophan Metabolism in Breast Cancer and Melanoma Cells Leading to the Formation of Indole-3-Acetonitrile, a Pro-Proliferative Metabolite.Biomolecules. 2019 Aug 24;9(9):409. doi: 10.3390/biom9090409.
• [874] DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop.Endocr Relat Cancer. 2019 Jan 1;26(1):197-214. doi: 10.1530/ERC-18-0310.
• [875] Inhibition of tumor-microenvironment interaction and tumor invasion by small-molecule allosteric inhibitor of DDR2 extracellular domain.Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):E7786-E7794. doi: 10.1073/pnas.1805020115. Epub 2018 Jul 30.
• [876] Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1.Oncogene. 2019 Jul;38(28):5725-5738. doi: 10.1038/s41388-019-0824-4. Epub 2019 Apr 23.
• [877] High Expression of DEPDC1 Promotes Malignant Phenotypes of Breast Cancer Cells and Predicts Poor Prognosis in Patients With Breast Cancer.Front Oncol. 2019 Apr 12;9:262. doi: 10.3389/fonc.2019.00262. eCollection 2019.
• [878] Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.Neoplasia. 2015 Mar;17(3):317-28. doi: 10.1016/j.neo.2015.02.003.
• [879] A multi-parametric PET/MRI study of breast cancer: Evaluation of DCE-MRI pharmacokinetic models and correlation with diffusion and functional parameters.NMR Biomed. 2019 Jan;32(1):e4026. doi: 10.1002/nbm.4026. Epub 2018 Oct 31.
• [880] Cis-eQTL-based trans-ethnic meta-analysis reveals novel genes associated with breast cancer risk.PLoS Genet. 2017 Mar 31;13(3):e1006690. doi: 10.1371/journal.pgen.1006690. eCollection 2017 Mar.
• [881] Reciprocal expression of survivin and SMAC/DIABLO in primary breast cancer.Med Oncol. 2012 Dec;29(4):2535-42. doi: 10.1007/s12032-011-0129-0. Epub 2011 Dec 8.
• [882] miR-559 polymorphism rs58450758 is linked to breast cancer.Br J Biomed Sci. 2020 Jan;77(1):29-34. doi: 10.1080/09674845.2019.1683309. Epub 2019 Nov 18.
• [883] Correlations of DKK1 with incidence and prognosis of breast cancer.J BUON. 2019 Jan-Feb;24(1):26-32.
• [884] High-frequency deregulated expression of Wnt signaling pathway members in breast carcinomas.Onco Targets Ther. 2018 Jan 11;11:323-335. doi: 10.2147/OTT.S154395. eCollection 2018.
• [885] Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer.Oncogene. 2019 Mar;38(12):2092-2107. doi: 10.1038/s41388-018-0562-z. Epub 2018 Nov 15.
• [886] Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism.Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3799-804. doi: 10.1073/pnas.0600065103. Epub 2006 Feb 24.
• [887] The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models.Exp Cell Res. 2019 Jul 15;380(2):141-148. doi: 10.1016/j.yexcr.2019.04.025. Epub 2019 Apr 26.
• [888] Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.Osteoporos Int. 2017 Apr;28(4):1413-1422. doi: 10.1007/s00198-016-3899-6. Epub 2017 Jan 12.
• [889] JDP1 (DNAJC12/Hsp40) expression in breast cancer and its association with estrogen receptor status.Int J Mol Med. 2006 Feb;17(2):363-7.
• [890] Identifying DNase I hypersensitive sites as driver distal regulatory elements in breast cancer.Nat Commun. 2017 Sep 5;8(1):436. doi: 10.1038/s41467-017-00100-x.
• [891] Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and doxorubicin for enhanced therapeutic efficacy.J Drug Target. 2017 Feb;25(2):140-148. doi: 10.1080/1061186X.2016.1207649. Epub 2016 Jul 12.
• [892] Dynamin impacts homology-directed repair and breast cancer response to chemotherapy.J Clin Invest. 2018 Dec 3;128(12):5307-5321. doi: 10.1172/JCI87191. Epub 2018 Oct 29.
• [893] Methylation-mediated silencing of miR-133a-3p promotes breast cancer cell migration and stemness via miR-133a-3p/MAML1/DNMT3A positive feedback loop.J Exp Clin Cancer Res. 2019 Oct 28;38(1):429. doi: 10.1186/s13046-019-1400-z.
• [894] A PAK5-DNPEP-USP4 axis dictates breast cancer growth and metastasis.Int J Cancer. 2020 Feb 15;146(4):1139-1151. doi: 10.1002/ijc.32523. Epub 2019 Jun 20.
• [895] Inhibition of histone methyltransferase DOT1L silences ER gene and blocks proliferation of antiestrogen-resistant breast cancer cells.Sci Adv. 2019 Feb 6;5(2):eaav5590. doi: 10.1126/sciadv.aav5590. eCollection 2019 Feb.
• [896] Comparison of diagnostic precision for bone metastasis of primary breast cancer between BONENAVI version 1 and BONENAVI version 2.Nucl Med Commun. 2019 Nov;40(11):1148-1153. doi: 10.1097/MNM.0000000000001081.
• [897] Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women.Breast Cancer Res Treat. 2010 Oct;123(3):885-93. doi: 10.1007/s10549-010-0804-4. Epub 2010 Feb 24.
• [898] The effects of spiritual intervention and changes in dopamine receptor gene expression in breast cancer patients.Breast Cancer. 2016 Nov;23(6):893-900. doi: 10.1007/s12282-015-0658-z. Epub 2015 Nov 23.
• [899] Chitosan-Dextran sulfate coated doxorubicin loaded PLGA-PVA-nanoparticles caused apoptosis in doxorubicin resistance breast cancer cells through induction of DNA damage.Sci Rep. 2017 May 19;7(1):2143. doi: 10.1038/s41598-017-02134-z.
• [900] Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.Sci Rep. 2017 Dec 13;7(1):17530. doi: 10.1038/s41598-017-17836-7.
• [901] Puerarin promotes DUSP1 expression by regulating miR?33a?p in breast cancer.Mol Med Rep. 2019 Jan;19(1):205-212. doi: 10.3892/mmr.2018.9682. Epub 2018 Nov 21.
• [902] Novel function of MKP-5/DUSP10, a phosphatase of stress-activated kinases, on ERK-dependent gene expression, and upregulation of its gene expression in colon carcinomas.Oncol Rep. 2012 Sep;28(3):931-6. doi: 10.3892/or.2012.1862. Epub 2012 Jun 12.
• [903] Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment.Cancer Res. 2018 Aug 1;78(15):4191-4202. doi: 10.1158/0008-5472.CAN-18-0270. Epub 2018 Jun 7.
• [904] Immuno-Affinity Mass Spectrometry: A Novel Approaches with Biomedical Relevance.Adv Exp Med Biol. 2019;1140:377-388. doi: 10.1007/978-3-030-15950-4_21.
• [905] Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis.Hum Pathol. 2017 Aug;66:48-58. doi: 10.1016/j.humpath.2017.02.033. Epub 2017 May 26.
• [906] Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.Oncogene. 2017 Mar 30;36(13):1862-1872. doi: 10.1038/onc.2016.349. Epub 2016 Oct 10.
• [907] E2F1 Drives Breast Cancer Metastasis by Regulating the Target Gene FGF13 and Altering Cell Migration.Sci Rep. 2019 Jul 24;9(1):10718. doi: 10.1038/s41598-019-47218-0.
• [908] Upregulated EBI3 Correlates with Poor Outcome and Tumor Progression in Breast Cancer.Oncol Res Treat. 2018;41(3):111-115. doi: 10.1159/000484935. Epub 2018 Feb 27.
• [909] The CCAAT/enhancer-binding protein beta-2 isoform (CEBP-2) upregulates galectin-7 expression in human breast cancer cells.PLoS One. 2014 May 2;9(5):e95087. doi: 10.1371/journal.pone.0095087. eCollection 2014.
• [910] On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer.Breast Cancer Res Treat. 2007 Dec;106(3):361-9. doi: 10.1007/s10549-007-9516-9. Epub 2007 Feb 13.
• [911] Overexpression of Endothelin-A-receptor in breast cancer: regulation by estradiol and cobalt-chloride induced hypoxia.Int J Oncol. 2005 Apr;26(4):951-60.
• [912] PHD2 Targeting Overcomes Breast Cancer Cell Death upon Glucose Starvation in a PP2A/B55-Mediated Manner.Cell Rep. 2017 Mar 21;18(12):2836-2844. doi: 10.1016/j.celrep.2017.02.081.
• [913] Detection of a 4-bp Insertion/deletion Polymorphism within the Promoter of EGLN2 Using Mismatch PCR-RFLP and Its Association with Susceptibility to Breast Cancer.Asian Pac J Cancer Prev. 2018 Apr 25;19(4):923-926. doi: 10.22034/APJCP.2018.19.4.923.
• [914] The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer.Int J Oncol. 2019 Jan;54(1):65-76. doi: 10.3892/ijo.2018.4608. Epub 2018 Oct 26.
• [915] PERK-Phosphorylated eIF2 Pathway Suppresses Tumor Metastasis Through Downregulating Expression of Programmed Death Ligand 1 and CXCL5 in Triple-Negative Breast Cancer.Cancer Biother Radiopharm. 2017 Oct;32(8):282-287. doi: 10.1089/cbr.2017.2237.
• [916] Regulation of PERK expression by FOXO3: a vulnerability of drug-resistant cancer cells.Oncogene. 2019 Sep;38(36):6382-6398. doi: 10.1038/s41388-019-0890-7. Epub 2019 Jul 16.
• [917] Small molecule nAS-E targeting cAMP response element binding protein (CREB) and CREB-binding protein interaction inhibits breast cancer bone metastasis.J Cell Mol Med. 2019 Feb;23(2):1224-1234. doi: 10.1111/jcmm.14024. Epub 2018 Nov 20.
• [918] Feedback Activation of SGK3 and AKT Contributes to Rapamycin Resistance by Reactivating mTORC1/4EBP1 Axis via TSC2 in Breast Cancer.Int J Biol Sci. 2019 Mar 9;15(5):929-941. doi: 10.7150/ijbs.32489. eCollection 2019.
• [919] EIF5A2 is a novel chemoresistance gene in breast cancer.Breast Cancer. 2015 Nov;22(6):602-7. doi: 10.1007/s12282-014-0526-2. Epub 2014 Mar 18.
• [920] Oncogenic functions of protein kinase D2 and D3 in regulating multiple cancer-related pathways in breast cancer.Cancer Med. 2019 Feb;8(2):729-741. doi: 10.1002/cam4.1938. Epub 2019 Jan 16.
• [921] Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression.Cancer Discov. 2016 May;6(5):516-31. doi: 10.1158/2159-8290.CD-15-1183. Epub 2016 Jan 25.
• [922] ITIH5 induces a shift in TGF- superfamily signaling involving Endoglin and reduces risk for breast cancer metastasis and tumor death.Mol Carcinog. 2018 Feb;57(2):167-181. doi: 10.1002/mc.22742. Epub 2017 Oct 30.
• [923] hnRNP F directs formation of an exon 4 minus variant of tumor-associated NADH oxidase (ENOX2).Mol Cell Biochem. 2011 Nov;357(1-2):55-63. doi: 10.1007/s11010-011-0875-5. Epub 2011 May 28.
• [924] Alternative polyadenylation of single cells delineates cell types and serves as a prognostic marker in early stage breast cancer.PLoS One. 2019 May 17;14(5):e0217196. doi: 10.1371/journal.pone.0217196. eCollection 2019.
• [925] Development of an ENPP1 Fluorescence Probe for Inhibitor Screening, Cellular Imaging, and Prognostic Assessment of Malignant Breast Cancer.J Med Chem. 2019 Oct 24;62(20):9254-9269. doi: 10.1021/acs.jmedchem.9b01213. Epub 2019 Oct 3.
• [926] HER2 regulates HIF-2 and drives an increased hypoxic response in breast cancer.Breast Cancer Res. 2019 Jan 22;21(1):10. doi: 10.1186/s13058-019-1097-0.
• [927] Sam68 Promotes the Progression of Human Breast Cancer through inducing Activation of EphA3.Curr Cancer Drug Targets. 2020;20(1):76-83. doi: 10.2174/1568009619666190718124541.
• [928] MicroRNA-335 suppresses the proliferation, migration, and invasion of breast cancer cells by targeting EphA4.Mol Cell Biochem. 2018 Feb;439(1-2):95-104. doi: 10.1007/s11010-017-3139-1. Epub 2017 Aug 9.
• [929] Erythropoietin-producing hepatocellular A6 overexpression is a novel biomarker of poor prognosis in patients with breast cancer.Oncol Lett. 2018 Apr;15(4):5257-5263. doi: 10.3892/ol.2018.7919. Epub 2018 Feb 1.
• [930] Plumbagin Increases Paclitaxel-Induced Cell Death and Overcomes Paclitaxel Resistance in Breast Cancer Cells through ERK-Mediated Apoptosis Induction.J Nat Prod. 2019 Apr 26;82(4):878-885. doi: 10.1021/acs.jnatprod.8b00964. Epub 2019 Feb 27.
• [931] Downregulation of miroRNA-141 mediates acquired resistance to trastuzumab and is associated with poor outcome in breast cancer by upregulating the expression of ERBB4.J Cell Biochem. 2019 Jul;120(7):11390-11400. doi: 10.1002/jcb.28416. Epub 2019 Feb 11.
• [932] Epiregulin-blocking antibody inhibits epiregulin-dependent EGFR signaling.Biochem Biophys Res Commun. 2017 Jul 15;489(1):83-88. doi: 10.1016/j.bbrc.2017.03.006. Epub 2017 Mar 6.
• [933] Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer.J Clin Invest. 2018 Apr 2;128(4):1283-1299. doi: 10.1172/JCI95873. Epub 2018 Feb 26.
• [934] The orphan nuclear receptor estrogen-related receptor beta (ERR) in triple-negative breast cancer.Breast Cancer Res Treat. 2020 Feb;179(3):585-604. doi: 10.1007/s10549-019-05485-5. Epub 2019 Nov 19.
• [935] Estrogen-related receptors alpha, beta and gamma expression and function is associated with transcriptional repressor EZH2 in breast carcinoma.BMC Cancer. 2018 Jun 26;18(1):690. doi: 10.1186/s12885-018-4586-0.
• [936] Differential expression of Ets-1 in breast cancer among North Indian population.J Cell Biochem. 2019 Sep;120(9):14552-14561. doi: 10.1002/jcb.28716. Epub 2019 Apr 23.
• [937] Ets2 in tumor fibroblasts promotes angiogenesis in breast cancer.PLoS One. 2013 Aug 16;8(8):e71533. doi: 10.1371/journal.pone.0071533. eCollection 2013.
• [938] Ezrin promotes breast cancer progression by modulating AKT signals.Br J Cancer. 2019 Apr;120(7):703-713. doi: 10.1038/s41416-019-0383-z. Epub 2019 Feb 26.
• [939] The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.J Thromb Haemost. 2019 Jun;17(6):951-963. doi: 10.1111/jth.14443. Epub 2019 Apr 29.
• [940] Differential contribution of tissue factor and FactorXII to thrombin generation triggered by breast and pancreatic cancer cells.Int J Oncol. 2017 Dec;51(6):1747-1756. doi: 10.3892/ijo.2017.4172. Epub 2017 Oct 20.
• [941] Functional inhibition of F11 receptor (F11R/junctional adhesion molecule-A/JAM-A) activity by a F11R-derived peptide in breast cancer and its microenvironment.Breast Cancer Res Treat. 2020 Jan;179(2):325-335. doi: 10.1007/s10549-019-05471-x. Epub 2019 Oct 24.
• [942] Protease-activated receptor 2 promotes actomyosin dependent transforming microvesicles generation from human breast cancer.Mol Carcinog. 2018 Dec;57(12):1707-1722. doi: 10.1002/mc.22891. Epub 2018 Sep 5.
• [943] Loss of the Par3 polarity protein promotes breast tumorigenesis and metastasis.Cancer Cell. 2012 Nov 13;22(5):601-14. doi: 10.1016/j.ccr.2012.10.003.
• [944] Novel Hydrophilic Copolymer-Based Nanoparticle Enhances the Therapeutic Efficiency of Doxorubicin in Cultured MCF-7 Cells.ACS Omega. 2019 Oct 11;4(17):17083-17089. doi: 10.1021/acsomega.8b02894. eCollection 2019 Oct 22.
• [945] 4-Amino-2-trifluoromethyl-phenyl retinate inhibits proliferation, invasion, and migration of breast cancer cells by independently regulating CRABP2 and FABP5.Drug Des Devel Ther. 2018 Apr 27;12:997-1008. doi: 10.2147/DDDT.S151029. eCollection 2018.
• [946] Expression of human delta-6-desaturase is associated with aggressiveness of human breast cancer.Int J Mol Med. 2003 Aug;12(2):253-7.
• [947] Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.Cell Death Dis. 2019 Sep 11;10(9):666. doi: 10.1038/s41419-019-1871-z.
• [948] Quantitative assessment of the association between three polymorphisms in FAS and FASL gene and breast cancer risk.Tumour Biol. 2014 Apr;35(4):3035-9. doi: 10.1007/s13277-013-1392-9. Epub 2013 Nov 19.
• [949] MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.Oncogene. 2016 Jan 28;35(4):448-58. doi: 10.1038/onc.2015.96. Epub 2015 Apr 13.
• [950] Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells.JCI Insight. 2019 Feb 21;4(4):e125138. doi: 10.1172/jci.insight.125138. eCollection 2019 Feb 21.
• [951] Pharmacogenetics as Personalized Medicine: Association Investigation of SOD2 rs4880, CYP2C19 rs4244285, and FCGR2A rs1801274 Polymorphisms in a Breast Cancer Population in Iraqi Women.Clin Breast Cancer. 2018 Oct;18(5):e863-e868. doi: 10.1016/j.clbc.2018.01.009. Epub 2018 Jan 31.
• [952] Ferrochelatase Deficiency Abrogated the Enhancement of Aminolevulinic Acid-mediated Protoporphyrin IX by Iron Chelator Deferoxamine.Photochem Photobiol. 2019 Jul;95(4):1052-1059. doi: 10.1111/php.13091. Epub 2019 Mar 15.
• [953] The feasibility of (18)F-FES and (18)F-FDG microPET/CT for early monitoring the effect of fulvestrant on sensitizing docetaxel by downregulating ER in ER+ breast cancer.Ann Nucl Med. 2018 May;32(4):272-280. doi: 10.1007/s12149-018-1245-0. Epub 2018 Feb 24.
• [954] Oleic acid induces ERK1/2 activation and AP-1 DNA binding activity through a mechanism involving Src kinase and EGFR transactivation in breast cancer cells.Mol Cell Endocrinol. 2008 Nov 6;294(1-2):81-91. doi: 10.1016/j.mce.2008.08.003. Epub 2008 Aug 15.
• [955] Humanization of fibroblast growth factor 1 single-chain antibody and validation for its antitumorigenic efficacy in breast cancer and glioma cells.J Cell Mol Med. 2018 Jun;22(6):3259-3263. doi: 10.1111/jcmm.13547. Epub 2018 Mar 24.
• [956] Association of single nucleotide polymorphisms in FGF-RAS/MAP signalling cascade with breast cancer susceptibility.Gen Physiol Biophys. 2017 Dec;36(5):565-572. doi: 10.4149/gpb_2017033.
• [957] FGF18 Enhances Migration and the Epithelial-Mesenchymal Transition in Breast Cancer by Regulating Akt/GSK3/-Catenin Signaling.Cell Physiol Biochem. 2018;49(3):1019-1032. doi: 10.1159/000493286. Epub 2018 Sep 7.
• [958] FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ER and PRB4 isoform to MYC regulatory sequences.Int J Cancer. 2019 Oct 1;145(7):1874-1888. doi: 10.1002/ijc.32252. Epub 2019 Mar 28.
• [959] The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy.Cancer Biomark. 2017;18(4):441-449. doi: 10.3233/CBM-161507.
• [960] Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011 Oct 27;54(20):7066-83. doi: 10.1021/jm2006222. Epub 2011 Sep 21.
• [961] Long noncoding RNA Linc00460 promotes breast cancer progression by regulating the miR-489-5p/FGF7/AKT axis.Cancer Manag Res. 2019 Jul 1;11:5983-6001. doi: 10.2147/CMAR.S207084. eCollection 2019.
• [962] The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF.Carcinogenesis. 2014 May;35(5):1144-53. doi: 10.1093/carcin/bgu021. Epub 2014 Jan 24.
• [963] Krppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1.Oncogene. 2009 Oct 22;28(42):3702-13. doi: 10.1038/onc.2009.235. Epub 2009 Aug 10.
• [964] Correlations of breast cancer FHIT gene with the incidence and prognosis of breast cancer.J BUON. 2019 Jan-Feb;24(1):40-47.
• [965] FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer.Cancer Chemother Pharmacol. 2019 Oct;84(4):861-872. doi: 10.1007/s00280-019-03923-1. Epub 2019 Aug 19.
• [966] FLNa negatively regulated proliferation and metastasis in lung adenocarcinoma A549 cells via suppression of EGFR.Acta Biochim Biophys Sin (Shanghai). 2018 Feb 1;50(2):164-170. doi: 10.1093/abbs/gmx135.
• [967] Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [(18)F]FLT and [(18)F]ISO-1 PET/CT.Clin Cancer Res. 2019 May 15;25(10):3063-3073. doi: 10.1158/1078-0432.CCR-18-2769. Epub 2019 Jan 28.
• [968] Extra domain A-containing fibronectin expression in Spin90-deficient fibroblasts mediates cancer-stroma interaction and promotes breast cancer progression.J Cell Physiol. 2020 May;235(5):4494-4507. doi: 10.1002/jcp.29326. Epub 2019 Oct 21.
• [969] 18F-PSMA 1007 Uptake in Brain Metastases From Breast Cancer.Clin Nucl Med. 2020 Feb;45(2):e77-e79. doi: 10.1097/RLU.0000000000002821.
• [970] Elucidating feed-forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome.Oncol Lett. 2018 Aug;16(2):2757-2763. doi: 10.3892/ol.2018.8957. Epub 2018 Jun 12.
• [971] Expression and function of FRA1 protein in tumors.Mol Biol Rep. 2020 Jan;47(1):737-752. doi: 10.1007/s11033-019-05123-9. Epub 2019 Oct 14.
• [972] The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells.Eur J Cancer. 2010 Jun;46(9):1650-60. doi: 10.1016/j.ejca.2010.02.008. Epub 2010 Mar 11.
• [973] Research progress on the forkhead box C1.Oncotarget. 2017 Nov 20;9(15):12471-12478. doi: 10.18632/oncotarget.22527. eCollection 2018 Feb 23.
• [974] Overexpression of forkhead box J2 can decrease the migration of breast cancer cells. J Cell Biochem. 2012 Aug;113(8):2729-37.
• [975] Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis.Cell Death Differ. 2020 Mar;27(3):966-983. doi: 10.1038/s41418-019-0389-3. Epub 2019 Jul 11.
• [976] Inhibition of the AnxA1/FPR1 autocrine axis reduces MDA-MB-231 breast cancer cell growth and aggressiveness in vitro and in vivo.Biochim Biophys Acta Mol Cell Res. 2018 Sep;1865(9):1368-1382. doi: 10.1016/j.bbamcr.2018.06.010. Epub 2018 Jun 20.
• [977] Leucine aminopeptidase 3 promotes migration and invasion of breast cancer cells through upregulation of fascin and matrix metalloproteinases-2/9 expression.J Cell Biochem. 2019 Mar;120(3):3611-3620. doi: 10.1002/jcb.27638. Epub 2018 Nov 11.
• [978] Interaction with the GDF8/11 pathway reveals treatment options for adenocarcinoma of the breast.Breast. 2018 Feb;37:134-141. doi: 10.1016/j.breast.2017.11.010. Epub 2017 Nov 20.
• [979] Serum Levels of Activins, Follistatins, and Growth Factors in Neoplasms of the Breast: A Case-Control Study.J Clin Endocrinol Metab. 2019 Feb 1;104(2):349-358. doi: 10.1210/jc.2018-01581.
• [980] A Self-Targeting, Dual ROS/pH-Responsive Apoferritin Nanocage for Spatiotemporally Controlled Drug Delivery to Breast Cancer.Biomacromolecules. 2018 Mar 12;19(3):1026-1036. doi: 10.1021/acs.biomac.8b00012. Epub 2018 Feb 23.
• [981] Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers.Discov Med. 2017 May;23(128):325-330.
• [982] Fut3 role in breast invasive ductal carcinoma: Investigating its gene promoter and protein expression.Exp Mol Pathol. 2015 Dec;99(3):409-15. doi: 10.1016/j.yexmp.2015.08.015. Epub 2015 Aug 29.
• [983] Long noncoding RNA GAS6-AS2 sponges microRNA-493, thereby enhancing the malignant characteristics of breast cancer cells via upregulation of FUT4.Pathol Res Pract. 2020 Feb;216(2):152772. doi: 10.1016/j.prp.2019.152772. Epub 2019 Nov 28.
• [984] Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells.Nanoscale. 2019 Jul 11;11(27):12858-12870. doi: 10.1039/c9nr01277j.
• [985] The roles and mechanisms of G3BP1 in tumour promotion. J Drug Target. 2019 Mar;27(3):300-305.
• [986] Post genome-wide gene-environment interaction study: The effect of genetically driven insulin resistance on breast cancer risk using Mendelian randomization.PLoS One. 2019 Jun 27;14(6):e0218917. doi: 10.1371/journal.pone.0218917. eCollection 2019.
• [987] The mRNA-edited form of GABRA3 suppresses GABRA3-mediated Akt activation and breast cancer metastasis.Nat Commun. 2016 Feb 12;7:10715. doi: 10.1038/ncomms10715.
• [988] Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer.Sci Rep. 2019 Oct 17;9(1):14934. doi: 10.1038/s41598-019-51453-w.
• [989] Concomitant gastrin and ERBB2 gene amplifications at 17q12-q21 in the intestinal type of gastric cancer.Genes Chromosomes Cancer. 1999 Jan;24(1):24-9. doi: 10.1002/(sici)1098-2264(199901)24:1<24::aid-gcc4>3.0.co;2-h.
• [990] Shortening of apparent transverse relaxation time of inorganic phosphate as a breast cancer biomarker.NMR Biomed. 2019 Oct;32(10):e4011. doi: 10.1002/nbm.4011. Epub 2018 Oct 12.
• [991] Growth arrest-specific gene 6 expression in human breast cancer.Br J Cancer. 2008 Mar 25;98(6):1141-6. doi: 10.1038/sj.bjc.6604260. Epub 2008 Feb 19.
• [992] NRG-1 Stimulates Serum DJ-1 Increase in Breast Cancers.Pathol Oncol Res. 2019 Jan;25(1):71-79. doi: 10.1007/s12253-017-0326-z. Epub 2017 Sep 30.
• [993] BMP9, but not BMP10, acts as a quiescence factor on tumor growth, vessel normalization and metastasis in a mouse model of breast cancer.J Exp Clin Cancer Res. 2018 Aug 30;37(1):209. doi: 10.1186/s13046-018-0885-1.
• [994] Breast Cancer Cell Apoptosis is Synergistically Induced by Curcumin, Trastuzumab, and Glutathione Peroxidase-1 but Robustly Inhibited by Glial Cell Line-Derived Neurotrophic Factor.Nutr Cancer. 2018 Feb-Mar;70(2):288-296. doi: 10.1080/01635581.2018.1412486. Epub 2018 Jan 3.
• [995] Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.Cancer Chemother Pharmacol. 2020 Jan;85(1):105-111. doi: 10.1007/s00280-019-03981-5. Epub 2019 Nov 21.
• [996] Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines.Br J Cancer. 2008 Jun 3;98(11):1790-6. doi: 10.1038/sj.bjc.6604386. Epub 2008 May 27.
• [997] Metabolic hormones and breast cancer risk among Mexican American Women in the Mano a Mano Cohort Study.Sci Rep. 2019 Jul 10;9(1):9989. doi: 10.1038/s41598-019-46429-9.
• [998] Spatial Arrangements of Connexin43 in Cancer Related Cells and Re-Arrangements under Treatment Conditions: Investigations on the Nano-Scale by Super-Resolution Localization Light Microscopy.Cancers (Basel). 2019 Mar 4;11(3):301. doi: 10.3390/cancers11030301.
• [999] Gap junction ? expression is negatively associated with the estrogen receptor status in breast cancer tissues and is a regulator of breast tumorigenesis.Oncol Rep. 2018 Dec;40(6):3645-3653. doi: 10.3892/or.2018.6764. Epub 2018 Oct 3.
• [1000] Correlation Between Doppler Ultrasound Blood Flow Parameters and Angiogenesis and Proliferation Activity in Breast Cancer.Med Sci Monit. 2019 Sep 19;25:7035-7041. doi: 10.12659/MSM.914395.
• [1001] Functional Proteomics of Breast Cancer Metabolism Identifies GLUL as Responder during Hypoxic Adaptation.J Proteome Res. 2019 Mar 1;18(3):1352-1362. doi: 10.1021/acs.jproteome.8b00944. Epub 2019 Jan 18.
• [1002] Identification of ganglioside GM2 activator playing a role in cancer cell migration through proteomic analysis of breast cancer secretomes.Cancer Sci. 2016 Jun;107(6):828-35. doi: 10.1111/cas.12935. Epub 2016 Apr 27.
• [1003] Correction: DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.Oncogene. 2019 Jun;38(24):4886. doi: 10.1038/s41388-019-0753-2.
• [1004] Glutamine-utilizing transaminases are a metabolic vulnerability of TAZ/YAP-activated cancer cells.EMBO Rep. 2018 Jun;19(6):e43577. doi: 10.15252/embr.201643577. Epub 2018 Apr 16.
• [1005] Lithocholic Acid, a Metabolite of the Microbiome, Increases Oxidative Stress in Breast Cancer.Cancers (Basel). 2019 Aug 27;11(9):1255. doi: 10.3390/cancers11091255.
• [1006] HPI/AMF inhibition halts the development of the aggressive phenotype of breast cancer stem cells.Biochim Biophys Acta Mol Cell Res. 2017 Oct;1864(10):1679-1690. doi: 10.1016/j.bbamcr.2017.06.015. Epub 2017 Jun 23.
• [1007] GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and -catenin activity.Oncogene. 2019 Jun;38(26):5294-5307. doi: 10.1038/s41388-019-0793-7. Epub 2019 Mar 26.
• [1008] GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy.J Exp Clin Cancer Res. 2018 Nov 29;37(1):295. doi: 10.1186/s13046-018-0949-2.
• [1009] Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis.Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):580-585. doi: 10.1073/pnas.1614035114. Epub 2017 Jan 3.
• [1010] Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship.Am J Hum Genet. 1989 Oct;45(4):521-9.
• [1011] The LPI/GPR55 axis enhances human breast cancer cell migration via HBXIP and p-MLC signaling.Acta Pharmacol Sin. 2018 Mar;39(3):459-471. doi: 10.1038/aps.2017.157. Epub 2017 Nov 30.
• [1012] Membrane androgen receptors (OXER1, GPRC6A AND ZIP9) in prostate and breast cancer: A comparative study of their expression.Steroids. 2019 Feb;142:100-108. doi: 10.1016/j.steroids.2019.01.006. Epub 2019 Jan 29.
• [1013] miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells.Cell Death Dis. 2018 Feb 7;9(2):188. doi: 10.1038/s41419-017-0211-4.
• [1014] The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.Cell Rep. 2019 Oct 22;29(4):889-903.e10. doi: 10.1016/j.celrep.2019.09.032.
• [1015] Identification of recurrent fusion genes across multiple cancer types.Sci Rep. 2019 Jan 31;9(1):1074. doi: 10.1038/s41598-019-38550-6.
• [1016] Glutamate Ionotropic Receptor Kainate Type Subunit 3 (GRIK3) promotes epithelial-mesenchymal transition in breast cancer cells by regulating SPDEF/CDH1 signaling.Mol Carcinog. 2019 Jul;58(7):1314-1323. doi: 10.1002/mc.23014. Epub 2019 Apr 11.
• [1017] Breast cancer expresses functional NMDA receptors.Breast Cancer Res Treat. 2010 Jul;122(2):307-14. doi: 10.1007/s10549-009-0556-1. Epub 2009 Sep 26.
• [1018] G Protein Coupled Receptor Kinase 3 Regulates Breast Cancer Migration, Invasion, and Metastasis.PLoS One. 2016 Apr 6;11(4):e0152856. doi: 10.1371/journal.pone.0152856. eCollection 2016.
• [1019] Downregulation of GRK5 hampers the migration of breast cancer cells.Sci Rep. 2019 Oct 29;9(1):15548. doi: 10.1038/s41598-019-51923-1.
• [1020] Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells.Oncotarget. 2017 Jul 4;8(27):44639-44653. doi: 10.18632/oncotarget.17961.
• [1021] B Cell-Attracting Chemokine-1 and Progranulin in Bronchoalveolar Lavage Fluid of Patients with Advanced Non-small Cell Lung Cancer: New Prognostic Factors.Adv Exp Med Biol. 2019;1150:11-16. doi: 10.1007/5584_2018_285.
• [1022] Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples.PLoS One. 2019 Jan 15;14(1):e0210905. doi: 10.1371/journal.pone.0210905. eCollection 2019.
• [1023] Flavonoid GL-V9 induces apoptosis and inhibits glycolysis of breast cancer via disrupting GSK-3-modulated mitochondrial binding of HKII.Free Radic Biol Med. 2020 Jan;146:119-129. doi: 10.1016/j.freeradbiomed.2019.10.413. Epub 2019 Oct 24.
• [1024] Comparative two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) of human milk to identify dysregulated proteins in breast cancer.Electrophoresis. 2018 May 13. doi: 10.1002/elps.201800025. Online ahead of print.
• [1025] Elevation of glutathione, glutathione-reductase and nucleic acids in both normal tissues and tumour of breast cancer patients.Cancer Lett. 1993 Aug 16;72(1-2):11-5. doi: 10.1016/0304-3835(93)90004-s.
• [1026] Lithocholic acid, a bacterial metabolite reduces breast cancer cell proliferation and aggressiveness.Biochim Biophys Acta Bioenerg. 2018 Sep;1859(9):958-974. doi: 10.1016/j.bbabio.2018.04.002. Epub 2018 Apr 13.
• [1027] Chemopreventive efficacy of oral curcumin: a prodrug hypothesis.FASEB J. 2019 Aug;33(8):9453-9465. doi: 10.1096/fj.201900166R. Epub 2019 May 28.
• [1028] HAX1 impact on collective cell migration, cell adhesion, and cell shape is linked to the regulation of actomyosin contractility.Mol Biol Cell. 2019 Dec 1;30(25):3024-3036. doi: 10.1091/mbc.E19-05-0304. Epub 2019 Oct 23.
• [1029] Microsatellite instability at a single locus (D11S988) on chromosome 11p15.5 as a late event in mammary tumorigenesis.Hum Mol Genet. 1995 Oct;4(10):1889-94. doi: 10.1093/hmg/4.10.1889.
• [1030] Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo.Oncogene. 2014 Jul 17;33(29):3784-93. doi: 10.1038/onc.2013.363. Epub 2013 Sep 9.
• [1031] Stimulation of lactate receptor (HCAR1) affects cellular DNA repair capacity.DNA Repair (Amst). 2017 Apr;52:49-58. doi: 10.1016/j.dnarep.2017.02.007. Epub 2017 Feb 20.
• [1032] Endocrine resistant breast cancer cells with loss of ER expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.Cell Oncol (Dordr). 2020 Feb;43(1):65-80. doi: 10.1007/s13402-019-00439-x. Epub 2019 Nov 7.
• [1033] miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis.Oncotarget. 2015 Jan 1;6(1):494-509. doi: 10.18632/oncotarget.2674.
• [1034] Correction: Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer.Oncogene. 2020 Jan;39(4):946-949. doi: 10.1038/s41388-019-0981-5.
• [1035] HDAC7-mediated control of tumour microenvironment maintains proliferative and stemness competence of human mammary epithelial cells.Mol Oncol. 2019 Aug;13(8):1651-1668. doi: 10.1002/1878-0261.12503. Epub 2019 Jun 27.
• [1036] Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy.Bioorg Chem. 2019 Jun;87:200-208. doi: 10.1016/j.bioorg.2019.03.027. Epub 2019 Mar 19.
• [1037] Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.Mol Cancer. 2015 Apr 1;14:72. doi: 10.1186/s12943-015-0345-x.
• [1038] PGC1 Regulates Breast Tumor Growth and Metastasis by SREBP1-Mediated HKDC1 Expression.Front Oncol. 2019 Apr 17;9:290. doi: 10.3389/fonc.2019.00290. eCollection 2019.
• [1039] Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome.Oncoimmunology. 2019 Jul 3;8(10):e1629780. doi: 10.1080/2162402X.2019.1629780. eCollection 2019.
• [1040] The Impact of HLA-G 3'UTR Polymorphisms in Breast Cancer in a Tunisian Population.Immunol Invest. 2019 Jul;48(5):521-532. doi: 10.1080/08820139.2019.1569043. Epub 2019 Apr 4.
• [1041] DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.J Natl Cancer Inst. 2010 Jan 6;102(1):54-68. doi: 10.1093/jnci/djp441. Epub 2009 Dec 14.
• [1042] High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer.Breast Cancer Res Treat. 2020 Jan;179(1):25-35. doi: 10.1007/s10549-019-05419-1. Epub 2019 Sep 17.
• [1043] HMGA2 and Bach-1 cooperate to promote breast cancer cell malignancy.J Cell Physiol. 2019 Aug;234(10):17714-17726. doi: 10.1002/jcp.28397. Epub 2019 Mar 1.
• [1044] HMGB2 is associated with malignancy and regulates Warburg effect by targeting LDHB and FBP1 in breast cancer.Cell Commun Signal. 2018 Feb 20;16(1):8. doi: 10.1186/s12964-018-0219-0.
• [1045] Heme Oxygenase-1 Inhibits Tumor Metastasis Mediated by Notch1 Pathway in Murine Mammary Carcinoma.Oncol Res. 2019 Jun 21;27(6):643-651. doi: 10.3727/096504018X15415906335771. Epub 2019 Feb 14.
• [1046] Opposing Regulation of Cancer Properties via KRT19-Mediated Differential Modulation of Wnt/-Catenin/Notch Signaling in Breast and Colon Cancers.Cancers (Basel). 2019 Jan 15;11(1):99. doi: 10.3390/cancers11010099.
• [1047] PKM2 promotes glucose metabolism through a let-7a-5p/Stat3/hnRNP-A1 regulatory feedback loop in breast cancer cells.J Cell Biochem. 2019 Apr;120(4):6542-6554. doi: 10.1002/jcb.27947. Epub 2018 Oct 28.
• [1048] HOXA5 determines cell fate transition and impedes tumor initiation and progression in breast cancer through regulation of E-cadherin and CD24.Oncogene. 2016 Oct 20;35(42):5539-5551. doi: 10.1038/onc.2016.95. Epub 2016 May 9.
• [1049] Homeobox A7 stimulates breast cancer cell proliferation by up-regulating estrogen receptor-alpha.Biochem Biophys Res Commun. 2013 Nov 1;440(4):652-7. doi: 10.1016/j.bbrc.2013.09.121. Epub 2013 Oct 4.
• [1050] Free paclitaxel-loaded E-selectin binding peptide modified micelle self-assembled from hyaluronic acid-paclitaxel conjugate inhibit breast cancer metastasis in a murine model.Int J Pharm. 2017 Aug 7;528(1-2):33-46. doi: 10.1016/j.ijpharm.2017.05.063. Epub 2017 May 31.
• [1051] Specific Inhibition of Heparanase by a Glycopolymer with Well-Defined Sulfation Pattern Prevents Breast Cancer Metastasis in Mice.ACS Appl Mater Interfaces. 2019 Jan 9;11(1):244-254. doi: 10.1021/acsami.8b17625. Epub 2018 Dec 31.
• [1052] Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer.Cancer Lett. 2018 Jun 28;424:70-83. doi: 10.1016/j.canlet.2018.03.014. Epub 2018 Mar 14.
• [1053] Immunomodulatory role of histamine H4 receptor in breast cancer.Br J Cancer. 2019 Jan;120(1):128-138. doi: 10.1038/s41416-018-0173-z. Epub 2018 Jul 10.
• [1054] Predictive value of genetic analysis for pathological complete response to preoperative treatment in HER2 positive, HR negative early breast cancer (PASSION trial).Jpn J Clin Oncol. 2018 Apr 1;48(4):388-391. doi: 10.1093/jjco/hyy024.
• [1055] FAM3C-YY1 axis is essential for TGF-promoted proliferation and migration of human breast cancer MDA-MB-231 cells via the activation of HSF1.J Cell Mol Med. 2019 May;23(5):3464-3475. doi: 10.1111/jcmm.14243. Epub 2019 Mar 19.
• [1056] HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.Naunyn Schmiedebergs Arch Pharmacol. 2020 Feb;393(2):253-262. doi: 10.1007/s00210-019-01725-z. Epub 2019 Sep 14.
• [1057] USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer.Cell Death Dis. 2019 Dec 4;10(12):911. doi: 10.1038/s41419-019-2141-9.
• [1058] GRP94 promotes brain metastasis by engaging pro-survival autophagy.Neuro Oncol. 2020 May 15;22(5):652-664. doi: 10.1093/neuonc/noz198.
• [1059] SMR peptide antagonizes mortalin promoted release of extracellular vesicles and affects mortalin protection from complement-dependent cytotoxicity in breast cancer cells and leukemia cells.Oncotarget. 2019 Sep 10;10(52):5419-5438. doi: 10.18632/oncotarget.27138. eCollection 2019 Sep 10.
• [1060] Simultaneous quantification of Cyt c interactions with HSP27 and Bcl-xL using molecularly imprinted polymers (MIPs) coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based targeted proteomics.J Proteomics. 2019 Feb 10;192:188-195. doi: 10.1016/j.jprot.2018.09.001. Epub 2018 Sep 17.
• [1061] The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8.Acta Pharmacol Sin. 2018 Aug;39(8):1338-1346. doi: 10.1038/aps.2017.181. Epub 2018 Jan 18.
• [1062] Mining Prognostic Significance of MEG3 in Human Breast Cancer Using Bioinformatics Analysis.Cell Physiol Biochem. 2018;50(1):41-51. doi: 10.1159/000493956. Epub 2018 Oct 2.
• [1063] Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth.ACS Med Chem Lett. 2017 Sep 14;8(10):1072-1076. doi: 10.1021/acsmedchemlett.7b00282. eCollection 2017 Oct 12.
• [1064] Serotonergic and BDNF genes associated with depression 1 week and 1 year after mastectomy for breast cancer.Psychosom Med. 2012 Jan;74(1):8-15. doi: 10.1097/PSY.0b013e318241530c. Epub 2011 Dec 30.
• [1065] Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer.PLoS One. 2013 Apr 8;8(4):e60359. doi: 10.1371/journal.pone.0060359. Print 2013.
• [1066] CAG repeat size in Huntingtin alleles is associated with cancer prognosis.Eur J Hum Genet. 2016 Aug;24(9):1310-5. doi: 10.1038/ejhg.2016.13. Epub 2016 Mar 16.
• [1067] Inhibitor of DNA Binding 2 Inhibits Epithelial-Mesenchymal Transition via Up-Regulation of Notch3 in Breast Cancer.Transl Oncol. 2018 Oct;11(5):1259-1270. doi: 10.1016/j.tranon.2018.07.015. Epub 2018 Aug 14.
• [1068] Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.Cancer Res. 2019 Jan 1;79(1):171-182. doi: 10.1158/0008-5472.CAN-18-1106. Epub 2018 Nov 9.
• [1069] Molecular mechanism of point mutation-induced Monopolar spindle 1 (Mps1/TTK) inhibitor resistance revealed by a comprehensive molecular modeling study.PeerJ. 2019 Jan 21;7:e6299. doi: 10.7717/peerj.6299. eCollection 2019.
• [1070] High level extracellular production of recombinant human interferon alpha 2b in glycoengineered Pichia pastoris: culture medium optimization, high cell density cultivation and biological characterization.J Appl Microbiol. 2019 May;126(5):1438-1453. doi: 10.1111/jam.14227. Epub 2019 Mar 19.
• [1071] Vitamin D Receptor Genetic Variation and Cancer Biomarkers among Breast Cancer Patients Supplemented with Vitamin D3: A Single-Arm Non-Randomized Before and After Trial.Nutrients. 2019 Jun 4;11(6):1264. doi: 10.3390/nu11061264.
• [1072] Interferon- regulates cell malignant growth via the c-Abl/HDAC2 signaling pathway in mammary epithelial cells.J Zhejiang Univ Sci B. 2019 Jan.;20(1):39-48. doi: 10.1631/jzus.B1800211.
• [1073] Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.Breast Cancer. 2019 May;26(3):272-281. doi: 10.1007/s12282-018-0922-0. Epub 2018 Oct 16.
• [1074] The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark.Growth Horm IGF Res. 2019 Feb;44:33-42. doi: 10.1016/j.ghir.2018.12.003. Epub 2018 Dec 20.
• [1075] Comparison of telomere length and insulin-like growth factor-binding protein 7 promoter methylation between breast cancer tissues and adjacent normal tissues in Turkish women.J Clin Lab Anal. 2017 Sep;31(5):e22083. doi: 10.1002/jcla.22083. Epub 2016 Oct 24.
• [1076] Piperlongumine Induces Cell Cycle Arrest via Reactive Oxygen Species Accumulation and IKK Suppression in Human Breast Cancer Cells.Antioxidants (Basel). 2019 Nov 14;8(11):553. doi: 10.3390/antiox8110553.
• [1077] HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer.Br J Cancer. 2006 Dec 18;95(12):1689-95. doi: 10.1038/sj.bjc.6603473. Epub 2006 Nov 21.
• [1078] IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis.Cell Death Dis. 2019 Apr 30;10(5):353. doi: 10.1038/s41419-019-1594-1.
• [1079] Interleukin-13 receptor alpha 2 expression in tumor cells is associated with reduced disease-free survival in patients with luminal subtype invasive breast cancer.Tumour Biol. 2018 Jun;40(6):1010428318783657. doi: 10.1177/1010428318783657.
• [1080] Inhibition of breast cancer cells by targeting E2F-1 gene and expressing IL15 oncolytic adenovirus.Biosci Rep. 2019 Jul 23;39(7):BSR20190384. doi: 10.1042/BSR20190384. Print 2019 Jul 31.
• [1081] A four-gene signature for prognosis in breast cancer patients with hypermethylated IL15RA.Oncol Lett. 2019 May;17(5):4245-4254. doi: 10.3892/ol.2019.10137. Epub 2019 Mar 12.
• [1082] High Serum Levels of Interleukin-18 Are Associated With Worse Outcomes in Patients With Breast Cancer.Anticancer Res. 2019 Sep;39(9):5009-5018. doi: 10.21873/anticanres.13691.
• [1083] The association between interleukin-1 gene rs1143634 polymorphism and the risk of breast cancer.Cytokine. 2019 Jan;113:475-476. doi: 10.1016/j.cyto.2018.07.030. Epub 2018 Jul 31.
• [1084] A transcriptional complex composed of ER(), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.Oncotarget. 2017 Jun 27;8(26):42752-42760. doi: 10.18632/oncotarget.17459.
• [1085] Aberrant expression of IL-23/IL-23R in patients with breast cancer and its clinical significance.Mol Med Rep. 2018 Mar;17(3):4639-4644. doi: 10.3892/mmr.2018.8427. Epub 2018 Jan 12.
• [1086] IL-24 Promotes Apoptosis through cAMP-Dependent PKA Pathways in Human Breast Cancer Cells.Int J Mol Sci. 2018 Nov 12;19(11):3561. doi: 10.3390/ijms19113561.
• [1087] Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer.Sci Signal. 2018 Jan 2;11(511):eaan0790. doi: 10.1126/scisignal.aan0790.
• [1088] Transgenic mice expressing the p75 CCAAT-displacement protein/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia.Cancer Res. 2006 Oct 1;66(19):9492-501. doi: 10.1158/0008-5472.CAN-05-4230.
• [1089] IL-9-producing CD8(+) T cells represent a distinctive subset with different transcriptional characteristics from conventional CD8(+) T cells, and partially infiltrate breast tumors.Int J Biochem Cell Biol. 2019 Oct;115:105576. doi: 10.1016/j.biocel.2019.105576. Epub 2019 Jul 27.
• [1090] ILK promotes cell proliferation in breast cancer cells by activating the PI3K/Akt pathway.Mol Med Rep. 2017 Oct;16(4):5036-5042. doi: 10.3892/mmr.2017.7180. Epub 2017 Aug 7.
• [1091] IMP3 promotes TNBC stem cell property through miRNA-34a regulation.Eur Rev Med Pharmacol Sci. 2018 May;22(9):2688-2696. doi: 10.26355/eurrev_201805_14965.
• [1092] RETRACTED ARTICLE: IMPDH2 is highly expressed in breast cancer and predicts unfavorable prognosis.Biomarkers. 2021 Feb;26(1):i-vi. doi: 10.1080/1354750X.2018.1496360. Epub 2020 Sep 1.
• [1093] PTEN and SHIP: Impact on lymphatic metastasis in breast cancer.J Cancer Res Ther. 2018 Dec;14(Supplement):S937-S941. doi: 10.4103/0973-1482.193894.
• [1094] Genetic polymorphisms of diabetes-related genes, their interaction with diabetes status, and breast cancer incidence and mortality: The Long Island Breast Cancer Study Project.Mol Carcinog. 2019 Mar;58(3):436-446. doi: 10.1002/mc.22940. Epub 2018 Dec 11.
• [1095] Proanthocyanidins attenuate breast cancer-induced bone metastasis by inhibiting Irf-3/c-jun activation.Anticancer Drugs. 2019 Nov;30(10):998-1005. doi: 10.1097/CAD.0000000000000852.
• [1096] Glucocorticoid receptor-IRS-1 axis controls EMT and the metastasis of breast cancers.J Mol Cell Biol. 2019 Dec 19;11(12):1042-1055. doi: 10.1093/jmcb/mjz001.
• [1097] Hypoxia Selectively Enhances Integrin (5)(1) Receptor Expression in Breast Cancer to Promote Metastasis.Mol Cancer Res. 2017 Jun;15(6):723-734. doi: 10.1158/1541-7786.MCR-16-0338. Epub 2017 Feb 17.
• [1098] Stromal integrin 11-deficiency reduces interstitial fluid pressure and perturbs collagen structure in triple-negative breast xenograft tumors.BMC Cancer. 2019 Mar 15;19(1):234. doi: 10.1186/s12885-019-5449-z.
• [1099] Aberrant DNA methylation of integrin 4 in human breast cancer.Tumour Biol. 2014 Jul;35(7):7079-84. doi: 10.1007/s13277-014-1952-7. Epub 2014 Apr 24.
• [1100] P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice.Mod Pathol. 2017 May;30(5):698-709. doi: 10.1038/modpathol.2016.232. Epub 2017 Jan 13.
• [1101] microRNA miR-142-3p Inhibits Breast Cancer Cell Invasiveness by Synchronous Targeting of WASL, Integrin Alpha V, and Additional Cytoskeletal Elements.PLoS One. 2015 Dec 10;10(12):e0143993. doi: 10.1371/journal.pone.0143993. eCollection 2015.
• [1102] 1 Integrin is essential for fascin-mediated breast cancer stem cell function and disease progression.Int J Cancer. 2019 Aug 1;145(3):830-841. doi: 10.1002/ijc.32183. Epub 2019 Feb 18.
• [1103] Heart toxicity from breast cancer radiotherapy : Current findings, assessment, and prevention.Strahlenther Onkol. 2019 Jan;195(1):1-12. doi: 10.1007/s00066-018-1378-z. Epub 2018 Oct 11.
• [1104] HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells.Tumour Biol. 2017 Mar;39(3):1010428317695028. doi: 10.1177/1010428317695028.
• [1105] Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10.Cancer Res. 2018 Mar 15;78(6):1404-1417. doi: 10.1158/0008-5472.CAN-17-0846. Epub 2018 Jan 12.
• [1106] Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells.Oncogene. 2011 Sep 29;30(39):4075-86. doi: 10.1038/onc.2011.122. Epub 2011 Apr 18.
• [1107] A novel variant of the putative demethylase gene, s-JMJD1C, is a coactivator of the AR.Arch Biochem Biophys. 2007 Apr 1;460(1):56-66. doi: 10.1016/j.abb.2007.01.017. Epub 2007 Feb 5.
• [1108] Chemical genomics reveals inhibition of breast cancer lung metastasis by Ponatinib via c-Jun.Protein Cell. 2019 Mar;10(3):161-177. doi: 10.1007/s13238-018-0533-8. Epub 2018 Apr 17.
• [1109] Combined Analysis of ChIP Sequencing and Gene Expression Dataset in Breast Cancer.Pathol Oncol Res. 2017 Apr;23(2):361-368. doi: 10.1007/s12253-016-0116-z. Epub 2016 Sep 21.
• [1110] Can unknown predisposition in familial breast cancer be family-specific?.Breast J. 2013 Sep-Oct;19(5):520-8. doi: 10.1111/tbj.12145. Epub 2013 Jun 26.
• [1111] Caveolin-1 facilitated KCNA5 expression, promoting breast cancer viability.Oncol Lett. 2018 Oct;16(4):4829-4838. doi: 10.3892/ol.2018.9261. Epub 2018 Aug 3.
• [1112] Inducing Polyclonal Eag1-Specific Antibodies by Vaccination with a Linear Epitope Immunogen and Its Relation to Breast Tumorigenesis.Pathol Oncol Res. 2017 Oct;23(4):761-767. doi: 10.1007/s12253-016-0158-2. Epub 2017 Jan 9.
• [1113] hERG1 channel expression associates with molecular subtypes and prognosis in breast cancer.Cancer Cell Int. 2018 Jul 5;18:93. doi: 10.1186/s12935-018-0592-1. eCollection 2018.
• [1114] GIRK1 triggers multiple cancer-related pathways in the benign mammary epithelial cell line MCF10A.Sci Rep. 2019 Dec 17;9(1):19277. doi: 10.1038/s41598-019-55683-w.
• [1115] TASK-3 Downregulation Triggers Cellular Senescence and Growth Inhibition in Breast Cancer Cell Lines.Int J Mol Sci. 2018 Mar 29;19(4):1033. doi: 10.3390/ijms19041033.
• [1116] The Maxi-K (BK) Channel Antagonist Penitrem A as a Novel Breast Cancer-Targeted Therapeutic.Mar Drugs. 2018 May 11;16(5):157. doi: 10.3390/md16050157.
• [1117] LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression.Oncogene. 2019 Oct;38(44):7017-7034. doi: 10.1038/s41388-019-0923-2. Epub 2019 Aug 13.
• [1118] JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.Breast Cancer Res. 2014 May 30;16(3):R56. doi: 10.1186/bcr3667.
• [1119] Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines.Cancers (Basel). 2019 Jan 15;11(1):92. doi: 10.3390/cancers11010092.
• [1120] KDM5B promotes breast cancer cell proliferation and migration via AMPK-mediated lipid metabolism reprogramming.Exp Cell Res. 2019 Jun 15;379(2):182-190. doi: 10.1016/j.yexcr.2019.04.006. Epub 2019 Apr 10.
• [1121] Targets and mechanisms of sulforaphane derivatives obtained from cruciferous plants with special focus on breast cancer - contradictory effects and future perspectives.Biomed Pharmacother. 2020 Jan;121:109635. doi: 10.1016/j.biopha.2019.109635. Epub 2019 Nov 15.
• [1122] KIF11 Functions as an Oncogene and Is Associated with Poor Outcomes from Breast Cancer.Cancer Res Treat. 2019 Jul;51(3):1207-1221. doi: 10.4143/crt.2018.460. Epub 2018 Dec 27.
• [1123] KIF20B promotes the progression of clear cell renal cell carcinoma by stimulating cell proliferation.J Cell Physiol. 2019 Sep;234(9):16517-16525. doi: 10.1002/jcp.28322. Epub 2019 Feb 25.
• [1124] KIF26B promotes cell proliferation and migration through the FGF2/ERK signaling pathway in breast cancer.Biomed Pharmacother. 2018 Dec;108:766-773. doi: 10.1016/j.biopha.2018.09.036. Epub 2018 Sep 22.
• [1125] Overexpression of kinesins mediates docetaxel resistance in breast cancer cells.Cancer Res. 2009 Oct 15;69(20):8035-42. doi: 10.1158/0008-5472.CAN-09-1224. Epub 2009 Sep 29.
• [1126] Increased susceptibility of breast cancer cells to stress mediated inhibition of protein synthesis.Cancer Res. 2008 Jun 15;68(12):4862-74. doi: 10.1158/0008-5472.CAN-08-0074.
• [1127] KISS1R induces invasiveness of estrogen receptor-negative human mammary epithelial and breast cancer cells.Endocrinology. 2013 Jun;154(6):1999-2014. doi: 10.1210/en.2012-2164. Epub 2013 Mar 24.
• [1128] C-Kit receptor and tryptase expressing mast cells correlate with angiogenesis in breast cancer patients.Oncotarget. 2017 Dec 22;9(8):7918-7927. doi: 10.18632/oncotarget.23722. eCollection 2018 Jan 30.
• [1129] A functional p53 responsive polymorphism in KITLG, rs4590952, does not affect the risk of breast cancer.Sci Rep. 2014 Sep 15;4:6371. doi: 10.1038/srep06371.
• [1130] Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.Biol Chem. 2018 Sep 25;399(9):937-957. doi: 10.1515/hsz-2018-0111.
• [1131] Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.Clin Cancer Res. 2019 Jan 15;25(2):881-891. doi: 10.1158/1078-0432.CCR-18-1521. Epub 2018 Sep 25.
• [1132] Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.Breast. 2016 Aug;28:191-8. doi: 10.1016/j.breast.2016.06.008. Epub 2016 Jun 20.
• [1133] The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway.Oncotarget. 2014 May 15;5(9):2390-403. doi: 10.18632/oncotarget.1235.
• [1134] Biochemical pathways mediated by KLK6 protease in breast cancer.Mol Oncol. 2019 Nov;13(11):2329-2343. doi: 10.1002/1878-0261.12493. Epub 2019 Sep 30.
• [1135] Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies.Cancer Sci. 2009 Apr;100(4):601-7. doi: 10.1111/j.1349-7006.2009.01090.x.
• [1136] Targeting Thioredoxin System with an Organosulfur Compound, Diallyl Trisulfide (DATS), Attenuates Progression and Metastasis of Triple-Negative Breast Cancer (TNBC). Cell Physiol Biochem. 2018;50(5):1945-1963. doi: 10.1159/000494874. Epub 2018 Nov 5.
• [1137] Monomethyltransferase SETD8 regulates breast cancer metabolism via stabilizing hypoxia-inducible factor 1.Cancer Lett. 2017 Apr 1;390:1-10. doi: 10.1016/j.canlet.2016.12.038. Epub 2017 Jan 13.
• [1138] SUV420H2 suppresses breast cancer cell invasion through down regulation of the SH2 domain-containing focal adhesion protein tensin-3.Exp Cell Res. 2015 May 15;334(1):90-9. doi: 10.1016/j.yexcr.2015.03.010. Epub 2015 Mar 23.
• [1139] Bioregulation of kallikrein-related peptidases 6, 10 and 11 by the kinin B?receptor in breast cancer cells.Anticancer Res. 2014 Dec;34(12):6925-38.
• [1140] Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.Hum Pathol. 2017 Apr;62:23-32. doi: 10.1016/j.humpath.2016.10.006. Epub 2016 Nov 2.
• [1141] Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer.Oncogene. 2011 Oct 27;30(43):4399-409. doi: 10.1038/onc.2011.147. Epub 2011 May 2.
• [1142] Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ER-positive advanced breast cancer.Pharmacogenomics J. 2015 Jun;15(3):235-40. doi: 10.1038/tpj.2014.58. Epub 2014 Oct 7.
• [1143] A novel role of kynureninase in the growth control of breast cancer cells and its relationships with breast cancer.J Cell Mol Med. 2019 Oct;23(10):6700-6707. doi: 10.1111/jcmm.14547. Epub 2019 Jul 22.
• [1144] L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.BMC Cancer. 2014 Dec 15;14:958. doi: 10.1186/1471-2407-14-958.
• [1145] Electrochemical immunoassay for lactalbumin based on the use of ferrocene-modified gold nanoparticles and lysozyme-modified magnetic beads.Mikrochim Acta. 2018 Sep 7;185(10):449. doi: 10.1007/s00604-018-2986-0.
• [1146] Gene expression profile and cancer-associated pathways linked to progesterone receptor isoform a (PRA) predominance in transgenic mouse mammary glands.BMC Cancer. 2018 Jun 25;18(1):682. doi: 10.1186/s12885-018-4550-z.
• [1147] LAMP1 expression is associated with poor prognosis in breast cancer.Oncol Lett. 2017 Oct;14(4):4729-4735. doi: 10.3892/ol.2017.6757. Epub 2017 Aug 16.
• [1148] Comparative expression of the LINE-1 p40 protein in human breast carcinomas and normal breast tissues.Oncol Res. 1996;8(6):239-47.
• [1149] Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.Breast Cancer Res Treat. 2020 Feb;179(3):557-564. doi: 10.1007/s10549-019-05488-2. Epub 2019 Nov 9.
• [1150] Lactate dehydrogenase A regulates autophagy and tamoxifen resistance in breast cancer.Biochim Biophys Acta Mol Cell Res. 2019 Jun;1866(6):1004-1018. doi: 10.1016/j.bbamcr.2019.03.004. Epub 2019 Mar 13.
• [1151] Metformin exhibited anticancer activity by lowering cellular cholesterol content in breast cancer cells.PLoS One. 2019 Jan 9;14(1):e0209435. doi: 10.1371/journal.pone.0209435. eCollection 2019.
• [1152] Tuning the surface coating of IONs toward efficient sonochemical tethering and sustained liberation of topoisomerase II poisons.Int J Nanomedicine. 2019 Sep 17;14:7609-7624. doi: 10.2147/IJN.S208810. eCollection 2019.
• [1153] LGR4 modulates breast cancer initiation, metastasis, and cancer stem cells.FASEB J. 2018 May;32(5):2422-2437. doi: 10.1096/fj.201700897R. Epub 2017 Dec 21.
• [1154] Prognostic impact of mRNA levels of LGR5 transcript variants in OSCC patients.BMC Cancer. 2019 Feb 15;19(1):155. doi: 10.1186/s12885-019-5327-8.
• [1155] A mandatory role of nuclear PAK4-LIFR axis in breast-to-bone metastasis of ER-positive breast cancer cells.Oncogene. 2019 Feb;38(6):808-821. doi: 10.1038/s41388-018-0456-0. Epub 2018 Sep 3.
• [1156] Inhibition of breast cancer growth via miR-7 suppressing ALDH1A3 activity concomitant with decreasing breast cancer stem cell subpopulation.J Cell Physiol. 2020 Feb;235(2):1405-1416. doi: 10.1002/jcp.29059. Epub 2019 Jul 25.
• [1157] GPER stabilizes F-actin cytoskeleton and activates TAZ via PLC-PKC and Rho/ROCK-LIMK-Cofilin pathway.Biochem Biophys Res Commun. 2019 Aug 27;516(3):976-982. doi: 10.1016/j.bbrc.2019.06.132. Epub 2019 Jul 2.
• [1158] GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis.Oncogene. 2017 Oct 5;36(40):5567-5575. doi: 10.1038/onc.2017.165. Epub 2017 Jun 5.
• [1159] Expression of Lipid Metabolism-Related Proteins Differs between Invasive Lobular Carcinoma and Invasive Ductal Carcinoma.Int J Mol Sci. 2017 Jan 23;18(1):232. doi: 10.3390/ijms18010232.
• [1160] LIPG-promoted lipid storage mediates adaptation to oxidative stress in breast cancer.Int J Cancer. 2019 Aug 15;145(4):901-915. doi: 10.1002/ijc.32138. Epub 2019 Feb 7.
• [1161] A comprehensive function analysis of LMO2 in different breast cancer subtypes.Oncotarget. 2017 Dec 21;9(10):8911-8926. doi: 10.18632/oncotarget.23542. eCollection 2018 Feb 6.
• [1162] Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.JAMA Oncol. 2019 Mar 1;5(3):366-375. doi: 10.1001/jamaoncol.2018.6012.
• [1163] MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells.Tumour Biol. 2014 Nov;35(11):11137-45. doi: 10.1007/s13277-014-2412-0. Epub 2014 Aug 8.
• [1164] Lysyl Oxidase-Like Protein 2 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer.Neoplasia. 2019 Apr;21(4):413-427. doi: 10.1016/j.neo.2019.03.003. Epub 2019 Mar 27.
• [1165] Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target.Oncotarget. 2018 May 4;9(34):23462-23481. doi: 10.18632/oncotarget.25231. eCollection 2018 May 4.
• [1166] Expression of AutotaxinLysophosphatidate Signaling-Related Proteins in Breast Cancer with Adipose Stroma.Int J Mol Sci. 2019 Apr 29;20(9):2102. doi: 10.3390/ijms20092102.
• [1167] Lysophosphatidic Acid Receptor 6 (LPAR6) Expression and Prospective Signaling Pathway Analysis in Breast Cancer.Mol Diagn Ther. 2019 Feb;23(1):127-138. doi: 10.1007/s40291-019-00384-3.
• [1168] LRP6 Ectodomain Prevents SDF-1/CXCR4-Induced Breast Cancer Metastasis to Lung.Clin Cancer Res. 2019 Aug 1;25(15):4832-4845. doi: 10.1158/1078-0432.CCR-18-3557. Epub 2019 Apr 22.
• [1169] IGHG, IGKC, and FCGR genes and endogenous antibody responses to GARP in patients with breast cancer and matched controls.Hum Immunol. 2018 Aug;79(8):632-637. doi: 10.1016/j.humimm.2018.06.001. Epub 2018 Jun 4.
• [1170] A sparse regulatory network of copy-number driven gene expression reveals putative breast cancer oncogenes.IEEE/ACM Trans Comput Biol Bioinform. 2012 Jul-Aug;9(4):947-54. doi: 10.1109/TCBB.2011.105.
• [1171] Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Mllerian serous carcinomas: clinical divergence without immunophenotypic differences.Gynecol Oncol. 2000 Dec;79(3):430-7. doi: 10.1006/gyno.2000.6000.
• [1172] The lymphotoxin- 252A>G polymorphism and breast cancer: a meta-analysis.Asian Pac J Cancer Prev. 2012;13(5):1949-52. doi: 10.7314/apjcp.2012.13.5.1949.
• [1173] Antibacterial Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Cytotoxic Effect against MDA-MB-468 and MDA-MB-231 Breast Cancer Cell Lines.Molecules. 2017 Sep 29;22(10):1641. doi: 10.3390/molecules22101641.
• [1174] Diagnostic utility of CD205 in breast cancer: Simultaneous detection of myoepithelial cells and dendritic cells in breast tissue by CD205.Histol Histopathol. 2020 May;35(5):481-488. doi: 10.14670/HH-18-164. Epub 2019 Sep 16.
• [1175] Dual Mechanisms of LYN Kinase Dysregulation Drive Aggressive Behavior in Breast Cancer Cells.Cell Rep. 2018 Dec 26;25(13):3674-3692.e10. doi: 10.1016/j.celrep.2018.11.103.
• [1176] The effect of neoadjuvant chemotherapy on the correlation of tumor-associated macrophages with CD31 and LYVE-1.Immunobiology. 2018 Jun-Jul;223(6-7):449-459. doi: 10.1016/j.imbio.2017.10.050. Epub 2017 Oct 31.
• [1177] An -tocopheryl succinate enzyme-based nanoassembly for cancer imaging and therapy.Drug Deliv. 2018 Nov;25(1):738-749. doi: 10.1080/10717544.2018.1446476.
• [1178] Mad1 destabilizes p53 by preventing PML from sequestering MDM2.Nat Commun. 2019 Apr 4;10(1):1540. doi: 10.1038/s41467-019-09471-9.
• [1179] MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation.Cancer Res. 1996 Jan 1;56(1):16-20.
• [1180] Minimal prognostic significance of sentinel lymph node metastasis in patients with cT1-2 and cN0 breast cancer.World J Surg Oncol. 2019 Feb 23;17(1):41. doi: 10.1186/s12957-019-1585-9.
• [1181] Heterogeneous Responses of Axillary Lymph Node Metastases to Neoadjuvant Chemotherapy are Common and Depend on Breast Cancer Subtype.Ann Surg Oncol. 2019 Dec;26(13):4381-4389. doi: 10.1245/s10434-019-07915-6. Epub 2019 Oct 11.
• [1182] Crk adaptor proteins act as key signaling integrators for breast tumorigenesis.Breast Cancer Res. 2012 May 8;14(3):R74. doi: 10.1186/bcr3183.
• [1183] Monoamine oxidase-A activity is required for clonal tumorsphere formation by human breast tumor cells.Cell Mol Biol Lett. 2019 Nov 12;24:59. doi: 10.1186/s11658-019-0183-8. eCollection 2019.
• [1184] Diet and lifestyle factors interact with MAPK genes to influence survival: the Breast Cancer Health Disparities Study.Cancer Causes Control. 2014 Sep;25(9):1211-25. doi: 10.1007/s10552-014-0426-y. Epub 2014 Jul 4.
• [1185] A kinome-wide high-content siRNA screen identifies MEK5-ERK5 signaling as critical for breast cancer cell EMT and metastasis.Oncogene. 2018 Aug;37(31):4197-4213. doi: 10.1038/s41388-018-0270-8. Epub 2018 May 1.
• [1186] MST-312 Alters Telomere Dynamics, Gene Expression Profiles and Growth in Human Breast Cancer Cells.J Nutrigenet Nutrigenomics. 2014;7(4-6):283-98. doi: 10.1159/000381346. Epub 2015 May 27.
• [1187] Mixed lineage kinase 3 promotes breast tumorigenesis via phosphorylation and activation of p21-activated kinase 1.Oncogene. 2019 May;38(19):3569-3584. doi: 10.1038/s41388-019-0690-0. Epub 2019 Jan 21.
• [1188] NF-kappa-inducing kinase regulates stem cell phenotype in breast cancer.Sci Rep. 2016 Nov 23;6:37340. doi: 10.1038/srep37340.
• [1189] Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells.J Pathol. 2014 Jan;232(1):75-86. doi: 10.1002/path.4283.
• [1190] HER2/HER3 regulates lactate secretion and expression of lactate receptor mRNA through the MAP3K4 associated protein GIT1.Sci Rep. 2019 Jul 25;9(1):10823. doi: 10.1038/s41598-019-46954-7.
• [1191] Upregulation of p38 pathway accelerates proliferation and migration of MDA-MB-231 breast cancer cells.Oncol Rep. 2017 Apr;37(4):2497-2505. doi: 10.3892/or.2017.5452. Epub 2017 Feb 14.
• [1192] Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation.Carcinogenesis. 2014 Jun;35(6):1352-61. doi: 10.1093/carcin/bgu044. Epub 2014 Feb 11.
• [1193] Function of microRNA?41 in human breast cancer through cytotoxic CD4+ T cells regulated by MAP4K4 expression.Mol Med Rep. 2018 Jun;17(6):7893-7901. doi: 10.3892/mmr.2018.8814. Epub 2018 Mar 28.
• [1194] MicroRNA-21 promotes progression of breast cancer via inhibition of mitogen-activated protein kinase10 (MAPK10).Biosci Rep. 2019 Aug 2:BSR20181000. doi: 10.1042/BSR20181000. Online ahead of print.
• [1195] A novel role for atypical MAPK kinase ERK3 in regulating breast cancer cell morphology and migration.Cell Adh Migr. 2015;9(6):483-94. doi: 10.1080/19336918.2015.1112485.
• [1196] Ribosomal protein small subunit 15A (RPS15A) inhibits the apoptosis of breast cancer MDA-MB-231 cells via upregulating phosphorylated ERK1/2, Bad, and Chk1.J Cell Biochem. 2020 Jan;121(1):587-595. doi: 10.1002/jcb.29304. Epub 2019 Sep 18.
• [1197] MicroRNA-155regulates the proliferation and metastasis of human breast cancers by targeting MAPK7.J BUON. 2019 May-Jun;24(3):1075-1080.
• [1198] Alternative promotion and suppression of metastasis by JNK2 governed by its phosphorylation.Oncotarget. 2017 Apr 28;8(34):56569-56581. doi: 10.18632/oncotarget.17507. eCollection 2017 Aug 22.
• [1199] Overexpression of MAPT-AS1 is associated with better patient survival in breast cancer.Biochem Cell Biol. 2019 Apr;97(2):158-164. doi: 10.1139/bcb-2018-0039. Epub 2018 Aug 3.
• [1200] Validation study of MARCKSL1 as a prognostic factor in lymph node-negative breast cancer patients.PLoS One. 2019 Mar 11;14(3):e0212527. doi: 10.1371/journal.pone.0212527. eCollection 2019.
• [1201] A novel estrogen receptor-microRNA 190a-PAR-1-pathway regulates breast cancer progression, a finding initially suggested by genome-wide analysis of loci associated with lymph-node metastasis.Hum Mol Genet. 2014 Jan 15;23(2):355-67. doi: 10.1093/hmg/ddt426. Epub 2013 Sep 5.
• [1202] Angiotensin 1-7 formation in breast tissue is attenuated in breast cancer - a study on the metabolism of angiotensinogen in breast cancer cell lines.J Physiol Pharmacol. 2019 Aug;70(4). doi: 10.26402/jpp.2019.4.02. Epub 2019 Oct 19.
• [1203] Dual function of MAZ mediated by FOXF2 in basal-like breast cancer: Promotion of proliferation and suppression of progression.Cancer Lett. 2017 Aug 28;402:142-152. doi: 10.1016/j.canlet.2017.05.020. Epub 2017 May 31.
• [1204] Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide.Eur J Cancer. 2017 Jan;71:15-24. doi: 10.1016/j.ejca.2016.10.035. Epub 2016 Dec 8.
• [1205] The natural compound neobractatin inhibits tumor metastasis by upregulating the RNA-binding-protein MBNL2.Cell Death Dis. 2019 Jul 18;10(8):554. doi: 10.1038/s41419-019-1789-5.
• [1206] A novel human ghrelin variant (In1-ghrelin) and ghrelin-O-acyltransferase are overexpressed in breast cancer: potential pathophysiological relevance.PLoS One. 2011;6(8):e23302. doi: 10.1371/journal.pone.0023302. Epub 2011 Aug 4.
• [1207] Expansion of Sphingosine Kinase and Sphingosine-1-Phosphate Receptor Function in Normal and Cancer Cells: From Membrane Restructuring to Mediation of Estrogen Signaling and Stem Cell Programming.Int J Mol Sci. 2018 Jan 31;19(2):420. doi: 10.3390/ijms19020420.
• [1208] MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk.Int J Cancer. 2006 Dec 1;119(11):2597-602. doi: 10.1002/ijc.22210.
• [1209] Aberrant promoter methylation may be responsible for the control of CD146 (MCAM) gene expression during breast cancer progression.Acta Biochim Pol. 2019 Dec 11;66(4):619-625. doi: 10.18388/abp.2019_2907.
• [1210] MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis.Neoplasia. 2019 Oct;21(10):1015-1035. doi: 10.1016/j.neo.2019.07.011. Epub 2019 Aug 30.
• [1211] A network-based approach to identify disease-associated gene modules through integrating DNA methylation and gene expression.Biochem Biophys Res Commun. 2015 Sep 25;465(3):437-42. doi: 10.1016/j.bbrc.2015.08.033. Epub 2015 Aug 14.
• [1212] The clinical and prognostic significance of midkine in breast cancer patients.Tumour Biol. 2015 Dec;36(12):9789-94. doi: 10.1007/s13277-015-3710-x. Epub 2015 Jul 10.
• [1213] Reduction in milk fat globule-EGF factor 8 inhibits triple-negative breast cancer cell viability and migration.Oncol Lett. 2019 Mar;17(3):3457-3465. doi: 10.3892/ol.2019.9968. Epub 2019 Jan 25.
• [1214] Epigenetic modulation of BRCA-1 and MGMT genes, and histones H4 and H3 are associated with breast tumors.J Cell Biochem. 2019 Aug;120(8):13726-13736. doi: 10.1002/jcb.28645. Epub 2019 Apr 2.
• [1215] Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy.Cancer Res. 2003 Oct 15;63(20):6815-24.
• [1216] Association of genetic polymorphisms in MIF with breast cancer risk in Chinese women.Clin Exp Med. 2017 Aug;17(3):395-401. doi: 10.1007/s10238-016-0439-9. Epub 2016 Nov 14.
• [1217] Impact of chemotherapy on the expression of claudins and cadherins in invasive breast cancer.Exp Ther Med. 2019 Oct;18(4):3014-3024. doi: 10.3892/etm.2019.7930. Epub 2019 Aug 20.
• [1218] Increased expression of MNK1b, the spliced isoform of MNK1, predicts poor prognosis and is associated with triple-negative breast cancer.Oncotarget. 2018 Feb 5;9(17):13501-13516. doi: 10.18632/oncotarget.24417. eCollection 2018 Mar 2.
• [1219] MNK1 and MNK2 regulation in HER2-overexpressing breast cancer lines.J Biol Chem. 2007 Feb 16;282(7):4243-4252. doi: 10.1074/jbc.M607368200. Epub 2006 Nov 27.
• [1220] False-positive cells in sentinel lymph nodes.Semin Diagn Pathol. 2008 May;25(2):116-9. doi: 10.1053/j.semdp.2008.03.001.
• [1221] Characterization of a P-Rex1 gene signature in breast cancer cells.Oncotarget. 2016 Aug 9;7(32):51335-51348. doi: 10.18632/oncotarget.10285.
• [1222] MMP11 expression in intratumoral inflammatory cells in breast cancer.Histopathology. 2019 Dec;75(6):916-930. doi: 10.1111/his.13956. Epub 2019 Oct 10.
• [1223] circRNACER mediates malignant progression of breast cancer through targeting the miR?36/MMP13 axis.Mol Med Rep. 2019 Apr;19(4):3314-3320. doi: 10.3892/mmr.2019.9965. Epub 2019 Feb 18.
• [1224] SNX27-retromer assembly recycles MT1-MMP to invadopodia and promotes breast cancer metastasis.J Cell Biol. 2020 Jan 6;219(1):e201812098. doi: 10.1083/jcb.201812098.
• [1225] MT4-MMP: The GPI-Anchored Membrane-Type Matrix Metalloprotease with Multiple Functions in Diseases.Int J Mol Sci. 2019 Jan 16;20(2):354. doi: 10.3390/ijms20020354.
• [1226] Investigating the regulation mechanism of baicalin on triple negative breast cancer's biological network by a systematic biological strategy.Biomed Pharmacother. 2019 Oct;118:109253. doi: 10.1016/j.biopha.2019.109253. Epub 2019 Aug 27.
• [1227] MicroRNA-429 inhibits bone metastasis in breast cancer by regulating CrkL and MMP-9.Bone. 2020 Jan;130:115139. doi: 10.1016/j.bone.2019.115139. Epub 2019 Nov 6.
• [1228] The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo.Cancer Res. 2007 Nov 1;67(21):10230-40. doi: 10.1158/0008-5472.CAN-06-3496.
• [1229] The RNA-binding protein Musashi 1 stabilizes the oncotachykinin 1 mRNA in breast cancer cells to promote cell growth. FASEB J. 2016 Jan;30(1):149-59.
• [1230] Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers. Clin Cancer Res. 2019 Aug 1;25(15):4723-4734.
• [1231] Clinical and transcriptional signatures of human CD204 reveal an applicable marker for the protumor phenotype of tumor-associated macrophages in breast cancer.Aging (Albany NY). 2019 Dec 4;11(23):10883-10901. doi: 10.18632/aging.102490. Epub 2019 Dec 4.
• [1232] Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy.Nat Commun. 2018 Nov 19;9(1):4848. doi: 10.1038/s41467-018-07058-4.
• [1233] A case-control study of Metallothionein-1 expression in breast cancer and breast fibroadenoma.Sci Rep. 2019 May 15;9(1):7407. doi: 10.1038/s41598-019-43565-0.
• [1234] Polymorphisms in circadian genes, night work and breast cancer: results from the GENICA study.Chronobiol Int. 2014 Dec;31(10):1115-22. doi: 10.3109/07420528.2014.957301. Epub 2014 Sep 17.
• [1235] The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases.Clin Cancer Res. 2019 Jun 1;25(11):3374-3383. doi: 10.1158/1078-0432.CCR-18-3049. Epub 2019 Feb 22.
• [1236] Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors.Oncotarget. 2018 Apr 24;9(31):22158-22183. doi: 10.18632/oncotarget.25243. eCollection 2018 Apr 24.
• [1237] Mucin synthesis and secretion in various human epithelial cancer cell lines that express the MUC-1 mucin gene.Cancer Res. 1993 Mar 15;53(6):1437-43.
• [1238] Chemokine C-C motif ligand 18 expression correlates with tumor malignancy in breast cancer.Pathol Biol (Paris). 2015 Sep;63(4-5):199-203. doi: 10.1016/j.patbio.2015.07.001. Epub 2015 Aug 17.
• [1239] MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cells.Oncogene. 2019 Jun;38(26):5239-5249. doi: 10.1038/s41388-019-0789-3. Epub 2019 Apr 10.
• [1240] MiR-155-3p acts as a tumor suppressor and reverses paclitaxel resistance via negative regulation of MYD88 in human breast cancer.Gene. 2019 Jun 5;700:85-95. doi: 10.1016/j.gene.2019.02.066. Epub 2019 Mar 13.
• [1241] Loss of MLCK leads to disruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling.Oncogene. 2016 Aug 25;35(34):4495-508. doi: 10.1038/onc.2015.508. Epub 2016 Feb 15.
• [1242] FOXO1 functions in the regulation of nicotinamide phosphoribosyltransferase (Nampt) expression.Biochem Biophys Res Commun. 2019 Apr 2;511(2):398-403. doi: 10.1016/j.bbrc.2019.02.069. Epub 2019 Feb 21.
• [1243] CD56 expression in breast cancer induces sensitivity to natural killer-mediated cytotoxicity by enhancing the formation of cytotoxic immunological synapse.Sci Rep. 2019 Jun 19;9(1):8756. doi: 10.1038/s41598-019-45377-8.
• [1244] Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene.Carcinogenesis. 2001 Sep;22(9):1521-6. doi: 10.1093/carcin/22.9.1521.
• [1245] Nectin-4 Expression Is an Independent Prognostic Biomarker and Associated With Better Survival in Triple-Negative Breast Cancer.Front Med (Lausanne). 2019 Sep 13;6:200. doi: 10.3389/fmed.2019.00200. eCollection 2019.
• [1246] Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFkappaB-dependent transcription.Nat Cell Biol. 2006 Oct;8(10):1171-7. doi: 10.1038/ncb1483. Epub 2006 Sep 24.
• [1247] Vesicular trafficking-related proteins as the potential therapeutic target for breast cancer.Protoplasma. 2020 Mar;257(2):345-352. doi: 10.1007/s00709-019-01462-3. Epub 2019 Dec 11.
• [1248] Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism.Oncogene. 2015 Mar 5;34(10):1220-30. doi: 10.1038/onc.2014.67. Epub 2014 Mar 24.
• [1249] Overexpression of NIMA-related kinase 6 (NEK6) contributes to malignant growth and dismal prognosis in Human Breast Cancer.Pathol Res Pract. 2018 Oct;214(10):1648-1654. doi: 10.1016/j.prp.2018.07.030. Epub 2018 Jul 27.
• [1250] miR-376a inhibits breast cancer cell progression by targeting neuropilin-1 NR.Onco Targets Ther. 2018 Aug 30;11:5293-5302. doi: 10.2147/OTT.S173416. eCollection 2018.
• [1251] The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).BMC Cancer. 2019 Feb 28;19(1):187. doi: 10.1186/s12885-019-5373-2.
• [1252] Deficiency of tumor suppressor Merlin facilitates metabolic adaptation by co-operative engagement of SMAD-Hippo signaling in breast cancer.Carcinogenesis. 2018 Sep 21;39(9):1165-1175. doi: 10.1093/carcin/bgy078.
• [1253] Fabrication and characterization of solid lipid nano-formulation of astraxanthin against DMBA-induced breast cancer via Nrf-2-Keap1 and NF-kB and mTOR/Maf-1/PTEN pathway.Drug Deliv. 2019 Dec;26(1):975-988. doi: 10.1080/10717544.2019.1667454.
• [1254] The p52 isoform of SHC1 is a key driver of breast cancer initiation.Breast Cancer Res. 2019 Jun 15;21(1):74. doi: 10.1186/s13058-019-1155-7.
• [1255] Selection of a breast cancer subpopulation-specific antibody using phage display on tissue sections.Immunol Res. 2015 Jul;62(3):263-72. doi: 10.1007/s12026-015-8657-x.
• [1256] Knockout model reveals the role of Nischarin in mammary gland development, breast tumorigenesis and response to metformin treatment.Int J Cancer. 2020 May 1;146(9):2576-2587. doi: 10.1002/ijc.32690. Epub 2019 Oct 31.
• [1257] Nkx3-1 and LEF-1 function as transcriptional inhibitors of estrogen receptor activity.Cancer Res. 2008 Sep 15;68(18):7380-5. doi: 10.1158/0008-5472.CAN-08-0133.
• [1258] miR-146a promoted breast cancer proliferation and invasion by regulating NM23-H1.J Biochem. 2020 Jan 1;167(1):41-48. doi: 10.1093/jb/mvz079.
• [1259] Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway.Oncotarget. 2017 May 30;8(22):36246-36265. doi: 10.18632/oncotarget.16121.
• [1260] Transcription Levels of nicotinamide nucleotide transhydrogenase and Its Antisense in Breast Cancer Samples.Cell J. 2019 Oct;21(3):331-336. doi: 10.22074/cellj.2019.6238. Epub 2019 Jun 15.
• [1261] MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ.Cancer Res. 2019 Apr 1;79(7):1646-1657. doi: 10.1158/0008-5472.CAN-18-1602. Epub 2019 Jan 18.
• [1262] Systemic RALA/iNOS Nanoparticles: A Potent Gene Therapy for Metastatic Breast Cancer Coupled as a Biomarker of Treatment.Mol Ther Nucleic Acids. 2017 Mar 17;6:249-258. doi: 10.1016/j.omtn.2016.12.010. Epub 2016 Dec 31.
• [1263] Deubiquitylation and stabilization of Notch1 intracellular domain by ubiquitin-specific protease 8 enhance tumorigenesis in breast cancer.Cell Death Differ. 2020 Apr;27(4):1341-1354. doi: 10.1038/s41418-019-0419-1. Epub 2019 Sep 17.
• [1264] Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry.Br J Cancer. 2019 Jul;121(2):157-171. doi: 10.1038/s41416-019-0501-y. Epub 2019 Jun 26.
• [1265] The frequency of CpG and non-CpG methylation of Notch3 gene promoter determines its expression levels in breast cancer cells.Exp Cell Res. 2020 Jan 15;386(2):111743. doi: 10.1016/j.yexcr.2019.111743. Epub 2019 Nov 23.
• [1266] The PI3K/Akt/GSK-3/ROS/eIF2B pathway promotes breast cancer growth and metastasis via suppression of NK cell cytotoxicity and tumor cell susceptibility.Cancer Biol Med. 2019 Feb;16(1):38-54. doi: 10.20892/j.issn.2095-3941.2018.0253.
• [1267] BNP as a potential biomarker for cardiac damage of breast cancer after radiotherapy: a meta-analysis.Medicine (Baltimore). 2019 Jul;98(29):e16507. doi: 10.1097/MD.0000000000016507.
• [1268] Identification of breast cancer candidate genes using gene co-expression and protein-protein interaction information.Oncotarget. 2016 Jun 14;7(24):36092-36100. doi: 10.18632/oncotarget.9132.
• [1269] Neuropeptide Y Y5 receptor promotes cell growth through extracellular signal-regulated kinase signaling and cyclic AMP inhibition in a human breast cancer cell line.Mol Cancer Res. 2010 Apr;8(4):604-14. doi: 10.1158/1541-7786.MCR-09-0301. Epub 2010 Mar 23.
• [1270] Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy.Pharmacogenet Genomics. 2011 Dec;21(12):808-19. doi: 10.1097/FPC.0b013e32834b6918.
• [1271] WMJ-8-B, a novel hydroxamate derivative, induces MDA-MB-231 breast cancer cell death via the SHP-1-STAT3-survivin cascade.Br J Pharmacol. 2017 Sep;174(17):2941-2961. doi: 10.1111/bph.13929. Epub 2017 Aug 1.
• [1272] High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy.Breast Cancer Res. 2019 Nov 28;21(1):127. doi: 10.1186/s13058-019-1197-x.
• [1273] Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells.Cell Oncol (Dordr). 2018 Feb;41(1):13-24. doi: 10.1007/s13402-017-0353-5. Epub 2017 Oct 9.
• [1274] LRH1 enhances cell resistance to chemotherapy by transcriptionally activating MDC1 expression and attenuating DNA damage in human breast cancer.Oncogene. 2018 Jun;37(24):3243-3259. doi: 10.1038/s41388-018-0193-4. Epub 2018 Mar 16.
• [1275] Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer.J Pathol. 2004 Jun;203(2):672-80. doi: 10.1002/path.1561.
• [1276] RNA binding protein PUM2 promotes the stemness of breast cancer cells via competitively binding to neuropilin-1 (NRP-1) mRNA with miR-376a.Biomed Pharmacother. 2019 Jun;114:108772. doi: 10.1016/j.biopha.2019.108772. Epub 2019 Mar 23.
• [1277] GLI1 regulates a novel neuropilin-2/61 integrin based autocrine pathway that contributes to breast cancer initiation.EMBO Mol Med. 2013 Apr;5(4):488-508. doi: 10.1002/emmm.201202078. Epub 2013 Feb 21.
• [1278] CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.J Clin Invest. 2020 Mar 2;130(3):1185-1198. doi: 10.1172/JCI128895.
• [1279] Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival.Clin Cancer Res. 2011 Apr 1;17(7):1741-52. doi: 10.1158/1078-0432.CCR-10-1890. Epub 2011 Feb 24.
• [1280] The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma.Hum Pathol. 2019 Apr;86:182-192. doi: 10.1016/j.humpath.2018.12.003. Epub 2018 Dec 27.
• [1281] Clinical characteristics of acinic cell carcinoma and secretory carcinoma of the parotid gland.Eur Arch Otorhinolaryngol. 2019 Dec;276(12):3461-3466. doi: 10.1007/s00405-019-05604-4. Epub 2019 Aug 22.
• [1282] Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.Oncotarget. 2014 Sep 30;5(18):8235-51. doi: 10.18632/oncotarget.1632.
• [1283] Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer.Int J Mol Med. 2019 Aug;44(2):390-404. doi: 10.3892/ijmm.2019.4239. Epub 2019 Jun 11.
• [1284] -ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis.Cell Death Dis. 2018 Jul 9;9(7):756. doi: 10.1038/s41419-018-0802-8.
• [1285] Pro-oncogenic action of LOX-1 and its splice variant LOX-14 in breast cancer phenotypes.Cell Death Dis. 2019 Jan 18;10(2):53. doi: 10.1038/s41419-018-1279-1.
• [1286] -Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer.Tumour Biol. 2015 Jun;36(6):4655-60. doi: 10.1007/s13277-015-3113-z. Epub 2015 Jan 25.
• [1287] ORAI1 and ORAI3 in Breast Cancer Molecular Subtypes and the Identification of ORAI3 as a Hypoxia Sensitive Gene and a Regulator of Hypoxia Responses.Cancers (Basel). 2019 Feb 11;11(2):208. doi: 10.3390/cancers11020208.
• [1288] miR-181b/Oncostatin m axis inhibits prostate cancer bone metastasis via modulating osteoclast differentiation.J Cell Biochem. 2020 Feb;121(2):1664-1674. doi: 10.1002/jcb.29401. Epub 2019 Nov 3.
• [1289] Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma.J Pathol. 2014 Mar;232(4):386-90. doi: 10.1002/path.4305.
• [1290] Preventive effects of oxytocin and oxytocin receptor in breast cancer pathogenesis.Per Med. 2019 Jan;16(1):25-34. doi: 10.2217/pme-2018-0009. Epub 2018 Nov 19.
• [1291] Involvement of the P2X7 receptor in the migration and metastasis of tamoxifen-resistant breast cancer: effects on small extracellular vesicles production.Sci Rep. 2019 Aug 12;9(1):11587. doi: 10.1038/s41598-019-47734-z.
• [1292] Altered purinergic receptor-Ca?signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells.Mol Oncol. 2016 Jan;10(1):166-78. doi: 10.1016/j.molonc.2015.09.006. Epub 2015 Sep 25.
• [1293] An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells. Cancer Sci. 2011 Jul;102(7):1410-7. doi: 10.1111/j.1349-7006.2011.01948.x. Epub 2011 May 5.
• [1294] IGHMBP2 Thr671Ala polymorphism might be a modifier for the effects of cigarette smoking and PAH-DNA adducts to breast cancer risk.Breast Cancer Res Treat. 2006 Sep;99(1):1-7. doi: 10.1007/s10549-006-9174-3. Epub 2006 Jun 5.
• [1295] MiR-142-3p functions as a tumor suppressor by targeting RAC1/PAK1 pathway in breast cancer.J Cell Physiol. 2020 May;235(5):4928-4940. doi: 10.1002/jcp.29372. Epub 2019 Oct 31.
• [1296] Effect of physical exercise on cognitive function and brain measures after chemotherapy in patients with breast cancer (PAM study): protocol of a randomised controlled trial.BMJ Open. 2019 Jun 20;9(6):e028117. doi: 10.1136/bmjopen-2018-028117.
• [1297] Inducible expression of maize polyamine oxidase in the nucleus of MCF-7 human breast cancer cells confers sensitivity to etoposide.Amino Acids. 2008 Apr;34(3):403-12. doi: 10.1007/s00726-007-0558-4. Epub 2007 Jul 4.
• [1298] Oncogenic activity of poly (ADP-ribose) glycohydrolase.Oncogene. 2019 Mar;38(12):2177-2191. doi: 10.1038/s41388-018-0568-6. Epub 2018 Nov 20.
• [1299] PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.Cell Death Differ. 2019 Sep;26(9):1615-1630. doi: 10.1038/s41418-018-0233-1. Epub 2018 Nov 15.
• [1300] The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells.J Cell Sci. 2005 Mar 15;118(Pt 6):1245-53. doi: 10.1242/jcs.01704. Epub 2005 Mar 1.
• [1301] Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer.Dev Cell. 2017 Nov 20;43(4):418-435.e13. doi: 10.1016/j.devcel.2017.10.027.
• [1302] Chaperonin Containing TCP-1 Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide.Clin Cancer Res. 2016 Sep 1;22(17):4366-79. doi: 10.1158/1078-0432.CCR-15-2502. Epub 2016 Mar 24.
• [1303] Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis.Mol Cancer Ther. 2020 Mar;19(3):802-811. doi: 10.1158/1535-7163.MCT-19-0495. Epub 2019 Dec 3.
• [1304] Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management.J Mol Diagn. 2019 Mar;21(2):307-317. doi: 10.1016/j.jmoldx.2018.10.006. Epub 2018 Dec 18.
• [1305] A microarray based expression profiling of paclitaxel and vincristine resistant MCF-7 cells.Eur J Pharmacol. 2011 Apr 25;657(1-3):4-9. doi: 10.1016/j.ejphar.2011.02.001. Epub 2011 Feb 18.
• [1306] Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.J Clin Oncol. 2003 Sep 15;21(18):3454-61. doi: 10.1200/JCO.2003.02.114.
• [1307] Epac1, PDE4, and PKC protein expression and their association with AKAP95, Cx43, and cyclinD2/E1 in breast cancer tissues.Thorac Cancer. 2017 Sep;8(5):495-500. doi: 10.1111/1759-7714.12475. Epub 2017 Jul 29.
• [1308] Systematic identification of regulatory variants associated with cancer risk.Genome Biol. 2017 Oct 23;18(1):194. doi: 10.1186/s13059-017-1322-z.
• [1309] Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.Clin Cancer Res. 2018 Apr 15;24(8):1987-2001. doi: 10.1158/1078-0432.CCR-17-2776. Epub 2018 Jan 31.
• [1310] Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression.Cancers (Basel). 2019 Nov 6;11(11):1740. doi: 10.3390/cancers11111740.
• [1311] Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth.Oncogene. 2019 Feb;38(7):1106-1120. doi: 10.1038/s41388-018-0499-2. Epub 2018 Sep 12.
• [1312] FoxM1 promotes breast tumorigenesis by activating PDGF-A and forming a positive feedback loop with the PDGF/AKT signaling pathway.Oncotarget. 2015 May 10;6(13):11281-94. doi: 10.18632/oncotarget.3596.
• [1313] Platelet-derived growth factor-D promotes colorectal cancer cell migration, invasion and proliferation by regulating Notch1 and matrix metalloproteinase-9.Oncol Lett. 2018 Feb;15(2):1573-1579. doi: 10.3892/ol.2017.7510. Epub 2017 Dec 5.
• [1314] Betulinic acid suppresses breast cancer aerobic glycolysis via caveolin-1/NF-B/c-Myc pathway.Biochem Pharmacol. 2019 Mar;161:149-162. doi: 10.1016/j.bcp.2019.01.016. Epub 2019 Jan 24.
• [1315] Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation.Cancers (Basel). 2019 Oct 31;11(11):1695. doi: 10.3390/cancers11111695.
• [1316] Downregulation of pancreatic-duodenal homeobox 1 expression in breast cancer patients: a mechanism of proliferation and apoptosis in cancer.Mol Med Rep. 2012 Nov;6(5):983-8. doi: 10.3892/mmr.2012.1067. Epub 2012 Sep 5.
• [1317] Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.Nat Genet. 2015 Apr;47(4):373-80. doi: 10.1038/ng.3242. Epub 2015 Mar 9.
• [1318] RKIP regulates CCL5 expression to inhibit breast cancer invasion and metastasis by controlling macrophage infiltration.Oncotarget. 2015 Nov 17;6(36):39050-61. doi: 10.18632/oncotarget.5176.
• [1319] 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.Clin Cancer Res. 2019 Sep 15;25(18):5702-5716. doi: 10.1158/1078-0432.CCR-18-3448. Epub 2019 Aug 7.
• [1320] Overall survival in women with breast cancer: the influence of pepsinogen C gene polymorphism.DNA Cell Biol. 2008 Jun;27(6):333-6. doi: 10.1089/dna.2007.0713.
• [1321] Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation.Clin Transl Oncol. 2018 Sep;20(9):1145-1152. doi: 10.1007/s12094-018-1833-4. Epub 2018 Jan 16.
• [1322] Development of diagnostic SCAR markers for genomic DNA amplifications in breast carcinoma by DNA cloning of high-GC RAMP-PCR fragments.Oncotarget. 2017 Jul 4;8(27):43866-43877. doi: 10.18632/oncotarget.16704.
• [1323] Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression.J Biol Chem. 2003 Aug 8;278(32):29420-34. doi: 10.1074/jbc.M301885200. Epub 2003 May 14.
• [1324] Targeting PML in triple negative breast cancer elicits growth suppression and senescence.Cell Death Differ. 2020 Apr;27(4):1186-1199. doi: 10.1038/s41418-019-0407-5. Epub 2019 Oct 1.
• [1325] Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer.Oncol Lett. 2018 Apr;15(4):5236-5242. doi: 10.3892/ol.2018.7915. Epub 2018 Jan 31.
• [1326] Detection and Differentiation of Breast Cancer Sub-Types using a cPLA2 Activatable Fluorophore.Sci Rep. 2019 Apr 16;9(1):6122. doi: 10.1038/s41598-019-41626-y.
• [1327] Prognostic significance of PLA2G4C gene polymorphism in patients with stage II colorectal cancer.Acta Oncol. 2016;55(4):474-9. doi: 10.3109/0284186X.2015.1073350. Epub 2015 Sep 12.
• [1328] PLAC1 as a serum biomarker for breast cancer.PLoS One. 2018 Feb 12;13(2):e0192106. doi: 10.1371/journal.pone.0192106. eCollection 2018.
• [1329] Mitochondrial targeting of TR3 is involved in TPA induced apoptosis in breast cancer cells.Gene. 2019 Apr 20;693:61-68. doi: 10.1016/j.gene.2018.12.072. Epub 2019 Jan 11.
• [1330] Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.J Med Chem. 2019 Feb 28;62(4):2172-2183. doi: 10.1021/acs.jmedchem.8b01908. Epub 2019 Feb 15.
• [1331] Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer.Cancer Res. 2013 Apr 1;73(7):2070-81. doi: 10.1158/0008-5472.CAN-12-3526. Epub 2013 Feb 11.
• [1332] Expression of phospholipase C isozymes in human breast cancer and their clinical significance.Oncol Rep. 2017 Mar;37(3):1707-1715. doi: 10.3892/or.2017.5394. Epub 2017 Jan 20.
• [1333] Co-Delivery of Paclitaxel and PLK1-Targeted siRNA Using Aptamer-Functionalized Cationic Liposome for Synergistic Anti-Breast Cancer Effects In Vivo.J Biomed Nanotechnol. 2019 Jun 1;15(6):1135-1148. doi: 10.1166/jbn.2019.2751.
• [1334] Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features.Nat Commun. 2018 Oct 16;9(1):4181. doi: 10.1038/s41467-018-06616-0.
• [1335] DT-13 suppresses breast cancer metastasis by modulating PLOD2 in the adipocytes microenvironment.Phytomedicine. 2019 Jun;59:152778. doi: 10.1016/j.phymed.2018.12.001. Epub 2018 Dec 2.
• [1336] Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.Int J Cancer. 2010 Mar 15;126(6):1445-53. doi: 10.1002/ijc.24826.
• [1337] Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells. Breast Cancer Res Treat. 2017 Apr;162(3):465-477. doi: 10.1007/s10549-017-4149-0. Epub 2017 Feb 11.
• [1338] Evolutionary recombination hotspot around GSDML-GSDM locus is closely linked to the oncogenomic recombination hotspot around the PPP1R1B-ERBB2-GRB7 amplicon.Int J Oncol. 2004 Apr;24(4):757-63.
• [1339] DNA polymerase deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts.Mol Oncol. 2014 May;8(3):520-32. doi: 10.1016/j.molonc.2014.01.001. Epub 2014 Jan 10.
• [1340] A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African Americans.Cancer Res. 2007 Apr 15;67(8):3565-8. doi: 10.1158/0008-5472.CAN-06-4801.
• [1341] WY-14643 Regulates CYP1B1 Expression through Peroxisome Proliferator-Activated Receptor -Mediated Signaling in Human Breast Cancer Cells.Int J Mol Sci. 2019 Nov 25;20(23):5928. doi: 10.3390/ijms20235928.
• [1342] PGC-1 cooperating with FOXA2 inhibits proliferation and migration of breast cancer cells.Cancer Cell Int. 2019 Apr 11;19:93. doi: 10.1186/s12935-019-0810-5. eCollection 2019.
• [1343] Single-Cell Transcriptome Analysis Reveals Estrogen Signaling Coordinately Augments One-Carbon, Polyamine, and Purine Synthesis in Breast Cancer.Cell Rep. 2018 Nov 20;25(8):2285-2298.e4. doi: 10.1016/j.celrep.2018.10.093.
• [1344] Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells.J Mol Endocrinol. 2010 Jun;44(6):319-29. doi: 10.1677/JME-09-0140. Epub 2010 Mar 17.
• [1345] Ribonucleotide reductase subunit M2B deficiency leads to mitochondrial permeability transition pore opening and is associated with aggressive clinicopathologic manifestations of breast cancer.Am J Transl Res. 2018 Nov 15;10(11):3635-3649. eCollection 2018.
• [1346] The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors.BMC Cancer. 2007 May 19;7:85. doi: 10.1186/1471-2407-7-85.
• [1347] Survival differences of CIMP subtypes integrated with CNA information in human breast cancer.Oncotarget. 2017 Jul 25;8(30):48807-48819. doi: 10.18632/oncotarget.16178.
• [1348] Knockdown of protein phosphatase 5 (PPP5C) suppresses the growth of leukemic cell line U937.Cell Mol Biol (Noisy-le-grand). 2016 Sep 30;62(11):27-31.
• [1349] The expression of neurokinin-1 and preprotachykinin-1 in breast cancer cells depends on the relative degree of invasive and metastatic potential.Clin Exp Metastasis. 2005;22(8):621-8. doi: 10.1007/s10585-006-9001-6. Epub 2006 Apr 27.
• [1350] Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts.Am J Pathol. 2009 Mar;174(3):746-61. doi: 10.2353/ajpath.2009.080658.
• [1351] PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.Oncogene. 2015 Apr 16;34(16):2061-71. doi: 10.1038/onc.2014.153. Epub 2014 Jun 9.
• [1352] Analysis of induced pluripotent stem cells from a BRCA1 mutant family.Stem Cell Reports. 2013 Oct 3;1(4):336-49. doi: 10.1016/j.stemcr.2013.08.004. eCollection 2013.
• [1353] High expression of PRKDC promotes breast cancer cell growth via p38 MAPK signaling and is associated with poor survival.Mol Genet Genomic Med. 2019 Nov;7(11):e908. doi: 10.1002/mgg3.908. Epub 2019 Sep 12.
• [1354] Concomitant Expression of Prolactin Receptor and TGF Receptors in Breast Cancer: Association with Less Aggressive Phenotype and Favorable Patient Outcome.Int J Mol Sci. 2019 Apr 2;20(7):1640. doi: 10.3390/ijms20071640.
• [1355] The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer.Oncogene. 2019 May;38(21):4015-4027. doi: 10.1038/s41388-019-0694-9. Epub 2019 Jan 28.
• [1356] Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.Cancer Med. 2019 May;8(5):2414-2428. doi: 10.1002/cam4.2114. Epub 2019 Apr 8.
• [1357] Examining Product Specificity in Protein Arginine Methyltransferase 7 (PRMT7) Using Quantum and Molecular Mechanical Simulations.J Chem Inf Model. 2019 Jun 24;59(6):2913-2923. doi: 10.1021/acs.jcim.9b00137. Epub 2019 May 7.
• [1358] Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.JCI Insight. 2019 Feb 26;5(6):e124092. doi: 10.1172/jci.insight.124092.
• [1359] Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction.Exp Cell Res. 2010 Feb 1;316(3):314-28. doi: 10.1016/j.yexcr.2009.10.024. Epub 2009 Nov 3.
• [1360] Seeking for Correlative Genes and Signaling Pathways With Bone Metastasis From Breast Cancer by Integrated Analysis.Front Oncol. 2019 Mar 13;9:138. doi: 10.3389/fonc.2019.00138. eCollection 2019.
• [1361] Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression.Oncotarget. 2017 Apr 29;8(33):54592-54603. doi: 10.18632/oncotarget.17523. eCollection 2017 Aug 15.
• [1362] A comparative characterization of estrogens used in hormone therapy via estrogen receptor (ER)- and -.J Steroid Biochem Mol Biol. 2017 Nov;174:27-39. doi: 10.1016/j.jsbmb.2017.07.022. Epub 2017 Jul 22.
• [1363] PSMB5 plays a dual role in cancer development and immunosuppression.Am J Cancer Res. 2017 Nov 1;7(11):2103-2120. eCollection 2017.
• [1364] PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer.Br J Cancer. 2010 Jan 19;102(2):361-8. doi: 10.1038/sj.bjc.6605478. Epub 2009 Dec 15.
• [1365] Integration of Distinct ShcA Signaling Complexes Promotes Breast Tumor Growth and Tyrosine Kinase Inhibitor Resistance.Mol Cancer Res. 2018 May;16(5):894-908. doi: 10.1158/1541-7786.MCR-17-0623. Epub 2018 Feb 16.
• [1366] EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.BMC Cancer. 2018 Apr 16;18(1):431. doi: 10.1186/s12885-018-4286-9.
• [1367] Cigarette Smoke Regulates Calcium-Independent Phospholipase A(2) Metabolic Pathways in Breast Cancer.Am J Pathol. 2017 Aug;187(8):1855-1866. doi: 10.1016/j.ajpath.2017.04.003. Epub 2017 Jun 12.
• [1368] 11-Prostaglandin F2, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer.Mol Cell Endocrinol. 2015 Sep 15;413:236-47. doi: 10.1016/j.mce.2015.07.008. Epub 2015 Jul 10.
• [1369] The SuprMam1 breast cancer susceptibility locus disrupts the vitamin D/ calcium/ parathyroid hormone pathway and alters bone structure in congenic mice.J Steroid Biochem Mol Biol. 2019 Apr;188:48-58. doi: 10.1016/j.jsbmb.2018.12.004. Epub 2018 Dec 7.
• [1370] PYK2 promotes HER2-positive breast cancer invasion.J Exp Clin Cancer Res. 2019 May 22;38(1):210. doi: 10.1186/s13046-019-1221-0.
• [1371] Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.BMC Cancer. 2019 Jan 16;19(1):78. doi: 10.1186/s12885-018-5186-8.
• [1372] miR-601 is a prognostic marker and suppresses cell growth and invasion by targeting PTP4A1 in breast cancer.Biomed Pharmacother. 2016 Apr;79:247-53. doi: 10.1016/j.biopha.2016.02.014. Epub 2016 Mar 11.
• [1373] Prospective validation in epithelial tumors of a gene expression predictor of liver metastasis derived from uveal melanoma.Sci Rep. 2019 Nov 20;9(1):17178. doi: 10.1038/s41598-019-52841-y.
• [1374] The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking.Sci Signal. 2015 Feb 17;8(364):ra18. doi: 10.1126/scisignal.2005547.
• [1375] The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.J Cancer Res Clin Oncol. 2019 Jul;145(7):1845-1856. doi: 10.1007/s00432-019-02918-y. Epub 2019 Apr 25.
• [1376] Clinical significance of the immune cell landscape in hepatocellular carcinoma patients with different degrees of fibrosis.Ann Transl Med. 2019 Oct;7(20):528. doi: 10.21037/atm.2019.09.122.
• [1377] Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.Mod Pathol. 1999 Dec;12(12):1083-9.
• [1378] Granular cell tumor in breast: a case report.Breast Cancer (Dove Med Press). 2017 Apr 11;9:245-248. doi: 10.2147/BCTT.S131446. eCollection 2017.
• [1379] Regulation of RAB22A by mir-193b inhibits breast cancer growth and metastasis mediated by exosomes.Int J Oncol. 2018 Dec;53(6):2705-2714. doi: 10.3892/ijo.2018.4571. Epub 2018 Sep 25.
• [1380] Rac3 regulates breast cancer invasion and metastasis by controlling adhesion and matrix degradation.J Cell Biol. 2017 Dec 4;216(12):4331-4349. doi: 10.1083/jcb.201704048. Epub 2017 Oct 23.
• [1381] Nuclear localized Raf1 isoform alters DNA-dependent protein kinase activity and the DNA damage response.FASEB J. 2019 Jan;33(1):1138-1150. doi: 10.1096/fj.201800336R. Epub 2018 Aug 14.
• [1382] Therapeutic potential of Bcl-x(L)/Mcl-1 synthetic inhibitor JY-1-106 and retinoids for human triple-negative breast cancer treatment.Oncol Lett. 2018 May;15(5):7231-7236. doi: 10.3892/ol.2018.8258. Epub 2018 Mar 14.
• [1383] Expression of the three components of linear ubiquitin assembly complex in breast cancer.PLoS One. 2018 May 15;13(5):e0197183. doi: 10.1371/journal.pone.0197183. eCollection 2018.
• [1384] miR-21 Might be Involved in Breast Cancer Promotion and Invasion Rather than in Initial Events of Breast Cancer Development.Mol Diagn Ther. 2016 Apr;20(2):97-110. doi: 10.1007/s40291-016-0186-3.
• [1385] Preliminary toxicity results using partial breast 3D-CRT with once daily hypo-fractionation and deep inspiratory breath hold.Radiat Oncol. 2018 Jul 27;13(1):135. doi: 10.1186/s13014-018-1079-x.
• [1386] Circulating renin-angiotensin system-regulating specific aminopeptidase activities in pre- and post- menopausal women with breast cancer treated or not with neoadyuvant chemotherapy. A two years follow up study.Breast. 2019 Feb;43:28-30. doi: 10.1016/j.breast.2018.10.010. Epub 2018 Nov 1.
• [1387] Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.Eur J Cancer. 2016 Dec;69:127-134. doi: 10.1016/j.ejca.2016.10.006. Epub 2016 Nov 4.
• [1388] Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer.BMC Cancer. 2019 Jan 8;19(1):41. doi: 10.1186/s12885-018-5262-0.
• [1389] Potential prognostic value of repulsive guidance molecules in breast cancer.Anticancer Res. 2011 May;31(5):1703-11.
• [1390] Downregulation of regulator of G protein signaling 2 expression in breast invasive carcinoma of no special type: Clinicopathological associations and prognostic relevance.Oncol Lett. 2018 Jan;15(1):213-220. doi: 10.3892/ol.2017.7351. Epub 2017 Nov 3.
• [1391] Growth inhibition of human breast carcinoma cells by overexpression of regulator of G-protein signaling 4.Oncol Lett. 2017 Jun;13(6):4357-4363. doi: 10.3892/ol.2017.6009. Epub 2017 Apr 7.
• [1392] High-resolution melting analysis for mutation screening of RGSL1, RGS16, and RGS8 in breast cancer.Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):397-407. doi: 10.1158/1055-9965.EPI-10-0514. Epub 2010 Dec 6.
• [1393] The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion.Curr Cancer Drug Targets. 2008 Aug;8(5):404-13. doi: 10.2174/156800908785133141.
• [1394] Replication of breast cancer susceptibility loci in whites and African Americans using a Bayesian approach.Am J Epidemiol. 2014 Feb 1;179(3):382-94. doi: 10.1093/aje/kwt258. Epub 2013 Nov 10.
• [1395] DLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway.Oncol Lett. 2019 Feb;17(2):2107-2116. doi: 10.3892/ol.2018.9874. Epub 2018 Dec 28.
• [1396] Genomic characterization of metastatic breast cancers.Nature. 2019 May;569(7757):560-564. doi: 10.1038/s41586-019-1056-z. Epub 2019 May 22.
• [1397] Ring finger protein 6 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha.Oncotarget. 2017 Mar 21;8(12):20103-20112. doi: 10.18632/oncotarget.15384.
• [1398] Oncogenic PIK3CA mutations increase dependency on the mRNA cap methyltransferase, RNMT, in breast cancer cells. Open Biol. 2019 Apr 26;9(4):190052.
• [1399] ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin).Anticancer Res. 2019 Mar;39(3):1267-1273. doi: 10.21873/anticanres.13237.
• [1400] MicroRNA-152 Inhibits Cell Proliferation, Migration, and Invasion in Breast Cancer.Oncol Res. 2020 Feb 7;28(1):13-19. doi: 10.3727/096504019X15519249902838. Epub 2019 Apr 8.
• [1401] ROCK isoforms differentially modulate cancer cell motility by mechanosensing the substrate stiffness.Acta Biomater. 2019 Apr 1;88:86-101. doi: 10.1016/j.actbio.2019.02.015. Epub 2019 Feb 13.
• [1402] Immobilization of HIV-1 TAT peptide on gold nanoparticles: A feasible approach for siRNA delivery.J Cell Physiol. 2020 Mar;235(3):2049-2059. doi: 10.1002/jcp.29105. Epub 2019 Jul 31.
• [1403] Ror2 Signaling and Its Relevance in Breast Cancer Progression.Front Oncol. 2017 Jun 26;7:135. doi: 10.3389/fonc.2017.00135. eCollection 2017.
• [1404] Interactions between FGFR2 and RSK2-implications for breast cancer prognosis.Tumour Biol. 2016 Oct;37(10):13721-13731. doi: 10.1007/s13277-016-5266-9. Epub 2016 Jul 30.
• [1405] RSK2-Mediated ELK3 Activation Enhances Cell Transformation and Breast Cancer Cell Growth by Regulation of c-fos Promoter Activity.Int J Mol Sci. 2019 Apr 23;20(8):1994. doi: 10.3390/ijms20081994.
• [1406] Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER(+) breast cancer.Nat Cell Biol. 2018 Aug;20(8):990. doi: 10.1038/s41556-018-0052-0.
• [1407] RSK4 inhibits breast cancer cell proliferation and invasion invitro, and is correlated with estrogen receptor upregulation in breast cancer.Oncol Rep. 2019 Dec;42(6):2777-2787. doi: 10.3892/or.2019.7328. Epub 2019 Sep 20.
• [1408] CircZNF609 promotes breast cancer cell growth, migration, and invasion by elevating p70S6K1 via sponging miR-145-5p.Cancer Manag Res. 2018 Sep 25;10:3881-3890. doi: 10.2147/CMAR.S174778. eCollection 2018.
• [1409] Identification of lncRNA NEAT1/miR-21/RRM2 axis as a novel biomarker in breast cancer.J Cell Physiol. 2020 Apr;235(4):3372-3381. doi: 10.1002/jcp.29225. Epub 2019 Oct 17.
• [1410] Effects of RSF-1 on proliferation and apoptosis of breast cancer cells.Oncol Lett. 2018 Oct;16(4):4279-4284. doi: 10.3892/ol.2018.9172. Epub 2018 Jul 18.
• [1411] R-spondin3 Is Associated with Basal-Progenitor Behavior in Normal and Tumor Mammary Cells.Cancer Res. 2018 Aug 15;78(16):4497-4511. doi: 10.1158/0008-5472.CAN-17-2676. Epub 2018 May 10.
• [1412] RUNX1-dependent mechanisms in biological control and dysregulation in cancer.J Cell Physiol. 2019 Jun;234(6):8597-8609. doi: 10.1002/jcp.27841. Epub 2018 Dec 4.
• [1413] miRNA-106a Promotes Breast Cancer Cell Proliferation, Clonogenicity, Migration, and Invasion Through Inhibiting Apoptosis and Chemosensitivity. DNA Cell Biol. 2019 Feb;38(2):198-207.
• [1414] Comparison of a calcitonin gene-related peptide receptor in a human neuroblastoma cell line (SK-N-MC) and a calcitonin receptor in a human breast carcinoma cell line (T47D).Ann N Y Acad Sci. 1992 Jun 30;657:106-16. doi: 10.1111/j.1749-6632.1992.tb22760.x.
• [1415] Effects of Platycodin D on S100A8/A9-induced inflammatory response in murine mammary carcinoma 4T1 cells.Int Immunopharmacol. 2019 Feb;67:239-247. doi: 10.1016/j.intimp.2018.12.008. Epub 2018 Dec 15.
• [1416] Promoter hypermethylation of RAR2, DAPK, hMLH1, p14, and p15 is associated with progression of breast cancer: A PRISMA-compliant meta-analysis.Medicine (Baltimore). 2018 Dec;97(51):e13666. doi: 10.1097/MD.0000000000013666.
• [1417] S100B expression in breast cancer as a predictive marker for cancer metastasis.Int J Oncol. 2018 Feb;52(2):433-440. doi: 10.3892/ijo.2017.4226. Epub 2017 Dec 12.
• [1418] Effects of S1P1 and S1P3 in ER(+) and ER(-) Breast Cancer Cells.Anticancer Res. 2017 Oct;37(10):5469-5475. doi: 10.21873/anticanres.11976.
• [1419] Pivotal role of human stearoyl-CoA desaturases (SCD1 and 5) in breast cancer progression: oleic acid-based effect of SCD1 on cell migration and a novel pro-cell survival role for SCD5.Oncotarget. 2018 May 11;9(36):24364-24380. doi: 10.18632/oncotarget.25273. eCollection 2018 May 11.
• [1420] Human mammaglobin in breast cancer: a brief review of its clinical utility.Indian J Med Res. 2014 May;139(5):675-85.
• [1421] Mammaglobin and lipophilin B expression in breast tumors and their lack of effect on breast cancer cell proliferation.Anticancer Res. 2008 May-Jun;28(3A):1493-8.
• [1422] 4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway.Biochem Biophys Res Commun. 2018 Oct 12;504(4):812-819. doi: 10.1016/j.bbrc.2018.08.043. Epub 2018 Sep 11.
• [1423] Sodium Channel Na(v)1.5 Controls Epithelial-to-Mesenchymal Transition and Invasiveness in Breast Cancer Cells Through its Regulation by the Salt-Inducible Kinase-1.Sci Rep. 2019 Dec 9;9(1):18652. doi: 10.1038/s41598-019-55197-5.
• [1424] Relationship between SDC1 and cadherin signalling activation in cancer.Pathol Res Pract. 2020 Jan;216(1):152756. doi: 10.1016/j.prp.2019.152756. Epub 2019 Nov 18.
• [1425] RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2.Oncogene. 2014 Jul 3;33(27):3528-37. doi: 10.1038/onc.2013.328. Epub 2013 Aug 26.
• [1426] A functional glycoproteomics approach identifies CD13 as a novel E-selectin ligand in breast cancer.Biochim Biophys Acta Gen Subj. 2018 Sep;1862(9):2069-2080. doi: 10.1016/j.bbagen.2018.05.013. Epub 2018 May 17.
• [1427] Stilbenoid-Mediated Epigenetic Activation of Semaphorin 3A in Breast Cancer Cells Involves Changes in Dynamic Interactions of DNA with DNMT3A and NF1C Transcription Factor.Mol Nutr Food Res. 2019 Oct;63(19):e1801386. doi: 10.1002/mnfr.201801386. Epub 2019 Jul 31.
• [1428] Expression of septin 2 and association with clinicopathological parameters in colorectal cancer.Oncol Lett. 2019 Sep;18(3):2376-2383. doi: 10.3892/ol.2019.10528. Epub 2019 Jun 26.
• [1429] Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.Int J Oncol. 2019 Jul;55(1):116-130. doi: 10.3892/ijo.2019.4796. Epub 2019 May 6.
• [1430] Chaperone Hsp47 Drives Malignant Growth and Invasion by Modulating an ECM Gene Network.Cancer Res. 2015 Apr 15;75(8):1580-91. doi: 10.1158/0008-5472.CAN-14-1027. Epub 2015 Mar 5.
• [1431] SETD7 is a prognosis predicting factor of breast cancer and regulates redox homeostasis.Oncotarget. 2017 Oct 6;8(55):94080-94090. doi: 10.18632/oncotarget.21583. eCollection 2017 Nov 7.
• [1432] Pathological Significance and Prognostic Value of Surfactant Protein D in Cancer.Front Immunol. 2018 Aug 6;9:1748. doi: 10.3389/fimmu.2018.01748. eCollection 2018.
• [1433] The clinical utility of circulating tumor cells in breast cancer patients: detection by a quantitative assay of h-MAM gene expression.Int J Biol Markers. 2014 Sep 30;29(3):e268-78. doi: 10.5301/jbm.5000065.
• [1434] First evidence of SGPL1 expression in the cell membrane silencing the extracellular S1P siren in mammary epithelial cells.PLoS One. 2018 May 2;13(5):e0196854. doi: 10.1371/journal.pone.0196854. eCollection 2018.
• [1435] Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.Breast Cancer Res. 2017 Oct 3;19(1):110. doi: 10.1186/s13058-017-0900-z.
• [1436] SHCBP1 is over-expressed in breast cancer and is important in the proliferation and apoptosis of the human malignant breast cancer cell line.Gene. 2016 Aug 1;587(1):91-7. doi: 10.1016/j.gene.2016.04.046. Epub 2016 Apr 26.
• [1437] LOC101930370/MiR-1471 Axis Modulates the Hedgehog Signaling Pathway in Breast Cancer.Cell Physiol Biochem. 2018;48(3):1139-1150. doi: 10.1159/000491980. Epub 2018 Jul 24.
• [1438] Imaging Sigma-1 Receptor (S1R) Expression Using Iodine-124-Labeled 1-(4-Iodophenyl)-3-(2-adamantyl)guanidine ([(124)I]IPAG).Mol Imaging Biol. 2020 Apr;22(2):358-366. doi: 10.1007/s11307-019-01369-8.
• [1439] Tumor suppression by LKB1: SIK-ness prevents metastasis.Sci Signal. 2009 Sep 1;2(86):pe55. doi: 10.1126/scisignal.286pe55.
• [1440] SIK2 attenuates proliferation and survival of breast cancer cells with simultaneous perturbation of MAPK and PI3K/Akt pathways.Oncotarget. 2018 Apr 24;9(31):21876-21892. doi: 10.18632/oncotarget.25082. eCollection 2018 Apr 24.
• [1441] Critical role of SIK3 in mediating high salt and IL-17 synergy leading to breast cancer cell proliferation.PLoS One. 2017 Jun 28;12(6):e0180097. doi: 10.1371/journal.pone.0180097. eCollection 2017.
• [1442] Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients.Clin Cancer Res. 2010 Sep 15;16(18):4625-35. doi: 10.1158/1078-0432.CCR-10-0349. Epub 2010 Aug 12.
• [1443] Small-Molecule Screen Identifies De Novo Nucleotide Synthesis as a Vulnerability of Cells Lacking SIRT3.Cell Rep. 2018 Feb 20;22(8):1945-1955. doi: 10.1016/j.celrep.2018.01.076.
• [1444] SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis.Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):26625-26632. doi: 10.1073/pnas.1911954116. Epub 2019 Dec 16.
• [1445] EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer.Cancers (Basel). 2019 Jul 28;11(8):1067. doi: 10.3390/cancers11081067.
• [1446] SKP2 promotes breast cancer tumorigenesis and radiation tolerance through PDCD4 ubiquitination.J Exp Clin Cancer Res. 2019 Feb 13;38(1):76. doi: 10.1186/s13046-019-1069-3.
• [1447] Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas.Anticancer Res. 2010 Mar;30(3):759-65.
• [1448] IGF-1 upregulates electroneutral K-Cl cotransporter KCC3 and KCC4 which are differentially required for breast cancer cell proliferation and invasiveness.J Cell Physiol. 2007 Mar;210(3):626-36. doi: 10.1002/jcp.20859.
• [1449] Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study.Nutr Cancer. 2020;72(4):627-634. doi: 10.1080/01635581.2019.1650942. Epub 2019 Sep 9.
• [1450] Specific association of thiamine-coated gadolinium nanoparticles with human breast cancer cells expressing thiamine transporters.Bioconjug Chem. 2003 Mar-Apr;14(2):404-11. doi: 10.1021/bc0340013.
• [1451] Hypoxia induced upregulation and function of the thiamine transporter, SLC19A3 in a breast cancer cell line.Cancer Biol Ther. 2010 Dec 1;10(11):1101-11. doi: 10.4161/cbt.10.11.13444. Epub 2010 Dec 1.
• [1452] Benzylserine inhibits breast cancer cell growth by disrupting intracellular amino acid homeostasis and triggering amino acid response pathways.BMC Cancer. 2018 Jun 26;18(1):689. doi: 10.1186/s12885-018-4599-8.
• [1453] ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors.Oncogene. 2008 Feb 14;27(8):1045-54. doi: 10.1038/sj.onc.1210727. Epub 2007 Aug 13.
• [1454] Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients.World J Surg. 2016 Jul;40(7):1600-10. doi: 10.1007/s00268-015-3263-6.
• [1455] Vitamin C promotes apoptosis in breast cancer cells by increasing TRAIL expression.Sci Rep. 2018 Mar 28;8(1):5306. doi: 10.1038/s41598-018-23714-7.
• [1456] Solute Carrier Family 27 Member 4 (SLC27A4) Enhances Cell Growth, Migration, and Invasion in Breast Cancer Cells.Int J Mol Sci. 2018 Nov 1;19(11):3434. doi: 10.3390/ijms19113434.
• [1457] GLUT12 and adipose tissue: Expression, regulation and its relation with obesity in mice.Acta Physiol (Oxf). 2019 Aug;226(4):e13283. doi: 10.1111/apha.13283. Epub 2019 May 11.
• [1458] Characterization of inorganic phosphate transport in the triple-negative breast cancer cell line, MDA-MB-231.PLoS One. 2018 Feb 7;13(2):e0191270. doi: 10.1371/journal.pone.0191270. eCollection 2018.
• [1459] Expression of reactive species related genes is associated with patient survival in luminal B breast cancer.Free Radic Biol Med. 2018 May 20;120:170-180. doi: 10.1016/j.freeradbiomed.2018.03.011. Epub 2018 Mar 12.
• [1460] Analysis association between mitochondrial genome instability and xenobiotic metabolizing genes in human breast cancer.Mol Med. 2009 May-Jun;15(5-6):160-5. doi: 10.2119/molmed.2008.00136. Epub 2009 Mar 6.
• [1461] Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer.Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12452-12461. doi: 10.1073/pnas.1818521116. Epub 2019 May 31.
• [1462] Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro.Mol Cancer Res. 2003 Sep;1(11):826-35.
• [1463] Zinc Transporters and the Progression of Breast Cancers.Biol Pharm Bull. 2018;41(10):1517-1522. doi: 10.1248/bpb.b18-00086.
• [1464] Tumor expression of environmental chemical-responsive genes and breast cancer mortality.Endocr Relat Cancer. 2019 Dec;26(12):843-851. doi: 10.1530/ERC-19-0357.
• [1465] SGLT1 is required for the survival of triple-negative breast cancer cells via potentiation of EGFR activity.Mol Oncol. 2019 Sep;13(9):1874-1886. doi: 10.1002/1878-0261.12530. Epub 2019 Jun 14.
• [1466] Mannose glycosylation is an integral step for NIS localization and function in human breast cancer cells.J Cell Sci. 2019 Oct 23;132(20):jcs232058. doi: 10.1242/jcs.232058.
• [1467] SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer.J Biol Chem. 2011 Sep 9;286(36):31830-8. doi: 10.1074/jbc.M111.229518. Epub 2011 Jul 19.
• [1468] Tamoxifen and its active metabolites inhibit dopamine transporter function independently of the estrogen receptors.J Neurochem. 2017 Apr;141(1):31-36. doi: 10.1111/jnc.13955. Epub 2017 Feb 14.
• [1469] Direct effect of morphine on breast cancer cell function in vitro: role of the NET1 gene.Br J Anaesth. 2011 Dec;107(6):916-23. doi: 10.1093/bja/aer259. Epub 2011 Aug 19.
• [1470] MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11.FEBS Lett. 2011 May 6;585(9):1363-7. doi: 10.1016/j.febslet.2011.04.018. Epub 2011 Apr 14.
• [1471] LLGL2 rescues nutrient stress by promoting leucine uptake in ER(+) breast cancer.Nature. 2019 May;569(7755):275-279. doi: 10.1038/s41586-019-1126-2. Epub 2019 Apr 17.
• [1472] Increased NHE1 expression is targeted by specific inhibitor cariporide to sensitize resistant breast cancer cells to doxorubicin in vitro and in vivo.BMC Cancer. 2019 Mar 8;19(1):211. doi: 10.1186/s12885-019-5397-7.
• [1473] Organic aniontransporting polypeptides contribute to the uptake of curcumin and its main metabolites by human breast cancer cells: Impact on antitumor activity.Oncol Rep. 2019 Apr;41(4):2558-2566. doi: 10.3892/or.2019.7011. Epub 2019 Feb 14.
• [1474] Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.Cancer Chemother Pharmacol. 2017 Jun;79(6):1179-1186. doi: 10.1007/s00280-017-3314-9. Epub 2017 Apr 26.
• [1475] Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk.Breast Cancer Res Treat. 2011 Jan;125(2):563-9. doi: 10.1007/s10549-010-1046-1. Epub 2010 Jul 16.
• [1476] Expression and localization of the uptake transporters OATP2B1, OATP3A1 and OATP5A1 in non-malignant and malignant breast tissue.Cancer Biol Ther. 2011 Mar 15;11(6):584-91. doi: 10.4161/cbt.11.6.14533. Epub 2011 Mar 15.
• [1477] Differential role of organic anion-transporting polypeptides in estrone-3-sulphate uptake by breast epithelial cells and breast cancer cells.J Pharmacol Exp Ther. 2012 Aug;342(2):510-9. doi: 10.1124/jpet.112.192344. Epub 2012 May 15.
• [1478] The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility.Oncogene. 2009 Aug 6;28(31):2839-48. doi: 10.1038/onc.2009.146. Epub 2009 Jun 15.
• [1479] SMYD3 promotes the epithelial-mesenchymal transition in breast cancer.Nucleic Acids Res. 2019 Feb 20;47(3):1278-1293. doi: 10.1093/nar/gky1221.
• [1480] Smad6 determines BMP-regulated invasive behaviour of breast cancer cells in a zebrafish xenograft model.Sci Rep. 2016 Apr 26;6:24968. doi: 10.1038/srep24968.
• [1481] SETDB1 regulates SMAD7 expression for breast cancer metastasis.BMB Rep. 2019 Feb;52(2):139-144. doi: 10.5483/BMBRep.2019.52.2.235.
• [1482] Brahma related gene 1 (BRG1) regulates breast cancer cell migration and invasion by activating MUC1 transcription.Biochem Biophys Res Commun. 2019 Apr 9;511(3):536-543. doi: 10.1016/j.bbrc.2019.02.088. Epub 2019 Feb 26.
• [1483] Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin. Biochim Biophys Acta. 2009 Nov-Dec;1789(11-12):681-90. doi: 10.1016/j.bbagrm.2009.08.006. Epub 2009 Aug 19.
• [1484] Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.Cell Rep. 2019 Nov 5;29(6):1482-1498.e4. doi: 10.1016/j.celrep.2019.10.004.
• [1485] Correlation between a variable number tandem repeat (VNTR) polymorphism in SMYD3 gene and breast cancer: A genotype-phenotype study.Gene. 2020 Feb 20;728:144281. doi: 10.1016/j.gene.2019.144281. Epub 2019 Dec 10.
• [1486] Suppressor of cytokine signaling (SOCS) genes are downregulated in breast cancer.World J Surg Oncol. 2018 Nov 19;16(1):226. doi: 10.1186/s12957-018-1529-9.
• [1487] circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p/SOCS3 axis.Cell Death Dis. 2019 Feb 20;10(3):175. doi: 10.1038/s41419-019-1382-y.
• [1488] Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Hum Mol Genet. 2012 Jan 15;21(2):300-10. doi: 10.1093/hmg/ddr459. Epub 2011 Oct 6.
• [1489] Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness.JCI Insight. 2019 Apr 9;5(9):e125543. doi: 10.1172/jci.insight.125543.
• [1490] SOX5 promotes breast cancer proliferation and invasion by transactivation of EZH2.Oncol Lett. 2019 Mar;17(3):2754-2762. doi: 10.3892/ol.2019.9914. Epub 2019 Jan 9.
• [1491] A Genetic Variant of rs145204276 in the Promoter Region of Long Noncoding RNA GAS5 Is Associated With a Reduced Risk of Breast Cancer.Clin Breast Cancer. 2019 Jun;19(3):e415-e421. doi: 10.1016/j.clbc.2018.11.006. Epub 2018 Nov 14.
• [1492] Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients.J Immunother. 2011 Jan;34(1):28-44. doi: 10.1097/CJI.0b013e3181fb64fa.
• [1493] Association of SPARC gene polymorphisms rs3210714 and rs7719521 with VEGF expression and utility of Nottingham Prognostic Index scoring in breast cancer in a sample of Egyptian women.Mol Biol Rep. 2018 Dec;45(6):2313-2324. doi: 10.1007/s11033-018-4394-2. Epub 2018 Sep 27.
• [1494] Identifying novel sphingosine kinase 1 inhibitors as therapeutics against breast cancer.J Enzyme Inhib Med Chem. 2020 Dec;35(1):172-186. doi: 10.1080/14756366.2019.1692828.
• [1495] EPCR promotes breast cancer progression by altering SPOCK1/testican 1-mediated 3D growth.J Hematol Oncol. 2017 Jan 19;10(1):23. doi: 10.1186/s13045-017-0399-x.
• [1496] Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype.Sci Rep. 2016 Mar 15;6:23216. doi: 10.1038/srep23216.
• [1497] The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation.Oncogene. 2018 Aug;37(34):4750-4768. doi: 10.1038/s41388-018-0281-5. Epub 2018 May 16.
• [1498] Optimizing multi-modal cancer treatment under 3D spatio-temporal tumor growth.Math Biosci. 2019 Jan;307:53-69. doi: 10.1016/j.mbs.2018.10.010. Epub 2018 Oct 31.
• [1499] Serglycin promotes breast cancer cell aggressiveness: Induction of epithelial to mesenchymal transition, proteolytic activity and IL-8 signaling.Matrix Biol. 2018 Dec;74:35-51. doi: 10.1016/j.matbio.2018.05.011. Epub 2018 May 26.
• [1500] The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1.FEBS J. 2013 Sep;280(18):4539-59. doi: 10.1111/febs.12420. Epub 2013 Aug 19.
• [1501] The many faces of SRPK1.J Pathol. 2017 Mar;241(4):437-440. doi: 10.1002/path.4846. Epub 2017 Feb 1.
• [1502] Effects of somatostatin, curcumin, and quercetin on the fatty acid profile of breast cancer cell membranes.Can J Physiol Pharmacol. 2020 Mar;98(3):131-138. doi: 10.1139/cjpp-2019-0352. Epub 2019 Sep 23.
• [1503] Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer.Ann Diagn Pathol. 2019 Feb;38:62-66. doi: 10.1016/j.anndiagpath.2018.11.002. Epub 2018 Nov 20.
• [1504] Targeting metastatic breast cancer with peptide epitopes derived from autocatalytic loop of Prss14/ST14 membrane serine protease and with monoclonal antibodies.J Exp Clin Cancer Res. 2019 Aug 19;38(1):363. doi: 10.1186/s13046-019-1373-y.
• [1505] Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer.J Immunol. 2019 May 15;202(10):3076-3086. doi: 10.4049/jimmunol.1801152. Epub 2019 Apr 1.
• [1506] STAT6 knockdown using multiple siRNA sequences inhibits proliferation and induces apoptosis of human colorectal and breast cancer cell lines.PLoS One. 2019 May 10;14(5):e0207558. doi: 10.1371/journal.pone.0207558. eCollection 2019.
• [1507] Role of stanniocalcin-1 in breast cancer.Oncol Lett. 2019 Oct;18(4):3946-3953. doi: 10.3892/ol.2019.10777. Epub 2019 Aug 22.
• [1508] Overexpression of microRNA-190 inhibits migration, invasion, epithelial-mesenchymal transition, and angiogenesis through suppression of protein kinase B-extracellular signal-regulated kinase signaling pathway via binding to stanniocalicin 2 in breast cancer.J Cell Physiol. 2019 Aug;234(10):17824-17838. doi: 10.1002/jcp.28409. Epub 2019 Apr 16.
• [1509] STEAP1 Inhibits Breast Cancer Metastasis and Is Associated With Epithelial-Mesenchymal Transition Procession.Clin Breast Cancer. 2019 Feb;19(1):e195-e207. doi: 10.1016/j.clbc.2018.08.010. Epub 2018 Aug 30.
• [1510] Epigenetic silencing of Stk39 in B-cell lymphoma inhibits apoptosis from genotoxic stress.Am J Pathol. 2009 Oct;175(4):1653-61. doi: 10.2353/ajpath.2009.090091. Epub 2009 Aug 28.
• [1511] Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome.Breast Cancer Res Treat. 2011 Dec;130(3):905-16. doi: 10.1007/s10549-011-1600-5. Epub 2011 Jun 1.
• [1512] Stathmin Is Required for Normal Mouse Mammary Gland Development and 16HER2-Driven Tumorigenesis.Cancer Res. 2019 Jan 15;79(2):397-409. doi: 10.1158/0008-5472.CAN-18-2488. Epub 2018 Nov 26.
• [1513] Molecular cloning and characterization of human MAWD, a novel protein containing WD-40 repeats frequently overexpressed in breast cancer.Cancer Res. 2000 Jan 1;60(1):13-7.
• [1514] In breast cancer subtypes steroid sulfatase (STS) is associated with less aggressive tumour characteristics.Br J Cancer. 2018 May;118(9):1208-1216. doi: 10.1038/s41416-018-0034-9. Epub 2018 Mar 22.
• [1515] A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment.Mol Biol Rep. 2008 Mar;35(1):23-7. doi: 10.1007/s11033-006-9047-1. Epub 2007 Apr 6.
• [1516] Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer.Oncogene. 2013 Mar 14;32(11):1351-62. doi: 10.1038/onc.2012.169. Epub 2012 May 7.
• [1517] Spleen Tyrosine Kinase-Mediated Autophagy Is Required for Epithelial-Mesenchymal Plasticity and Metastasis in Breast Cancer.Cancer Res. 2019 Apr 15;79(8):1831-1843. doi: 10.1158/0008-5472.CAN-18-2636. Epub 2019 Feb 7.
• [1518] HRD1 sensitizes breast cancer cells to Tamoxifen by promoting S100A8 degradation.Oncotarget. 2017 Apr 4;8(14):23564-23574. doi: 10.18632/oncotarget.15797.
• [1519] Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration.Breast Cancer (Dove Med Press). 2019 Feb 19;11:87-97. doi: 10.2147/BCTT.S178721. eCollection 2019.
• [1520] IL-13R2 mediates PNR-induced migration and metastasis in ER-negative breast cancer.Oncogene. 2015 Mar 19;34(12):1596-607. doi: 10.1038/onc.2014.53. Epub 2014 Apr 21.
• [1521] Epigenetic Silencing of TAP1 in Aldefluor(+) Breast Cancer Stem Cells Contributes to Their Enhanced Immune Evasion.Stem Cells. 2018 May;36(5):641-654. doi: 10.1002/stem.2780. Epub 2018 Jan 30.
• [1522] Transducin -like protein 1 recruits nuclear factor B to the target gene promoter for transcriptional activation.Mol Cell Biol. 2011 Mar;31(5):924-34. doi: 10.1128/MCB.00576-10. Epub 2010 Dec 28.
• [1523] Control of breast cancer growth and initiation by the stem cell-associated transcription factor TCF3.Cancer Res. 2012 Nov 1;72(21):5613-24. doi: 10.1158/0008-5472.CAN-12-0119. Epub 2012 Oct 22.
• [1524] Genome-wide analysis reveals a role for TDG in estrogen receptor-mediated enhancer RNA transcription and 3-dimensional reorganization.Epigenetics Chromatin. 2018 Jan 29;11(1):5. doi: 10.1186/s13072-018-0176-2.
• [1525] Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression.Mol Cancer Res. 2019 Jan;17(1):30-41. doi: 10.1158/1541-7786.MCR-18-0246. Epub 2018 Sep 13.
• [1526] Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.BMC Cancer. 2019 Nov 29;19(1):1158. doi: 10.1186/s12885-019-6371-0.
• [1527] Single-cell RNA sequencing reveals gene expression signatures of breast cancer-associated endothelial cells.Oncotarget. 2017 Dec 29;9(13):10945-10961. doi: 10.18632/oncotarget.23760. eCollection 2018 Feb 16.
• [1528] Association Between Single Nucleotide Polymorphisms in DNA Polymerase Kappa Gene and Breast Cancer Risk in Chinese Han Population: A STROBE-Compliant Observational Study.Medicine (Baltimore). 2016 Jan;95(2):e2466. doi: 10.1097/MD.0000000000002466.
• [1529] miR-155 drives telomere fragility in human breast cancer by targeting TRF1.Cancer Res. 2014 Aug 1;74(15):4145-56. doi: 10.1158/0008-5472.CAN-13-2038. Epub 2014 May 29.
• [1530] Molecular and cellular basis of mammary gland fibrosis and cancer risk.Int J Cancer. 2019 May 1;144(9):2239-2253. doi: 10.1002/ijc.32000. Epub 2018 Dec 28.
• [1531] Estrogen regulation of transferrin gene expression in MCF-7 human breast cancer cells.J Mol Endocrinol. 2002 Dec;29(3):305-17. doi: 10.1677/jme.0.0290305.
• [1532] Protein-Polymer Conjugates Synthesized Using Water-Soluble Azlactone-Functionalized Polymers Enable Receptor-Specific Cellular Uptake toward Targeted Drug Delivery.Bioconjug Chem. 2019 Apr 17;30(4):1220-1231. doi: 10.1021/acs.bioconjchem.9b00155. Epub 2019 Apr 5.
• [1533] In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model.EJNMMI Res. 2018 May 25;8(1):39. doi: 10.1186/s13550-018-0388-2.
• [1534] Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice.Blood Adv. 2019 Oct 22;3(20):3080-3091. doi: 10.1182/bloodadvances.2019000250.
• [1535] Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients.Breast Cancer. 2019 May;26(3):282-289. doi: 10.1007/s12282-018-0920-2. Epub 2018 Oct 13.
• [1536] High baseline Tie1 level predicts poor survival in metastatic breast cancer.BMC Cancer. 2019 Jul 24;19(1):732. doi: 10.1186/s12885-019-5959-8.
• [1537] TCDD-Inducible Poly-ADP-Ribose Polymerase (TIPARP), A Novel Therapeutic Target Of Breast Cancer.Cancer Manag Res. 2019 Oct 18;11:8991-9004. doi: 10.2147/CMAR.S219289. eCollection 2019.
• [1538] Effect of hypoxia on human equilibrative nucleoside transporters hENT1 and hENT2 in breast cancer.FASEB J. 2019 Dec;33(12):13837-13851. doi: 10.1096/fj.201900870RR. Epub 2019 Oct 10.
• [1539] Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor.Front Immunol. 2019 Apr 5;10:650. doi: 10.3389/fimmu.2019.00650. eCollection 2019.
• [1540] No genetic relationship between TLR2 rs4696480, rs3804100, and rs3804099 gene polymorphisms and female breast cancer in Saudi populations.Onco Targets Ther. 2017 Apr 27;10:2325-2333. doi: 10.2147/OTT.S121618. eCollection 2017.
• [1541] Toll-like receptor 3 -926T>A increased the risk of breast cancer through decreased transcriptional activity.Oncoimmunology. 2019 Oct 15;8(12):e1673126. doi: 10.1080/2162402X.2019.1673126. eCollection 2019.
• [1542] Ribosomal DNA as DAMPs Signal for MCF7 Cancer Cells.Front Oncol. 2019 May 30;9:445. doi: 10.3389/fonc.2019.00445. eCollection 2019.
• [1543] Expression and functional analysis of Bax inhibitor-1 in human breast cancer cells.J Pathol. 2006 Feb;208(3):340-9. doi: 10.1002/path.1902.
• [1544] Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer.J Biol Chem. 2010 Sep 24;285(39):30233-46. doi: 10.1074/jbc.M110.122226. Epub 2010 Mar 30.
• [1545] Neuroprotective Efficacy of a Sigma 2 Receptor/TMEM97 Modulator (DKR-1677) after Traumatic Brain Injury.ACS Chem Neurosci. 2019 Mar 20;10(3):1595-1602. doi: 10.1021/acschemneuro.8b00543. Epub 2018 Dec 3.
• [1546] Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines.Biochem Pharmacol. 2017 Aug 15;138:163-173. doi: 10.1016/j.bcp.2017.04.015. Epub 2017 Apr 18.
• [1547] Matriptase-2 gene (TMPRSS6) variants associate with breast cancer survival, and reduced expression is related to triple-negative breast cancer.Int J Cancer. 2013 Nov 15;133(10):2334-40. doi: 10.1002/ijc.28254. Epub 2013 Jun 4.
• [1548] Tenascin-C increases lung metastasis by impacting blood vessel invasions.Matrix Biol. 2019 Oct;83:26-47. doi: 10.1016/j.matbio.2019.07.001. Epub 2019 Jul 6.
• [1549] Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk.Carcinogenesis. 2005 Nov;26(11):1975-7. doi: 10.1093/carcin/bgi164. Epub 2005 Jun 23.
• [1550] Polyethyleneimine-polyethylene glycol copolymer targeted by anti-HER2 nanobody for specific delivery of transcriptionally targeted tBid containing construct.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):501-511. doi: 10.1080/21691401.2018.1549063.
• [1551] Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: A systematic review and network meta-analysis.Crit Rev Oncol Hematol. 2019 May;137:1-8. doi: 10.1016/j.critrevonc.2019.02.004. Epub 2019 Feb 19.
• [1552] TNFR2 but not TNFR1 is the main TNFR expressed by B and T lymphocytes in breast cancer draining lymph nodes.Immunol Lett. 2019 May;209:36-44. doi: 10.1016/j.imlet.2019.03.013. Epub 2019 Mar 22.
• [1553] c-MYC Drives Breast Cancer Metastasis to the Brain, but Promotes Synthetic Lethality with TRAIL.Mol Cancer Res. 2019 Feb;17(2):544-554. doi: 10.1158/1541-7786.MCR-18-0630. Epub 2018 Sep 28.
• [1554] Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer.Oncotarget. 2017 Aug 5;8(53):90825-90841. doi: 10.18632/oncotarget.19967. eCollection 2017 Oct 31.
• [1555] LncRNA LINC00963 Promotes Tumorigenesis and Radioresistance in Breast Cancer by Sponging miR-324-3p and Inducing ACK1 Expression.Mol Ther Nucleic Acids. 2019 Dec 6;18:871-881. doi: 10.1016/j.omtn.2019.09.033. Epub 2019 Oct 22.
• [1556] Angiomotin-p130 inhibits -catenin stability by competing with Axin for binding to tankyrase in breast cancer.Cell Death Dis. 2019 Feb 21;10(3):179. doi: 10.1038/s41419-019-1427-2.
• [1557] Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis.Eur J Cancer. 2009 Nov;45(17):3008-16. doi: 10.1016/j.ejca.2009.08.012. Epub 2009 Sep 18.
• [1558] Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast.J Pathol. 1997 Aug;182(4):421-8. doi: 10.1002/(SICI)1096-9896(199708)182:4<421::AID-PATH886>3.0.CO;2-U.
• [1559] Tryptophan hydroxylase 1 and 5-HT(7) receptor preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling.Mol Cancer. 2016 Nov 21;15(1):75. doi: 10.1186/s12943-016-0559-6.
• [1560] Thyroid peroxidase as a dual active site enzyme: Focus on biosynthesis, hormonogenesis and thyroid disorders of autoimmunityand cancer.Biochimie. 2019 May;160:34-45. doi: 10.1016/j.biochi.2019.02.003. Epub 2019 Feb 10.
• [1561] Radiosensitivity of Cancer Cells Is Regulated by Translationally Controlled Tumor Protein.Cancers (Basel). 2019 Mar 19;11(3):386. doi: 10.3390/cancers11030386.
• [1562] Tumor necrosis factor receptor-associated factor 6 contributes to malignant behavior of human cancers through promoting AKT ubiquitination and phosphorylation.Cancer Sci. 2019 Jun;110(6):1909-1920. doi: 10.1111/cas.14012. Epub 2019 Apr 29.
• [1563] Differences in transcriptional effects of 1,25 dihydroxyvitamin D3 on fibroblasts associated to breast carcinomas and from paired normal breast tissues.J Steroid Biochem Mol Biol. 2013 Jan;133:12-24. doi: 10.1016/j.jsbmb.2012.08.002. Epub 2012 Aug 23.
• [1564] The forgotten effects of thyrotropin-releasing hormone: Metabolic functions and medical applications.Front Neuroendocrinol. 2019 Jan;52:29-43. doi: 10.1016/j.yfrne.2018.06.006. Epub 2018 Jun 22.
• [1565] TRIM24 links glucose metabolism with transformation of human mammary epithelial cells.Oncogene. 2015 May 28;34(22):2836-45. doi: 10.1038/onc.2014.220. Epub 2014 Jul 28.
• [1566] miR-140-3p inhibits breast cancer proliferation and migration by directly regulating the expression of tripartite motif 28.Oncol Lett. 2019 Apr;17(4):3835-3841. doi: 10.3892/ol.2019.10038. Epub 2019 Feb 13.
• [1567] TRIM59 deficiency curtails breast cancer metastasis through SQSTM1-selective autophagic degradation of PDCD10.Autophagy. 2019 Apr;15(4):747-749. doi: 10.1080/15548627.2019.1569951. Epub 2019 Jan 22.
• [1568] CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.Oncotarget. 2015 Apr 20;6(11):9397-408. doi: 10.18632/oncotarget.3351.
• [1569] TRPC1 is a differential regulator of hypoxia-mediated events and Akt signalling in PTEN-deficient breast cancer cells.J Cell Sci. 2017 Jul 15;130(14):2292-2305. doi: 10.1242/jcs.196659. Epub 2017 May 30.
• [1570] TRPC3 Regulates the Proliferation and Apoptosis Resistance of Triple Negative Breast Cancer Cells through the TRPC3/RASA4/MAPK Pathway.Cancers (Basel). 2019 Apr 18;11(4):558. doi: 10.3390/cancers11040558.
• [1571] Increasing circulating exosomes-carrying TRPC5 predicts chemoresistance in metastatic breast cancer patients.Cancer Sci. 2017 Mar;108(3):448-454. doi: 10.1111/cas.13150.
• [1572] Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site.J Immunother. 2000 Jan;23(1):2-10. doi: 10.1097/00002371-200001000-00002.
• [1573] TRPM7 residue S1269 mediates cAMP dependence of Ca2+ influx.PLoS One. 2019 Jan 7;14(1):e0209563. doi: 10.1371/journal.pone.0209563. eCollection 2019.
• [1574] Assessment of the TRPM8 inhibitor AMTB in breast cancer cells and its identification as an inhibitor of voltage gated sodium channels.Life Sci. 2018 Apr 1;198:128-135. doi: 10.1016/j.lfs.2018.02.030. Epub 2018 Feb 26.
• [1575] Intracellular aggregated TRPV1 is associated with lower survival in breast cancer patients.Breast Cancer (Dove Med Press). 2018 Oct 15;10:161-168. doi: 10.2147/BCTT.S170208. eCollection 2018.
• [1576] TRPV4 plays a role in breast cancer cell migration via Ca(2+)-dependent activation of AKT and downregulation of E-cadherin cell cortex protein.Oncogenesis. 2017 May 22;6(5):e338. doi: 10.1038/oncsis.2017.39.
• [1577] Genetic variants in EBV reactivation-related genes and the risk and survival of breast cancer.Tumour Biol. 2016 Jun;37(6):8337-47. doi: 10.1007/s13277-015-4562-0. Epub 2016 Jan 5.
• [1578] Optimized Translocator Protein Ligand for Optical Molecular Imaging and Screening.Bioconjug Chem. 2017 Apr 19;28(4):1016-1023. doi: 10.1021/acs.bioconjchem.6b00711. Epub 2017 Feb 13.
• [1579] Downregulation of TXNIP leads to high proliferative activity and estrogen-dependent cell growth in breast cancer.Biochem Biophys Res Commun. 2018 Apr 6;498(3):566-572. doi: 10.1016/j.bbrc.2018.03.020. Epub 2018 Mar 13.
• [1580] miR526b and miR655 Induce Oxidative Stress in Breast Cancer.Int J Mol Sci. 2019 Aug 19;20(16):4039. doi: 10.3390/ijms20164039.
• [1581] -Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):E707-E716. doi: 10.1073/pnas.1610383114. Epub 2017 Jan 17.
• [1582] Synthesis, thymidine phosphorylase inhibitory and computational study of novel 1,3,4-oxadiazole-2-thione derivatives as potential anticancer agents.Comput Biol Chem. 2018 Oct;76:151-160. doi: 10.1016/j.compbiolchem.2018.05.013. Epub 2018 May 16.
• [1583] Isolation, characterization, and bioactivities of compounds from Fuscoporia torulosa mushroom.J Food Biochem. 2019 Dec;43(12):e13074. doi: 10.1111/jfbc.13074. Epub 2019 Oct 10.
• [1584] The Emerging Role of TYRO3 as a Therapeutic Target in Cancer.Cancers (Basel). 2018 Nov 29;10(12):474. doi: 10.3390/cancers10120474.
• [1585] Genetic variation in the vitamin D related pathway and breast cancer risk in women of African ancestry in the root consortium.Int J Cancer. 2018 Jan 1;142(1):36-43. doi: 10.1002/ijc.31038. Epub 2017 Sep 23.
• [1586] Mining the tissue-tissue gene co-expression network for tumor microenvironment study and biomarker prediction.BMC Genomics. 2013;14 Suppl 5(Suppl 5):S4. doi: 10.1186/1471-2164-14-S5-S4. Epub 2013 Oct 16.
• [1587] ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells.Exp Biol Med (Maywood). 2012 Jan;237(1):38-49. doi: 10.1258/ebm.2011.011236. Epub 2011 Dec 20.
• [1588] Proteomic identification of E6AP as a molecular target of tamoxifen in MCF7 cells.Proteomics. 2012 May;12(9):1363-77. doi: 10.1002/pmic.201100572.
• [1589] A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination.Genes Dev. 2016 Dec 1;30(23):2581-2595. doi: 10.1101/gad.289439.116. Epub 2016 Dec 9.
• [1590] Altered methylation of glucosylceramide synthase promoter regulates its expression and associates with acquired multidrug resistance in invasive ductal breast cancer.Oncotarget. 2016 Jun 14;7(24):36755-36766. doi: 10.18632/oncotarget.9337.
• [1591] Cinnamaldehyde/chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer.Mol Med Rep. 2014 Feb;9(2):669-76. doi: 10.3892/mmr.2013.1830. Epub 2013 Nov 26.
• [1592] USP1 (ubiquitin specific peptidase 1) targets ULK1 and regulates its cellular compartmentalization and autophagy.Autophagy. 2019 Apr;15(4):613-630. doi: 10.1080/15548627.2018.1535291. Epub 2018 Oct 29.
• [1593] USP2 promotes cell migration and invasion in triple negative breast cancer cell lines.Tumour Biol. 2015 Jul;36(7):5415-23. doi: 10.1007/s13277-015-3207-7. Epub 2015 Feb 17.
• [1594] Deubiquitinating enzyme USP33/VDU1 is required for Slit signaling in inhibiting breast cancer cell migration.Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14530-5. doi: 10.1073/pnas.0801262106. Epub 2009 Aug 12.
• [1595] Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity.J Exp Clin Cancer Res. 2018 Nov 27;37(1):287. doi: 10.1186/s13046-018-0934-9.
• [1596] Homozygous T172T and Heterozygous G135C Variants of Homologous Recombination Repairing Protein RAD51 are Related to Sporadic Breast Cancer Susceptibility.Biochem Genet. 2016 Feb;54(1):83-94. doi: 10.1007/s10528-015-9703-z. Epub 2015 Dec 9.
• [1597] The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.Breast Cancer Res. 2012 Nov 12;14(6):R145. doi: 10.1186/bcr3354.
• [1598] Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer.Pathol Oncol Res. 2019 Oct;25(4):1477-1486. doi: 10.1007/s12253-018-0527-0. Epub 2018 Nov 1.
• [1599] Association between ER gene Pvu II polymorphism and breast cancer susceptibility: A meta-analysis.Medicine (Baltimore). 2018 Apr;97(17):e0317. doi: 10.1097/MD.0000000000010317.
• [1600] 3D structure prediction of VAPC1 and identification of dual natural inhibitors for VPAC1 and EGFR.J Bioenerg Biomembr. 2019 Apr;51(2):89-102. doi: 10.1007/s10863-019-09790-y. Epub 2019 Feb 27.
• [1601] Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.Regul Pept. 2007 Dec 4;144(1-3):101-8. doi: 10.1016/j.regpep.2007.06.006. Epub 2007 Jun 28.
• [1602] A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.Clin Cancer Res. 2019 May 1;25(9):2925-2934. doi: 10.1158/1078-0432.CCR-17-3123. Epub 2019 Feb 8.
• [1603] Increased RNA Expression of von Willebrand Factor Gene Is Associated With Infiltrating Lobular Breast Cancer and Normal PAM50 Subtype.Cancer Genomics Proteomics. 2019 May-Jun;16(3):147-153. doi: 10.21873/cgp.20120.
• [1604] Induction of the fatty acid 2-hydroxylase (FA2H) gene by (9)-tetrahydrocannabinol in human breast cancer cells. J Toxicol Sci. 2013;38(2):305-8. doi: 10.2131/jts.38.305.
• [1605] Salinomycin reduces growth, proliferation and metastasis of cisplatin resistant breast cancer cells via NF-kB deregulation.Toxicol In Vitro. 2019 Oct;60:125-133. doi: 10.1016/j.tiv.2019.05.004. Epub 2019 May 8.
• [1606] Wnt5a induces ROR1 and ROR2 to activate RhoA in esophageal squamous cell carcinoma cells.Cancer Manag Res. 2019 Apr 10;11:2803-2815. doi: 10.2147/CMAR.S190999. eCollection 2019.
• [1607] Wnt7a Deficiency Could Predict Worse Disease-Free and Overall Survival in Estrogen Receptor-Positive Breast Cancer.J Breast Cancer. 2017 Dec;20(4):361-367. doi: 10.4048/jbc.2017.20.4.361. Epub 2017 Dec 19.
• [1608] Analysis of DNA Repair Genes Polymorphisms in Breast Cancer.Pathol Oncol Res. 2017 Jan;23(1):117-123. doi: 10.1007/s12253-016-0110-5. Epub 2016 Aug 29.
• [1609] WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer.Br J Cancer. 2018 Dec;119(12):1508-1517. doi: 10.1038/s41416-018-0317-1. Epub 2018 Oct 30.
• [1610] Xanthine oxidoreductase is required for genotoxic stress-induced NKG2D ligand expression and gemcitabine-mediated antitumor activity.Oncotarget. 2016 Sep 13;7(37):59220-59235. doi: 10.18632/oncotarget.11042.
• [1611] XIAP Regulation by MNK Links MAPK and NFB Signaling to Determine an Aggressive Breast Cancer Phenotype.Cancer Res. 2018 Apr 1;78(7):1726-1738. doi: 10.1158/0008-5472.CAN-17-1667. Epub 2018 Jan 19.
• [1612] Association of XPA polymorphism with breast cancer risk: A meta-analysis.Medicine (Baltimore). 2018 Jun;97(26):e11276. doi: 10.1097/MD.0000000000011276.
• [1613] CRM1, a novel independent prognostic factor overexpressed in invasive breast carcinoma of poor prognosis.Oncol Lett. 2018 May;15(5):7515-7522. doi: 10.3892/ol.2018.8316. Epub 2018 Mar 22.
• [1614] Association between polymorphisms at promoters of XRCC5 and XRCC6 genes and risk of breast cancer.Med Oncol. 2014 Apr;31(4):885. doi: 10.1007/s12032-014-0885-8. Epub 2014 Mar 11.
• [1615] Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues.Hum Pathol. 2017 Oct;68:166-174. doi: 10.1016/j.humpath.2017.08.032. Epub 2017 Sep 9.
• [1616] Structural Comparison of Gene Relevance Networks for Breast Cancer Tissues in Different Grades.Comb Chem High Throughput Screen. 2016;19(9):714-719. doi: 10.2174/1386207319666160831152801.
• [1617] Silencing of hsa_circ_0004771 inhibits proliferation and induces apoptosis in breast cancer through activation of miR-653 by targeting ZEB2 signaling pathway.Biosci Rep. 2019 May 17;39(5):BSR20181919. doi: 10.1042/BSR20181919. Print 2019 May 31.
• [1618] Targeting AU-rich element-mediated mRNA decay with a truncated active form of the zinc-finger protein TIS11b/BRF1 impairs major hallmarks of mammary tumorigenesis.Oncogene. 2019 Jun;38(26):5174-5190. doi: 10.1038/s41388-019-0784-8. Epub 2019 Mar 26.
• [1619] ZNF224, Krppel like zinc finger protein, induces cell growth and apoptosis-resistance by down-regulation of p21 and p53 via miR-663a.Oncotarget. 2016 May 24;7(21):31177-90. doi: 10.18632/oncotarget.8870.
• [1620] Centchroman: A safe reversible postcoital contraceptive with curative and prophylactic activity in many disorders.Front Biosci (Elite Ed). 2018 Jan 1;10(1):1-14. doi: 10.2741/e807.
• [1621] Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case-control study.Eur J Cancer. 2009 Feb;45(3):435-42. doi: 10.1016/j.ejca.2008.10.001. Epub 2008 Nov 12.
• [1622] Carbonic Anhydrase 1-Mediated Calcification Is Associated With Atherosclerosis, and Methazolamide Alleviates Its Pathogenesis.Front Pharmacol. 2019 Jul 10;10:766. doi: 10.3389/fphar.2019.00766. eCollection 2019.
• [1623] Ca(2+) and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMF.EBioMedicine. 2019 Jun;44:194-208. doi: 10.1016/j.ebiom.2019.05.038. Epub 2019 May 23.
• [1624] Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence.Cancer Immunol Immunother. 2015 Apr;64(4):467-78. doi: 10.1007/s00262-015-1658-8. Epub 2015 Jan 25.
• [1625] -Conotoxin ImI-modified polymeric micelles as potential nanocarriers for targeted docetaxel delivery to 7-nAChR overexpressed non-small cell lung cancer.Drug Deliv. 2018 Nov;25(1):493-503. doi: 10.1080/10717544.2018.1436097.
• [1626] Membrane protein-regulated networks across human cancers.Nat Commun. 2019 Jul 16;10(1):3131. doi: 10.1038/s41467-019-10920-8.
• [1627] Sensitization of breast cancer cells to doxorubicin via stable cell line generation and overexpression of DFF40.Biochem Cell Biol. 2015 Dec;93(6):604-10. doi: 10.1139/bcb-2015-0007. Epub 2015 Sep 15.
• [1628] ZnR/GPR39 upregulation of K(+)/Cl(-)-cotransporter 3 in tamoxifen resistant breast cancer cells.Cell Calcium. 2019 Jul;81:12-20. doi: 10.1016/j.ceca.2019.05.005. Epub 2019 May 22.
• [1629] LncRNA HOTTIP-Mediated HOXA11 Expression Promotes Cell Growth, Migration and Inhibits Cell Apoptosis in Breast Cancer.Int J Mol Sci. 2018 Feb 6;19(2):472. doi: 10.3390/ijms19020472.
• [1630] HPD overexpression predicts poor prognosis in breast cancer.Pathol Res Pract. 2019 Sep;215(9):152524. doi: 10.1016/j.prp.2019.152524. Epub 2019 Jun 28.
• [1631] A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system.Oncoimmunology. 2019 Apr 12;8(7):1596005. doi: 10.1080/2162402X.2019.1596005. eCollection 2019.
• [1632] The proinflammatory LTB4/BLT1 signal axis confers resistance to TGF-1-induced growth inhibition by targeting Smad3 linker region.Oncotarget. 2015 Dec 8;6(39):41650-66. doi: 10.18632/oncotarget.6146.
• [1633] SNP-SNP interaction analysis of NF-B signaling pathway on breast cancer survival.Oncotarget. 2015 Nov 10;6(35):37979-94. doi: 10.18632/oncotarget.4991.
• [1634] Down-Regulation of NDUFB9 Promotes Breast Cancer Cell Proliferation, Metastasis by Mediating Mitochondrial Metabolism.PLoS One. 2015 Dec 7;10(12):e0144441. doi: 10.1371/journal.pone.0144441. eCollection 2015.
• [1635] Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer.J Exp Clin Cancer Res. 2019 May 9;38(1):187. doi: 10.1186/s13046-019-1187-y.
• [1636] OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATH-Based Proteomic Approach.Proteomics. 2019 Nov;19(21-22):e1800446. doi: 10.1002/pmic.201800446. Epub 2019 Aug 8.
• [1637] Effects of immunization against PCSK9 in an experimental model of breast cancer.Arch Med Sci. 2019 May;15(3):570-579. doi: 10.5114/aoms.2019.84734. Epub 2019 Apr 30.
• [1638] Inhibition of breast cancer cell migration by activation of cAMP signaling.Breast Cancer Res Treat. 2015 Jul;152(1):17-28. doi: 10.1007/s10549-015-3445-9. Epub 2015 May 29.
• [1639] Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression.Nat Commun. 2019 Aug 14;10(1):3668. doi: 10.1038/s41467-019-11640-9.
• [1640] PRDX4 and Its Roles in Various Cancers.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819864313. doi: 10.1177/1533033819864313.
• [1641] Analysis of PKC- protein levels in normal and malignant breast tissue subtypes.Oncol Lett. 2019 Feb;17(2):1537-1546. doi: 10.3892/ol.2018.9792. Epub 2018 Dec 4.
• [1642] RIP2 enhances cell survival by activation of NF-B in triple negative breast cancer cells.Biochem Biophys Res Commun. 2018 Feb 26;497(1):115-121. doi: 10.1016/j.bbrc.2018.02.034. Epub 2018 Feb 6.
• [1643] Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.J Natl Cancer Inst. 2018 Aug 1;110(8):871-879. doi: 10.1093/jnci/djx280.
• [1644] Overexpression of the steroidogenic acute regulatory protein in breast cancer: Regulation by histone deacetylase inhibition.Biochem Biophys Res Commun. 2019 Feb 5;509(2):476-482. doi: 10.1016/j.bbrc.2018.12.145. Epub 2018 Dec 27.
• [1645] Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/-catenin pathway.J Exp Clin Cancer Res. 2019 Jul 12;38(1):305. doi: 10.1186/s13046-019-1315-8.
• [1646] Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.Oncologist. 2018 Sep;23(9):1092-1102. doi: 10.1634/theoncologist.2017-0379. Epub 2018 Apr 26.
• [1647] The pleiotropic effects of TNF in breast cancer subtypes is regulated by TNFAIP3/A20.Oncogene. 2019 Jan;38(4):469-482. doi: 10.1038/s41388-018-0472-0. Epub 2018 Aug 30.
• [1648] CD137 promotes bone metastasis of breast cancer by enhancing the migration and osteoclast differentiation of monocytes/macrophages.Theranostics. 2019 May 9;9(10):2950-2966. doi: 10.7150/thno.29617. eCollection 2019.
• [1649] UCH-L1 promotes invasion of breast cancer cells through activating Akt signaling pathway.J Cell Biochem. 2018 Jan;119(1):691-700. doi: 10.1002/jcb.26232. Epub 2017 Jul 31.
• [1650] USP44+ Cancer Stem Cell Subclones Contribute to Breast Cancer Aggressiveness by Promoting Vasculogenic Mimicry.Mol Cancer Ther. 2015 Sep;14(9):2121-31. doi: 10.1158/1535-7163.MCT-15-0114-T. Epub 2015 Jul 31.
• [1651] Transcriptional profiling of breast cancer-associated lymphatic vessels reveals VCAM-1 as regulator of lymphatic invasion and permeability.Int J Cancer. 2019 Nov 15;145(10):2804-2815. doi: 10.1002/ijc.32594. Epub 2019 Aug 8.
• [1652] ABCB5-ZEB1 Axis Promotes Invasion and Metastasis in Breast Cancer Cells.Oncol Res. 2017 Mar 13;25(3):305-316. doi: 10.3727/096504016X14734149559061.
• [1653] Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response.Br J Cancer. 2014 Aug 12;111(4):696-707. doi: 10.1038/bjc.2014.326. Epub 2014 Jun 17.
• [1654] CACNG2 polymorphisms associate with chronic pain after mastectomy.Pain. 2019 Mar;160(3):561-568. doi: 10.1097/j.pain.0000000000001432.
• [1655] MicroRNA 362-3p Reduces hERG-related Current and Inhibits Breast Cancer Cells Proliferation.Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):433-442. doi: 10.21873/cgp.20147.
• [1656] Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome.BMC Cancer. 2013 Jan 2;13:1. doi: 10.1186/1471-2407-13-1.
• [1657] Zip1, Zip2, and Zip8 mRNA expressions were associated with growth hormone level during the growth hormone provocation test in children with short stature.Biol Trace Elem Res. 2013 Oct;155(1):11-22. doi: 10.1007/s12011-013-9764-y. Epub 2013 Aug 7.
• [1658] The novel sugar transporter SLC50A1 as a potential serum-based diagnostic and prognostic biomarker for breast cancer.Cancer Manag Res. 2019 Jan 17;11:865-876. doi: 10.2147/CMAR.S190591. eCollection 2019.
• [1659] Modification of ASC1 by UFM1 is crucial for ER transactivation and breast cancer development.Mol Cell. 2014 Oct 23;56(2):261-274. doi: 10.1016/j.molcel.2014.08.007. Epub 2014 Sep 11.
• [1660] SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE).Breast Cancer Res Treat. 2012 Jul;134(1):101-15. doi: 10.1007/s10549-011-1925-0. Epub 2012 Jan 3.
• [1661] Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration.J Cell Biochem. 2012 Nov;113(11):3363-70. doi: 10.1002/jcb.24212.
• [1662] Unraveling FATP1, regulated by ER-, as a targeted breast cancer innovative therapy.Sci Rep. 2019 Oct 1;9(1):14107. doi: 10.1038/s41598-019-50531-3.
• [1663] Activation of lncRNA lnc-SLC4A1-1 induced by H3K27 acetylation promotes the development of breast cancer via activating CXCL8 and NF-kB pathway.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3765-3773. doi: 10.1080/21691401.2019.1664559.
• [1664] Targeting Taurine Transporter (TauT) for Cancer Immunotherapy of p53 Mutation Mediated Cancers - Molecular Basis and Preclinical Implication.Adv Exp Med Biol. 2019;1155:543-553. doi: 10.1007/978-981-13-8023-5_50.
• [1665] Organellar (Na+, K+)/H+ exchanger NHE7 regulates cell adhesion, invasion and anchorage-independent growth of breast cancer MDA-MB-231 cells.Oncol Rep. 2012 Feb;27(2):311-7. doi: 10.3892/or.2011.1542. Epub 2011 Nov 9.
• [1666] Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.Curr Drug Metab. 2019;20(2):124-129. doi: 10.2174/1389200219666181003142036.
• [1667] The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.Breast Cancer (Dove Med Press). 2017 Jul 11;9:495-514. doi: 10.2147/BCTT.S139963. eCollection 2017.
• [1668] A functional single nucleotide polymorphism in ABCC11, rs17822931, is associated with the risk of breast cancer in Japanese.Carcinogenesis. 2019 Jun 10;40(4):537-543. doi: 10.1093/carcin/bgz005.
• [1669] Expression of plasma membrane calcium pump isoform mRNAs in breast cancer cell lines.Cell Signal. 2002 Dec;14(12):1015-22. doi: 10.1016/s0898-6568(02)00049-9.
• [1670] Inhibiting the MNK-eIF4E--catenin axis increases the responsiveness of aggressive breast cancer cells to chemotherapy.Oncotarget. 2017 Jan 10;8(2):2906-2915. doi: 10.18632/oncotarget.13772.
• [1671] Estrone-3-Sulfate Stimulates the Proliferation of T47D Breast Cancer Cells Stably Transfected With the Sodium-Dependent Organic Anion Transporter SOAT (SLC10A6). Front Pharmacol. 2018 Aug 21;9:941. doi: 10.3389/fphar.2018.00941. eCollection 2018.
• [1672] Treatment of breast cancer cells with DNA demethylating agents leads to a release of Pol II stalling at genes with DNA-hypermethylated regions upstream of TSS.Nucleic Acids Res. 2011 Dec;39(22):9508-20. doi: 10.1093/nar/gkr611. Epub 2011 Aug 31.
• [1673] Associations between genetic polymorphisms of membrane transporter genes and prognosis after chemotherapy: meta-analysis and finding from Seoul Breast Cancer Study (SEBCS).Pharmacogenomics J. 2018 Sep;18(5):633-645. doi: 10.1038/s41397-018-0016-6. Epub 2018 Apr 4.
• [1674] New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity.Anticancer Agents Med Chem. 2018;18(2):295-301. doi: 10.2174/1871520617666171003145533.
• [1675] Adipocytes promote malignant growth of breast tumours with monocarboxylate transporter 2 expression via beta-hydroxybutyrate. Nat Commun. 2017 Mar 10;8:14706.
• [1676] Mammalian protein homologous to VAT-1 of Torpedo californica: isolation from Ehrlich ascites tumor cells, biochemical characterization, and organization of its gene.J Cell Biochem. 1998 Jun 1;69(3):304-15.
• [1677] POU1F1 transcription factor promotes breast cancer metastasis via recruitment and polarization of macrophages.J Pathol. 2019 Nov;249(3):381-394. doi: 10.1002/path.5324. Epub 2019 Aug 27.
• [1678] Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study.Endocr Relat Cancer. 2013 Nov 4;20(6):875-87. doi: 10.1530/ERC-13-0349. Print 2013 Dec.
• [1679] Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi.Int J Cancer. 2008 May 1;122(9):1999-2007. doi: 10.1002/ijc.23321.
• [1680] Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells.Exp Mol Med. 2012 Apr 30;44(4):251-9. doi: 10.3858/emm.2012.44.4.019.
• [1681] Uptake transporter organic anion transporting polypeptide 1B3 contributes to the growth of estrogen-dependent breast cancer.J Steroid Biochem Mol Biol. 2010 Oct;122(4):180-5. doi: 10.1016/j.jsbmb.2010.06.014. Epub 2010 Jul 6.
• [1682] A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line Encyclopedia.Sci Rep. 2016 Mar 10;6:22811. doi: 10.1038/srep22811.
• [1683] New Insight on Solute Carrier Family 27 Member 6 (SLC27A6) in Tumoral and Non-Tumoral Breast Cells.Int J Med Sci. 2019 Jan 24;16(3):366-375. doi: 10.7150/ijms.29946. eCollection 2019.
• [1684] Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells.Biochem Pharmacol. 2008 Feb 1;75(3):639-48. doi: 10.1016/j.bcp.2007.10.005. Epub 2007 Oct 13.
• [1685] An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer.Nat Genet. 2014 Oct;46(10):1051-9. doi: 10.1038/ng.3073. Epub 2014 Aug 24.
• [1686] Expression and function of hexose transporters GLUT1, GLUT2, and GLUT5 in breast cancer-effects of hypoxia.FASEB J. 2018 Sep;32(9):5104-5118. doi: 10.1096/fj.201800360R. Epub 2018 Apr 13.
• [1687] Glucose Transporter 3 is Essential for the Survival of Breast Cancer Cells in the Brain.Cells. 2019 Dec 4;8(12):1568. doi: 10.3390/cells8121568.
• [1688] Sugar Concentration and Arrangement on the Surface of Glycopolymer Micelles Affect the Interaction with Cancer Cells.Biomacromolecules. 2019 Jan 14;20(1):273-284. doi: 10.1021/acs.biomac.8b01406. Epub 2018 Dec 14.
• [1689] Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.Cancer Res. 2016 Oct 1;76(19):5881-5893. doi: 10.1158/0008-5472.CAN-15-3372. Epub 2016 Aug 5.
• [1690] Expression of the SART-1 tumor rejection antigen in breast cancer.Int J Cancer. 1999 Jan 5;80(1):64-7. doi: 10.1002/(sici)1097-0215(19990105)80:1<64::aid-ijc13>3.0.co;2-7.
• [1691] SLC35B2 expression is associated with a poor prognosis of invasive ductal breast carcinoma.Asian Pac J Cancer Prev. 2014;15(15):6065-70. doi: 10.7314/apjcp.2014.15.15.6065.
• [1692] SLC37A1 gene expression is up-regulated by epidermal growth factor in breast cancer cells.Breast Cancer Res Treat. 2010 Aug;122(3):755-64. doi: 10.1007/s10549-009-0620-x. Epub 2009 Nov 6.
• [1693] Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs.J Hematol Oncol. 2017 Apr 17;10(1):89. doi: 10.1186/s13045-017-0462-7.
• [1694] Zinc and its transporter ZIP10 are involved in invasive behavior of breast cancer cells.Cancer Sci. 2007 May;98(5):692-7. doi: 10.1111/j.1349-7006.2007.00446.x. Epub 2007 Mar 14.
• [1695] Over-expression of Zip-13 mRNA in kidney and lung during dietary zinc deficiency in Wistar rats.Mol Biol Rep. 2011 Mar;38(3):1869-74. doi: 10.1007/s11033-010-0304-y. Epub 2010 Sep 22.
• [1696] Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer.Metallomics. 2019 Sep 1;11(9):1579-1592. doi: 10.1039/c9mt00136k. Epub 2019 Sep 4.
• [1697] Cysteine transporter SLC3A1 promotes breast cancer tumorigenesis. Theranostics. 2017 Feb 26;7(4):1036-1046.
• [1698] CYP1A1 gene polymorphisms: lack of association with breast cancer susceptibility in the southern region (Madurai) of India.Asian Pac J Cancer Prev. 2011;12(8):2133-8.
• [1699] MRTF/SRF dependent transcriptional regulation of TAZ in breast cancer cells.Oncotarget. 2016 Mar 22;7(12):13706-16. doi: 10.18632/oncotarget.7333.
• [1700] Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma.Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8703-8. doi: 10.1073/pnas.95.15.8703.
• [1701] Protease-activated receptor 2 (PAR2) upregulates granulocyte colony stimulating factor (G-CSF) expression in breast cancer cells.Biochem Biophys Res Commun. 2018 Sep 26;504(1):270-276. doi: 10.1016/j.bbrc.2018.08.169. Epub 2018 Aug 30.
• [1702] The plasma membrane transporter SLC5A8 suppresses tumour progression through depletion of survivin without involving its transport function.Biochem J. 2013 Feb 15;450(1):169-78. doi: 10.1042/BJ20121248.
• [1703] Targeting Apoptosis Inhibition to Activate Antitumor Immunity.Trends Immunol. 2019 Dec;40(12):1073-1075. doi: 10.1016/j.it.2019.11.002. Epub 2019 Nov 14.
• [1704] Na(+),HCO(3)(-)-cotransporter NBCn1 (Slc4a7) accelerates ErbB2-induced breast cancer development and tumor growth in mice.Oncogene. 2018 Oct;37(41):5569-5584. doi: 10.1038/s41388-018-0353-6. Epub 2018 Jun 15.
• [1705] Breast cancer survivorship: state of the science.Breast Cancer Res Treat. 2018 Apr;168(3):593-600. doi: 10.1007/s10549-017-4650-5. Epub 2018 Jan 13.
• [1706] Down-regulation of asparagine synthetase induces cell cycle arrest and inhibits cell proliferation of breast cancer.Chem Biol Drug Des. 2014 Nov;84(5):578-84. doi: 10.1111/cbdd.12348. Epub 2014 Jul 12.
• [1707] Plasma carotenoid- and retinol-weighted multi-SNP scores and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):927-36. doi: 10.1158/1055-9965.EPI-13-0017. Epub 2013 Mar 20.
• [1708] Polymorphisms in the carcinogen detoxification genes CYB5A and CYB5R3 and breast cancer risk in African American women.Cancer Causes Control. 2014 Nov;25(11):1513-21. doi: 10.1007/s10552-014-0454-7. Epub 2014 Sep 16.
• [1709] An Introduction to the Performance of Immunohistochemistry.Methods Mol Biol. 2019;1897:289-298. doi: 10.1007/978-1-4939-8935-5_25.
• [1710] Nuclear Factor Erythroid-Derived 2-Like 2-Induced Reductive Stress Favors Self-Renewal of Breast Cancer Stem-Like Cells via the FoxO3a-Bmi-1 Axis.Antioxid Redox Signal. 2020 Jun;32(18):1313-1329. doi: 10.1089/ars.2019.7730. Epub 2020 Jan 8.
• [1711] Oxidative stress in susceptibility to breast cancer: study in Spanish population.BMC Cancer. 2014 Nov 21;14:861. doi: 10.1186/1471-2407-14-861.
• [1712] Diagnostic and prognostic value of the cancer-testis antigen lactate dehydrogenase C4 in breast cancer.Clin Chim Acta. 2020 Apr;503:203-209. doi: 10.1016/j.cca.2019.11.032. Epub 2019 Nov 30.
• [1713] Blood and Tissue Enzymatic Activities of GDH and LDH, Index of Glutathione, and Oxidative Stress among Breast Cancer Patients Attending Referral Hospitals of Addis Ababa, Ethiopia: Hospital-Based Comparative Cross-Sectional Study.Oxid Med Cell Longev. 2018 Mar 26;2018:6039453. doi: 10.1155/2018/6039453. eCollection 2018.
• [1714] Resveratrol represses estrogen-induced mammary carcinogenesis through NRF2-UGT1A8-estrogen metabolic axis activation.Biochem Pharmacol. 2018 Sep;155:252-263. doi: 10.1016/j.bcp.2018.07.006. Epub 2018 Jul 20.
• [1715] Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment.Ther Clin Risk Manag. 2018 Mar 14;14:543-549. doi: 10.2147/TCRM.S156466. eCollection 2018.
• [1716] Hormone-related pathways and risk of breast cancer subtypes in African American women.Breast Cancer Res Treat. 2015 Nov;154(1):145-54. doi: 10.1007/s10549-015-3594-x. Epub 2015 Oct 12.
• [1717] Effect of genetic variants in two chemokine decoy receptor genes, DARC and CCBP2, on metastatic potential of breast cancer.PLoS One. 2013 Nov 15;8(11):e78901. doi: 10.1371/journal.pone.0078901. eCollection 2013.
• [1718] Human 3-hydroxysteroid dehydrogenase type 1 in human breast cancer: clinical significance and prognostic associations.Cancer Med. 2016 Jul;5(7):1405-15. doi: 10.1002/cam4.708. Epub 2016 May 3.
• [1719] NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer.Mol Cell Proteomics. 2015 Nov;14(11):2988-99. doi: 10.1074/mcp.M115.050385. Epub 2015 Sep 8.
• [1720] Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial.Breast Cancer Res Treat. 2018 Feb;167(3):797-802. doi: 10.1007/s10549-017-4562-4. Epub 2017 Nov 7.
• [1721] Expression of CYP2S1 and CYP2W1 in breast cancer epithelial cells and modulation of their expression by synthetic methoxy stilbenes.Pharmacol Rep. 2019 Dec;71(6):1001-1005. doi: 10.1016/j.pharep.2019.08.005. Epub 2019 Aug 14.
• [1722] Salivary Gland Function, Antioxidant Defence and Oxidative Damage in the Saliva of Patients with Breast Cancer: Does the BRCA1 Mutation Disturb the Salivary Redox Profile?.Cancers (Basel). 2019 Oct 8;11(10):1501. doi: 10.3390/cancers11101501.
• [1723] Over-expression of EPS15 is a favorable prognostic factor in breast cancer.Mol Biosyst. 2015 Nov;11(11):2978-85. doi: 10.1039/c5mb00219b.
• [1724] The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China.Clin Breast Cancer. 2019 Apr;19(2):e370-e375. doi: 10.1016/j.clbc.2018.12.009. Epub 2018 Dec 19.
• [1725] UDP-glucuronosyltransferase 1A6 overexpression in breast cancer cells resistant to methotrexate. Biochem Pharmacol. 2011 Jan 1;81(1):60-70.
• [1726] UGT2B4 previously implicated in the risk of breast cancer is associated with menarche timing in Ukrainian females.Gene. 2016 Sep 15;590(1):85-9. doi: 10.1016/j.gene.2016.06.015. Epub 2016 Jun 7.
• [1727] Increased proliferation and chemosensitivity of human mesenchymal stromal cells expressing fusion yeast cytosine deaminase.Stem Cell Res. 2012 Mar;8(2):247-58. doi: 10.1016/j.scr.2011.11.006. Epub 2011 Dec 6.
• [1728] Blood groups type linked to breast cancer in a Greek cohort of women - a case control study.J BUON. 2019 Sep-Oct;24(5):1884-1888.
• [1729] RNA interference of ecto-5'-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion.Clin Exp Metastasis. 2007;24(6):439-48. doi: 10.1007/s10585-007-9081-y. Epub 2007 Jun 21.
• [1730] ADH3 genotype, alcohol intake and breast cancer risk.Carcinogenesis. 2006 Apr;27(4):840-7. doi: 10.1093/carcin/bgi285. Epub 2005 Dec 12.
• [1731] ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming.J Clin Invest. 2018 Jan 2;128(1):323-340. doi: 10.1172/JCI93815. Epub 2017 Nov 27.
• [1732] AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells.Mol Carcinog. 2018 Oct;57(10):1300-1310. doi: 10.1002/mc.22844. Epub 2018 Jun 28.
• [1733] Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk.Am J Epidemiol. 2009 Nov 15;170(10):1241-9. doi: 10.1093/aje/kwp298. Epub 2009 Oct 21.
• [1734] Phytosomal-curcumin antagonizes cell growth and migration, induced by thrombin through AMP-Kinase in breast cancer.J Cell Biochem. 2018 Jul;119(7):5996-6007. doi: 10.1002/jcb.26796. Epub 2018 Mar 30.
• [1735] Allelic variation of BAT-25 and BAT-26 mononucleotide repeat loci in tumours from a group of young women with breast cancer.Int J Oncol. 2004 Sep;25(3):771-5. doi: 10.3892/ijo.25.3.771.
• [1736] Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.Pharmacogenet Genomics. 2008 Jul;18(7):621-31. doi: 10.1097/FPC.0b013e328301a869.
• [1737] Carboxylesterase-2-Selective Two-Photon Ratiometric Probe Reveals Decreased Carboxylesterase-2 Activity in Breast Cancer Cells.Anal Chem. 2018 Aug 7;90(15):9465-9471. doi: 10.1021/acs.analchem.8b02101. Epub 2018 Jul 27.
• [1738] Genotranscriptomic meta-analysis of the CHD family chromatin remodelers in human cancers - initial evidence of an oncogenic role for CHD7.Mol Oncol. 2017 Oct;11(10):1348-1360. doi: 10.1002/1878-0261.12104. Epub 2017 Jul 21.
• [1739] Diagnostic and Prognostic Significance of Carboxypeptidase A4 (CPA4) in Breast Cancer.Biomolecules. 2019 Mar 14;9(3):103. doi: 10.3390/biom9030103.
• [1740] The synthesis of 4,6-diaryl-2-pyridones and their bioactivation in CYP1 expressing breast cancer cells.Bioorg Med Chem Lett. 2019 Jun 1;29(11):1403-1406. doi: 10.1016/j.bmcl.2019.03.030. Epub 2019 Mar 22.
• [1741] CYP2C and IL-6 expression in breast cancer.Breast. 2004 Feb;13(1):28-34. doi: 10.1016/j.breast.2003.07.002.
• [1742] Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study.Cancer Res. 1998 Feb 15;58(4):667-71.
• [1743] Thiamine transporter gene expression and exogenous thiamine modulate the expression of genes involved in drug and prostaglandin metabolism in breast cancer cells.Mol Cancer Res. 2004 Aug;2(8):477-87.
• [1744] Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.Am J Epidemiol. 2017 Jan 15;185(2):75-85. doi: 10.1093/aje/kww178. Epub 2016 Dec 17.
• [1745] Recruitment of monocytes and epigenetic silencing of intratumoral CYP7B1 primarily contribute to the accumulation of 27-hydroxycholesterol in breast cancer.Am J Cancer Res. 2019 Oct 1;9(10):2194-2208. eCollection 2019.
• [1746] A candidate CpG SNP approach identifies a breast cancer associated ESR1-SNP.Int J Cancer. 2011 Oct 1;129(7):1689-98. doi: 10.1002/ijc.25786. Epub 2011 Mar 11.
• [1747] Small molecule inhibition of DDAH1 significantly attenuates triple negative breast cancer cell vasculogenic mimicry in vitro.Biomed Pharmacother. 2019 Mar;111:602-612. doi: 10.1016/j.biopha.2018.12.117. Epub 2019 Jan 3.
• [1748] The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1 and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.Breast Cancer Res. 2011 Feb 3;13(1):R16. doi: 10.1186/bcr2825.
• [1749] Polyunsaturated Fatty Acids Differentially Modulate Cell Proliferation and Endocannabinoid System in Two Human Cancer Lines.Arch Med Res. 2017 Jan;48(1):46-54. doi: 10.1016/j.arcmed.2017.01.009.
• [1750] Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo--linolenic acid peroxidation dependent mechanism.BMC Cancer. 2018 Mar 27;18(1):330. doi: 10.1186/s12885-018-4250-8.
• [1751] Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.Breast Cancer Res. 2004;6(3):R252-63. doi: 10.1186/bcr784. Epub 2004 Mar 26.
• [1752] Transforming growth factor beta 1 (TGF1) polymorphisms and haplotype structures have dual roles in breast cancer pathogenesis.J Cancer Res Clin Oncol. 2018 Apr;144(4):645-655. doi: 10.1007/s00432-018-2585-9. Epub 2018 Jan 23.
• [1753] Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1.Breast Cancer Res Treat. 2010 Jun;121(2):485-96. doi: 10.1007/s10549-009-0585-9. Epub 2009 Oct 24.
• [1754] Effect of resveratrol on the radiosensitivity of 5-FU in human breast cancer MCF-7 cells.J Cell Biochem. 2019 Sep;120(9):15671-15677. doi: 10.1002/jcb.28836. Epub 2019 May 8.
• [1755] The Glycolytic Enzyme PFKFB3 Is Involved in Estrogen-Mediated Angiogenesis via GPER1.J Pharmacol Exp Ther. 2017 Jun;361(3):398-407. doi: 10.1124/jpet.116.238212. Epub 2017 Mar 27.
• [1756] 15-Deoxy-(12,14)-prostaglandin J(2) up-regulates the expression of 15-hydroxyprostaglandin dehydrogenase through DNA methyltransferase 1 inactivation.Free Radic Res. 2019 Mar;53(3):335-347. doi: 10.1080/10715762.2019.1576867. Epub 2019 Mar 1.
• [1757] Single nucleotide instability: a wide involvement in human and rat mammary carcinogenesis?.Mutat Res. 2002 Sep 30;506-507:101-11. doi: 10.1016/s0027-5107(02)00156-2.
• [1758] Inhibition of 3-Hydroxysteroid Dehydrogenase Type 1 Suppresses Interleukin-6 in Breast Cancer.J Surg Res. 2019 Sep;241:8-14. doi: 10.1016/j.jss.2019.03.024. Epub 2019 Apr 17.
• [1759] Genetic Variants in CD44 and MAT1A Confer Susceptibility to Acute Skin Reaction in Breast Cancer Patients Undergoing Radiation Therapy.Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):118-127. doi: 10.1016/j.ijrobp.2016.09.017. Epub 2016 Sep 20.
• [1760] Socioeconomic and demographic disparities in breast cancer stage at presentation and survival: A Swiss population-based study.Int J Cancer. 2017 Oct 15;141(8):1529-1539. doi: 10.1002/ijc.30856. Epub 2017 Jul 7.
• [1761] Genetic polymorphisms (rs10636 and rs28366003) in metallothionein 2A increase breast cancer risk in Chinese Han population.Aging (Albany NY). 2017 Feb 22;9(2):547-555. doi: 10.18632/aging.101177.
• [1762] Suppression of mitochondrial complex I influences cell metastatic properties.PLoS One. 2013 Apr 22;8(4):e61677. doi: 10.1371/journal.pone.0061677. Print 2013.
• [1763] Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.Lancet Oncol. 2019 Aug;20(8):1124-1135. doi: 10.1016/S1470-2045(19)30328-6. Epub 2019 Jun 27.
• [1764] Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines.FEBS J. 2011 Sep;278(18):3360-9. doi: 10.1111/j.1742-4658.2011.08260.x. Epub 2011 Aug 16.
• [1765] The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer.Br J Cancer. 2009 May 19;100(10):1687-96. doi: 10.1038/sj.bjc.6605042.
• [1766] Inhibition of the Hexosamine Biosynthetic Pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis.Cell Death Dis. 2018 Mar 7;9(3):377. doi: 10.1038/s41419-018-0405-4.
• [1767] Increasing the low lipid phosphate phosphatase 1 activity in breast cancer cells decreases transcription by AP-1 and expressions of matrix metalloproteinases and cyclin D1/D3.Theranostics. 2019 Aug 14;9(21):6129-6142. doi: 10.7150/thno.37094. eCollection 2019.
• [1768] Pyridoxine 5'-phosphate oxidase is correlated with human breast invasive ductal carcinoma development.Aging (Albany NY). 2019 Apr 14;11(7):2151-2176. doi: 10.18632/aging.101908.
• [1769] Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease.Cancer Detect Prev. 2007;31(2):95-101. doi: 10.1016/j.cdp.2007.02.004. Epub 2007 Apr 10.
• [1770] Elevated 80K-H protein in breast cancer: a role for FGF-1 stimulation of 80K-H.Int J Biol Markers. 2003 Apr-Jun;18(2):89-98. doi: 10.1177/172460080301800201.
• [1771] Functional Consequences of Intracellular Proline Levels Manipulation Affecting PRODH/POX-Dependent Pro-Apoptotic Pathways in a Novel in Vitro Cell Culture Model.Cell Physiol Biochem. 2017;43(2):670-684. doi: 10.1159/000480653. Epub 2017 Sep 22.
• [1772] Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer.J Natl Cancer Inst. 2019 Jun 1;111(6):597-608. doi: 10.1093/jnci/djy149.
• [1773] The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.Cancer Chemother Pharmacol. 2010 May;65(6):1067-81. doi: 10.1007/s00280-009-1112-8. Epub 2009 Aug 30.
• [1774] Altered expression of the hormone- and xenobiotic-metabolizing sulfotransferase enzymes 1A2 and 1C1 in malignant breast tissue.Int J Oncol. 2005 Apr;26(4):1079-85.
• [1775] SULT1E1 inhibits cell proliferation and invasion by activating PPAR in breast cancer.J Cancer. 2018 Feb 28;9(6):1078-1087. doi: 10.7150/jca.23596. eCollection 2018.
• [1776] Breast cancer: from estrogen to androgen receptor.Mol Cell Endocrinol. 2002 Jul 31;193(1-2):121-8. doi: 10.1016/s0303-7207(02)00105-3.
• [1777] Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells.Breast Cancer Res Treat. 2002 Jul;74(2):155-65. doi: 10.1023/a:1016114026769.
• [1778] Overexpression of Uridine-Cytidine Kinase 2 Correlates with Breast Cancer Progression and Poor Prognosis.J Breast Cancer. 2017 Jun;20(2):132-141. doi: 10.4048/jbc.2017.20.2.132. Epub 2017 Jun 26.
• [1779] Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study.Clin Pharmacol Ther. 2019 Aug;106(2):422-431. doi: 10.1002/cpt.1391. Epub 2019 Mar 28.
• [1780] Uridine phosphorylase 1 associates to biological and clinical significance in thyroid carcinoma cell lines.J Cell Mol Med. 2019 Nov;23(11):7438-7448. doi: 10.1111/jcmm.14612. Epub 2019 Sep 9.
• [1781] Distinct prognostic values of ALDH1 isoenzymes in breast cancer.Tumour Biol. 2015 Apr;36(4):2421-6. doi: 10.1007/s13277-014-2852-6. Epub 2015 Jan 13.
• [1782] Nucleoside diphosphate kinase 2 confers acquired 5-fluorouracil resistance in colorectal cancer cells.Artif Cells Nanomed Biotechnol. 2018;46(sup1):896-905. doi: 10.1080/21691401.2018.1439835. Epub 2018 Feb 23.
• [1783] Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization.Breast Cancer Res. 2019 May 17;21(1):64. doi: 10.1186/s13058-019-1150-z.
• [1784] Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.Pharmacogenomics J. 2020 Feb;20(1):19-26. doi: 10.1038/s41397-019-0087-z. Epub 2019 Apr 10.
• [1785] The impact of angio-associated migratory cell protein (AAMP) on breast cancer cells in vitro and its clinical significance.Anticancer Res. 2013 Apr;33(4):1499-509.
• [1786] Che-1 gene silencing induces osteosarcoma cell apoptosis by inhibiting mutant p53 expression.Biochem Biophys Res Commun. 2016 Apr 22;473(1):168-173. doi: 10.1016/j.bbrc.2016.03.073. Epub 2016 Mar 21.
• [1787] Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study.Breast Cancer Res. 2017 Dec 11;19(1):131. doi: 10.1186/s13058-017-0914-6.
• [1788] HBXIP up-regulates ACSL1 through activating transcriptional factor Sp1 in breast cancer.Biochem Biophys Res Commun. 2017 Mar 11;484(3):565-571. doi: 10.1016/j.bbrc.2017.01.126. Epub 2017 Jan 26.
• [1789] Increased -actinin-1 destabilizes E-cadherin-based adhesions and associates with poor prognosis in basal-like breast cancer.PLoS One. 2018 May 9;13(5):e0196986. doi: 10.1371/journal.pone.0196986. eCollection 2018.
• [1790] miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.Cell Physiol Biochem. 2018;50(1):136-149. doi: 10.1159/000493964. Epub 2018 Oct 2.
• [1791] A disintegrin and metalloprotease 23 hypermethylation predicts decreased disease-free survival in low-risk breast cancer patients.Cancer Sci. 2019 May;110(5):1695-1704. doi: 10.1111/cas.13985. Epub 2019 Mar 18.
• [1792] Interaction between the ADAMTS-12 metalloprotease and fibulin-2 induces tumor-suppressive effects in breast cancer cells.Oncotarget. 2014 Mar 15;5(5):1253-64. doi: 10.18632/oncotarget.1690.
• [1793] Effects of targeted CD97 immune epitopes small interference RNA on cellular biological behaviors in MDA-MB231 malignant breast cancer cell line.Am J Transl Res. 2017 Oct 15;9(10):4640-4651. eCollection 2017.
• [1794] High expression of GPR116 indicates poor survival outcome and promotes tumor progression in colorectal carcinoma.Oncotarget. 2017 Jul 18;8(29):47943-47956. doi: 10.18632/oncotarget.18203.
• [1795] A comparison of succinyladenylate lyase activity and serum sialic acid as markers of malignancy.Biochem Med. 1985 Dec;34(3):327-34. doi: 10.1016/0006-2944(85)90095-x.
• [1796] Clinical implications of AGBL2 expression and its inhibitor latexin in breast cancer.World J Surg Oncol. 2014 May 7;12:142. doi: 10.1186/1477-7819-12-142.
• [1797] Absence of AIF1L contributes to cell migration and a poor prognosis of breast cancer.Onco Targets Ther. 2018 Sep 5;11:5485-5498. doi: 10.2147/OTT.S165874. eCollection 2018.
• [1798] The KIP/CIP family members p21^{Waf1/Cip1} and p57^{Kip2} as diagnostic markers for breast cancer.Cancer Biomark. 2017;18(4):413-423. doi: 10.3233/CBM-160308.
• [1799] A novel cancer testis antigen, A-kinase anchor protein 4 (AKAP4) is a potential biomarker for breast cancer.PLoS One. 2013;8(2):e57095. doi: 10.1371/journal.pone.0057095. Epub 2013 Feb 22.
• [1800] Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.J Cell Physiol. 2019 Feb;234(2):1904-1912. doi: 10.1002/jcp.27066. Epub 2018 Aug 26.
• [1801] MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells.Tumour Biol. 2014 Jul;35(7):6327-34. doi: 10.1007/s13277-014-1834-z. Epub 2014 Mar 20.
• [1802] Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.Breast Cancer Res Treat. 2019 Jul;176(1):63-73. doi: 10.1007/s10549-019-05216-w. Epub 2019 Apr 2.
• [1803] Mask is required for the activity of the Hippo pathway effector Yki/YAP.Curr Biol. 2013 Feb 4;23(3):229-35. doi: 10.1016/j.cub.2012.12.033. Epub 2013 Jan 17.
• [1804] Prognostic roles of MAGE family members in breast cancer based on KM-Plotter Data.Oncol Lett. 2019 Oct;18(4):3501-3516. doi: 10.3892/ol.2019.10722. Epub 2019 Aug 6.
• [1805] Diversin is overexpressed in breast cancer and accelerates cell proliferation and invasion.PLoS One. 2014 May 23;9(5):e98591. doi: 10.1371/journal.pone.0098591. eCollection 2014.
• [1806] Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A Population-Based Analysis.Oncologist. 2019 Nov;24(11):e1014-e1023. doi: 10.1634/theoncologist.2018-0727. Epub 2019 Apr 24.
• [1807] Api5 a new cofactor of estrogen receptor alpha involved in breast cancer outcome.Oncotarget. 2017 Apr 20;8(32):52511-52526. doi: 10.18632/oncotarget.17281. eCollection 2017 Aug 8.
• [1808] ARHGAP8 is a novel member of the RHOGAP family related to ARHGAP1/CDC42GAP/p50RHOGAP: mutation and expression analyses in colorectal and breast cancers.Gene. 2004 Jul 7;336(1):59-71. doi: 10.1016/j.gene.2004.01.025.
• [1809] Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.Breast Cancer Res. 2014 Mar 19;16(2):R28. doi: 10.1186/bcr3629.
• [1810] JWA suppresses the invasion of human breast carcinoma cells by downregulating the expression of CXCR4.Mol Med Rep. 2018 Jun;17(6):8137-8144. doi: 10.3892/mmr.2018.8866. Epub 2018 Apr 11.
• [1811] The Role of Arrestin Domain-Containing 3 in Regulating Endocytic Recycling and Extracellular Vesicle Sorting of Integrin 4 in Breast Cancer.Cancers (Basel). 2018 Dec 11;10(12):507. doi: 10.3390/cancers10120507.
• [1812] Anticancer effect of acid ceramidase inhibitor ceranib-2 in human breast cancer cell lines MCF-7, MDA MB-231 by the activation of SAPK/JNK, p38 MAPK apoptotic pathways, inhibition of the Akt pathway, downregulation of ER.Anticancer Drugs. 2018 Jan;29(1):50-60. doi: 10.1097/CAD.0000000000000566.
• [1813] Absent, small or homeotic 2-like protein (ASH2L) enhances the transcription of the estrogen receptor gene through GATA-binding protein 3 (GATA3).J Biol Chem. 2014 Nov 7;289(45):31373-81. doi: 10.1074/jbc.M114.579839. Epub 2014 Sep 25.
• [1814] Defining the human copper proteome and analysis of its expression variation in cancers.Metallomics. 2017 Feb 22;9(2):112-123. doi: 10.1039/c6mt00202a.
• [1815] Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells.BMC Cancer. 2018 Oct 23;18(1):1029. doi: 10.1186/s12885-018-4945-x.
• [1816] Osteoclast proton pump regulator Atp6v1c1 enhances breast cancer growth by activating the mTORC1 pathway and bone metastasis by increasing V-ATPase activity.Oncotarget. 2017 Jul 18;8(29):47675-47690. doi: 10.18632/oncotarget.17544.
• [1817] Novel ADC Solidifies Role in Breast Cancer.Cancer Discov. 2020 Feb;10(2):167. doi: 10.1158/2159-8290.CD-NB2019-139. Epub 2019 Dec 16.
• [1818] Roles of BCCIP deficiency in mammary tumorigenesis.Breast Cancer Res. 2017 Oct 18;19(1):115. doi: 10.1186/s13058-017-0907-5.
• [1819] Bcl-3 regulates TGF signaling by stabilizing Smad3 during breast cancer pulmonary metastasis.Cell Death Dis. 2016 Dec 1;7(12):e2508. doi: 10.1038/cddis.2016.405.
• [1820] Knockdown of BRCC3 exerts an antitumor effect on cervical cancer invitro.Mol Med Rep. 2018 Dec;18(6):4886-4894. doi: 10.3892/mmr.2018.9511. Epub 2018 Sep 26.
• [1821] Nifedipine promotes the proliferation and migration of breast cancer cells.PLoS One. 2014 Dec 1;9(12):e113649. doi: 10.1371/journal.pone.0113649. eCollection 2014.
• [1822] The LIM protein Ajuba recruits DBC1 and CBP/p300 to acetylate ER and enhances ER target gene expression in breast cancer cells.Nucleic Acids Res. 2019 Mar 18;47(5):2322-2335. doi: 10.1093/nar/gky1306.
• [1823] LSECtin on tumor-associated macrophages enhances breast cancer stemness via interaction with its receptor BTN3A3.Cell Res. 2019 May;29(5):365-378. doi: 10.1038/s41422-019-0155-6. Epub 2019 Mar 11.
• [1824] Dysregulation of POPDC1 promotes breast cancer cell migration and proliferation.Biosci Rep. 2017 Nov 21;37(6):BSR20171039. doi: 10.1042/BSR20171039. Print 2017 Dec 22.
• [1825] CAP2 is a Valuable Biomarker for Diagnosis and Prognostic in Patients with Gastric Cancer.Pathol Oncol Res. 2020 Jan;26(1):273-279. doi: 10.1007/s12253-018-0450-4. Epub 2018 Jul 26.
• [1826] CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription.Theranostics. 2018 Apr 3;8(9):2549-2564. doi: 10.7150/thno.22523. eCollection 2018.
• [1827] Caprin-1 is a novel microRNA-223 target for regulating the proliferation and invasion of human breast cancer cells.Biomed Pharmacother. 2013 Sep;67(7):629-36. doi: 10.1016/j.biopha.2013.06.006. Epub 2013 Jul 12.
• [1828] Capping Protein Regulator and Myosin 1 Linker 3 Is Required for Tumor Metastasis.Mol Cancer Res. 2020 Feb;18(2):240-252. doi: 10.1158/1541-7786.MCR-19-0722. Epub 2019 Nov 6.
• [1829] NIM: a node influence based method for cancer classification.Comput Math Methods Med. 2014;2014:826373. doi: 10.1155/2014/826373. Epub 2014 Aug 11.
• [1830] The diversity in the expression profile of caveolin II transcripts, considering its new transcript in breast cancer.J Cell Biochem. 2018 Feb;119(2):2168-2178. doi: 10.1002/jcb.26378. Epub 2017 Oct 30.
• [1831] A novel approach to modelling transcriptional heterogeneity identifies the oncogene candidate CBX2 in invasive breast carcinoma.Br J Cancer. 2019 Apr;120(7):746-753. doi: 10.1038/s41416-019-0387-8. Epub 2019 Mar 1.
• [1832] CK2-mediated CCDC106 phosphorylation is required for p53 degradation in cancer progression.J Exp Clin Cancer Res. 2019 Mar 18;38(1):131. doi: 10.1186/s13046-019-1137-8.
• [1833] Enhanced Identification of Potential Pleiotropic Genetic Variants for Bone Mineral Density and Breast Cancer.Calcif Tissue Int. 2017 Nov;101(5):489-500. doi: 10.1007/s00223-017-0308-x. Epub 2017 Jul 31.
• [1834] DDT exposure during pregnancy and DNA methylation alterations in female offspring in the Child Health and Development Study.Reprod Toxicol. 2020 Mar;92:138-147. doi: 10.1016/j.reprotox.2019.02.010. Epub 2019 Feb 26.
• [1835] Equal Pro-inflammatory Profiles of CCLs, CXCLs, and Matrix Metalloproteinases in the Extracellular Microenvironment In Vivo in Human Dense Breast Tissue and Breast Cancer.Front Immunol. 2018 Jan 16;8:1994. doi: 10.3389/fimmu.2017.01994. eCollection 2017.
• [1836] Osteoblasts are "educated" by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment.Breast Cancer Res. 2019 Feb 27;21(1):31. doi: 10.1186/s13058-019-1117-0.
• [1837] Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer.PLoS One. 2013 Aug 8;8(8):e72210. doi: 10.1371/journal.pone.0072210. eCollection 2013.
• [1838] Exosomal MicroRNA MiR-1246 Promotes Cell Proliferation, Invasion and Drug Resistance by Targeting CCNG2 in Breast Cancer.Cell Physiol Biochem. 2017;44(5):1741-1748. doi: 10.1159/000485780. Epub 2017 Dec 6.
• [1839] Copper Chaperone for Superoxide Dismutase Promotes Breast Cancer Cell Proliferation and Migration via ROS-Mediated MAPK/ERK Signaling.Front Pharmacol. 2019 Apr 5;10:356. doi: 10.3389/fphar.2019.00356. eCollection 2019.
• [1840] Role of TGF- receptor III localization in polarity and breast cancer progression.Mol Biol Cell. 2014 Aug 1;25(15):2291-304. doi: 10.1091/mbc.E14-03-0825. Epub 2014 May 28.
• [1841] A Potent CD1d-binding Glycolipid for iNKT-Cell-based Therapy Against Human Breast Cancer.Anticancer Res. 2019 Feb;39(2):549-555. doi: 10.21873/anticanres.13147.
• [1842] The prognostic significance of Cdc6 and Cdt1 in breast cancer.Sci Rep. 2017 Apr 20;7(1):985. doi: 10.1038/s41598-017-00998-9.
• [1843] The PDGFR/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.BMC Cancer. 2018 May 23;18(1):586. doi: 10.1186/s12885-018-4500-9.
• [1844] Bioinformatics prediction and experimental validation of a novel microRNA: hsa-miR-B43 within human CDH4 gene with a potential metastasis-related function in breast cancer.J Cell Biochem. 2020 Feb;121(2):1307-1316. doi: 10.1002/jcb.29367. Epub 2019 Sep 6.
• [1845] CEP135 isoform dysregulation promotes centrosome amplification in breast cancer cells.Mol Biol Cell. 2019 May 1;30(10):1230-1244. doi: 10.1091/mbc.E18-10-0674. Epub 2019 Feb 27.
• [1846] Discovery of Centrosomal Protein 70 as an Important Player in the Development and Progression of Breast Cancer.Am J Pathol. 2017 Mar;187(3):679-688. doi: 10.1016/j.ajpath.2016.11.005. Epub 2017 Jan 5.
• [1847] Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer.Horm Cancer. 2018 Oct;9(5):338-348. doi: 10.1007/s12672-018-0339-4. Epub 2018 Jun 28.
• [1848] Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC1.J Comp Eff Res. 2017 Oct;6(7):563-574. doi: 10.2217/cer-2017-0015. Epub 2017 Sep 19.
• [1849] Aberrant promoter methylation of the CHD1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis.Tumour Biol. 2014 Sep;35(9):9395-404. doi: 10.1007/s13277-014-2235-z. Epub 2014 Jun 22.
• [1850] Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy.Oncoimmunology. 2018 Mar 13;7(6):e1436922. doi: 10.1080/2162402X.2018.1436922. eCollection 2018.
• [1851] CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer.Oncotarget. 2017 Feb 28;8(9):15789-15801. doi: 10.18632/oncotarget.15004.
• [1852] NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth.Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14676-81. doi: 10.1073/pnas.1313198110. Epub 2013 Aug 19.
• [1853] CITED2 attenuates macrophage recruitment concordant with the downregulation of CCL20 in breast cancer cells.Oncol Lett. 2018 Jan;15(1):871-878. doi: 10.3892/ol.2017.7420. Epub 2017 Nov 15.
• [1854] Overexpression of CKS2 is associated with a poor prognosis and promotes cell proliferation and invasion in breast cancer.Mol Med Rep. 2019 Jun;19(6):4761-4769. doi: 10.3892/mmr.2019.10134. Epub 2019 Apr 5.
• [1855] Along with its favorable prognostic role, CLCA2 inhibits growth and metastasis of nasopharyngeal carcinoma cells via inhibition of FAK/ERK signaling.J Exp Clin Cancer Res. 2018 Feb 20;37(1):34. doi: 10.1186/s13046-018-0692-8.
• [1856] Afadin cooperates with Claudin-2 to promote breast cancer metastasis.Genes Dev. 2019 Feb 1;33(3-4):180-193. doi: 10.1101/gad.319194.118. Epub 2019 Jan 28.
• [1857] Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.BMC Cancer. 2019 Jul 15;19(1):695. doi: 10.1186/s12885-019-5908-6.
• [1858] Soy Foods Might Weaken the Sensitivity of Tamoxifen in Premenopausal Patients With Lumina A Subtype of Breast Cancer.Clin Breast Cancer. 2019 Apr;19(2):e337-e342. doi: 10.1016/j.clbc.2018.12.003. Epub 2018 Dec 12.
• [1859] CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer.J Cell Sci. 2014 Sep 15;127(Pt 18):3893-901. doi: 10.1242/jcs.135947. Epub 2014 Jul 11.
• [1860] CMTM1_v17 is a novel potential therapeutic target in breast cancer.Oncol Rep. 2014 Nov;32(5):1829-36. doi: 10.3892/or.2014.3429. Epub 2014 Aug 20.
• [1861] Genetic variants of genes in the NER pathway associated with risk of breast cancer: A large-scale analysis of 14 published GWAS datasets in the DRIVE study.Int J Cancer. 2019 Sep 1;145(5):1270-1279. doi: 10.1002/ijc.32371. Epub 2019 May 13.
• [1862] miR-26 suppresses renal cell cancer via down-regulating coronin-3.Mol Cell Biochem. 2020 Jan;463(1-2):137-146. doi: 10.1007/s11010-019-03636-2. Epub 2019 Oct 8.
• [1863] Detection of mitochondrial DNA mutations by high-throughput sequencing in the blood of breast cancer patients.Int J Mol Med. 2014 Jan;33(1):77-82. doi: 10.3892/ijmm.2013.1559. Epub 2013 Nov 19.
• [1864] Identification of a metabolic and canonical biomarker signature in Mexican HR+/HER2-, triple positive and triple-negative breast cancer patients.Int J Oncol. 2014 Dec;45(6):2549-59. doi: 10.3892/ijo.2014.2676. Epub 2014 Sep 25.
• [1865] MiR-4458 inhibits breast cancer cell growth, migration, and invasiveness by targeting CPSF4.Biochem Cell Biol. 2019 Dec;97(6):722-730. doi: 10.1139/bcb-2019-0008. Epub 2019 Apr 10.
• [1866] Overexpression of MUC1 predicts poor prognosis in patients with breast cancer.Oncol Rep. 2019 Feb;41(2):801-810. doi: 10.3892/or.2018.6887. Epub 2018 Nov 27.
• [1867] The impact of cysteine-rich intestinal protein 1 (CRIP1) in human breast cancer.Mol Cancer. 2013 Apr 9;12:28. doi: 10.1186/1476-4598-12-28.
• [1868] ITIH5 mediates epigenetic reprogramming of breast cancer cells.Mol Cancer. 2017 Feb 23;16(1):44. doi: 10.1186/s12943-017-0610-2.
• [1869] Nuclear CSPP1 expression defined subtypes of basal-like breast cancer.Br J Cancer. 2014 Jul 15;111(2):326-38. doi: 10.1038/bjc.2014.297. Epub 2014 Jun 5.
• [1870] Hypoxia promotes breast cancer cell invasion through HIF-1-mediated up-regulation of the invadopodial actin bundling protein CSRP2.Sci Rep. 2018 Jul 5;8(1):10191. doi: 10.1038/s41598-018-28637-x.
• [1871] Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.J Pathol. 2017 Dec;243(4):496-509. doi: 10.1002/path.4990. Epub 2017 Oct 31.
• [1872] ACE: A Workbench Using Evolutionary Genetic Algorithms for Analyzing Association in TCGA.Cancer Res. 2019 Apr 15;79(8):2072-2075. doi: 10.1158/0008-5472.CAN-18-1976. Epub 2019 Feb 13.
• [1873] Detection of KK-LC-1 Protein, a Cancer/Testis Antigen, in Patients with Breast Cancer.Anticancer Res. 2018 Oct;38(10):5923-5928. doi: 10.21873/anticanres.12937.
• [1874] Association of CYBA gene (-930 A/G and 242 C/T) polymorphisms with oxidative stress in breast cancer: a case-control study.PeerJ. 2018 Oct 4;6:e5509. doi: 10.7717/peerj.5509. eCollection 2018.
• [1875] Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions.Naunyn Schmiedebergs Arch Pharmacol. 2019 Feb;392(2):165-175. doi: 10.1007/s00210-018-1579-0. Epub 2018 Nov 21.
• [1876] Disabled-1 is down-regulated in clinical breast cancer and regulates cell apoptosis through NF-B/Bcl-2/caspase-9.J Cell Mol Med. 2019 Feb;23(2):1622-1627. doi: 10.1111/jcmm.14047. Epub 2018 Nov 28.
• [1877] DACT1, an antagonist to Wnt/-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer.Breast Cancer Res. 2013 Mar 12;15(2):R23. doi: 10.1186/bcr3399.
• [1878] One-view digital breast tomosynthesis as a stand-alone modality for breast cancer detection: do we need more?.Eur Radiol. 2018 May;28(5):1938-1948. doi: 10.1007/s00330-017-5167-3. Epub 2017 Dec 11.
• [1879] Half-sandwich Ru((6)-p-cymene) complexes featuring pyrazole appended ligands: Synthesis, DNA binding and in vitro cytotoxicity.J Inorg Biochem. 2019 May;194:74-84. doi: 10.1016/j.jinorgbio.2019.02.012. Epub 2019 Feb 23.
• [1880] DDT and Breast Cancer: Prospective Study of Induction Time and Susceptibility Windows.J Natl Cancer Inst. 2019 Aug 1;111(8):803-810. doi: 10.1093/jnci/djy198.
• [1881] The role of DEAD-box RNA helicase p68 (DDX5) in the development and treatment of breast cancer.J Cell Physiol. 2019 May;234(5):5478-5487. doi: 10.1002/jcp.26912. Epub 2018 Nov 11.
• [1882] IBP regulates epithelial-to-mesenchymal transition and the motility of breast cancer cells via Rac1, RhoA and Cdc42 signaling pathways.Oncogene. 2014 Jun 26;33(26):3374-82. doi: 10.1038/onc.2013.337. Epub 2013 Aug 26.
• [1883] Association between polymorphisms in the thymidylate synthase gene and risk of breast cancer in a Mexican population.Genet Mol Res. 2014 Oct 27;13(4):8749-56. doi: 10.4238/2014.October.27.16.
• [1884] LncRNA AK023948 is a positive regulator of AKT.Nat Commun. 2017 Feb 8;8:14422. doi: 10.1038/ncomms14422.
• [1885] Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes.Sci Rep. 2015 Jul 16;5:12136. doi: 10.1038/srep12136.
• [1886] DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation.Oncotarget. 2015 Sep 8;6(26):22467-79. doi: 10.18632/oncotarget.4164.
• [1887] ETV7-Mediated DNAJC15 Repression Leads to Doxorubicin Resistance in Breast Cancer Cells.Neoplasia. 2018 Aug;20(8):857-870. doi: 10.1016/j.neo.2018.06.008. Epub 2018 Jul 17.
• [1888] Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer.J Pathol. 2019 Mar;247(3):381-391. doi: 10.1002/path.5197. Epub 2019 Jan 25.
• [1889] The downstream of tyrosine kinase 7 is reduced in lung cancer and is associated with poor survival of patients with lung cancer.Oncol Rep. 2017 May;37(5):2695-2701. doi: 10.3892/or.2017.5538. Epub 2017 Mar 31.
• [1890] Exposure to bisphenol A: current levels from food intake are toxic to human cells.Mol Biol Rep. 2019 Apr;46(2):2555-2559. doi: 10.1007/s11033-019-04666-1. Epub 2019 Feb 7.
• [1891] E2F6 is essential for cell viability in breast cancer cells during replication stress.Turk J Biol. 2019 Oct 14;43(5):293-304. doi: 10.3906/biy-1905-6. eCollection 2019.
• [1892] Expression patterns of E2F transcription factors and their potential prognostic roles in breast cancer.Oncol Lett. 2018 Jun;15(6):9216-9230. doi: 10.3892/ol.2018.8514. Epub 2018 Apr 17.
• [1893] Weighted gene co-expression network analysis reveals modules and hub genes associated with the development of breast cancer.Medicine (Baltimore). 2019 Feb;98(6):e14345. doi: 10.1097/MD.0000000000014345.
• [1894] FBLN-4 and BCRP genes as two prognostic markers are downregulated in breast cancer tissue.Cancer Biomark. 2017;19(1):51-55. doi: 10.3233/CBM-160335.
• [1895] Increased expression of EHF contributes to thyroid tumorigenesis through transcriptionally regulating HER2 and HER3.Oncotarget. 2016 Sep 6;7(36):57978-57990. doi: 10.18632/oncotarget.11154.
• [1896] CLE-10 from Carpesium abrotanoides L. Suppresses the Growth of Human Breast Cancer Cells (MDA-MB-231) In Vitro by Inducing Apoptosis and Pro-Death Autophagy Via the PI3K/Akt/mTOR Signaling Pathway.Molecules. 2019 Mar 20;24(6):1091. doi: 10.3390/molecules24061091.
• [1897] INT6/EIF3E Controls the RNF8-Dependent Ubiquitylation Pathway and Facilitates DNA Double-Strand Break Repair in Human Cells.Cancer Res. 2016 Oct 15;76(20):6054-6065. doi: 10.1158/0008-5472.CAN-16-0723. Epub 2016 Aug 22.
• [1898] Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade.Hum Mol Genet. 2014 Nov 15;23(22):6034-46. doi: 10.1093/hmg/ddu300. Epub 2014 Jun 13.
• [1899] The CXCR4-LASP1-eIF4F Axis Promotes Translation of Oncogenic Proteins in Triple-Negative Breast Cancer Cells.Front Oncol. 2019 Apr 24;9:284. doi: 10.3389/fonc.2019.00284. eCollection 2019.
• [1900] Runx2 induces bone osteolysis by transcriptional suppression of TSSC1.Biochem Biophys Res Commun. 2013 Sep 6;438(4):635-9. doi: 10.1016/j.bbrc.2013.07.131. Epub 2013 Aug 8.
• [1901] Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes.Breast Cancer Res Treat. 2013 Feb;138(1):37-45. doi: 10.1007/s10549-013-2408-2. Epub 2013 Jan 18.
• [1902] Embigin, regulated by HOXC8, plays a suppressive role in breast tumorigenesis.Oncotarget. 2015 Sep 15;6(27):23496-509. doi: 10.18632/oncotarget.4360.
• [1903] A novel protein is lower expressed in renal cell carcinoma.Int J Mol Sci. 2014 Apr 29;15(5):7398-408. doi: 10.3390/ijms15057398.
• [1904] EPB41L5 Mediates TGF-Induced Metastasis of Gastric Cancer.Clin Cancer Res. 2019 Jun 15;25(12):3617-3629. doi: 10.1158/1078-0432.CCR-18-2959. Epub 2019 Feb 27.
• [1905] Increased Eps15 homology domain 1 and RAB11FIP3 expression regulate breast cancer progression via promoting epithelial growth factor receptor recycling.Tumour Biol. 2017 Feb;39(2):1010428317691010. doi: 10.1177/1010428317691010.
• [1906] Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways.EMBO Rep. 2019 Feb;20(2):e46078. doi: 10.15252/embr.201846078. Epub 2019 Jan 21.
• [1907] Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes.Histopathology. 2008 Jun;52(7):840-6. doi: 10.1111/j.1365-2559.2008.03046.x. Epub 2008 May 6.
• [1908] Rare coding variants and breast cancer risk: evaluation of susceptibility Loci identified in genome-wide association studies.Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):622-8. doi: 10.1158/1055-9965.EPI-13-1043. Epub 2014 Jan 27.
• [1909] The appearance of breast cancer metastases on dry bone: Implications for forensic anthropology.J Forensic Leg Med. 2019 Feb;61:5-12. doi: 10.1016/j.jflm.2018.10.007. Epub 2018 Oct 25.
• [1910] TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer.Oncotarget. 2017 Mar 14;8(11):18381-18398. doi: 10.18632/oncotarget.15110.
• [1911] Expression analysis of two cancer-testis genes, FBXO39 and TDRD4, in breast cancer tissues and cell lines.Asian Pac J Cancer Prev. 2014 Jan;14(11):6625-9. doi: 10.7314/apjcp.2013.14.11.6625.
• [1912] Expression of kindlin-3 in melanoma cells impedes cell migration and metastasis.Cell Adh Migr. 2017 Sep 3;11(5-6):419-433. doi: 10.1080/19336918.2016.1243645. Epub 2016 Nov 2.
• [1913] FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium.Br J Cancer. 2014 Feb 18;110(4):1088-100. doi: 10.1038/bjc.2013.769.
• [1914] FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.BMC Cancer. 2019 Apr 11;19(1):351. doi: 10.1186/s12885-019-5500-0.
• [1915] A novel FLI1 exonic circular RNA promotes metastasis in breast cancer by coordinately regulating TET1 and DNMT1.Genome Biol. 2018 Dec 11;19(1):218. doi: 10.1186/s13059-018-1594-y.
• [1916] An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer.Elife. 2018 Jul 30;7:e37184. doi: 10.7554/eLife.37184.
• [1917] Propensity for different vascular distributions and cerebral edema of intraparenchymal brain metastases from different primary cancers.J Neurooncol. 2019 May;143(1):115-122. doi: 10.1007/s11060-019-03142-x. Epub 2019 Mar 5.
• [1918] The fragile X mental retardation protein regulates tumor invasiveness-related pathways in melanoma cells.Cell Death Dis. 2017 Nov 16;8(11):e3169. doi: 10.1038/cddis.2017.521.
• [1919] FOXF2 reprograms breast cancer cells into bone metastasis seeds.Nat Commun. 2019 Jun 20;10(1):2707. doi: 10.1038/s41467-019-10379-7.
• [1920] Identification of FOXN4 as a tumor suppressor of breast carcinogenesis via the activation of TP53 and deactivation of Notch signaling.Gene. 2020 Jan 5;722:144057. doi: 10.1016/j.gene.2019.144057. Epub 2019 Aug 17.
• [1921] Downregulation of FOXP2 promotes breast cancer migration and invasion through TGF/SMAD signaling pathway.Oncol Lett. 2018 Jun;15(6):8582-8588. doi: 10.3892/ol.2018.8402. Epub 2018 Mar 30.
• [1922] FSIP1 is correlated with estrogen receptor status and poor prognosis.Mol Carcinog. 2020 Jan;59(1):126-135. doi: 10.1002/mc.23134. Epub 2019 Nov 12.
• [1923] Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin.Int J Oncol. 2013 Nov;43(5):1481-6. doi: 10.3892/ijo.2013.2063. Epub 2013 Aug 20.
• [1924] FUN14 domain-containing 1 promotes breast cancer proliferation and migration by activating calcium-NFATC1-BMI1 axis.EBioMedicine. 2019 Mar;41:384-394. doi: 10.1016/j.ebiom.2019.02.032. Epub 2019 Feb 23.
• [1925] Elevated expression of Gab1 promotes breast cancer metastasis by dissociating the PAR complex.J Exp Clin Cancer Res. 2019 Jan 21;38(1):27. doi: 10.1186/s13046-019-1025-2.
• [1926] EFEMP2 Mediates GALNT14-Dependent Breast Cancer Cell Invasion.Transl Oncol. 2018 Apr;11(2):346-352. doi: 10.1016/j.tranon.2018.01.021. Epub 2018 Feb 8.
• [1927] T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression.Acta Neuropathol. 2018 Apr;135(4):581-599. doi: 10.1007/s00401-018-1806-2. Epub 2018 Jan 19.
• [1928] Genetic Variants in Group-Specific Component (GC) Gene Are Associated with Breast Cancer Risk among Chinese Women.Biomed Res Int. 2019 Nov 15;2019:3295781. doi: 10.1155/2019/3295781. eCollection 2019.
• [1929] Investigation of chemotherapy-induced brain structural alterations in breast cancer patients with generalized q-sampling MRI and graph theoretical analysis.BMC Cancer. 2018 Dec 4;18(1):1211. doi: 10.1186/s12885-018-5113-z.
• [1930] Loss of glutaredoxin 3 impedes mammary lobuloalveolar development during pregnancy and lactation.Am J Physiol Endocrinol Metab. 2017 Mar 1;312(3):E136-E149. doi: 10.1152/ajpendo.00150.2016. Epub 2016 Nov 15.
• [1931] NDF, a nucleosome-destabilizing factor that facilitates transcription through nucleosomes.Genes Dev. 2018 May 1;32(9-10):682-694. doi: 10.1101/gad.313973.118. Epub 2018 May 14.
• [1932] Lack of expression of the proteins GMPR2 and PPAR are associated with the basal phenotype and patient outcome in breast cancer.Breast Cancer Res Treat. 2013 Jan;137(1):127-37. doi: 10.1007/s10549-012-2302-3. Epub 2012 Dec 4.
• [1933] c-Jun Contributes to Transcriptional Control of GNA12 Expression in Prostate Cancer Cells.Molecules. 2017 Apr 10;22(4):612. doi: 10.3390/molecules22040612.
• [1934] Nucleostemin expression in breast cancer is a marker of more aggressive phenotype and unfavorable patients' outcome: A STROBE-compliant article.Medicine (Baltimore). 2019 Mar;98(9):e14744. doi: 10.1097/MD.0000000000014744.
• [1935] Implications of differences in expression of sarcosine metabolism-related proteins according to the molecular subtype of breast cancer.J Transl Med. 2014 May 28;12:149. doi: 10.1186/1479-5876-12-149.
• [1936] Preventing BRCA1/ZBRK1 repressor complex binding to the GOT2 promoter results in accelerated aspartate biosynthesis and promotion of cell proliferation.Mol Oncol. 2019 Apr;13(4):959-977. doi: 10.1002/1878-0261.12466. Epub 2019 Mar 1.
• [1937] Small non-coding RNA landscape is modified by GPAT2 silencing in MDA-MB-231 cells.Oncotarget. 2018 Jun 15;9(46):28141-28154. doi: 10.18632/oncotarget.25582. eCollection 2018 Jun 15.
• [1938] AGPAT9 suppresses cell growth, invasion and metastasis by counteracting acidic tumor microenvironment through KLF4/LASS2/V-ATPase signaling pathway in breast cancer.Oncotarget. 2015 Jul 30;6(21):18406-17. doi: 10.18632/oncotarget.4074.
• [1939] Her2-Functionalized Gold-Nanoshelled Magnetic Hybrid Nanoparticles: a Theranostic Agent for Dual-Modal Imaging and Photothermal Therapy of Breast Cancer.Nanoscale Res Lett. 2019 Aug 26;14(1):235. doi: 10.1186/s11671-019-3053-4.
• [1940] Breast carcinoma progression and tumour vascular markers related to apoptotic mechanisms.Dis Markers. 2014;2014:156034. doi: 10.1155/2014/156034. Epub 2014 Feb 18.
• [1941] The Prognosis Of Peroxiredoxin Family In Breast Cancer.Cancer Manag Res. 2019 Nov 14;11:9685-9699. doi: 10.2147/CMAR.S229389. eCollection 2019.
• [1942] Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers.Eur J Hum Genet. 2017 Apr;25(4):432-438. doi: 10.1038/ejhg.2016.203. Epub 2017 Feb 1.
• [1943] Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells.J Biol Chem. 2017 Feb 10;292(6):2237-2254. doi: 10.1074/jbc.M116.764233. Epub 2016 Dec 29.
• [1944] A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer.Horm Cancer. 2015 Dec;6(5-6):214-24. doi: 10.1007/s12672-015-0230-5. Epub 2015 Jun 26.
• [1945] Expression of Pentose Phosphate Pathway-Related Proteins in Breast Cancer.Dis Markers. 2018 Feb 25;2018:9369358. doi: 10.1155/2018/9369358. eCollection 2018.
• [1946] Transcriptional regulation of the human thromboxane A2 receptor gene by Wilms' tumor (WT)1 and hypermethylated in cancer (HIC) 1 in prostate and breast cancers.Biochim Biophys Acta. 2014 Jun;1839(6):476-92. doi: 10.1016/j.bbagrm.2014.04.010. Epub 2014 Apr 18.
• [1947] Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer.PLoS One. 2014 Jun 20;9(6):e100691. doi: 10.1371/journal.pone.0100691. eCollection 2014.
• [1948] TIMELESS contributes to the progression of breast cancer through activation of MYC.Breast Cancer Res. 2017 May 2;19(1):53. doi: 10.1186/s13058-017-0838-1.
• [1949] MicroRNA related polymorphisms and breast cancer risk.PLoS One. 2014 Nov 12;9(11):e109973. doi: 10.1371/journal.pone.0109973. eCollection 2014.
• [1950] A miRNA-HERC4 pathway promotes breast tumorigenesis by inactivating tumor suppressor LATS1.Protein Cell. 2019 Aug;10(8):595-605. doi: 10.1007/s13238-019-0607-2. Epub 2019 Feb 1.
• [1951] Overexpression of HES6 has prognostic value and promotes metastasis via the Wnt/-catenin signaling pathway in colorectal cancer.Oncol Rep. 2018 Sep;40(3):1261-1274. doi: 10.3892/or.2018.6539. Epub 2018 Jul 2.
• [1952] Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers.Oncotarget. 2015 Jul 30;6(21):18641-52. doi: 10.18632/oncotarget.4080.
• [1953] SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.Br J Cancer. 2019 Apr;120(7):728-745. doi: 10.1038/s41416-019-0405-x. Epub 2019 Feb 28.
• [1954] The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.Cancer Chemother Pharmacol. 2013 Mar;71(3):593-601. doi: 10.1007/s00280-012-2034-4. Epub 2012 Dec 11.
• [1955] High-mobility group boxes mediate cell proliferation and radiosensitivity via retinoblastoma-interaction-dependent and -independent mechanisms.Cancer Biother Radiopharm. 2012 Jun;27(5):329-35. doi: 10.1089/cbr.2012.1199. Epub 2012 Jun 1.
• [1956] HOXA1 upregulation is associated with poor prognosis and tumor progression in breast cancer.Exp Ther Med. 2019 Mar;17(3):1896-1902. doi: 10.3892/etm.2018.7145. Epub 2018 Dec 28.
• [1957] Analysis of HOX gene expression patterns in human breast cancer.Mol Biotechnol. 2014 Jan;56(1):64-71. doi: 10.1007/s12033-013-9682-4.
• [1958] Transcriptional activation of EGFR by HOXB5 and its role in breast cancer cell invasion.Biochem Biophys Res Commun. 2018 Sep 18;503(4):2924-2930. doi: 10.1016/j.bbrc.2018.08.071. Epub 2018 Aug 13.
• [1959] Identification of ApoA1, HPX and POTEE genes by omic analysis in breast cancer.Oncol Rep. 2014 Sep;32(3):1078-86. doi: 10.3892/or.2014.3277. Epub 2014 Jun 23.
• [1960] Melatonin charge transfer complex with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone: Molecular structure, DFT studies, thermal analyses, evaluation of biological activity and utility for determination of melatonin in pure and dosage forms.Spectrochim Acta A Mol Biomol Spectrosc. 2017 Jul 5;182:143-159. doi: 10.1016/j.saa.2017.03.068. Epub 2017 Apr 4.
• [1961] HSP105 recruits protein phosphatase 2A to dephosphorylate -catenin.Mol Cell Biol. 2015 Apr;35(8):1390-400. doi: 10.1128/MCB.01307-14. Epub 2015 Feb 2.
• [1962] Association between variants of 5-hydroxytryptamine receptor 3C (HTR3C) and chemotherapy-induced symptoms in women receiving adjuvant treatment for breast cancer.Breast Cancer Res Treat. 2014 Feb;144(1):123-31. doi: 10.1007/s10549-014-2832-y. Epub 2014 Jan 30.
• [1963] Over expression of hRad9 protein correlates with reduced chemosensitivity in breast cancer with administration of neoadjuvant chemotherapy.Sci Rep. 2014 Dec 18;4:7548. doi: 10.1038/srep07548.
• [1964] Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages.Breast Cancer Res. 2018 Jun 19;20(1):59. doi: 10.1186/s13058-018-0990-2.
• [1965] Absence of gamma-interferon-inducible lysosomal thiol reductase (GILT) is associated with poor disease-free survival in breast cancer patients.PLoS One. 2014 Oct 21;9(10):e109449. doi: 10.1371/journal.pone.0109449. eCollection 2014.
• [1966] G1P3 (IFI6), a mitochondrial localised antiapoptotic protein, promotes metastatic potential of breast cancer cells through mtROS.Br J Cancer. 2018 Jul;119(1):52-64. doi: 10.1038/s41416-018-0137-3. Epub 2018 Jun 14.
• [1967] IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer invivo by JAK/STAT-mediated induction of p21.Cancer Lett. 2017 Jul 28;399:29-43. doi: 10.1016/j.canlet.2017.04.005. Epub 2017 Apr 12.
• [1968] Recurrent read-through fusion transcripts in breast cancer.Breast Cancer Res Treat. 2014 Jul;146(2):287-97. doi: 10.1007/s10549-014-3019-2. Epub 2014 Jun 15.
• [1969] 4 is highly expressed in carcinogen-transformed human cells and primary human cancers.Oncogene. 2011 Jun 30;30(26):2943-53. doi: 10.1038/onc.2011.20. Epub 2011 Feb 21.
• [1970] NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer.Cancer Res. 2017 Jul 15;77(14):3802-3813. doi: 10.1158/0008-5472.CAN-16-2794. Epub 2017 May 17.
• [1971] mda-7/IL-24 expression inhibits breast cancer through upregulation of growth arrest-specific gene 3 (gas3) and disruption of 1 integrin function.Mol Cancer Res. 2013 Jun;11(6):593-603. doi: 10.1158/1541-7786.MCR-12-0496. Epub 2013 Mar 6.
• [1972] Interleukin enhancer-binding factor 3 and HOXC8 co-activate cadherin 11 transcription to promote breast cancer cells proliferation and migration.Oncotarget. 2017 Nov 18;8(64):107477-107491. doi: 10.18632/oncotarget.22491. eCollection 2017 Dec 8.
• [1973] The nucleocytoplasmic translocation and up-regulation of ING5 protein in breast cancer: a potential target for gene therapy.Oncotarget. 2017 May 17;8(47):81953-81966. doi: 10.18632/oncotarget.17918. eCollection 2017 Oct 10.
• [1974] Effects of high fat diet-induced obesity on mammary tumorigenesis in the PyMT/MMTV murine model.Cancer Biol Ther. 2019;20(4):487-496. doi: 10.1080/15384047.2018.1537574. Epub 2018 Nov 2.
• [1975] Use of lung-specific exosomes for miRNA-126 delivery in non-small cell lung cancer.Nanoscale. 2020 Jan 2;12(2):877-887. doi: 10.1039/c9nr09011h.
• [1976] Quantifying Tip60 (Kat5) stratifies breast cancer.Sci Rep. 2019 Mar 7;9(1):3819. doi: 10.1038/s41598-019-40221-5.
• [1977] Histone lysine demethylases in breast cancer.Crit Rev Oncol Hematol. 2013 May;86(2):97-103. doi: 10.1016/j.critrevonc.2012.11.008. Epub 2012 Dec 23.
• [1978] Soybean (Glycine max) prevents the progression of breast cancer cells by downregulating the level of histone demethylase JMJD5.J Cancer Res Ther. 2018 Sep;14(Supplement):S609-S615. doi: 10.4103/0973-1482.187292.
• [1979] Nuclear T-STAR protein expression correlates with HER2 status, hormone receptor negativity and prolonged recurrence free survival in primary breast cancer and decreased cancer cell growth in vitro.PLoS One. 2013 Jul 29;8(7):e70596. doi: 10.1371/journal.pone.0070596. Print 2013.
• [1980] Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity.Oncol Rep. 2014 Aug;32(2):505-12. doi: 10.3892/or.2014.3262. Epub 2014 Jun 13.
• [1981] Down-regulation of KIF2A inhibits gastric cancer cell invasion via suppressing MT1-MMP.Clin Exp Pharmacol Physiol. 2018 Oct;45(10):1010-1018. doi: 10.1111/1440-1681.12974. Epub 2018 Jun 26.
• [1982] An integrated bioinformatical analysis to evaluate the role of KIF4A as a prognostic biomarker for breast cancer.Onco Targets Ther. 2018 Aug 10;11:4755-4768. doi: 10.2147/OTT.S164730. eCollection 2018.
• [1983] Low doses of Paclitaxel repress breast cancer invasion through DJ-1/KLF17 signalling pathway.Clin Exp Pharmacol Physiol. 2018 Apr 27. doi: 10.1111/1440-1681.12960. Online ahead of print.
• [1984] PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression.Cell Rep. 2019 Apr 2;27(1):294-306.e5. doi: 10.1016/j.celrep.2019.02.111.
• [1985] Integrin 31 can function to promote spontaneous metastasis and lung colonization of invasive breast carcinoma.Mol Cancer Res. 2014 Jan;12(1):143-154. doi: 10.1158/1541-7786.MCR-13-0184. Epub 2013 Sep 3.
• [1986] LARP7 suppresses P-TEFb activity to inhibit breast cancer progression and metastasis.Elife. 2014 Jul 22;3:e02907. doi: 10.7554/eLife.02907.
• [1987] Importance of RIP140 and LCoR Sub-Cellular Localization for Their Association With Breast Cancer Aggressiveness and Patient Survival.Transl Oncol. 2018 Oct;11(5):1090-1096. doi: 10.1016/j.tranon.2018.06.006. Epub 2018 Jul 11.
• [1988] LIM-homeobox gene 2 promotes tumor growth and metastasis by inducing autocrine and paracrine PDGF-B signaling.Mol Oncol. 2014 Mar;8(2):401-16. doi: 10.1016/j.molonc.2013.12.009. Epub 2013 Dec 25.
• [1989] LHX6 inhibits the proliferation, invasion and migration of breast cancer cells by modulating the PI3K/Akt/mTOR signaling pathway.Eur Rev Med Pharmacol Sci. 2018 May;22(10):3067-3073. doi: 10.26355/eurrev_201805_15066.
• [1990] Polymorphisms in homologous recombination repair genes and the risk and survival of breast cancer.J Gene Med. 2017 Sep;19(9-10). doi: 10.1002/jgm.2988. Epub 2017 Oct 10.
• [1991] LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer.Oncotarget. 2017 Feb 14;8(7):11977-11989. doi: 10.18632/oncotarget.14450.
• [1992] Breast Cancer-Derived Exosomes Alter Macrophage Polarization via gp130/STAT3 Signaling.Front Immunol. 2018 May 8;9:871. doi: 10.3389/fimmu.2018.00871. eCollection 2018.
• [1993] A lymph node metastasis-related protein-coding genes combining with long noncoding RNA signature for breast cancer survival prediction.J Cell Physiol. 2019 Nov;234(11):20036-20045. doi: 10.1002/jcp.28600. Epub 2019 Apr 4.
• [1994] Increased macroH2A1.1 expression correlates with poor survival of triple-negative breast cancer patients.PLoS One. 2014 Jun 9;9(6):e98930. doi: 10.1371/journal.pone.0098930. eCollection 2014.
• [1995] Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit.Eur J Surg Oncol. 2019 Feb;45(2):110-117. doi: 10.1016/j.ejso.2018.09.027. Epub 2018 Oct 17.
• [1996] MAP1S controls breast cancer cell TLR5 signaling pathway and promotes TLR5 signaling-based tumor suppression.PLoS One. 2014 Jan 23;9(1):e86839. doi: 10.1371/journal.pone.0086839. eCollection 2014.
• [1997] MAPK kinase 3 is a tumor suppressor with reduced copy number in breast cancer.Cancer Res. 2014 Jan 1;74(1):162-72. doi: 10.1158/0008-5472.CAN-13-1310. Epub 2013 Nov 14.
• [1998] Pro-necrotic molecules impact local immunosurveillance in human breast cancer.Oncoimmunology. 2017 Apr 17;6(4):e1299302. doi: 10.1080/2162402X.2017.1299302. eCollection 2017.
• [1999] MARK4 inhibits Hippo signaling to promote proliferation and migration of breast cancer cells.EMBO Rep. 2017 Mar;18(3):420-436. doi: 10.15252/embr.201642455. Epub 2017 Feb 9.
• [2000] Myoglobin induces mitochondrial fusion, thereby inhibiting breast cancer cell proliferation.J Biol Chem. 2019 May 3;294(18):7269-7282. doi: 10.1074/jbc.RA118.006673. Epub 2019 Mar 14.
• [2001] Methylcrotonoyl-CoA carboxylase 2 overexpression predicts an unfavorable prognosis and promotes cell proliferation in breast cancer.Biomark Med. 2019 Apr;13(6):427-436. doi: 10.2217/bmm-2018-0475. Epub 2019 Mar 21.
• [2002] Fluoro-Chromogenic Labelling for Detection of MCM2 to Assess Proliferation Activity in HER2-amplified Breast Carcinomas.Appl Immunohistochem Mol Morphol. 2020 Mar;28(3):175-186. doi: 10.1097/PAI.0000000000000716.
• [2003] Mitochondrial calcium uniporter as a target of microRNA-340 and promoter of metastasis via enhancing the Warburg effect.Oncotarget. 2017 Jul 31;8(48):83831-83844. doi: 10.18632/oncotarget.19747. eCollection 2017 Oct 13.
• [2004] Med19 is involved in chemoresistance by mediating autophagy through HMGB1 in breast cancer.J Cell Biochem. 2019 Jan;120(1):507-518. doi: 10.1002/jcb.27406. Epub 2018 Aug 30.
• [2005] Class IIa HDACs repressive activities on MEF2-depedent transcription are associated with poor prognosis of ER?breast tumors.FASEB J. 2013 Mar;27(3):942-54. doi: 10.1096/fj.12-209346. Epub 2012 Nov 16.
• [2006] Integrated analysis of microfibrillar-associated proteins reveals MFAP4 as a novel biomarker in human cancers.Epigenomics. 2019 Jan;11(1):1635-1651. doi: 10.2217/epi-2018-0080. Epub 2018 Aug 9.
• [2007] MiR-195 regulates mitochondrial function by targeting mitofusin-2 in breast cancer cells.RNA Biol. 2019 Jul;16(7):918-929. doi: 10.1080/15476286.2019.1600999. Epub 2019 Apr 25.
• [2008] Abbreviated MRI Protocols for Detecting Breast Cancer in Women with Dense Breasts.Korean J Radiol. 2017 May-Jun;18(3):470-475. doi: 10.3348/kjr.2017.18.3.470. Epub 2017 Apr 3.
• [2009] Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling.Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8838-43. doi: 10.1073/pnas.1320769111. Epub 2014 May 29.
• [2010] Recombinant expression and purification of AF1q and its interaction with T-cell Factor 7.Protein Expr Purif. 2020 Jan;165:105499. doi: 10.1016/j.pep.2019.105499. Epub 2019 Sep 18.
• [2011] Fresh and ozonized black carbon promoted DNA damage and repair responses in A549 cells.Toxicol Res (Camb). 2018 Nov 30;8(2):180-187. doi: 10.1039/c8tx00281a. eCollection 2019 Mar 1.
• [2012] Newly characterized motile sperm domain-containing protein 2 promotes human breast cancer metastasis.Int J Cancer. 2019 Jan 1;144(1):125-135. doi: 10.1002/ijc.31665. Epub 2018 Oct 29.
• [2013] MiR-1301-3p inhibits human breast cancer cell proliferation by regulating cell cycle progression and apoptosis through directly targeting ICT1.Breast Cancer. 2018 Nov;25(6):742-752. doi: 10.1007/s12282-018-0881-5. Epub 2018 Jun 27.
• [2014] MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival.Mol Cancer Res. 2014 Sep;12(9):1216-24. doi: 10.1158/1541-7786.MCR-14-0069. Epub 2014 May 27.
• [2015] Circular RNAMTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis.Int J Oncol. 2018 Oct;53(4):1752-1762. doi: 10.3892/ijo.2018.4485. Epub 2018 Jul 17.
• [2016] Microtubule-associated tumor suppressors as prognostic biomarkers in breast cancer.Breast Cancer Res Treat. 2020 Jan;179(2):267-273. doi: 10.1007/s10549-019-05463-x. Epub 2019 Oct 12.
• [2017] Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasis.Br J Cancer. 2014 Jul 29;111(3):539-50. doi: 10.1038/bjc.2014.298. Epub 2014 Jun 12.
• [2018] Myosin Va interacts with the exosomal protein spermine synthase.Biosci Rep. 2019 Mar 1;39(3):BSR20182189. doi: 10.1042/BSR20182189. Print 2019 Mar 29.
• [2019] Repression of ESR1 transcription by MYOD potentiates letrozole-resistance in ER-positive breast cancer cells.Biochem Biophys Res Commun. 2017 Oct 21;492(3):425-433. doi: 10.1016/j.bbrc.2017.08.082. Epub 2017 Aug 24.
• [2020] Tumor suppressor p53 induces miR-15a processing to inhibit neuronal apoptosis inhibitory protein (NAIP) in the apoptotic response DNA damage in breast cancer cell.Am J Transl Res. 2017 Feb 15;9(2):683-691. eCollection 2017.
• [2021] Long non-coding RNA LINC00673 promotes breast cancer proliferation and metastasis through regulating B7-H6 and epithelial-mesenchymal transition.Am J Cancer Res. 2018 Jul 1;8(7):1273-1287. eCollection 2018.
• [2022] NCS-1 expression is higher in basal breast cancers and regulates calcium influx and cytotoxic responses to doxorubicin.Mol Oncol. 2020 Jan;14(1):87-104. doi: 10.1002/1878-0261.12589. Epub 2019 Nov 11.
• [2023] Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study.Cancer Chemother Pharmacol. 2019 Jun;83(6):1091-1097. doi: 10.1007/s00280-019-03831-4. Epub 2019 Apr 8.
• [2024] Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer.FEBS J. 2014 Oct;281(20):4718-30. doi: 10.1111/febs.13012. Epub 2014 Sep 30.
• [2025] Does Proton Conduction in the Voltage-Gated H(+) Channel hHv1 Involve Grotthuss-Like Hopping via Acidic Residues?.J Phys Chem B. 2017 Apr 20;121(15):3340-3351. doi: 10.1021/acs.jpcb.6b08339. Epub 2016 Nov 18.
• [2026] DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers.PLoS Genet. 2014 Apr 3;10(4):e1004256. doi: 10.1371/journal.pgen.1004256. eCollection 2014 Apr.
• [2027] Nuclear factor of activated T cells 5 maintained by Hotair suppression of miR-568 upregulates S100 calcium binding protein A4 to promote breast cancer metastasis.Breast Cancer Res. 2014 Oct 14;16(5):454. doi: 10.1186/s13058-014-0454-2.
• [2028] E4BP4 is a repressor of epigenetically regulated SOSTDC1 expression in breast cancer cells.Cell Oncol (Dordr). 2014 Dec;37(6):409-19. doi: 10.1007/s13402-014-0204-6. Epub 2014 Oct 22.
• [2029] Dissecting the 17-estradiol pathways necessary for neuroglobin anti-apoptotic activity in breast cancer.J Cell Physiol. 2018 Jul;233(7):5087-5103. doi: 10.1002/jcp.26378. Epub 2018 Jan 19.
• [2030] NKD1 down-regulation is associated with poor prognosis in breast invasive ductal carcinoma.Int J Clin Exp Pathol. 2015 Apr 1;8(4):4015-21. eCollection 2015.
• [2031] Epigenetic silencing of NKD2, a major component of Wnt signaling, promotes breast cancer growth.Oncotarget. 2015 Sep 8;6(26):22126-38. doi: 10.18632/oncotarget.4244.
• [2032] Investigation of Novel Regulation of N-myristoyltransferase by Mammalian Target of Rapamycin in Breast Cancer Cells.Sci Rep. 2018 Aug 28;8(1):12969. doi: 10.1038/s41598-018-30447-0.
• [2033] NR2F6 Expression Correlates with Pelvic Lymph Node Metastasis and Poor Prognosis in Early-Stage Cervical Cancer.Int J Mol Sci. 2016 Oct 20;17(10):1694. doi: 10.3390/ijms17101694.
• [2034] Overexpression of NOTCH-regulated ankyrin repeat protein is associated with breast cancer cell proliferation.Anticancer Res. 2014 May;34(5):2165-71.
• [2035] Increased expression of mitochondrial transcription factor A and nuclear respiratory factor-1 predicts a poor clinical outcome of breast cancer.Oncol Lett. 2018 Feb;15(2):1449-1458. doi: 10.3892/ol.2017.7487. Epub 2017 Nov 24.
• [2036] Identification of Nucleobindin-2 as a Potential Biomarker for Breast Cancer Metastasis Using iTRAQ-based Quantitative Proteomic Analysis.J Cancer. 2017 Sep 2;8(15):3062-3069. doi: 10.7150/jca.19619. eCollection 2017.
• [2037] Effect of NUCKS-1 overexpression on cytokine profiling in obese women with breast cancer.Asian Pac J Cancer Prev. 2014;15(2):837-45. doi: 10.7314/apjcp.2014.15.2.837.
• [2038] Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel.Cancer Lett. 2018 Apr 10;419:233-244. doi: 10.1016/j.canlet.2018.01.054. Epub 2018 Feb 2.
• [2039] Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study.Breast Cancer. 2017 Jan;24(1):161-170. doi: 10.1007/s12282-016-0691-6. Epub 2016 Mar 26.
• [2040] A rare eicosanoid precursor analogue, sciadonic acid (5Z,11Z,14Z-20:3), detected in vivo in hormone positive breast cancer tissue.Prostaglandins Leukot Essent Fatty Acids. 2018 Jul;134:1-6. doi: 10.1016/j.plefa.2018.05.002. Epub 2018 May 16.
• [2041] Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts.Stem Cells. 2012 Oct;30(10):2065-75. doi: 10.1002/stem.1139.
• [2042] Collagen prolyl hydroxylase 3 has a tumor suppressive activity in human lung cancer.Exp Cell Res. 2018 Feb 1;363(1):121-128. doi: 10.1016/j.yexcr.2017.12.020. Epub 2017 Dec 23.
• [2043] Delivery of Amonafide from Fructose-Coated Nanodiamonds by Oxime Ligation for the Treatment of Human Breast Cancer.Biomacromolecules. 2018 Feb 12;19(2):481-489. doi: 10.1021/acs.biomac.7b01592. Epub 2018 Jan 23.
• [2044] -Parvin promotes breast cancer progression and metastasis through interaction with G3BP2 and regulation of TWIST1 signaling.Oncogene. 2019 Jun;38(24):4856-4874. doi: 10.1038/s41388-019-0762-1. Epub 2019 Feb 25.
• [2045] Pyruvate carboxylase supports the pulmonary tropism of metastatic breast cancer.Breast Cancer Res. 2018 Jul 13;20(1):76. doi: 10.1186/s13058-018-1008-9.
• [2046] PCP4/PEP19 upregulates aromatase gene expression via CYP19A1 promoter I.1 in human breast cancer SK-BR-3 cells.Oncotarget. 2018 Jul 3;9(51):29619-29633. doi: 10.18632/oncotarget.25651. eCollection 2018 Jul 3.
• [2047] PDLIM2 Is a Marker of Adhesion and -Catenin Activity in Triple-Negative Breast Cancer.Cancer Res. 2019 May 15;79(10):2619-2633. doi: 10.1158/0008-5472.CAN-18-2787. Epub 2019 Mar 18.
• [2048] Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome.BMC Cancer. 2012 Jun 13;12:243. doi: 10.1186/1471-2407-12-243.
• [2049] Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer.Oncotarget. 2018 Apr 3;9(25):17334-17348. doi: 10.18632/oncotarget.24671. eCollection 2018 Apr 3.
• [2050] Knockdown of PEBP4 suppresses proliferation, migration and invasion of human breast cancer cells.Biomed Pharmacother. 2017 Jun;90:659-664. doi: 10.1016/j.biopha.2017.03.098. Epub 2017 Apr 14.
• [2051] CXADR-Mediated Formation of an AKT Inhibitory Signalosome at Tight Junctions Controls Epithelial-Mesenchymal Plasticity in Breast Cancer.Cancer Res. 2019 Jan 1;79(1):47-60. doi: 10.1158/0008-5472.CAN-18-1742. Epub 2018 Nov 1.
• [2052] Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells.Oncogene. 2020 Jan;39(4):801-813. doi: 10.1038/s41388-019-1010-4. Epub 2019 Sep 25.
• [2053] The PIAS3-Smurf2 sumoylation pathway suppresses breast cancer organoid invasiveness.Oncotarget. 2017 Mar 28;8(13):21001-21014. doi: 10.18632/oncotarget.15471.
• [2054] PIH1D1 interacts with mTOR complex 1 and enhances ribosome RNA transcription.FEBS Lett. 2013 Oct 11;587(20):3303-8. doi: 10.1016/j.febslet.2013.09.001. Epub 2013 Sep 11.
• [2055] Group X secreted phospholipase A(2) induces lipid droplet formation and prolongs breast cancer cell survival.Mol Cancer. 2013 Sep 27;12(1):111. doi: 10.1186/1476-4598-12-111.
• [2056] Secreted phospholipases Aare differentially expressed and epigenetically silenced in human breast cancer cells.Biochem Biophys Res Commun. 2014 Feb 28;445(1):230-5. doi: 10.1016/j.bbrc.2014.01.182. Epub 2014 Feb 6.
• [2057] PLCA8 suppresses breast cancer apoptosis by activating the PI3k/AKT/NF-B pathway.J Cell Mol Med. 2019 Oct;23(10):6930-6941. doi: 10.1111/jcmm.14578. Epub 2019 Aug 26.
• [2058] Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers.Int J Oncol. 2014 Dec;45(6):2250-66. doi: 10.3892/ijo.2014.2648. Epub 2014 Sep 9.
• [2059] Plastin 3 down-regulation augments the sensitivity of MDA-MB-231 cells to paclitaxel via the p38 MAPK signalling pathway.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):685-695. doi: 10.1080/21691401.2019.1576707.
• [2060] Utilization of adipocyte-derived lipids and enhanced intracellular trafficking of fatty acids contribute to breast cancer progression.Cell Commun Signal. 2018 Jun 18;16(1):32. doi: 10.1186/s12964-018-0221-6.
• [2061] An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.BMC Cancer. 2018 Sep 27;18(1):932. doi: 10.1186/s12885-018-4843-2.
• [2062] CXCL7 promotes proliferation and invasion of cholangiocarcinoma cells.Oncol Rep. 2017 Feb;37(2):1114-1122. doi: 10.3892/or.2016.5312. Epub 2016 Dec 12.
• [2063] Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.Biomed Pharmacother. 2017 Feb;86:595-604. doi: 10.1016/j.biopha.2016.12.041. Epub 2016 Dec 24.
• [2064] The anti-apoptotic proteins NAF-1 and iASPP interact to drive apoptosis in cancer cells.Chem Sci. 2018 Nov 20;10(3):665-673. doi: 10.1039/c8sc03390k. eCollection 2019 Jan 21.
• [2065] Protein phosphatase 1, regulatory subunit 15B is a survival factor for ER-positive breast cancer.Int J Cancer. 2013 Jun 1;132(11):2714-9. doi: 10.1002/ijc.27945. Epub 2012 Dec 27.
• [2066] DNA primase polypeptide 1 (PRIM1) involves in estrogen-induced breast cancer formation through activation of the G2/M cell cycle checkpoint.Int J Cancer. 2019 Feb 1;144(3):615-630. doi: 10.1002/ijc.31788. Epub 2018 Nov 21.
• [2067] p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.J Biol Chem. 2019 Mar 8;294(10):3670-3682. doi: 10.1074/jbc.RA118.004671. Epub 2019 Jan 2.
• [2068] Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome.Int J Cancer. 2013 May 1;132(9):2044-55. doi: 10.1002/ijc.27884. Epub 2012 Oct 25.
• [2069] The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.Oncotarget. 2017 Nov 18;8(68):112245-112257. doi: 10.18632/oncotarget.22496. eCollection 2017 Dec 22.
• [2070] PTPN12 Affects Nasopharyngeal Carcinoma Cell Proliferation and Migration Through Regulating EGFR.Cancer Biother Radiopharm. 2018 Mar;33(2):60-64. doi: 10.1089/cbr.2017.2254.
• [2071] Suppression of protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation of FYN kinase.Genes Dev. 2017 Oct 1;31(19):1939-1957. doi: 10.1101/gad.304261.117. Epub 2017 Oct 24.
• [2072] Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer.J Cancer Res Clin Oncol. 2013 Jul;139(7):1129-39. doi: 10.1007/s00432-013-1421-5. Epub 2013 Apr 4.
• [2073] Scorpion Venom Analgesic Peptide, BmK AGAP Inhibits Stemness, and Epithelial-Mesenchymal Transition by Down-Regulating PTX3 in Breast Cancer.Front Oncol. 2019 Jan 25;9:21. doi: 10.3389/fonc.2019.00021. eCollection 2019.
• [2074] PUF60 accelerates the progression of breast cancer through downregulation of PTEN expression.Cancer Manag Res. 2019 Jan 17;11:821-830. doi: 10.2147/CMAR.S180242. eCollection 2019.
• [2075] MiR-183/-96/-182 cluster is up-regulated in most breast cancers and increases cell proliferation and migration.Breast Cancer Res. 2014 Nov 14;16(6):473. doi: 10.1186/s13058-014-0473-z.
• [2076] Integrative functional genomics identifies regulatory genetic variant modulating RAB31 expression and altering susceptibility to breast cancer.Mol Carcinog. 2018 Dec;57(12):1845-1854. doi: 10.1002/mc.22902. Epub 2018 Sep 19.
• [2077] Suppression of RAD21 Induces Senescence of MDA-MB-231 Human Breast Cancer Cells Through RB1 Pathway Activation Via c-Myc Downregulation.J Cell Biochem. 2016 Jun;117(6):1359-69. doi: 10.1002/jcb.25426. Epub 2015 Nov 20.
• [2078] Replication Stress Response Links RAD52 to Protecting Common Fragile Sites.Cancers (Basel). 2019 Sep 29;11(10):1467. doi: 10.3390/cancers11101467.
• [2079] Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells.Mol Ther. 2013 Jan;21(1):185-91. doi: 10.1038/mt.2012.180. Epub 2012 Oct 2.
• [2080] RAI1 Alternate Probe Identifies Additional Breast Cancer Cases as Amplified Following Equivocal HER2 Fluorescence In Situ Hybridization Testing: Experience From a National Reference Laboratory.Arch Pathol Lab Med. 2017 Feb;141(2):274-278. doi: 10.5858/arpa.2016-0201-OA. Epub 2016 Dec 13.
• [2081] Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer.Clin Epigenetics. 2018 May 23;10:69. doi: 10.1186/s13148-018-0501-4. eCollection 2018.
• [2082] RanBPM inhibits BLT2-mediated IL-8 production and invasiveness in aggressive breast cancer cells.Biochem Biophys Res Commun. 2017 Jan 29;483(1):305-311. doi: 10.1016/j.bbrc.2016.12.147. Epub 2016 Dec 25.
• [2083] Increased expression of Rab25 in breast cancer correlates with lymphatic metastasis.Tumour Biol. 2012 Oct;33(5):1581-7. doi: 10.1007/s13277-012-0412-5. Epub 2012 May 30.
• [2084] Function of RasGRP3 in the formation and progression of human breast cancer.Mol Cancer. 2014 Apr 29;13:96. doi: 10.1186/1476-4598-13-96.
• [2085] The RNA binding protein RBMS3 inhibits the metastasis of breast cancer by regulating Twist1 expression.J Exp Clin Cancer Res. 2019 Feb 28;38(1):105. doi: 10.1186/s13046-019-1111-5.
• [2086] TRPS1 regulates oestrogen receptor binding and histone acetylation at enhancers.Oncogene. 2018 Sep;37(39):5281-5291. doi: 10.1038/s41388-018-0312-2. Epub 2018 Jun 12.
• [2087] Expression of regulatory factor X1 can predict the prognosis of breast cancer.Oncol Lett. 2017 Jun;13(6):4334-4340. doi: 10.3892/ol.2017.6005. Epub 2017 Apr 7.
• [2088] Estrogen receptor dependent regulation of estrogen related receptor and its role in cell cycle in breast cancer.BMC Cancer. 2018 May 30;18(1):607. doi: 10.1186/s12885-018-4528-x.
• [2089] Bioinformatic Identification of miR-622 Key Target Genes and Experimental Validation of the miR-622-RNF8 Axis in Breast Cancer.Front Oncol. 2019 Oct 23;9:1114. doi: 10.3389/fonc.2019.01114. eCollection 2019.
• [2090] Assessing SNP-SNP interactions among DNA repair, modification and metabolism related pathway genes in breast cancer susceptibility.PLoS One. 2013 Jun 3;8(6):e64896. doi: 10.1371/journal.pone.0064896. Print 2014.
• [2091] The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types.Oncotarget. 2017 Feb 28;8(9):14462-14478. doi: 10.18632/oncotarget.14895.
• [2092] Estradiol promotes the progression of ER+ breast cancer through methylation-mediated RSK4 inactivation.Onco Targets Ther. 2019 Jul 22;12:5907-5916. doi: 10.2147/OTT.S208988. eCollection 2019.
• [2093] HSPC111 governs breast cancer growth by regulating ribosomal biogenesis.Mol Cancer Res. 2014 Apr;12(4):583-94. doi: 10.1158/1541-7786.MCR-13-0168. Epub 2014 Jan 14.
• [2094] Rac-specific guanine nucleotide exchange factor DOCK1 is a critical regulator of HER2-mediated breast cancer metastasis.Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7434-9. doi: 10.1073/pnas.1213050110. Epub 2013 Apr 16.
• [2095] SARNP, a participant in mRNA splicing and export, negatively regulates E-cadherin expression via interaction with pinin.J Cell Physiol. 2020 Feb;235(2):1543-1555. doi: 10.1002/jcp.29073. Epub 2019 Jul 17.
• [2096] Tissue factor-specific ultra-bright SERRS nanostars for Raman detection of pulmonary micrometastases.Nanoscale. 2017 Jan 19;9(3):1110-1119. doi: 10.1039/c6nr08217c.
• [2097] Correlation of SASH1 expression and ultrasonographic features in breast cancer.Onco Targets Ther. 2017 Jan 10;10:271-276. doi: 10.2147/OTT.S119244. eCollection 2017.
• [2098] The sodium channel 1 subunit mediates outgrowth of neurite-like processes on breast cancer cells and promotes tumour growth and metastasis.Int J Cancer. 2014 Nov 15;135(10):2338-51. doi: 10.1002/ijc.28890. Epub 2014 Apr 26.
• [2099] Repression of miR-135b-5p promotes metastasis of early-stage breast cancer by regulating downstream target SDCBP.Lab Invest. 2019 Sep;99(9):1296-1308. doi: 10.1038/s41374-019-0258-1. Epub 2019 Apr 25.
• [2100] Identification of 3q oncogene SEC62 as a marker for distant metastasis and poor clinical outcome in invasive ductal breast cancer.Arch Gynecol Obstet. 2019 May;299(5):1405-1413. doi: 10.1007/s00404-019-05081-4. Epub 2019 Feb 12.
• [2101] Sema4A Responds to Hypoxia and Is Involved in Breast Cancer Progression.Biol Pharm Bull. 2018 Dec 1;41(12):1791-1796. doi: 10.1248/bpb.b18-00423. Epub 2018 Sep 28.
• [2102] Association of SENPs single-nucleotide polymorphism and breast cancer in Chinese population.Medicine (Baltimore). 2019 Feb;98(6):e14168. doi: 10.1097/MD.0000000000014168.
• [2103] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [2104] SETDB1 induces epithelialmesenchymal transition in breast carcinoma by directly binding with Snail promoter.Oncol Rep. 2019 Feb;41(2):1284-1292. doi: 10.3892/or.2018.6871. Epub 2018 Nov 19.
• [2105] Sphingomyelin synthase 2 promotes an aggressive breast cancer phenotype by disrupting the homoeostasis of ceramide and sphingomyelin.Cell Death Dis. 2019 Feb 15;10(3):157. doi: 10.1038/s41419-019-1303-0.
• [2106] Expression and prognostic role of SGTA in human breast carcinoma correlates with tumor cell proliferation.J Mol Histol. 2014 Dec;45(6):665-77. doi: 10.1007/s10735-014-9586-z. Epub 2014 Jul 16.
• [2107] Atypical ubiquitin-binding protein SHARPIN promotes breast cancer progression.Biomed Pharmacother. 2019 Nov;119:109414. doi: 10.1016/j.biopha.2019.109414. Epub 2019 Sep 10.
• [2108] Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors.Breast Cancer Res. 2017 Oct 11;19(1):112. doi: 10.1186/s13058-017-0905-7.
• [2109] Deciphering Macrophage and Monocyte Code to Stratify Human Breast Cancer Patients.Cancer Cell. 2019 Apr 15;35(4):538-539. doi: 10.1016/j.ccell.2019.03.010.
• [2110] Nucleotide exchange factor SIL1 promotes the progress of breast cancer cells via regulating the cell cycle and apoptosis.Sci Prog. 2020 Jan-Mar;103(1):36850419891046. doi: 10.1177/0036850419891046. Epub 2019 Dec 2.
• [2111] P-Rex1 is dispensable for Erk activation and mitogenesis in breast cancer.Oncotarget. 2018 Jun 19;9(47):28612-28624. doi: 10.18632/oncotarget.25584. eCollection 2018 Jun 19.
• [2112] SLFN5 suppresses cancer cell migration and invasion by inhibiting MT1-MMP expression via AKT/GSK-3/-catenin pathway.Cell Signal. 2019 Jul;59:1-12. doi: 10.1016/j.cellsig.2019.03.004. Epub 2019 Mar 4.
• [2113] A low-frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (<60 years) and is associated with reduced DNA repair capacity.Int J Cancer. 2018 Feb 15;142(4):757-768. doi: 10.1002/ijc.31105. Epub 2017 Oct 30.
• [2114] SMARCAD1 in Breast Cancer Progression.Cell Physiol Biochem. 2018;50(2):489-500. doi: 10.1159/000494163. Epub 2018 Oct 11.
• [2115] CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis.Cancer Cell. 2014 Jan 13;25(1):21-36. doi: 10.1016/j.ccr.2013.12.007.
• [2116] Low power blue LED exposure increases effects of doxorubicin on MDA-MB-231 breast cancer cells.Photodiagnosis Photodyn Ther. 2018 Dec;24:250-255. doi: 10.1016/j.pdpdt.2018.07.016. Epub 2018 Jul 29.
• [2117] PRL-3 promotes breast cancer progression by downregulating p14(ARF)-mediated p53 expression.Oncol Lett. 2018 Mar;15(3):2795-2800. doi: 10.3892/ol.2017.7639. Epub 2017 Dec 19.
• [2118] SND1 expression in breast cancer tumors is associated with poor prognosis.Ann N Y Acad Sci. 2018 Dec;1433(1):53-60. doi: 10.1111/nyas.13970. Epub 2018 Sep 14.
• [2119] In vitro and in vivo effects of suppressor of cytokine signalling 7 knockdown in breast cancer: the influence on cellular response to hepatocyte growth factor.Biomed Res Int. 2014;2014:648040. doi: 10.1155/2014/648040. Epub 2014 Aug 4.
• [2120] Sohlh2 inhibits breast cancer cell proliferation by suppressing Wnt/-catenin signaling pathway.Mol Carcinog. 2019 Jun;58(6):1008-1018. doi: 10.1002/mc.22989. Epub 2019 Mar 5.
• [2121] Long noncoding RNA HAND2-AS1 restrains proliferation and metastasis of breast cancer cells through sponging miR-1275 and promoting SOX7.Cancer Biomark. 2020;27(1):85-94. doi: 10.3233/CBM-190530.
• [2122] SOX8 acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer.Carcinogenesis. 2019 Oct 16;40(10):1278-1287. doi: 10.1093/carcin/bgz034.
• [2123] Clinicopathological significance of reduced SPARCL1 expression in human breast cancer.Asian Pac J Cancer Prev. 2013;14(1):195-200. doi: 10.7314/apjcp.2013.14.1.195.
• [2124] PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.BMC Cancer. 2018 Jun 19;18(1):669. doi: 10.1186/s12885-018-4412-8.
• [2125] Clinical significance of SPRR1A expression in progesterone receptor-positive breast cancer.Tumour Biol. 2015 Apr;36(4):2601-5. doi: 10.1007/s13277-014-2879-8. Epub 2014 Nov 26.
• [2126] Autophagy mediates free fatty acid effects on MDA-MB-231 cell proliferation, migration and invasion.Oncol Lett. 2017 Oct;14(4):4715-4721. doi: 10.3892/ol.2017.6807. Epub 2017 Aug 24.
• [2127] Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo.Breast Cancer Res Treat. 2014 Jan;143(2):287-99. doi: 10.1007/s10549-013-2809-2. Epub 2013 Dec 15.
• [2128] Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment.Cancer Chemother Pharmacol. 2019 Nov;84(5):1133-1143. doi: 10.1007/s00280-019-03945-9. Epub 2019 Sep 12.
• [2129] circFBXL5 promotes breast cancer progression by sponging miR-660.J Cell Mol Med. 2020 Jan;24(1):356-361. doi: 10.1111/jcmm.14737. Epub 2019 Nov 15.
• [2130] Suppression of the proliferation and invasion of breast cancer cells by ST7L occurs through inhibition of activation of Wnt/GSK-3/-catenin signalling.Clin Exp Pharmacol Physiol. 2020 Jan;47(1):119-126. doi: 10.1111/1440-1681.13166. Epub 2019 Sep 9.
• [2131] TNF differentially regulates ganglioside biosynthesis and expression in breast cancer cell lines.PLoS One. 2018 Apr 26;13(4):e0196369. doi: 10.1371/journal.pone.0196369. eCollection 2018.
• [2132] Prognostic roles of signal transducers and activators of transcription family in human breast cancer.Biosci Rep. 2018 Dec 11;38(6):BSR20171175. doi: 10.1042/BSR20171175. Print 2018 Dec 21.
• [2133] Genome-wide expression analysis reveals six contravened targets of EZH2 associated with breast cancer patient survival.Sci Rep. 2019 Feb 13;9(1):1974. doi: 10.1038/s41598-019-39122-4.
• [2134] Differential expression and molecular interactions of chromosome region maintenance 1 and calreticulin exportins in breast cancer cells.J Steroid Biochem Mol Biol. 2019 Jan;185:7-16. doi: 10.1016/j.jsbmb.2018.07.003. Epub 2018 Jul 5.
• [2135] SYNJ2BP promotes the degradation of PTEN through the lysosome-pathway and enhances breast tumor metastasis via PI3K/AKT/SNAI1 signaling.Oncotarget. 2017 Sep 19;8(52):89692-89706. doi: 10.18632/oncotarget.21058. eCollection 2017 Oct 27.
• [2136] TACC2 (transforming acidic coiled-coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell proliferation.Cancer Med. 2016 Aug;5(8):1973-82. doi: 10.1002/cam4.736. Epub 2016 Jun 22.
• [2137] Cancer/Testis OIP5 and TAF7L Genes are Up-Regulated in Breast Cancer.Asian Pac J Cancer Prev. 2015;16(11):4623-8. doi: 10.7314/apjcp.2015.16.11.4623.
• [2138] A siRNA screen identifies RAD21, EIF3H, CHRAC1 and TANC2 as driver genes within the 8q23, 8q24.3 and 17q23 amplicons in breast cancer with effects on cell growth, survival and transformation.Carcinogenesis. 2014 Mar;35(3):670-82. doi: 10.1093/carcin/bgt351. Epub 2013 Oct 22.
• [2139] Downregulation of TAP1 and TAP2 in early stage breast cancer.PLoS One. 2017 Nov 1;12(11):e0187323. doi: 10.1371/journal.pone.0187323. eCollection 2017.
• [2140] Transactivation of SOX5 by Brachyury promotes breast cancer bone metastasis.Carcinogenesis. 2020 Jul 10;41(5):551-560. doi: 10.1093/carcin/bgz142.
• [2141] Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers.BMC Cancer. 2019 Mar 12;19(1):219. doi: 10.1186/s12885-019-5403-0.
• [2142] Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer.PLoS One. 2017 May 4;12(5):e0177244. doi: 10.1371/journal.pone.0177244. eCollection 2017.
• [2143] Reduced Expression of TET1, TET2, TET3 and TDG mRNAs Are Associated with Poor Prognosis of Patients with Early Breast Cancer.PLoS One. 2015 Jul 24;10(7):e0133896. doi: 10.1371/journal.pone.0133896. eCollection 2015.
• [2144] TFDP3 regulates the apoptosis and autophagy in breast cancer cell line MDA-MB-231.PLoS One. 2018 Sep 20;13(9):e0203833. doi: 10.1371/journal.pone.0203833. eCollection 2018.
• [2145] Network analysis of icb-1 gene function in human breast cancer cells.J Cell Biochem. 2012 Sep;113(9):2979-88. doi: 10.1002/jcb.24175.
• [2146] 4-HPR Is an Endoplasmic Reticulum Stress Aggravator and Sensitizes Breast Cancer Cells Resistant to TRAIL/Apo2L.Anticancer Res. 2018 Aug;38(8):4403-4416. doi: 10.21873/anticanres.12742.
• [2147] Tumor-Contacted Neutrophils Promote Metastasis by a CD90-TIMP-1 Juxtacrine-Paracrine Loop.Clin Cancer Res. 2019 Mar 15;25(6):1957-1969. doi: 10.1158/1078-0432.CCR-18-2544. Epub 2018 Nov 27.
• [2148] Improvement of implantation potential in mouse blastocysts derived from IVF by combined treatment with prolactin, epidermal growth factor and 4-hydroxyestradiol.Mol Hum Reprod. 2017 Aug 1;23(8):557-570. doi: 10.1093/molehr/gax035.
• [2149] Validation of DNA promoter hypermethylation biomarkers in breast cancer--a short report.Cell Oncol (Dordr). 2014 Aug;37(4):297-303. doi: 10.1007/s13402-014-0189-1. Epub 2014 Aug 16.
• [2150] TMED3 promotes cell proliferation and motility in breast cancer and is negatively modulated by miR-188-3p.Cancer Cell Int. 2019 Mar 29;19:75. doi: 10.1186/s12935-019-0791-4. eCollection 2019.
• [2151] Loss of TMEM126A promotes extracellular matrix remodeling, epithelial-to-mesenchymal transition, and breast cancer metastasis by regulating mitochondrial retrograde signaling.Cancer Lett. 2019 Jan;440-441:189-201. doi: 10.1016/j.canlet.2018.10.018. Epub 2018 Oct 26.
• [2152] Global methylation levels in peripheral blood leukocyte DNA by LUMA and breast cancer: a case-control study in Japanese women.Br J Cancer. 2014 May 27;110(11):2765-71. doi: 10.1038/bjc.2014.223. Epub 2014 May 1.
• [2153] Negative regulation of ER by a novel protein CAC1 through association with histone demethylase LSD1.FEBS Lett. 2013 Jan 4;587(1):17-22. doi: 10.1016/j.febslet.2012.10.054. Epub 2012 Nov 20.
• [2154] Type II transmembrane serine protease gene variants associate with breast cancer.PLoS One. 2014 Jul 16;9(7):e102519. doi: 10.1371/journal.pone.0102519. eCollection 2014.
• [2155] Estrogen receptor alpha (ERS1) SNPs c454-397T>C (PvuII) and c454-351A>G (XbaI) are risk biomarkers for breast cancer development.Mol Biol Rep. 2014 Aug;41(8):5459-66. doi: 10.1007/s11033-014-3419-8. Epub 2014 Jun 14.
• [2156] SKP2 overexpression is associated with increased serine 10 phosphorylation of p27 (pSer10p27) in triple-negative breast cancer.J Cell Physiol. 2014 Sep;229(9):1160-9. doi: 10.1002/jcp.24545.
• [2157] Transcriptome and Proteome Analyses of TNFAIP8 Knockdown Cancer Cells Reveal New Insights into Molecular Determinants of Cell Survival and Tumor Progression.Methods Mol Biol. 2017;1513:83-100. doi: 10.1007/978-1-4939-6539-7_7.
• [2158] Gene delivery of TIPE2 inhibits breast cancer development and metastasis via CD8(+) T and NK cell-mediated antitumor responses.Mol Immunol. 2017 May;85:230-237. doi: 10.1016/j.molimm.2017.03.007. Epub 2017 Mar 15.
• [2159] Harnessing copper-palladium alloy tetrapod nanoparticle-induced pro-survival autophagy for optimized photothermal therapy of drug-resistant cancer.Nat Commun. 2018 Oct 12;9(1):4236. doi: 10.1038/s41467-018-06529-y.
• [2160] RIP-Chip analysis supports different roles for AGO2 and GW182 proteins in recruiting and processing microRNA targets.BMC Bioinformatics. 2019 Apr 18;20(Suppl 4):120. doi: 10.1186/s12859-019-2683-y.
• [2161] TP53I11 suppresses epithelial-mesenchymal transition and metastasis of breast cancer cells.BMB Rep. 2019 Jun;52(6):379-384. doi: 10.5483/BMBRep.2019.52.6.173.
• [2162] TP53INP1 inhibits hypoxia-induced vasculogenic mimicry formation via the ROS/snail signalling axis in breast cancer.J Cell Mol Med. 2018 Jul;22(7):3475-3488. doi: 10.1111/jcmm.13625. Epub 2018 Apr 14.
• [2163] Correction to: Retraction of: Tumor Protein D52-Like 2 Contributes to Proliferation of Breast Cancer Cells; 10.10.89/cbr.2014.1723Cancer Biother Radiopharm 2017;32(10):387. DOI: 10.1089/cbr.2014.1723.retract.Cancer Biother Radiopharm. 2018 Oct 1;33(8):361. doi: 10.1089/cbr.2014.1723.retract.correx. Epub 2018 Oct 18.
• [2164] Integrative "omic" analysis for tamoxifen sensitivity through cell based models.PLoS One. 2014 Apr 3;9(4):e93420. doi: 10.1371/journal.pone.0093420. eCollection 2014.
• [2165] Downregulation of ubiquitin E3 ligase TNF receptor-associated factor 7 leads to stabilization of p53 in breast cancer.Oncol Rep. 2013 Jan;29(1):283-7. doi: 10.3892/or.2012.2121. Epub 2012 Nov 1.
• [2166] Cytosolic Hsp90 and its mitochondrial isoform Trap1 are differentially required in a breast cancer model.Oncotarget. 2017 Mar 14;8(11):17428-17442. doi: 10.18632/oncotarget.15659.
• [2167] Cancer-associated mutation abolishes the impact of TRIM21 on the invasion of breast cancer cells.Int J Biol Macromol. 2020 Jan 1;142:782-789. doi: 10.1016/j.ijbiomac.2019.10.019. Epub 2019 Oct 14.
• [2168] Blockade of miR-3614 maturation by IGF2BP3 increases TRIM25 expression and promotes breast cancer cell proliferation.EBioMedicine. 2019 Mar;41:357-369. doi: 10.1016/j.ebiom.2018.12.061. Epub 2019 Feb 20.
• [2169] Prognostic role of Tif1 expression and circulating tumor cells in patients with breast cancer.Mol Med Rep. 2019 May;19(5):3685-3695. doi: 10.3892/mmr.2019.10033. Epub 2019 Mar 14.
• [2170] Regulation of estrogen signaling and breast cancer proliferation by an ubiquitin ligase TRIM56.Oncogenesis. 2019 Apr 18;8(5):30. doi: 10.1038/s41389-019-0139-x.
• [2171] Single Nucleotide Polymorphisms in the Acylphosphatase 2 Gene and The SNP-SNP Interactions on the Risk of Breast Cancer in Chinese Han Women.Clin Breast Cancer. 2018 Jun;18(3):e329-e333. doi: 10.1016/j.clbc.2017.09.003. Epub 2017 Sep 19.
• [2172] The 3p14.2 tumour suppressor ADAMTS9 is inactivated by promoter CpG methylation and inhibits tumour cell growth in breast cancer.J Cell Mol Med. 2018 Feb;22(2):1257-1271. doi: 10.1111/jcmm.13404. Epub 2017 Nov 29.
• [2173] Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2.Lab Invest. 2018 Jan;98(1):117-129. doi: 10.1038/labinvest.2017.106. Epub 2017 Oct 16.
• [2174] CdGAP/ARHGAP31 is regulated by RSK phosphorylation and binding to 14-3-3 adaptor protein.Oncotarget. 2018 Jan 10;9(14):11646-11664. doi: 10.18632/oncotarget.24126. eCollection 2018 Feb 20.
• [2175] Cross-cancer profiling of molecular alterations within the human autophagy interaction network.Autophagy. 2015;11(9):1668-87. doi: 10.1080/15548627.2015.1067362.
• [2176] Risk of leptomeningeal carcinomatosis in patients with brain metastases treated with stereotactic radiosurgery.J Neurooncol. 2018 Jan;136(2):395-401. doi: 10.1007/s11060-017-2666-7. Epub 2017 Nov 20.
• [2177] Restin suppressed epithelial-mesenchymal transition and tumor metastasis in breast cancer cells through upregulating mir-200a/b expression via association with p73.Mol Cancer. 2015 May 14;14:102. doi: 10.1186/s12943-015-0370-9.
• [2178] Rational design for heterologous production of aurovertin-type compounds in Aspergillus nidulans.Appl Microbiol Biotechnol. 2018 Jan;102(1):297-304. doi: 10.1007/s00253-017-8606-9. Epub 2017 Nov 2.
• [2179] Leupaxin is expressed in mammary carcinoma and acts as a transcriptional activator of the estrogen receptor .Int J Oncol. 2015 Jul;47(1):106-14. doi: 10.3892/ijo.2015.2988. Epub 2015 May 6.
• [2180] Drivers of advanced stage at breast cancer diagnosis in the multicountry African breast cancer - disparities in outcomes (ABC-DO) study.Int J Cancer. 2018 Apr 15;142(8):1568-1579. doi: 10.1002/ijc.31187. Epub 2017 Dec 23.
• [2181] Aberrant high expression level of MORC2 is a common character in multiple cancers.Hum Pathol. 2018 Jun;76:58-67. doi: 10.1016/j.humpath.2018.03.011. Epub 2018 Mar 16.
• [2182] Epigenetic silencing of neurofilament genes promotes an aggressive phenotype in breast cancer.Epigenetics. 2015;10(7):622-32. doi: 10.1080/15592294.2015.1050173.
• [2183] NOP14 suppresses breast cancer progression by inhibiting NRIP1/Wnt/-catenin pathway.Oncotarget. 2015 Sep 22;6(28):25701-14. doi: 10.18632/oncotarget.4573.
• [2184] The effect of the Progesterone-Induced Blocking Factor (PIBF) on E-cadherin expression, cell motility and invasion of primary tumour cell lines.J Reprod Immunol. 2018 Feb;125:8-15. doi: 10.1016/j.jri.2017.10.047. Epub 2017 Nov 2.
• [2185] PTBP3-Mediated Regulation of ZEB1 mRNA Stability Promotes Epithelial-Mesenchymal Transition in Breast Cancer.Cancer Res. 2018 Jan 15;78(2):387-398. doi: 10.1158/0008-5472.CAN-17-0883. Epub 2017 Nov 29.
• [2186] Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status.Mol Carcinog. 2013 Nov;52 Suppl 1:E52-9. doi: 10.1002/mc.21979. Epub 2012 Nov 9.
• [2187] Downregulation of hsa_circ_0011946 suppresses the migration and invasion of the breast cancer cell line MCF-7 by targeting RFC3.Cancer Manag Res. 2018 Mar 19;10:535-544. doi: 10.2147/CMAR.S155923. eCollection 2018.
• [2188] ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.Breast Cancer Res. 2016 Nov 16;18(1):113. doi: 10.1186/s13058-016-0770-9.
• [2189] New advances of TMEM88 in cancer initiation and progression, with special emphasis on Wnt signaling pathway.J Cell Physiol. 2018 Jan;233(1):79-87. doi: 10.1002/jcp.25853. Epub 2017 Apr 27.
• [2190] Focal adhesion kinase regulates the phosphorylation protein tyrosine phosphatase- at Tyr789 in breast cancer cells.Mol Med Rep. 2015 Jun;11(6):4303-8. doi: 10.3892/mmr.2015.3262. Epub 2015 Jan 27.
• [2191] Metabolic Studies of Tumor Cells Using [1-(13) C] Pyruvate Hyperpolarized by Means of PHIP-Side Arm Hydrogenation.Chemphyschem. 2019 Jan 21;20(2):318-325. doi: 10.1002/cphc.201800652. Epub 2018 Oct 24.
• [2192] High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma.Mol Med Rep. 2019 Feb;19(2):877-884. doi: 10.3892/mmr.2018.9716. Epub 2018 Dec 3.
• [2193] Actinin-4 as a Diagnostic Biomarker in Serum of Breast Cancer Patients.Med Sci Monit. 2019 May 4;25:3298-3302. doi: 10.12659/MSM.912404.
• [2194] Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system.Breast Cancer Res. 2012 Jan 31;14(1):R20. doi: 10.1186/bcr3105.
• [2195] ADAM15 mediates upregulation of Claudin-1 expression in breast cancer cells.Sci Rep. 2019 Aug 29;9(1):12540. doi: 10.1038/s41598-019-49021-3.
• [2196] Epigenetic identification of ADCY4 as a biomarker for breast cancer: an integrated analysis of adenylate cyclases.Epigenomics. 2019 Nov;11(14):1561-1579. doi: 10.2217/epi-2019-0207. Epub 2019 Oct 4.
• [2197] AKAP3 correlates with triple negative status and disease free survival in breast cancer.BMC Cancer. 2015 Oct 12;15:681. doi: 10.1186/s12885-015-1668-0.
• [2198] Interactome-transcriptome integration for predicting distant metastasis in breast cancer.Bioinformatics. 2012 Mar 1;28(5):672-8. doi: 10.1093/bioinformatics/bts025. Epub 2012 Jan 11.
• [2199] AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.Breast Cancer Res Treat. 2013 Oct;141(3):397-408. doi: 10.1007/s10549-013-2702-z. Epub 2013 Oct 5.
• [2200] Loss of ANCO1 repression at AIB1/YAP targets drives breast cancer progression.EMBO Rep. 2020 Jan 7;21(1):e48741. doi: 10.15252/embr.201948741. Epub 2019 Dec 2.
• [2201] Common genetic variants contribute to incomplete penetrance: evidence from cancer-free BRCA1 mutation carriers.Eur J Cancer. 2019 Jan;107:68-78. doi: 10.1016/j.ejca.2018.10.022. Epub 2018 Dec 11.
• [2202] miR-937 regulates the proliferation and apoptosis via targeting APAF1 in breast cancer.Onco Targets Ther. 2019 Jul 17;12:5687-5699. doi: 10.2147/OTT.S207091. eCollection 2019.
• [2203] Fe65 Suppresses Breast Cancer Cell Migration and Invasion through Tip60 Mediated Cortactin Acetylation.Sci Rep. 2015 Jul 13;5:11529. doi: 10.1038/srep11529.
• [2204] Regulation of ADP-ribosylation factor 4 expression by small leucine zipper protein and involvement in breast cancer cell migration.Cancer Lett. 2012 Jan 28;314(2):185-97. doi: 10.1016/j.canlet.2011.09.028. Epub 2011 Sep 29.
• [2205] MUC1 induces M2 type macrophage influx during postpartum mammary gland involution and triggers breast cancer.Oncotarget. 2017 Dec 15;9(3):3446-3458. doi: 10.18632/oncotarget.23316. eCollection 2018 Jan 9.
• [2206] ARID4B is a good biomarker to predict tumour behaviour and decide WHO grades in gliomas and meningiomas.J Clin Pathol. 2017 Feb;70(2):162-167. doi: 10.1136/jclinpath-2016-203804. Epub 2016 Jul 22.
• [2207] Arl13b Regulates Breast Cancer Cell Migration and Invasion by Controlling Integrin-Mediated Signaling.Cancers (Basel). 2019 Sep 29;11(10):1461. doi: 10.3390/cancers11101461.
• [2208] Expression of HIF-1 and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy.PLoS One. 2015 Jun 5;10(6):e0129356. doi: 10.1371/journal.pone.0129356. eCollection 2015.
• [2209] Loss of SNAIL regulated miR-128-2 on chromosome 3p22.3 targets multiple stem cell factors to promote transformation of mammary epithelial cells.Cancer Res. 2012 Nov 15;72(22):6036-50. doi: 10.1158/0008-5472.CAN-12-1507. Epub 2012 Sep 26.
• [2210] RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformation.Carcinogenesis. 2013 Nov;34(11):2498-504. doi: 10.1093/carcin/bgt247. Epub 2013 Jul 10.
• [2211] Optimism outweighs neuroticism and anxiety sensitivity to predict insomnia symptoms in women after surgery for breast cancer.Support Care Cancer. 2019 Aug;27(8):2903-2909. doi: 10.1007/s00520-018-4610-6. Epub 2018 Dec 17.
• [2212] CCL18-dependent translocation of AMAP1 is critical for epithelial to mesenchymal transition in breast cancer.J Cell Physiol. 2018 Apr;233(4):3207-3217. doi: 10.1002/jcp.26164. Epub 2017 Sep 27.
• [2213] Functional and cancer genomics of ASXL family members.Br J Cancer. 2013 Jul 23;109(2):299-306. doi: 10.1038/bjc.2013.281. Epub 2013 Jun 4.
• [2214] ASXL2 promotes proliferation of breast cancer cells by linking ER to histone methylation.Oncogene. 2016 Jul 14;35(28):3742-52. doi: 10.1038/onc.2015.443. Epub 2015 Dec 7.
• [2215] Integrative analysis of deep sequencing data identifies estrogen receptor early response genes and links ATAD3B to poor survival in breast cancer.PLoS Comput Biol. 2013;9(6):e1003100. doi: 10.1371/journal.pcbi.1003100. Epub 2013 Jun 20.
• [2216] Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.Oncotarget. 2012 Dec;3(12):1600-14. doi: 10.18632/oncotarget.742.
• [2217] A mammosphere formation RNAi screen reveals that ATG4A promotes a breast cancer stem-like phenotype.Breast Cancer Res. 2013 Nov 14;15(6):R109. doi: 10.1186/bcr3576.
• [2218] Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer.Mol Cell Endocrinol. 2012 May 15;355(1):15-24. doi: 10.1016/j.mce.2011.12.020. Epub 2012 Jan 18.
• [2219] Mitochondrial complex I and V gene polymorphisms associated with breast cancer in mizo-mongloid population.Breast Cancer. 2016 Jul;23(4):607-16. doi: 10.1007/s12282-015-0611-1. Epub 2015 Apr 21.
• [2220] Estrogen induced -1,4-galactosyltransferase 1 expression regulates proliferation of human breast cancer MCF-7 cells.Biochem Biophys Res Commun. 2012 Oct 5;426(4):620-5. doi: 10.1016/j.bbrc.2012.08.140. Epub 2012 Sep 6.
• [2221] The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the -Catenin Coactivator BCL9-2 in Breast Cancer Cells.Mol Cancer Res. 2015 May;13(5):902-12. doi: 10.1158/1541-7786.MCR-14-0180. Epub 2015 Feb 12.
• [2222] A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.Cancer Chemother Pharmacol. 2019 Oct;84(4):759-770. doi: 10.1007/s00280-019-03908-0. Epub 2019 Jul 31.
• [2223] Epithelial-to-mesenchymal transition induced by TGF-1 is mediated by Blimp-1-dependent repression of BMP-5.Cancer Res. 2012 Dec 1;72(23):6268-78. doi: 10.1158/0008-5472.CAN-12-2270. Epub 2012 Oct 10.
• [2224] Interaction of HCCR-1 and Bax in breast cancer.J BUON. 2019 May-Jun;24(3):1027-1037.
• [2225] Comparative profiling of plasma proteome from breast cancer patients reveals thrombospondin-1 and BRWD3 as serological biomarkers.Exp Mol Med. 2012 Jan 31;44(1):36-44. doi: 10.3858/emm.2012.44.1.003.
• [2226] Effect of TP53 16-bp and -TrCP 9-bp INS/DEL polymorphisms in relation to risk of breast cancer.Gene. 2015 Sep 1;568(2):181-5. doi: 10.1016/j.gene.2015.05.048. Epub 2015 May 21.
• [2227] Is axillary lymph node dissection necessary for positive preoperative aspiration cytology lymph node results?.Eur J Surg Oncol. 2020 Apr;46(4 Pt A):504-510. doi: 10.1016/j.ejso.2019.10.043. Epub 2019 Nov 1.
• [2228] Expression and prognostic value of L1-CAM in breast cancer.Oncol Rep. 2009 Nov;22(5):1109-17. doi: 10.3892/or_00000543.
• [2229] Calcium/calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells. Cancer Res. 2005 Jun 15;65(12):5408-16. doi: 10.1158/0008-5472.CAN-05-0271.
• [2230] Phosphorylation of calcium/calmodulin-stimulated protein kinase II at T286 enhances invasion and migration of human breast cancer cells.Sci Rep. 2016 Sep 8;6:33132. doi: 10.1038/srep33132.
• [2231] RSK-mediated down-regulation of PDCD4 is required for proliferation, survival, and migration in a model of triple-negative breast cancer.Oncotarget. 2016 May 10;7(19):27567-83. doi: 10.18632/oncotarget.8375.
• [2232] Calpain4 is required for activation of HER2 in breast cancer cells exposed to trastuzumab and its suppression decreases survival and enhances response.Int J Cancer. 2012 Nov 15;131(10):2420-32. doi: 10.1002/ijc.27510. Epub 2012 Mar 28.
• [2233] SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis.Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):638-43. doi: 10.1073/pnas.1514663113. Epub 2016 Jan 6.
• [2234] Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.PLoS One. 2012;7(10):e47537. doi: 10.1371/journal.pone.0047537. Epub 2012 Oct 31.
• [2235] Chromobox homolog 2 protein: A novel biomarker for predicting prognosis and Taxol sensitivity in patients with breast cancer.Oncol Lett. 2017 Mar;13(3):1149-1156. doi: 10.3892/ol.2016.5529. Epub 2016 Dec 23.
• [2236] CBX6 is negatively regulated by EZH2 and plays a potential tumor suppressor role in breast cancer.Sci Rep. 2019 Jan 17;9(1):197. doi: 10.1038/s41598-018-36560-4.
• [2237] Weighted gene correlation network analysis identifies RSAD2, HERC5, and CCL8 as prognostic candidates for breast cancer.J Cell Physiol. 2020 Jan;235(1):394-407. doi: 10.1002/jcp.28980. Epub 2019 Jun 21.
• [2238] Impact of WNT1-inducible signaling pathway protein-1 (WISP-1) genetic polymorphisms and clinical aspects of breast cancer.Medicine (Baltimore). 2019 Nov;98(44):e17854. doi: 10.1097/MD.0000000000017854.
• [2239] miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-, CCNJ, and MEGF9.PLoS One. 2013 Oct 3;8(10):e76247. doi: 10.1371/journal.pone.0076247. eCollection 2013.
• [2240] Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling.Breast Cancer Res Treat. 2013 Nov;142(2):271-82. doi: 10.1007/s10549-013-2735-3. Epub 2013 Oct 29.
• [2241] Cadherin-23 mediates heterotypic cell-cell adhesion between breast cancer epithelial cells and fibroblasts.PLoS One. 2012;7(3):e33289. doi: 10.1371/journal.pone.0033289. Epub 2012 Mar 7.
• [2242] H3K27me3 loss plays a vital role in CEMIP mediated carcinogenesis and progression of breast cancer with poor prognosis.Biomed Pharmacother. 2020 Mar;123:109728. doi: 10.1016/j.biopha.2019.109728. Epub 2019 Dec 14.
• [2243] Elevated expression of the centromere protein-A(CENP-A)-encoding gene as a prognostic and predictive biomarker in human cancers.Int J Cancer. 2016 Aug 15;139(4):899-907. doi: 10.1002/ijc.30133. Epub 2016 Apr 21.
• [2244] Long noncoding RNA CERS6-AS1 functions as a malignancy promoter in breast cancer by binding to IGF2BP3 to enhance the stability of CERS6 mRNA.Cancer Med. 2020 Jan;9(1):278-289. doi: 10.1002/cam4.2675. Epub 2019 Nov 8.
• [2245] Design and synthesis of substituted dihydropyrimidinone derivatives as cytotoxic and tubulin polymerization inhibitors.Bioorg Chem. 2019 Dec;93:103317. doi: 10.1016/j.bioorg.2019.103317. Epub 2019 Sep 26.
• [2246] Apatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer: Case report and literature review.Medicine (Baltimore). 2018 Apr;97(15):e0349. doi: 10.1097/MD.0000000000010349.
• [2247] CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancer.PLoS One. 2017 Aug 3;12(8):e0182107. doi: 10.1371/journal.pone.0182107. eCollection 2017.
• [2248] Loss of CLCA4 promotes epithelial-to-mesenchymal transition in breast cancer cells.PLoS One. 2013 Dec 26;8(12):e83943. doi: 10.1371/journal.pone.0083943. eCollection 2013.
• [2249] HITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancer. Breast Cancer Res Treat. 2014 Jul;146(1):85-97.
• [2250] Genetic polymorphisms in centrobin and Nek2 are associated with breast cancer susceptibility in a Chinese Han population.Breast Cancer Res Treat. 2012 Nov;136(1):241-51. doi: 10.1007/s10549-012-2244-9. Epub 2012 Sep 23.
• [2251] MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion.J Pathol. 2013 Nov;231(3):388-99. doi: 10.1002/path.4248.
• [2252] CRABP2 regulates invasion and metastasis of breast cancer through hippo pathway dependent on ER status.J Exp Clin Cancer Res. 2019 Aug 16;38(1):361. doi: 10.1186/s13046-019-1345-2.
• [2253] Collagen triple helix repeat containing-1 negatively regulated by microRNA-30c promotes cell proliferation and metastasis and indicates poor prognosis in breast cancer.J Exp Clin Cancer Res. 2017 Jul 12;36(1):92. doi: 10.1186/s13046-017-0564-7.
• [2254] Systematic identification of Ctr9 regulome in ER-positive breast cancer.BMC Genomics. 2016 Nov 9;17(1):902. doi: 10.1186/s12864-016-3248-3.
• [2255] Anti-breast Cancer Activity of SPG-56 from Sweet Potato in MCF-7 Bearing Mice in Situ through Promoting Apoptosis and Inhibiting Metastasis.Sci Rep. 2019 Jan 16;9(1):146. doi: 10.1038/s41598-018-29099-x.
• [2256] Overexpressed DAAM1 correlates with metastasis and predicts poor prognosis in breast cancer.Pathol Res Pract. 2020 Mar;216(3):152736. doi: 10.1016/j.prp.2019.152736. Epub 2019 Nov 11.
• [2257] Identification of androgen-responsive microRNAs and androgen-related genes in breast cancer.Anticancer Res. 2013 Nov;33(11):4811-9.
• [2258] Simvastatin downregulates HER2 via upregulation of PEA3 to induce cell death in HER2-positive breast cancer cells.Oncol Res. 2012;20(5-6):187-95. doi: 10.3727/096504013x13589503482699.
• [2259] Evaluation of genetic variants in microRNA biosynthesis genes and risk of breast cancer in Chinese women.Int J Cancer. 2013 Nov;133(9):2216-24. doi: 10.1002/ijc.28237. Epub 2013 Jul 11.
• [2260] Effect of the knockdown of death-associated protein 1 expression on cell adhesion, growth and migration in breast cancer cells.Oncol Rep. 2015 Mar;33(3):1450-8. doi: 10.3892/or.2014.3686. Epub 2014 Dec 22.
• [2261] Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to PK oncolytic activity in melanoma.Gene Ther. 2014 Apr;21(4):371-8. doi: 10.1038/gt.2014.6. Epub 2014 Feb 20.
• [2262] DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia.Cancer Med. 2019 Oct;8(14):6393-6402. doi: 10.1002/cam4.2540. Epub 2019 Sep 4.
• [2263] Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition.Mol Oncol. 2016 Aug;10(7):1008-29. doi: 10.1016/j.molonc.2016.04.001. Epub 2016 Apr 12.
• [2264] Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry.Hum Genet. 2016 Oct;135(10):1145-59. doi: 10.1007/s00439-016-1707-1. Epub 2016 Jul 5.
• [2265] Development of a novel approach, the epigenome-based outlier approach, to identify tumor-suppressor genes silenced by aberrant DNA methylation.Cancer Lett. 2012 Sep 28;322(2):204-12. doi: 10.1016/j.canlet.2012.03.016. Epub 2012 Mar 17.
• [2266] Breast cancer, placenta and pregnancy.Eur J Cancer. 2019 Jul;115:68-78. doi: 10.1016/j.ejca.2019.03.021. Epub 2019 May 20.
• [2267] MiR-548-3p functions as an anti-oncogenic regulator in breast cancer.Biomed Pharmacother. 2015 Oct;75:111-6. doi: 10.1016/j.biopha.2015.07.027. Epub 2015 Aug 18.
• [2268] Extracellular matrix protein 1 recruits moesin to facilitate invadopodia formation and breast cancer metastasis.Cancer Lett. 2018 Nov 28;437:44-55. doi: 10.1016/j.canlet.2018.08.022. Epub 2018 Aug 27.
• [2269] Hypoxia-inducible factor-1 (HIF-1) promotes cap-dependent translation of selective mRNAs through up-regulating initiation factor eIF4E1 in breast cancer cells under hypoxia conditions.J Biol Chem. 2013 Jun 28;288(26):18732-42. doi: 10.1074/jbc.M113.471466. Epub 2013 May 10.
• [2270] Subdivision of molecularly-classified groups by new gene signatures in breast cancer patients.Oncol Rep. 2012 Dec;28(6):2255-63. doi: 10.3892/or.2012.2018. Epub 2012 Sep 5.
• [2271] Development and Evaluation of Antibody Proteomics Technology for Rapid and Comprehensive Identification of Potential Biomarkers and Therapeutic Targets.Biol Pharm Bull. 2018;41(5):663-669. doi: 10.1248/bpb.b17-01041.
• [2272] Estrogen receptor- regulation of microRNA-590 targets FAM171A1-a modifier of breast cancer invasiveness.Oncogenesis. 2019 Jan 9;8(1):5. doi: 10.1038/s41389-018-0113-z.
• [2273] FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice.J Clin Invest. 2012 Sep;122(9):3211-20. doi: 10.1172/JCI60498. Epub 2012 Aug 13.
• [2274] Hereditary truncating mutations of DNA repair and other genes in BRCA1/BRCA2/PALB2-negatively tested breast cancer patients.Clin Genet. 2016 Oct;90(4):324-33. doi: 10.1111/cge.12748. Epub 2016 Mar 4.
• [2275] Fibulin-2 is required for basement membrane integrity of mammary epithelium.Sci Rep. 2018 Sep 20;8(1):14139. doi: 10.1038/s41598-018-32507-x.
• [2276] FBP1 modulates cell metabolism of breast cancer cells by inhibiting the expression of HIF-1.Neoplasma. 2017;64(4):535-542. doi: 10.4149/neo_2017_407.
• [2277] A comparison of the inhibitory effect of nano-encapsulated helenalin and free helenalin on telomerase gene expression in the breast cancer cell line, by real-time PCR.Artif Cells Nanomed Biotechnol. 2016;44(2):695-703. doi: 10.3109/21691401.2014.981270. Epub 2014 Dec 1.
• [2278] Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation.Cell Mol Life Sci. 2020 Jul;77(13):2605-2620. doi: 10.1007/s00018-019-03306-y. Epub 2019 Sep 27.
• [2279] Differential 12-O-Tetradecanoylphorbol-13-acetate-induced activation of rat mammary carcinoma susceptibility Fbxo10 variant promoters via a PKC-AP1 pathway.Mol Carcinog. 2015 Feb;54(2):134-47. doi: 10.1002/mc.22081. Epub 2013 Sep 5.
• [2280] Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21737-42. doi: 10.1073/pnas.1007863107. Epub 2010 Nov 22.
• [2281] Suppression of estrogen receptor-alpha transactivation by thyroid transcription factor-2 in breast cancer cells.Biochem Biophys Res Commun. 2012 May 11;421(3):532-7. doi: 10.1016/j.bbrc.2012.04.039. Epub 2012 Apr 13.
• [2282] Transcriptional repression of AIB1 by FoxG1 leads to apoptosis in breast cancer cells.Mol Endocrinol. 2013 Jul;27(7):1113-27. doi: 10.1210/me.2012-1353. Epub 2013 May 9.
• [2283] FOXN2 is downregulated in breast cancer and regulates migration, invasion, and epithelial- mesenchymal transition through regulation of SLUG.Cancer Manag Res. 2019 Jan 4;11:525-535. doi: 10.2147/CMAR.S176938. eCollection 2019.
• [2284] Transcription Factors in Breast Cancer-Lessons From Recent Genomic Analyses and Therapeutic Implications.Adv Protein Chem Struct Biol. 2017;107:223-273. doi: 10.1016/bs.apcsb.2016.10.003. Epub 2016 Dec 12.
• [2285] The autophagy GABARAPL1 gene is epigenetically regulated in breast cancer models.BMC Cancer. 2015 Oct 17;15:729. doi: 10.1186/s12885-015-1761-4.
• [2286] GABARAPL1 tumor suppressive function is independent of its conjugation to autophagosomes in MCF-7 breast cancer cells.Oncotarget. 2017 Jul 27;8(34):55998-56020. doi: 10.18632/oncotarget.19639. eCollection 2017 Aug 22.
• [2287] GALNT6 Promotes Tumorigenicity and Metastasis of Breast Cancer Cell via -catenin/MUC1-C Signaling Pathway.Int J Biol Sci. 2019 Jan 1;15(1):169-182. doi: 10.7150/ijbs.29048. eCollection 2019.
• [2288] Pseudopodium-enriched atypical kinase 1 mediates angiogenesis by modulating GATA2-dependent VEGFR2 transcription.Cell Discov. 2018 May 29;4:26. doi: 10.1038/s41421-018-0024-3. eCollection 2018.
• [2289] Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.NMR Biomed. 2012 Sep;25(9):1033-42. doi: 10.1002/nbm.2766. Epub 2012 Jan 26.
• [2290] Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer.Oncotarget. 2018 May 1;9(33):22960-22975. doi: 10.18632/oncotarget.25160. eCollection 2018 May 1.
• [2291] GINS2 regulates cell proliferation and apoptosis in human epithelial ovarian cancer.Oncol Lett. 2018 Aug;16(2):2591-2598. doi: 10.3892/ol.2018.8944. Epub 2018 Jun 11.
• [2292] GLS2 is protumorigenic in breast cancers.Oncogene. 2020 Jan;39(3):690-702. doi: 10.1038/s41388-019-1007-z. Epub 2019 Sep 20.
• [2293] Loss of GM130 in breast cancer cells and its effects on cell migration, invasion and polarity.Cell Cycle. 2015;14(8):1139-47. doi: 10.1080/15384101.2015.1007771.
• [2294] Gpn3 Is Essential for Cell Proliferation of Breast Cancer Cells Independent of Their Malignancy Degree.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819870823. doi: 10.1177/1533033819870823.
• [2295] GPRC5A exerts its tumor-suppressive effects in breast cancer cells by inhibiting EGFR and its downstream pathway.Oncol Rep. 2016 Nov;36(5):2983-2990. doi: 10.3892/or.2016.5062. Epub 2016 Sep 2.
• [2296] Oxygen sensor FIH inhibits HACE1-dependent ubiquitination of Rac1 to enhance metastatic potential in breast cancer cells.Oncogene. 2019 May;38(19):3651-3666. doi: 10.1038/s41388-019-0676-y. Epub 2019 Jan 18.
• [2297] HAP1 gene expression is associated with radiosensitivity in breast cancer cells.Biochem Biophys Res Commun. 2015 Jan 2;456(1):162-6. doi: 10.1016/j.bbrc.2014.11.052. Epub 2014 Nov 22.
• [2298] DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer.Nat Commun. 2018 Jan 16;9(1):248. doi: 10.1038/s41467-017-02630-w.
• [2299] CTLA-4 polymorphisms associate with breast cancer susceptibility in Asians: a meta-analysis.PeerJ. 2017 Jan 10;5:e2815. doi: 10.7717/peerj.2815. eCollection 2017.
• [2300] Heterogenous ribonucleoprotein A18 (hnRNP A18) promotes tumor growth by increasing protein translation of selected transcripts in cancer cells.Oncotarget. 2016 Mar 1;7(9):10578-93. doi: 10.18632/oncotarget.7020.
• [2301] A long-range interactive DNA methylation marker panel for the promoters of HOXA9 and HOXA10 predicts survival in breast cancer patients.Clin Epigenetics. 2017 Jul 24;9:73. doi: 10.1186/s13148-017-0373-z. eCollection 2017.
• [2302] Targeting the HOX/PBX dimer in breast cancer.Breast Cancer Res Treat. 2012 Nov;136(2):389-98. doi: 10.1007/s10549-012-2259-2. Epub 2012 Sep 30.
• [2303] Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen.Epigenetics. 2012 Jul;7(7):701-9. doi: 10.4161/epi.20445. Epub 2012 Jul 1.
• [2304] HtrA4 Protease Promotes Chemotherapeutic-Dependent Cancer Cell Death.Cells. 2019 Sep 20;8(10):1112. doi: 10.3390/cells8101112.
• [2305] Clinicopathological and biological significance of human voltage-gated proton channel Hv1 protein overexpression in breast cancer.J Biol Chem. 2012 Apr 20;287(17):13877-88. doi: 10.1074/jbc.M112.345280. Epub 2012 Feb 24.
• [2306] Role of HYAL1 expression in primary breast cancer in the formation of brain metastases.Breast Cancer Res Treat. 2017 Apr;162(3):427-438. doi: 10.1007/s10549-017-4135-6. Epub 2017 Feb 6.
• [2307] Validation of the European Health Literacy Survey Questionnaire in Women With Breast Cancer.Cancer Nurs. 2018 Mar/Apr;41(2):E40-E48. doi: 10.1097/NCC.0000000000000475.
• [2308] Identification of a Novel Invasion-Promoting Region in Insulin Receptor Substrate 2.Mol Cell Biol. 2018 Jun 28;38(14):e00590-17. doi: 10.1128/MCB.00590-17. Print 2018 Jul 15.
• [2309] The Arabian camel, Camelus dromedarius interferon epsilon: Functional expression, in vitro refolding, purification and cytotoxicity on breast cancer cell lines.PLoS One. 2019 Sep 6;14(9):e0213880. doi: 10.1371/journal.pone.0213880. eCollection 2019.
• [2310] Modulation of IFN- receptor 1 expression by AP-2 influences IFN- sensitivity of cancer cells.Am J Pathol. 2012 Feb;180(2):661-71. doi: 10.1016/j.ajpath.2011.10.040. Epub 2011 Dec 16.
• [2311] Upregulation of SHIP2 participates in the development of breast cancer via promoting Wnt/-catenin signaling.Onco Targets Ther. 2019 Aug 30;12:7067-7077. doi: 10.2147/OTT.S223422. eCollection 2019.
• [2312] A Novel Strategy to Investigate Tissue-Secreted Tumor Microenvironmental Proteins in Serum toward Development of Breast Cancer Early Diagnosis Biomarker Signature.Proteomics Clin Appl. 2019 May;13(3):e1700119. doi: 10.1002/prca.201700119. Epub 2018 Oct 18.
• [2313] Integral membrane protein 2A inhibits cell growth in human breast cancer via enhancing autophagy induction.Cell Commun Signal. 2019 Aug 22;17(1):105. doi: 10.1186/s12964-019-0422-7.
• [2314] Intersectin 1 (ITSN1) identified by comprehensive bioinformatic analysis and experimental validation as a key candidate biological target in breast cancer.Onco Targets Ther. 2019 Aug 30;12:7079-7093. doi: 10.2147/OTT.S216286. eCollection 2019.
• [2315] Characterization of Kelch domain-containing protein 7B in breast tumours and breast cancer cell lines.Oncol Lett. 2019 Sep;18(3):2853-2860. doi: 10.3892/ol.2019.10672. Epub 2019 Jul 26.
• [2316] JHDM1B expression regulates ribosome biogenesis and cancer cell growth in a p53 dependent manner.Int J Cancer. 2015 Mar 1;136(5):E272-81. doi: 10.1002/ijc.29240. Epub 2014 Oct 10.
• [2317] KLP-PI: a new prognostic index for luminal B HER-2-negative breast cancer.Hum Cell. 2019 Apr;32(2):172-184. doi: 10.1007/s13577-018-00229-x. Epub 2018 Dec 17.
• [2318] Prognostic and clinicopathological significance of kinesin family member C1 in various cancers: A meta-analysis.Medicine (Baltimore). 2019 Oct;98(40):e17346. doi: 10.1097/MD.0000000000017346.
• [2319] Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cells.Oncotarget. 2016 Dec 20;7(51):84645-84657. doi: 10.18632/oncotarget.13175.
• [2320] Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells.Clin Cancer Res. 2012 Feb 15;18(4):993-1003. doi: 10.1158/1078-0432.CCR-11-2100. Epub 2012 Jan 6.
• [2321] Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1.Breast Cancer Res Treat. 2012 May;133(1):127-35. doi: 10.1007/s10549-011-1716-7. Epub 2011 Aug 12.
• [2322] PINCH-1 interacts with myoferlin to promote breast cancer progression and metastasis.Oncogene. 2020 Mar;39(10):2069-2087. doi: 10.1038/s41388-019-1135-5. Epub 2019 Dec 4.
• [2323] The clinicopathological significance of lamin A/C, lamin B1 and lamin B receptor mRNA expression in human breast cancer.Cell Mol Biol Lett. 2013 Dec;18(4):595-611. doi: 10.2478/s11658-013-0109-9. Epub 2013 Nov 30.
• [2324] Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis.J Mol Med (Berl). 2012 Jul;90(7):803-15. doi: 10.1007/s00109-011-0855-y. Epub 2012 Jan 10.
• [2325] Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.Oncogene. 2016 Mar 3;35(9):1143-52. doi: 10.1038/onc.2015.169. Epub 2015 Jul 6.
• [2326] A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese.Hum Mol Genet. 2012 Apr 1;21(7):1665-72. doi: 10.1093/hmg/ddr597. Epub 2011 Dec 16.
• [2327] Nuclear localization of LDL receptor-related protein 1B in mammary gland carcinogenesis.J Mol Med (Berl). 2019 Feb;97(2):257-268. doi: 10.1007/s00109-018-01732-2. Epub 2019 Jan 3.
• [2328] CAPC negatively regulates NF-B activation and suppresses tumor growth and metastasis.Oncogene. 2012 Mar 29;31(13):1673-82. doi: 10.1038/onc.2011.355. Epub 2011 Aug 8.
• [2329] Versican G1 and G3 domains are upregulated and latent transforming growth factor- binding protein-4 is downregulated in breast cancer stroma.Breast Cancer. 2012 Jan;19(1):46-53. doi: 10.1007/s12282-011-0264-7. Epub 2011 Apr 20.
• [2330] Overexpression of MTA1 inhibits the metastatic ability of ZR-75-30 cells in vitro by promoting MTA2 degradation.Cell Commun Signal. 2019 Jan 14;17(1):4. doi: 10.1186/s12964-019-0318-6.
• [2331] Knockdown of REV7 Inhibits Breast Cancer Cell Migration and Invasion.Oncol Res. 2016;24(5):315-325. doi: 10.3727/096504016X14666990347590.
• [2332] MAML1 regulates EMT markers expression through NOTCH-independent pathway in breast cancer cell line MCF7.Biochem Biophys Res Commun. 2019 Mar 12;510(3):376-382. doi: 10.1016/j.bbrc.2019.01.101. Epub 2019 Feb 4.
• [2333] The role of Runx2 in facilitating autophagy in metastatic breast cancer cells.J Cell Physiol. 2018 Jan;233(1):559-571. doi: 10.1002/jcp.25916. Epub 2017 May 19.
• [2334] Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer.PLoS Genet. 2012;8(2):e1002532. doi: 10.1371/journal.pgen.1002532. Epub 2012 Feb 23.
• [2335] MARCH5 overexpression contributes to tumor growth and metastasis and associates with poor survival in breast cancer.Cancer Manag Res. 2018 Dec 24;11:201-215. doi: 10.2147/CMAR.S190694. eCollection 2019.
• [2336] Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion.Mol Ther. 2012 Dec;20(12):2326-34. doi: 10.1038/mt.2012.201. Epub 2012 Oct 2.
• [2337] Impact of germinal center-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population.Breast Cancer. 2019 Sep;26(5):562-572. doi: 10.1007/s12282-019-00956-5. Epub 2019 Feb 27.
• [2338] Semaphorin signaling via MICAL3 induces symmetric cell division to expand breast cancer stem-like cells.Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):625-630. doi: 10.1073/pnas.1806851116. Epub 2018 Dec 26.
• [2339] HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.J Immunol. 2012 Mar 1;188(5):2136-45. doi: 10.4049/jimmunol.1102237. Epub 2012 Feb 1.
• [2340] Is calcitonin an active hormone in the onset and prevention of hypocalcemia in dairy cattle?.J Dairy Sci. 2016 Apr;99(4):3023-3030. doi: 10.3168/jds.2015-10229. Epub 2016 Feb 3.
• [2341] CRISPR deletion of MIEN1 in breast cancer cells.PLoS One. 2018 Oct 4;13(10):e0204976. doi: 10.1371/journal.pone.0204976. eCollection 2018.
• [2342] MORC4 is a novel breast cancer oncogene regulated by miR-193b-3p.J Cell Biochem. 2019 Mar;120(3):4634-4643. doi: 10.1002/jcb.27751. Epub 2018 Oct 15.
• [2343] Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics.Cell Res. 2015 Jun;25(6):707-25. doi: 10.1038/cr.2015.56. Epub 2015 May 8.
• [2344] Assessment of changes in expression and presentation of NKG2D under influence of MICA serum factor in different stages of breast cancer.Tumour Biol. 2016 May;37(5):6953-62. doi: 10.1007/s13277-015-4584-7. Epub 2015 Dec 11.
• [2345] BRCA1 regulates PIG3-mediated apoptosis in a p53-dependent manner.Oncotarget. 2015 Apr 10;6(10):7608-18. doi: 10.18632/oncotarget.3263.
• [2346] Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer.Oncogene. 2018 Jan 11;37(2):197-207. doi: 10.1038/onc.2017.327. Epub 2017 Sep 11.
• [2347] MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells.Int J Oncol. 2016 May;48(5):2113-23. doi: 10.3892/ijo.2016.3434. Epub 2016 Mar 10.
• [2348] The MicroRNA-382-5p/MXD1 Axis Relates to Breast Cancer Progression and Promotes Cell Malignant Phenotypes.J Surg Res. 2020 Feb;246:442-449. doi: 10.1016/j.jss.2019.09.018. Epub 2019 Oct 18.
• [2349] MYO1D binds with kinase domain of the EGFR family to anchor them to plasma membrane before their activation and contributes carcinogenesis.Oncogene. 2019 Dec;38(49):7416-7432. doi: 10.1038/s41388-019-0954-8. Epub 2019 Aug 16.
• [2350] Myocardin inhibits estrogen receptor alpha-mediated proliferation of human breast cancer MCF-7 cells via regulating MicroRNA expression.IUBMB Life. 2016 Jun;68(6):477-87. doi: 10.1002/iub.1507. Epub 2016 May 9.
• [2351] VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-B and -catenin.Cancer Lett. 2016 Apr 1;373(1):1-11. doi: 10.1016/j.canlet.2016.01.010. Epub 2016 Jan 19.
• [2352] Association between mitochondrial genetic variation and breast cancer risk: The Multiethnic Cohort.PLoS One. 2019 Oct 2;14(10):e0222284. doi: 10.1371/journal.pone.0222284. eCollection 2019.
• [2353] Necdin is a breast cancer metastasis suppressor that regulates the transcription of c-Myc.Oncotarget. 2015 Oct 13;6(31):31557-68. doi: 10.18632/oncotarget.5230.
• [2354] The expression of the Nectin complex in human breast cancer and the role of Nectin-3 in the control of tight junctions during metastasis.PLoS One. 2013 Dec 26;8(12):e82696. doi: 10.1371/journal.pone.0082696. eCollection 2013.
• [2355] T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients.Oncoimmunology. 2019 Sep 30;8(12):e1663107. doi: 10.1080/2162402X.2019.1663107. eCollection 2019.
• [2356] Overexpression of neogenin inhibits cell proliferation and induces apoptosis in human MDA-MB-231 breast carcinoma cells.Oncol Rep. 2015 Jul;34(1):258-64. doi: 10.3892/or.2015.4004. Epub 2015 May 22.
• [2357] miR-151-3p Targets TWIST1 to Repress Migration of Human Breast Cancer Cells.PLoS One. 2016 Dec 8;11(12):e0168171. doi: 10.1371/journal.pone.0168171. eCollection 2016.
• [2358] Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer.Breast Cancer Res. 2012 Oct 26;14(5):R138. doi: 10.1186/bcr3343.
• [2359] Effects of the ninein-like protein centrosomal protein on breast cancer cell invasion and migration.Mol Med Rep. 2015 Aug;12(2):1659-64. doi: 10.3892/mmr.2015.3650. Epub 2015 Apr 20.
• [2360] Nemo-like kinase associated with proliferation and apoptosis by c-Myb degradation in breast cancer.PLoS One. 2013 Jul 23;8(7):e69148. doi: 10.1371/journal.pone.0069148. Print 2013.
• [2361] siRNA mediated silencing of NIN1/RPN12 binding protein 1 homolog inhibits proliferation and growth of breast cancer cells.Asian Pac J Cancer Prev. 2012;13(5):1823-7. doi: 10.7314/apjcp.2012.13.5.1823.
• [2362] Folic acid-functionalized graphene oxide nanosheets via plasma etching as a platform to combine NIR anticancer phototherapy and targeted drug delivery.Mater Sci Eng C Mater Biol Appl. 2020 Feb;107:110201. doi: 10.1016/j.msec.2019.110201. Epub 2019 Sep 13.
• [2363] RNA-binding protein NONO promotes breast cancer proliferation by post-transcriptional regulation of SKP2 and E2F8.Cancer Sci. 2020 Jan;111(1):148-159. doi: 10.1111/cas.14240. Epub 2019 Dec 11.
• [2364] Nephronectin is Correlated with Poor Prognosis in Breast Cancer and Promotes Metastasis via its Integrin-Binding Motifs.Neoplasia. 2018 Apr;20(4):387-400. doi: 10.1016/j.neo.2018.02.008. Epub 2018 Mar 11.
• [2365] Breast cancer and synchronous multiple myeloma as a diagnostic challenge: Case report and review of literature.Curr Probl Cancer. 2018 Mar-Apr;42(2):231-234. doi: 10.1016/j.currproblcancer.2017.11.001. Epub 2017 Nov 22.
• [2366] Influence of genomic variation in FTO at 16q12.2, MC4R at 18q22 and NRXN3 at 14q31 genes on breast cancer risk.Mol Biol Rep. 2012 Mar;39(3):2915-9. doi: 10.1007/s11033-011-1053-2. Epub 2011 Jun 19.
• [2367] Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3.Breast Cancer Res Treat. 2017 Jul;164(2):349-358. doi: 10.1007/s10549-017-4258-9. Epub 2017 May 8.
• [2368] Cytokeratin 19 (KRT19) has a Role in the Reprogramming of Cancer Stem Cell-Like Cells to Less Aggressive and More Drug-Sensitive Cells.Int J Mol Sci. 2018 May 9;19(5):1423. doi: 10.3390/ijms19051423.
• [2369] ODAM inhibits RhoA-dependent invasion in breast cancer.Cell Biochem Funct. 2015 Oct;33(7):451-61. doi: 10.1002/cbf.3132. Epub 2015 Sep 10.
• [2370] Gene expression of O-GlcNAc cycling enzymes in human breast cancers.Clin Exp Med. 2012 Mar;12(1):61-5. doi: 10.1007/s10238-011-0138-5. Epub 2011 May 13.
• [2371] Effective Antiemetic Therapy Is Important With Adjuvant Anthracycline-based Chemotherapy in Breast Cancer.Anticancer Res. 2019 Jan;39(1):279-283. doi: 10.21873/anticanres.13108.
• [2372] Identifying genes with tri-modal association with survival and tumor grade in cancer patients.BMC Bioinformatics. 2019 Jan 8;20(1):13. doi: 10.1186/s12859-018-2582-7.
• [2373] Genome-wide identification of OTP gene as a novel methylation marker of breast cancer.Oncol Rep. 2012 May;27(5):1681-8. doi: 10.3892/or.2012.1691. Epub 2012 Feb 17.
• [2374] Suppression of mitochondrial respiration with local anesthetic ropivacaine targets breast cancer cells.J Thorac Dis. 2018 May;10(5):2804-2812. doi: 10.21037/jtd.2018.05.21.
• [2375] The role of PAQR3 gene promoter hypermethylation in breast cancer and prognosis.Oncol Rep. 2016 Sep;36(3):1612-8. doi: 10.3892/or.2016.4951. Epub 2016 Jul 19.
• [2376] circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer.Oncogene. 2019 Oct;38(42):6850-6866. doi: 10.1038/s41388-019-0926-z. Epub 2019 Aug 12.
• [2377] KIAA0101 inhibition suppresses cell proliferation and cell cycle progression by promoting the interaction between p53 and Sp1 in breast cancer.Biochem Biophys Res Commun. 2018 Sep 5;503(2):600-606. doi: 10.1016/j.bbrc.2018.06.046. Epub 2018 Jun 15.
• [2378] The influence of socio-cultural factors on breast cancer screening behaviors in Lagos, Nigeria.Ethn Health. 2019 Jul;24(5):544-559. doi: 10.1080/13557858.2017.1348489. Epub 2017 Jul 5.
• [2379] Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis.EMBO Rep. 2015 Oct;16(10):1394-408. doi: 10.15252/embr.201540107. Epub 2015 Aug 31.
• [2380] Recombinant human PDCD5 protein enhances chemosensitivity of breast cancer in vitro and in vivo.Biochem Cell Biol. 2013 Dec;91(6):526-31. doi: 10.1139/bcb-2013-0052. Epub 2013 Sep 13.
• [2381] Autoantibodies against TYMS and PDLIM1 proteins detected as circulatory signatures in Indian breast cancer patients.Proteomics Clin Appl. 2016 May;10(5):564-73. doi: 10.1002/prca.201500138.
• [2382] APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer.EMBO J. 2012 Mar 7;31(5):1160-76. doi: 10.1038/emboj.2011.490. Epub 2012 Jan 31.
• [2383] Detection of early breast cancer beyond mammographic screening: a promising biomarker panel.Biomark Med. 2019 Sep;13(13):1107-1117. doi: 10.2217/bmm-2019-0085. Epub 2019 Aug 30.
• [2384] Parkinson's disease genes do not segregate with breast cancer genes' loci.Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1464-72. doi: 10.1158/1055-9965.EPI-13-0472. Epub 2013 Jun 13.
• [2385] PIR promotes tumorigenesis of breast cancer by upregulating cell cycle activator E2F1.Cell Cycle. 2019 Nov;18(21):2914-2927. doi: 10.1080/15384101.2019.1662259. Epub 2019 Sep 10.
• [2386] A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density.Breast Cancer Res. 2015 Aug 16;17(1):110. doi: 10.1186/s13058-015-0625-9.
• [2387] Novel inhibitors induce large conformational changes of GAB1 pleckstrin homology domain and kill breast cancer cells.PLoS Comput Biol. 2015 Jan 8;11(1):e1004021. doi: 10.1371/journal.pcbi.1004021. eCollection 2015 Jan.
• [2388] Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers.Cancers (Basel). 2019 May 28;11(6):738. doi: 10.3390/cancers11060738.
• [2389] A Novel lncRNA HOXC-AS3 Acts as a miR-3922-5p Sponge to Promote Breast Cancer Metastasis.Cancer Invest. 2020 Jan;38(1):1-12. doi: 10.1080/07357907.2019.1695816. Epub 2019 Dec 4.
• [2390] Protein Phosphatase 1 Regulatory Subunit SDS22 Inhibits Breast Cancer Cell Tumorigenesis by Functioning as a Negative Regulator of the AKT Signaling Pathway.Neoplasia. 2019 Jan;21(1):30-40. doi: 10.1016/j.neo.2018.10.009. Epub 2018 Nov 27.
• [2391] Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer.BMC Cancer. 2015 Apr 15;15:285. doi: 10.1186/s12885-015-1266-1.
• [2392] High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma.Mol Cancer. 2015 Apr 28;14:95. doi: 10.1186/s12943-015-0356-7.
• [2393] Silencing PRDM14 via Oligonucleotide Therapeutics Suppresses Tumorigenicity and Metastasis of Breast Cancer.Methods Mol Biol. 2019;1974:233-243. doi: 10.1007/978-1-4939-9220-1_18.
• [2394] Identification of a functional estrogen-responsive enhancer element in the promoter 2 of PRDM2 gene in breast cancer cell lines.J Cell Physiol. 2012 Mar;227(3):964-75. doi: 10.1002/jcp.22803.
• [2395] P-Rex1 and P-Rex2 RacGEFs and cancer.Biochem Soc Trans. 2017 Aug 15;45(4):963-77. doi: 10.1042/BST20160269. Epub 2017 Jul 14.
• [2396] Protein arginine N-methyltransferase2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-36.Oncol Rep. 2018 Jun;39(6):2604-2612. doi: 10.3892/or.2018.6350. Epub 2018 Apr 2.
• [2397] PRPF4 is a novel therapeutic target for the treatment of breast cancer by influencing growth, migration, invasion, and apoptosis of breast cancer cells via p38 MAPK signaling pathway.Mol Cell Probes. 2019 Oct;47:101440. doi: 10.1016/j.mcp.2019.101440. Epub 2019 Aug 22.
• [2398] Silencing of Prrx2 Inhibits the Invasion and Metastasis of Breast Cancer both In Vitro and In Vivo by Reversing Epithelial-Mesenchymal Transition.Cell Physiol Biochem. 2017;42(5):1847-1856. doi: 10.1159/000479542. Epub 2017 Jul 27.
• [2399] Serine protease PRSS23 is upregulated by estrogen receptor and associated with proliferation of breast cancer cells.PLoS One. 2012;7(1):e30397. doi: 10.1371/journal.pone.0030397. Epub 2012 Jan 23.
• [2400] Touch imprint cytology with massively parallel sequencing (TIC-seq): a simple and rapid method to snapshot genetic alterations in tumors.Cancer Med. 2016 Dec;5(12):3426-3436. doi: 10.1002/cam4.950. Epub 2016 Oct 24.
• [2401] Knockdown of PSMC3IP suppresses the proliferation and xenografted tumorigenesis of hepatocellular carcinoma cell.J Cell Biochem. 2019 Apr;120(4):5449-5458. doi: 10.1002/jcb.27824. Epub 2018 Oct 25.
• [2402] Protein tyrosine phosphatase (PTP or PTPRM), a negative regulator of proliferation and invasion of breast cancer cells, is associated with disease prognosis.PLoS One. 2012;7(11):e50183. doi: 10.1371/journal.pone.0050183. Epub 2012 Nov 20.
• [2403] PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2.Oncogene. 2017 Jan 19;36(3):410-422. doi: 10.1038/onc.2016.213. Epub 2016 Jun 27.
• [2404] Identification of lncRNA TRPM2-AS/miR-140-3p/PYCR1 axis's proliferates and anti-apoptotic effect on breast cancer using co-expression network analysis.Cancer Biol Ther. 2019;20(6):760-773. doi: 10.1080/15384047.2018.1564563. Epub 2019 Feb 27.
• [2405] Breast cancers utilize hypoxic glycogen stores via PYGB, the brain isoform of glycogen phosphorylase, to promote metastatic phenotypes.PLoS One. 2019 Sep 19;14(9):e0220973. doi: 10.1371/journal.pone.0220973. eCollection 2019.
• [2406] The emerging role of QSOX1 in cancer.Antioxid Redox Signal. 2014 Jul 20;21(3):485-96. doi: 10.1089/ars.2013.5572. Epub 2014 Feb 19.
• [2407] Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-/SMAD signaling.Oncotarget. 2015 Jun 30;6(18):16352-65. doi: 10.18632/oncotarget.3877.
• [2408] RAB2A controls MT1-MMP endocytic and E-cadherin polarized Golgi trafficking to promote invasive breast cancer programs.EMBO Rep. 2016 Jul;17(7):1061-80. doi: 10.15252/embr.201642032. Epub 2016 Jun 2.
• [2409] RBM10 truncation in astroblastoma in a patient with history of mandibular ameloblastoma: A case report.Cancer Genet. 2019 Feb;231-232:41-45. doi: 10.1016/j.cancergen.2019.01.001. Epub 2019 Jan 9.
• [2410] A novel role for an RCAN3-derived peptide as a tumor suppressor in breast cancer.Carcinogenesis. 2015 Jul;36(7):792-9. doi: 10.1093/carcin/bgv056. Epub 2015 Apr 26.
• [2411] Downregulated PIRH2 Can Decrease the Proliferation of Breast Cancer Cells.Arch Med Res. 2016 Apr;47(3):186-95. doi: 10.1016/j.arcmed.2016.06.004. Epub 2016 Jul 6.
• [2412] RECQL4 helicase has oncogenic potential in sporadic breast cancers.J Pathol. 2016 Mar;238(4):495-501. doi: 10.1002/path.4681. Epub 2016 Feb 2.
• [2413] Human REV3 DNA Polymerase Zeta Localizes to Mitochondria and Protects the Mitochondrial Genome.PLoS One. 2015 Oct 13;10(10):e0140409. doi: 10.1371/journal.pone.0140409. eCollection 2015.
• [2414] Mitogen-inducible Gene-2 (MIG2) and migfilin expression is reduced in samples of human breast cancer.Anticancer Res. 2013 May;33(5):1977-81.
• [2415] Synergistic inhibition of aggressive breast cancer cell migration and invasion by cytoplasmic delivery of anti-RhoC silencing RNA and presentation of EPPT1 peptide on "smart" particles.J Control Release. 2018 Nov 10;289:79-93. doi: 10.1016/j.jconrel.2018.07.042. Epub 2018 Aug 24.
• [2416] shRNA mediated RHOXF1 silencing influences expression of BCL2 but not CASP8 in MCF-7 and MDA-MB-231 cell lines.Asian Pac J Cancer Prev. 2012;13(11):5865-9. doi: 10.7314/apjcp.2012.13.11.5865.
• [2417] RILPL2 regulates breast cancer proliferation, metastasis, and chemoresistance via the TUBB3/PTEN pathway.Am J Cancer Res. 2019 Aug 1;9(8):1583-1606. eCollection 2019.
• [2418] Crosstalks of the PTPIP51 interactome revealed in Her2 amplified breast cancer cells by the novel small molecule LDC3/Dynarrestin.PLoS One. 2019 May 10;14(5):e0216642. doi: 10.1371/journal.pone.0216642. eCollection 2019.
• [2419] RNF144A functions as a tumor suppressor in breast cancer through ubiquitin ligase activity-dependent regulation of stability and oncogenic functions of HSPA2.Cell Death Differ. 2020 Mar;27(3):1105-1118. doi: 10.1038/s41418-019-0400-z. Epub 2019 Aug 13.
• [2420] Pre-diagnostic derivatives of reactive oxygen metabolites and the occurrence of lung, colorectal, breast and prostate cancer: An individual participant data meta-analysis of two large population-based studies.Int J Cancer. 2019 Jul 1;145(1):49-57. doi: 10.1002/ijc.32073. Epub 2019 Jan 5.
• [2421] DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA.Oncotarget. 2016 Sep 27;7(39):64191-64202. doi: 10.18632/oncotarget.11640.
• [2422] Effect of RRS1 gene knockdown on BT549 cell line proliferation and apoptosis in breast cancer.Neoplasma. 2019 Jan 15;66(1):28-32. doi: 10.4149/neo_2018_171229N853. Epub 2018 Aug 9.
• [2423] Inhibition of Breast Cancer Cell Invasion by Ras Suppressor-1 (RSU-1) Silencing Is Reversed by Growth Differentiation Factor-15 (GDF-15).Int J Mol Sci. 2019 Jan 4;20(1):163. doi: 10.3390/ijms20010163.
• [2424] Long noncoding RNA RUSC1ASN promotes cell proliferation and metastasis through Wnt/catenin signaling in human breast cancer.Mol Med Rep. 2019 Feb;19(2):861-868. doi: 10.3892/mmr.2018.9763. Epub 2018 Dec 14.
• [2425] Co-expression of S100A14 and S100A16 correlates with a poor prognosis in human breast cancer and promotes cancer cell invasion.BMC Cancer. 2015 Feb 13;15:53. doi: 10.1186/s12885-015-1059-6.
• [2426] Knockdown of sal-like 4 expression by small interfering RNA induces apoptosis in breast cancer cells.J Cell Biochem. 2019 Jun;120(6):9392-9399. doi: 10.1002/jcb.28214. Epub 2018 Dec 5.
• [2427] Inhibition of RIF1 by SCAI Allows BRCA1-Mediated Repair.Cell Rep. 2017 Jul 11;20(2):297-307. doi: 10.1016/j.celrep.2017.06.056.
• [2428] The histone demethylase LSD1 is required for estrogen-dependent S100A7 gene expression in human breast cancer cells.Biochem Biophys Res Commun. 2012 Oct 19;427(2):336-42. doi: 10.1016/j.bbrc.2012.09.057. Epub 2012 Sep 18.
• [2429] The 811 C/T polymorphism in the 3' untranslated region of the selenoprotein 15-kDa (Sep15) gene and breast cancer in Caucasian women.Tumour Biol. 2016 Jan;37(1):1009-15. doi: 10.1007/s13277-015-3847-7. Epub 2015 Aug 12.
• [2430] SEPP1 influences breast cancer risk among women with greater native american ancestry: the breast cancer health disparities study.PLoS One. 2013 Nov 20;8(11):e80554. doi: 10.1371/journal.pone.0080554. eCollection 2013.
• [2431] Analysis of SEMA6B gene expression in breast cancer: identification of a new isoform.Biochim Biophys Acta. 2013 Oct;1830(10):4543-53. doi: 10.1016/j.bbagen.2013.05.003. Epub 2013 May 9.
• [2432] The Vitamin D Analog, MART-10, Attenuates Triple Negative Breast Cancer Cells Metastatic Potential.Int J Mol Sci. 2016 Apr 21;17(4):606. doi: 10.3390/ijms17040606.
• [2433] DNA homologous recombination factor SFR1 physically and functionally interacts with estrogen receptor alpha.PLoS One. 2013 Jul 9;8(7):e68075. doi: 10.1371/journal.pone.0068075. Print 2013.
• [2434] A novel somatic mutation of SIN3A detected in breast cancer by whole-exome sequencing enhances cell proliferation through ER expression.Sci Rep. 2018 Oct 30;8(1):16000. doi: 10.1038/s41598-018-34290-1.
• [2435] Recruitment of the Mammalian Histone-modifying EMSY Complex to Target Genes Is Regulated by ZNF131.J Biol Chem. 2016 Apr 1;291(14):7313-24. doi: 10.1074/jbc.M115.701227. Epub 2016 Feb 3.
• [2436] SIRT7 depletion inhibits cell proliferation, migration, and increases drug sensitivity by activating p38MAPK in breast cancer cells.J Cell Physiol. 2018 Sep;233(9):6767-6778. doi: 10.1002/jcp.26398. Epub 2018 Mar 25.
• [2437] Identification of hub genes to regulate breast cancer metastasis to brain by bioinformatics analyses.J Cell Biochem. 2019 Jun;120(6):9522-9531. doi: 10.1002/jcb.28228. Epub 2018 Dec 3.
• [2438] BRUCE regulates DNA double-strand break response by promoting USP8 deubiquitination of BRIT1.Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1210-9. doi: 10.1073/pnas.1418335112. Epub 2015 Mar 2.
• [2439] Overexpression of SMARCA5 correlates with cell proliferation and migration in breast cancer.Tumour Biol. 2015 Mar;36(3):1895-902. doi: 10.1007/s13277-014-2791-2. Epub 2014 Nov 7.
• [2440] TP53 upregulates smooth muscle actin expression in tamoxifenresistant breast cancer cells.Oncol Rep. 2019 Feb;41(2):1075-1082. doi: 10.3892/or.2018.6910. Epub 2018 Dec 6.
• [2441] USF2 inhibits the transcriptional activity of Smurf1 and Smurf2 to promote breast cancer tumorigenesis.Cell Signal. 2019 Jan;53:49-58. doi: 10.1016/j.cellsig.2018.09.013. Epub 2018 Sep 21.
• [2442] Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy.Cancer Res. 2013 Apr 1;73(7):2247-58. doi: 10.1158/0008-5472.CAN-12-2501. Epub 2013 Jan 28.
• [2443] Inhibition of SNW1 association with spliceosomal proteins promotes apoptosis in breast cancer cells.Cancer Med. 2015 Feb;4(2):268-77. doi: 10.1002/cam4.366. Epub 2014 Dec 1.
• [2444] MAST2 and NOTCH1 translocations in breast carcinoma and associated pre-invasive lesions.Hum Pathol. 2013 Dec;44(12):2837-44. doi: 10.1016/j.humpath.2013.08.001. Epub 2013 Oct 18.
• [2445] Sperm-associated antigen 9 (SPAG9) promotes the survival and tumor growth of triple-negative breast cancer cells.Tumour Biol. 2016 Oct;37(10):13101-13110. doi: 10.1007/s13277-016-5240-6. Epub 2016 Jul 23.
• [2446] Up-regulation of SPC25 promotes breast cancer.Aging (Albany NY). 2019 Aug 10;11(15):5689-5704. doi: 10.18632/aging.102153. Epub 2019 Aug 10.
• [2447] Genetic polymorphisms and protein expression of NRF2 and Sulfiredoxin predict survival outcomes in breast cancer.Cancer Res. 2012 Nov 1;72(21):5537-46. doi: 10.1158/0008-5472.CAN-12-1474. Epub 2012 Sep 10.
• [2448] Heparan sulfate mediates trastuzumab effect in breast cancer cells.BMC Cancer. 2013 Oct 1;13:444. doi: 10.1186/1471-2407-13-444.
• [2449] Rescue of tropomyosin deficiency in Drosophila and human cancer cells by synaptopodin reveals a role of tropomyosin in RhoA stabilization.EMBO J. 2012 Feb 15;31(4):1028-40. doi: 10.1038/emboj.2011.464. Epub 2011 Dec 13.
• [2450] Efficient downregulation of ErbB-2 induces TACC1 upregulation in breast cancer cell lines.Oncol Rep. 2013 Apr;29(4):1517-23. doi: 10.3892/or.2013.2253. Epub 2013 Jan 24.
• [2451] Ranked retrieval of segmented nuclei for objective assessment of cancer gene repositioning.BMC Bioinformatics. 2012 Sep 12;13:232. doi: 10.1186/1471-2105-13-232.
• [2452] Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer.Sci Rep. 2017 Jul 7;7(1):4846. doi: 10.1038/s41598-017-05129-y.
• [2453] Bisphenol S induced epigenetic and transcriptional changes in human breast cancer cell line MCF-7.Environ Pollut. 2019 Mar;246:697-703. doi: 10.1016/j.envpol.2018.12.084. Epub 2018 Dec 31.
• [2454] Conjugated linoleic acid (CLA) inhibits expression of the Spot 14 (THRSP) and fatty acid synthase genes and impairs the growth of human breast cancer and liposarcoma cells.Nutr Cancer. 2009;61(1):114-22. doi: 10.1080/01635580802348666.
• [2455] Expression of THSD7A in neoplasm tissues and its relationship with proteinuria.BMC Nephrol. 2019 Aug 23;20(1):332. doi: 10.1186/s12882-019-1489-5.
• [2456] TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells.BMC Cancer. 2012 Sep 6;12:391. doi: 10.1186/1471-2407-12-391.
• [2457] A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis.Breast Cancer Res. 2013 Dec 13;15(6):R116. doi: 10.1186/bcr3585.
• [2458] Thymopoietin Beta and Gamma Isoforms as a Potential Diagnostic Molecular Marker for Breast Cancer: Preliminary Data.Pathol Oncol Res. 2015 Sep;21(4):1045-50. doi: 10.1007/s12253-015-9907-x. Epub 2015 Apr 4.
• [2459] Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients.J Mol Med (Berl). 2019 Aug;97(8):1155-1167. doi: 10.1007/s00109-019-01805-w. Epub 2019 Jun 10.
• [2460] DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA.J Biol Chem. 2020 Jan 10;295(2):645-656. doi: 10.1074/jbc.RA119.011929. Epub 2019 Dec 5.
• [2461] TRIM14 Promotes Breast Cancer Cell Proliferation by Inhibiting Apoptosis.Oncol Res. 2019 Mar 29;27(4):439-447. doi: 10.3727/096504018X15214994641786. Epub 2018 Mar 21.
• [2462] High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients.Cancer Lett. 2016 May 1;374(2):315-23. doi: 10.1016/j.canlet.2016.02.021. Epub 2016 Feb 20.
• [2463] Down-regulation of tripartite-motif containing 22 expression in breast cancer is associated with a lack of p53-mediated induction.Biochem Biophys Res Commun. 2013 Nov 22;441(3):600-6. doi: 10.1016/j.bbrc.2013.10.110. Epub 2013 Oct 29.
• [2464] A novel oncogene TRIM63 promotes cell proliferation and migration via activating Wnt/-catenin signaling pathway in breast cancer.Pathol Res Pract. 2019 Oct;215(10):152573. doi: 10.1016/j.prp.2019.152573. Epub 2019 Jul 31.
• [2465] Inhibition of the aberrant A1CF-FAM224A-miR-590-3p-ZNF143 positive feedback loop attenuated malignant biological behaviors of glioma cells.J Exp Clin Cancer Res. 2019 Jun 11;38(1):248. doi: 10.1186/s13046-019-1200-5.
• [2466] An immunochemical analysis of mdm2 expression in human breast cancer and the identification of a growth-regulated cross-reacting species p170.J Pathol. 1998 Nov;186(3):254-61. doi: 10.1002/(SICI)1096-9896(1998110)186:3<254::AID-PATH185>3.0.CO;2-U.
• [2467] Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment.PLoS One. 2011;6(11):e27355. doi: 10.1371/journal.pone.0027355. Epub 2011 Nov 4.
• [2468] The biogenesis and biological functions of circular RNAs and their molecular diagnostic values in cancers.J Clin Lab Anal. 2020 Jan;34(1):e23049. doi: 10.1002/jcla.23049. Epub 2019 Sep 25.
• [2469] MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer.Proc Natl Acad Sci U S A. 2002 May 14;99(10):6997-7002. doi: 10.1073/pnas.102187299.
• [2470] Dual inhibition of ABCE1 and LCP1 by microRNA-96 results in an additive effect in breast cancer mouse model.Oncotarget. 2019 Mar 12;10(21):2086-2094. doi: 10.18632/oncotarget.26747. eCollection 2019 Mar 12.
• [2471] Expression of Abl interactor 1 and its prognostic significance in breast cancer: a tissue-array-based investigation.Breast Cancer Res Treat. 2011 Sep;129(2):373-86. doi: 10.1007/s10549-010-1241-0. Epub 2010 Nov 3.
• [2472] Functionalization of nanotextured substrates for enhanced identification of metastatic breast cancer cells.Nanotechnology. 2017 Sep 20;28(38):385101. doi: 10.1088/1361-6528/aa7f84. Epub 2017 Jul 13.
• [2473] Increased risk of breast cancer in first-degree relatives of Crohn's disease patients. An IG-IBD study.Dig Liver Dis. 2006 Jan;38(1):18-23. doi: 10.1016/j.dld.2005.07.006. Epub 2005 Sep 19.
• [2474] Caspase-1 cleaves PPAR for potentiating the pro-tumor action of TAMs.Nat Commun. 2017 Oct 3;8(1):766. doi: 10.1038/s41467-017-00523-6.
• [2475] Common genetic variants in the vitamin D pathway including genome-wide associated variants are not associated with breast cancer risk among Chinese women.Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2313-6. doi: 10.1158/1055-9965.EPI-11-0704. Epub 2011 Aug 9.
• [2476] Leptin promotes the migration and invasion of breast cancer cells by upregulating ACAT2.Cell Oncol (Dordr). 2017 Dec;40(6):537-547. doi: 10.1007/s13402-017-0342-8. Epub 2017 Aug 2.
• [2477] Overexpressed ACBD3 has prognostic value in human breast cancer and promotes the self-renewal potential of breast cancer cells by activating the Wnt/beta-catenin signaling pathway.Exp Cell Res. 2018 Feb 1;363(1):39-47. doi: 10.1016/j.yexcr.2018.01.003. Epub 2018 Jan 4.
• [2478] A Novel ACKR2-Dependent Role of Fibroblast-Derived CXCL14 in Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer.Clin Cancer Res. 2019 Jun 15;25(12):3702-3717. doi: 10.1158/1078-0432.CCR-18-1294. Epub 2019 Mar 8.
• [2479] Effect of functional genetic variants in chemokine decoy receptors on the recurrence risk of breast cancer.Cancer Med. 2018 Nov;7(11):5497-5504. doi: 10.1002/cam4.1823. Epub 2018 Oct 24.
• [2480] EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma.Biomaterials. 2012 Jan;33(1):270-82. doi: 10.1016/j.biomaterials.2011.09.035. Epub 2011 Oct 2.
• [2481] Association of long-chain acyl-coenzyme A synthetase5 expression in human breast cancer by estrogen receptor status and its clinical significance.Oncol Rep. 2017 Jun;37(6):3253-3260. doi: 10.3892/or.2017.5610. Epub 2017 Apr 28.
• [2482] High ASMA(+) Fibroblasts and Low Cytoplasmic HMGB1(+) Breast Cancer Cells Predict PoorPrognosis.Clin Breast Cancer. 2017 Oct;17(6):441-452.e2. doi: 10.1016/j.clbc.2017.04.007. Epub 2017 Apr 21.
• [2483] Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.EMBO Mol Med. 2014 Dec;6(12):1542-60. doi: 10.15252/emmm.201404402.
• [2484] Involvement of Actin Cytoskeletal Components in Breast Cancer Cell Fusion with Human Mesenchymal Stroma/Stem-Like Cells.Int J Mol Sci. 2019 Feb 18;20(4):876. doi: 10.3390/ijms20040876.
• [2485] Identification of genes and pathways associated with MDR in MCF-7/MDR breast cancer cells by RNA-seq analysis.Mol Med Rep. 2018 May;17(5):6211-6226. doi: 10.3892/mmr.2018.8704. Epub 2018 Mar 7.
• [2486] ALK7 Signaling Manifests a Homeostatic Tissue Barrier That Is Abrogated during Tumorigenesis and Metastasis.Dev Cell. 2019 May 6;49(3):409-424.e6. doi: 10.1016/j.devcel.2019.04.015.
• [2487] Proteomic screening identifies the zonula occludens protein ZO-1 as a new partner for ADAM12 in invadopodia-like structures.Oncotarget. 2018 Apr 20;9(30):21366-21382. doi: 10.18632/oncotarget.25106. eCollection 2018 Apr 20.
• [2488] ADAM29 Expression in Human Breast Cancer and its Effects on Breast Cancer Cells In Vitro.Anticancer Res. 2016 Mar;36(3):1251-8.
• [2489] Sp1 is necessary for gene activation of Adamts17 by estrogen.J Cell Biochem. 2014 Oct;115(10):1829-39. doi: 10.1002/jcb.24855.
• [2490] Epigenetic silencing of ADAMTS18 promotes cell migration and invasion of breast cancer through AKT and NF-B signaling.Cancer Med. 2017 Jun;6(6):1399-1408. doi: 10.1002/cam4.1076. Epub 2017 May 15.
• [2491] The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.Breast Cancer Res Treat. 2016 Feb;156(1):9-20. doi: 10.1007/s10549-016-3709-z. Epub 2016 Feb 23.
• [2492] ADAMTS6 suppresses tumor progression via the ERK signaling pathway and serves as a prognostic marker in human breast cancer.Oncotarget. 2016 Sep 20;7(38):61273-61283. doi: 10.18632/oncotarget.11341.
• [2493] ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma.Int J Cancer. 2006 Mar 1;118(5):1241-7. doi: 10.1002/ijc.21476.
• [2494] Sensitive ADAR editing reporter in cancer cells enables high-throughput screening of small molecule libraries.Nucleic Acids Res. 2019 Feb 28;47(4):e22. doi: 10.1093/nar/gky1228.
• [2495] RNA-editing enzymes ADAR1 and ADAR2 coordinately regulate the editing and expression of Ctn RNA.FEBS Lett. 2017 Sep;591(18):2890-2904. doi: 10.1002/1873-3468.12795. Epub 2017 Aug 30.
• [2496] Genomic structure and expression profile of LPHH1, a 7TM gene variably expressed in breast cancer cell lines.Biochim Biophys Acta. 2000 Apr 25;1491(1-3):75-92. doi: 10.1016/s0167-4781(00)00020-8.
• [2497] Effects of two types of energy restriction on methylation levels of adiponectin receptor 1 and leptin receptor overlapping transcript in a mouse mammary tumour virus-transforming growth factor- breast cancer mouse model.Br J Nutr. 2021 Jan 14;125(1):1-9. doi: 10.1017/S0007114519002757. Epub 2019 Nov 5.
• [2498] Expression of AdipoR1 and AdipoR2 Receptors as Leptin-Breast Cancer Regulation Mechanisms.Dis Markers. 2017;2017:4862016. doi: 10.1155/2017/4862016. Epub 2017 Sep 5.
• [2499] Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome.Int J Cancer. 2013 Dec 15;133(12):2791-800. doi: 10.1002/ijc.28304. Epub 2013 Aug 9.
• [2500] Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.Clin Breast Cancer. 2020 Apr;20(2):131-144.e3. doi: 10.1016/j.clbc.2019.07.009. Epub 2019 Sep 3.
• [2501] Proteome Profiling Outperforms Transcriptome Profiling for Coexpression Based Gene Function Prediction.Mol Cell Proteomics. 2017 Jan;16(1):121-134. doi: 10.1074/mcp.M116.060301. Epub 2016 Nov 11.
• [2502] Expression analysis of AFAP1-AS1 and AFAP1 in breast cancer.Cancer Biomark. 2018;22(1):49-54. doi: 10.3233/CBM-170831.
• [2503] AFF3 upregulation mediates tamoxifen resistance in breast cancers.J Exp Clin Cancer Res. 2018 Oct 16;37(1):254. doi: 10.1186/s13046-018-0928-7.
• [2504] Afamin expression in breast cancer.Asian J Surg. 2020 Jul;43(7):750-754. doi: 10.1016/j.asjsur.2019.09.014. Epub 2019 Oct 23.
• [2505] Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis.Am J Cancer Res. 2017 Sep 1;7(9):1959-1970. eCollection 2017.
• [2506] Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells.Endocrinology. 2009 Jan;150(1):14-23. doi: 10.1210/en.2008-0984. Epub 2008 Sep 11.
• [2507] Doxorubicin resistance in breast cancer: A novel role for the human protein AHNAK.Biochem Pharmacol. 2018 Feb;148:174-183. doi: 10.1016/j.bcp.2018.01.012. Epub 2018 Jan 5.
• [2508] Suppressive effect of aryl hydrocarbon receptor repressor on transcriptional activity of estrogen receptor alpha by protein-protein interaction in stably and transiently expressing cell lines.Mol Cell Endocrinol. 2008 Sep 10;291(1-2):87-94. doi: 10.1016/j.mce.2008.05.004. Epub 2008 May 14.
• [2509] Suppression of oncoprotein Her-2 and DNA damage after treatment with Flavan-3- ol vitis labrusca extract.Anticancer Agents Med Chem. 2013 Sep;13(7):1088-95. doi: 10.2174/18715206113139990135.
• [2510] Clinical implications of a novel prognostic factor AIFM3 in breast cancer patients.BMC Cancer. 2019 May 14;19(1):451. doi: 10.1186/s12885-019-5659-4.
• [2511] Clinicopathological and immunohistochemical analysis of autoimmune regulator expression in patients with osteosarcoma.Clin Exp Metastasis. 2018 Oct;35(7):641-648. doi: 10.1007/s10585-018-9928-4. Epub 2018 Aug 18.
• [2512] AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion.Dis Markers. 2019 Nov 20;2019:8186091. doi: 10.1155/2019/8186091. eCollection 2019.
• [2513] Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs).BMC Cancer. 2018 Feb 12;18(1):174. doi: 10.1186/s12885-018-4021-6.
• [2514] The functional genetic variant Ile646Val located in the kinase binding domain of the A-kinase anchoring protein 10 is associated with familial breast cancer.Carcinogenesis. 2007 Feb;28(2):423-6. doi: 10.1093/carcin/bgl164. Epub 2006 Sep 6.
• [2515] A-kinase anchor protein 12 (AKAP12) inhibits cell migration in breast cancer.Exp Mol Pathol. 2018 Dec;105(3):364-370. doi: 10.1016/j.yexmp.2018.10.010. Epub 2018 Oct 30.
• [2516] Metabolic fingerprinting in breast cancer stages through (1)H NMR spectroscopy-based metabolomic analysis of plasma.J Pharm Biomed Anal. 2018 Oct 25;160:38-45. doi: 10.1016/j.jpba.2018.07.024. Epub 2018 Jul 18.
• [2517] Breast cancer-associated gene 3 interacts with Rac1 and augments NF-B signaling in vitro, but has no effect on RANKL-induced bone resorption in vivo.Int J Mol Med. 2017 Oct;40(4):1067-1077. doi: 10.3892/ijmm.2017.3091. Epub 2017 Aug 4.
• [2518] Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.Neuro Oncol. 2019 Nov 4;21(11):1401-1411. doi: 10.1093/neuonc/noz105.
• [2519] Apoptosis-linked gene 2 promotes breast cancer growth and metastasis by regulating the cytoskeleton.Oncotarget. 2017 Jan 10;8(2):2745-2757. doi: 10.18632/oncotarget.13740.
• [2520] ALG3 Is Activated by Heat Shock Factor 2 and Promotes Breast Cancer Growth.Med Sci Monit. 2018 May 25;24:3479-3487. doi: 10.12659/MSM.907461.
• [2521] CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer.BMC Cancer. 2017 Jul 5;17(1):469. doi: 10.1186/s12885-017-3453-8.
• [2522] Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer.J Exp Med. 2016 Oct 17;213(11):2503-2523. doi: 10.1084/jem.20160397. Epub 2016 Oct 10.
• [2523] ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer.Oncotarget. 2016 Dec 13;7(50):83278-83293. doi: 10.18632/oncotarget.13086.
• [2524] Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer.Cancer Res. 1996 Sep 1;56(17):3886-90.
• [2525] Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.PLoS One. 2019 Mar 15;14(3):e0209392. doi: 10.1371/journal.pone.0209392. eCollection 2019.
• [2526] ALX4, an epigenetically down regulated tumor suppressor, inhibits breast cancer progression by interfering Wnt/-catenin pathway.J Exp Clin Cancer Res. 2017 Nov 28;36(1):170. doi: 10.1186/s13046-017-0643-9.
• [2527] Ambra1 inhibits paclitaxel-induced apoptosis in breast cancer cells by modulating the Bim/mitochondrial pathway.Neoplasma. 2019 May 23;66(3):377-385. doi: 10.4149/neo_2018_180710N467. Epub 2019 Feb 14.
• [2528] Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer.Oncogene. 2016 Mar 24;35(12):1517-28. doi: 10.1038/onc.2015.214. Epub 2015 Jun 29.
• [2529] Association of BRCA Mutations and Anti-mllerian Hormone Level in Young Breast Cancer Patients.Front Endocrinol (Lausanne). 2019 Apr 11;10:235. doi: 10.3389/fendo.2019.00235. eCollection 2019.
• [2530] Reporters to mark and eliminate basal or luminal epithelial cells in culture and in vivo.PLoS Biol. 2018 Jun 20;16(6):e2004049. doi: 10.1371/journal.pbio.2004049. eCollection 2018 Jun.
• [2531] AMOTL1 Promotes Breast Cancer Progression and Is Antagonized by Merlin.Neoplasia. 2016 Jan;18(1):10-24. doi: 10.1016/j.neo.2015.11.010.
• [2532] Contribution of cell culture, RNA extraction, and reverse transcription to the measurement error in quantitative reverse transcription polymerase chain reaction-based gene expression quantification.Anal Biochem. 2009 Oct 1;393(1):29-35. doi: 10.1016/j.ab.2009.06.010. Epub 2009 Jun 13.
• [2533] ANGPTL1 attenuates colorectal cancer metastasis by up-regulating microRNA-138.J Exp Clin Cancer Res. 2017 Jun 12;36(1):78. doi: 10.1186/s13046-017-0548-7.
• [2534] Moderating Effects of Genetic Polymorphisms on Improvements in Cognitive Impairment in Breast Cancer Survivors Participating in a 6-Week Mindfulness-Based Stress Reduction Program.Biol Res Nurs. 2015 Jul;17(4):393-404. doi: 10.1177/1099800415577633. Epub 2015 Apr 15.
• [2535] LEM-3 is a midbody-tethered DNA nuclease that resolves chromatin bridges during late mitosis.Nat Commun. 2018 Feb 20;9(1):728. doi: 10.1038/s41467-018-03135-w.
• [2536] LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ER pathway.Nat Commun. 2018 Oct 9;9(1):4180. doi: 10.1038/s41467-018-06309-8.
• [2537] A transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic mice.BMC Cancer. 2019 Sep 13;19(1):914. doi: 10.1186/s12885-019-6102-6.
• [2538] Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth.Breast Cancer Res. 2011 Jan 10;13(1):R2. doi: 10.1186/bcr2803.
• [2539] Expression of pp32 gene family members in breast cancer.Breast Cancer Res Treat. 2001 Jul;68(1):65-73. doi: 10.1023/a:1017919507109.
• [2540] Tumor endothelial marker 8 promotes cancer progression and metastasis.Oncotarget. 2018 Jul 10;9(53):30173-30188. doi: 10.18632/oncotarget.25734. eCollection 2018 Jul 10.
• [2541] Analysis of breast cancer subtypes by AP-ISA biclustering.BMC Bioinformatics. 2017 Nov 14;18(1):481. doi: 10.1186/s12859-017-1926-z.
• [2542] The expression of ANXA3 and its relationship with the occurrence and development of breast cancer.J BUON. 2018 May-Jun;23(3):713-719.
• [2543] Annexin A7 is correlated with better clinical outcomes of patients with breast cancer.J Cell Biochem. 2018 Sep;119(9):7577-7584. doi: 10.1002/jcb.27087. Epub 2018 Jun 12.
• [2544] AP-2 reverses vincristine-induced multidrug resistance of SGC7901 gastric cancer cells by inhibiting the Notch pathway.Apoptosis. 2017 Jul;22(7):933-941. doi: 10.1007/s10495-017-1379-x.
• [2545] New Gene Profiling in Determination of Breast Cancer Recurrence and Prognosis in Iranian Women.Asian Pac J Cancer Prev. 2016;17(S3):155-60. doi: 10.7314/apjcp.2016.17.s3.155.
• [2546] Mitochondria-targeted delivery of doxorubicin to enhance antitumor activity with HER-2 peptide-mediated multifunctional pH-sensitive DQAsomes.Int J Nanomedicine. 2018 Jul 18;13:4209-4226. doi: 10.2147/IJN.S163858. eCollection 2018.
• [2547] Mint3 in bone marrow-derived cells promotes lung metastasis in breast cancer model mice.Biochem Biophys Res Commun. 2017 Aug 26;490(3):688-692. doi: 10.1016/j.bbrc.2017.06.102. Epub 2017 Jun 19.
• [2548] Identification of new human coding steroid receptor RNA activator isoforms.Biochem Biophys Res Commun. 2003 Feb 7;301(2):509-15. doi: 10.1016/s0006-291x(02)03070-x.
• [2549] APC downregulated 1 inhibits breast cancer cell invasion by inhibiting the canonical WNT signaling pathway.Oncol Lett. 2017 Oct;14(4):4845-4852. doi: 10.3892/ol.2017.6801. Epub 2017 Aug 23.
• [2550] Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.BMC Med Genomics. 2019 Sep 18;12(1):131. doi: 10.1186/s12920-019-0579-3.
• [2551] 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes.Cancer Res. 2000 Oct 1;60(19):5371-5.
• [2552] APPL proteins promote TGF-induced nuclear transport of the TGF type I receptor intracellular domain.Oncotarget. 2016 Jan 5;7(1):279-92. doi: 10.18632/oncotarget.6346.
• [2553] Aquaporin-4 antibody positive short transverse myelitis associated with breast cancer.Mult Scler Relat Disord. 2019 May;30:119-122. doi: 10.1016/j.msard.2019.02.011. Epub 2019 Feb 8.
• [2554] AQP8 inhibits colorectal cancer growth and metastasis by down-regulating PI3K/AKT signaling and PCDH7 expression.Am J Cancer Res. 2018 Feb 1;8(2):266-279. eCollection 2018.
• [2555] Bioinformatic analysis of prognostic value of ARAP3 in breast cancer and the associated signaling pathways.Eur Rev Med Pharmacol Sci. 2017 May;21(10):2405-2412.
• [2556] Up-regulated ADP-Ribosylation factor 3 promotes breast cancer cell proliferation through the participation of FOXO1.Exp Cell Res. 2019 Nov 15;384(2):111624. doi: 10.1016/j.yexcr.2019.111624. Epub 2019 Sep 17.
• [2557] Roles of Arf6 in cancer cell invasion, metastasis and proliferation.Life Sci. 2017 Aug 1;182:80-84. doi: 10.1016/j.lfs.2017.06.008. Epub 2017 Jun 15.
• [2558] Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.Cancer. 2019 Jan 15;125(2):307-316. doi: 10.1002/cncr.31784. Epub 2018 Oct 18.
• [2559] Arginine and glutamate-rich 1 (ARGLU1) interacts with mediator subunit 1 (MED1) and is required for estrogen receptor-mediated gene transcription and breast cancer cell growth.J Biol Chem. 2011 May 20;286(20):17746-54. doi: 10.1074/jbc.M110.206029. Epub 2011 Mar 28.
• [2560] The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells.Cancer Res. 2005 Jul 15;65(14):6042-53. doi: 10.1158/0008-5472.CAN-04-3043.
• [2561] Downregulated expression of ARHGAP10 correlates with advanced stage and high Ki-67 index in breast cancer.PeerJ. 2019 Aug 1;7:e7431. doi: 10.7717/peerj.7431. eCollection 2019.
• [2562] PIWI-interacting RNA 021285 is involved in breast tumorigenesis possibly by remodeling the cancer epigenome.Carcinogenesis. 2015 Oct;36(10):1094-102. doi: 10.1093/carcin/bgv105. Epub 2015 Jul 25.
• [2563] Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network.Int J Cancer. 2018 Dec 1;143(11):2905-2918. doi: 10.1002/ijc.31645. Epub 2018 Oct 9.
• [2564] Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer.Br J Cancer. 2017 Oct 10;117(8):1176-1184. doi: 10.1038/bjc.2017.261. Epub 2017 Aug 22.
• [2565] P190-B, a Rho-GTPase-activating protein, is differentially expressed in terminal end buds and breast cancer.Cell Growth Differ. 2000 Jul;11(7):343-54.
• [2566] Bioinformatics analysis of potential therapeutic targets among ARHGAP genes in breast cancer.Oncol Lett. 2019 Dec;18(6):6017-6025. doi: 10.3892/ol.2019.10949. Epub 2019 Oct 2.
• [2567] Differentially expressed proteins in ER+ MCF7 and ER- MDA- MB-231 human breast cancer cells by RhoGDI- silencing and overexpression.Asian Pac J Cancer Prev. 2014;15(7):3311-7. doi: 10.7314/apjcp.2014.15.7.3311.
• [2568] Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers.Clin Cancer Res. 2003 Dec 15;9(17):6432-40.
• [2569] The exon 38-containing ARHGEF11 splice isoform is differentially expressed and is required for migration and growth in invasive breast cancer cells.Oncotarget. 2017 Sep 18;8(54):92157-92170. doi: 10.18632/oncotarget.20985. eCollection 2017 Nov 3.
• [2570] LARG at chromosome 11q23 has functional characteristics of a tumor suppressor in human breast and colorectal cancer.Oncogene. 2009 Nov 26;28(47):4189-200. doi: 10.1038/onc.2009.266. Epub 2009 Sep 7.
• [2571] ARID3B expression in primary breast cancers and breast cancer-derived cell lines.Cell Oncol (Dordr). 2014 Aug;37(4):289-96. doi: 10.1007/s13402-014-0185-5. Epub 2014 Aug 14.
• [2572] Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells.J Biol Chem. 2008 Mar 21;283(12):7438-44. doi: 10.1074/jbc.M709446200. Epub 2008 Jan 22.
• [2573] ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer.Mol Biol Rep. 2011 Jan;38(1):343-8. doi: 10.1007/s11033-010-0113-3. Epub 2010 Apr 1.
• [2574] siRNA-mediated knockdown of aryl hydrocarbon receptor nuclear translocator 2 affects hypoxia-inducible factor-1 regulatory signaling and metabolism in human breast cancer cells.FEBS Lett. 2011 Oct 20;585(20):3310-5. doi: 10.1016/j.febslet.2011.09.017. Epub 2011 Sep 19.
• [2575] Cortical branched actin determines cell cycle progression.Cell Res. 2019 Jun;29(6):432-445. doi: 10.1038/s41422-019-0160-9. Epub 2019 Apr 10.
• [2576] RBM3 upregulates ARPC2 by binding the 3'UTR and contributes to breast cancer progression.Int J Oncol. 2019 Apr;54(4):1387-1397. doi: 10.3892/ijo.2019.4698. Epub 2019 Jan 28.
• [2577] Aberrant expression of Arpin in human breast cancer and its clinical significance.J Cell Mol Med. 2016 Mar;20(3):450-8. doi: 10.1111/jcmm.12740. Epub 2015 Dec 9.
• [2578] Clinically assessed posttraumatic stress in patients with breast cancer during the first year after diagnosis in the prospective, longitudinal, controlled COGNICARES study.Psychooncology. 2017 Jan;26(1):74-80. doi: 10.1002/pon.4102. Epub 2016 Feb 22.
• [2579] Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. Oncogene. 2010 Jun 3;29(22):3228-40. doi: 10.1038/onc.2010.71. Epub 2010 Mar 22.
• [2580] Silencing lnc-ASAH2B-2 Inhibits Breast Cancer Cell Growth via the mTOR Pathway.Anticancer Res. 2018 Jun;38(6):3427-3434. doi: 10.21873/anticanres.12611.
• [2581] Identification of core genes and clinical roles in pregnancy-associated breast cancer based on integrated analysis of different microarray profile datasets.Biosci Rep. 2019 Jun 25;39(6):BSR20190019. doi: 10.1042/BSR20190019. Print 2019 Jun 28.
• [2582] Human achaete-scute homolog-1 expression in neuroendocrine breast carcinoma.Virchows Arch. 2012 Apr;460(4):415-21. doi: 10.1007/s00428-012-1223-1. Epub 2012 Mar 16.
• [2583] Elevated ASCL2 expression in breast cancer is associated with the poor prognosis of patients.Am J Cancer Res. 2017 Apr 1;7(4):955-961. eCollection 2017.
• [2584] Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer.EMBO J. 2011 Feb 2;30(3):480-93. doi: 10.1038/emboj.2010.335. Epub 2010 Dec 21.
• [2585] Argininosuccinate lyase is a potential therapeutic target in breast cancer.Oncol Rep. 2015 Dec;34(6):3131-9. doi: 10.3892/or.2015.4280. Epub 2015 Sep 16.
• [2586] Cell growth stimulation by CRASH, an asparaginase-like protein overexpressed in human tumors and metastatic breast cancers.Anticancer Res. 2009 Apr;29(4):951-63.
• [2587] Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan.Br J Cancer. 1999 Aug;80(11):1838-43. doi: 10.1038/sj.bjc.6690608.
• [2588] Mitochondrial ATAD3A combines with GRP78 to regulate the WASF3 metastasis-promoting protein.Oncogene. 2016 Jan 21;35(3):333-43. doi: 10.1038/onc.2015.86. Epub 2015 Mar 30.
• [2589] BCL-2 is a downstream target of ATF5 that mediates the prosurvival function of ATF5 in a cell type-dependent manner.J Biol Chem. 2011 Mar 4;286(9):7705-13. doi: 10.1074/jbc.M110.207639. Epub 2011 Jan 6.
• [2590] B-crystallin, an effector of unfolded protein response, confers anti-VEGF resistance to breast cancer via maintenance of intracrine VEGF in endothelial cells.Mol Cancer Res. 2011 Dec;9(12):1632-43. doi: 10.1158/1541-7786.MCR-11-0327. Epub 2011 Oct 7.
• [2591] Effect of the LncRNA GAS5-MiR-23a-ATG3 Axis in Regulating Autophagy in Patients with Breast Cancer.Cell Physiol Biochem. 2018;48(1):194-207. doi: 10.1159/000491718. Epub 2018 Jul 13.
• [2592] ATM kinase sustains breast cancer stem-like cells by promoting ATG4C expression and autophagy.Oncotarget. 2017 Mar 28;8(13):21692-21709. doi: 10.18632/oncotarget.15537.
• [2593] The functional role of the EZH2 gene in controlling breast cancer stem cells.J BUON. 2019 May-Jun;24(3):1060-1066.
• [2594] Comparative epigenomics of human and mouse mammary tumors.Genes Chromosomes Cancer. 2009 Jan;48(1):83-97. doi: 10.1002/gcc.20620.
• [2595] Resveratrol up-regulates ATP2A3 gene expression in breast cancer cell lines through epigenetic mechanisms.Int J Biochem Cell Biol. 2019 Aug;113:37-47. doi: 10.1016/j.biocel.2019.05.020. Epub 2019 Jun 4.
• [2596] Plasma membrane Ca2+-ATPase expression during colon cancer cell line differentiation.Biochem Biophys Res Commun. 2007 Apr 20;355(4):932-6. doi: 10.1016/j.bbrc.2007.02.050. Epub 2007 Feb 20.
• [2597] SPCA2 couples Ca(2+) influx via Orai1 to Ca(2+) uptake into the Golgi/secretory pathway.Tissue Cell. 2017 Apr;49(2 Pt A):141-149. doi: 10.1016/j.tice.2016.09.004. Epub 2016 Sep 17.
• [2598] Complete sequence of the ATP6 and ND3 mitochondrial genes in breast cancer tissue of postmenopausal women with different body mass indexes.Ann Diagn Pathol. 2018 Feb;32:23-27. doi: 10.1016/j.anndiagpath.2017.09.001. Epub 2017 Sep 10.
• [2599] CAPER, a novel regulator of human breast cancer progression.Cell Cycle. 2014;13(8):1256-64. doi: 10.4161/cc.28156. Epub 2014 Feb 17.
• [2600] VAAST 2.0: improved variant classification and disease-gene identification using a conservation-controlled amino acid substitution matrix.Genet Epidemiol. 2013 Sep;37(6):622-34. doi: 10.1002/gepi.21743. Epub 2013 Jul 8.
• [2601] Common nonsense mutations in RAD52.Cancer Res. 1999 Aug 15;59(16):3883-8.
• [2602] Ataxin-1 regulates epithelial-mesenchymal transition of cervical cancer cells.Oncotarget. 2017 Mar 14;8(11):18248-18259. doi: 10.18632/oncotarget.15319.
• [2603] Rad51C-ATXN7 fusion gene expression in colorectal tumors.Mol Cancer. 2016 Jun 13;15(1):47. doi: 10.1186/s12943-016-0527-1.
• [2604] Cytoplasmic ATXN7L3B Interferes with Nuclear Functions of the SAGA Deubiquitinase Module.Mol Cell Biol. 2016 Oct 28;36(22):2855-2866. doi: 10.1128/MCB.00193-16. Print 2016 Nov 15.
• [2605] Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer.Cell Cycle. 2017 Feb 16;16(4):312-318. doi: 10.1080/15384101.2016.1237325. Epub 2017 Jan 5.
• [2606] Enhanced hexosamine metabolism drives metabolic and signaling networks involving hyaluronan production and O-GlcNAcylation to exacerbate breast cancer.Cell Death Dis. 2019 Oct 23;10(11):803. doi: 10.1038/s41419-019-2034-y.
• [2607] Involvement of B3GALNT2 overexpression in the cell growth of breast cancer.Int J Oncol. 2014 Feb;44(2):427-34. doi: 10.3892/ijo.2013.2187. Epub 2013 Nov 27.
• [2608] Downregulation of gangliotetraosylceramide and 1,3-galactosyltransferase-4 gene expression by Smads during transforming growth factor -induced epithelial-mesenchymal transition.Mol Med Rep. 2015 Mar;11(3):2241-7. doi: 10.3892/mmr.2014.2912. Epub 2014 Nov 10.
• [2609] Evaluating genome-wide association study-identified breast cancer risk variants in African-American women.PLoS One. 2013 Apr 8;8(4):e58350. doi: 10.1371/journal.pone.0058350. Print 2013.
• [2610] Expression of the BRCA1 complex member BRE predicts disease free survival in breast cancer.Breast Cancer Res Treat. 2012 Aug;135(1):125-33. doi: 10.1007/s10549-012-2122-5. Epub 2012 Jun 16.
• [2611] Downregulation of BAG? in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway.Oncol Rep. 2019 Mar;41(3):1901-1910. doi: 10.3892/or.2019.6978. Epub 2019 Jan 22.
• [2612] BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells.Neoplasia. 2018 Mar;20(3):263-279. doi: 10.1016/j.neo.2018.01.001. Epub 2018 Feb 22.
• [2613] SMAR1 favors immunosurveillance of cancer cells by modulating calnexin and MHC I expression.Neoplasia. 2019 Oct;21(10):945-962. doi: 10.1016/j.neo.2019.07.002. Epub 2019 Aug 15.
• [2614] BARHL1 Is Downregulated in Alzheimer's Disease and May Regulate Cognitive Functions through ESR1 and Multiple Pathways.Genes (Basel). 2017 Sep 28;8(10):245. doi: 10.3390/genes8100245.
• [2615] BARX2 and estrogen receptor-alpha (ESR1) coordinately regulate the production of alternatively spliced ESR1 isoforms and control breast cancer cell growth and invasion.Oncogene. 2006 Aug 31;25(39):5426-35. doi: 10.1038/sj.onc.1209529. Epub 2006 Apr 24.
• [2616] BASP1 interacts with oestrogen receptor and modifies the tamoxifen response.Cell Death Dis. 2017 May 11;8(5):e2771. doi: 10.1038/cddis.2017.179.
• [2617] Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1,25-dihydroxyvitamin D(3).J Steroid Biochem Mol Biol. 2018 Mar;177:171-178. doi: 10.1016/j.jsbmb.2017.06.003. Epub 2017 Jun 10.
• [2618] Oxygen-generating Hybrid Polymeric Nanoparticles with Encapsulated Doxorubicin and Chlorin e6 for Trimodal Imaging-Guided Combined Chemo-Photodynamic Therapy.Theranostics. 2018 Feb 7;8(6):1558-1574. doi: 10.7150/thno.22989. eCollection 2018.
• [2619] Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer.Oncotarget. 2017 Mar 7;8(10):16642-16649. doi: 10.18632/oncotarget.15120.
• [2620] Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer.Genes Chromosomes Cancer. 2002 Dec;35(4):311-7. doi: 10.1002/gcc.10121.
• [2621] RNA methyltransferase BCDIN3D is crucial for female fertility and miRNA and mRNA profiles in Drosophila ovaries.PLoS One. 2019 May 30;14(5):e0217603. doi: 10.1371/journal.pone.0217603. eCollection 2019.
• [2622] Mouse ER+/PIK3CA(H1047R) breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents.Oncogene. 2019 Jan;38(1):47-59. doi: 10.1038/s41388-018-0436-4. Epub 2018 Aug 3.
• [2623] Breathing New Life into TRAIL for Breast Cancer Therapy: Co-Delivery of pTRAIL and Complementary siRNAs Using Lipopolymers.Hum Gene Ther. 2019 Dec;30(12):1531-1546. doi: 10.1089/hum.2019.096. Epub 2019 Oct 29.
• [2624] Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex.Br J Cancer. 1999 Sep;81(2):252-60. doi: 10.1038/sj.bjc.6690685.
• [2625] BCoR-L1 variation and breast cancer.Breast Cancer Res. 2007;9(4):R54. doi: 10.1186/bcr1759.
• [2626] Impact of Awake Breast Cancer Surgery on Postoperative Lymphocyte Responses.In Vivo. 2019 Nov-Dec;33(6):1879-1884. doi: 10.21873/invivo.11681.
• [2627] Molecular functions of brain expressed X-linked 2 (BEX2) in malignancies.Exp Cell Res. 2019 Mar 15;376(2):221-226. doi: 10.1016/j.yexcr.2019.02.014. Epub 2019 Feb 16.
• [2628] Differential gene expression pattern in human mammary epithelial cells induced by realistic organochlorine mixtures described in healthy women and in women diagnosed with breast cancer.Toxicol Lett. 2016 Mar 30;246:42-8. doi: 10.1016/j.toxlet.2016.02.003. Epub 2016 Feb 4.
• [2629] Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance.Cancers (Basel). 2018 Aug 18;10(8):274. doi: 10.3390/cancers10080274.
• [2630] Interaction with SP1, but not binding to the E-box motifs, is responsible for BHLHE40/DEC1-induced transcriptional suppression of CLDN1 and cell invasion in MCF-7 cells.Mol Carcinog. 2018 Sep;57(9):1116-1129. doi: 10.1002/mc.22829. Epub 2018 May 2.
• [2631] Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells. J Toxicol Sci. 2014;39(5):711-6.
• [2632] Breast cancer cell line MDA-MB-231 miRNA profile expression after BIK interference: BIK involvement in autophagy.Tumour Biol. 2016 May;37(5):6749-59. doi: 10.1007/s13277-015-4494-8. Epub 2015 Dec 10.
• [2633] Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity.Int J Cancer. 2000 Feb 1;85(3):376-83.
• [2634] Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation.Br J Cancer. 2009 Mar 10;100(5):739-46. doi: 10.1038/sj.bjc.6604927. Epub 2009 Feb 17.
• [2635] Long non-coding RNA MALAT1 regulates BLCAP mRNA expression through binding to miR-339-5p and promotes poor prognosis in breast cancer.Biosci Rep. 2019 Feb 15;39(2):BSR20181284. doi: 10.1042/BSR20181284. Print 2019 Feb 28.
• [2636] BLID: A Novel Tumor-Suppressor Gene.Oncol Res. 2014;22(5-6):333-8. doi: 10.3727/096504015X14410238486568.
• [2637] Restraining FOXO3-dependent transcriptional BMF activation underpins tumour growth and metastasis of E-cadherin-negative breast cancer.Cell Death Differ. 2016 Sep 1;23(9):1483-92. doi: 10.1038/cdd.2016.33. Epub 2016 Apr 1.
• [2638] Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression.Cell Physiol Biochem. 2018;45(5):1759-1771. doi: 10.1159/000487784. Epub 2018 Feb 23.
• [2639] A comparison of folic acid deficiency-induced genomic instability in lymphocytes of breast cancer patients and normal non-cancer controls from a Chinese population in Yunnan.Mutagenesis. 2006 Jan;21(1):41-7. doi: 10.1093/mutage/gei069. Epub 2005 Dec 8.
• [2640] NIP1/DUOXA1 expression in epithelial breast cancer cells: regulation of cell adhesion and actin dynamics.Breast Cancer Res Treat. 2010 Feb;119(3):773-86. doi: 10.1007/s10549-009-0372-7. Epub 2009 Mar 26.
• [2641] RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.Mol Cancer. 2019 Mar 28;18(1):46. doi: 10.1186/s12943-019-1004-4.
• [2642] Blockade of epidermal growth factor receptors chemosensitizes breast cancer cells through up-regulation of Bnip3L.Cancer Res. 2005 Sep 15;65(18):8151-7. doi: 10.1158/0008-5472.CAN-05-1134.
• [2643] miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro.Tumour Biol. 2018 Aug;40(8):1010428318791887. doi: 10.1177/1010428318791887.
• [2644] Novel post-transcriptional and post-translational regulation of pro-apoptotic protein BOK and anti-apoptotic protein Mcl-1 determine the fate of breast cancer cells to survive or die.Oncotarget. 2017 Sep 12;8(49):85984-85996. doi: 10.18632/oncotarget.20841. eCollection 2017 Oct 17.
• [2645] The biological effect of the nitroimidazole derivative of a polypyridyl ruthenium complex on cancer and endothelial cells.Metallomics. 2015 Mar;7(3):553-66. doi: 10.1039/c5mt00037h.
• [2646] The single nucleotide polymorphisms in BRAP decrease the risk of metabolic syndrome in a Chinese young adult population.Diab Vasc Dis Res. 2013 May;10(3):202-7. doi: 10.1177/1479164112455535. Epub 2012 Sep 10.
• [2647] Alcohol Intake and Abnormal Expression of Brf1 in Breast Cancer.Oxid Med Cell Longev. 2019 Oct 31;2019:4818106. doi: 10.1155/2019/4818106. eCollection 2019.
• [2648] Understanding the functional impact of copy number alterations in breast cancer using a network modeling approach.Mol Biosyst. 2016 Mar;12(3):963-72. doi: 10.1039/c5mb00655d.
• [2649] Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.Adv Med Sci. 2019 Sep;64(2):235-240. doi: 10.1016/j.advms.2018.12.007. Epub 2019 Feb 26.
• [2650] Genes up- and down-regulated by dermcidin in breast cancer: a microarray analysis.Genet Mol Res. 2008 Sep 30;7(3):925-32. doi: 10.4238/vol7-3x-meeting009.
• [2651] Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker.BMC Cancer. 2010 Mar 26;10:114. doi: 10.1186/1471-2407-10-114.
• [2652] Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3K inhibition through the transcriptional regulation of ER.Cancer Lett. 2019 Jan;440-441:54-63. doi: 10.1016/j.canlet.2018.09.030. Epub 2018 Oct 10.
• [2653] Translational downregulation of Twist1 expression by antiproliferative gene, B-cell translocation gene 2, in the triple negative breast cancer cells.Cell Death Dis. 2019 May 28;10(6):410. doi: 10.1038/s41419-019-1640-z.
• [2654] BTN3A2 serves as a prognostic marker and favors immune infiltration in triple-negative breast cancer.J Cell Biochem. 2020 Mar;121(3):2643-2654. doi: 10.1002/jcb.29485. Epub 2019 Nov 6.
• [2655] Breast cancer risk associated with genotypic polymorphism of the mitotic checkpoint genes: a multigenic study on cancer susceptibility.Carcinogenesis. 2007 May;28(5):1079-86. doi: 10.1093/carcin/bgl256. Epub 2007 Jan 8.
• [2656] Amplified in Breast Cancer Regulates Transcription and Translation in Breast Cancer Cells.Neoplasia. 2016 Feb;18(2):100-10. doi: 10.1016/j.neo.2016.01.001.
• [2657] The value of FATS expression in predicting sensitivity to radiotherapy in breast cancer.Oncotarget. 2017 Jun 13;8(24):38491-38500. doi: 10.18632/oncotarget.16630.
• [2658] Up-regulation of C1GALT1 promotes breast cancer cell growth through MUC1-C signaling pathway.Oncotarget. 2015 Mar 20;6(8):6123-35. doi: 10.18632/oncotarget.3045.
• [2659] BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses.Br J Cancer. 2017 Jun 6;116(12):1585-1594. doi: 10.1038/bjc.2017.130. Epub 2017 May 16.
• [2660] Anticancer activity of synthetic ()-kusunokinin and its derivative ()-bursehernin on human cancer cell lines.Biomed Pharmacother. 2019 Sep;117:109115. doi: 10.1016/j.biopha.2019.109115. Epub 2019 Jun 17.
• [2661] Characterization of a novel human breast cancer associated gene (BCA3) encoding an alternatively spliced proline-rich protein.Biochim Biophys Acta. 2003 Jan 3;1625(1):116-21. doi: 10.1016/s0167-4781(02)00562-6.
• [2662] Association of repeat polymorphisms in the estrogen receptors alpha, beta (ESR1, ESR2) and androgen receptor (AR) genes with the occurrence of breast cancer.Breast. 2008 Apr;17(2):159-66. doi: 10.1016/j.breast.2007.08.007. Epub 2007 Sep 29.
• [2663] The role of calcineurin/NFAT in SFRP2 induced angiogenesis--a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus.PLoS One. 2011;6(6):e20412. doi: 10.1371/journal.pone.0020412. Epub 2011 Jun 3.
• [2664] Association of mRNA expression levels of Cullin family members with prognosis in breast cancer: An online database analysis.Medicine (Baltimore). 2019 Aug;98(31):e16625. doi: 10.1097/MD.0000000000016625.
• [2665] TGF- drives epithelial-mesenchymal transition through EF1-mediated downregulation of ESRP.Oncogene. 2012 Jun 28;31(26):3190-201. doi: 10.1038/onc.2011.493. Epub 2011 Oct 31.
• [2666] Coactosin-like protein CLP/Cotl1 suppresses breast cancer growth through activation of IL-24/PERP and inhibition of non-canonical TGF signaling.Oncogene. 2018 Jan 18;37(3):323-331. doi: 10.1038/onc.2017.342. Epub 2017 Sep 18.
• [2667] EF Hand Protein IBA2 Promotes Cell Proliferation in Breast Cancers via Transcriptional Control of Cyclin D1.Cancer Res. 2016 Aug 1;76(15):4535-45. doi: 10.1158/0008-5472.CAN-15-2927. Epub 2016 Jun 4.
• [2668] CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer.Mol Oncol. 2008 Dec;2(4):327-39. doi: 10.1016/j.molonc.2008.09.004. Epub 2008 Oct 2.
• [2669] CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.Breast Cancer Res Treat. 2011 Nov;130(1):19-27. doi: 10.1007/s10549-010-1274-4. Epub 2010 Dec 3.
• [2670] Long Noncoding RNA CAMTA1 Promotes Proliferation and Mobility of the Human Breast Cancer Cell Line MDA-MB-231 via Targeting miR-20b.Oncol Res. 2018 May 7;26(4):625-635. doi: 10.3727/096504017X14953948675395. Epub 2017 May 21.
• [2671] Genome-wide testing of putative functional exonic variants in relationship with breast and prostate cancer risk in a multiethnic population.PLoS Genet. 2013 Mar;9(3):e1003419. doi: 10.1371/journal.pgen.1003419. Epub 2013 Mar 28.
• [2672] Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer.Oncogene. 2019 Nov;38(45):7106-7112. doi: 10.1038/s41388-019-0936-x. Epub 2019 Aug 13.
• [2673] Multiple susceptibility loci for radiation-induced mammary tumorigenesis in F2[Dahl S x R]-intercross rats.PLoS One. 2013 Aug 14;8(8):e72143. doi: 10.1371/journal.pone.0072143. eCollection 2013.
• [2674] A novel isoform of TUCAN is overexpressed in human cancer tissues and suppresses both caspase-8- and caspase-9-mediated apoptosis.Cancer Res. 2005 Oct 1;65(19):8706-14. doi: 10.1158/0008-5472.CAN-04-4649.
• [2675] Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.Lab Invest. 2008 May;88(5):491-503. doi: 10.1038/labinvest.2008.19. Epub 2008 Mar 10.
• [2676] Caspase14 expression is associated with triple negative phenotypes and cancer stem cell marker expression in breast cancer patients.J Surg Oncol. 2017 Nov;116(6):706-715. doi: 10.1002/jso.24705. Epub 2017 Jun 1.
• [2677] Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor.Anticancer Res. 2012 Jul;32(7):2523-9.
• [2678] Med19 promotes breast cancer cell proliferation by regulating CBFA2T3/HEB expression.Breast Cancer. 2017 May;24(3):433-441. doi: 10.1007/s12282-016-0722-3. Epub 2016 Aug 29.
• [2679] The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription.Nat Commun. 2019 May 6;10(1):2071. doi: 10.1038/s41467-019-10102-6.
• [2680] Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.Oncotarget. 2015 May 10;6(13):10746-58. doi: 10.18632/oncotarget.3628.
• [2681] CBLL1 is highly expressed in non-small cell lung cancer and promotes cell proliferation and invasion.Thorac Cancer. 2019 Jun;10(6):1479-1488. doi: 10.1111/1759-7714.13097. Epub 2019 May 23.
• [2682] miR-129-5p suppresses breast cancer proliferation by targeting CBX4.Neoplasma. 2018;65(4):572-578. doi: 10.4149/neo_2018_170814N530.
• [2683] Regulatory dissection of the CBX5 and hnRNPA1 bi-directional promoter in human breast cancer cells reveals novel transcript variants differentially associated with HP1 down-regulation in metastatic cells.BMC Cancer. 2016 Jan 20;16:32. doi: 10.1186/s12885-016-2059-x.
• [2684] Increased Expression of Circular RNA circ_0005230 Indicates Dismal Prognosis in Breast Cancer and Regulates Cell Proliferation and Invasion via miR-618/ CBX8 Signal Pathway.Cell Physiol Biochem. 2018;51(4):1710-1722. doi: 10.1159/000495675. Epub 2018 Nov 30.
• [2685] Scanning copy number and gene expression on the 18q21-qter chromosomal region by the systematic multiplex PCR and reverse transcription-PCR methods.Electrophoresis. 2007 Jun;28(12):1882-95. doi: 10.1002/elps.200700093.
• [2686] A cis-eQTL genetic variant of the cancer-testis gene CCDC116 is associated with risk of multiple cancers.Hum Genet. 2017 Aug;136(8):987-997. doi: 10.1007/s00439-017-1827-2. Epub 2017 Jun 26.
• [2687] DNA methylation marker to estimate the breast cancer cell fraction in DNA samples.Med Oncol. 2018 Sep 14;35(11):147. doi: 10.1007/s12032-018-1207-3.
• [2688] Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.Oncotarget. 2017 Aug 10;8(43):74378-74390. doi: 10.18632/oncotarget.20102. eCollection 2017 Sep 26.
• [2689] Prognostic impact of total and tyrosine phosphorylated GIV/Girdin in breast cancers.FASEB J. 2016 Nov;30(11):3702-3713. doi: 10.1096/fj.201600500. Epub 2016 Jul 20.
• [2690] CCL1 is a major regulatory T cell attracting factor in human breast cancer.BMC Cancer. 2018 Dec 20;18(1):1278. doi: 10.1186/s12885-018-5117-8.
• [2691] Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14.Cancer Res. 2011 Nov 1;71(21):6899-908. doi: 10.1158/0008-5472.CAN-11-1523. Epub 2011 Sep 21.
• [2692] Positive expression of chemokine (C-C Motif) ligand 18 and prognosis in cancer: A meta-analysis.J BUON. 2018 Jul-Aug;23(4):1185-1194.
• [2693] CCR7 mediates human breast cancer cell invasion, migration by inducing epithelial-mesenchymal transition and suppressing apoptosis through AKT pathway.Cancer Med. 2017 May;6(5):1062-1071. doi: 10.1002/cam4.1039. Epub 2017 Apr 4.
• [2694] Complicated prognostic values of CCL28 in breast cancer by subtype.J Thorac Dis. 2019 Mar;11(3):777-787. doi: 10.21037/jtd.2019.02.26.
• [2695] Deficiency of CCN5/WISP-2-Driven Program in breast cancer Promotes Cancer Epithelial cells to mesenchymal stem cells and Breast Cancer growth.Sci Rep. 2017 Apr 27;7(1):1220. doi: 10.1038/s41598-017-00916-z.
• [2696] Matricellular CCN6 (WISP3) protein: a tumor suppressor for mammary metaplastic carcinomas.J Cell Commun Signal. 2018 Mar;12(1):13-19. doi: 10.1007/s12079-018-0451-9. Epub 2018 Jan 22.
• [2697] Sulforaphane Decrease of SERTAD1 Expression Triggers G1/S Arrest in Breast Cancer Cells.J Med Food. 2019 May;22(5):444-450. doi: 10.1089/jmf.2018.4195.
• [2698] A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.Mol Biosyst. 2012 Apr;8(5):1553-70. doi: 10.1039/c2mb05512k. Epub 2012 Mar 23.
• [2699] A fine balance between CCNL1 and TIMP1 contributes to the development of breast cancer cells.Biochem Biophys Res Commun. 2011 Jun 3;409(2):344-9. doi: 10.1016/j.bbrc.2011.05.021. Epub 2011 May 8.
• [2700] CCR10 activation stimulates the invasion and migration of breast cancer cells through the ERK1/2/MMP-7 signaling pathway.Int Immunopharmacol. 2017 Oct;51:124-130. doi: 10.1016/j.intimp.2017.07.018. Epub 2017 Aug 19.
• [2701] Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.Clin Epigenetics. 2019 Nov 1;11(1):155. doi: 10.1186/s13148-019-0750-x.
• [2702] Structure elucidation {spectroscopic, single crystal X-ray diffraction and computational DFT studies} of new tailored benzenesulfonamide derived Schiff base copper(II) intercalating complexes: Comprehensive biological profile {DNA binding, pBR322 DNA cleavage, Topo I inhibition and cytotoxic activity}.Bioorg Chem. 2020 Jan;94:103427. doi: 10.1016/j.bioorg.2019.103427. Epub 2019 Nov 9.
• [2703] Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen.Breast Cancer Res Treat. 2008 Jun;109(3):491-501. doi: 10.1007/s10549-007-9673-x. Epub 2007 Jul 21.
• [2704] Bioinformatics analysis of the prognostic value of CCT6A and associated signalling pathways in breast cancer.Mol Med Rep. 2019 May;19(5):4344-4352. doi: 10.3892/mmr.2019.10100. Epub 2019 Mar 28.
• [2705] CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration.Life Sci. 2019 Aug 15;231:116543. doi: 10.1016/j.lfs.2019.116543. Epub 2019 Jun 6.
• [2706] Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes.Int J Cancer. 2016 Jan 1;138(1):87-97. doi: 10.1002/ijc.29684. Epub 2015 Jul 30.
• [2707] A pilot randomized controlled trial of cognitive bias modification to reduce fear of breast cancer recurrence.Cancer. 2017 Apr 15;123(8):1424-1433. doi: 10.1002/cncr.30478. Epub 2017 Jan 5.
• [2708] Novel breast cancer screening: combined expression of miR-21 and MMP-1 in urinary exosomes detects 95% of breast cancer without metastasis.Sci Rep. 2019 Sep 19;9(1):13595. doi: 10.1038/s41598-019-50084-5.
• [2709] Fibrotic aortic valve disease after radiotherapy: an immunohistochemical study in breast cancer and lymphoma patients.Cardiovasc Pathol. 2020 Mar-Apr;45:107176. doi: 10.1016/j.carpath.2019.107176. Epub 2019 Nov 15.
• [2710] Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32.Mol Ther. 2013 Dec;21(12):2195-204. doi: 10.1038/mt.2013.191. Epub 2013 Aug 20.
• [2711] A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways.J Biol Chem. 2006 Nov 17;281(46):34833-47. doi: 10.1074/jbc.M605483200. Epub 2006 Sep 19.
• [2712] Evaluation of associations between common variation in mitotic regulatory pathways and risk of overall and high grade breast cancer.Breast Cancer Res Treat. 2011 Sep;129(2):617-22. doi: 10.1007/s10549-011-1587-y. Epub 2011 May 24.
• [2713] PCBP1/HNRNP E1 Protects Chromosomal Integrity by Translational Regulation of CDC27.Mol Cancer Res. 2016 Jul;14(7):634-46. doi: 10.1158/1541-7786.MCR-16-0018. Epub 2016 Apr 21.
• [2714] Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs.Cells. 2019 Feb 11;8(2):146. doi: 10.3390/cells8020146.
• [2715] FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis.Breast Cancer Res Treat. 2017 Apr;162(2):243-253. doi: 10.1007/s10549-017-4125-8. Epub 2017 Jan 25.
• [2716] A Synthetic Dosage Lethal Genetic Interaction Between CKS1B and PLK1 Is Conserved in Yeast and Human Cancer Cells.Genetics. 2016 Oct;204(2):807-819. doi: 10.1534/genetics.116.190231. Epub 2016 Aug 24.
• [2717] CDCA4, a downstream gene of the Nrf2 signaling pathway, regulates cell proliferation and apoptosis in the MCF?/ADM human breast cancer cell line.Mol Med Rep. 2018 Jan;17(1):1507-1512. doi: 10.3892/mmr.2017.8095. Epub 2017 Nov 15.
• [2718] Distinct expression of CDCA3, CDCA5, and CDCA8 leads to shorter relapse free survival in breast cancer patient.Oncotarget. 2018 Jan 9;9(6):6977-6992. doi: 10.18632/oncotarget.24059. eCollection 2018 Jan 23.
• [2719] Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.Int J Cancer. 2018 Nov 15;143(10):2602-2613. doi: 10.1002/ijc.31766. Epub 2018 Sep 19.
• [2720] A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis.PLoS One. 2016 May 6;11(5):e0149185. doi: 10.1371/journal.pone.0149185. eCollection 2016.
• [2721] Lost in translation? A systematic database of gene expression in breast cancer.Pathobiology. 2008;75(2):112-8. doi: 10.1159/000123849. Epub 2008 Jun 10.
• [2722] Expression of Cadherin-17 Promotes Metastasis in a Highly Bone Marrow Metastatic Murine Breast Cancer Model.Biomed Res Int. 2017;2017:8494286. doi: 10.1155/2017/8494286. Epub 2017 Jan 19.
• [2723] CDH22 hypermethylation is an independent prognostic biomarker in breast cancer.Clin Epigenetics. 2017 Jan 24;9:7. doi: 10.1186/s13148-016-0309-z. eCollection 2017.
• [2724] Downregulated CDK10 expression in gastric cancer: Association with tumor progression and poor prognosis.Mol Med Rep. 2018 May;17(5):6812-6818. doi: 10.3892/mmr.2018.8662. Epub 2018 Mar 1.
• [2725] Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.Cancer Sci. 2018 Feb;109(2):363-372. doi: 10.1111/cas.13459. Epub 2018 Jan 13.
• [2726] mRNA Expression of CDK2AP1 in Human Breast Cancer: Correlation with Clinical and Pathological Parameters.Cancer Genomics Proteomics. 2018 Nov-Dec;15(6):447-452. doi: 10.21873/cgp.20103.
• [2727] Genetic variants in the mTOR pathway and interaction with body size and weight gain on breast cancer risk in African-American and European American women.Cancer Causes Control. 2016 Aug;27(8):965-76. doi: 10.1007/s10552-016-0774-x. Epub 2016 Jun 17.
• [2728] Silencing cyclin-dependent kinase inhibitor3 inhibits the migration of breast cancer cell lines.Mol Med Rep. 2016 Aug;14(2):1523-30. doi: 10.3892/mmr.2016.5401. Epub 2016 Jun 14.
• [2729] Differential Prognostic Relevance of Promoter DNA Methylation of CDO1 and HOPX in Primary Breast Cancer.Anticancer Res. 2019 May;39(5):2289-2298. doi: 10.21873/anticanres.13345.
• [2730] Large-scale genotyping identifies 41 new loci associated with breast cancer risk.Nat Genet. 2013 Apr;45(4):353-61, 361e1-2. doi: 10.1038/ng.2563.
• [2731] High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer.Clin Exp Med. 2017 Nov;17(4):547-553. doi: 10.1007/s10238-016-0442-1. Epub 2016 Dec 1.
• [2732] C/EBP links IL-6 and HIF-1 signaling to promote breast cancer stem cell-associated phenotypes.Oncogene. 2019 May;38(20):3765-3780. doi: 10.1038/s41388-018-0516-5. Epub 2018 Sep 27.
• [2733] TMEM2 Is a SOX4-Regulated Gene That Mediates Metastatic Migration and Invasion in Breast Cancer.Cancer Res. 2016 Sep 1;76(17):4994-5005. doi: 10.1158/0008-5472.CAN-15-2322. Epub 2016 Jun 21.
• [2734] Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer.Cancer Cell Int. 2019 Oct 11;19:264. doi: 10.1186/s12935-019-0986-8. eCollection 2019.
• [2735] Overexpression of centromere protein H is significantly associated with breast cancer progression and overall patient survival.Chin J Cancer. 2011 Sep;30(9):627-37. doi: 10.5732/cjc.010.10599.
• [2736] CENPI is overexpressed in colorectal cancer and regulates cell migration and invasion.Gene. 2018 Oct 20;674:80-86. doi: 10.1016/j.gene.2018.06.067. Epub 2018 Jun 21.
• [2737] Overexpression of the Ets-1 transcription factor in human breast cancer.Br J Cancer. 2004 Oct 4;91(7):1308-15. doi: 10.1038/sj.bjc.6602128.
• [2738] Centromere protein U (CENPU) enhances angiogenesis in triple-negative breast cancer by inhibiting ubiquitin-proteasomal degradation of COX-2.Cancer Lett. 2020 Jul 10;482:102-111. doi: 10.1016/j.canlet.2019.11.003. Epub 2019 Nov 6.
• [2739] USP9X regulates centrosome duplication and promotes breast carcinogenesis.Nat Commun. 2017 Mar 31;8:14866. doi: 10.1038/ncomms14866.
• [2740] MiR-144 suppresses proliferation, invasion, and migration of breast cancer cells through inhibiting CEP55.Cancer Biol Ther. 2018 Apr 3;19(4):306-315. doi: 10.1080/15384047.2017.1416934. Epub 2018 Mar 26.
• [2741] Candidate tumour suppressor genes at 11q23-q24 in breast cancer: evidence of alterations in PIG8, a gene involved in p53-induced apoptosis.Oncogene. 2001 Nov 22;20(53):7753-60. doi: 10.1038/sj.onc.1204993.
• [2742] CERS2 suppresses tumor cell invasion and is associated with decreased V-ATPase and MMP-2/MMP-9 activities in breast cancer.J Cell Biochem. 2015 Apr;116(4):502-13. doi: 10.1002/jcb.24978.
• [2743] Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer.Climacteric. 2009 Dec;12(6):502-13. doi: 10.3109/13697130902939913.
• [2744] Loss of the ceramide transfer protein augments EGF receptor signaling in breast cancer.Cancer Res. 2012 Jun 1;72(11):2855-66. doi: 10.1158/0008-5472.CAN-11-3069. Epub 2012 Apr 3.
• [2745] Prognostic Value of the Expression of DNA Repair-Related Biomarkers Mediated by Alcohol in Gastric Cancer Patients.Am J Pathol. 2018 Feb;188(2):367-377. doi: 10.1016/j.ajpath.2017.10.010. Epub 2018 Jan 10.
• [2746] MiR-519d-3p suppresses breast cancer cell growth and motility via targeting LIM domain kinase 1.Mol Cell Biochem. 2018 Jul;444(1-2):169-178. doi: 10.1007/s11010-017-3241-4. Epub 2017 Nov 29.
• [2747] A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells.J Transl Med. 2013 Mar 5;11:57. doi: 10.1186/1479-5876-11-57.
• [2748] CGRRF1, a growth suppressor, regulates EGFR ubiquitination in breast cancer.Breast Cancer Res. 2019 Dec 4;21(1):134. doi: 10.1186/s13058-019-1212-2.
• [2749] Clinical significance and prognostic value of chromatin assembly factor-1 overexpression in human solid tumours.Histopathology. 2010 Nov;57(5):716-24. doi: 10.1111/j.1365-2559.2010.03681.x.
• [2750] Mitochondrial autoimmunity and MNRR1 in breast carcinogenesis.BMC Cancer. 2019 May 2;19(1):411. doi: 10.1186/s12885-019-5575-7.
• [2751] CHD1L promotes cell cycle progression and cell motility by up-regulating MDM2 in breast cancer.Am J Transl Res. 2019 Mar 15;11(3):1581-1592. eCollection 2019.
• [2752] The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2(+) breast cancer cells.Biol Open. 2019 Apr 18;8(4):bio038323. doi: 10.1242/bio.038323.
• [2753] Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer.Breast Cancer Res. 2012 May 8;14(3):R73. doi: 10.1186/bcr3182.
• [2754] Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families.Breast Cancer Res Treat. 2017 Dec;166(3):937-949. doi: 10.1007/s10549-017-4469-0. Epub 2017 Aug 24.
• [2755] Poly(ADPribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer.Oncol Rep. 2019 Oct;42(4):1467-1474. doi: 10.3892/or.2019.7242. Epub 2019 Jul 18.
• [2756] Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expression.Carcinogenesis. 2004 Mar;25(3):405-11. doi: 10.1093/carcin/bgh024. Epub 2003 Nov 21.
• [2757] miR-122-5p promotes aggression and epithelial-mesenchymal transition in triple-negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen-activated protein kinase signaling.J Cell Physiol. 2020 Mar;235(3):2825-2835. doi: 10.1002/jcp.29188. Epub 2019 Sep 20.
• [2758] The IKK/NF-B signalingpathway requires Morgana to drive breast cancer metastasis.Nat Commun. 2017 Nov 21;8(1):1636. doi: 10.1038/s41467-017-01829-1.
• [2759] CHP2 Promotes Cell Proliferation in Breast Cancer via Suppression of FOXO3a.Mol Cancer Res. 2018 Oct;16(10):1512-1522. doi: 10.1158/1541-7786.MCR-18-0157. Epub 2018 Jul 2.
• [2760] Allelic expression imbalance polymorphisms in susceptibility chromosome regions and the risk and survival of breast cancer.Mol Carcinog. 2017 Jan;56(1):300-311. doi: 10.1002/mc.22493. Epub 2016 Apr 29.
• [2761] Chordin-Like 1 Suppresses Bone Morphogenetic Protein 4-Induced Breast Cancer Cell Migration and Invasion.Mol Cell Biol. 2016 May 2;36(10):1509-25. doi: 10.1128/MCB.00600-15. Print 2016 May 15.
• [2762] Chondroitin sulfate-mediated N-cadherin/-catenin signaling is associated with basal-like breast cancer cell invasion.J Biol Chem. 2018 Jan 12;293(2):444-465. doi: 10.1074/jbc.M117.814509. Epub 2017 Nov 28.
• [2763] Upregulation of microRNA-143 reverses drug resistance in human breast cancer cells via inhibition of cytokine-induced apoptosis inhibitor 1.Oncol Lett. 2017 Jun;13(6):4695-4700. doi: 10.3892/ol.2017.6078. Epub 2017 Apr 24.
• [2764] Subtype-Based Prognostic Analysis of Cell-in-Cell Structures in Early Breast Cancer.Front Oncol. 2019 Sep 20;9:895. doi: 10.3389/fonc.2019.00895. eCollection 2019.
• [2765] The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.J Cancer Res Clin Oncol. 2018 Dec;144(12):2339-2349. doi: 10.1007/s00432-018-2765-7. Epub 2018 Oct 20.
• [2766] Cold-inducible RNA-binding protein contributes to human antigen R and cyclin E1 deregulation in breast cancer.Mol Carcinog. 2010 Feb;49(2):130-40. doi: 10.1002/mc.20582.
• [2767] ERalpha-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis.Oncogene. 2007 Sep 27;26(44):6406-19. doi: 10.1038/sj.onc.1210468. Epub 2007 May 7.
• [2768] Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer.Breast Cancer Res Treat. 2011 Nov;130(1):319-29. doi: 10.1007/s10549-011-1657-1. Epub 2011 Jul 14.
• [2769] Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines.Int J Mol Med. 2004 Oct;14(4):729-35. doi: 10.3892/ijmm.14.4.729.
• [2770] Downregulation of CKS1B restrains the proliferation, migration, invasion and angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway.Int J Mol Med. 2019 Jul;44(1):103-114. doi: 10.3892/ijmm.2019.4183. Epub 2019 May 8.
• [2771] CLDN10 single nucleotide polymorphism rs1325774 alters the risk of breast cancer in south chinese women.Medicine (Baltimore). 2018 Dec;97(49):e13187. doi: 10.1097/MD.0000000000013187.
• [2772] Interleukin-18 enhances breast cancer cell migration via down-regulation of claudin-12 and induction of the p38 MAPK pathway.Biochem Biophys Res Commun. 2015 Apr 10;459(3):379-86. doi: 10.1016/j.bbrc.2015.02.108. Epub 2015 Feb 27.
• [2773] Claudin-16/paracellin-1, cloning, expression, and its role in tight junction functions in cancer and endothelial cells.Methods Mol Biol. 2011;762:383-407. doi: 10.1007/978-1-61779-185-7_28.
• [2774] Claudin-5 is involved in breast cancer cell motility through the N-WASP and ROCK signalling pathways.J Exp Clin Cancer Res. 2012 May 4;31(1):43. doi: 10.1186/1756-9966-31-43.
• [2775] Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling.PLoS One. 2008 Apr 30;3(4):e2079. doi: 10.1371/journal.pone.0002079.
• [2776] Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer.Onco Targets Ther. 2018 Jun 4;11:3303-3312. doi: 10.2147/OTT.S161311. eCollection 2018.
• [2777] Reciprocal modifications of CLIC4 in tumor epithelium and stroma mark malignant progression of multiple human cancers.Clin Cancer Res. 2007 Jan 1;13(1):121-31. doi: 10.1158/1078-0432.CCR-06-1562.
• [2778] Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry.Breast Cancer Res Treat. 2012 Feb;132(1):341-5. doi: 10.1007/s10549-011-1890-7. Epub 2011 Nov 29.
• [2779] Long-term Follow-up of Autologous Fat Transfer vs Conventional Breast Reconstruction and Association With Cancer Relapse in Patients With Breast Cancer.JAMA Surg. 2019 Jan 1;154(1):56-63. doi: 10.1001/jamasurg.2018.3744.
• [2780] Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c.Exp Cell Res. 2003 Jan 15;282(2):132-7. doi: 10.1016/s0014-4827(02)00023-x.
• [2781] CNK1 promotes invasion of cancer cells through NF-kappaB-dependent signaling.Mol Cancer Res. 2010 Mar;8(3):395-406. doi: 10.1158/1541-7786.MCR-09-0296. Epub 2010 Mar 2.
• [2782] Regulation of CNKSR2 protein stability by the HECT E3 ubiquitin ligase Smurf2, and its role in breast cancer progression.BMC Cancer. 2018 Mar 13;18(1):284. doi: 10.1186/s12885-018-4188-x.
• [2783] Screening for Excessive Alcohol Use and Brief Counseling of Adults - 17 States and the District of Columbia, 2014.MMWR Morb Mortal Wkly Rep. 2017 Mar 31;66(12):313-319. doi: 10.15585/mmwr.mm6612a1.
• [2784] Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells.Int J Oncol. 2009 Oct;35(4):673-81.
• [2785] Katanin P80 expression correlates with lymph node metastasis and worse overall survival in patients with breast cancer.Cancer Biomark. 2018;23(3):363-371. doi: 10.3233/CBM-181369.
• [2786] MMP13 is potentially a new tumor marker for breast cancer diagnosis.Oncol Rep. 2009 Nov;22(5):1119-27. doi: 10.3892/or_00000544.
• [2787] Development of novel real-time PCR methodology for quantification of COL11A1 mRNA variants and evaluation in breast cancer tissue specimens.BMC Cancer. 2015 Oct 14;15:694. doi: 10.1186/s12885-015-1725-8.
• [2788] Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.Biochem Biophys Res Commun. 2020 Jan 29;522(1):121-126. doi: 10.1016/j.bbrc.2019.11.050. Epub 2019 Nov 18.
• [2789] Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice.Breast Cancer Res Treat. 2008 Jul;110(2):283-95. doi: 10.1007/s10549-007-9731-4. Epub 2007 Sep 26.
• [2790] Vitamin D receptor gene polymorphism(s) and breast cancer risk in north Indians.Cancer Detect Prev. 2009;32(5-6):386-94. doi: 10.1016/j.canep.2009.04.012.
• [2791] Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry.Oncol Rep. 2019 Jul;42(1):151-175. doi: 10.3892/or.2019.7147. Epub 2019 May 3.
• [2792] The ubiquitin ligase COP1 regulates cell cycle and apoptosis by affecting p53 function in human breast cancer cell lines.Breast Cancer. 2018 Sep;25(5):529-538. doi: 10.1007/s12282-018-0849-5. Epub 2018 Mar 7.
• [2793] The prognostic value of CSN6 expression in upper tract urothelial carcinomas.Kaohsiung J Med Sci. 2019 Sep;35(9):559-565. doi: 10.1002/kjm2.12104. Epub 2019 Jul 24.
• [2794] COPS5 amplification and overexpression confers tamoxifen-resistance in ER-positive breast cancer by degradation of NCoR.Nat Commun. 2016 Jul 4;7:12044. doi: 10.1038/ncomms12044.
• [2795] Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode.Breast Cancer Res. 2016 Mar 8;18(1):29. doi: 10.1186/s13058-016-0689-1.
• [2796] 4,5-Diaryl 3(2H)Furanones: Anti-Inflammatory Activity and Influence on Cancer Growth.Molecules. 2019 May 6;24(9):1751. doi: 10.3390/molecules24091751.
• [2797] Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study.Geburtshilfe Frauenheilkd. 2017 Jun;77(6):651-659. doi: 10.1055/s-0042-113189. Epub 2017 Jun 28.
• [2798] FEAT expression correlates with tumor size, PR status, HER2 expression, Ki67 index, and molecular subtype and predicts recurrence in breast cancer.Neoplasma. 2017;64(1):123-130. doi: 10.4149/neo_2017_115.
• [2799] High expression of COX5B is associated with poor prognosis in breast cancer.Future Oncol. 2017 Aug;13(19):1711-1719. doi: 10.2217/fon-2017-0058. Epub 2017 Jun 8.
• [2800] Mitochondrial protein enriched extracellular vesicles discovered in human melanoma tissues can be detected in patient plasma.J Extracell Vesicles. 2019 Aug 27;8(1):1635420. doi: 10.1080/20013078.2019.1635420. eCollection 2019.
• [2801] Mitochondrial supercomplex assembly promotes breast and endometrial tumorigenesis by metabolic alterations and enhanced hypoxia tolerance.Nat Commun. 2019 Sep 11;10(1):4108. doi: 10.1038/s41467-019-12124-6.
• [2802] The influence of radiotherapy on ceruloplasmin and transferrin in whole blood of breast cancer patients.Radiat Environ Biophys. 2017 Nov;56(4):345-352. doi: 10.1007/s00411-017-0708-3. Epub 2017 Aug 28.
• [2803] CPEB1 mediates epithelial-to-mesenchyme transition and breast cancer metastasis.Oncogene. 2016 Jun 2;35(22):2893-901. doi: 10.1038/onc.2015.350. Epub 2015 Sep 28.
• [2804] Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells.BMC Cancer. 2019 Jun 11;19(1):561. doi: 10.1186/s12885-019-5771-5.
• [2805] CPEB4 promotes cell migration and invasion via upregulating Vimentin expression in breast cancer.Biochem Biophys Res Commun. 2017 Jul 22;489(2):135-141. doi: 10.1016/j.bbrc.2017.05.112. Epub 2017 May 20.
• [2806] Copine-III interacts with ErbB2 and promotes tumor cell migration.Oncogene. 2010 Mar 18;29(11):1598-610. doi: 10.1038/onc.2009.456. Epub 2009 Dec 14.
• [2807] CPSF6 is a Clinically Relevant Breast Cancer Vulnerability Target: Role of CPSF6 in Breast Cancer.EBioMedicine. 2017 Jul;21:65-78. doi: 10.1016/j.ebiom.2017.06.023. Epub 2017 Jun 24.
• [2808] Long noncoding RNA nuclear paraspeckle assembly transcript 1 interacts with microRNA?07 to modulate breast cancer growth and metastasis by targeting carnitine palmitoyltransferase?.Int J Oncol. 2019 Nov;55(5):1125-1136. doi: 10.3892/ijo.2019.4869. Epub 2019 Sep 4.
• [2809] Molecular characterization, genomic structure and expression analysis of a gene (CATL1/CPT1C) encoding a third member of the human carnitine acyltransferase family.Genomics. 2019 May 22:S0888-7543(18)30715-8. doi: 10.1016/j.ygeno.2019.05.019. Online ahead of print.
• [2810] CPT1A/2-Mediated FAO Enhancement-A Metabolic Target in Radioresistant Breast Cancer.Front Oncol. 2019 Nov 15;9:1201. doi: 10.3389/fonc.2019.01201. eCollection 2019.
• [2811] Familial Cancer Variant Prioritization Pipeline version 2 (FCVPPv2) applied to a papillary thyroid cancer family.Sci Rep. 2018 Aug 2;8(1):11635. doi: 10.1038/s41598-018-29952-z.
• [2812] Crumbs protein homolog 3 (CRB3) expression is associated with oestrogen and progesterone receptor positivity in breast cancer.Clin Exp Pharmacol Physiol. 2019 Sep;46(9):837-844. doi: 10.1111/1440-1681.13104. Epub 2019 Jun 10.
• [2813] RCP is a human breast cancer-promoting gene with Ras-activating function.J Clin Invest. 2009 Aug;119(8):2171-83. doi: 10.1172/JCI37622. Epub 2009 Jul 20.
• [2814] Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1.Nat Commun. 2017 Oct 20;8(1):1079. doi: 10.1038/s41467-017-01052-y.
• [2815] Smartphone problem-solving and behavioural activation therapy to reduce fear of recurrence among patients with breast cancer (SMartphone Intervention to LEssen fear of cancer recurrence: SMILE project): protocol for a randomised controlled trial.BMJ Open. 2018 Nov 8;8(11):e024794. doi: 10.1136/bmjopen-2018-024794.
• [2816] Macrophagic "Crown-like Structures" Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease.Cancer Prev Res (Phila). 2018 Feb;11(2):113-119. doi: 10.1158/1940-6207.CAPR-17-0245. Epub 2017 Nov 22.
• [2817] Primary cilia are increased in number and demonstrate structural abnormalities in human cancer.J Clin Pathol. 2017 Jul;70(7):571-574. doi: 10.1136/jclinpath-2016-204103. Epub 2016 Nov 21.
• [2818] Evaluation of SAT-1, SAT-2 and GalNAcT-1 mRNA in colon cancer by real-time PCR.Mol Cell Biochem. 2007 Apr;298(1-2):59-68. doi: 10.1007/s11010-006-9350-0. Epub 2006 Nov 21.
• [2819] Placental lactogen is expressed but is not translated into protein in breast cancer.PLoS One. 2014 Jan 24;9(1):e87325. doi: 10.1371/journal.pone.0087325. eCollection 2014.
• [2820] Loss of CSMD1 expression disrupts mammary duct formation while enhancing proliferation, migration and invasion.Oncol Rep. 2017 Jul;38(1):283-292. doi: 10.3892/or.2017.5656. Epub 2017 May 22.
• [2821] Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial.Breast. 2013 Apr;22(2):130-137. doi: 10.1016/j.breast.2013.01.015. Epub 2013 Feb 28.
• [2822] TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.Oncotarget. 2014 Mar 30;5(6):1609-20. doi: 10.18632/oncotarget.1707.
• [2823] Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.PLoS One. 2015 Apr 1;10(4):e0120020. doi: 10.1371/journal.pone.0120020. eCollection 2015.
• [2824] Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer.Int J Cancer. 2009 Jun 15;124(12):2893-8. doi: 10.1002/ijc.24296.
• [2825] Identification of a new cancer/testis gene family, CT47, among expressed multicopy genes on the human X chromosome.Genes Chromosomes Cancer. 2006 Apr;45(4):392-400. doi: 10.1002/gcc.20298.
• [2826] Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding protein.Cell Death Dis. 2019 Sep 18;10(10):689. doi: 10.1038/s41419-019-1892-7.
• [2827] C-terminal binding protein-2 promotes cell proliferation and migration in breast cancer via suppression of p16INK4A.Oncotarget. 2017 Apr 18;8(16):26154-26168. doi: 10.18632/oncotarget.15402.
• [2828] E-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.J Pathol. 2018 Aug;245(4):456-467. doi: 10.1002/path.5099. Epub 2018 Jun 20.
• [2829] Frequent inactivation of MCC/CTNNBIP1 and overexpression of phospho-beta-catenin(Y654) are associated with breast carcinoma: Clinical and prognostic significance.Biochim Biophys Acta. 2016 Sep;1862(9):1472-84. doi: 10.1016/j.bbadis.2016.05.009. Epub 2016 May 18.
• [2830] -catenin promotes the malignant phenotype in breast cancer.Tumour Biol. 2015 Feb;36(2):569-75. doi: 10.1007/s13277-014-2680-8. Epub 2014 Oct 2.
• [2831] Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.Oncogene. 2010 Mar 11;29(10):1509-18. doi: 10.1038/onc.2009.434. Epub 2009 Nov 30.
• [2832] SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ER-positive breast cancer through regulation of BRCA1.PLoS Genet. 2017 Oct 2;13(10):e1007031. doi: 10.1371/journal.pgen.1007031. eCollection 2017 Oct.
• [2833] Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice.Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2497-502. doi: 10.1073/pnas.0907240107. Epub 2010 Jan 21.
• [2834] Modulation of interaction of mutant TP53 and wild type BRCA1 by alkaloids: a computational approach towards targeting protein-protein interaction as a futuristic therapeutic intervention strategy for breast cancer impediment.J Biomol Struct Dyn. 2018 Oct;36(13):3376-3387. doi: 10.1080/07391102.2017.1388286. Epub 2017 Oct 23.
• [2835] CUEDC1 is a primary target of ER essential for the growth of breast cancer cells.Cancer Lett. 2018 Nov 1;436:87-95. doi: 10.1016/j.canlet.2018.08.018. Epub 2018 Aug 23.
• [2836] CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome.EMBO J. 2007 Apr 4;26(7):1831-42. doi: 10.1038/sj.emboj.7601602. Epub 2007 Mar 8.
• [2837] CUL1 Knockdown Attenuates the Adhesion, Invasion, and Migration of Triple-Negative Breast Cancer Cells via Inhibition of Epithelial-Mesenchymal Transition.Pathol Oncol Res. 2020 Apr;26(2):1153-1163. doi: 10.1007/s12253-019-00681-6. Epub 2019 Jun 7.
• [2838] CXCL3 is a potential target for breast cancer metastasis.Curr Cancer Drug Targets. 2014;14(3):294-309. doi: 10.2174/1568009614666140305222328.
• [2839] Downregulation of CYB5D2 is associated with breast cancer progression.Sci Rep. 2019 Apr 29;9(1):6624. doi: 10.1038/s41598-019-43006-y.
• [2840] DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms.Breast Cancer Res. 2017 Mar 7;19(1):25. doi: 10.1186/s13058-017-0814-9.
• [2841] Different transcriptional strategies for ccn2/ctgf gene induction between human chondrocytic and breast cancer cell lines.Biochimie. 2007 Mar;89(3):278-88. doi: 10.1016/j.biochi.2006.12.006. Epub 2007 Jan 3.
• [2842] Wild-type p53 upregulates an early onset breast cancer-associated gene GAS7 to suppress metastasis via GAS7-CYFIP1-mediated signaling pathway.Oncogene. 2018 Jul;37(30):4137-4150. doi: 10.1038/s41388-018-0253-9. Epub 2018 Apr 30.
• [2843] Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013 Jan 17;493(7432):406-10. doi: 10.1038/nature11725. Epub 2012 Dec 16.
• [2844] The epigenetically downregulated factor CYGB suppresses breast cancer through inhibition of glucose metabolism.J Exp Clin Cancer Res. 2018 Dec 13;37(1):313. doi: 10.1186/s13046-018-0979-9.
• [2845] CYP2D6 gene variants and their association with breast cancer susceptibility.Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1255-8. doi: 10.1158/1055-9965.EPI-11-0321. Epub 2011 Apr 28.
• [2846] Correction to: The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.Breast Cancer Res Treat. 2020 Jan;179(2):521-522. doi: 10.1007/s10549-019-05478-4.
• [2847] miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.IUBMB Life. 2018 Jan;70(1):71-80. doi: 10.1002/iub.1705. Epub 2017 Dec 16.
• [2848] Dachshund Depletion Disrupts Mammary Gland Development and Diverts the Composition of the Mammary Gland Progenitor Pool.Stem Cell Reports. 2019 Jan 8;12(1):135-151. doi: 10.1016/j.stemcr.2018.11.010. Epub 2018 Dec 13.
• [2849] Association between promoter hypermethylation of the DACT2 gene and tumor stages in breast cancer.J BUON. 2018 Mar-Apr;23(2):361-365.
• [2850] Increased hypermethylation of glutathione S-transferase P1, DNA-binding protein inhibitor, death associated protein kinase and paired box protein-5... Asian Pac J Cancer Prev. 2015;16(2):541-9.
• [2851] Effects of the knockdown of death-associated protein 3 expression on cell adhesion, growth and migration in breast cancer cells.Oncol Rep. 2015 May;33(5):2575-82. doi: 10.3892/or.2015.3825. Epub 2015 Mar 2.
• [2852] Correlation between Candidate Single Nucleotide Variants and Several Clinicopathological Risk Factors Related to Breast Cancer in Jordanian Women: A Genotype-Phenotype Study.J Cancer. 2019 Aug 8;10(19):4647-4654. doi: 10.7150/jca.33857. eCollection 2019.
• [2853] HLA-DBR 1 alleles and the susceptibility of Iranian patients with breast cancer.Pathol Oncol Res. 2001;7(1):39-41. doi: 10.1007/BF03032603.
• [2854] The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer.BMC Cancer. 2010 Apr 6;10:126. doi: 10.1186/1471-2407-10-126.
• [2855] Genetic association of deleted in colorectal carcinoma variants with breast cancer risk: A case-control study.Oncotarget. 2016 May 31;7(22):32765-73. doi: 10.18632/oncotarget.9024.
• [2856] Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling.BMC Cancer. 2015 Feb 19;15:70. doi: 10.1186/s12885-015-1022-6.
• [2857] The hSNM1B/Apollo variant rs11552449 is associated with cellular sensitivity towards mitomycin C and ionizing radiation.DNA Repair (Amst). 2018 Dec;72:93-98. doi: 10.1016/j.dnarep.2018.09.004. Epub 2018 Sep 12.
• [2858] Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial.Mod Pathol. 2017 Aug;30(8):1069-1077. doi: 10.1038/modpathol.2017.30. Epub 2017 May 26.
• [2859] IL-1 induces p62/SQSTM1 and autophagy in ER(+) /PR(+) BCa cell lines concomitant with ER and PR repression, conferring an ER(-) /PR(-) BCa-like phenotype.J Cell Biochem. 2019 Feb;120(2):1477-1491. doi: 10.1002/jcb.27340. Epub 2018 Oct 15.
• [2860] MultiDCoX: Multi-factor analysis of differential co-expression.BMC Bioinformatics. 2017 Dec 28;18(Suppl 16):576. doi: 10.1186/s12859-017-1963-7.
• [2861] miR-503 represses human cell proliferation and directly targets the oncogene DDHD2 by non-canonical target pairing.BMC Genomics. 2015 Feb 5;16(1):40. doi: 10.1186/s12864-015-1279-9.
• [2862] BB-Cl-Amidine as a novel therapeutic for canine and feline mammary cancer via activation of the endoplasmic reticulum stress pathway.BMC Cancer. 2018 Apr 12;18(1):412. doi: 10.1186/s12885-018-4323-8.
• [2863] DEAD box 1 (DDX1) expression predicts for local control and overall survival in early stage, node-negative breast cancer.Cancer. 2012 Feb 15;118(4):888-98. doi: 10.1002/cncr.26352. Epub 2011 Jul 14.
• [2864] Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer.BMC Cancer. 2018 Oct 22;18(1):1016. doi: 10.1186/s12885-018-4950-0.
• [2865] The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer.Oncogene. 2009 Nov 19;28(46):4053-64. doi: 10.1038/onc.2009.261. Epub 2009 Aug 31.
• [2866] SMARCAD1 knockdown uncovers its role in breast cancer cell migration, invasion, and metastasis.Expert Opin Ther Targets. 2016 Sep;20(9):1035-43. doi: 10.1080/14728222.2016.1195059. Epub 2016 Jun 13.
• [2867] A double-negative feedback loop between DEAD-box protein DDX21 and Snail regulates epithelial-mesenchymal transition and metastasis in breast cancer.Cancer Lett. 2018 Nov 28;437:67-78. doi: 10.1016/j.canlet.2018.08.021. Epub 2018 Aug 27.
• [2868] Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment.Oncogene. 2018 Jan 4;37(1):63-74. doi: 10.1038/onc.2017.308. Epub 2017 Sep 4.
• [2869] A size-shrinkable nanoparticle-based combined anti-tumor and anti-inflammatory strategy for enhanced cancer therapy.Nanoscale. 2018 May 31;10(21):9957-9970. doi: 10.1039/c8nr01184b.
• [2870] Regulation of nuclear receptor transcriptional activity by a novel DEAD box RNA helicase (DP97).J Biol Chem. 2003 Feb 14;278(7):4628-38. doi: 10.1074/jbc.M210066200. Epub 2002 Dec 3.
• [2871] The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis.Traffic. 2009 Aug;10(8):982-93. doi: 10.1111/j.1600-0854.2009.00917.x. Epub 2009 Apr 21.
• [2872] High levels of DEPDC1B predict shorter biochemical recurrence-free survival of patients with prostate cancer.Oncol Lett. 2017 Dec;14(6):6801-6808. doi: 10.3892/ol.2017.7027. Epub 2017 Sep 22.
• [2873] Decreased expression of C10orf10 and its prognostic significance in human breast cancer.PLoS One. 2014 Jun 17;9(6):e99730. doi: 10.1371/journal.pone.0099730. eCollection 2014.
• [2874] MiR-34a modulates ErbB2 in breast cancer.Cell Biol Int. 2017 Jan;41(1):93-101. doi: 10.1002/cbin.10700. Epub 2016 Dec 1.
• [2875] Overexpression of Derlin 3 is associated with malignant phenotype of breast cancer cells.Oncol Rep. 2017 Sep;38(3):1760-1766. doi: 10.3892/or.2017.5800. Epub 2017 Jul 10.
• [2876] Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53.Mol Cell Biol. 2010 Aug;30(16):3981-93. doi: 10.1128/MCB.01284-09. Epub 2010 Jun 14.
• [2877] DHX32 expression is an indicator of poor breast cancer prognosis.Oncol Lett. 2017 Feb;13(2):942-948. doi: 10.3892/ol.2016.5503. Epub 2016 Dec 14.
• [2878] DIP2C expression in breast cancer and its clinical significance.Pathol Res Pract. 2017 Nov;213(11):1394-1399. doi: 10.1016/j.prp.2017.09.007. Epub 2017 Sep 12.
• [2879] Breast cancer cells are arrested at different phases of the cell cycle following the re-expression of ARHI.Oncol Rep. 2014 May;31(5):2358-64. doi: 10.3892/or.2014.3107. Epub 2014 Mar 21.
• [2880] Novel dyskerin-mediated mechanism of p53 inactivation through defective mRNA translation.Cancer Res. 2010 Jun 1;70(11):4767-77. doi: 10.1158/0008-5472.CAN-09-4024. Epub 2010 May 25.
• [2881] Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer.Breast Cancer Res Treat. 2016 Apr;156(3):557-566. doi: 10.1007/s10549-016-3777-0. Epub 2016 Apr 9.
• [2882] High expression of DLG3 is associated with decreased survival from breast cancer.Clin Exp Pharmacol Physiol. 2019 Oct;46(10):937-943. doi: 10.1111/1440-1681.13132. Epub 2019 Jul 31.
• [2883] DLG5 suppresses breast cancer stem cell-like characteristics to restore tamoxifen sensitivity by inhibiting TAZ expression.J Cell Mol Med. 2019 Jan;23(1):512-521. doi: 10.1111/jcmm.13954. Epub 2018 Nov 18.
• [2884] EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming.Nat Commun. 2019 Nov 6;10(1):5033. doi: 10.1038/s41467-019-13034-3.
• [2885] Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231.BMC Cancer. 2010 Nov 25;10:649. doi: 10.1186/1471-2407-10-649.
• [2886] BP1, a potential biomarker for breast cancer prognosis.Biomark Med. 2018 May;12(5):535-545. doi: 10.2217/bmm-2017-0212. Epub 2018 Mar 26.
• [2887] Identifying breast cancer risk loci by global differential allele-specific expression (DASE) analysis in mammary epithelial transcriptome.BMC Genomics. 2012 Oct 30;13:570. doi: 10.1186/1471-2164-13-570.
• [2888] DMP1, a splice isoform of the tumour suppressor DMP1 locus, induces proliferation and progression of breast cancer.J Pathol. 2015 May;236(1):90-102. doi: 10.1002/path.4504. Epub 2015 Feb 9.
• [2889] The dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer.BMC Cancer. 2012 Feb 29;12:79. doi: 10.1186/1471-2407-12-79.
• [2890] Tid1 negatively regulates the migratory potential of cancer cells by inhibiting the production of interleukin-8.Cancer Res. 2005 Oct 1;65(19):8784-91. doi: 10.1158/0008-5472.CAN-04-4422.
• [2891] Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer.Breast Cancer Res. 2008;10(2):R22. doi: 10.1186/bcr1874. Epub 2008 Mar 7.
• [2892] Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.BMC Cancer. 2018 Mar 15;18(1):292. doi: 10.1186/s12885-018-4214-z.
• [2893] RME-8 regulates trafficking of the epidermal growth factor receptor.FEBS Lett. 2008 Mar 19;582(6):961-6. doi: 10.1016/j.febslet.2008.02.042. Epub 2008 Feb 26.
• [2894] Role for the transcriptional activator ZRF1 in early metastatic events in breast cancer progression and endocrine resistance.Oncotarget. 2018 Jun 19;9(47):28666-28690. doi: 10.18632/oncotarget.25596. eCollection 2018 Jun 19.
• [2895] Small GTPase RBJ promotes cancer progression by mobilizing MDSCs via IL-6.Oncoimmunology. 2016 Dec 23;6(1):e1245265. doi: 10.1080/2162402X.2016.1245265. eCollection 2017.
• [2896] ERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58IPK.Lab Invest. 2012 Feb;92(2):200-13. doi: 10.1038/labinvest.2011.163. Epub 2011 Nov 7.
• [2897] RNA-Binding Protein Dnd1 Promotes Breast Cancer Apoptosis by Stabilizing the Bim mRNA in a miR-221 Binding Site.Biomed Res Int. 2017;2017:9596152. doi: 10.1155/2017/9596152. Epub 2017 Jan 16.
• [2898] MiR-486-5p inhibits IL-22-induced epithelial-mesenchymal transition of breast cancer cell by repressing Dock1.J Cancer. 2019 Aug 19;10(19):4695-4706. doi: 10.7150/jca.30596. eCollection 2019.
• [2899] Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk.Exp Mol Pathol. 2004 Jun;76(3):260-3. doi: 10.1016/j.yexmp.2003.12.005.
• [2900] Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer.Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10848-53. doi: 10.1073/pnas.96.19.10848.
• [2901] Homozygous deletion and reduced expression of the DOCK8 gene in human lung cancer.Int J Oncol. 2006 Feb;28(2):321-8.
• [2902] Co-expression and significance of Dok2 and Ras p21 protein activator 1 in breast cancer.Oncol Lett. 2017 Nov;14(5):5386-5392. doi: 10.3892/ol.2017.6844. Epub 2017 Aug 28.
• [2903] Diagnostic significance of alternative splice variants of REST and DOPEY1 in the peripheral blood of patients with breast cancer.Tumour Biol. 2015 Apr;36(4):2473-80. doi: 10.1007/s13277-014-2860-6. Epub 2014 Nov 26.
• [2904] Downregulation of DPF3 promotes the proliferation and motility of breast cancer cells through activating JAK2/STAT3 signaling.Biochem Biophys Res Commun. 2019 Jun 30;514(3):639-644. doi: 10.1016/j.bbrc.2019.04.170. Epub 2019 May 7.
• [2905] NRF2 Induction Supporting Breast Cancer Cell Survival Is Enabled by Oxidative Stress-Induced DPP3-KEAP1 Interaction.Cancer Res. 2017 Jun 1;77(11):2881-2892. doi: 10.1158/0008-5472.CAN-16-2204. Epub 2017 Apr 17.
• [2906] Network-Based Methods to Identify Highly Discriminating Subsets of Biomarkers.IEEE/ACM Trans Comput Biol Bioinform. 2014 Nov-Dec;11(6):1029-37. doi: 10.1109/TCBB.2014.2325014.
• [2907] DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer.Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E11978-E11987. doi: 10.1073/pnas.1810598115. Epub 2018 Nov 29.
• [2908] Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer.Breast Cancer. 2008;15(1):73-8. doi: 10.1007/s12282-007-0015-y.
• [2909] Proteomics Identification and Validation of Desmocollin-1 and Catechol-O-Methyltransferase as Proteins Associated with Breast Cancer Cell Migration and Metastasis.Proteomics. 2019 Nov;19(21-22):e1900073. doi: 10.1002/pmic.201900073. Epub 2019 Oct 28.
• [2910] Down-regulation of the desmosomal cadherin desmocollin 3 in human breast cancer.Int J Oncol. 2001 Jul;19(1):169-74. doi: 10.3892/ijo.19.1.169.
• [2911] 5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene. 2007 Jan 4;26(1):77-90. doi: 10.1038/sj.onc.1209763. Epub 2006 Jun 26.
• [2912] Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers.Clin Cancer Res. 2004 Dec 15;10(24):8501-11. doi: 10.1158/1078-0432.CCR-04-1072.
• [2913] DUOX1 Silencing in Mammary Cell Alters the Response to Genotoxic Stress.Oxid Med Cell Longev. 2018 Apr 19;2018:3570526. doi: 10.1155/2018/3570526. eCollection 2018.
• [2914] DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118.Oncogene. 2007 Sep 6;26(41):6038-49. doi: 10.1038/sj.onc.1210426. Epub 2007 Mar 26.
• [2915] VHZ is a novel centrosomal phosphatase associated with cell growth and human primary cancers.Mol Cancer. 2010 May 28;9:128. doi: 10.1186/1476-4598-9-128.
• [2916] Erratum: Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity.Oncotarget. 2018 Oct 16;9(81):35286. doi: 10.18632/oncotarget.26258. eCollection 2018 Oct 16.
• [2917] Ras and TGF- signaling enhance cancer progression by promoting the Np63 transcriptional program.Sci Signal. 2016 Aug 23;9(442):ra84. doi: 10.1126/scisignal.aag3232.
• [2918] Long non-coding RNA MIAT promotes breast cancer progression and functions as ceRNA to regulate DUSP7 expression by sponging miR-155-5p.Oncotarget. 2017 Jul 12;8(44):76153-76164. doi: 10.18632/oncotarget.19190. eCollection 2017 Sep 29.
• [2919] Downregulated miR-1247-5p associates with poor prognosis and facilitates tumor cell growth via DVL1/Wnt/-catenin signaling in breast cancer.Biochem Biophys Res Commun. 2018 Oct 20;505(1):302-308. doi: 10.1016/j.bbrc.2018.09.103. Epub 2018 Sep 22.
• [2920] AMPK activators suppress breast cancer cell growth by inhibiting DVL3-facilitated Wnt/-catenin signaling pathway activity.Mol Med Rep. 2017 Feb;15(2):899-907. doi: 10.3892/mmr.2016.6094. Epub 2016 Dec 29.
• [2921] Loss of p27(kip1) expression is associated with poor prognosis in patients with taxane-treated breast cancer.Pathol Res Pract. 2018 Apr;214(4):565-571. doi: 10.1016/j.prp.2018.02.004. Epub 2018 Feb 14.
• [2922] RETRACTED: Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Breast Cancer.Mol Ther. 2019 Jun 5;27(6):1153-1165. doi: 10.1016/j.ymthe.2019.03.019. Epub 2019 Apr 6.
• [2923] Lowly methylated region analysis identifies EBF1 as a potential epigenetic modifier in breast cancer.Epigenetics. 2017;12(11):964-972. doi: 10.1080/15592294.2017.1373919. Epub 2017 Nov 10.
• [2924] Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib.EMBO J. 2018 May 15;37(10):e98359. doi: 10.15252/embj.201798359. Epub 2018 Apr 18.
• [2925] X-linked ectodermal dysplasia receptor is downregulated in breast cancer via promoter methylation.Clin Cancer Res. 2010 Feb 15;16(4):1140-8. doi: 10.1158/1078-0432.CCR-09-2463. Epub 2010 Feb 9.
• [2926] Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1.Nat Commun. 2018 Mar 6;9(1):967. doi: 10.1038/s41467-018-03433-3.
• [2927] Tumor derived EDIL3 modulates the expansion and osteoclastogenesis of myeloid derived suppressor cells in murine breast cancer model.J Bone Oncol. 2019 Apr 29;16:100238. doi: 10.1016/j.jbo.2019.100238. eCollection 2019 Jun.
• [2928] Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer.Breast Cancer Res. 2009;11(3):R34. doi: 10.1186/bcr2319. Epub 2009 Jun 15.
• [2929] Contradictory mRNA and protein misexpression of EEF1A1 in ductal breast carcinoma due to cell cycle regulation and cellular stress.Sci Rep. 2018 Sep 17;8(1):13904. doi: 10.1038/s41598-018-32272-x.
• [2930] Expression of the actin-binding proteins indicates that cofilin and fascin are related to breast tumour size.J Int Med Res. 2010 May-Jun;38(3):1042-8. doi: 10.1177/147323001003800331.
• [2931] The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.Breast Cancer Res. 2017 Nov 16;19(1):122. doi: 10.1186/s13058-017-0912-8.
• [2932] Fibulin-3 is a novel TGF- pathway inhibitor in the breast cancer microenvironment.Oncogene. 2015 Nov 5;34(45):5635-47. doi: 10.1038/onc.2015.13. Epub 2015 Mar 30.
• [2933] Protein expression of the Ets transcription factor Elf-1 in breast cancer cells is negatively correlated with histological grading, but not with clinical outcome.Oncol Rep. 2011 Nov;26(5):1121-5. doi: 10.3892/or.2011.1409. Epub 2011 Aug 2.
• [2934] EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination.Oncogene. 2015 May 14;34(20):2609-20. doi: 10.1038/onc.2014.200. Epub 2014 Jul 14.
• [2935] Resident Breast T Cells: The Troops Are Already There.Trends Mol Med. 2018 Oct;24(10):821-822. doi: 10.1016/j.molmed.2018.07.006. Epub 2018 Aug 1.
• [2936] EphrinB2 inhibits cell proliferation and motility invitro and predicts longer metastasisfree survival in breast cancer.Int J Oncol. 2019 Dec;55(6):1275-1286. doi: 10.3892/ijo.2019.4892. Epub 2019 Oct 4.
• [2937] Estrogen signaling in cancer microenvironment and prediction of response to hormonal therapy.J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):201-6. doi: 10.1016/j.jsbmb.2008.03.013. Epub 2008 Mar 12.
• [2938] Decreased expression and prognostic role of EHD2 in human breast carcinoma: correlation with E-cadherin.J Mol Histol. 2015 Apr;46(2):221-31. doi: 10.1007/s10735-015-9614-7. Epub 2015 Mar 12.
• [2939] Ei24-deficiency attenuates protein kinase C signaling and skin carcinogenesis in mice.Int J Biochem Cell Biol. 2012 Nov;44(11):1887-96. doi: 10.1016/j.biocel.2012.06.034. Epub 2012 Jul 6.
• [2940] Upregulation of EID3 sensitizes breast cancer cells to ionizing radiation-induced cellular senescence.Biomed Pharmacother. 2018 Nov;107:606-614. doi: 10.1016/j.biopha.2018.08.022. Epub 2018 Aug 14.
• [2941] EIF2A promotes cell survival during paclitaxel treatment in vitro and in vivo.J Cell Mol Med. 2019 Sep;23(9):6060-6071. doi: 10.1111/jcmm.14469. Epub 2019 Jun 18.
• [2942] Decreasing Eukaryotic Initiation Factor 3C (EIF3C) Suppresses Proliferation and Stimulates Apoptosis in Breast Cancer Cell Lines Through Mammalian Target of Rapamycin (mTOR) Pathway.Med Sci Monit. 2017 Aug 30;23:4182-4191. doi: 10.12659/msm.906389.
• [2943] Nuclear distribution of eIF3g and its interacting nuclear proteins in breast cancer cells.Mol Med Rep. 2016 Apr;13(4):2973-80. doi: 10.3892/mmr.2016.4935. Epub 2016 Feb 23.
• [2944] FGFR1-Activated Translation of WNT Pathway Components with Structured 5' UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation Initiation.Cancer Res. 2018 Aug 1;78(15):4229-4240. doi: 10.1158/0008-5472.CAN-18-0631. Epub 2018 May 29.
• [2945] The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape.Cell Death Dis. 2015 Jan 22;6(1):e1603. doi: 10.1038/cddis.2014.542.
• [2946] Inconsistent Results With Different Secondary Reflex Assays for Resolving HER2 Status.Am J Clin Pathol. 2016 Nov 1;146(5):618-626. doi: 10.1093/ajcp/aqw177.
• [2947] ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2(+) Breast Cancer Cells.Anticancer Res. 2017 Dec;37(12):6583-6591. doi: 10.21873/anticanres.12115.
• [2948] 15-methoxypuupehenol Induces Antitumor Effects In Vitro and In Vivo against Human Glioblastoma and Breast Cancer Models.Mol Cancer Ther. 2017 Apr;16(4):601-613. doi: 10.1158/1535-7163.MCT-16-0291. Epub 2017 Jan 9.
• [2949] Coordinate regulation of ELF5 and EHF at the chr11p13 CF modifier region.J Cell Mol Med. 2019 Nov;23(11):7726-7740. doi: 10.1111/jcmm.14646. Epub 2019 Sep 26.
• [2950] 15-Deoxy-12,14-prostaglandin J2 induces expression of 15-hydroxyprostaglandin dehydrogenase through Elk-1 activation in human breast cancer MDA-MB-231 cells.Mutat Res. 2014 Oct;768:6-15. doi: 10.1016/j.mrfmmm.2014.06.005. Epub 2014 Jun 24.
• [2951] Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome.Mod Pathol. 2010 Apr;23(4):603-10. doi: 10.1038/modpathol.2010.5. Epub 2010 Feb 5.
• [2952] A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells.Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4700-5. doi: 10.1073/pnas.0409894102. Epub 2005 Mar 21.
• [2953] EMILIN2 down-modulates the Wnt signalling pathway and suppresses breast cancer cell growth and migration.J Pathol. 2014 Mar;232(4):391-404. doi: 10.1002/path.4316.
• [2954] BTG1 expression correlates with the pathogenesis and progression of breast carcinomas.Tumour Biol. 2014 Apr;35(4):3317-26. doi: 10.1007/s13277-013-1437-0. Epub 2013 Nov 24.
• [2955] EMP1, EMP 2, and EMP3 as novel therapeutic targets in human cancer.Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):199-211. doi: 10.1016/j.bbcan.2017.04.004. Epub 2017 Apr 10.
• [2956] Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.BMC Cancer. 2017 Jul 24;17(1):496. doi: 10.1186/s12885-017-3488-x.
• [2957] Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells.Cancer Res. 1989 Jul 15;49(14):3904-9.
• [2958] Effects of Chronic and Intermittent Calorie Restriction on Adropin Levels in Breast Cancer.Nutr Cancer. 2017 Oct;69(7):1003-1010. doi: 10.1080/01635581.2017.1359314. Epub 2017 Sep 18.
• [2959] Expression of Alpha-Enolase (ENO1), Myc Promoter-Binding Protein-1 (MBP-1) and Matrix Metalloproteinases (MMP-2 and MMP-9) Reflect the Nature and Aggressiveness of Breast Tumors.Int J Mol Sci. 2019 Aug 14;20(16):3952. doi: 10.3390/ijms20163952.
• [2960] Serum tumor marker levels at the development of intracranial metastasis in patients with lung or breast cancer.J Thorac Dis. 2019 May;11(5):1765-1771. doi: 10.21037/jtd.2019.05.37.
• [2961] Deregulated expression of the PCPH proto-oncogene in human breast cancers.Int J Oncol. 2004 Oct;25(4):821-30.
• [2962] Expression of Protein 4.1 Family in Breast Cancer: Database Mining for 4.1 Family Members in Malignancies.Med Sci Monit. 2019 May 7;25:3374-3389. doi: 10.12659/MSM.914085.
• [2963] CDK10 is not a target for aberrant DNA methylation in breast cancer.Anticancer Res. 2009 Oct;29(10):3939-44.
• [2964] Clinical implications of the influence of Ehm2 on the aggressiveness of breast cancer cells through regulation of matrix metalloproteinase-9 expression.Mol Cancer Res. 2010 Nov;8(11):1501-12. doi: 10.1158/1541-7786.MCR-10-0186. Epub 2010 Oct 5.
• [2965] Comparative integromics on the breast cancer-associated gene KIAA1632: clues to a cancer antigen domain.Int J Oncol. 2007 Jul;31(1):205-10.
• [2966] EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer.Oncotarget. 2016 Oct 25;7(43):69592-69605. doi: 10.18632/oncotarget.11870.
• [2967] LncRNA DSCAM-AS1 acts as a sponge of miR-137 to enhance Tamoxifen resistance in breast cancer.J Cell Physiol. 2019 Mar;234(3):2880-2894. doi: 10.1002/jcp.27105. Epub 2018 Sep 10.
• [2968] Regulation of inflammatory gene expression in macrophages by epithelial-stromal interaction 1 (Epsti1).Biochem Biophys Res Commun. 2018 Feb 5;496(2):778-783. doi: 10.1016/j.bbrc.2017.12.014. Epub 2017 Dec 5.
• [2969] Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.Anticancer Res. 2019 Feb;39(2):797-802. doi: 10.21873/anticanres.13177.
• [2970] The Ras-related gene ERAS is involved in human and murine breast cancer.Sci Rep. 2018 Aug 29;8(1):13038. doi: 10.1038/s41598-018-31326-4.
• [2971] ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers.Cancers (Basel). 2019 Aug 10;11(8):1149. doi: 10.3390/cancers11081149.
• [2972] A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer.Cancer Discov. 2016 Nov;6(11):1267-1275. doi: 10.1158/2159-8290.CD-16-0487. Epub 2016 Sep 21.
• [2973] Let-7c-5p inhibits cell proliferation and induces cell apoptosis by targeting ERCC6 in breast cancer.Oncol Rep. 2017 Sep;38(3):1851-1856. doi: 10.3892/or.2017.5839. Epub 2017 Jul 19.
• [2974] Loss of PICH promotes chromosome instability and cell death in triple-negative breast cancer.Cell Death Dis. 2019 Jun 3;10(6):428. doi: 10.1038/s41419-019-1662-6.
• [2975] The PEA3 group of ETS-related transcription factors. Role in breast cancer metastasis.Adv Exp Med Biol. 2000;480:107-16. doi: 10.1007/0-306-46832-8_13.
• [2976] MiR-410 Acts as a Tumor Suppressor in Estrogen Receptor-Positive Breast Cancer Cells by Directly Targeting ERLIN2 via the ERS Pathway.Cell Physiol Biochem. 2018;48(2):461-474. doi: 10.1159/000491777. Epub 2018 Jul 17.
• [2977] Cancer-associated oxidoreductase ERO1- promotes immune escape through up-regulation of PD-L1 in human breast cancer.Oncotarget. 2017 Apr 11;8(15):24706-24718. doi: 10.18632/oncotarget.14960.
• [2978] miR-205-5p downregulation decreases gemcitabine sensitivity of breast cancer cells via ERp29 upregulation.Exp Ther Med. 2019 Nov;18(5):3525-3533. doi: 10.3892/etm.2019.7962. Epub 2019 Aug 30.
• [2979] Tocotrienol-treated MCF-7 human breast cancer cells show down-regulation of API5 and up-regulation of MIG6 genes.Cancer Genomics Proteomics. 2011 Jan-Feb;8(1):19-31.
• [2980] Expression of human endogenous retrovirus k envelope transcripts in human breast cancer.Clin Cancer Res. 2001 Jun;7(6):1553-60.
• [2981] Separase is a marker for prognosis and mitotic activity in breast cancer.Br J Cancer. 2017 Oct 24;117(9):1383-1391. doi: 10.1038/bjc.2017.301. Epub 2017 Aug 31.
• [2982] Genome-wide screen for differentially methylated long noncoding RNAs identifies Esrp2 and lncRNA Esrp2-as regulated by enhancer DNA methylation with prognostic relevance for human breast cancer.Oncogene. 2017 Nov 16;36(46):6446-6461. doi: 10.1038/onc.2017.246. Epub 2017 Jul 31.
• [2983] Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.Anticancer Agents Med Chem. 2018;18(8):1184-1196. doi: 10.2174/1871520618666180412123833.
• [2984] Modulation of translation factor's gene expression by histone deacetylase inhibitors in breast cancer cells.Clin Chem Lab Med. 2005;43(2):151-6. doi: 10.1515/CCLM.2005.025.
• [2985] Evaluating triptorelin as a treatment option for breast cancer.Expert Opin Pharmacother. 2019 Oct;20(15):1809-1818. doi: 10.1080/14656566.2019.1650020. Epub 2019 Sep 9.
• [2986] ER81-shRNA inhibits growth of triple-negative human breast cancer cell line MDA-MB-231 in vivo and in vitro.Asian Pac J Cancer Prev. 2012;13(5):2385-92. doi: 10.7314/apjcp.2012.13.5.2385.
• [2987] Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness.Neoplasia. 2019 Jul;21(7):627-640. doi: 10.1016/j.neo.2019.04.006. Epub 2019 May 14.
• [2988] Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases.Clin Exp Metastasis. 2017 Jun;34(5):333-344. doi: 10.1007/s10585-017-9853-y. Epub 2017 Jun 17.
• [2989] Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.Oncol Rep. 2007 Feb;17(2):465-9.
• [2990] MDA-MB-231 breast cancer cell viability, motility and matrix adhesion are regulated by a complex interplay of heparan sulfate, chondroitin-/dermatan sulfate and hyaluronan biosynthesis.Glycoconj J. 2017 Jun;34(3):411-420. doi: 10.1007/s10719-016-9735-6. Epub 2016 Oct 15.
• [2991] Tumor suppression and therapy sensitization of localized and metastatic breast cancer by adenovirus p53.Hum Gene Ther. 2001 May 1;12(7):763-72. doi: 10.1089/104303401750148685.
• [2992] FA2H Exhibits Tumor Suppressive Roles on Breast Cancers via Cancer Stemness Control.Front Oncol. 2019 Oct 24;9:1089. doi: 10.3389/fonc.2019.01089. eCollection 2019.
• [2993] FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis.Oncogene. 2019 Sep;38(37):6445-6460. doi: 10.1038/s41388-019-0893-4. Epub 2019 Jul 19.
• [2994] Mutation analysis of the Fanconi anaemia A gene in breast tumours with loss of heterozygosity at 16q24.3.Br J Cancer. 1999 Mar;79(7-8):1049-52. doi: 10.1038/sj.bjc.6690168.
• [2995] Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer.Hum Mol Genet. 2010 Nov 1;19(21):4273-7. doi: 10.1093/hmg/ddq351. Epub 2010 Aug 19.
• [2996] Role of Polymorphisms of FAM13A, PHLDB1, and CYP24A1 in Breast Cancer Risk.Curr Mol Med. 2019;19(8):579-588. doi: 10.2174/1566524019666190619125109.
• [2997] TGF promotes breast cancer stem cell self-renewal through an ILEI/LIFR signaling axis.Oncogene. 2019 May;38(20):3794-3811. doi: 10.1038/s41388-019-0703-z. Epub 2019 Jan 28.
• [2998] FAM53A Affects Breast Cancer Cell Proliferation, Migration, and Invasion in a p53-Dependent Manner.Front Oncol. 2019 Nov 14;9:1244. doi: 10.3389/fonc.2019.01244. eCollection 2019.
• [2999] FAN1 variants identified in multiple-case early-onset breast cancer families via exome sequencing: no evidence for association with risk for breast cancer.Breast Cancer Res Treat. 2011 Dec;130(3):1043-9. doi: 10.1007/s10549-011-1704-y. Epub 2011 Aug 21.
• [3000] Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer.Oncol Lett. 2019 Apr;17(4):3687-3700. doi: 10.3892/ol.2019.10046. Epub 2019 Feb 18.
• [3001] Coordination of the recruitment of the FANCD2 and PALB2 Fanconi anemia proteins by an ubiquitin signaling network.Chromosoma. 2017 Jun;126(3):417-430. doi: 10.1007/s00412-016-0602-9. Epub 2016 Jun 8.
• [3002] PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression.Cancer Res. 2018 Jun 15;78(12):3190-3206. doi: 10.1158/0008-5472.CAN-17-3514. Epub 2018 Apr 26.
• [3003] A novel transcription complex that selectively modulates apoptosis of breast cancer cells through regulation of FASTKD2.Mol Cell Biol. 2011 Jun;31(11):2287-98. doi: 10.1128/MCB.01381-10. Epub 2011 Mar 28.
• [3004] Down-regulated long non-coding RNA RNAZFHX4-AS1 suppresses invasion and migration of breast cancer cells via FAT4-dependent Hippo signaling pathway.Cancer Gene Ther. 2019 Nov;26(11-12):374-387. doi: 10.1038/s41417-018-0066-6. Epub 2018 Dec 14.
• [3005] Targeting the Ribosome Biogenesis Key Molecule Fibrillarin to Avoid Chemoresistance.Curr Med Chem. 2019;26(33):6020-6032. doi: 10.2174/0929867326666181203133332.
• [3006] Fibulin-1 interacts with Sex Hormone Binding Globulin and is linked to less aggressive estrogen-dependent breast cancers.Life Sci. 2018 Aug 15;207:372-380. doi: 10.1016/j.lfs.2018.06.024. Epub 2018 Jun 22.
• [3007] FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation.Oncogene. 2018 Oct;37(43):5794-5809. doi: 10.1038/s41388-018-0372-3. Epub 2018 Jul 4.
• [3008] Pathway-based classification of cancer subtypes.Biol Direct. 2012 Jul 3;7:21. doi: 10.1186/1745-6150-7-21.
• [3009] SCF(FBXO22) targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis.Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11754-11763. doi: 10.1073/pnas.1820990116. Epub 2019 May 28.
• [3010] FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex.Cancer Res. 2005 Dec 15;65(24):11304-13. doi: 10.1158/0008-5472.CAN-05-0936.
• [3011] FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation.Oncogene. 2017 Jun 8;36(23):3312-3321. doi: 10.1038/onc.2016.479. Epub 2017 Jan 9.
• [3012] Prognostic values of F-box members in breast cancer: an online database analysis and literature review.Biosci Rep. 2019 Jan 3;39(1):BSR20180949. doi: 10.1042/BSR20180949. Print 2019 Jan 31.
• [3013] Assessment of a FBXW8 frameshift mutation, c.1312_1313delGT, in breast cancer patients and controls from Central Europe.Cancer Genet. 2018 Jan;220:38-43. doi: 10.1016/j.cancergen.2017.11.006. Epub 2017 Nov 28.
• [3014] Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.Carcinogenesis. 2009 Sep;30(9):1528-31. doi: 10.1093/carcin/bgp084. Epub 2009 Apr 16.
• [3015] Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets.J Immunol. 2013 Mar 1;190(5):2424-36. doi: 10.4049/jimmunol.1200140. Epub 2013 Jan 28.
• [3016] MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer.Oncogene. 2020 Jan;39(1):234-247. doi: 10.1038/s41388-019-0986-0. Epub 2019 Aug 30.
• [3017] Kindlin-1 Promotes Pulmonary Breast Cancer Metastasis.Cancer Res. 2018 Mar 15;78(6):1484-1496. doi: 10.1158/0008-5472.CAN-17-1518. Epub 2018 Jan 12.
• [3018] Integrin-interacting protein Kindlin-2 induces mammary tumors in transgenic mice.Sci China Life Sci. 2019 Feb;62(2):225-234. doi: 10.1007/s11427-018-9336-6. Epub 2018 Nov 19.
• [3019] Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer.Cancer Res. 2005 Feb 15;65(4):1207-12. doi: 10.1158/0008-5472.CAN-04-3461.
• [3020] Serum degradome markers for the detection of breast cancer.J Proteome Res. 2010 Aug 6;9(8):3781-8. doi: 10.1021/pr100395s.
• [3021] Faciogenital dysplasia protein Fgd1 regulates invadopodia biogenesis and extracellular matrix degradation and is up-regulated in prostate and breast cancer.Cancer Res. 2009 Feb 1;69(3):747-52. doi: 10.1158/0008-5472.CAN-08-1980. Epub 2009 Jan 13.
• [3022] Expression of FGD3 gene as prognostic factor in young breast cancer patients.Sci Rep. 2019 Oct 23;9(1):15204. doi: 10.1038/s41598-019-51766-w.
• [3023] Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.Br J Cancer. 2016 Nov 22;115(11):1335-1342. doi: 10.1038/bjc.2016.326. Epub 2016 Oct 13.
• [3024] Characterization of FGD5 Expression in Primary Breast Cancers and Lymph Node Metastases.J Histochem Cytochem. 2018 Nov;66(11):787-799. doi: 10.1369/0022155418792032. Epub 2018 Jul 27.
• [3025] Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer.Endocr Relat Cancer. 2008 Mar;15(1):101-11. doi: 10.1677/ERC-07-0080.
• [3026] Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.Clin Cancer Res. 2020 Mar 15;26(6):1432-1448. doi: 10.1158/1078-0432.CCR-19-0353. Epub 2019 Nov 7.
• [3027] The FHL2 regulation in the transcriptional circuitry of human cancers.Gene. 2015 Nov 1;572(1):1-7. doi: 10.1016/j.gene.2015.07.043. Epub 2015 Jul 26.
• [3028] Downregulation and antiproliferative role of FHL3 in breast cancer.IUBMB Life. 2011 Sep;63(9):764-71. doi: 10.1002/iub.502.
• [3029] Formin Proteins FHOD1 and INF2 in Triple-Negative Breast Cancer: Association With Basal Markers and Functional Activities.Breast Cancer (Auckl). 2018 Aug 24;12:1178223418792247. doi: 10.1177/1178223418792247. eCollection 2018.
• [3030] Association between Birt Hogg Dube syndrome and cancer predisposition.Anticancer Res. 2010 Mar;30(3):751-7.
• [3031] BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers.Oncogene. 1991 Apr;6(4):659-63.
• [3032] Functional roles of Fli-1, a member of the Ets family of transcription factors, in human breast malignancy.Cancer Sci. 2007;98(11):1775-84. doi: 10.1111/j.1349-7006.2007.00598.x.
• [3033] Increase in fatty acids and flotillins upon resveratrol treatment of human breast cancer cells.Sci Rep. 2019 Sep 27;9(1):13960. doi: 10.1038/s41598-019-50416-5.
• [3034] Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model.Cancer Res. 1997 Aug 15;57(16):3511-6.
• [3035] Wnt/-Catenin Pathway-Regulated Fibromodulin Expression Is Crucial for Breast Cancer Metastasis and Inhibited by Aspirin.Front Pharmacol. 2019 Nov 25;10:1308. doi: 10.3389/fphar.2019.01308. eCollection 2019.
• [3036] Toca-1 is suppressed by p53 to limit breast cancer cell invasion and tumor metastasis.Breast Cancer Res. 2014 Dec 30;16(6):3413. doi: 10.1186/s13058-014-0503-x.
• [3037] Forkhead box D1 promotes proliferation and suppresses apoptosis via regulating polo-like kinase 2 in colorectal cancer.Biomed Pharmacother. 2018 Jul;103:1369-1375. doi: 10.1016/j.biopha.2018.04.190. Epub 2018 May 7.
• [3038] Methylomics of breast cancer: Seeking epimarkers in peripheral blood of young subjects. Tumour Biol. 2017 Mar;39(3):1010428317695040.
• [3039] FOXF1 Induces Epithelial-Mesenchymal Transition in Colorectal Cancer Metastasis by Transcriptionally Activating SNAI1.Neoplasia. 2018 Oct;20(10):996-1007. doi: 10.1016/j.neo.2018.08.004. Epub 2018 Sep 10.
• [3040] Expression of FOXJ1 in hepatocellular carcinoma: correlation with patients' prognosis and tumor cell proliferation.Mol Carcinog. 2013 Aug;52(8):647-59. doi: 10.1002/mc.21904. Epub 2012 Apr 4.
• [3041] FOXK1 promotes malignant progression of breast cancer by activating PI3K/AKT/mTOR signaling pathway.Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9978-9987. doi: 10.26355/eurrev_201911_19564.
• [3042] Forkhead box K2 inhibits the proliferation, migration, and invasion of human glioma cells and predicts a favorable prognosis.Onco Targets Ther. 2018 Feb 27;11:1067-1075. doi: 10.2147/OTT.S157126. eCollection 2018.
• [3043] Overexpression of Forkhead Box L1 (FOXL1) Inhibits the Proliferation and Invasion of Breast Cancer Cells.Oncol Res. 2017 Jul 5;25(6):959-965. doi: 10.3727/096504016X14803482769179. Epub 2016 Nov 29.
• [3044] Upregulation of FOXP4 in breast cancer promotes migration and invasion through facilitating EMT.Cancer Manag Res. 2019 Apr 8;11:2783-2793. doi: 10.2147/CMAR.S191641. eCollection 2019.
• [3045] Identification of novel GLI1 target genes and regulatory circuits in human cancer cells.Mol Oncol. 2018 Oct;12(10):1718-1734. doi: 10.1002/1878-0261.12366. Epub 2018 Aug 30.
• [3046] Molecular cloning and expression of proto-oncogene FRAT1 in human cancer.Int J Oncol. 2002 Apr;20(4):785-9.
• [3047] Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.Oncotarget. 2017 Feb 14;8(7):11442-11459. doi: 10.18632/oncotarget.14546.
• [3048] Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.Oncogene. 2006 Sep 28;25(44):6003-14. doi: 10.1038/sj.onc.1209592. Epub 2006 May 8.
• [3049] Fry Is Required for Mammary Gland Development During Pregnant Periods and Affects the Morphology and Growth of Breast Cancer Cells.Front Oncol. 2019 Nov 21;9:1279. doi: 10.3389/fonc.2019.01279. eCollection 2019.
• [3050] Association of single nucleotide polymorphisms in Wnt signaling pathway genes with breast cancer in Saudi patients.PLoS One. 2013;8(3):e59555. doi: 10.1371/journal.pone.0059555. Epub 2013 Mar 14.
• [3051] Identification of microRNA expression in sentinel lymph nodes from patients with breast cancer via RNA sequencing for diagnostic accuracy.J Gene Med. 2019 Apr;21(4):e3075. doi: 10.1002/jgm.3075. Epub 2019 Mar 3.
• [3052] MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.Oncogene. 2016 Dec 1;35(48):6189-6202. doi: 10.1038/onc.2016.151. Epub 2016 May 9.
• [3053] Reduced expression of -L-Fucosidase-1 (FUCA-1) predicts recurrence and shorter cancer specific survival in luminal B LN+ breast cancer patients.Oncotarget. 2018 Feb 7;9(20):15228-15238. doi: 10.18632/oncotarget.24445. eCollection 2018 Mar 16.
• [3054] Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis.Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11667-72. doi: 10.1073/pnas.0804979105. Epub 2008 Aug 6.
• [3055] MicroRNA-106b targets FUT6 to promote cell migration, invasion, and proliferation in human breast cancer.IUBMB Life. 2016 Sep;68(9):764-75. doi: 10.1002/iub.1541. Epub 2016 Aug 13.
• [3056] SOX9/FXYD3/Src Axis Is Critical for ER(+) Breast Cancer Stem Cell Function.Mol Cancer Res. 2019 Jan;17(1):238-249. doi: 10.1158/1541-7786.MCR-18-0610. Epub 2018 Sep 11.
• [3057] FXYD5 (dysadherin) may mediate metastatic progression through regulation of the -Na(+)-K(+)-ATPase subunit in the 4T1 mouse breast cancer model.Am J Physiol Cell Physiol. 2017 Jul 1;313(1):C108-C117. doi: 10.1152/ajpcell.00206.2016. Epub 2017 May 17.
• [3058] Identification of aberrant gene expression during breast ductal carcinoma in situ progression to invasive ductal carcinoma.J Int Med Res. 2020 Jan;48(1):300060518815364. doi: 10.1177/0300060518815364. Epub 2019 Feb 3.
• [3059] A tRNA fragment, 5'-tiRNA(Val), suppresses the Wnt/-catenin signaling pathway by targeting FZD3 in breast cancer.Cancer Lett. 2019 Aug 10;457:60-73. doi: 10.1016/j.canlet.2019.05.007. Epub 2019 May 9.
• [3060] Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer.J Pathol. 2017 Feb;241(3):350-361. doi: 10.1002/path.4841. Epub 2016 Dec 29.
• [3061] Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer.Am J Clin Pathol. 2008 Sep;130(3):414-24. doi: 10.1309/J3QV9763DYPV338D.
• [3062] G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer.Cell Cycle. 2017;16(21):2146-2155. doi: 10.1080/15384101.2017.1371884. Epub 2017 Sep 14.
• [3063] Stress granule-associated protein G3BP2 regulates breast tumor initiation.Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1033-1038. doi: 10.1073/pnas.1525387114. Epub 2017 Jan 17.
• [3064] MiR-98-5p regulates proliferation and metastasis of MCF-7 breast cancer cells by targeting Gab2.Eur Rev Med Pharmacol Sci. 2019 Apr;23(7):2847-2855. doi: 10.26355/eurrev_201904_17562.
• [3065] The expression and clinical significance of GADD45A in breast cancer patients.PeerJ. 2018 Aug 15;6:e5344. doi: 10.7717/peerj.5344. eCollection 2018.
• [3066] (--)-Xanthatin selectively induces GADD45 and stimulates caspase-independent cell death in human breast cancer MDA-MB-231 cells.Chem Res Toxicol. 2011 Jun 20;24(6):855-65. doi: 10.1021/tx200046s. Epub 2011 May 13.
• [3067] Sulfatide decreases the resistance to stress-induced apoptosis and increases P-selectin-mediated adhesion: a two-edged sword in breast cancer progression.Breast Cancer Res. 2018 Nov 6;20(1):133. doi: 10.1186/s13058-018-1058-z.
• [3068] Evaluation of GALNT16 polymorphisms to breast cancer risk in Chinese population.Mol Genet Genomic Med. 2019 Aug;7(8):e848. doi: 10.1002/mgg3.848. Epub 2019 Jul 8.
• [3069] Overexpression of microRNA-365 inhibits breast cancer cell growth and chemo-resistance through GALNT4.Eur Rev Med Pharmacol Sci. 2016 Nov;20(22):4710-4718.
• [3070] Hypoxia activates the cyclin D1 promoter via the Jak2/STAT5b pathway in breast cancer cells.Exp Mol Med. 2005 Aug 31;37(4):353-64. doi: 10.1038/emm.2005.45.
• [3071] Characterization and screening for mutations of the growth arrest-specific 11 (GAS11) and C16orf3 genes at 16q24.3 in breast cancer.Genomics. 1998 Sep 15;52(3):325-31. doi: 10.1006/geno.1998.5457.
• [3072] The transcription factor GATA1 and the histone methyltransferase SET7 interact to promote VEGF-mediated angiogenesis and tumor growth and predict clinical outcome of breast cancer.Oncotarget. 2016 Mar 1;7(9):9859-75. doi: 10.18632/oncotarget.7126.
• [3073] GATA5 activation of the progesterone receptor gene promoter in breast cancer cells is influenced by the +331G/A polymorphism.Cancer Res. 2006 Feb 1;66(3):1384-90. doi: 10.1158/0008-5472.CAN-05-2715.
• [3074] Correction: Guanylate-binding protein 2 regulates Drp1-mediated mitochondrial fission to suppress breast cancer cell invasion.Cell Death Dis. 2018 Nov 13;9(11):1127. doi: 10.1038/s41419-018-1133-5.
• [3075] Downregulated GBX2 gene suppresses proliferation, invasion and angiogenesis of breast cancer cells through inhibiting the Wnt/-catenin signaling pathway.Cancer Biomark. 2018;23(3):405-418. doi: 10.3233/CBM-181466.
• [3076] Recent Topics Around Multiple Endocrine Neoplasia Type 1.J Clin Endocrinol Metab. 2018 Apr 1;103(4):1296-1301. doi: 10.1210/jc.2017-02340.
• [3077] Engagement of I-branching {beta}-1, 6-N-acetylglucosaminyltransferase 2 in breast cancer metastasis and TGF-{beta} signaling.Cancer Res. 2011 Jul 15;71(14):4846-56. doi: 10.1158/0008-5472.CAN-11-0414. Epub 2011 Jul 12.
• [3078] GCSH antisense regulation determines breast cancer cells' viability.Sci Rep. 2018 Oct 18;8(1):15399. doi: 10.1038/s41598-018-33677-4.
• [3079] A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study.BMC Cancer. 2008 Feb 20;8:54. doi: 10.1186/1471-2407-8-54.
• [3080] Genetic variation in bone morphogenetic proteins and breast cancer risk in hispanic and non-hispanic white women: The breast cancer health disparities study.Int J Cancer. 2013 Jun 15;132(12):2928-39. doi: 10.1002/ijc.27960. Epub 2012 Dec 13.
• [3081] GDF3 inhibits the growth of breast cancer cells and promotes the apoptosis induced by Taxol.J Cancer Res Clin Oncol. 2012 Jun;138(6):1073-9. doi: 10.1007/s00432-012-1213-3. Epub 2012 Apr 10.
• [3082] Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells.Elife. 2017 Aug 29;6:e23649. doi: 10.7554/eLife.23649.
• [3083] Regulation of vimentin by SIP1 in human epithelial breast tumor cells.Oncogene. 2006 Aug 17;25(36):4975-85. doi: 10.1038/sj.onc.1209511. Epub 2006 Mar 27.
• [3084] Earlier age of onset of BRCA mutation-related cancers in subsequent generations.Cancer. 2012 Jan 15;118(2):321-5. doi: 10.1002/cncr.26284. Epub 2011 Sep 12.
• [3085] Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line.Oncogene. 1999 Nov 11;18(47):6513-20. doi: 10.1038/sj.onc.1203042.
• [3086] GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation.Breast Cancer Res Treat. 2019 Feb;174(1):65-78. doi: 10.1007/s10549-018-5052-z. Epub 2018 Nov 19.
• [3087] RNA-sequence-based microRNA expression signature in breast cancer: tumor-suppressive miR-101-5p regulates molecular pathogenesis.Mol Oncol. 2020 Feb;14(2):426-446. doi: 10.1002/1878-0261.12602. Epub 2019 Dec 29.
• [3088] RGS-GAIP-interacting protein controls breast cancer progression.Mol Cancer Res. 2010 Dec;8(12):1591-600. doi: 10.1158/1541-7786.MCR-10-0209. Epub 2010 Oct 27.
• [3089] Up-regulation of GIPC2 in human gastric cancer.Int J Oncol. 2002 Jun;20(6):1183-7.
• [3090] Targeting of GIT1 by miR-149* in breast cancer suppresses cell proliferation and metastasis in vitro and tumor growth in vivo.Onco Targets Ther. 2017 Dec 11;10:5873-5882. doi: 10.2147/OTT.S144280. eCollection 2017.
• [3091] GLCE rs3865014 (Val597Ile) polymorphism is associated with breast cancer susceptibility and triple-negative breast cancer in Siberian population.Gene. 2017 Sep 10;628:224-229. doi: 10.1016/j.gene.2017.07.054. Epub 2017 Jul 20.
• [3092] Modulation of cellular bioenergetics by CO-releasing molecules and NO-donors inhibits the interaction of cancer cells with human lung microvascular endothelial cells.Pharmacol Res. 2018 Oct;136:160-171. doi: 10.1016/j.phrs.2018.09.005. Epub 2018 Sep 6.
• [3093] Glutamate dehydrogenase (GLUD1) expression in breast cancer.Breast Cancer Res Treat. 2019 Feb;174(1):79-91. doi: 10.1007/s10549-018-5060-z. Epub 2018 Nov 23.
• [3094] MicroRNA-31 controls G protein alpha-13 (GNA13) expression and cell invasion in breast cancer cells.Mol Cancer. 2015 Mar 26;14:67. doi: 10.1186/s12943-015-0337-x.
• [3095] Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.Breast Cancer Res Treat. 2009 Nov;118(1):45-56. doi: 10.1007/s10549-008-0207-y. Epub 2008 Oct 17.
• [3096] Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin.Oncoimmunology. 2019 Jul 22;8(11):1641392. doi: 10.1080/2162402X.2019.1641392. eCollection 2019.
• [3097] Golgi tethering factor golgin-97 suppresses breast cancer cell invasiveness by modulating NF-B activity.Cell Commun Signal. 2018 Apr 27;16(1):19. doi: 10.1186/s12964-018-0230-5.
• [3098] Golgi Membrane Protein 1 (GOLM1) Promotes Growth and Metastasis of Breast Cancer Cells via Regulating Matrix Metalloproteinase-13 (MMP13).Med Sci Monit. 2019 Jan 29;25:847-855. doi: 10.12659/MSM.911667.
• [3099] Clinicopathological significance of miR-27b targeting Golgi protein 73 in patients with hepatocellular carcinoma.Anticancer Drugs. 2019 Feb;30(2):186-194. doi: 10.1097/CAD.0000000000000711.
• [3100] Profiling the expression pattern of GPI transamidase complex subunits in human cancer.Mod Pathol. 2008 Aug;21(8):979-91. doi: 10.1038/modpathol.2008.76. Epub 2008 May 16.
• [3101] Involvement of G-patch domain containing 2 overexpression in breast carcinogenesis.Cancer Sci. 2009 Aug;100(8):1443-50. doi: 10.1111/j.1349-7006.2009.01185.x. Epub 2009 May 4.
• [3102] Advanced fabrication of biosensor on detection of Glypican-1 using S-Acetylmercaptosuccinic anhydride (SAMSA) modification of antibody.Sci Rep. 2018 Sep 10;8(1):13541. doi: 10.1038/s41598-018-31994-2.
• [3103] Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells.Cancer Res. 2001 Jul 15;61(14):5562-9.
• [3104] NFAT promotes carcinoma invasive migration through glypican-6.Biochem J. 2011 Nov 15;440(1):157-66. doi: 10.1042/BJ20110530.
• [3105] PLD-Specific Small-Molecule Inhibitors Decrease Tumor-Associated Macrophages and Neutrophils Infiltration in Breast Tumors and Lung and Liver Metastases.PLoS One. 2016 Nov 16;11(11):e0166553. doi: 10.1371/journal.pone.0166553. eCollection 2016.
• [3106] G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion.Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4191-6. doi: 10.1073/pnas.1320239111. Epub 2014 Mar 5.
• [3107] G protein-coupled receptor GPR19 regulates E-cadherin expression and invasion of breast cancer cells.Biochim Biophys Acta Mol Cell Res. 2017 Jul;1864(7):1318-1327. doi: 10.1016/j.bbamcr.2017.05.001. Epub 2017 May 2.
• [3108] The orphan GPR50 receptor promotes constitutive TGF receptor signaling and protects against cancer development.Nat Commun. 2018 Mar 23;9(1):1216. doi: 10.1038/s41467-018-03609-x.
• [3109] Critical roles of LGN/GPSM2 phosphorylation by PBK/TOPK in cell division of breast cancer cells.Genes Chromosomes Cancer. 2010 Oct;49(10):861-72. doi: 10.1002/gcc.20795.
• [3110] Glutamic Pyruvate Transaminase GPT2 Promotes Tumorigenesis of Breast Cancer Cells by Activating Sonic Hedgehog Signaling.Theranostics. 2017 Jul 22;7(12):3021-3033. doi: 10.7150/thno.18992. eCollection 2017.
• [3111] Sulfasalazineinduced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor.Oncol Rep. 2019 Aug;42(2):826-838. doi: 10.3892/or.2019.7189. Epub 2019 Jun 6.
• [3112] Identification of a novel putative non-selenocysteine containing phospholipid hydroperoxide glutathione peroxidase (NPGPx) essential for alleviating oxidative stress generated from polyunsaturated fatty acids in breast cancer cells.J Biol Chem. 2004 Oct 15;279(42):43522-9. doi: 10.1074/jbc.M407141200. Epub 2004 Aug 4.
• [3113] GRAMD1B regulates cell migration in breast cancer cells through JAK/STAT and Akt signaling.Sci Rep. 2018 Jun 22;8(1):9511. doi: 10.1038/s41598-018-27864-6.
• [3114] FGF receptor phosphotyrosine 766 is a target for Grb14 to inhibit MDA-MB-231 human breast cancer cell signaling.Anticancer Res. 2005 Nov-Dec;25(6B):3877-82.
• [3115] GRB7 dependent proliferation of basal-like, HER-2 positive human breast cancer cell lines is mediated in part by HER-1 signaling.Mol Carcinog. 2019 May;58(5):699-707. doi: 10.1002/mc.22963. Epub 2019 Jan 28.
• [3116] Expression of G protein-coupled receptor kinase 4 is associated with breast cancer tumourigenesis.J Pathol. 2008 Nov;216(3):317-27. doi: 10.1002/path.2414.
• [3117] Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness.Clin Cancer Res. 2019 Aug 1;25(15):4846-4858. doi: 10.1158/1078-0432.CCR-18-2381. Epub 2019 May 7.
• [3118] DFNA5 promoter methylation a marker for breast tumorigenesis.Oncotarget. 2017 May 9;8(19):31948-31958. doi: 10.18632/oncotarget.16654.
• [3119] GSE1 negative regulation by miR-489-5p promotes breast cancer cell proliferation and invasion.Biochem Biophys Res Commun. 2016 Feb 26;471(1):123-8. doi: 10.1016/j.bbrc.2016.01.168. Epub 2016 Jan 30.
• [3120] GGCn polymorphism of eRF3a/GSPT1 gene and breast cancer susceptibility.Med Oncol. 2012 Sep;29(3):1581-5. doi: 10.1007/s12032-011-0111-x. Epub 2011 Nov 19.
• [3121] Comprehensive epigenetic analyses reveal master regulators driving lung metastasis of breast cancer.J Cell Mol Med. 2019 Aug;23(8):5415-5431. doi: 10.1111/jcmm.14424. Epub 2019 Jun 19.
• [3122] AP2 Transcription Factors Regulate Expression of CRABPII in hormone responsive breast carcinoma. J Surg Res. 2007 Mar;138(1):71-8.
• [3123] GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner.J Exp Clin Cancer Res. 2019 Apr 8;38(1):152. doi: 10.1186/s13046-019-1157-4.
• [3124] Upfront brain radiotherapy may improve survival for unfavorable prognostic breast cancer brain metastasis patients with Breast-GPA 0-2.0.Breast J. 2019 Nov;25(6):1134-1142. doi: 10.1111/tbj.13426. Epub 2019 Jul 8.
• [3125] Breast cancer and the MNSs blood groups.Dis Markers. 1989 Oct-Dec;7(4):253-6.
• [3126] DACH1 suppresses breast cancer as a negative regulator of CD44.Sci Rep. 2017 Jun 28;7(1):4361. doi: 10.1038/s41598-017-04709-2.
• [3127] The histone H2A isoform Hist2h2ac is a novel regulator of proliferation and epithelial-mesenchymal transition in mammary epithelial and in breast cancer cells.Cancer Lett. 2017 Jun 28;396:42-52. doi: 10.1016/j.canlet.2017.03.007. Epub 2017 Mar 11.
• [3128] Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression.Cancer Res. 2006 Apr 15;66(8):4065-78. doi: 10.1158/0008-5472.CAN-05-4083.
• [3129] Expression of -H2AX and patient prognosis in breast cancer cohort.J Cell Biochem. 2019 Aug;120(8):12958-12965. doi: 10.1002/jcb.28567. Epub 2019 Mar 28.
• [3130] Expressing Status and Correlation of ARID1A and Histone H2B on Breast Cancer.Biomed Res Int. 2016;2016:7593787. doi: 10.1155/2016/7593787. Epub 2016 Jan 21.
• [3131] A novel histone H4 variant H4G regulates rDNA transcription in breast cancer.Nucleic Acids Res. 2019 Sep 19;47(16):8399-8409. doi: 10.1093/nar/gkz547.
• [3132] Significant elevation of CLDN16 and HAPLN3 gene expression in human breast cancer.Oncol Rep. 2010 Sep;24(3):759-66. doi: 10.3892/or_00000918.
• [3133] Has2 natural antisense RNA and Hmga2 promote Has2 expression during TGF-induced EMT in breast cancer.Matrix Biol. 2019 Jul;80:29-45. doi: 10.1016/j.matbio.2018.09.002. Epub 2018 Sep 5.
• [3134] Epigenetic modifications, chromatin distribution and TP53 transcription in a model of breast cancer progression.J Cell Biochem. 2015 Apr;116(4):533-41. doi: 10.1002/jcb.25003.
• [3135] Interaction of Breast Cancer and Insulin Resistance on PD1 and TIM3 Expression in Peripheral Blood CD8 T Cells.Pathol Oncol Res. 2019 Jul;25(3):1233-1243. doi: 10.1007/s12253-019-00610-7. Epub 2019 Feb 13.
• [3136] miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1.Breast Cancer Res Treat. 2011 Apr;126(3):565-75. doi: 10.1007/s10549-010-0954-4. Epub 2010 May 27.
• [3137] Phenotype of vigilin expressing breast cancer cells binding to the 69 nt 3'UTR element in CSF-1R mRNA.Transl Oncol. 2019 Jan;12(1):106-115. doi: 10.1016/j.tranon.2018.09.012. Epub 2018 Oct 3.
• [3138] Concise approach for screening long non-coding RNAs functionally linked to human breast cancer associated genes.Exp Mol Pathol. 2019 Jun;108:89-96. doi: 10.1016/j.yexmp.2019.04.003. Epub 2019 Apr 3.
• [3139] Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma.Int J Cancer. 2009 Jun 15;124(12):2829-36. doi: 10.1002/ijc.24266.
• [3140] Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21.Oncotarget. 2016 Dec 6;7(49):80140-80163. doi: 10.18632/oncotarget.12818.
• [3141] G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin.Nat Commun. 2017 Aug 17;8(1):274. doi: 10.1038/s41467-017-00350-9.
• [3142] Splice variants and expression patterns of SHEP1, BCAR3 and NSP1, a gene family involved in integrin and receptor tyrosine kinase signaling.Gene. 2007 Apr 15;391(1-2):161-70. doi: 10.1016/j.gene.2006.12.016. Epub 2007 Jan 8.
• [3143] Nrf2 promotes breast cancer cell migration via up-regulation of G6PD/HIF-1/Notch1 axis.J Cell Mol Med. 2019 May;23(5):3451-3463. doi: 10.1111/jcmm.14241. Epub 2019 Feb 26.
• [3144] Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation.Anticancer Res. 2010 Oct;30(10):3853-67.
• [3145] Total polyphenol intake and breast cancer risk in the Seguimiento Universidad de Navarra (SUN) cohort.Br J Nutr. 2019 Sep 14;122(5):542-551. doi: 10.1017/S0007114518003811. Epub 2019 Feb 12.
• [3146] BACH1 Ser919Pro variant and breast cancer risk.BMC Cancer. 2006 Jan 24;6:19. doi: 10.1186/1471-2407-6-19.
• [3147] Tumor suppressor HIC1 is synergistically compromised by cancer-associated fibroblasts and tumor cells through the IL-6/pSTAT3 axis in breast cancer.BMC Cancer. 2019 Dec 3;19(1):1180. doi: 10.1186/s12885-019-6333-6.
• [3148] Frequent down-regulation of HIVEP2 in human breast cancer.Breast Cancer Res Treat. 2005 May;91(2):103-12. doi: 10.1007/s10549-004-5779-6.
• [3149] Novel estrogen target gene ZAS3 is overexpressed in systemic lupus erythematosus.Mol Immunol. 2013 May;54(1):23-31. doi: 10.1016/j.molimm.2012.10.026. Epub 2012 Nov 22.
• [3150] Misregulation of Scm3p/HJURP causes chromosome instability in Saccharomyces cerevisiae and human cells.PLoS Genet. 2011 Sep;7(9):e1002303. doi: 10.1371/journal.pgen.1002303. Epub 2011 Sep 29.
• [3151] Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles.Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11451-4. doi: 10.1073/pnas.97.21.11451.
• [3152] HLA class II variants in Chinese breast cancer patients.Asian Pac J Cancer Prev. 2011;12(11):3075-9.
• [3153] Signal peptide peptidase promotes tumor progression via facilitating FKBP8 degradation.Oncogene. 2019 Mar;38(10):1688-1701. doi: 10.1038/s41388-018-0539-y. Epub 2018 Oct 22.
• [3154] HMGB3 small interfere RNA suppresses mammosphere formation of MDA-MB-231 cells by down-regulating expression of HIF1.Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9506-9516. doi: 10.26355/eurrev_201911_19445.
• [3155] Effect of HMGN2 on proliferation and apoptosis of MCF-7 breast cancer cells.Oncol Lett. 2019 Jan;17(1):1160-1166. doi: 10.3892/ol.2018.9668. Epub 2018 Nov 5.
• [3156] The high-mobility group nucleosome-binding domain 5 is highly expressed in breast cancer and promotes the proliferation and invasion of breast cancer cells.Tumour Biol. 2015 Feb;36(2):959-66. doi: 10.1007/s13277-014-2715-1. Epub 2014 Oct 15.
• [3157] Function of HNRNPC in breast cancer cells by controlling the dsRNA-induced interferon response.EMBO J. 2018 Dec 3;37(23):e99017. doi: 10.15252/embj.201899017. Epub 2018 Aug 29.
• [3158] RNA G-quadruplex secondary structure promotes alternative splicing via the RNA-binding protein hnRNPF.Genes Dev. 2017 Nov 15;31(22):2296-2309. doi: 10.1101/gad.305862.117. Epub 2017 Dec 21.
• [3159] Inclusion of hnRNP L Alternative Exon 7 Is Associated with Good Prognosis and Inhibited by Oncogene SRSF3 in Head and Neck Squamous Cell Carcinoma.Biomed Res Int. 2019 Nov 13;2019:9612425. doi: 10.1155/2019/9612425. eCollection 2019.
• [3160] Heterogeneous nuclear ribonucleoprotein M promotes the progression of breast cancer by regulating the axin/-catenin signaling pathway.Biomed Pharmacother. 2018 Sep;105:848-855. doi: 10.1016/j.biopha.2018.05.014. Epub 2018 Jun 18.
• [3161] Development of Thiazole-5-carboxylate Derivatives as Selective Inhibitors of Monoacylglycerol Lipase as Target in Cancer.Mini Rev Med Chem. 2019;19(5):410-423. doi: 10.2174/1389557518666180702103542.
• [3162] Microarray-based analysis of whole-genome DNA methylation profiling in early detection of breast cancer.J Cell Biochem. 2019 Jan;120(1):658-670. doi: 10.1002/jcb.27423. Epub 2018 Sep 11.
• [3163] A functional in vivo screen for regulators of tumor progression identifies HOXB2 as a regulator of tumor growth in breast cancer.Genomics. 2011 Sep;98(3):164-72. doi: 10.1016/j.ygeno.2011.05.011. Epub 2011 Jun 13.
• [3164] Homeobox B4 inhibits breast cancer cell migration by directly binding to StAR-related lipid transfer domain protein 13.Oncol Lett. 2017 Oct;14(4):4625-4632. doi: 10.3892/ol.2017.6825. Epub 2017 Aug 25.
• [3165] HOXB7 promotes malignant progression by activating the TGF signaling pathway.Cancer Res. 2015 Feb 15;75(4):709-19. doi: 10.1158/0008-5472.CAN-14-3100. Epub 2014 Dec 26.
• [3166] Long non-coding RNA MIF-AS1 promotes breast cancer cell proliferation, migration and EMT process through regulating miR-1249-3p/HOXB8 axis.Pathol Res Pract. 2019 Jul;215(7):152376. doi: 10.1016/j.prp.2019.03.005. Epub 2019 May 4.
• [3167] Endocrine disrupting chemical, bisphenol-A, induces breast cancer associated gene HOXB9 expression in vitro and in vivo. Gene. 2016 Sep 30;590(2):234-43. doi: 10.1016/j.gene.2016.05.009. Epub 2016 May 13.
• [3168] HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells.Cancer Res. 2016 Aug 1;76(15):4443-56. doi: 10.1158/0008-5472.CAN-16-0774. Epub 2016 Jun 14.
• [3169] Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer.Breast Cancer Res. 2015 Sep 4;17(1):123. doi: 10.1186/s13058-015-0636-6.
• [3170] Bisphenol-A induces expression of HOXC6, an estrogen-regulated homeobox-containing gene associated with breast cancer.Biochim Biophys Acta. 2015 Jun;1849(6):697-708. doi: 10.1016/j.bbagrm.2015.02.003. Epub 2015 Feb 25.
• [3171] HOXC8 regulates self-renewal, differentiation and transformation of breast cancer stem cells.Mol Cancer. 2017 Feb 16;16(1):38. doi: 10.1186/s12943-017-0605-z.
• [3172] RNA Binding Protein RNPC1 Inhibits Breast Cancer Cell Metastasis via Activating STARD13-Correlated ceRNA Network.Mol Pharm. 2018 Jun 4;15(6):2123-2132. doi: 10.1021/acs.molpharmaceut.7b01123. Epub 2018 May 15.
• [3173] Identification of 20 genes aberrantly methylated in human breast cancers.Int J Cancer. 2005 Sep 1;116(3):407-14. doi: 10.1002/ijc.21054.
• [3174] HOXD3 Plays a Critical Role in Breast Cancer Stemness and Drug Resistance.Cell Physiol Biochem. 2018;46(4):1737-1747. doi: 10.1159/000489249. Epub 2018 Apr 23.
• [3175] Clonal origins of human breast cancer.J Pathol. 2001 Aug;194(4):406-12. doi: 10.1002/path.937.
• [3176] Progesterone impairs Herceptin effect on breast cancer cells.Oncol Lett. 2018 Feb;15(2):1817-1822. doi: 10.3892/ol.2017.7493. Epub 2017 Nov 27.
• [3177] Hornerin, an S100 family protein, is functional in breast cells and aberrantly expressed in breast cancer.BMC Cancer. 2012 Jun 22;12:266. doi: 10.1186/1471-2407-12-266.
• [3178] The Pro-Tumoral Activity of Heparan Sulfate 3-O-Sulfotransferase 3B (HS3ST3B) in Breast Cancer MDA-MB-231 Cells Is Dependent on the Expression of Neuropilin-1.Molecules. 2018 Oct 22;23(10):2718. doi: 10.3390/molecules23102718.
• [3179] The heparan sulfate 3-O-sulfotransferases (HS3ST) 2, 3B and 4 enhance proliferation and survival in breast cancer MDA-MB-231 cells.PLoS One. 2018 Mar 16;13(3):e0194676. doi: 10.1371/journal.pone.0194676. eCollection 2018.
• [3180] Silencing HS6ST3 inhibits growth and progression of breast cancer cells through suppressing IGF1R and inducing XAF1.Exp Cell Res. 2017 Jan 15;350(2):380-389. doi: 10.1016/j.yexcr.2016.12.019. Epub 2016 Dec 23.
• [3181] Ectopic expression of HSDL2 is related to cell proliferation and prognosis in breast cancer.Cancer Manag Res. 2019 Jul 12;11:6531-6542. doi: 10.2147/CMAR.S205316. eCollection 2019.
• [3182] Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo.Int J Cancer. 2020 Jan 15;146(2):531-541. doi: 10.1002/ijc.32694. Epub 2019 Nov 1.
• [3183] Amplification of FGF-related genes in human tumors: possible involvement of HST in breast carcinomas.Oncogene. 1989 Jul;4(7):915-22.
• [3184] Role of ALDH1A1 and HTRA2 expression in CCL2/CCR2-mediated breast cancer cell growth and invasion.Biol Open. 2019 Jun 28;8(7):bio040873. doi: 10.1242/bio.040873.
• [3185] Global Analysis of miRNA-mRNA Interaction Network in Breast Cancer with Brain Metastasis.Anticancer Res. 2017 Aug;37(8):4455-4468. doi: 10.21873/anticanres.11841.
• [3186] DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood.Int J Cancer. 2015 Apr 15;136(8):1845-55. doi: 10.1002/ijc.29205. Epub 2014 Sep 24.
• [3187] HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis.Eur Rev Med Pharmacol Sci. 2019 Jan;23(10):4126-4135. doi: 10.26355/eurrev_201901_17914.
• [3188] Sustained conditional knockdown reveals intracellular bone sialoprotein as essential for breast cancer skeletal metastasis.Oncotarget. 2014 Jul 30;5(14):5510-22. doi: 10.18632/oncotarget.2132.
• [3189] Role of ICAM1 in invasion of human breast cancer cells.Carcinogenesis. 2005 May;26(5):943-50. doi: 10.1093/carcin/bgi070. Epub 2005 Mar 17.
• [3190] The genetic polymorphisms of intercellular cell adhesion molecules and breast cancer susceptibility: a meta-analysis.Mol Biol Rep. 2013 Feb;40(2):1855-60. doi: 10.1007/s11033-012-2241-4. Epub 2012 Oct 19.
• [3191] Differential regulation of estrogen receptor expression in breast cancer cells by metastasis-associated protein 1.Cancer Res. 2014 Mar 1;74(5):1484-94. doi: 10.1158/0008-5472.CAN-13-2020. Epub 2014 Jan 10.
• [3192] Androgen receptor coactivator p44/Mep50 in breast cancer growth and invasion.J Cell Mol Med. 2010 Dec;14(12):2780-9. doi: 10.1111/j.1582-4934.2009.00936.x.
• [3193] Mechanism and biological significance of the overexpression of IFITM3 in gastric cancer.Oncol Rep. 2014 Dec;32(6):2648-56. doi: 10.3892/or.2014.3522. Epub 2014 Oct 1.
• [3194] Integrative genomic analyses on IL28RA, the common receptor of interferon-lambda1, -lambda2 and -lambda3.Int J Mol Med. 2010 May;25(5):807-12.
• [3195] Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.J Pathol. 2008 Feb;214(3):357-67. doi: 10.1002/path.2278.
• [3196] IMP1 regulates UCA1-mediated cell invasion through facilitating UCA1 decay and decreasing the sponge effect of UCA1 for miR-122-5p.Breast Cancer Res. 2018 Apr 18;20(1):32. doi: 10.1186/s13058-018-0959-1.
• [3197] CCN6 regulates IGF2BP2and HMGA2 signaling in metaplastic carcinomas of the breast.Breast Cancer Res Treat. 2018 Dec;172(3):577-586. doi: 10.1007/s10549-018-4960-2. Epub 2018 Sep 15.
• [3198] Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes.Clin Cancer Res. 2007 Jul 15;13(14):4061-8. doi: 10.1158/1078-0432.CCR-06-3052.
• [3199] Activated kinase screening identifies the IKBKE oncogene as a positive regulator of autophagy.Autophagy. 2019 Feb;15(2):312-326. doi: 10.1080/15548627.2018.1517855. Epub 2018 Oct 5.
• [3200] Biological Properties and the Role of IL-25 in Disease Pathogenesis.J Immunol Res. 2018 Sep 23;2018:6519465. doi: 10.1155/2018/6519465. eCollection 2018.
• [3201] The expression and clinical significance of secretory leukocyte proteinase inhibitor (SLPI) in mammary carcinoma using bioinformatics analysis.Gene. 2019 Dec 15;720:144088. doi: 10.1016/j.gene.2019.144088. Epub 2019 Aug 30.
• [3202] Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers.Mol Cancer Ther. 2017 Jul;16(7):1299-1311. doi: 10.1158/1535-7163.MCT-16-0839. Epub 2017 Apr 4.
• [3203] IL-27 -964A>G polymorphism and the risk of breast cancer: a case-control study.Tumour Biol. 2014 Dec;35(12):12099-102. doi: 10.1007/s13277-014-2512-x. Epub 2014 Aug 22.
• [3204] Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the Breast Cancer Health Disparities Study.Carcinogenesis. 2014 Aug;35(8):1750-9. doi: 10.1093/carcin/bgu078. Epub 2014 Mar 26.
• [3205] Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line.Breast Cancer. 2018 Sep;25(5):566-574. doi: 10.1007/s12282-018-0853-9. Epub 2018 Mar 19.
• [3206] miR-188-5p suppresses cellular proliferation and migration via IL6ST: A potential noninvasive diagnostic biomarker for breast cancer.J Cell Physiol. 2020 May;235(5):4890-4901. doi: 10.1002/jcp.29367. Epub 2019 Oct 24.
• [3207] Interleukin enhancer binding factor 2 is a prognostic biomarker for breast cancer that also predicts neoadjuvant chemotherapy responses.Am J Transl Res. 2018 Jun 15;10(6):1677-1689. eCollection 2018.
• [3208] PP2C inhibits p300-mediated p53 acetylation via ATM/BRCA1 pathway to impede DNA damage response in breast cancer.Sci Adv. 2019 Oct 16;5(10):eaaw8417. doi: 10.1126/sciadv.aaw8417. eCollection 2019 Oct.
• [3209] C6orf106 accelerates pancreatic cancer cell invasion and proliferation via activating ERK signaling pathway.Mol Cell Biochem. 2019 Apr;454(1-2):87-95. doi: 10.1007/s11010-018-3455-0. Epub 2018 Oct 11.
• [3210] Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.Mod Pathol. 2019 Jan;32(1):81-87. doi: 10.1038/s41379-018-0116-5. Epub 2018 Aug 29.
• [3211] C1orf106, an innate immunity activator, is amplified in breast cancer and is required for basal-like/luminal progenitor fate decision.Sci China Life Sci. 2019 Sep;62(9):1229-1242. doi: 10.1007/s11427-019-9570-y. Epub 2019 Aug 1.
• [3212] Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer.Carcinogenesis. 2015 Feb;36(2):256-71. doi: 10.1093/carcin/bgu326. Epub 2015 Jan 13.
• [3213] Stromal ING1 expression induces a secretory phenotype and correlates with breast cancer patient survival.Mol Cancer. 2015 Aug 27;14:164. doi: 10.1186/s12943-015-0434-x.
• [3214] Suberoylanilide hydroxamic acid (SAHA)-induced dynamics of a human histone deacetylase protein interaction network.Mol Cell Proteomics. 2014 Nov;13(11):3114-25. doi: 10.1074/mcp.M113.037127. Epub 2014 Jul 29.
• [3215] Differential cellular localization of CELSR2 and ING4 and correlations with hormone receptor status in breast cancer.Histol Histopathol. 2018 Aug;33(8):835-842. doi: 10.14670/HH-11-979. Epub 2018 Feb 28.
• [3216] Common genetic variation and novel loci associated with volumetric mammographic density.Breast Cancer Res. 2018 Apr 17;20(1):30. doi: 10.1186/s13058-018-0954-6.
• [3217] miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer.Int J Cancer. 2017 May 15;140(10):2310-2320. doi: 10.1002/ijc.30661. Epub 2017 Mar 11.
• [3218] Coumarin-Fatty Acid Conjugates as Potential ER/AKT-1 Antagonists for ER Positive Breast Cancer.Anticancer Agents Med Chem. 2020;20(4):437-449. doi: 10.2174/1871520619666191028104339.
• [3219] Psychiatric disorders and cardiovascular diseases during the diagnostic workup of potential breast cancer: a population-based cohort study in Skne, Sweden.Breast Cancer Res. 2019 Dec 10;21(1):139. doi: 10.1186/s13058-019-1232-y.
• [3220] Identification of breast cancer-restricted antigens by antibody screening of SKBR3 cDNA library using a preselected patient's serum.Breast Cancer Res Treat. 2002 Jun;73(3):245-56. doi: 10.1023/a:1015854415746.
• [3221] The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer.Cancer Res. 2008 Jan 15;68(2):537-44. doi: 10.1158/0008-5472.CAN-07-5682.
• [3222] Downregulation of importin-9 protects MCF-7 cells against apoptosis induced by the combination of garlic-derived alliin and paclitaxel.Oncol Rep. 2016 May;35(5):3084-93. doi: 10.3892/or.2016.4628. Epub 2016 Feb 22.
• [3223] Ras GTPase-Activating-Like Protein IQGAP1 (IQGAP1) Promotes Breast Cancer Proliferation and Invasion and Correlates with Poor Clinical Outcomes.Med Sci Monit. 2018 May 20;24:3315-3323. doi: 10.12659/MSM.909916.
• [3224] IQ Motif Containing GTPase-Activating Protein 3 (IQGAP3) Inhibits Kaempferol-Induced Apoptosis in Breast Cancer Cells by Extracellular Signal-Regulated Kinases 1/2 (ERK1/2) Signaling Activation.Med Sci Monit. 2019 Oct 12;25:7666-7674. doi: 10.12659/MSM.915642.
• [3225] GEP100 regulates epidermal growth factor-induced MDA-MB-231 breast cancer cell invasion through the activation of Arf6/ERK/uPAR signaling pathway.Exp Cell Res. 2013 Aug 1;319(13):1932-1941. doi: 10.1016/j.yexcr.2013.05.028. Epub 2013 Jun 5.
• [3226] Upregulated IQUB promotes cell proliferation and migration via activating Akt/GSK3/-catenin signaling pathway in breast cancer.Cancer Med. 2018 Aug;7(8):3875-3888. doi: 10.1002/cam4.1568. Epub 2018 Jul 2.
• [3227] IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5(+) B- and T-cell trafficking to tumor-conditioned media.Immunol Cell Biol. 2015 May-Jun;93(5):486-99. doi: 10.1038/icb.2014.110. Epub 2014 Dec 23.
• [3228] Polymorphisms associated with oral clefts as potential susceptibility markers for oral and breast cancer.Arch Oral Biol. 2019 Mar;99:9-14. doi: 10.1016/j.archoralbio.2018.12.004. Epub 2018 Dec 14.
• [3229] Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells.Cancer Res. 2001 Sep 1;61(17):6540-7.
• [3230] IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation.Nat Commun. 2016 Nov 23;7:13567. doi: 10.1038/ncomms13567.
• [3231] FTO Gene Affects Obesity and Breast Cancer Through Similar Mechanisms: A New Insight into the Molecular Therapeutic Targets.Nutr Cancer. 2018 Jan;70(1):30-36. doi: 10.1080/01635581.2018.1397709. Epub 2017 Dec 8.
• [3232] Transcription of human endogenous retroviral sequences related to mouse mammary tumor virus in human breast and placenta: similar pattern in most malignant and nonmalignant breast tissues.AIDS Res Hum Retroviruses. 1997 Apr 10;13(6):507-16. doi: 10.1089/aid.1997.13.507.
• [3233] ISL1 is upregulated in breast cancer and promotes cell proliferation, invasion, and angiogenesis.Onco Targets Ther. 2018 Feb 14;11:781-789. doi: 10.2147/OTT.S144241. eCollection 2018.
• [3234] Knockdown of ISOC1 suppresses cell proliferation in pancreatic cancer in vitro.Oncol Lett. 2019 May;17(5):4263-4270. doi: 10.3892/ol.2019.10082. Epub 2019 Feb 28.
• [3235] OLC1 is overexpressed in breast cancer and its expression correlates with poor patient survival.Tumour Biol. 2014 Sep;35(9):8823-7. doi: 10.1007/s13277-014-2130-7. Epub 2014 Jun 1.
• [3236] RUVBL1-ITFG1 interaction is required for collective invasion in breast cancer.Biochim Biophys Acta Gen Subj. 2017 Jul;1861(7):1788-1800. doi: 10.1016/j.bbagen.2017.03.016. Epub 2017 Mar 21.
• [3237] Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells.Transfusion. 2006 Jul;46(7):1199-209. doi: 10.1111/j.1537-2995.2006.00871.x.
• [3238] Integrin 7 high expression correlates with deteriorative tumor features and worse overall survival, and its knockdown inhibits cell proliferation and invasion but increases apoptosis in breast cancer.J Clin Lab Anal. 2019 Oct;33(8):e22979. doi: 10.1002/jcla.22979. Epub 2019 Jul 19.
• [3239] Fas Activated Serine-Threonine Kinase Domains 2 (FASTKD2) mediates apoptosis of breast and prostate cancer cells through its novel FAST2 domain.BMC Cancer. 2014 Nov 20;14:852. doi: 10.1186/1471-2407-14-852.
• [3240] Integrin 5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways.Oncogene. 2013 Jun 20;32(25):3049-58. doi: 10.1038/onc.2012.320. Epub 2012 Jul 23.
• [3241] Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype.J Clin Oncol. 2011 Feb 20;29(6):660-6. doi: 10.1200/JCO.2010.31.1258. Epub 2011 Jan 10.
• [3242] Inositol-1,4,5-trisphosphate 3-kinase-A (ITPKA) is frequently over-expressed and functions as an oncogene in several tumor types.Biochem Pharmacol. 2017 Aug 1;137:1-9. doi: 10.1016/j.bcp.2017.03.023. Epub 2017 Apr 2.
• [3243] JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity.Oncogene. 2019 Feb;38(7):980-997. doi: 10.1038/s41388-018-0466-y. Epub 2018 Sep 5.
• [3244] Clipping of arginine-methylated histone tails by JMJD5 and JMJD7.Proc Natl Acad Sci U S A. 2017 Sep 12;114(37):E7717-E7726. doi: 10.1073/pnas.1706831114. Epub 2017 Aug 28.
• [3245] HN1 contributes to migration, invasion, and tumorigenesis of breast cancer by enhancing MYC activity.Mol Cancer. 2017 May 11;16(1):90. doi: 10.1186/s12943-017-0656-1.
• [3246] HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway.Stem Cell Reports. 2018 Jan 9;10(1):212-227. doi: 10.1016/j.stemcr.2017.11.010. Epub 2017 Dec 14.
• [3247] Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. Genome Biol. 2014 Jan 7;15(1):R9.
• [3248] JUNB governs a feed-forward network of TGF signaling that aggravates breast cancer invasion.Nucleic Acids Res. 2018 Feb 16;46(3):1180-1195. doi: 10.1093/nar/gkx1190.
• [3249] Cis-guggulsterone inhibits the IKK/NF-B pathway, whereas trans-guggulsterone inhibits MAPK/AP-1 in MCF? breast cancer cells: guggulsterone regulates MMP? expression in an isomer-specific manner.Int J Mol Med. 2013 Feb;31(2):393-9. doi: 10.3892/ijmm.2012.1214. Epub 2012 Dec 14.
• [3250] Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.Breast Cancer Res Treat. 2020 Jan;179(2):349-357. doi: 10.1007/s10549-019-05466-8. Epub 2019 Nov 2.
• [3251] Function of GCN5 in the TGF-1-induced epithelial-to-mesenchymal transition in breast cancer.Oncol Lett. 2018 Sep;16(3):3955-3963. doi: 10.3892/ol.2018.9134. Epub 2018 Jul 11.
• [3252] Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.Cancer Res. 2013 Sep 1;73(17):5556-68. doi: 10.1158/0008-5472.CAN-13-0013. Epub 2013 Aug 16.
• [3253] Artificial intelligence in breast imaging.Clin Radiol. 2019 May;74(5):357-366. doi: 10.1016/j.crad.2019.02.006. Epub 2019 Mar 18.
• [3254] Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers.Breast. 2019 Oct;47:85-92. doi: 10.1016/j.breast.2019.07.001. Epub 2019 Jul 10.
• [3255] The two-pore domain potassium channel KCNK5: induction by estrogen receptor alpha and role in proliferation of breast cancer cells.Mol Endocrinol. 2011 Aug;25(8):1326-36. doi: 10.1210/me.2011-0045. Epub 2011 Jun 16.
• [3256] Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.Cancer Res. 2019 Jan 1;79(1):86-98. doi: 10.1158/0008-5472.CAN-18-1310. Epub 2018 Nov 20.
• [3257] GATA3 recruits UTX for gene transcriptional activation to suppress metastasis of breast cancer.Cell Death Dis. 2019 Nov 4;10(11):832. doi: 10.1038/s41419-019-2062-7.
• [3258] Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.Oncol Rep. 2013 Mar;29(3):1043-52. doi: 10.3892/or.2013.2229. Epub 2013 Jan 8.
• [3259] Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Res Treat. 2012 Feb;131(3):849-58. doi: 10.1007/s10549-011-1500-8. Epub 2011 Apr 9.
• [3260] KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. Neoplasia. 2014 Mar;16(3):247-56, 256.e2. doi: 10.1016/j.neo.2014.03.008.
• [3261] Distinct Diagnostic and Prognostic Values of Kinesin Family Member Genes Expression in Patients with Breast Cancer.Med Sci Monit. 2018 Dec 29;24:9442-9464. doi: 10.12659/MSM.913401.
• [3262] Modulation of estrogen related receptor alpha activity by the kinesin KIF17.Oncotarget. 2017 May 23;8(31):50359-50375. doi: 10.18632/oncotarget.18104. eCollection 2017 Aug 1.
• [3263] Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.Oncogene. 2016 Feb 25;35(8):990-1002. doi: 10.1038/onc.2015.152. Epub 2015 May 11.
• [3264] A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients.Breast Cancer Res Treat. 2011 Aug;128(3):765-73. doi: 10.1007/s10549-011-1603-2. Epub 2011 Jun 1.
• [3265] Human Mitotic Centromere-Associated Kinesin Is Targeted by MicroRNA 485-5p/181c and Prognosticates Poor Survivability of Breast Cancer.J Oncol. 2019 Apr 3;2019:2316237. doi: 10.1155/2019/2316237. eCollection 2019.
• [3266] A role for kinesin-1 subunits KIF5B/KLC1 in regulating epithelial mesenchymal plasticity in breast tumorigenesis.EBioMedicine. 2019 Jul;45:92-107. doi: 10.1016/j.ebiom.2019.06.009. Epub 2019 Jun 14.
• [3267] Knockdown of DNA/RNA-binding protein KIN17 promotes apoptosis of triple-negative breast cancer cells.Oncol Lett. 2019 Jan;17(1):288-293. doi: 10.3892/ol.2018.9597. Epub 2018 Oct 18.
• [3268] The Killer Cell Ig-like Receptor 2DL4 Expression in Human Mast Cells and Its Potential Role in Breast Cancer Invasion.Cancer Immunol Res. 2015 Aug;3(8):871-80. doi: 10.1158/2326-6066.CIR-14-0199. Epub 2015 Mar 3.
• [3269] The Hormone KL1: A Regulator of Breast Cancer Cell Metabolism.Isr Med Assoc J. 2019 Jul;21(7):504.
• [3270] TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway.Mol Cell Biol. 2012 Jan;32(1):50-63. doi: 10.1128/MCB.06152-11. Epub 2011 Oct 24.
• [3271] microRNA-30d mediated breast cancer invasion, migration, and EMT by targeting KLF11 and activating STAT3 pathway.J Cell Biochem. 2018 Nov;119(10):8138-8145. doi: 10.1002/jcb.26767. Epub 2018 Jun 19.
• [3272] KLF15 in breast cancer: a novel tumor suppressor?.Cell Oncol (Dordr). 2015 Jun;38(3):227-35. doi: 10.1007/s13402-015-0226-8. Epub 2015 Apr 14.
• [3273] USP3 promotes breast cancer cell proliferation by deubiquitinating KLF5.J Biol Chem. 2019 Nov 22;294(47):17837-17847. doi: 10.1074/jbc.RA119.009102. Epub 2019 Oct 17.
• [3274] Mutations and Krppel-like factor 6 (KLF6) expression levels in breast cancer.Tumour Biol. 2014 Jun;35(6):5219-25. doi: 10.1007/s13277-014-1678-6. Epub 2014 Feb 12.
• [3275] KLF8 and FAK cooperatively enrich the active MMP14 on the cell surface required for the metastatic progression of breast cancer.Oncogene. 2014 May 29;33(22):2909-17. doi: 10.1038/onc.2013.247. Epub 2013 Jul 1.
• [3276] Expression of long non-coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death.Mol Oncol. 2019 Apr;13(4):909-927. doi: 10.1002/1878-0261.12446. Epub 2019 Feb 9.
• [3277] KLHL22 activates amino-acid-dependent mTORC1 signalling to promote tumorigenesis and ageing.Nature. 2018 May;557(7706):585-589. doi: 10.1038/s41586-018-0128-9. Epub 2018 May 16.
• [3278] Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.Breast Cancer Res Treat. 2018 Aug;170(3):525-533. doi: 10.1007/s10549-018-4777-z. Epub 2018 Apr 9.
• [3279] Identification of KLK10 as a therapeutic target to reverse trastuzumab resistance in breast cancer.Oncotarget. 2016 Nov 29;7(48):79494-79502. doi: 10.18632/oncotarget.13104.
• [3280] Identification, Molecular Characterization and Alternative Splicing of Three Novel Members of the Canine Kallikrein (Klk)-related Peptidase Family.Anticancer Res. 2015 May;35(5):2715-23.
• [3281] Human kallikrein-related peptidase 12 (KLK12) splice variants discriminate benign from cancerous breast tumors.Clin Biochem. 2018 Aug;58:78-85. doi: 10.1016/j.clinbiochem.2018.05.017. Epub 2018 May 25.
• [3282] Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer.Br J Cancer. 2002 May 6;86(9):1457-64. doi: 10.1038/sj.bjc.6600283.
• [3283] Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer.Clin Biochem. 2003 Mar;36(2):135-43. doi: 10.1016/s0009-9120(02)00446-0.
• [3284] The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer.Breast Cancer Res Treat. 2003 Mar;78(2):149-58. doi: 10.1023/a:1022931403825.
• [3285] Regulation of IL-20 Expression by Estradiol through KMT2B-Mediated Epigenetic Modification.PLoS One. 2016 Nov 2;11(11):e0166090. doi: 10.1371/journal.pone.0166090. eCollection 2016.
• [3286] Autoantibody Response to ZRF1 and KRR1 SEREX Antigens in Patients with Breast Tumors of Different Histological Types and Grades.Dis Markers. 2016;2016:5128720. doi: 10.1155/2016/5128720. Epub 2016 Oct 25.
• [3287] Breast Cancer Targeting Peptide Binds Keratin 1: A New Molecular Marker for Targeted Drug Delivery to Breast Cancer.Mol Pharm. 2017 Mar 6;14(3):593-604. doi: 10.1021/acs.molpharmaceut.6b00652. Epub 2017 Feb 16.
• [3288] Downregulation of cytokeratin 18 enhances BCRP-mediated multidrug resistance through induction of epithelial-mesenchymal transition and predicts poor prognosis in breast cancer.Oncol Rep. 2019 May;41(5):3015-3026. doi: 10.3892/or.2019.7069. Epub 2019 Mar 15.
• [3289] Adult-onset Still's disease-like manifestation accompanied by the cancer recurrence after long-term resting state.Mod Rheumatol. 2019 Jul;29(4):704-707. doi: 10.1080/14397595.2016.1259547. Epub 2016 Dec 9.
• [3290] SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ER breast cancer.Nat Commun. 2019 May 9;10(1):2115. doi: 10.1038/s41467-019-09676-y.
• [3291] Hair keratin KRT81 is expressed in normal and breast cancer cells and contributes to their invasiveness.Oncol Rep. 2017 May;37(5):2964-2970. doi: 10.3892/or.2017.5564. Epub 2017 Apr 11.
• [3292] Loss, mutation and deregulation of L3MBTL4 in breast cancers.Mol Cancer. 2010 Aug 10;9:213. doi: 10.1186/1476-4598-9-213.
• [3293] Overexpression of LACTB, a Mitochondrial Protein That Inhibits Proliferation and Invasion in Glioma Cells.Oncol Res. 2019 Mar 29;27(4):423-429. doi: 10.3727/096504017X15030178624579. Epub 2017 Aug 23.
• [3294] Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.Clin Cancer Res. 2003 Dec 15;9(17):6389-94.
• [3295] Hypoxic regulation and prognostic value of LAMP3 expression in breast cancer.Cancer. 2011 Aug 15;117(16):3670-81. doi: 10.1002/cncr.25938. Epub 2011 Feb 11.
• [3296] LAMTOR5 raises abnormal initiation of O-glycosylation in breast cancer metastasis via modulating GALNT1 activity.Oncogene. 2020 Mar;39(11):2290-2304. doi: 10.1038/s41388-019-1146-2. Epub 2019 Dec 13.
• [3297] Corosolic Acid Induces Non-Apoptotic Cell Death through Generation of Lipid Reactive Oxygen Species Production in Human Renal Carcinoma Caki Cells.Int J Mol Sci. 2018 Apr 27;19(5):1309. doi: 10.3390/ijms19051309.
• [3298] A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression.Genes Dev. 2009 Aug 1;23(15):1737-42. doi: 10.1101/gad.1809309.
• [3299] Identification of LCN1 as a Potential Biomarker for Breast Cancer by Bioinformatic Analysis.DNA Cell Biol. 2019 Oct;38(10):1088-1099. doi: 10.1089/dna.2019.4843. Epub 2019 Aug 19.
• [3300] The LIM domain binding protein 1, Ldb1, has distinct roles in Neu-induced mammary tumorigenesis.Biochim Biophys Acta Mol Cell Res. 2018 Nov;1865(11 Pt A):1590-1597. doi: 10.1016/j.bbamcr.2018.08.013. Epub 2018 Aug 23.
• [3301] LEF1 supports metastatic brain colonization by regulating glutathione metabolism and increasing ROS resistance in breast cancer.Int J Cancer. 2020 Jun 1;146(11):3170-3183. doi: 10.1002/ijc.32742. Epub 2019 Nov 11.
• [3302] Two E-selectin ligands, BST-2 and LGALS3BP, predict metastasis and poor survival of ER-negative breast cancer.Int J Oncol. 2016 Jul;49(1):265-75. doi: 10.3892/ijo.2016.3521. Epub 2016 May 13.
• [3303] Intracellular galectin-7 expression in cancer cells results from an autocrine transcriptional mechanism and endocytosis of extracellular galectin-7.PLoS One. 2017 Nov 8;12(11):e0187194. doi: 10.1371/journal.pone.0187194. eCollection 2017.
• [3304] HSPC159 promotes proliferation and metastasis by inducing epithelial-mesenchymal transition and activating the PI3K/Akt pathway in breast cancer.Cancer Sci. 2018 Jul;109(7):2153-2163. doi: 10.1111/cas.13631. Epub 2018 Jun 9.
• [3305] Analysis of the human CGB/LHB gene cluster in breast tumors by real-time quantitative RT-PCR assays.Cancer Lett. 2001 Jul 10;168(1):93-100. doi: 10.1016/s0304-3835(01)00496-7.
• [3306] A Novel Benzocoumarin-Stilbene Hybrid as a DNA ligase I inhibitor with in vitro and in vivo anti-tumor activity in breast cancer models.Sci Rep. 2017 Sep 6;7(1):10715. doi: 10.1038/s41598-017-10864-3.
• [3307] Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome.Mol Cancer. 2008 Sep 16;7:71. doi: 10.1186/1476-4598-7-71.
• [3308] Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer.J Biol Chem. 2010 Apr 16;285(16):11786-92. doi: 10.1074/jbc.M109.086561. Epub 2010 Feb 25.
• [3309] Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment to suppress cancer stemness and metastasis.Oncogene. 2019 Jun;38(23):4527-4539. doi: 10.1038/s41388-019-0735-4. Epub 2019 Feb 11.
• [3310] LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.Sci China Life Sci. 2020 Mar;63(3):419-428. doi: 10.1007/s11427-019-9581-8. Epub 2019 Aug 14.
• [3311] ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment.Clin Cancer Res. 2018 Mar 15;24(6):1500-1510. doi: 10.1158/1078-0432.CCR-17-1181. Epub 2017 Dec 28.
• [3312] LPIN1 promotes epithelial cell transformation and mammary tumourigenesis via enhancing insulin receptor substrate 1 stability.Carcinogenesis. 2016 Dec;37(12):1199-1209. doi: 10.1093/carcin/bgw104. Epub 2016 Oct 11.
• [3313] LPP is a Src substrate required for invadopodia formation and efficient breast cancer lung metastasis.Nat Commun. 2017 Apr 24;8:15059. doi: 10.1038/ncomms15059.
• [3314] Deletion of the murine ortholog of the 8q24 gene desert has anti-cancer effects in transgenic mammary cancer models.BMC Cancer. 2018 Dec 10;18(1):1233. doi: 10.1186/s12885-018-5109-8.
• [3315] LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.Mol Oncol. 2016 Oct;10(8):1363-73. doi: 10.1016/j.molonc.2016.07.004. Epub 2016 Jul 25.
• [3316] Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.Cancer Lett. 2018 Dec 1;438:165-173. doi: 10.1016/j.canlet.2018.09.022. Epub 2018 Sep 15.
• [3317] The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/-Catenin Signaling.Stem Cell Reports. 2018 Nov 13;11(5):1040-1050. doi: 10.1016/j.stemcr.2018.09.008. Epub 2018 Oct 18.
• [3318] Silencing of LRRC49 and THAP10 genes by bidirectional promoter hypermethylation is a frequent event in breast cancer.Int J Oncol. 2008 Jul;33(1):25-31.
• [3319] Translating Proteomic Into Functional Data: An High Mobility Group A1 (HMGA1) Proteomic Signature Has Prognostic Value in Breast Cancer.Mol Cell Proteomics. 2016 Jan;15(1):109-23. doi: 10.1074/mcp.M115.050401. Epub 2015 Nov 2.
• [3320] Val158Met Polymorphism in catechol-O-methyltransferase gene associated with risk factors for breast cancer.Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):838-47.
• [3321] HMGA1a Induces Alternative Splicing of the Estrogen Receptor-lpha Gene by Trapping U1 snRNP to an Upstream Pseudo-5' Splice Site.Front Mol Biosci. 2018 Jun 8;5:52. doi: 10.3389/fmolb.2018.00052. eCollection 2018.
• [3322] Genetic variants of ESR1 and SGSM3 are associated with the susceptibility of breast cancer in the Chinese population.Breast Cancer. 2017 May;24(3):369-374. doi: 10.1007/s12282-016-0712-5. Epub 2016 Jul 18.
• [3323] Nuclear Localized LSR: A Novel Regulator of Breast Cancer Behavior and Tumorigenesis.Mol Cancer Res. 2017 Feb;15(2):165-178. doi: 10.1158/1541-7786.MCR-16-0085-T. Epub 2016 Nov 17.
• [3324] Epithelial-to-mesenchymal transition and invadopodia markers in breast cancer: Lumican a key regulator.Semin Cancer Biol. 2020 May;62:125-133. doi: 10.1016/j.semcancer.2019.08.003. Epub 2019 Aug 8.
• [3325] LY6E: a conductor of malignant tumor growth through modulation of the PTEN/PI3K/Akt/HIF-1 axis.Oncotarget. 2016 Oct 4;7(40):65837-65848. doi: 10.18632/oncotarget.11670.
• [3326] Cause-specific mortality in women with breast cancer in situ.Int J Cancer. 2017 Jun 1;140(11):2414-2421. doi: 10.1002/ijc.30413. Epub 2016 Sep 19.
• [3327] microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1.BMC Cancer. 2019 Jul 27;19(1):738. doi: 10.1186/s12885-019-5951-3.
• [3328] LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer.Oncotarget. 2014 Feb 28;5(4):970-7. doi: 10.18632/oncotarget.1630.
• [3329] Genetic Variation in Metastasis-Associated in Colon Cancer-1 and the Risk of Breast Cancer Among the Chinese Han Population: A STROBE-Compliant Observational Study.Medicine (Baltimore). 2016 Feb;95(6):e2801. doi: 10.1097/MD.0000000000002801.
• [3330] Microtubule actin cross-linking factor 1, a novel potential target in cancer.Cancer Sci. 2017 Oct;108(10):1953-1958. doi: 10.1111/cas.13344. Epub 2017 Sep 21.
• [3331] Correlation between expression of LRP16, Ki67 and EGFR and breast cancer clinical pathologic factors and prognosis.Eur Rev Med Pharmacol Sci. 2017 Jul;21(3 Suppl):47-51.
• [3332] TRAIL suppresses human breast cancer cell migration via MADD/CXCR7.Asian Pac J Cancer Prev. 2015;16(7):2751-6. doi: 10.7314/apjcp.2015.16.7.2751.
• [3333] Chemotherapy acutely impairs neurovascular and hemodynamic responses in women with breast cancer.Am J Physiol Heart Circ Physiol. 2019 Jul 1;317(7):H1-H12. doi: 10.1152/ajpheart.00756.2018. Epub 2019 Apr 19.
• [3334] Tissue-specific Co-expression of Long Non-coding and Coding RNAs Associated with Breast Cancer.Sci Rep. 2016 Sep 6;6:32731. doi: 10.1038/srep32731.
• [3335] Premature polyadenylation of MAGI3 produces a dominantly-acting oncogene in human breast cancer.Elife. 2016 May 20;5:e14730. doi: 10.7554/eLife.14730.
• [3336] Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing.Genes Dev. 2014 Jun 1;28(11):1191-203. doi: 10.1101/gad.241968.114. Epub 2014 May 19.
• [3337] MAL2 promotes proliferation, migration, and invasion through regulating epithelial-mesenchymal transition in breast cancer cell lines.Biochem Biophys Res Commun. 2018 Oct 2;504(2):434-439. doi: 10.1016/j.bbrc.2018.08.187. Epub 2018 Sep 6.
• [3338] Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation.Br J Cancer. 2019 Nov;121(11):944-953. doi: 10.1038/s41416-019-0607-2. Epub 2019 Oct 29.
• [3339] Recombinant attenuated Salmonella typhimurium carrying a plasmid co-expressing ENDO-VEGI151 and survivin siRNA inhibits the growth of breast cancer in vivo.Mol Med Rep. 2013 Apr;7(4):1215-22. doi: 10.3892/mmr.2013.1308. Epub 2013 Feb 5.
• [3340] Expression of autophagy-related proteins according to androgen receptor and HER-2 status in estrogen receptor-negative breast cancer.PLoS One. 2014 Aug 20;9(8):e105666. doi: 10.1371/journal.pone.0105666. eCollection 2014.
• [3341] Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.Clin Cancer Res. 2010 Jan 15;16(2):681-90. doi: 10.1158/1078-0432.CCR-09-1091. Epub 2010 Jan 12.
• [3342] MAP2K4 interacts with Vimentin to activate the PI3K/AKT pathway and promotes breast cancer pathogenesis.Aging (Albany NY). 2019 Nov 25;11(22):10697-10710. doi: 10.18632/aging.102485. Epub 2019 Nov 25.
• [3343] Expression of the microtubule-associated protein MAP9/ASAP and its partners AURKA and PLK1 in colorectal and breast cancers.Dis Markers. 2014;2014:798170. doi: 10.1155/2014/798170. Epub 2014 Apr 30.
• [3344] Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells.Cancer Res. 2009 Dec 1;69(23):8853-61. doi: 10.1158/0008-5472.CAN-09-1636. Epub 2009 Nov 17.
• [3345] Extracellular signal-regulated kinase 7, a regulator of hormone-dependent estrogen receptor destruction.Mol Cell Biol. 2003 Sep;23(17):5979-88. doi: 10.1128/MCB.23.17.5979-5988.2003.
• [3346] Long non-coding RNA SNHG6 enhances cell proliferation, migration and invasion by regulating miR-26a-5p/MAPK6 in breast cancer.Biomed Pharmacother. 2019 Feb;110:294-301. doi: 10.1016/j.biopha.2018.11.016. Epub 2018 Dec 3.
• [3347] Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis.Breast Cancer Res Treat. 2019 Feb;173(3):573-583. doi: 10.1007/s10549-018-5026-1. Epub 2018 Oct 27.
• [3348] Differential Expression of MicroRNAs in Breast Cancers from Four Different Ethnicities.Pathobiology. 2018;85(4):220-226. doi: 10.1159/000488456. Epub 2018 May 23.
• [3349] Identification and characterization of MARVELD1, a novel nuclear protein that is down-regulated in multiple cancers and silenced by DNA methylation.Cancer Lett. 2009 Sep 8;282(1):77-86. doi: 10.1016/j.canlet.2009.03.008. Epub 2009 Apr 11.
• [3350] Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.Cell Death Differ. 2018 May;25(5):828-840. doi: 10.1038/s41418-017-0024-0. Epub 2017 Dec 11.
• [3351] Csk homologous kinase (CHK) and ErbB-2 interactions are directly coupled with CHK negative growth regulatory function in breast cancer.J Biol Chem. 2002 Sep 27;277(39):36465-70. doi: 10.1074/jbc.M206018200. Epub 2002 Jul 16.
• [3352] Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA.Glycoconj J. 2001 Nov-Dec;18(11-12):883-93. doi: 10.1023/a:1022200525695.
• [3353] Plasma Metabolomic Signatures Associated with Long-term Breast Cancer Risk in the SU.VI.MAX Prospective Cohort.Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1300-1307. doi: 10.1158/1055-9965.EPI-19-0154. Epub 2019 Jun 4.
• [3354] Epigenetic silencing of RNF144A expression in breast cancer cells through promoter hypermethylation and MBD4.Cancer Med. 2018 Apr;7(4):1317-1325. doi: 10.1002/cam4.1324. Epub 2018 Feb 23.
• [3355] Risk of breast cancer and residential proximity to industrial installations: New findings from a multicase-control study (MCC-Spain).Environ Pollut. 2018 Jun;237:559-568. doi: 10.1016/j.envpol.2018.02.065. Epub 2018 Mar 15.
• [3356] The rho-specific guanine nucleotide exchange factor Dbs regulates breast cancer cell migration.J Biol Chem. 2009 Jun 5;284(23):15771-80. doi: 10.1074/jbc.M901853200. Epub 2009 Apr 14.
• [3357] Should Breast Cancer Surgery Be Done in an Outpatient Setting?: Health Economics From the Perspective of Service Providers.Geburtshilfe Frauenheilkd. 2017 Aug;77(8):879-886. doi: 10.1055/s-0043-114427. Epub 2017 Aug 24.
• [3358] MCM10 facilitates the invaded/migrated potentials of breast cancer cells via Wnt/-catenin signaling and is positively interlinked with poor prognosis in breast carcinoma.J Biochem Mol Toxicol. 2019 Jul;33(7):e22330. doi: 10.1002/jbt.22330. Epub 2019 Apr 16.
• [3359] Variants associating with uterine leiomyoma highlight genetic background shared by various cancers and hormone-related traits.Nat Commun. 2018 Sep 7;9(1):3636. doi: 10.1038/s41467-018-05428-6.
• [3360] Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.Oncotarget. 2017 Jun 20;8(25):40434-40453. doi: 10.18632/oncotarget.17107.
• [3361] Estrogen receptor coactivator Mediator Subunit 1 (MED1) as a tissue-specific therapeutic target in breast cancer.J Zhejiang Univ Sci B. 2019 May;20(5):381-390. doi: 10.1631/jzus.B1900163.
• [3362] Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer.Curr Cancer Drug Targets. 2015;15(8):739-49. doi: 10.2174/156800961508151001105814.
• [3363] Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.Genet Med. 2016 Dec;18(12):1190-1198. doi: 10.1038/gim.2016.31. Epub 2016 Apr 14.
• [3364] MED23 in endocrinotherapy for breast cancer.Oncol Lett. 2017 Jun;13(6):4679-4684. doi: 10.3892/ol.2017.6036. Epub 2017 Apr 13.
• [3365] Oxyprenylated Phenylpropanoids Bind to MT1 Melatonin Receptors and Inhibit Breast Cancer Cell Proliferation and Migration.J Nat Prod. 2017 Dec 22;80(12):3324-3329. doi: 10.1021/acs.jnatprod.7b00853. Epub 2017 Nov 16.
• [3366] MED28 increases the colony-forming ability of breast cancer cells by stabilizing the ZNF224 protein upon DNA damage.Oncol Lett. 2018 Mar;15(3):3147-3154. doi: 10.3892/ol.2017.7718. Epub 2017 Dec 29.
• [3367] Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.Br J Cancer. 2018 Apr;118(8):1142-1151. doi: 10.1038/s41416-018-0041-x. Epub 2018 Mar 28.
• [3368] TMEM25, REPS2 and Meis 1: favourable prognostic and predictive biomarkers for breast cancer.Tumour Biol. 2009;30(4):200-9. doi: 10.1159/000239795. Epub 2009 Sep 21.
• [3369] Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A.Oncology. 2019;96(3):147-155. doi: 10.1159/000493348. Epub 2018 Oct 3.
• [3370] MEOX1 Promotes Tumor Progression and Predicts Poor Prognosis in Human Non-Small-Cell Lung Cancer.Int J Med Sci. 2019 Jan 1;16(1):68-74. doi: 10.7150/ijms.27595. eCollection 2019.
• [3371] ZFP57 suppress proliferation of breast cancer cells through down-regulation of MEST-mediated Wnt/-catenin signalling pathway.Cell Death Dis. 2019 Feb 20;10(3):169. doi: 10.1038/s41419-019-1335-5.
• [3372] N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.Gene. 2020 Jan 5;722:144076. doi: 10.1016/j.gene.2019.144076. Epub 2019 Aug 24.
• [3373] Detection of mammaglogin A in blood from breast cancer patients, before and after treatment, using a one-tube nested PCR protocol. Association with the absence of tumor estrogen receptors.Clin Biochem. 2011 Dec;44(17-18):1429-33. doi: 10.1016/j.clinbiochem.2011.08.1140. Epub 2011 Sep 12.
• [3374] Epigenetic activation of MGAT3 and corresponding bisecting GlcNAc shortens the survival of cancer patients.Oncotarget. 2016 Aug 9;7(32):51674-51686. doi: 10.18632/oncotarget.10543.
• [3375] Decreased miR-124-3p promoted breast cancer proliferation and metastasis by targeting MGAT5.Am J Cancer Res. 2019 Mar 1;9(3):585-596. eCollection 2019.
• [3376] Downregulation of matrix Gla protein is a biomarker for tamoxifen-resistant and radioresistant breast cancer.Biomark Med. 2019 Jul;13(10):841-850. doi: 10.2217/bmm-2019-0050. Epub 2019 Jul 18.
• [3377] Prognostic implication of p53 protein expression in relation to nuclear pleomorphism and the MIB-1 counts in breast cancer.Breast Cancer. 2004;11(2):160-8. doi: 10.1007/BF02968296.
• [3378] ZNF121 interacts with ZBRK1 and BRCA1 to regulate their target genes in mammary epithelial cells.FEBS Open Bio. 2018 Nov 8;8(12):1943-1952. doi: 10.1002/2211-5463.12530. eCollection 2018 Dec.
• [3379] MICAL1 facilitates breast cancer cell proliferation via ROS-sensitive ERK/cyclin D pathway.J Cell Mol Med. 2018 Jun;22(6):3108-3118. doi: 10.1111/jcmm.13588. Epub 2018 Mar 10.
• [3380] MICAL2 promotes breast cancer cell migration by maintaining epidermal growth factor receptor (EGFR) stability and EGFR/P38 signalling activation.Acta Physiol (Oxf). 2018 Feb;222(2). doi: 10.1111/apha.12920. Epub 2017 Aug 19.
• [3381] Rat Mcs1b is concordant to the genome-wide association-identified breast cancer risk locus at human 5q11.2 and MIER3 is a candidate cancer susceptibility gene.Cancer Res. 2012 Nov 15;72(22):6002-12. doi: 10.1158/0008-5472.CAN-12-0748. Epub 2012 Sep 19.
• [3382] Upregulation of MIIP regulates human breast cancer proliferation, invasion and migration by mediated by IGFBP2.Pathol Res Pract. 2019 Jul;215(7):152440. doi: 10.1016/j.prp.2019.152440. Epub 2019 May 6.
• [3383] MINAR1 is a Notch2-binding protein that inhibits angiogenesis and breast cancer growth.J Mol Cell Biol. 2018 Jun 1;10(3):195-204. doi: 10.1093/jmcb/mjy002.
• [3384] Biallelic germline nonsense variant of MLH3 underlies polyposis predisposition.Genet Med. 2019 Aug;21(8):1868-1873. doi: 10.1038/s41436-018-0405-x. Epub 2018 Dec 21.
• [3385] Miconazole triggers various forms of cell death in human breast cancer MDA-MB-231 cells.Pharmazie. 2019 May 1;74(5):290-294. doi: 10.1691/ph.2019.8812.
• [3386] Genetic polymorphisms of PPAR gamma, arsenic methylation capacity and breast cancer risk in Mexican women.Salud Publica Mex. 2016 Apr;58(2):220-7. doi: 10.21149/spm.v58i2.7791.
• [3387] Calcium regulates tertiary structure and enzymatic activity of human endometase/matrilysin-2 and its role in promoting human breast cancer cell invasion.Biochem J. 2007 Apr 1;403(1):31-42. doi: 10.1042/BJ20061390.
• [3388] Transcriptome profiling revealed multiple genes and ECM-receptor interaction pathways that may be associated with breast cancer.Cell Mol Biol Lett. 2019 Jun 6;24:38. doi: 10.1186/s11658-019-0162-0. eCollection 2019.
• [3389] PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12.
• [3390] Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer.Clin Cancer Res. 2016 Dec 1;22(23):5929-5938. doi: 10.1158/1078-0432.CCR-15-1104. Epub 2016 Jun 14.
• [3391] On the difference of micronucleus frequencies in peripheral blood lymphocytes between breast cancer patients and controls.Mutagenesis. 2006 Sep;21(5):313-20. doi: 10.1093/mutage/gel035. Epub 2006 Aug 22.
• [3392] MNX1-AS1 is a functional oncogene that induces EMT and activates the AKT/mTOR pathway and MNX1 in breast cancer.Cancer Manag Res. 2019 Jan 17;11:803-812. doi: 10.2147/CMAR.S188007. eCollection 2019.
• [3393] Quantitative proteomics study of breast cancer cell lines isolated from a single patient: discovery of TIMM17A as a marker for breast cancer.Proteomics. 2010 Apr;10(7):1374-90. doi: 10.1002/pmic.200900380.
• [3394] Imbalancing the DNA base excision repair pathway in the mitochondria; targeting and overexpressing N-methylpurine DNA glycosylase in mitochondria leads to enhanced cell killing.Cancer Res. 2003 Feb 1;63(3):608-15.
• [3395] Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model.Cancer Gene Ther. 2006 Jul;13(7):706-19. doi: 10.1038/sj.cgt.7700945. Epub 2006 Mar 3.
• [3396] Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial.J Clin Oncol. 2010 Mar 20;28(9):1450-7. doi: 10.1200/JCO.2009.23.0839. Epub 2010 Feb 22.
• [3397] Inhibition of PTEN activates bovine non-growing follicles in vitro but increases DNA damage and reduces DNA repair response.Hum Reprod. 2019 Feb 1;34(2):297-307. doi: 10.1093/humrep/dey354.
• [3398] Association of Single-Nucleotide Polymorphisms in Monoubiquitinated FANCD2-DNA Damage Repair Pathway Genes With Breast Cancer in the Chinese Population.Technol Cancer Res Treat. 2018 Jan 1;17:1533033818819841. doi: 10.1177/1533033818819841.
• [3399] Upregulation of Mrps18a in breast cancer identified by selecting phage antibody libraries on breast tissue sections.BMC Cancer. 2017 Jan 5;17(1):19. doi: 10.1186/s12885-016-2987-5.
• [3400] Down-regulation of MRPS23 inhibits rat breast cancer proliferation and metastasis.Oncotarget. 2017 May 15;8(42):71772-71781. doi: 10.18632/oncotarget.17888. eCollection 2017 Sep 22.
• [3401] Integrative Genomic Analysis Predicts Causative Cis-Regulatory Mechanisms of the Breast Cancer-Associated Genetic Variant rs4415084.Cancer Res. 2018 Apr 1;78(7):1579-1591. doi: 10.1158/0008-5472.CAN-17-3486. Epub 2018 Jan 19.
• [3402] Association of common variants in mismatch repair genes and breast cancer susceptibility: a multigene study.BMC Cancer. 2009 Sep 25;9:344. doi: 10.1186/1471-2407-9-344.
• [3403] Moesin is an independent prognostic marker for ER-positive breast cancer.Oncol Lett. 2019 Feb;17(2):1921-1933. doi: 10.3892/ol.2018.9799. Epub 2018 Dec 6.
• [3404] A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability.Nat Med. 2017 May;23(5):568-578. doi: 10.1038/nm.4323. Epub 2017 Apr 10.
• [3405] Homeobox transcription factor muscle segment homeobox 2 (Msx2) correlates with good prognosis in breast cancer patients and induces apoptosis in vitro.Breast Cancer Res. 2010;12(4):R59. doi: 10.1186/bcr2621. Epub 2010 Aug 3.
• [3406] The unique C- and N-terminal sequences of Metallothionein isoform 3 mediate growth inhibition and Vectorial active transport in MCF-7 cells.BMC Cancer. 2017 May 25;17(1):369. doi: 10.1186/s12885-017-3355-9.
• [3407] MicroRNA-589 serves as a tumor suppressor microRNA through directly targeting metastasis-associated protein 2 in breast cancer.Oncol Lett. 2019 Sep;18(3):2232-2239. doi: 10.3892/ol.2019.10548. Epub 2019 Jun 28.
• [3408] The Homeotic Protein SIX3 Suppresses Carcinogenesis and Metastasis through Recruiting the LSD1/NuRD(MTA3) Complex.Theranostics. 2018 Jan 1;8(4):972-989. doi: 10.7150/thno.22328. eCollection 2018.
• [3409] Mitochondrial fission regulator 2 (MTFR2) promotes growth, migration, invasion and tumour progression in breast cancer cells.Aging (Albany NY). 2019 Nov 18;11(22):10203-10219. doi: 10.18632/aging.102442. Epub 2019 Nov 18.
• [3410] The effect of folate-related SNPs on clinicopathological features, response to neoadjuvant treatment and survival in pre- and postmenopausal breast cancer patients.Gene. 2013 Apr 15;518(2):397-404. doi: 10.1016/j.gene.2012.12.095. Epub 2013 Jan 4.
• [3411] Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer.Nat Commun. 2014;5:3128. doi: 10.1038/ncomms4128.
• [3412] MTMR3 is upregulated in patients with breast cancer and regulates proliferation, cell cycle progression and autophagy in breast cancer cells.Oncol Rep. 2019 Nov;42(5):1915-1923. doi: 10.3892/or.2019.7292. Epub 2019 Aug 23.
• [3413] 9-cis Retinoic acid modulates myotrophin expression and its miR in physiological and pathophysiological cell models.Exp Cell Res. 2017 May 1;354(1):25-30. doi: 10.1016/j.yexcr.2017.03.022. Epub 2017 Mar 12.
• [3414] MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer.Cell Death Dis. 2018 Mar 1;9(3):344. doi: 10.1038/s41419-018-0364-9.
• [3415] High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next?.J Cancer Res Clin Oncol. 2014 Aug;140(8):1359-65. doi: 10.1007/s00432-014-1670-y. Epub 2014 Apr 10.
• [3416] Downregulation of hsa_circ_0007534 suppresses breast cancer cell proliferation and invasion by targeting miR-593/MUC19 signal pathway.Biochem Biophys Res Commun. 2018 Sep 18;503(4):2603-2610. doi: 10.1016/j.bbrc.2018.08.007. Epub 2018 Aug 20.
• [3417] Mucin 2 (MUC2) modulates the aggressiveness of breast cancer.Breast Cancer Res Treat. 2019 Jan;173(2):289-299. doi: 10.1007/s10549-018-4989-2. Epub 2018 Oct 13.
• [3418] Lynch syndrome-associated breast cancers do not overexpress chromosome 11-encoded mucins.Mod Pathol. 2013 Jul;26(7):944-54. doi: 10.1038/modpathol.2012.232. Epub 2013 Feb 1.
• [3419] HER2 drives Mucin-like 1 to control proliferation in breast cancer cells.Oncogene. 2016 Aug 11;35(32):4225-34. doi: 10.1038/onc.2015.487. Epub 2016 Jan 4.
• [3420] Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.Breast Cancer Res Treat. 2010 May;121(1):147-56. doi: 10.1007/s10549-009-0518-7. Epub 2009 Aug 28.
• [3421] Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein(MVP).Breast Cancer Res. 2019 Jan 17;21(1):7. doi: 10.1186/s13058-018-1088-6.
• [3422] Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel.Oncotarget. 2016 Mar 15;7(11):12267-85. doi: 10.18632/oncotarget.7860.
• [3423] MYBL2 Is Targeted by miR-143-3p and Regulates Breast Cancer Cell Proliferation and Apoptosis.Oncol Res. 2018 Jul 5;26(6):913-922. doi: 10.3727/096504017X15135941182107. Epub 2017 Dec 21.
• [3424] IL-25 blockade inhibits metastasis in breast cancer.Protein Cell. 2017 Mar;8(3):191-201. doi: 10.1007/s13238-016-0345-7. Epub 2016 Dec 1.
• [3425] MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer.Int J Cancer. 2002 Dec 20;102(6):608-14. doi: 10.1002/ijc.10765.
• [3426] Somatic mutation analysis of MYH11 in breast and prostate cancer.BMC Cancer. 2008 Sep 17;8:263. doi: 10.1186/1471-2407-8-263.
• [3427] TFPI-2 suppresses breast cancer cell proliferation and invasion through regulation of ERK signaling and interaction with actinin-4 and myosin-9.Sci Rep. 2018 Sep 26;8(1):14402. doi: 10.1038/s41598-018-32698-3.
• [3428] MiR-340 suppresses cell migration and invasion by targeting MYO10 in breast cancer.Oncol Rep. 2016 Feb;35(2):709-16. doi: 10.3892/or.2015.4411. Epub 2015 Nov 12.
• [3429] Downregulation of MYO1C mediated by cepharanthine inhibits autophagosome-lysosome fusion through blockade of the F-actin network.J Exp Clin Cancer Res. 2019 Nov 7;38(1):457. doi: 10.1186/s13046-019-1449-8.
• [3430] Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression.Biochim Biophys Acta Gene Regul Mech. 2018 Nov;1861(11):983-995. doi: 10.1016/j.bbagrm.2018.10.005. Epub 2018 Oct 10.
• [3431] Release of transcriptional repression via ErbB2-induced, SUMO-directed phosphorylation of myeloid zinc finger-1 serine 27 activates lysosome redistribution and invasion.Oncogene. 2019 Apr;38(17):3170-3184. doi: 10.1038/s41388-018-0653-x. Epub 2019 Jan 8.
• [3432] ARD1 contributes to IKK-mediated breast cancer tumorigenesis.Cell Death Dis. 2018 Aug 28;9(9):860. doi: 10.1038/s41419-018-0921-2.
• [3433] Antitumor effects of saikosaponin b2 on breast cancer cell proliferation and migration.Mol Med Rep. 2019 Aug;20(2):1943-1951. doi: 10.3892/mmr.2019.10385. Epub 2019 Jun 13.
• [3434] E-cadherin regulates human Nanos1, which interacts with p120ctn and induces tumor cell migration and invasion.Cancer Res. 2006 Oct 15;66(20):10007-15. doi: 10.1158/0008-5472.CAN-05-3096.
• [3435] Evaluation of a New Hydroxyapatite Nanoparticle as a Drug Delivery System to Oral Squamous Cell Carcinoma Cells.Anticancer Res. 2018 Dec;38(12):6715-6720. doi: 10.21873/anticanres.13040.
• [3436] Methylation of NBPF1 as a novel marker for the detection of plasma cell-free DNA of breast cancer patients.Clin Chim Acta. 2018 Sep;484:81-86. doi: 10.1016/j.cca.2018.05.030. Epub 2018 May 15.
• [3437] Expression of BRCA1, NBR1 and NBR2 genes in human breast cancer cells.Folia Biol (Praha). 2001;47(4):120-7.
• [3438] Neural cell adhesion molecule 2 as a target molecule for prostate and breast cancer gene therapy.Cancer Sci. 2011 Apr;102(4):808-14. doi: 10.1111/j.1349-7006.2011.01855.x. Epub 2011 Feb 25.
• [3439] Re-expression of miR-200c suppresses proliferation, colony formation and in vivo tumor growth of murine claudin-low mammary tumor cells.Oncotarget. 2017 Apr 4;8(14):23727-23749. doi: 10.18632/oncotarget.15829.
• [3440] Arpin downregulation in breast cancer is associated with poor prognosis.Br J Cancer. 2016 Mar 1;114(5):545-53. doi: 10.1038/bjc.2016.18. Epub 2016 Feb 11.
• [3441] Steroid receptor coactivator-1 regulates glioma angiogenesis through polyomavirus enhancer activator 3 signaling.Biochem Cell Biol. 2019 Aug;97(4):488-496. doi: 10.1139/bcb-2018-0114. Epub 2018 Dec 11.
• [3442] NCOA5 is correlated with progression and prognosis in luminal breast cancer.Biochem Biophys Res Commun. 2017 Jan 8;482(2):253-256. doi: 10.1016/j.bbrc.2016.11.051. Epub 2016 Nov 12.
• [3443] A Bi-Functional Targeted P28-NRC Chimeric Protein with Enhanced Cytotoxic Effects on Breast Cancer Cell Lines.Iran J Pharm Res. 2019 Spring;18(2):735-744. doi: 10.22037/ijpr.2019.2392.
• [3444] A multistage association study identifies a breast cancer genetic locus at NCOA7.Cancer Res. 2011 Jun 1;71(11):3881-8. doi: 10.1158/0008-5472.CAN-10-2653. Epub 2011 May 24.
• [3445] The nuclear corepressor 1 and the thyroid hormone receptor suppress breast tumor lymphangiogenesis.Oncotarget. 2016 Nov 29;7(48):78971-78984. doi: 10.18632/oncotarget.12978.
• [3446] BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen-Resistant Breast Cancer.Clin Cancer Res. 2018 Aug 1;24(15):3681-3691. doi: 10.1158/1078-0432.CCR-17-2259. Epub 2018 Feb 2.
• [3447] Altered expression of miR-181a and miR-146a does not change the expression of surface NCRs in human NK cells.Sci Rep. 2017 Feb 1;7:41381. doi: 10.1038/srep41381.
• [3448] Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.Breast Cancer Res. 2014 Jun 11;16(3):R62. doi: 10.1186/bcr3675.
• [3449] The variation of mitochondrial NADH dehydrogenase subunit 4 (mtND4) and molecular dynamics simulation of SNPs among Iranian women with breast cancer.J Mol Graph Model. 2018 Oct;85:242-249. doi: 10.1016/j.jmgm.2018.08.011. Epub 2018 Sep 4.
• [3450] Evaluating mitochondrial DNA in patients with breast cancer and benign breast disease.J Cancer Res Clin Oncol. 2011 Apr;137(4):669-75. doi: 10.1007/s00432-010-0912-x. Epub 2010 Jun 16.
• [3451] NDP-K/nm23 expression in human breast cancer in relation to relapse, survival, and other prognostic factors: an immunohistochemical study.J Pathol. 1994 Jan;172(1):27-34. doi: 10.1002/path.1711720107.
• [3452] NDRG2 promotes adriamycin sensitivity through a Bad/p53 complex at the mitochondria in breast cancer.Oncotarget. 2017 Apr 25;8(17):29038-29047. doi: 10.18632/oncotarget.16035.
• [3453] Clinical significance of NDRG3 in patients with breast cancer.Future Oncol. 2017 May;13(11):961-969. doi: 10.2217/fon-2016-0457. Epub 2017 Feb 27.
• [3454] Dietary intake of folate, vitamin B6, and vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: a case-control study in Brazilian women.BMC Cancer. 2009 Apr 24;9:122. doi: 10.1186/1471-2407-9-122.
• [3455] Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers.Mol Cancer. 2013 Jun 12;12:60. doi: 10.1186/1476-4598-12-60.
• [3456] The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L.Oncogene. 2018 Jul;37(28):3879-3893. doi: 10.1038/s41388-018-0239-7. Epub 2018 Apr 17.
• [3457] Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.Nat Genet. 2009 May;41(5):585-90. doi: 10.1038/ng.354. Epub 2009 Mar 29.
• [3458] Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development.Sci Rep. 2018 Feb 9;8(1):2731. doi: 10.1038/s41598-018-21044-2.
• [3459] NEMP1 Promotes Tamoxifen Resistance in Breast Cancer Cells.Biochem Genet. 2019 Dec;57(6):813-826. doi: 10.1007/s10528-019-09926-0. Epub 2019 May 11.
• [3460] Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis.Breast Cancer Res. 2018 May 16;20(1):41. doi: 10.1186/s13058-018-0966-2.
• [3461] ZEB1 confers stem cell-like properties in breast cancer by targeting neurogenin-3.Oncotarget. 2017 Apr 13;8(33):54388-54401. doi: 10.18632/oncotarget.17077. eCollection 2017 Aug 15.
• [3462] Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications.J Pathol. 2019 Feb;247(2):214-227. doi: 10.1002/path.5184. Epub 2018 Dec 20.
• [3463] Simvastatin and MBCD Inhibit Breast Cancer-Induced Osteoclast Activity by Targeting Osteoclastogenic Factors.Cancer Invest. 2017 Jul 3;35(6):403-413. doi: 10.1080/07357907.2017.1309548. Epub 2017 May 2.
• [3464] NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene.Oncogene. 2010 Apr 15;29(15):2292-301. doi: 10.1038/onc.2009.499. Epub 2010 Jan 25.
• [3465] A regulation loop between Nrf1 and MRTF-A controls migration and invasion in MDA-MB-231 breast cancer cells.Int J Mol Med. 2018 Nov;42(5):2459-2468. doi: 10.3892/ijmm.2018.3816. Epub 2018 Aug 9.
• [3466] NRF3 suppresses breast cancer cell metastasis and cell proliferation and is a favorable predictor of survival in breast cancer.Onco Targets Ther. 2019 Apr 18;12:3019-3030. doi: 10.2147/OTT.S197409. eCollection 2019.
• [3467] ER Binding by Transcription Factors NFIB and YBX1 Enables FGFR2 Signaling to Modulate Estrogen Responsiveness in Breast Cancer.Cancer Res. 2018 Jan 15;78(2):410-421. doi: 10.1158/0008-5472.CAN-17-1153. Epub 2017 Nov 27.
• [3468] Overexpression and alternative splicing of NF-YA in breast cancer.Sci Rep. 2019 Sep 10;9(1):12955. doi: 10.1038/s41598-019-49297-5.
• [3469] Can mammogram readers swiftly and effectively learn to interpret first post-contrast acquisition subtracted (FAST) MRI, a type of abbreviated breast MRI?: a single centre data-interpretation study.Br J Radiol. 2019 Dec;92(1104):20190663. doi: 10.1259/bjr.20190663. Epub 2019 Oct 3.
• [3470] FAM129B, an antioxidative protein, reduces chemosensitivity by competing with Nrf2 for Keap1 binding.EBioMedicine. 2019 Jul;45:25-38. doi: 10.1016/j.ebiom.2019.06.022. Epub 2019 Jun 28.
• [3471] Identification of Nidogen 1 as a lung metastasis protein through secretome analysis.Genes Dev. 2017 Jul 15;31(14):1439-1455. doi: 10.1101/gad.301937.117. Epub 2017 Aug 21.
• [3472] Centrosome-related genes, genetic variation, and risk of breast cancer.Breast Cancer Res Treat. 2011 Jan;125(1):221-8. doi: 10.1007/s10549-010-0950-8. Epub 2010 May 28.
• [3473] Downregulation of Cohesin Loading Factor Nipped-B-Like Protein (NIPBL) Induces Cell Cycle Arrest, Apoptosis, and Autophagy of Breast Cancer Cell Lines.Med Sci Monit. 2017 Oct 7;23:4817-4825. doi: 10.12659/msm.906583.
• [3474] NKAP functions as an oncogene and its expression is induced by CoCl(2) treatment in breast cancer via AKT/mTOR signaling pathway.Cancer Manag Res. 2018 Oct 29;10:5091-5100. doi: 10.2147/CMAR.S178919. eCollection 2018.
• [3475] Expression of thyroid transcription factor-1 is associated with a basal-like phenotype in breast carcinomas.Diagn Pathol. 2013 May 15;8:80. doi: 10.1186/1746-1596-8-80.
• [3476] Neuroligin 4X overexpression in human breast cancer is associated with poor relapse-free survival.PLoS One. 2017 Dec 15;12(12):e0189662. doi: 10.1371/journal.pone.0189662. eCollection 2017.
• [3477] Hypoxia regulates the expression of the neuromedin B receptor through a mechanism dependent on hypoxia-inducible factor-1.PLoS One. 2013 Dec 9;8(12):e82868. doi: 10.1371/journal.pone.0082868. eCollection 2013.
• [3478] Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone.J Immunol Res. 2019 May 9;2019:4260987. doi: 10.1155/2019/4260987. eCollection 2019.
• [3479] LMO4 inhibits p53-mediated proliferative inhibition of breast cancer cells through interacting p53.Life Sci. 2012 Sep 24;91(9-10):358-63. doi: 10.1016/j.lfs.2012.08.005. Epub 2012 Aug 11.
• [3480] Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker.Clin Exp Med. 2019 Aug;19(3):377-384. doi: 10.1007/s10238-019-00554-x. Epub 2019 Apr 20.
• [3481] TATDN1 promotes the development and progression of breast cancer by targeting microRNA-140-3p.Eur Rev Med Pharmacol Sci. 2019 Jun;23(12):5293-5300. doi: 10.26355/eurrev_201906_18196.
• [3482] High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA-Mutation Testing without Prior Face-to-Face Genetic Counseling.J Genet Couns. 2016 Jun;25(3):504-14. doi: 10.1007/s10897-015-9899-4. Epub 2015 Nov 4.
• [3483] Dihydrotanshinone-Induced NOX5 Activation Inhibits Breast Cancer Stem Cell through the ROS/Stat3 Signaling Pathway.Oxid Med Cell Longev. 2019 Mar 24;2019:9296439. doi: 10.1155/2019/9296439. eCollection 2019.
• [3484] Growth of Triple Negative and Progesterone Positive Breast Cancer Causes Oxidative Stress and Down-Regulates Neuroprotective Transcription Factor NPAS4 and NPAS4-Regulated Genes in Hippocampal Tissues of TumorGraft Mice-an Aging Connection.Front Genet. 2018 Mar 5;9:58. doi: 10.3389/fgene.2018.00058. eCollection 2018.
• [3485] Characterization of Niemann-Pick Type C2 protein expression in multiple cancers using a novel NPC2 monoclonal antibody.PLoS One. 2013 Oct 17;8(10):e77586. doi: 10.1371/journal.pone.0077586. eCollection 2013.
• [3486] Are self-reported unhealthy food choices associated with an increased risk of breast cancer? Prospective cohort study using the British Food Standards Agency nutrient profiling system.BMJ Open. 2017 Jun 8;7(6):e013718. doi: 10.1136/bmjopen-2016-013718.
• [3487] The Neuroplastin adhesion molecules: key regulators of neuronal plasticity and synaptic function.J Neurochem. 2014 Nov;131(3):268-83. doi: 10.1111/jnc.12816. Epub 2014 Aug 14.
• [3488] The contribution of SIPA1 and RRP1B germline polymorphisms to breast cancer phenotype, lymph node status and survival in a group of Lithuanian young breast cancer patients.Biomarkers. 2016;21(4):363-70. doi: 10.3109/1354750X.2016.1141989. Epub 2016 Feb 22.
• [3489] NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients.Breast Cancer Res. 2018 Oct 16;20(1):120. doi: 10.1186/s13058-018-1049-0.
• [3490] High NR2F2 transcript level is associated with increased survival and its expression inhibits TGF--dependent epithelial-mesenchymal transition in breast cancer.Breast Cancer Res Treat. 2014 Sep;147(2):265-81. doi: 10.1007/s10549-014-3095-3. Epub 2014 Aug 17.
• [3491] Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression.Am J Hum Genet. 2015 Jul 2;97(1):22-34. doi: 10.1016/j.ajhg.2015.05.002. Epub 2015 Jun 11.
• [3492] Genetic variation in the genome-wide predicted estrogen response element-related sequences is associated with breast cancer development.Breast Cancer Res. 2011 Jan 31;13(1):R13. doi: 10.1186/bcr2821.
• [3493] Elevated NRD1 metalloprotease expression plays a role in breast cancer growth and proliferation.Genes Chromosomes Cancer. 2011 Oct;50(10):837-47. doi: 10.1002/gcc.20905. Epub 2011 Jul 18.
• [3494] ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis.Ann Oncol. 2008 Jan;19(1):73-80. doi: 10.1093/annonc/mdm431. Epub 2007 Oct 24.
• [3495] The role of NRG3 in mammary development.J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):195-203. doi: 10.1007/s10911-008-9082-8. Epub 2008 Apr 17.
• [3496] Prognostic relevance of RIP140 and ER expression in unifocal versus multifocal breast cancers: a preliminary report.Int J Mol Sci. 2019 Jan 18;20(2):418. doi: 10.3390/ijms20020418.
• [3497] Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.Cancer Lett. 2016 Aug 10;378(2):69-79. doi: 10.1016/j.canlet.2016.05.004. Epub 2016 May 6.
• [3498] Depletion of SUMO ligase hMMS21 impairs G1 to S transition in MCF-7 breast cancer cells.Biochim Biophys Acta. 2012 Dec;1820(12):1893-900. doi: 10.1016/j.bbagen.2012.08.002. Epub 2012 Aug 10.
• [3499] Overexpression of NSUN2 by DNA hypomethylation is associated with metastatic progression in human breast cancer.Oncotarget. 2017 Mar 28;8(13):20751-20765. doi: 10.18632/oncotarget.10612.
• [3500] A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis.Nat Cell Biol. 2017 Feb;19(2):106-119. doi: 10.1038/ncb3464. Epub 2017 Jan 23.
• [3501] Labdane diterpenoids from Curcuma amada rhizomes collected in Myanmar and their antiproliferative activities.Fitoterapia. 2017 Oct;122:34-39. doi: 10.1016/j.fitote.2017.08.006. Epub 2017 Aug 18.
• [3502] Select human cancer mutants of NRMT1 alter its catalytic activity and decrease N-terminal trimethylation.Protein Sci. 2017 Aug;26(8):1639-1652. doi: 10.1002/pro.3202. Epub 2017 Jun 11.
• [3503] Biological characterisation and application of human MTH1 and monoclonal antibody preparation.Oncol Rep. 2019 Mar;41(3):1851-1862. doi: 10.3892/or.2018.6942. Epub 2018 Dec 19.
• [3504] Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation. Int J Cancer. 2011 Apr 15;128(8):1770-82. doi: 10.1002/ijc.25505.
• [3505] Expression of Oncogenic Drivers in 3D Cell Culture Depends on Nuclear ATP Synthesis by NUDT5.Cancers (Basel). 2019 Sep 10;11(9):1337. doi: 10.3390/cancers11091337.
• [3506] Comprehensive analysis of NuMA variation in breast cancer.BMC Cancer. 2008 Mar 10;8:71. doi: 10.1186/1471-2407-8-71.
• [3507] Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice.Iran J Basic Med Sci. 2018 Jan;21(1):26-32. doi: 10.22038/IJBMS.2017.25686.6335.
• [3508] High NUP43 expression might independently predict poor overall survival in luminal A and in HER2+ breast cancer.Future Oncol. 2018 Jun;14(15):1431-1442. doi: 10.2217/fon-2017-0690. Epub 2018 Feb 6.
• [3509] Nup88 mRNA overexpression is associated with high aggressiveness of breast cancer.Int J Cancer. 2004 May 1;109(5):717-20. doi: 10.1002/ijc.20034.
• [3510] NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer.BMC Cancer. 2019 Apr 2;19(1):236. doi: 10.1186/s12885-019-5407-9.
• [3511] Expression of Com-1/P8 in human breast cancer and its relevance to clinical outcome and ER status.Int J Cancer. 2005 Dec 10;117(5):730-7. doi: 10.1002/ijc.21221.
• [3512] Effects of decitabine on the expression of selected endogenous control genes in human breast cancer cells.Mol Cell Probes. 2010 Apr;24(2):87-92. doi: 10.1016/j.mcp.2009.10.007. Epub 2009 Oct 22.
• [3513] OCA2 rs4778137 polymorphism predicts survival of breast cancer patients receiving neoadjuvant chemotherapy.Gene. 2018 Apr 20;651:161-165. doi: 10.1016/j.gene.2018.01.100. Epub 2018 Feb 2.
• [3514] Silencing of casein kinase 1 delta reduces migration and metastasis of triple negative breast cancer cells.Oncotarget. 2018 Jul 20;9(56):30821-30836. doi: 10.18632/oncotarget.25738. eCollection 2018 Jul 20.
• [3515] Discovery of rare coding variants in OGDHL and BRCA2 in relation to breast cancer risk in Chinese women.Int J Cancer. 2020 Apr 15;146(8):2175-2181. doi: 10.1002/ijc.32825. Epub 2019 Dec 27.
• [3516] Osteoglycin (OGN) Inhibits Cell Proliferation and Invasiveness in Breast Cancer via PI3K/Akt/mTOR Signaling Pathway.Onco Targets Ther. 2019 Dec 4;12:10639-10650. doi: 10.2147/OTT.S222967. eCollection 2019.
• [3517] O-GlcNAc-Dependent Regulation of Progesterone Receptor Function in Breast Cancer.Horm Cancer. 2018 Feb;9(1):12-21. doi: 10.1007/s12672-017-0310-9. Epub 2017 Sep 19.
• [3518] Downregulation of long non-coding RNA Opa interacting protein 5-antisense RNA 1 inhibits breast cancer progression by targeting sex-determining region Y-box 2 by microRNA-129-5p upregulation.Cancer Sci. 2019 Jan;110(1):289-302. doi: 10.1111/cas.13879. Epub 2018 Dec 13.
• [3519] Depletion of mitochondrial protease OMA1 alters proliferative properties and promotes metastatic growth of breast cancer cells.Sci Rep. 2019 Oct 14;9(1):14746. doi: 10.1038/s41598-019-49327-2.
• [3520] The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.Mol Cancer Ther. 2017 Oct;16(10):2246-2256. doi: 10.1158/1535-7163.MCT-17-0081. Epub 2017 Aug 3.
• [3521] Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach.Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):675-82. doi: 10.1158/1055-9965.EPI-05-0679.
• [3522] pH protective Y(1) receptor ligand functionalized antiphagocytosis BPLP-WPU micelles for enhanced tumor imaging and therapy with prolonged survival time.Biomaterials. 2018 Jul;170:70-81. doi: 10.1016/j.biomaterials.2018.04.002. Epub 2018 Apr 4.
• [3523] Haptoglobin polymorphism in breast cancer patients form Jordan.Clin Chim Acta. 2004 Mar;341(1-2):17-21. doi: 10.1016/j.cccn.2003.10.032.
• [3524] The Olfactory Receptor Family 2, Subfamily T, Member 6 (OR2T6) Is Involved in Breast Cancer Progression via Initiating Epithelial-Mesenchymal Transition and MAPK/ERK Pathway.Front Oncol. 2019 Nov 11;9:1210. doi: 10.3389/fonc.2019.01210. eCollection 2019.
• [3525] Early induction of the orphan nuclear receptor NOR-1 during cell death of the human breast cancer cell line MCF-7.Mol Cell Endocrinol. 2000 Apr 25;162(1-2):151-6. doi: 10.1016/s0303-7207(00)00222-7.
• [3526] Docosahexaenoic acid increases the expression of oxidative stress-induced growth inhibitor 1 through the PI3K/Akt/Nrf2 signaling pathway in breast cancer cells. Food Chem Toxicol. 2017 Oct;108(Pt A):276-288. doi: 10.1016/j.fct.2017.08.010. Epub 2017 Aug 12.
• [3527] OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance.Oncogene. 2016 Mar 17;35(11):1433-44. doi: 10.1038/onc.2015.208. Epub 2015 Jul 6.
• [3528] Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7.Nat Commun. 2017 Dec 13;8(1):2116. doi: 10.1038/s41467-017-02029-7.
• [3529] The deubiquitylase OTUD3 stabilizes GRP78 and promotes lung tumorigenesis.Nat Commun. 2019 Jul 2;10(1):2914. doi: 10.1038/s41467-019-10824-7.
• [3530] Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.Breast Cancer Res. 2015 Sep 14;17(1):125. doi: 10.1186/s13058-015-0637-5.
• [3531] OTX1 expression in breast cancer is regulated by p53.Oncogene. 2011 Jul 7;30(27):3096-103. doi: 10.1038/onc.2011.31. Epub 2011 Apr 11.
• [3532] Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels.Int J Oncol. 2012 Aug;41(2):629-38. doi: 10.3892/ijo.2012.1464. Epub 2012 May 8.
• [3533] LRH-1 drives hepatocellular carcinoma partially through induction of c-myc and cyclin E1, and suppression of p21.Cancer Manag Res. 2018 Aug 1;10:2389-2400. doi: 10.2147/CMAR.S162887. eCollection 2018.
• [3534] Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells.J Exp Clin Cancer Res. 2019 Oct 10;38(1):414. doi: 10.1186/s13046-019-1404-8.
• [3535] Anticancer Activity and Cisplatin Binding Ability of Bis-Quinoline and Bis-Isoquinoline Derived [Pd(2)L(4)](4+) Metallosupramolecular Cages.Front Chem. 2018 Nov 22;6:563. doi: 10.3389/fchem.2018.00563. eCollection 2018.
• [3536] PTIP associated protein 1, PA1, is an independent prognostic factor for lymphnode negative breast cancer.PLoS One. 2013 Nov 18;8(11):e80552. doi: 10.1371/journal.pone.0080552. eCollection 2013.
• [3537] Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer.Oncotarget. 2017 Mar 15;8(13):20572-20587. doi: 10.18632/oncotarget.16244.
• [3538] Paip1 affects breast cancer cell growth and represents a novel prognostic biomarker.Hum Pathol. 2018 Mar;73:33-40. doi: 10.1016/j.humpath.2017.10.037. Epub 2017 Dec 16.
• [3539] Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins.Prostate. 2008 Oct 1;68(14):1510-6. doi: 10.1002/pros.20787.
• [3540] Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin.Cell Adh Migr. 2011 May-Jun;5(3):211-4. doi: 10.4161/cam.5.3.15790. Epub 2011 May 1.
• [3541] Identification of novel epigenetically inactivated gene PAMR1 in breast carcinoma.Oncol Rep. 2015 Jan;33(1):267-73. doi: 10.3892/or.2014.3581. Epub 2014 Nov 3.
• [3542] Pannexin1 Is Associated with Enhanced Epithelial-To-Mesenchymal Transition in Human Patient Breast Cancer Tissues and in Breast Cancer Cell Lines.Cancers (Basel). 2019 Dec 7;11(12):1967. doi: 10.3390/cancers11121967.
• [3543] Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions.J Cell Biochem. 1995 Apr;57(4):680-90. doi: 10.1002/jcb.240570413.
• [3544] Collagen and PAPP-A in the Etiology of Postpartum Breast Cancer.Horm Cancer. 2019 Dec;10(4-6):137-144. doi: 10.1007/s12672-019-00368-z. Epub 2019 Oct 20.
• [3545] Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.Cancer Res. 2018 Dec 1;78(23):6691-6702. doi: 10.1158/0008-5472.CAN-18-1362. Epub 2018 Oct 8.
• [3546] PARP9 is overexpressed in human breast cancer and promotes cancer cell migration.Oncol Lett. 2018 Sep;16(3):4073-4077. doi: 10.3892/ol.2018.9124. Epub 2018 Jul 11.
• [3547] Parvin-beta inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor gamma 1 phosphorylation.Mol Cell Biol. 2008 Jan;28(2):687-704. doi: 10.1128/MCB.01617-06. Epub 2007 Nov 12.
• [3548] The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.Ann Oncol. 2013 May;24(5):1244-52. doi: 10.1093/annonc/mds613. Epub 2012 Dec 9.
• [3549] Unexpected PAX8 Immunoreactivity in Metastatic High-grade Breast Cancer.Appl Immunohistochem Mol Morphol. 2019 Oct;27(9):637-643. doi: 10.1097/PAI.0000000000000707.
• [3550] DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis.Cancer Biol Ther. 2017 Jun 3;18(6):439-449. doi: 10.1080/15384047.2017.1323590. Epub 2017 May 5.
• [3551] PBOV1 is a human de novo gene with tumor-specific expression that is associated with a positive clinical outcome of cancer.PLoS One. 2013;8(2):e56162. doi: 10.1371/journal.pone.0056162. Epub 2013 Feb 13.
• [3552] uc.38 induces breast cancer cell apoptosis via PBX1.Am J Cancer Res. 2017 Dec 1;7(12):2438-2451. eCollection 2017.
• [3553] Hematopoietic PBX-interacting protein (HPIP) is over expressed in breast infiltrative ductal carcinoma and regulates cell adhesion and migration through modulation of focal adhesion dynamics.Oncogene. 2015 Aug 27;34(35):4601-12. doi: 10.1038/onc.2014.389. Epub 2014 Dec 8.
• [3554] Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data.Gene. 2018 Jun 5;658:28-35. doi: 10.1016/j.gene.2018.03.011. Epub 2018 Mar 5.
• [3555] Aberrant promoter methylation of PCDH10 as a potential diagnostic and prognostic biomarker for patients with breast cancer.Oncol Lett. 2018 Oct;16(4):4462-4470. doi: 10.3892/ol.2018.9214. Epub 2018 Jul 25.
• [3556] Protocadherin 17 functions as a tumor suppressor suppressing Wnt/-catenin signaling and cell metastasis and is frequently methylated in breast cancer.Oncotarget. 2016 Aug 9;7(32):51720-51732. doi: 10.18632/oncotarget.10102.
• [3557] Modulation of Mutant Kras(G12D) -Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function.Mol Cancer Res. 2019 Feb;17(2):594-603. doi: 10.1158/1541-7786.MCR-18-0739. Epub 2018 Nov 8.
• [3558] Frequent silencing of protocadherin 8 by promoter methylation, a candidate tumor suppressor for human gastric cancer.Oncol Rep. 2012 Nov;28(5):1785-91. doi: 10.3892/or.2012.1997. Epub 2012 Aug 30.
• [3559] Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.J Natl Cancer Inst. 2019 Jun 1;111(6):609-619. doi: 10.1093/jnci/djy151.
• [3560] Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression.Int J Cancer. 2003 Nov 10;107(3):346-52. doi: 10.1002/ijc.11408.
• [3561] TRIM59 promotes breast cancer motility by suppressing p62-selective autophagic degradation of PDCD10.PLoS Biol. 2018 Nov 8;16(11):e3000051. doi: 10.1371/journal.pbio.3000051. eCollection 2018 Nov.
• [3562] MicroRNA-124-3p directly targets PDCD6 to inhibit metastasis in breast cancer.Oncol Lett. 2018 Jan;15(1):984-990. doi: 10.3892/ol.2017.7358. Epub 2017 Nov 8.
• [3563] ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation.Cell Rep. 2018 Jul 17;24(3):630-641. doi: 10.1016/j.celrep.2018.06.066.
• [3564] Suppression of PDHX by microRNA-27b deregulates cell metabolism and promotes growth in breast cancer.Mol Cancer. 2018 Jul 16;17(1):100. doi: 10.1186/s12943-018-0851-8.
• [3565] Downregulation of ER60 protease inhibits cellular proliferation by inducing G1/S arrest in breast cancer cells in vitro.Anat Rec (Hoboken). 2012 Mar;295(3):410-6. doi: 10.1002/ar.22413. Epub 2012 Jan 20.
• [3566] In vivo selection for metastasis promoting genes in the mouse.Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6696-701. doi: 10.1073/pnas.0701145104. Epub 2007 Apr 9.
• [3567] Silencing of casein kinase 2 inhibits PKCinduced cell invasion by targeting MMP? in MCF? cells.Mol Med Rep. 2018 Jun;17(6):8397-8402. doi: 10.3892/mmr.2018.8885. Epub 2018 Apr 13.
• [3568] Targeting PDK4 inhibits breast cancer metabolism.Am J Cancer Res. 2018 Sep 1;8(9):1725-1738. eCollection 2018.
• [3569] Intensity and Pattern of Enhancement on CESM: Prognostic Significance and its Relation to Expression of Podoplanin in Tumor Stroma - A Preliminary Report.Anticancer Res. 2018 Feb;38(2):1085-1095. doi: 10.21873/anticanres.12327.
• [3570] SCC-112, a novel cell cycle-regulated molecule, exhibits reduced expression in human renal carcinomas.Gene. 2004 Mar 17;328:187-96. doi: 10.1016/j.gene.2003.12.013.
• [3571] PEG10 is a c-MYC target gene in cancer cells.Cancer Res. 2006 Jan 15;66(2):665-72. doi: 10.1158/0008-5472.CAN-05-1553.
• [3572] Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression.Nat Med. 2011 Jan;17(1):123-9. doi: 10.1038/nm.2269. Epub 2010 Dec 12.
• [3573] Analyses of BMAL1 and PER2 Oscillations in a Model of Breast Cancer Progression Reveal Changes With Malignancy.Integr Cancer Ther. 2019 Jan-Dec;18:1534735419836494. doi: 10.1177/1534735419836494.
• [3574] PES1 In Liver Cancer: A Prognostic Biomarker With Tumorigenic Roles.Cancer Manag Res. 2019 Nov 14;11:9641-9653. doi: 10.2147/CMAR.S226471. eCollection 2019.
• [3575] Identification of novel susceptibility markers for the risk of overall breast cancer as well as subtypes defined by hormone receptor status in the Chinese population.J Hum Genet. 2016 Dec;61(12):1027-1034. doi: 10.1038/jhg.2016.97. Epub 2016 Sep 8.
• [3576] Abnormal expression of PFDN4 in colorectal cancer: a novel marker for prognosis.Ann Surg Oncol. 2010 Nov;17(11):3030-6. doi: 10.1245/s10434-010-1138-5. Epub 2010 Jun 15.
• [3577] High expression of metabolic enzyme PFKFB4 is associated with poor prognosis of operable breast cancer.Cancer Cell Int. 2019 Jun 18;19:165. doi: 10.1186/s12935-019-0882-2. eCollection 2019.
• [3578] A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age.Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):658-69. doi: 10.1158/1055-9965.EPI-13-0340. Epub 2014 Feb 3.
• [3579] Differential expression of phosphofructokinase-1 isoforms correlates with the glycolytic efficiency of breast cancer cells.Mol Genet Metab. 2010 Aug;100(4):372-8. doi: 10.1016/j.ymgme.2010.04.006. Epub 2010 Apr 18.
• [3580] Tocotrienols Modulate Breast Cancer Secretomes and Affect Cancer-Signaling Pathways in MDA-MB-231 Cells: A Label-Free Quantitative Proteomic Analysis.Nutr Cancer. 2019;71(8):1263-1271. doi: 10.1080/01635581.2019.1607407. Epub 2019 May 14.
• [3581] Long noncoding RNA FOXD2AS1/miR?50?p/PFN2 axis regulates breast cancer malignancy and tumorigenesis.Int J Oncol. 2019 Mar;54(3):1043-1052. doi: 10.3892/ijo.2019.4671. Epub 2019 Jan 3.
• [3582] The diagnostic value and functional roles of phosphoglycerate mutase 1 in glioma.Oncol Rep. 2016 Oct;36(4):2236-44. doi: 10.3892/or.2016.5046. Epub 2016 Aug 25.
• [3583] PGK1 is a Potential Survival Biomarker and Invasion Promoter by Regulating the HIF-1-Mediated Epithelial-Mesenchymal Transition Process in Breast Cancer.Cell Physiol Biochem. 2018;51(5):2434-2444. doi: 10.1159/000495900. Epub 2018 Dec 11.
• [3584] Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma.Mol Cancer. 2008 Nov 6;7:84. doi: 10.1186/1476-4598-7-84.
• [3585] An integrated genomic analysis of Tudor domain-containing proteins identifies PHD finger protein 20-like 1 (PHF20L1) as a candidate oncogene in breast cancer.Mol Oncol. 2016 Feb;10(2):292-302. doi: 10.1016/j.molonc.2015.10.013. Epub 2015 Oct 28.
• [3586] PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing.Cancer Med. 2019 May;8(5):2429-2441. doi: 10.1002/cam4.2115. Epub 2019 Apr 1.
• [3587] PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer.Cell Rep. 2018 Feb 27;22(9):2469-2481. doi: 10.1016/j.celrep.2018.02.028.
• [3588] IPH-926 lobular breast cancer cells harbor a p53 mutant with temperature-sensitive functional activity and allow for profiling of p53-responsive genes.Lab Invest. 2012 Nov;92(11):1635-47. doi: 10.1038/labinvest.2012.126. Epub 2012 Sep 3.
• [3589] B-CAN: a resource sharing platform to improve the operation, visualization and integrated analysis of TCGA breast cancer data.Oncotarget. 2017 Oct 19;8(65):108778-108785. doi: 10.18632/oncotarget.21947. eCollection 2017 Dec 12.
• [3590] Diagnostic and prognostic value of plasma and tissue ubiquitin-like, containing PHD and RING finger domains 1 in breast cancer patients.Cancer Sci. 2013 Feb;104(2):194-9. doi: 10.1111/cas.12052. Epub 2012 Dec 13.
• [3591] The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase.Oncogene. 2015 Jul;34(27):3556-67. doi: 10.1038/onc.2014.284. Epub 2014 Sep 8.
• [3592] Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer.PLoS One. 2017 May 11;12(5):e0177639. doi: 10.1371/journal.pone.0177639. eCollection 2017.
• [3593] Piezo1 forms mechanosensitive ion channels in the human MCF-7 breast cancer cell line.Sci Rep. 2015 Feb 10;5:8364. doi: 10.1038/srep08364.
• [3594] Five miRNAs-mediated PIEZO2 downregulation, accompanied with activation of Hedgehog signaling pathway, predicts poor prognosis of breast cancer.Aging (Albany NY). 2019 May 6;11(9):2628-2652. doi: 10.18632/aging.101934.
• [3595] Overexpression of glycosylphosphatidylinositol (GPI) transamidase subunits phosphatidylinositol glycan class T and/or GPI anchor attachment 1 induces tumorigenesis and contributes to invasion in human breast cancer.Cancer Res. 2006 Oct 15;66(20):9829-36. doi: 10.1158/0008-5472.CAN-06-0506.
• [3596] Phosphatidylinositol glycan anchor biosynthesis, class X containing complex promotes cancer cell proliferation through suppression of EHD2 and ZIC1, putative tumor suppressors.Int J Oncol. 2016 Sep;49(3):868-76. doi: 10.3892/ijo.2016.3607. Epub 2016 Jul 6.
• [3597] Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2 Scaffolding Function.Cancer Cell. 2017 Oct 9;32(4):444-459.e7. doi: 10.1016/j.ccell.2017.09.002.
• [3598] Class II phosphoinositide 3-kinase C2 regulates a novel signaling pathway involved in breast cancer progression.Oncotarget. 2016 Apr 5;7(14):18325-45. doi: 10.18632/oncotarget.7761.
• [3599] Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib.Cancer Lett. 2018 Oct 28;435:32-43. doi: 10.1016/j.canlet.2018.07.028. Epub 2018 Jul 25.
• [3600] HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical -catenin signaling.Oncotarget. 2017 Jul 22;8(35):58918-58933. doi: 10.18632/oncotarget.19441. eCollection 2017 Aug 29.
• [3601] Candidate tumor suppressor gene IRF6 is involved in human breast cancer pathogenesis via modulating PI3K-regulatory subunit PIK3R2 expression.Cancer Manag Res. 2019 Jun 21;11:5557-5572. doi: 10.2147/CMAR.S203060. eCollection 2019.
• [3602] Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer.Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5314-21. doi: 10.1158/1078-0432.CCR-06-2660.
• [3603] Up-regulation of FAM64A promotes epithelial-to-mesenchymal transition and enhances stemness features in breast cancer cells.Biochem Biophys Res Commun. 2019 May 28;513(2):472-478. doi: 10.1016/j.bbrc.2019.03.207. Epub 2019 Apr 9.
• [3604] The phosphorylation status of PIP5K1C at serine 448 can be predictive for invasive ductal carcinoma of the breast.Oncotarget. 2018 Nov 20;9(91):36358-36370. doi: 10.18632/oncotarget.26357. eCollection 2018 Nov 20.
• [3605] The lipid-transfer protein Nir2 enhances epithelial-mesenchymal transition and facilitates breast cancer metastasis.J Cell Sci. 2014 Nov 1;127(Pt 21):4740-9. doi: 10.1242/jcs.155721. Epub 2014 Sep 1.
• [3606] Discovery of CCL18 antagonist blocking breast cancer metastasis.Clin Exp Metastasis. 2019 Jun;36(3):243-255. doi: 10.1007/s10585-019-09965-2. Epub 2019 May 6.
• [3607] The estrogen-regulated transcription factor PITX1 coordinates gene-specific regulation by estrogen receptor-alpha in breast cancer cells.Mol Endocrinol. 2011 Oct;25(10):1699-709. doi: 10.1210/me.2011-0102. Epub 2011 Aug 25.
• [3608] Interplay between AP-1 and estrogen receptor in regulating gene expression and proliferation networks in breast cancer cells.Carcinogenesis. 2012 Sep;33(9):1684-91. doi: 10.1093/carcin/bgs223. Epub 2012 Jul 12.
• [3609] High expression of PLA2G16 is associated with a better prognosis in HER2-positive breast cancer.J Thorac Dis. 2017 Apr;9(4):1002-1011. doi: 10.21037/jtd.2017.03.108.
• [3610] LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, is epigenetically regulated in cancer.J Biol Chem. 2003 Feb 21;278(8):6041-9. doi: 10.1074/jbc.M210361200. Epub 2002 Dec 6.
• [3611] MiR-449a suppresses cell migration and invasion by targeting PLAGL2 in breast cancer.Pathol Res Pract. 2018 May;214(5):790-795. doi: 10.1016/j.prp.2017.12.012. Epub 2018 Jan 5.
• [3612] Phospholipase C1 suppresses cell migration and invasion of breast cancer cells by modulating KIF3A-mediated ERK1/2/- catenin/MMP7 signalling.Oncotarget. 2017 Apr 25;8(17):29056-29066. doi: 10.18632/oncotarget.16072.
• [3613] Phospholipase C delta-4 overexpression upregulates ErbB1/2 expression, Erk signaling pathway, and proliferation in MCF-7 cells.Mol Cancer. 2004 May 13;3:15. doi: 10.1186/1476-4598-3-15.
• [3614] Paradoxical hormone responses of KPL-1 breast cancer cells in vivo: a significant role of angiogenesis in tumor growth.Oncology. 2000 Aug;59(2):158-65. doi: 10.1159/000012154.
• [3615] GIPC1 interacts with MyoGEF and promotes MDA-MB-231 breast cancer cell invasion.J Biol Chem. 2010 Sep 10;285(37):28643-50. doi: 10.1074/jbc.M110.107649. Epub 2010 Jul 15.
• [3616] The significance of lipid accumulation in breast carcinoma cells through perilipin 2 and its clinicopathological significance.Pathol Int. 2019 Aug;69(8):463-471. doi: 10.1111/pin.12831. Epub 2019 Jul 4.
• [3617] Calcium-dependent inhibition of polo-like kinase 3 activity by CIB1 in breast cancer cells.Int J Cancer. 2011 Feb 1;128(3):587-96. doi: 10.1002/ijc.25388.
• [3618] PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung tumors.Am J Pathol. 2013 Nov;183(5):1634-1644. doi: 10.1016/j.ajpath.2013.07.028. Epub 2013 Sep 17.
• [3619] Semaphorin-plexin signalling genes associated with human breast tumourigenesis.Gene. 2011 Dec 10;489(2):63-9. doi: 10.1016/j.gene.2011.08.024. Epub 2011 Sep 2.
• [3620] Association between prognosis and SEMA4D/Plexin-B1 expression in various malignancies: A meta-analysis.Medicine (Baltimore). 2019 Feb;98(7):e13298. doi: 10.1097/MD.0000000000013298.
• [3621] Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2594-E2603. doi: 10.1073/pnas.1717820115. Epub 2018 Feb 23.
• [3622] PMEPA1/TMEPAI knockout impairs tumour growth and lung metastasis in MDA-MB-231 cells without changing monolayer culture cell growth.J Biochem. 2019 May 1;165(5):411-414. doi: 10.1093/jb/mvz022.
• [3623] The caM kinase, Pnck, is spatially and temporally regulated during murine mammary gland development and may identify an epithelial cell subtype involved in breast cancer.Cancer Res. 2000 Oct 1;60(19):5571-7.
• [3624] Myofibrillogenesis regulator 1 (MR-1): a potential therapeutic target for cancer and PNKD.J Drug Target. 2018 Sep;26(8):643-648. doi: 10.1080/1061186X.2017.1401077. Epub 2017 Nov 15.
• [3625] Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy.Breast Cancer Res. 2015 Mar 27;17(1):46. doi: 10.1186/s13058-015-0562-7.
• [3626] Overexpression of Pofut1 and activated Notch1 may be associated with poor prognosis in breast cancer.Biochem Biophys Res Commun. 2017 Sep 9;491(1):104-111. doi: 10.1016/j.bbrc.2017.07.053. Epub 2017 Jul 11.
• [3627] Novel POLE pathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures.Hum Mutat. 2019 Jan;40(1):36-41. doi: 10.1002/humu.23676. Epub 2018 Nov 20.
• [3628] DNA polymerase iota (Pol ) promotes the migration and invasion of breast cancer cell via EGFR-ERK-mediated epithelial to mesenchymal transition.Cancer Biomark. 2019;24(3):363-370. doi: 10.3233/CBM-181516.
• [3629] DNA polymerase (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse.J Biol Chem. 2019 Mar 15;294(11):3909-3919. doi: 10.1074/jbc.RA118.005188. Epub 2019 Jan 17.
• [3630] MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.Mol Cell. 2015 Jul 16;59(2):243-57. doi: 10.1016/j.molcel.2015.05.036. Epub 2015 Jul 2.
• [3631] The effect of chemotherapeutic agents on telomere length maintenance in breast cancer cell lines.Breast Cancer Res Treat. 2014 Jun;145(3):581-91. doi: 10.1007/s10549-014-2975-x. Epub 2014 May 8.
• [3632] POTE paralogs are induced and differentially expressed in many cancers.Cancer Res. 2006 Jan 1;66(1):52-6. doi: 10.1158/0008-5472.CAN-05-3014.
• [3633] Effects of Histone Deacetylase Inhibitor (HDACi); Trichostatin-A (TSA) on the expression of housekeeping genes.Mol Cell Probes. 2006 Apr;20(2):81-6. doi: 10.1016/j.mcp.2005.09.008. Epub 2005 Dec 2.
• [3634] Examination of POU homeobox gene expression in human breast cancer cells.Int J Cancer. 1999 Mar 31;81(1):104-12. doi: 10.1002/(sici)1097-0215(19990331)81:1<104::aid-ijc18>3.0.co;2-q.
• [3635] Hypoxia modulates stem cell properties and induces EMT through N-glycosylation of EpCAM in breast cancer cells.J Cell Physiol. 2020 Apr;235(4):3626-3633. doi: 10.1002/jcp.29252. Epub 2019 Oct 4.
• [3636] Identification of Critical Elements for Regulation of Inorganic Pyrophosphatase (PPA1) in MCF7 Breast Cancer Cells.PLoS One. 2015 Apr 29;10(4):e0124864. doi: 10.1371/journal.pone.0124864. eCollection 2015.
• [3637] PGC-1 induced browning promotes involution and inhibits lactation in mammary glands.Cell Mol Life Sci. 2019 Dec;76(24):5011-5025. doi: 10.1007/s00018-019-03160-y. Epub 2019 Jun 1.
• [3638] Liprin-1 modulates cancer cell signaling by transmembrane protein CD82 in adhesive membrane domains linked to cytoskeleton.Cell Commun Signal. 2018 Jul 13;16(1):41. doi: 10.1186/s12964-018-0253-y.
• [3639] Association of CYP gene polymorphisms with breast cancer risk and prognostic factors in the Jordanian population.BMC Med Genet. 2019 Sep 2;20(1):148. doi: 10.1186/s12881-019-0884-x.
• [3640] U-box ubiquitin ligase PPIL2 suppresses breast cancer invasion and metastasis by altering cell morphology and promoting SNAI1 ubiquitination and degradation.Cell Death Dis. 2018 Jan 19;9(2):63. doi: 10.1038/s41419-017-0094-4.
• [3641] Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing.Tumour Biol. 2016 Oct;37(10):13111-13119. doi: 10.1007/s13277-016-5190-z. Epub 2016 Jul 23.
• [3642] Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.Nat Genet. 2017 Aug;49(8):1219-1230. doi: 10.1038/ng.3905. Epub 2017 Jun 26.
• [3643] Expression of the protein phosphatase 1 inhibitor KEPI is downregulated in breast cancer cell lines and tissues and involved in the regulation of the tumor suppressor EGR1 via the MEK-ERK pathway.Biol Chem. 2007 May;388(5):489-95. doi: 10.1515/BC.2007.062.
• [3644] Darpp-32 and t-Darpp protein products of PPP1R1B: Old dogs with new tricks.Biochem Pharmacol. 2019 Feb;160:71-79. doi: 10.1016/j.bcp.2018.12.008. Epub 2018 Dec 12.
• [3645] Dopamine and cAMP-regulated phosphoprotein 32kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression.Sci Rep. 2019 Nov 18;9(1):16987. doi: 10.1038/s41598-019-53529-z.
• [3646] NRBE3 promotes metastasis of breast cancer by down-regulating E-cadherin expression.Biochim Biophys Acta Mol Cell Res. 2018 Dec;1865(12):1869-1877. doi: 10.1016/j.bbamcr.2018.09.003. Epub 2018 Sep 11.
• [3647] The role of posttraumatic stress and posttraumatic growth on online information use in breast cancer survivors.Psychooncology. 2018 Aug;27(8):1971-1978. doi: 10.1002/pon.4753. Epub 2018 May 25.
• [3648] Low spinophilin expression enhances aggressive biological behavior of breast cancer.Oncotarget. 2015 May 10;6(13):11191-202. doi: 10.18632/oncotarget.3586.
• [3649] Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk.Cancer. 2010 Jan 1;116(1):8-19. doi: 10.1002/cncr.24702.
• [3650] The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function.Genes Chromosomes Cancer. 2006 Feb;45(2):182-90. doi: 10.1002/gcc.20284.
• [3651] Meta-analysis of the diagnostic accuracy of ultrasound-guided fine-needle aspiration and core needle biopsy in diagnosing axillary lymph node metastasis.Br J Surg. 2018 Sep;105(10):1244-1253. doi: 10.1002/bjs.10920. Epub 2018 Jul 4.
• [3652] In vitro cytotoxic potential of friedelin in human MCF-7 breast cancer cell: Regulate early expression of Cdkn2a and pRb1, neutralize mdm2-p53 amalgamation and functional stabilization of p53.Exp Toxicol Pathol. 2017 Oct 2;69(8):630-636. doi: 10.1016/j.etp.2017.05.011. Epub 2017 Jun 12.
• [3653] Polycomb complexes associate with enhancers and promote oncogenic transcriptional programs in cancer through multiple mechanisms.Nat Commun. 2018 Aug 23;9(1):3377. doi: 10.1038/s41467-018-05728-x.
• [3654] Dysregulation of Blimp1 transcriptional repressor unleashes p130Cas/ErbB2 breast cancer invasion.Sci Rep. 2017 Apr 25;7(1):1145. doi: 10.1038/s41598-017-01332-z.
• [3655] The peroxidase PRDX1 inhibits the activated phenotype in mammary fibroblasts through regulating c-Jun N-terminal kinases.BMC Cancer. 2019 Aug 16;19(1):812. doi: 10.1186/s12885-019-6031-4.
• [3656] Identification of potential breast cancer markers in nipple discharge by protein profile analysis using two-dimensional nano-liquid chromatography/nanoelectrospray ionization-mass spectrometry.Proteomics Clin Appl. 2016 May;10(5):605-13. doi: 10.1002/prca.201500016. Epub 2016 Apr 26.
• [3657] Silencing the Peroxiredoxin III gene inhibits cell proliferation in breast cancer.Int J Oncol. 2010 Feb;36(2):359-64.
• [3658] Correction to: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.Breast Cancer Res. 2018 Jul 2;20(1):63. doi: 10.1186/s13058-018-0984-0.
• [3659] Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.Breast Cancer Res. 2008;10(3):R47. doi: 10.1186/bcr2100. Epub 2008 May 28.
• [3660] Ouabain impairs cancer metabolism and activates AMPK-Src signaling pathway in human cancer cell lines.Acta Pharmacol Sin. 2020 Jan;41(1):110-118. doi: 10.1038/s41401-019-0290-0. Epub 2019 Sep 12.
• [3661] Association of breast cancer risk and the mTOR pathway in women of African ancestry in 'The Root' Consortium.Carcinogenesis. 2017 Aug 1;38(8):789-796. doi: 10.1093/carcin/bgx055.
• [3662] The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.Cell Physiol Biochem. 2019;52(3):382-396. doi: 10.33594/000000027. Epub 2019 Mar 8.
• [3663] Attendance and compliance with an exercise program during localized breast cancer treatment in a randomized controlled trial: The PACT study.PLoS One. 2019 May 8;14(5):e0215517. doi: 10.1371/journal.pone.0215517. eCollection 2019.
• [3664] Proline-Rich Homeodomain protein (PRH/HHEX) is a suppressor of breast tumour growth.Oncogenesis. 2017 Jun 12;6(6):e346. doi: 10.1038/oncsis.2017.42.
• [3665] PELP1 oncogenic functions involve alternative splicing via PRMT6.Mol Oncol. 2014 Mar;8(2):389-400. doi: 10.1016/j.molonc.2013.12.012. Epub 2013 Dec 30.
• [3666] Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers.Cell Res. 2019 Oct;29(10):832-845. doi: 10.1038/s41422-019-0225-9. Epub 2019 Sep 3.
• [3667] Involvement of Prokineticin 2-expressing Neutrophil Infiltration in 5-Fluorouracil-induced Aggravation of Breast Cancer Metastasis to Lung.Mol Cancer Ther. 2018 Jul;17(7):1515-1525. doi: 10.1158/1535-7163.MCT-17-0845. Epub 2018 Apr 11.
• [3668] Long non-coding RNA LINC00968 reduces cell proliferation and migration and angiogenesis in breast cancer through up-regulation of PROX1 by reducing hsa-miR-423-5p.Cell Cycle. 2019 Aug;18(16):1908-1924. doi: 10.1080/15384101.2019.1632641. Epub 2019 Jun 29.
• [3669] 22 genes from chromosome 17q21: cloning, sequencing, and characterization of mutations in breast cancer families and tumors.Genomics. 1995 Jan 1;25(1):256-63. doi: 10.1016/0888-7543(95)80133-7.
• [3670] Integrative transcriptome data mining for identification of core lncRNAs in breast cancer.PeerJ. 2019 Oct 7;7:e7821. doi: 10.7717/peerj.7821. eCollection 2019.
• [3671] PRPS1 silencing reverses cisplatin resistance in human breast cancer cells.Biochem Cell Biol. 2017 Jun;95(3):385-393. doi: 10.1139/bcb-2016-0106. Epub 2016 Nov 3.
• [3672] PRR11 and SKA2 gene pair is overexpressed and regulated by p53 in breast cancer.BMB Rep. 2019 Feb;52(2):157-162. doi: 10.5483/BMBRep.2019.52.2.207.
• [3673] PRR5 encodes a conserved proline-rich protein predominant in kidney: analysis of genomic organization, expression, and mutation status in breast and colorectal carcinomas.Genomics. 2005 Mar;85(3):338-51. doi: 10.1016/j.ygeno.2004.11.002.
• [3674] The identification of specific methylation patterns across different cancers.PLoS One. 2015 Mar 16;10(3):e0120361. doi: 10.1371/journal.pone.0120361. eCollection 2015.
• [3675] Rictor ablation in BMSCs inhibits bone metastasis of TM40D cells by attenuating osteolytic destruction and CAF formation.Int J Biol Sci. 2019 Sep 7;15(11):2448-2460. doi: 10.7150/ijbs.37241. eCollection 2019.
• [3676] The P(2)' residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity.Biochem J. 2011 Nov 15;440(1):95-105. doi: 10.1042/BJ20110788.
• [3677] Testes-specific protease 50 as an independent risk factor for poor prognosis in patients with non-small cell lung cancer.Oncol Lett. 2018 Jun;15(6):8796-8804. doi: 10.3892/ol.2018.8387. Epub 2018 Mar 29.
• [3678] Phosphorylation of nm23-H1 by CKI induces its complex formation with h-prune and promotes cell motility.Oncogene. 2008 Mar 20;27(13):1853-64. doi: 10.1038/sj.onc.1210822. Epub 2007 Oct 1.
• [3679] Mechano-Signal Transduction in Mesenchymal Stem Cells Induces Prosaposin Secretion to Drive the Proliferation of Breast Cancer Cells.Cancer Res. 2017 Nov 15;77(22):6179-6189. doi: 10.1158/0008-5472.CAN-17-0569. Epub 2017 Sep 28.
• [3680] PSMB4 overexpression enhances the cell growth and viability of breast cancer cells leading to a poor prognosis.Oncol Rep. 2018 Oct;40(4):2343-2352. doi: 10.3892/or.2018.6588. Epub 2018 Jul 20.
• [3681] Proteasome 26S subunit PSMD1 regulates breast cancer cell growth through p53 protein degradation.J Biochem. 2018 Jan 1;163(1):19-29. doi: 10.1093/jb/mvx053.
• [3682] RPN11 deubiquitinase promotes proliferation and migration of breast cancer cells.Mol Med Rep. 2017 Jul;16(1):331-338. doi: 10.3892/mmr.2017.6587. Epub 2017 May 16.
• [3683] PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation.Cancer Lett. 2018 Aug 28;430:109-122. doi: 10.1016/j.canlet.2018.05.018. Epub 2018 May 17.
• [3684] Proteasome 26S Subunit, non-ATPase 3 (PSMD3) Regulates Breast Cancer by Stabilizing HER2 from Degradation.Cancers (Basel). 2019 Apr 12;11(4):527. doi: 10.3390/cancers11040527.
• [3685] Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi.Genes Chromosomes Cancer. 2017 Aug;56(8):589-597. doi: 10.1002/gcc.22459. Epub 2017 May 4.
• [3686] PSME3 induces epithelial-mesenchymal transition with inducing the expression of CSC markers and immunosuppression in breast cancer.Exp Cell Res. 2017 Sep 15;358(2):87-93. doi: 10.1016/j.yexcr.2017.05.017. Epub 2017 May 19.
• [3687] Re-expression of SPR1 in breast cancer cells by phorbol 12-myristate 13-acetate (PMA) or UV irradiation is mediated by the AP-1 binding site in the SPR1 promoter.Mol Med. 1999 Aug;5(8):526-41.
• [3688] Regulation of prothymosin alpha by estrogen receptor alpha: molecular mechanisms and relevance in estrogen-mediated breast cell growth.Oncogene. 2002 Aug 8;21(34):5233-44. doi: 10.1038/sj.onc.1205645.
• [3689] Novel effect and the mechanistic insights of fruiting body extract of medicinal fungus Antrodia cinnamomea against T47D breast cancer.Phytomedicine. 2017 Jan 15;24:39-48. doi: 10.1016/j.phymed.2016.11.006. Epub 2016 Nov 8.
• [3690] Efficacy of a novel LyP-1-containing self-microemulsifying drug delivery system (SMEDDS) for active targeting to breast cancer.Eur J Pharm Biopharm. 2019 Mar;136:138-146. doi: 10.1016/j.ejpb.2019.01.017. Epub 2019 Jan 22.
• [3691] PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.J Cell Physiol. 2019 Feb;234(2):1071-1079. doi: 10.1002/jcp.27211. Epub 2018 Sep 6.
• [3692] Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells.PLoS One. 2018 Mar 28;13(3):e0194913. doi: 10.1371/journal.pone.0194913. eCollection 2018.
• [3693] Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression.Pathol Oncol Res. 2016 Jul;22(3):555-65. doi: 10.1007/s12253-015-0038-1. Epub 2015 Dec 29.
• [3694] Increased metastasis with loss of E2F2 in Myc-driven tumors.Oncotarget. 2015 Nov 10;6(35):38210-24. doi: 10.18632/oncotarget.5690.
• [3695] PPAR inhibits breast cancer progression by upregulating PTPRF expression.Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9965-9977. doi: 10.26355/eurrev_201911_19563.
• [3696] The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14.Cancer Res. 1996 Nov 1;56(21):4871-5.
• [3697] Aberrant Expression of proPTPRN2 in Cancer Cells Confers Resistance to Apoptosis.Cancer Res. 2015 May 1;75(9):1846-58. doi: 10.1158/0008-5472.CAN-14-2718. Epub 2015 Apr 15.
• [3698] TLE1 is an anoikis regulator and is downregulated by Bit1 in breast cancer cells.Mol Cancer Res. 2012 Nov;10(11):1482-95. doi: 10.1158/1541-7786.MCR-12-0144. Epub 2012 Sep 4.
• [3699] Correlation of securin and Ki67 in invasive breast carcinoma.Histol Histopathol. 2019 Jun;34(6):697-709. doi: 10.14670/HH-18-071. Epub 2018 Dec 3.
• [3700] PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival.BMC Cancer. 2017 Oct 27;17(1):705. doi: 10.1186/s12885-017-3694-6.
• [3701] High expression of soluble CD155 in estrogen receptor-negative breast cancer.Breast Cancer. 2020 Jan;27(1):92-99. doi: 10.1007/s12282-019-00999-8. Epub 2019 Aug 1.
• [3702] High peroxidasin-like expression is a potential and independent prognostic biomarker in breast cancer.Medicine (Baltimore). 2019 Nov;98(44):e17703. doi: 10.1097/MD.0000000000017703.
• [3703] (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.Nutrients. 2019 Feb 15;11(2):412. doi: 10.3390/nu11020412.
• [3704] The CNGRCLLII(KLAKLAK)2 peptide shows cytotoxicity against HUVECs by inducing apoptosis: An in vitro and in vivo study.Tumour Biol. 2017 May;39(5):1010428317701649. doi: 10.1177/1010428317701649.
• [3705] miR-516a-3p inhibits breast cancer cell growth and EMT by blocking the Pygo2/Wnt signalling pathway.J Cell Mol Med. 2019 Sep;23(9):6295-6307. doi: 10.1111/jcmm.14515. Epub 2019 Jul 5.
• [3706] Antitumor activity of IFIX, a novel interferon-inducible HIN-200 gene, in breast cancer.Oncogene. 2004 Jun 3;23(26):4556-66. doi: 10.1038/sj.onc.1207592.
• [3707] Comprehensive analysis of the GATA transcription factor gene family in breast carcinoma using gene microarrays, online databases and integrated bioinformatics.Sci Rep. 2019 Mar 14;9(1):4467. doi: 10.1038/s41598-019-40811-3.
• [3708] Association of Single-Nucleotide Polymorphisms of CD44 Gene with Susceptibility to Breast Cancer in Chinese Women.Med Sci Monit. 2018 May 11;24:3077-3083. doi: 10.12659/MSM.907422.
• [3709] The breast cancer antigen 5T4 interacts with Rab11, and is a target and regulator of Rab11 mediated trafficking.Int J Biochem Cell Biol. 2018 Jun;99:28-37. doi: 10.1016/j.biocel.2018.03.002. Epub 2018 Mar 13.
• [3710] Downregulation of ARID1A, a component of the SWI/SNF chromatin remodeling complex, in breast cancer.J Cancer. 2017 Jan 1;8(1):1-8. doi: 10.7150/jca.16602. eCollection 2017.
• [3711] miR?39?p suppresses the invasion and migration properties of breast cancer cells by targeting RAB1A.Oncol Rep. 2019 Nov;42(5):1699-1708. doi: 10.3892/or.2019.7297. Epub 2019 Aug 29.
• [3712] MiR-577 suppresses epithelial-mesenchymal transition and metastasis of breast cancer by targeting Rab25.Thorac Cancer. 2018 Apr;9(4):472-479. doi: 10.1111/1759-7714.12612. Epub 2018 Mar 10.
• [3713] Functional implications of Rab27 GTPases in Cancer.Cell Commun Signal. 2018 Aug 6;16(1):44. doi: 10.1186/s12964-018-0255-9.
• [3714] Inactivation of Rab27B-dependent signaling pathway by calycosin inhibits migration and invasion of ER-negative breast cancer cells.Gene. 2019 Aug 15;709:48-55. doi: 10.1016/j.gene.2019.04.005. Epub 2019 Apr 16.
• [3715] Rab34 regulates adhesion, migration, and invasion of breast cancer cells.Oncogene. 2018 Jul;37(27):3698-3714. doi: 10.1038/s41388-018-0202-7. Epub 2018 Apr 6.
• [3716] Evidence of Rab3A expression, regulation of vesicle trafficking, and cellular secretion in response to heregulin in mammary epithelial cells.Mol Cell Biol. 2000 Dec;20(23):9092-101. doi: 10.1128/MCB.20.23.9092-9101.2000.
• [3717] Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis.J Natl Cancer Inst. 2010 Jun 16;102(12):866-80. doi: 10.1093/jnci/djq153. Epub 2010 May 18.
• [3718] The Protease Activated Receptor2 Promotes Rab5a Mediated Generation of Pro-metastatic Microvesicles.Sci Rep. 2018 May 9;8(1):7357. doi: 10.1038/s41598-018-25725-w.
• [3719] MiR-130a-3p inhibits migration and invasion by regulating RAB5B in human breast cancer stem cell-like cells.Biochem Biophys Res Commun. 2018 Jun 22;501(2):486-493. doi: 10.1016/j.bbrc.2018.05.018. Epub 2018 May 10.
• [3720] Phospholipase Cgamma1 is required for metastasis development and progression.Cancer Res. 2008 Dec 15;68(24):10187-96. doi: 10.1158/0008-5472.CAN-08-1181.
• [3721] Epigenetic regulation of WTH3 in primary and cultured drug-resistant breast cancer cells.Cancer Res. 2005 Nov 1;65(21):10024-31. doi: 10.1158/0008-5472.CAN-05-1944.
• [3722] The Cytoskeletal Protein Cyclase-Associated Protein 1 (CAP1) in Breast Cancer: Context-Dependent Roles in Both the Invasiveness and Proliferation of Cancer Cells and Underlying Cell Signals.Int J Mol Sci. 2019 May 30;20(11):2653. doi: 10.3390/ijms20112653.
• [3723] RBEL1 is a novel gene that encodes a nucleocytoplasmic Ras superfamily GTP-binding protein and is overexpressed in breast cancer.J Biol Chem. 2007 Dec 28;282(52):37640-9. doi: 10.1074/jbc.M704760200. Epub 2007 Oct 25.
• [3724] Identification of prognostic biomarkers for breast cancer based on miRNA and mRNA co-expression network.J Cell Biochem. 2019 Sep;120(9):15378-15388. doi: 10.1002/jcb.28805. Epub 2019 Apr 29.
• [3725] Regulation of Rad17 protein turnover unveils an impact of Rad17-APC cascade in breast carcinogenesis and treatment.J Biol Chem. 2013 Jun 21;288(25):18134-45. doi: 10.1074/jbc.M113.456962. Epub 2013 May 1.
• [3726] Genetic polymorphisms in RAD23B and XPC modulate DNA repair capacity and breast cancer risk in Puerto Rican women.Mol Carcinog. 2013 Nov;52 Suppl 1(0 1):E127-38. doi: 10.1002/mc.22056. Epub 2013 Jun 18.
• [3727] RAD54B potentiates tumor growth and predicts poor prognosis of patients with luminal A breast cancer.Biomed Pharmacother. 2019 Oct;118:109341. doi: 10.1016/j.biopha.2019.109341. Epub 2019 Aug 21.
• [3728] RAE1 mediated ZEB1 expression promotes epithelial-mesenchymal transition in breast cancer.Sci Rep. 2019 Feb 27;9(1):2977. doi: 10.1038/s41598-019-39574-8.
• [3729] Downregulation of RAI14 inhibits the proliferation and invasion of breast cancer cells.J Cancer. 2019 Oct 18;10(25):6341-6348. doi: 10.7150/jca.34910. eCollection 2019.
• [3730] Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.Carcinogenesis. 2014 May;35(5):1012-9. doi: 10.1093/carcin/bgt404. Epub 2013 Dec 9.
• [3731] Anti-Invasive and Anti-Proliferative Effects of shRNA-Loaded Poly(Lactide-Co-Glycolide) Nanoparticles Following RAN Silencing in MDA-MB231 Breast Cancer Cells.Pharm Res. 2018 Dec 17;36(2):26. doi: 10.1007/s11095-018-2555-6.
• [3732] The SmgGDS splice variant SmgGDS-558 is a key promoter of tumor growth and RhoA signaling in breast cancer.Mol Cancer Res. 2014 Jan;12(1):130-42. doi: 10.1158/1541-7786.MCR-13-0362. Epub 2013 Nov 6.
• [3733] Expression of RPIP9 (Rap2 interacting protein 9) is activated in breast carcinoma and correlates with a poor prognosis.Int J Cancer. 2005 Dec 20;117(6):934-41. doi: 10.1002/ijc.21252.
• [3734] Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase.Breast Cancer Res. 2011 Mar 23;13(2):R31. doi: 10.1186/bcr2853.
• [3735] Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.Breast Cancer Res Treat. 2018 Nov;172(1):61-68. doi: 10.1007/s10549-018-4891-y. Epub 2018 Jul 28.
• [3736] Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1.Oncotarget. 2016 Jul 12;7(28):44096-44112. doi: 10.18632/oncotarget.9858.
• [3737] Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers.Cancer Discov. 2017 Feb;7(2):202-217. doi: 10.1158/2159-8290.CD-16-0520. Epub 2016 Dec 14.
• [3738] Rasal2 suppresses breast cancer cell proliferation modulated by secretory autophagy.Mol Cell Biochem. 2019 Dec;462(1-2):115-122. doi: 10.1007/s11010-019-03615-7. Epub 2019 Aug 31.
• [3739] Comprehensive analysis of the lncRNAassociated competing endogenous RNA network in breast cancer.Oncol Rep. 2019 Dec;42(6):2572-2582. doi: 10.3892/or.2019.7374. Epub 2019 Oct 15.
• [3740] Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.Int J Oncol. 2009 Feb;34(2):517-28.
• [3741] Downregulation of RASSF6 promotes breast cancer growth and chemoresistance through regulation of Hippo signaling.Biochem Biophys Res Commun. 2018 Sep 18;503(4):2340-2347. doi: 10.1016/j.bbrc.2018.06.159. Epub 2018 Jul 2.
• [3742] E4BP4/NFIL3 modulates the epigenetically repressed RAS effector RASSF8 function through histone methyltransferases.J Biol Chem. 2018 Apr 13;293(15):5624-5635. doi: 10.1074/jbc.RA117.000623. Epub 2018 Feb 21.
• [3743] MicroRNA-1254 exertsoncogenic effects by directly targeting RASSF9 in human breast cancer.Int J Oncol. 2018 Nov;53(5):2145-2156. doi: 10.3892/ijo.2018.4530. Epub 2018 Aug 21.
• [3744] Expression of LC3B and FIP200/Atg17 in brain metastases of breast cancer.J Neurooncol. 2018 Nov;140(2):237-248. doi: 10.1007/s11060-018-2959-5. Epub 2018 Aug 9.
• [3745] Aberrant expression of X-linked genes RbAp46, Rsk4, and Cldn2 in breast cancer.Mol Cancer Res. 2007 Feb;5(2):171-81. doi: 10.1158/1541-7786.MCR-06-0071.
• [3746] Demethylation and alterations in the expression level of the cell cycle-related genes as possible mechanisms in arsenic trioxide-induced cell cycle arrest in human breast cancer cells.Tumour Biol. 2017 Feb;39(2):1010428317692255. doi: 10.1177/1010428317692255.
• [3747] Decrease of RBM4 indicates poor prognosis in patients with hepatocellular carcinoma after hepatectomy.Onco Targets Ther. 2017 Jan 11;10:339-345. doi: 10.2147/OTT.S125250. eCollection 2017.
• [3748] Expression of RBM5-related factors in primary breast tissue.J Cell Biochem. 2007 Apr 15;100(6):1440-58. doi: 10.1002/jcb.21134.
• [3749] RBMS2 inhibits the proliferation by stabilizing P21 mRNA in breast cancer.J Exp Clin Cancer Res. 2018 Dec 4;37(1):298. doi: 10.1186/s13046-018-0968-z.
• [3750] Positive correlation between the expression of X-chromosome RBM genes (RBMX, RBM3, RBM10) and the proapoptotic Bax gene in human breast cancer.J Cell Biochem. 2006 Apr 15;97(6):1275-82. doi: 10.1002/jcb.20725.
• [3751] CRBP-1 over-expression is associated with poor prognosis in tongue squamous cell carcinoma.BMC Cancer. 2018 May 2;18(1):514. doi: 10.1186/s12885-018-4249-1.
• [3752] Exome sequencing and case-control analyses identify RCC1 as a candidate breast cancer susceptibility gene.Int J Cancer. 2018 Jun 15;142(12):2512-2517. doi: 10.1002/ijc.31273. Epub 2018 Feb 5.
• [3753] RCC2 promotes breast cancer progression through regulation of Wnt signaling and inducing EMT.J Cancer. 2019 Nov 1;10(27):6837-6847. doi: 10.7150/jca.36430. eCollection 2019.
• [3754] RDM1 promotes critical processes in breast cancer tumorigenesis.J Cell Mol Med. 2019 Aug;23(8):5432-5439. doi: 10.1111/jcmm.14425. Epub 2019 Jun 20.
• [3755] PAK4 suppresses RELB to prevent senescence-like growth arrest in breast cancer.Nat Commun. 2019 Aug 9;10(1):3589. doi: 10.1038/s41467-019-11510-4.
• [3756] Astrocyte-induced Reelin expression drives proliferation of Her2(+) breast cancer metastases.Clin Exp Metastasis. 2017 Feb;34(2):185-196. doi: 10.1007/s10585-017-9839-9. Epub 2017 Feb 17.
• [3757] Synthesis and Anticancer Activity Evaluation of Hydrolyzed Derivatives of Panaxnotoginseng Saponins.Molecules. 2018 Nov 19;23(11):3021. doi: 10.3390/molecules23113021.
• [3758] The Transcription Factor AP4 Promotes Oncogenic Phenotypes and Cisplatin Resistance by Regulating LAPTM4B Expression.Mol Cancer Res. 2018 May;16(5):857-868. doi: 10.1158/1541-7786.MCR-17-0519. Epub 2018 Jan 29.
• [3759] Expression and clinical significance of REPS2 in human esophageal squamous cell carcinoma.Asian Pac J Cancer Prev. 2013;14(5):2851-7. doi: 10.7314/apjcp.2013.14.5.2851.
• [3760] Production and characterization of monoclonal antibodies against the DNA binding domain of the RE1-silencing transcription factor.J Biochem. 2019 Nov 1;166(5):393-402. doi: 10.1093/jb/mvz046.
• [3761] Adipocytokines and breast cancer.Curr Probl Cancer. 2018 Mar-Apr;42(2):208-214. doi: 10.1016/j.currproblcancer.2018.01.004. Epub 2018 Jan 8.
• [3762] Downregulation of hPMC2 imparts chemotherapeutic sensitivity to alkylating agents in breast cancer cells.Cancer Biol Ther. 2015;16(4):518-27. doi: 10.1080/15384047.2015.1016661. Epub 2015 Apr 7.
• [3763] PGC-1 alpha interacts with microRNA-217 to functionally regulate breast cancer cell proliferation.Biomed Pharmacother. 2017 Jan;85:541-548. doi: 10.1016/j.biopha.2016.11.062.
• [3764] Repulsive guidance molecule B (RGMB) plays negative roles in breast cancer by coordinating BMP signaling.J Cell Biochem. 2012 Jul;113(7):2523-31. doi: 10.1002/jcb.24128.
• [3765] [Erratum] Exogenous regucalcin suppresses the proliferation of human breast cancer MDA-MB-231 bone metastatic cells in vitro.Mol Med Rep. 2018 Feb;17(2):3432. doi: 10.3892/mmr.2017.8276. Epub 2017 Dec 12.
• [3766] Finding fusion genes resulting from chromosome rearrangement by analyzing the expressed sequence databases.Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13257-61. doi: 10.1073/pnas.0405490101. Epub 2004 Aug 23.
• [3767] Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.Biochem Biophys Res Commun. 2017 Apr 8;485(3):693-697. doi: 10.1016/j.bbrc.2017.02.106. Epub 2017 Feb 22.
• [3768] Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.Breast Cancer Res Treat. 2007 Mar;101(3):305-15. doi: 10.1007/s10549-006-9293-x. Epub 2006 Jul 5.
• [3769] MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1.Breast Cancer. 2019 Nov;26(6):817-825. doi: 10.1007/s12282-019-00989-w. Epub 2019 Jun 26.
• [3770] Fas-associated protein with death domain (FADD) regulates autophagy through promoting the expression of Ras homolog enriched in brain (Rheb) in human breast adenocarcinoma cells.Oncotarget. 2016 Apr 26;7(17):24572-84. doi: 10.18632/oncotarget.8249.
• [3771] Evaluation of the RHINO gene for breast cancer predisposition in Finnish breast cancer families.Breast Cancer Res Treat. 2014 Apr;144(2):437-41. doi: 10.1007/s10549-014-2884-z. Epub 2014 Feb 22.
• [3772] The tumor suppressor RhoBTB1 controls Golgi integrity and breast cancer cell invasion through METTL7B.BMC Cancer. 2017 Feb 20;17(1):145. doi: 10.1186/s12885-017-3138-3.
• [3773] DBC2/RhoBTB2 functions as a tumor suppressor protein via Musashi-2 ubiquitination in breast cancer.Oncogene. 2017 May 18;36(20):2802-2812. doi: 10.1038/onc.2016.441. Epub 2016 Dec 12.
• [3774] Coexpression of alpha6beta4 integrin and guanine nucleotide exchange factor Net1 identifies node-positive breast cancer patients at high risk for distant metastasis.Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):80-6. doi: 10.1158/1055-9965.EPI-08-0842.
• [3775] Magnetic Resonance Imaging-Guided Drug Delivery to Breast Cancer Stem-Like Cells.Adv Healthc Mater. 2018 Nov;7(21):e1800266. doi: 10.1002/adhm.201800266. Epub 2018 Aug 26.
• [3776] Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling.J Biol Chem. 2009 May 8;284(19):12956-65. doi: 10.1074/jbc.M807845200. Epub 2009 Mar 6.
• [3777] c-Myc induced the regulation of long non-coding RNA RHPN1-AS1 on breast cancer cell proliferation via inhibiting P53.Mol Genet Genomics. 2019 Oct;294(5):1219-1229. doi: 10.1007/s00438-019-01572-w. Epub 2019 May 14.
• [3778] The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior.EBioMedicine. 2017 Jun;20:79-97. doi: 10.1016/j.ebiom.2017.04.015. Epub 2017 Apr 12.
• [3779] The human ROX gene: genomic structure and mutation analysis in human breast tumors.Genomics. 1998 Apr 15;49(2):275-82. doi: 10.1006/geno.1998.5241.
• [3780] Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells.BMB Rep. 2010 Feb;43(2):91-6. doi: 10.5483/bmbrep.2010.43.2.091.
• [3781] High-mobility group box 1 released by autophagic cancer-associated fibroblasts maintains the stemness of luminal breast cancer cells.J Pathol. 2017 Nov;243(3):376-389. doi: 10.1002/path.4958. Epub 2017 Sep 21.
• [3782] Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ER/VEGFR-2 ligands with anti-breast cancer activity.Eur J Med Chem. 2018 Apr 25;150:783-795. doi: 10.1016/j.ejmech.2018.03.018. Epub 2018 Mar 7.
• [3783] Differentially expressed mitochondrial genes in breast cancer cells: Potential new targets for anti-cancer therapies.Gene. 2017 Jan 5;596:45-52. doi: 10.1016/j.gene.2016.10.005. Epub 2016 Oct 6.
• [3784] Aicardi-Goutires syndrome gene Rnaseh2c is a metastasis susceptibility gene in breast cancer.PLoS Genet. 2019 May 24;15(5):e1008020. doi: 10.1371/journal.pgen.1008020. eCollection 2019 May.
• [3785] The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11.Oncogene. 2008 Nov 20;27(54):6845-55. doi: 10.1038/onc.2008.288. Epub 2008 Aug 25.
• [3786] Deubiquitinase ubiquitin-specific protease 9X regulates the stability and function of E3 ubiquitin ligase ring finger protein 115 in breast cancer cells.Cancer Sci. 2019 Apr;110(4):1268-1278. doi: 10.1111/cas.13953. Epub 2019 Feb 21.
• [3787] RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells.Clin Cancer Res. 2018 Apr 1;24(7):1629-1643. doi: 10.1158/1078-0432.CCR-17-2242. Epub 2018 Jan 11.
• [3788] Dual-utility NLS drives RNF169-dependent DNA damage responses.Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2872-E2881. doi: 10.1073/pnas.1616602114. Epub 2017 Mar 21.
• [3789] RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer.Cell Death Differ. 2017 Apr;24(4):694-704. doi: 10.1038/cdd.2016.126. Epub 2017 Feb 3.
• [3790] Correction: The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor and modulates estrogen-stimulated breast cancer cell proliferation.Oncogene. 2019 Jan;38(2):299-300. doi: 10.1038/s41388-018-0502-y.
• [3791] Ubiquitin ligase RNF5 serves an important role in the development of human glioma.Oncol Lett. 2019 Nov;18(5):4659-4666. doi: 10.3892/ol.2019.10801. Epub 2019 Sep 4.
• [3792] 17-beta-estradiol increases expression of 52-kDa and 60-kDa SS-A/Ro autoantigens in human keratinocytes and breast cancer cell line MCF-7.J Invest Dermatol. 1996 Oct;107(4):610-4. doi: 10.1111/1523-1747.ep12584194.
• [3793] Upregulation of RPA2 promotes NF-B activation in breast cancer by relieving the antagonistic function of menin on NF-B-regulated transcription.Carcinogenesis. 2017 Feb 1;38(2):196-206. doi: 10.1093/carcin/bgw123.
• [3794] Clinical Implications of Rabphillin-3A-Like Gene Alterations in Breast Cancer.PLoS One. 2015 Jun 12;10(6):e0129216. doi: 10.1371/journal.pone.0129216. eCollection 2015.
• [3795] Exclusion of BBC1 and CMAR as candidate breast tumour-suppressor genes.Br J Cancer. 1997;76(12):1550-3. doi: 10.1038/bjc.1997.594.
• [3796] Co-expression network analysis of gene expression profiles of HER2(+) breast cancer-associated brain metastasis.Oncol Lett. 2018 Dec;16(6):7008-7019. doi: 10.3892/ol.2018.9562. Epub 2018 Oct 10.
• [3797] RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth.Oncotarget. 2014 Jul 15;5(13):5165-76. doi: 10.18632/oncotarget.2099.
• [3798] Role of RPL39 in Metaplastic Breast Cancer.J Natl Cancer Inst. 2016 Dec 31;109(6):djw292. doi: 10.1093/jnci/djw292. Print 2017 Jun.
• [3799] Modulation of expression of ribosomal protein L7a (rpL7a) by ethanol in human breast cancer cells.Breast Cancer Res Treat. 2001 Sep;69(1):29-38. doi: 10.1023/a:1012293507534.
• [3800] Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer.Oncotarget. 2015 Feb 20;6(5):3335-45. doi: 10.18632/oncotarget.2793.
• [3801] MiR-454-3p-Mediated Wnt/-catenin Signaling Antagonists Suppression Promotes Breast Cancer Metastasis.Theranostics. 2019 Jan 1;9(2):449-465. doi: 10.7150/thno.29055. eCollection 2019.
• [3802] CREPT regulated by miR-138 promotes breast cancer progression.Biochem Biophys Res Commun. 2017 Nov 4;493(1):263-269. doi: 10.1016/j.bbrc.2017.09.033. Epub 2017 Sep 8.
• [3803] MicroRNA-7641 is a regulator of ribosomal proteins and a promising targeting factor to improve the efficacy of cancer therapy.Sci Rep. 2017 Aug 21;7(1):8365. doi: 10.1038/s41598-017-08737-w.
• [3804] Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen.PLoS One. 2012;7(5):e36559. doi: 10.1371/journal.pone.0036559. Epub 2012 May 11.
• [3805] Ribosomal protein S27-like regulates autophagy via the -TrCP-DEPTOR-mTORC1 axis.Cell Death Dis. 2018 Nov 13;9(11):1131. doi: 10.1038/s41419-018-1168-7.
• [3806] High nuclear MSK1 is associated with longer survival in breast cancer patients.J Cancer Res Clin Oncol. 2018 Mar;144(3):509-517. doi: 10.1007/s00432-018-2579-7. Epub 2018 Jan 11.
• [3807] Gene expression profiling in women with breast cancer in a Saudi population.Saudi Med J. 2008 Apr;29(4):507-13.
• [3808] Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery.Biomaterials. 2014 Aug;35(26):7543-52. doi: 10.1016/j.biomaterials.2014.05.021. Epub 2014 Jun 2.
• [3809] A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.Cancer Res. 2008 Dec 1;68(23):9799-808. doi: 10.1158/0008-5472.CAN-08-0247.
• [3810] Mammary epithelial morphogenesis and early breast cancer. Evidence of involvement of basal components of the RNA Polymerase I transcription machinery.Cell Cycle. 2016 Sep 16;15(18):2515-26. doi: 10.1080/15384101.2016.1215385. Epub 2016 Aug 2.
• [3811] Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly.Theranostics. 2017 Oct 17;7(19):4805-4824. doi: 10.7150/thno.20771. eCollection 2017.
• [3812] miR-145 inhibits breast cancer cell growth through RTKN.Int J Oncol. 2009 May;34(5):1461-6.
• [3813] The pro-apoptotic paradox: the BH3-only protein Bcl-2 interacting killer (Bik) is prognostic for unfavorable outcomes in breast cancer.Oncotarget. 2016 May 31;7(22):33272-85. doi: 10.18632/oncotarget.8924.
• [3814] Human TIP49b/RUVBL2 gene: genomic structure, expression pattern, physical link to the human CGB/LHB gene cluster on chromosome 19q13.3.Ann Genet. 2000 Apr-Jun;43(2):69-74. doi: 10.1016/s0003-3995(00)01016-9.
• [3815] RING1 and YY1 binding protein suppresses breast cancer growth and metastasis.Int J Oncol. 2016 Dec;49(6):2442-2452. doi: 10.3892/ijo.2016.3718. Epub 2016 Oct 5.
• [3816] Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification.Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13653-8. doi: 10.1073/pnas.1103360108. Epub 2011 Aug 2.
• [3817] A multiomics analysis of S100 protein family in breast cancer.Oncotarget. 2018 Jun 26;9(49):29064-29081. doi: 10.18632/oncotarget.25561. eCollection 2018 Jun 26.
• [3818] Silencing of the annexin II gene down-regulates the levels of S100A10, c-Myc, and plasmin and inhibits breast cancer cell proliferation and invasion.Saudi Med J. 2010 Apr;31(4):374-81.
• [3819] HGF-mediated S100A11 overexpression enhances proliferation and invasion of gastric cancer.Am J Transl Res. 2018 Nov 15;10(11):3385-3394. eCollection 2018.
• [3820] Prognostic and clinicopathological significance of S100A14 expression in cancer patients: A meta-analysis.Medicine (Baltimore). 2019 Jul;98(28):e16356. doi: 10.1097/MD.0000000000016356.
• [3821] Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation.Cell Calcium. 1997 Oct;22(4):243-54. doi: 10.1016/s0143-4160(97)90063-4.
• [3822] Highly homologous hS100A15 and hS100A7 proteins are distinctly expressed in normal breast tissue and breast cancer.Cancer Lett. 2009 May 8;277(1):101-7. doi: 10.1016/j.canlet.2008.11.032. Epub 2009 Jan 10.
• [3823] Regulation of CD44 expression and focal adhesion by Golgi phosphatidylinositol 4-phosphate in breast cancer.Cancer Sci. 2016 Jul;107(7):981-90. doi: 10.1111/cas.12968. Epub 2016 Jun 24.
• [3824] A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.Science. 2012 Jan 20;335(6066):348-53. doi: 10.1126/science.1212728. Epub 2011 Dec 8.
• [3825] Unravelling the RNA-Binding Properties of SAFB Proteins in Breast Cancer Cells.Biomed Res Int. 2015;2015:395816. doi: 10.1155/2015/395816. Epub 2015 Jul 26.
• [3826] No germline mutations in supposed tumour suppressor genes SAFB1 and SAFB2 in familial breast cancer with linkage to 19p.BMC Med Genet. 2008 Dec 13;9:108. doi: 10.1186/1471-2350-9-108.
• [3827] Differential expression of neurogenes among breast cancer subtypes identifies high risk patients.Oncotarget. 2016 Feb 2;7(5):5313-26. doi: 10.18632/oncotarget.6543.
• [3828] SALL1 functions as a tumor suppressor in breast cancer by regulating cancer cell senescence and metastasis through the NuRD complex.Mol Cancer. 2018 Apr 6;17(1):78. doi: 10.1186/s12943-018-0824-y.
• [3829] Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer.EMBO Mol Med. 2019 Dec;11(12):e10638. doi: 10.15252/emmm.201910638. Epub 2019 Oct 28.
• [3830] Pharmacological explorations of eco-friendly amide substituted (Z)--enaminones as anti-breast cancer drugs.Arch Pharm (Weinheim). 2019 Jan;352(1):e1800244. doi: 10.1002/ardp.201800244. Epub 2018 Dec 5.
• [3831] Identification of novel SNPs in glioblastoma using targeted resequencing.PLoS One. 2011;6(6):e18158. doi: 10.1371/journal.pone.0018158. Epub 2011 Jun 10.
• [3832] DNA methylation as a promising landscape: A simple blood test for breast cancer prediction.Tumour Biol. 2015 Jul;36(7):4905-12. doi: 10.1007/s13277-015-3567-z. Epub 2015 Jun 16.
• [3833] SATB2 suppresses non-small cell lung cancer invasiveness by G9a.Clin Exp Med. 2018 Feb;18(1):37-44. doi: 10.1007/s10238-017-0464-3. Epub 2017 Jun 30.
• [3834] Prognostic significance of the expression of SR-A1, encoding a novel SR-related CTD-associated factor, in breast cancer.Biol Chem. 2006 Dec;387(12):1613-8. doi: 10.1515/BC.2006.201.
• [3835] Downregulation of the anaphase-promoting complex (APC)7 in invasive ductal carcinomas of the breast and its clinicopathologic relationships.Breast Cancer Res. 2005;7(2):R238-47. doi: 10.1186/bcr978. Epub 2005 Jan 14.
• [3836] Downregulation of SCARA5 may contribute to breast cancer via promoter hypermethylation.Gene. 2018 Oct 5;673:102-106. doi: 10.1016/j.gene.2018.06.036. Epub 2018 Jun 13.
• [3837] In vitro selections of mammaglobin A and mammaglobin B aptamers for the recognition of circulating breast tumor cells.Sci Rep. 2017 Nov 3;7(1):14487. doi: 10.1038/s41598-017-13751-z.
• [3838] DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study.Epigenetics. 2016 Sep;11(9):643-652. doi: 10.1080/15592294.2016.1192735. Epub 2016 May 31.
• [3839] Scinderin-knockdown inhibits proliferation and promotes apoptosis in human breast carcinoma cells.Oncol Lett. 2018 Sep;16(3):3207-3214. doi: 10.3892/ol.2018.9009. Epub 2018 Jun 21.
• [3840] SCN4B acts as a metastasis-suppressor gene preventing hyperactivation of cell migration in breast cancer.Nat Commun. 2016 Dec 5;7:13648. doi: 10.1038/ncomms13648.
• [3841] A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGF-mediated breast cancer cell migration and invasion.Breast Cancer Res. 2012 Sep 20;14(5):R127. doi: 10.1186/bcr3322.
• [3842] Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis.Cancer Cell. 2014 Nov 10;26(5):707-21. doi: 10.1016/j.ccell.2014.09.005. Epub 2014 Oct 23.
• [3843] Sulfated Glycoaminoglycans and Proteoglycan Syndecan-4 Are Involved in Membrane Fixation of LL-37 and Its Pro-Migratory Effect in Breast Cancer Cells.Biomolecules. 2019 Sep 12;9(9):481. doi: 10.3390/biom9090481.
• [3844] Transcript analyses of stromal cell derived factors (SDFs): SDF-2, SDF-4 and SDF-5 reveal a different pattern of expression and prognostic association in human breast cancer.Int J Oncol. 2009 Jul;35(1):205-11. doi: 10.3892/ijo_00000330.
• [3845] Identification of endogenous reference genes for qRT-PCR analysis in normal matched breast tumor tissues.Oncol Res. 2009;17(8):353-65. doi: 10.3727/096504009788428460.
• [3846] The Assembly Factor SDHAF2 Is Dispensable for Flavination of the Catalytic Subunit of Mitochondrial Complex II in Breast Cancer Cells.J Biol Chem. 2016 Oct 7;291(41):21414-21420. doi: 10.1074/jbc.C116.755017. Epub 2016 Sep 1.
• [3847] Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum.J Clin Endocrinol Metab. 2015 Oct;100(10):E1386-93. doi: 10.1210/jc.2015-2689. Epub 2015 Aug 10.
• [3848] Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.Mod Pathol. 2018 Nov;31(11):1675-1682. doi: 10.1038/s41379-018-0092-9. Epub 2018 Jun 28.
• [3849] Are breast cancers driven by fusion genes?.Breast Cancer Res. 2012 Mar 16;14(2):303. doi: 10.1186/bcr3122.
• [3850] Breast cancer family history and allele-specific DNA methylation in the legacy girls study.Epigenetics. 2018;13(3):240-250. doi: 10.1080/15592294.2018.1435243. Epub 2018 Apr 2.
• [3851] Protein profile changes in the human breast cancer cell line MCF-7 in response to SEL1L gene induction.Proteomics. 2005 Jun;5(9):2433-42. doi: 10.1002/pmic.200401283.
• [3852] PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA.Mol Cancer. 2019 Jan 12;18(1):9. doi: 10.1186/s12943-019-0940-3.
• [3853] Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival.BMC Cancer. 2013 Dec 1;13:562. doi: 10.1186/1471-2407-13-562.
• [3854] Silencing of semaphorin 3C suppresses cell proliferation and migration in MCF-7 breast cancer cells.Oncol Lett. 2017 Nov;14(5):5913-5917. doi: 10.3892/ol.2017.6920. Epub 2017 Sep 8.
• [3855] Alternative Splicing in Adhesion- and Motility-Related Genes in Breast Cancer.Int J Mol Sci. 2016 Jan 16;17(1):121. doi: 10.3390/ijms17010121.
• [3856] Reverse signaling by semaphorin 4C elicits SMAD1/5- and ID1/3-dependent invasive reprogramming in cancer cells.Sci Signal. 2019 Aug 20;12(595):eaav2041. doi: 10.1126/scisignal.aav2041.
• [3857] Downregulation of miR-302b is associated with poor prognosis and tumor progression of breast cancer.Breast Cancer. 2020 Mar;27(2):291-298. doi: 10.1007/s12282-019-01022-w. Epub 2019 Nov 13.
• [3858] Semaphorin 7A Promotes Macrophage-Mediated Lymphatic Remodeling during Postpartum Mammary Gland Involution and in Breast Cancer.Cancer Res. 2018 Nov 15;78(22):6473-6485. doi: 10.1158/0008-5472.CAN-18-1642. Epub 2018 Sep 25.
• [3859] Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancer.Sci Rep. 2019 Nov 6;9(1):16131. doi: 10.1038/s41598-019-52718-0.
• [3860] The requirement of SEPT2 and SEPT7 for migration and invasion in human breast cancer via MEK/ERK activation.Oncotarget. 2016 Sep 20;7(38):61587-61600. doi: 10.18632/oncotarget.11402.
• [3861] SEPT9_i1 regulates human breast cancer cell motility through cytoskeletal and RhoA/FAK signaling pathway regulation.Cell Death Dis. 2019 Sep 26;10(10):720. doi: 10.1038/s41419-019-1947-9.
• [3862] Using post-column infused internal standard assisted quantitative metabolomics for establishing prediction models for breast cancer detection.Rapid Commun Mass Spectrom. 2020 Apr;34 Suppl 1:e8581. doi: 10.1002/rcm.8581. Epub 2020 Feb 5.
• [3863] Protease Nexin I is a feedback regulator of EGF/PKC/MAPK/EGR1 signaling in breast cancer cells metastasis and stemness.Cell Death Dis. 2019 Sep 9;10(9):649. doi: 10.1038/s41419-019-1882-9.
• [3864] SET Domain-Containing Protein 4 Epigenetically Controls Breast Cancer Stem Cell Quiescence.Cancer Res. 2019 Sep 15;79(18):4729-4743. doi: 10.1158/0008-5472.CAN-19-1084. Epub 2019 Jul 15.
• [3865] Lysines 207 and 325 methylation of WDR5 catalyzed by SETD6 promotes breast cancer cell proliferation and migration.Oncol Rep. 2018 Nov;40(5):3069-3077. doi: 10.3892/or.2018.6669. Epub 2018 Aug 23.
• [3866] SNP variants at the MAP3K1/SETD9 locus 5q11.2 associate with somatic PIK3CA variants in breast cancers.Eur J Hum Genet. 2017 Feb;25(3):384-387. doi: 10.1038/ejhg.2016.179. Epub 2016 Dec 28.
• [3867] Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis.Carcinogenesis. 2008 May;29(5):991-8. doi: 10.1093/carcin/bgn076. Epub 2008 Mar 19.
• [3868] Association between TIMP-2 gene polymorphism and breast cancer in Han Chinese women.BMC Cancer. 2019 May 14;19(1):446. doi: 10.1186/s12885-019-5655-8.
• [3869] Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.ACS Chem Biol. 2019 Sep 20;14(9):2024-2034. doi: 10.1021/acschembio.9b00505. Epub 2019 Sep 5.
• [3870] Synthesis and molecular docking studies of new furochromone derivatives as p38 MAPK inhibitors targeting human breast cancer MCF-7 cells.Bioorg Med Chem. 2017 Apr 15;25(8):2423-2436. doi: 10.1016/j.bmc.2017.02.065. Epub 2017 Mar 3.
• [3871] Systematic Analysis of AU-Rich Element Expression in Cancer Reveals Common Functional Clusters Regulated by Key RNA-Binding Proteins.Cancer Res. 2016 Jul 15;76(14):4068-80. doi: 10.1158/0008-5472.CAN-15-3110. Epub 2016 May 17.
• [3872] Mitochondrial Reprogramming Regulates Breast Cancer Progression.Clin Cancer Res. 2016 Jul 1;22(13):3348-60. doi: 10.1158/1078-0432.CCR-15-2456. Epub 2016 Feb 17.
• [3873] Bif-1 suppresses breast cancer cell migration by promoting EGFR endocytic degradation.Cancer Biol Ther. 2012 Aug;13(10):956-66. doi: 10.4161/cbt.20951. Epub 2012 Aug 1.
• [3874] The Pro-Oncogenic Adaptor CIN85 Acts as an Inhibitory Binding Partner of Hypoxia-Inducible Factor Prolyl Hydroxylase 2.Cancer Res. 2019 Aug 15;79(16):4042-4056. doi: 10.1158/0008-5472.CAN-18-3852. Epub 2019 May 29.
• [3875] Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.Nat Cell Biol. 2018 Aug;20(8):954-965. doi: 10.1038/s41556-018-0140-1. Epub 2018 Jul 18.
• [3876] Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers.Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):E3816-25. doi: 10.1073/pnas.1510077112. Epub 2015 Jun 29.
• [3877] MiR-107 down-regulates SIAH1 expression in human breast cancer cells and silencing of miR-107 inhibits tumor growth in a nude mouse model of triple-negative breast cancer.Mol Carcinog. 2016 May;55(5):768-77. doi: 10.1002/mc.22320. Epub 2015 Apr 7.
• [3878] Overexpression of seven in absentia homolog 2 protein in human breast cancer tissues is associated with the promotion of tumor cell malignant behavior in in vitro.Oncol Rep. 2016 Sep;36(3):1301-12. doi: 10.3892/or.2016.4976. Epub 2016 Jul 25.
• [3879] High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity.Oncotarget. 2017 Jul 25;8(30):49470-49483. doi: 10.18632/oncotarget.17713.
• [3880] Loss of SIM2s inhibits RAD51 binding and leads to unresolved replication stress.Breast Cancer Res. 2019 Nov 27;21(1):125. doi: 10.1186/s13058-019-1207-z.
• [3881] Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells.Eur J Pharmacol. 2019 Oct 15;861:172599. doi: 10.1016/j.ejphar.2019.172599. Epub 2019 Aug 9.
• [3882] SIX2 Mediates Late-Stage Metastasis via Direct Regulation of SOX2 and Induction of a Cancer Stem Cell Program.Cancer Res. 2019 Feb 15;79(4):720-734. doi: 10.1158/0008-5472.CAN-18-1791. Epub 2019 Jan 3.
• [3883] Expression profile of SIX family members correlates with clinic-pathological features and prognosis of breast cancer: A systematic review and meta-analysis.Medicine (Baltimore). 2016 Jul;95(27):e4085. doi: 10.1097/MD.0000000000004085.
• [3884] A chemical probe of CARM1 alters epigenetic plasticity against breast cancer cell invasion.Elife. 2019 Oct 28;8:e47110. doi: 10.7554/eLife.47110.
• [3885] Involvement of an Orphan Transporter, SLC22A18, in Cell Growth and Drug Resistance of Human Breast Cancer MCF7 Cells.J Pharm Sci. 2018 Dec;107(12):3163-3170. doi: 10.1016/j.xphs.2018.08.011. Epub 2018 Aug 23.
• [3886] Decreased expression of the mitochondrial solute carrier SLC25A43 in basal cell carcinoma compared with healthy skin.Oncol Lett. 2017 Aug;14(2):2218-2222. doi: 10.3892/ol.2017.6452. Epub 2017 Jun 21.
• [3887] Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.Breast Cancer Res Treat. 2019 Sep;177(2):335-343. doi: 10.1007/s10549-019-05313-w. Epub 2019 Jun 20.
• [3888] Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers.Br J Cancer. 2004 Dec 13;91(12):2071-8. doi: 10.1038/sj.bjc.6602222.
• [3889] Axillary Dissection vs. no Axillary Dissection in Breast Cancer Patients With Positive Sentinel Lymph Node: A Single Institution Experience.In Vivo. 2019 Nov-Dec;33(6):1941-1947. doi: 10.21873/invivo.11689.
• [3890] miR-190 suppresses breast cancer metastasis by regulation of TGF--induced epithelial-mesenchymal transition.Mol Cancer. 2018 Mar 6;17(1):70. doi: 10.1186/s12943-018-0818-9.
• [3891] Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells.Oncotarget. 2017 Sep 1;8(53):91803-91816. doi: 10.18632/oncotarget.20610. eCollection 2017 Oct 31.
• [3892] SMARCE1 regulates metastatic potential of breast cancer cells through the HIF1A/PTK2 pathway.Breast Cancer Res. 2016 Aug 5;18(1):81. doi: 10.1186/s13058-016-0738-9.
• [3893] Multiparametric (18)F-FDG PET/MRI of the Breast: Are There Differences in Imaging Biomarkers of Contralateral Healthy Tissue Between Patients With and Without Breast Cancer?.J Nucl Med. 2020 Jan;61(1):20-25. doi: 10.2967/jnumed.119.230003. Epub 2019 Jun 28.
• [3894] Altered Expression and Localization of Tumor Suppressive E3 Ubiquitin Ligase SMURF2 in Human Prostate and Breast Cancer.Cancers (Basel). 2019 Apr 18;11(4):556. doi: 10.3390/cancers11040556.
• [3895] miR-1307-3p Stimulates Breast Cancer Development and Progression by Targeting SMYD4.J Cancer. 2019 Jan 1;10(2):441-448. doi: 10.7150/jca.30041. eCollection 2019.
• [3896] Transcription factor AP-2gamma is essential in the extra-embryonic lineages for early postimplantation development.Development. 2002 Jun;129(11):2733-47. doi: 10.1242/dev.129.11.2733.
• [3897] Elevated expression of GNAS promotes breast cancer cell proliferation and migration via the PI3K/AKT/Snail1/E-cadherin axis.Clin Transl Oncol. 2019 Sep;21(9):1207-1219. doi: 10.1007/s12094-019-02042-w. Epub 2019 Feb 14.
• [3898] Estrogen receptor--miR-1271-SNAI2 feedback loop regulates transforming growth factor--induced breast cancer progression.J Exp Clin Cancer Res. 2019 Mar 1;38(1):109. doi: 10.1186/s13046-019-1112-4.
• [3899] Discovery of over-expressed genes and genetic alterations in breast cancer cells using a combination of suppression subtractive hybridization, multiplex FISH and comparative genomic hybridization.Int J Oncol. 2002 Sep;21(3):499-507.
• [3900] Gamma-synuclein: cell-type-specific promoter activity and binding to transcription factors.J Mol Neurosci. 2008 Jul;35(3):267-71. doi: 10.1007/s12031-008-9074-6. Epub 2008 May 23.
• [3901] A ligation assay for multiplex analysis of CpG methylation using bisulfite-treated DNA.Nucleic Acids Res. 2007;35(21):e144. doi: 10.1093/nar/gkm984. Epub 2007 Nov 12.
• [3902] Role of SNTA1 in Rac1 activation, modulation of ROS generation, and migratory potential of human breast cancer cells.Br J Cancer. 2014 Feb 4;110(3):706-14. doi: 10.1038/bjc.2013.723. Epub 2014 Jan 16.
• [3903] CD147 (EMMPRIN) controls malignant properties of breast cancer cells by interdependent signaling of Wnt and JAK/STAT pathways.Mol Cell Biochem. 2019 Jan;451(1-2):197-209. doi: 10.1007/s11010-018-3406-9. Epub 2018 Jul 18.
• [3904] Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs: the Breast Cancer Health Disparities Study.Breast Cancer Res Treat. 2014 Aug;147(1):145-58. doi: 10.1007/s10549-014-3071-y. Epub 2014 Aug 8.
• [3905] Artificial neural network-based exploration of gene-nutrient interactions in folate and xenobiotic metabolic pathways that modulate susceptibility to breast cancer.Gene. 2016 Apr 15;580(2):159-168. doi: 10.1016/j.gene.2016.01.023. Epub 2016 Jan 16.
• [3906] MiR-142-5p Acts as a Significant Regulator Through Promoting Proliferation, Invasion, and Migration in Breast Cancer Modulated by Targeting SORBS1.Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819892264. doi: 10.1177/1533033819892264.
• [3907] hsa-miR-301a- and SOX10-dependent miRNA-TF-mRNA regulatory circuits in breast cancer.Turk J Biol. 2018 Apr 27;42(2):103-112. doi: 10.3906/biy-1708-17. eCollection 2018.
• [3908] Clinical and prognostic significance of SOX11 in breast cancer.Asian Pac J Cancer Prev. 2014;15(13):5483-6. doi: 10.7314/apjcp.2014.15.13.5483.
• [3909] Functional analyses of microRNA-326 in breast cancer development.Biosci Rep. 2019 Jul 29;39(7):BSR20190787. doi: 10.1042/BSR20190787. Print 2019 Jul 31.
• [3910] Knockdown of miR-194-5p inhibits cell proliferation, migration and invasion in breast cancer by regulating the Wnt/-catenin signaling pathway.Int J Mol Med. 2018 Dec;42(6):3355-3363. doi: 10.3892/ijmm.2018.3897. Epub 2018 Sep 25.
• [3911] Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice.Elife. 2017 Jan 31;6:e21221. doi: 10.7554/eLife.21221.
• [3912] MiR-483 suppresses cell proliferation and promotes cell apoptosis by targeting SOX3 in breast cancer.Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):2069-2074. doi: 10.26355/eurrev_201903_17248.
• [3913] Long noncoding RNA HOXD-AS1 induces epithelial-mesenchymal transition in breast cancer by acting as a competing endogenous RNA of miR-421.J Cell Biochem. 2019 Jun;120(6):10633-10642. doi: 10.1002/jcb.28353. Epub 2019 Feb 7.
• [3914] LncRNA-mediated regulation of SOX9 expression in basal subtype breast cancer cells.RNA. 2020 Feb;26(2):175-185. doi: 10.1261/rna.073254.119. Epub 2019 Nov 5.
• [3915] Sperm Protein Antigen 17 Expression Correlates With Lymph Node Metastasis and Worse Overall Survival in Patients With Breast Cancer.Front Oncol. 2019 Jul 31;9:710. doi: 10.3389/fonc.2019.00710. eCollection 2019.
• [3916] High expression of SPAG5 sustains the malignant growth and invasion of breast cancer cells through the activation of Wnt/-catenin signalling.Clin Exp Pharmacol Physiol. 2019 Jun;46(6):597-606. doi: 10.1111/1440-1681.13082. Epub 2019 Apr 3.
• [3917] Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.Cancer Lett. 2006 Nov 8;243(1):23-31. doi: 10.1016/j.canlet.2005.11.010. Epub 2006 Mar 23.
• [3918] Expression of PH-20 in normal and neoplastic breast tissue.J Surg Res. 2002 Apr;103(2):203-7. doi: 10.1006/jsre.2002.6351.
• [3919] Possible role of p53/Mieap-regulated mitochondrial quality control as a tumor suppressor in human breast cancer.Cancer Sci. 2018 Dec;109(12):3910-3920. doi: 10.1111/cas.13824. Epub 2018 Nov 2.
• [3920] SPC24 Regulates breast cancer progression by PI3K/AKT signaling.Gene. 2018 Oct 30;675:272-277. doi: 10.1016/j.gene.2018.07.017. Epub 2018 Jul 6.
• [3921] SPIN1, negatively regulated by miR-148/152, enhances Adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer.J Exp Clin Cancer Res. 2018 May 9;37(1):100. doi: 10.1186/s13046-018-0748-9.
• [3922] Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer.EMBO Mol Med. 2011 Aug;3(8):451-64. doi: 10.1002/emmm.201100150. Epub 2011 Jun 8.
• [3923] ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival.Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2133-42. doi: 10.1158/1055-9965.EPI-10-0418. Epub 2010 Aug 17.
• [3924] The hepatocyte growth factor regulatory factors in human breast cancer.Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):202-11. doi: 10.1158/1078-0432.ccr-0553-3.
• [3925] Estrogen-induced miR-196a elevation promotes tumor growth and metastasis via targeting SPRED1 in breast cancer.Mol Cancer. 2018 Apr 23;17(1):83. doi: 10.1186/s12943-018-0830-0.
• [3926] The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer.Cancer Res. 2004 Sep 1;64(17):6127-36. doi: 10.1158/0008-5472.CAN-04-1207.
• [3927] MicroRNA?81 serves an oncogenic role in breast cancer via the inhibition of SPRY4.Mol Med Rep. 2018 Dec;18(6):5603-5613. doi: 10.3892/mmr.2018.9572. Epub 2018 Oct 22.
• [3928] SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling.Cancer Discov. 2014 Jul;4(7):790-803. doi: 10.1158/2159-8290.CD-13-0548. Epub 2014 Apr 30.
• [3929] Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination.Sci Rep. 2019 Oct 22;9(1):15099. doi: 10.1038/s41598-019-51537-7.
• [3930] ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.Oncotarget. 2017 May 30;8(22):36054-36066. doi: 10.18632/oncotarget.16425.
• [3931] miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway.Clin Cancer Res. 2017 Feb 15;23(4):1091-1103. doi: 10.1158/1078-0432.CCR-16-0943. Epub 2016 Jul 19.
• [3932] Genetic variants at 1p11.2 and breast cancer risk: a two-stage study in Chinese women.PLoS One. 2011;6(6):e21563. doi: 10.1371/journal.pone.0021563. Epub 2011 Jun 27.
• [3933] SRSF1-Regulated Alternative Splicing in Breast Cancer.Mol Cell. 2015 Oct 1;60(1):105-17. doi: 10.1016/j.molcel.2015.09.005.
• [3934] Unique CD44 intronic SNP is associated with tumor grade in breast cancer: a case control study and in silico analysis.Cancer Cell Int. 2018 Feb 23;18:28. doi: 10.1186/s12935-018-0522-2. eCollection 2018.
• [3935] Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer.Clin Chim Acta. 2007 Sep;384(1-2):69-74. doi: 10.1016/j.cca.2007.06.001. Epub 2007 Jun 15.
• [3936] Slingshot-1L, a cofilin phosphatase, induces primary breast cancer metastasis.Oncotarget. 2017 Aug 3;8(39):66195-66203. doi: 10.18632/oncotarget.19855. eCollection 2017 Sep 12.
• [3937] Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene.Cancer Res. 2004 Jan 1;64(1):7-12. doi: 10.1158/0008-5472.can-03-2623.
• [3938] Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability.Mol Oncol. 2015 Feb;9(2):437-49. doi: 10.1016/j.molonc.2014.09.001. Epub 2014 Oct 6.
• [3939] Sialylation of vasorin by ST3Gal1 facilitates TGF-1-mediated tumor angiogenesis and progression.Int J Cancer. 2019 Apr 15;144(8):1996-2007. doi: 10.1002/ijc.31891. Epub 2019 Jan 3.
• [3940] ST3Gal III modulates breast cancer cell adhesion and invasion by altering the expression of invasion-related molecules.Oncol Rep. 2016 Dec;36(6):3317-3324. doi: 10.3892/or.2016.5180. Epub 2016 Oct 18.
• [3941] Triple-negative and HER2-overexpressing breast cancer cell sialylation impacts tumor microenvironment T-lymphocyte subset recruitment: a possible mechanism of tumor escape.Cancer Manag Res. 2018 May 4;10:1051-1059. doi: 10.2147/CMAR.S162932. eCollection 2018.
• [3942] Breast cancer cells expressing cancer-associated sialyl-Tn antigen have less capacity to develop osteolytic lesions in a mouse model of skeletal colonization.Clin Exp Metastasis. 2019 Dec;36(6):539-549. doi: 10.1007/s10585-019-09999-6. Epub 2019 Oct 8.
• [3943] ST6GalNAcII mediates the invasive properties of breast carcinoma through PI3K/Akt/NF-B signaling pathway.IUBMB Life. 2014 Apr;66(4):300-8. doi: 10.1002/iub.1268. Epub 2014 Apr 23.
• [3944] Myricetin suppresses breast cancer metastasis through down-regulating the activity of matrix metalloproteinase (MMP)-2/9.Phytother Res. 2018 Jul;32(7):1373-1381. doi: 10.1002/ptr.6071. Epub 2018 Mar 13.
• [3945] Mutations in the ST7/RAY1/HELG locus rarely occur in primary colorectal, gastric, and hepatocellular carcinomas.Br J Cancer. 2003 Jun 16;88(12):1909-13. doi: 10.1038/sj.bjc.6600942.
• [3946] RWCFusion: identifying phenotype-specific cancer driver gene fusions based on fusion pair random walk scoring method.Oncotarget. 2016 Sep 20;7(38):61054-61068. doi: 10.18632/oncotarget.11064.
• [3947] EGF- and cell-cycle-regulated STAG1/PMEPA1/ERG1.2 belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer.Mol Carcinog. 2003 Dec;38(4):188-200. doi: 10.1002/mc.10162.
• [3948] Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells.Cancer Sci. 2011 Apr;102(4):756-61. doi: 10.1111/j.1349-7006.2010.01842.x. Epub 2011 Jan 23.
• [3949] Star-related lipid transfer protein 10 (STARD10): a novel key player in alcohol-induced breast cancer progression.J Exp Clin Cancer Res. 2019 Jan 5;38(1):4. doi: 10.1186/s13046-018-1013-y.
• [3950] Elevated levels of StAR-related lipid transfer protein 3 alter cholesterol balance and adhesiveness of breast cancer cells: potential mechanisms contributing to progression of HER2-positive breast cancers.Am J Pathol. 2015 Apr;185(4):987-1000. doi: 10.1016/j.ajpath.2014.12.018. Epub 2015 Feb 12.
• [3951] miRNA-dependent regulation of STIM1 expression in breast cancer.Sci Rep. 2019 Sep 10;9(1):13076. doi: 10.1038/s41598-019-49629-5.
• [3952] Calcium-sensing stromal interaction molecule 2 upregulates nuclear factor of activated T cells 1 and transforming growth factor- signaling to promote breast cancer metastasis.Breast Cancer Res. 2019 Aug 29;21(1):99. doi: 10.1186/s13058-019-1185-1.
• [3953] FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis.Cell Death Differ. 2019 Dec;26(12):2577-2593. doi: 10.1038/s41418-019-0321-x. Epub 2019 Mar 22.
• [3954] Identification of differently expressed genes with specific SNP Loci for breast cancer by the integration of SNP and gene expression profiling analyses.Pathol Oncol Res. 2015 Apr;21(2):469-75. doi: 10.1007/s12253-014-9851-1. Epub 2014 Nov 19.
• [3955] Post-translational modification of OCT4 in breast cancer tumorigenesis.Cell Death Differ. 2018 Nov;25(10):1781-1795. doi: 10.1038/s41418-018-0079-6. Epub 2018 Mar 6.
• [3956] Effective stimulation of growth in MCF-7 human breast cancer cells by inhibition of syntaxin18 by external guide sequence and ribonuclease P.Cancer Lett. 2008 Dec 8;272(1):167-75. doi: 10.1016/j.canlet.2008.07.014. Epub 2008 Aug 22.
• [3957] STX3 represses the stability of the tumor suppressor PTEN to activate the PI3K-Akt-mTOR signaling and promotes the growth of breast cancer cells.Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1684-1692. doi: 10.1016/j.bbadis.2018.01.031. Epub 2018 Feb 2.
• [3958] The pseudophosphatase STYX targets the F-box of FBXW7 and inhibits SCFFBXW7 function.EMBO J. 2017 Feb 1;36(3):260-273. doi: 10.15252/embj.201694795. Epub 2016 Dec 22.
• [3959] Transcriptional positive cofactor 4 promotes breast cancer proliferation and metastasis through c-Myc mediated Warburg effect.Cell Commun Signal. 2019 Apr 16;17(1):36. doi: 10.1186/s12964-019-0348-0.
• [3960] HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells.Cancer Res. 2011 Mar 15;71(6):2152-61. doi: 10.1158/0008-5472.CAN-10-3059. Epub 2011 Jan 25.
• [3961] Genomic profiling of histological special types of breast cancer.Breast Cancer Res Treat. 2013 Nov;142(2):257-69. doi: 10.1007/s10549-013-2740-6. Epub 2013 Oct 27.
• [3962] Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cells.Oncogene. 2015 Jan 15;34(3):323-33. doi: 10.1038/onc.2013.553. Epub 2014 Jan 13.
• [3963] The Oncogenic Potential of SUV39H2: A Comprehensive and Perspective View.J Cancer. 2019 Jan 1;10(3):721-729. doi: 10.7150/jca.28254. eCollection 2019.
• [3964] SYCP2 expression is a novel prognostic biomarker in luminal A/B breast cancer.Future Oncol. 2019 Mar;15(8):817-826. doi: 10.2217/fon-2018-0821. Epub 2018 Dec 4.
• [3965] Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer.Oncotarget. 2017 May 23;8(51):88453-88463. doi: 10.18632/oncotarget.18188. eCollection 2017 Oct 24.
• [3966] Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer.Sci Signal. 2015 Jan 20;8(360):ra7. doi: 10.1126/scisignal.2005537.
• [3967] Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.Oncogene. 2010 Aug 26;29(34):4814-25. doi: 10.1038/onc.2010.229. Epub 2010 Jun 14.
• [3968] Metastatic breast cancer simulating well-differentiated neuroendocrine neoplasms of visceral organs.Hum Pathol. 2018 Dec;82:76-86. doi: 10.1016/j.humpath.2018.07.011. Epub 2018 Jul 18.
• [3969] A Novel Functional Domain of Tab2 Involved in the Interaction with Estrogen Receptor Alpha in Breast Cancer Cells.PLoS One. 2016 Dec 19;11(12):e0168639. doi: 10.1371/journal.pone.0168639. eCollection 2016.
• [3970] MicroRNA-374c-5p inhibits the development of breast cancer through TATA-box binding protein associated factor 7-mediated transcriptional regulation of DEP domain containing 1.J Cell Biochem. 2019 Sep;120(9):15360-15368. doi: 10.1002/jcb.28803. Epub 2019 Jun 4.
• [3971] The expression of stem cell protein Piwil2 and piR-932 in breast cancer.Surg Oncol. 2013 Dec;22(4):217-23. doi: 10.1016/j.suronc.2013.07.001. Epub 2013 Aug 27.
• [3972] Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers.Nat Commun. 2018 Oct 15;9(1):4274. doi: 10.1038/s41467-018-06651-x.
• [3973] High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGF pathways as fundamental Notch regulators in breast cancer.Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1714-9. doi: 10.1073/pnas.1214014110. Epub 2013 Jan 14.
• [3974] The PDZ protein TIP-1 facilitates cell migration and pulmonary metastasis of human invasive breast cancer cells in athymic mice.Biochem Biophys Res Commun. 2012 May 25;422(1):139-45. doi: 10.1016/j.bbrc.2012.04.123. Epub 2012 Apr 30.
• [3975] RNA variant identification discrepancy among splice-aware alignment algorithms.PLoS One. 2018 Aug 2;13(8):e0201822. doi: 10.1371/journal.pone.0201822. eCollection 2018.
• [3976] Downregulation of TBC1 Domain Family Member 24 (BC1D24) Inhibits Breast Carcinoma Growth via IGF1R/PI3K/AKT Pathway.Med Sci Monit. 2018 Jun 12;24:3987-3996. doi: 10.12659/MSM.906736.
• [3977] Up-regulation of OLR1 expression by TBC1D3 through activation of TNF/NF-B pathway promotes the migration of human breast cancer cells.Cancer Lett. 2017 Nov 1;408:60-70. doi: 10.1016/j.canlet.2017.08.021. Epub 2017 Aug 24.
• [3978] TBL1 is required for the mesenchymal phenotype of transformed breast cancer cells.Cell Death Dis. 2019 Jan 31;10(2):95. doi: 10.1038/s41419-019-1310-1.
• [3979] Prognostic significance of high metabolic activity in breast cancer: PET signature in breast cancer.Biochem Biophys Res Commun. 2019 Mar 26;511(1):185-191. doi: 10.1016/j.bbrc.2019.02.035. Epub 2019 Feb 15.
• [3980] Knockdown of TFIIS by RNA silencing inhibits cancer cell proliferation and induces apoptosis.BMC Cancer. 2008 May 12;8:133. doi: 10.1186/1471-2407-8-133.
• [3981] TCF21 genetic polymorphisms and breast cancer risk in Chinese women.Oncotarget. 2016 Aug 23;7(34):55757-55764. doi: 10.18632/oncotarget.9825.
• [3982] MiR-591 functions as tumor suppressor in breast cancer by targeting TCF4 and inhibits Hippo-YAP/TAZ signaling pathway.Cancer Cell Int. 2019 Apr 24;19:108. doi: 10.1186/s12935-019-0818-x. eCollection 2019.
• [3983] A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.Breast Cancer Res Treat. 2019 Jan;173(2):255-266. doi: 10.1007/s10549-018-4981-x. Epub 2018 Oct 15.
• [3984] TC-1 (c8orf4) enhances aggressive biologic behavior in lung cancer through the Wnt/-catenin pathway.J Surg Res. 2013 Nov;185(1):255-63. doi: 10.1016/j.jss.2013.05.075. Epub 2013 Jun 11.
• [3985] Overexpression of Transcobalamin 1 is an Independent Negative Prognosticator in Rectal Cancers Receiving Concurrent Chemoradiotherapy.J Cancer. 2017 May 12;8(8):1330-1337. doi: 10.7150/jca.18274. eCollection 2017.
• [3986] Tudor Domain Containing Protein 3 Promotes Tumorigenesis and Invasive Capacity of Breast Cancer Cells.Sci Rep. 2017 Jul 11;7(1):5153. doi: 10.1038/s41598-017-04955-4.
• [3987] A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer.Mol Cell. 2019 Aug 22;75(4):791-806.e8. doi: 10.1016/j.molcel.2019.06.010. Epub 2019 Jul 11.
• [3988] Enriched variations in TEKT4 and breast cancer resistance to paclitaxel.Nat Commun. 2014 May 13;5:3802. doi: 10.1038/ncomms4802.
• [3989] Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy.Cancer. 2018 Jan 1;124(1):36-45. doi: 10.1002/cncr.30938. Epub 2017 Sep 20.
• [3990] Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.Theranostics. 2019 Jan 24;9(3):761-777. doi: 10.7150/thno.29520. eCollection 2019.
• [3991] Retinoic acid directs breast cancer cell state changes through regulation of TET2-PKC pathway.Oncogene. 2017 Jun 1;36(22):3193-3206. doi: 10.1038/onc.2016.467. Epub 2017 Feb 20.
• [3992] Genetic variation in the chromosome 17q23 amplicon and breast cancer risk.Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1864-8. doi: 10.1158/1055-9965.EPI-08-0486. Epub 2009 May 19.
• [3993] Dystonia, facial dysmorphism, intellectual disability and breast cancer associated with a chromosome 13q34 duplication and overexpression of TFDP1: case report.BMC Med Genet. 2013 Jul 13;14:70. doi: 10.1186/1471-2350-14-70.
• [3994] Inhibiting ROS-TFE3-dependent autophagy enhances the therapeutic response to metformin in breast cancer.Free Radic Res. 2018 Aug;52(8):872-886. doi: 10.1080/10715762.2018.1485075. Epub 2018 Jul 25.
• [3995] STAT3 contributes to lysosomal-mediated cell death in a novel derivative of riccardin D-treated breast cancer cells in association with TFEB.Biochem Pharmacol. 2018 Apr;150:267-279. doi: 10.1016/j.bcp.2018.02.026. Epub 2018 Feb 21.
• [3996] Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with breast cancer.Anticancer Res. 2003 Jan-Feb;23(1A):223-9.
• [3997] The influence of genetic ancestry and ethnicity on breast cancer survival associated with genetic variation in the TGF--signaling pathway: The Breast Cancer Health Disparities Study.Cancer Causes Control. 2014 Mar;25(3):293-307. doi: 10.1007/s10552-013-0331-9. Epub 2013 Dec 12.
• [3998] CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.Oncotarget. 2017 May 2;8(18):29699-29710. doi: 10.18632/oncotarget.10719.
• [3999] Cytosolic THUMPD1 promotes breast cancer cells invasion and metastasis via the AKT-GSK3-Snail pathway.Oncotarget. 2017 Feb 21;8(8):13357-13366. doi: 10.18632/oncotarget.14528.
• [4000] Circadian gene variants and breast cancer.Cancer Lett. 2017 Apr 1;390:137-145. doi: 10.1016/j.canlet.2017.01.012. Epub 2017 Jan 18.
• [4001] LncRNA NEAT1 Silenced miR-133b Promotes Migration and Invasion of Breast Cancer Cells.Int J Mol Sci. 2019 Jul 24;20(15):3616. doi: 10.3390/ijms20153616.
• [4002] A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis.Aging (Albany NY). 2017 Oct 27;9(10):2098-2116. doi: 10.18632/aging.101304.
• [4003] TIMM50 promotes tumor progression via ERK signaling and predicts poor prognosis of non-small cell lung cancer patients.Mol Carcinog. 2019 May;58(5):767-776. doi: 10.1002/mc.22969. Epub 2019 Jan 22.
• [4004] miR-616 promotes breast cancer migration and invasion by targeting TIMP2 and regulating MMP signaling.Oncol Lett. 2019 Sep;18(3):2348-2355. doi: 10.3892/ol.2019.10546. Epub 2019 Jun 28.
• [4005] TIMP3 Promoter Methylation Represents an Epigenetic Marker of BRCA1ness Breast Cancer Tumours.Pathol Oncol Res. 2018 Oct;24(4):937-940. doi: 10.1007/s12253-018-0398-4. Epub 2018 Mar 9.
• [4006] TIMP4 Modulates ER- Signalling in MCF7 Breast Cancer Cells.Folia Biol (Praha). 2016;62(2):75-81.
• [4007] Loss of the tight junction MAGUK ZO-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity.Am J Pathol. 1998 Dec;153(6):1767-73. doi: 10.1016/S0002-9440(10)65691-X.
• [4008] Increased ceramide synthase 2 and 6 mRNA levels in breast cancer tissues and correlation with sphingosine kinase expression.Biochem Biophys Res Commun. 2010 Jan 1;391(1):219-23. doi: 10.1016/j.bbrc.2009.11.035. Epub 2009 Nov 11.
• [4009] Clinicopathologic and Prognostic Significance of Transducin-Like Enhancer of Split 1 Protein Expression in Invasive Breast Cancer.J Breast Cancer. 2017 Mar;20(1):45-53. doi: 10.4048/jbc.2017.20.1.45. Epub 2017 Mar 24.
• [4010] Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.J Clin Oncol. 2009 Feb 1;27(4):542-9. doi: 10.1200/JCO.2008.17.1462. Epub 2008 Dec 15.
• [4011] Down syndrome: molecular mapping of the congenital heart disease and duodenal stenosis.Am J Hum Genet. 1992 Feb;50(2):294-302.
• [4012] Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint.Mol Cancer Res. 2016 Oct;14(10):920-927. doi: 10.1158/1541-7786.MCR-16-0161. Epub 2016 Aug 3.
• [4013] Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion.J Exp Clin Cancer Res. 2010 Jul 10;29(1):92. doi: 10.1186/1756-9966-29-92.
• [4014] MicroRNA-206 inhibits metastasis of triple-negative breast cancer by targeting transmembrane 4 L6 family member 1.Cancer Manag Res. 2019 Jul 22;11:6755-6764. doi: 10.2147/CMAR.S199027. eCollection 2019.
• [4015] Knockdown of TM9SF4 boosts ER stress to trigger cell death of chemoresistant breast cancer cells.Oncogene. 2019 Jul;38(29):5778-5791. doi: 10.1038/s41388-019-0846-y. Epub 2019 Jun 27.
• [4016] Increased expression of TMED2 is an unfavorable prognostic factor in patients with breast cancer.Cancer Manag Res. 2019 Mar 18;11:2203-2214. doi: 10.2147/CMAR.S192949. eCollection 2019.
• [4017] Lack of transforming growth factor- signaling promotes collective cancer cell invasion through tumor-stromal crosstalk.Breast Cancer Res. 2012 Jul 2;14(4):R98. doi: 10.1186/bcr3217.
• [4018] Incorporating prior biological knowledge for network-based differential gene expression analysis using differentially weighted graphical LASSO.BMC Bioinformatics. 2017 Feb 10;18(1):99. doi: 10.1186/s12859-017-1515-1.
• [4019] Analysis of the candidate tumor suppressor Ris-1 in primary human breast carcinomas.Mutat Res. 2006 Feb 22;594(1-2):78-85. doi: 10.1016/j.mrfmmm.2005.07.017. Epub 2005 Nov 8.
• [4020] TMEM17 promotes malignant progression of breast cancer via AKT/GSK3 signaling.Cancer Manag Res. 2018 Aug 2;10:2419-2428. doi: 10.2147/CMAR.S168723. eCollection 2018.
• [4021] Transmembrane protein 170B is a novel breast tumorigenesis suppressor gene that inhibits the Wnt/-catenin pathway.Cell Death Dis. 2018 Jan 24;9(2):91. doi: 10.1038/s41419-017-0128-y.
• [4022] Complex sense-antisense architecture of TNFAIP1/POLDIP2 on 17q11.2 represents a novel transcriptional structural-functional gene module involved in breast cancer progression.BMC Genomics. 2010 Feb 10;11 Suppl 1(Suppl 1):S9. doi: 10.1186/1471-2164-11-S1-S9.
• [4023] Expression of transmembrane protein 26 (TMEM26) in breast cancer and its association with drug response.Oncotarget. 2016 Jun 21;7(25):38408-38426. doi: 10.18632/oncotarget.9493.
• [4024] NGX6 expression improves the sensitivity of tamoxifen-resistant MCF-7 cells through modulation of the Smad signaling pathway.Int J Oncol. 2013 Jun;42(6):2060-8. doi: 10.3892/ijo.2013.1886. Epub 2013 Apr 8.
• [4025] Tropomodulin 1 expression driven by NF-B enhances breast cancer growth.Cancer Res. 2015 Jan 1;75(1):62-72. doi: 10.1158/0008-5472.CAN-13-3455. Epub 2014 Nov 14.
• [4026] Dysregulation of TMPRSS3 and TNFRSF11B correlates with tumorigenesis and poor prognosis in patients with breast cancer.Oncol Rep. 2017 Apr;37(4):2057-2062. doi: 10.3892/or.2017.5449. Epub 2017 Feb 14.
• [4027] Role of TMPRSS4 Modulation in Breast Cancer Cell Proliferation.Asian Pac J Cancer Prev. 2019 Jun 1;20(6):1849-1856. doi: 10.31557/APJCP.2019.20.6.1849.
• [4028] Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer.Breast Cancer Res. 2017 Feb 8;19(1):15. doi: 10.1186/s13058-016-0785-2.
• [4029] KLF5 promotes breast cancer proliferation, migration and invasion in part by upregulating the transcription of TNFAIP2.Oncogene. 2016 Apr 21;35(16):2040-51. doi: 10.1038/onc.2015.263. Epub 2015 Jul 20.
• [4030] Hyaluronan preconditioning of monocytes/macrophages affects their angiogenic behavior and regulation of TSG-6 expression in a tumor type-specific manner.FEBS J. 2019 Sep;286(17):3433-3449. doi: 10.1111/febs.14871. Epub 2019 May 16.
• [4031] TIPE1 suppresses the invasion and migration of breast cancer cells and inhibits epithelial-to-mesenchymal transition primarily via the ERK signaling pathway.Acta Biochim Biophys Sin (Shanghai). 2019 Sep 6;51(10):1008-1015. doi: 10.1093/abbs/gmz099.
• [4032] TIPE3 protein promotes breast cancer metastasis through activating AKT and NF-B signaling pathways.Oncotarget. 2017 Jul 25;8(30):48889-48904. doi: 10.18632/oncotarget.16522.
• [4033] Subgrouping breast cancer patients based on immune evasion mechanisms unravels a high involvement of transforming growth factor-beta and decoy receptor 3.PLoS One. 2018 Dec 4;13(12):e0207799. doi: 10.1371/journal.pone.0207799. eCollection 2018.
• [4034] Expression of AITR and AITR ligand in breast cancer patients.Oncol Rep. 2007 Nov;18(5):1189-94.
• [4035] A genome-wide scan for breast cancer risk haplotypes among African American women.PLoS One. 2013;8(2):e57298. doi: 10.1371/journal.pone.0057298. Epub 2013 Feb 28.
• [4036] TNNT1 facilitates proliferation of breast cancer cells by promoting G(1)/S phase transition.Life Sci. 2018 Sep 1;208:161-166. doi: 10.1016/j.lfs.2018.07.034. Epub 2018 Jul 19.
• [4037] Genome-wide association study identifies five new breast cancer susceptibility loci.Nat Genet. 2010 Jun;42(6):504-7. doi: 10.1038/ng.586. Epub 2010 May 9.
• [4038] Distribution bias and biochemical characterization of TOP1MT single nucleotide variants.Sci Rep. 2017 Aug 17;7(1):8614. doi: 10.1038/s41598-017-09258-2.
• [4039] Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study.BMC Cancer. 2009 May 11;9:140. doi: 10.1186/1471-2407-9-140.
• [4040] Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers.PLoS One. 2012;7(4):e34850. doi: 10.1371/journal.pone.0034850. Epub 2012 Apr 4.
• [4041] Overexpression of Tumor Protein p53-regulated Apoptosis-inducing Protein 1 Regulates Proliferation and Apoptosis of Breast Cancer Cells through the PI3K/Akt Pathway.J Breast Cancer. 2019 Jun;22(2):172-184. doi: 10.4048/jbc.2019.22.e21.
• [4042] Silencing of ASPP2 promotes the proliferation, migration and invasion of triple-negative breast cancer cells via the PI3K/AKT pathway.Int J Oncol. 2018 Jun;52(6):2001-2010. doi: 10.3892/ijo.2018.4331. Epub 2018 Mar 20.
• [4043] Reduction in breast cancer susceptibility due to XbaI gene polymorphism of alpha estrogen receptor gene in Jordanians.Breast Cancer (Dove Med Press). 2017 Jan 24;9:45-49. doi: 10.2147/BCTT.S125652. eCollection 2017.
• [4044] Delivery of platelet TPM3 mRNA into breast cancer cells via microvesicles enhances metastasis.FEBS Open Bio. 2019 Dec;9(12):2159-2169. doi: 10.1002/2211-5463.12759. Epub 2019 Nov 21.
• [4045] TRA2A promotes proliferation, migration, invasion and epithelial mesenchymal transition of glioma cells.Brain Res Bull. 2018 Oct;143:138-144. doi: 10.1016/j.brainresbull.2018.10.006. Epub 2018 Oct 24.
• [4046] Differential Functions of Splicing Factors in Mammary Transformation and Breast Cancer Metastasis.Cell Rep. 2019 Nov 26;29(9):2672-2688.e7. doi: 10.1016/j.celrep.2019.10.110.
• [4047] MicroRNA-30c-2-3p negatively regulates NF-B signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer.Mol Oncol. 2015 Jun;9(6):1106-19. doi: 10.1016/j.molonc.2015.01.008. Epub 2015 Feb 10.
• [4048] TRAF2 Cooperates with Focal Adhesion Signaling to Regulate Cancer Cell Susceptibility to Anoikis.Mol Cancer Ther. 2019 Jan;18(1):139-146. doi: 10.1158/1535-7163.MCT-17-1261. Epub 2018 Oct 29.
• [4049] Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer.Sci Rep. 2017 Jan 10;7:40487. doi: 10.1038/srep40487.
• [4050] Down-regulation of TRAF4 targeting RSK4 inhibits proliferation, invasion and metastasis in breast cancer xenografts.Biochem Biophys Res Commun. 2018 Jun 7;500(3):810-816. doi: 10.1016/j.bbrc.2018.04.164. Epub 2018 Apr 24.
• [4051] ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance.Mol Cell Biol. 2004 Jun;24(12):5157-71. doi: 10.1128/MCB.24.12.5157-5171.2004.
• [4052] miR-3188 Regulates Cell Proliferation, Apoptosis, and Migration in Breast Cancer by Targeting TUSC5 and Regulating the p38 MAPK Signaling Pathway.Oncol Res. 2018 Apr 10;26(3):363-372. doi: 10.3727/096504017X14953948675421. Epub 2017 May 26.
• [4053] DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.PLoS Med. 2009 May 26;6(5):e1000068. doi: 10.1371/journal.pmed.1000068. Epub 2009 May 5.
• [4054] Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs.Cancer Immunol Res. 2018 Aug;6(8):910-920. doi: 10.1158/2326-6066.CIR-17-0581. Epub 2018 Jun 15.
• [4055] Bayesian Network Inference Modeling Identifies TRIB1 as a Novel Regulator of Cell-Cycle Progression and Survival in Cancer Cells.Cancer Res. 2017 Apr 1;77(7):1575-1585. doi: 10.1158/0008-5472.CAN-16-0512. Epub 2017 Jan 13.
• [4056] Tripartite motifcontaining11 regulates the proliferation and apoptosis of breast cancer cells.Oncol Rep. 2019 Apr;41(4):2567-2574. doi: 10.3892/or.2019.7015. Epub 2019 Feb 14.
• [4057] The Breast Cancer Tumor Suppressor TRIM29 Is Expressed via ATM-dependent Signaling in Response to Hypoxia.J Biol Chem. 2016 Oct 7;291(41):21541-21552. doi: 10.1074/jbc.M116.730960. Epub 2016 Aug 17.
• [4058] miR-4513 promotes breast cancer progression through targeting TRIM3.Am J Transl Res. 2019 Apr 15;11(4):2431-2438. eCollection 2019.
• [4059] TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway.J Neurooncol. 2019 Nov;145(2):211-222. doi: 10.1007/s11060-019-03301-0. Epub 2019 Oct 11.
• [4060] Mmu-miR-1894-3p Inhibits Cell Proliferation and Migration of Breast Cancer Cells by Targeting Trim46.Int J Mol Sci. 2016 Apr 22;17(4):609. doi: 10.3390/ijms17040609.
• [4061] Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.J Pathol. 2014 Sep;234(1):108-19. doi: 10.1002/path.4385. Epub 2014 Jul 16.
• [4062] DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer.Oncotarget. 2016 Jul 28;8(38):62834-62841. doi: 10.18632/oncotarget.10886. eCollection 2017 Sep 8.
• [4063] Chromosome 8 BAC array comparative genomic hybridization and expression analysis identify amplification and overexpression of TRMT12 in breast cancer.Genes Chromosomes Cancer. 2007 Jul;46(7):694-707. doi: 10.1002/gcc.20454.
• [4064] TROAP Promotes Breast Cancer Proliferation and Metastasis.Biomed Res Int. 2019 May 6;2019:6140951. doi: 10.1155/2019/6140951. eCollection 2019.
• [4065] TRPS1 Suppresses Breast Cancer Epithelial-mesenchymal Transition Program as a Negative Regulator of SUZ12.Transl Oncol. 2018 Apr;11(2):416-425. doi: 10.1016/j.tranon.2018.01.009. Epub 2018 Feb 20.
• [4066] Identification of new TSGA10 transcript variants in human testis with conserved regulatory RNA elements in 5'untranslated region and distinct expression in breast cancer.Biochim Biophys Acta Gene Regul Mech. 2017 Sep;1860(9):973-982. doi: 10.1016/j.bbagrm.2017.07.007. Epub 2017 Jul 21.
• [4067] The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women.Breast Cancer Res. 2005;7(3):R353-6. doi: 10.1186/bcr1009. Epub 2005 Mar 4.
• [4068] Master Regulators of Signaling Pathways: An Application to the Analysis of Gene Regulation in Breast Cancer.Front Genet. 2019 Dec 3;10:1180. doi: 10.3389/fgene.2019.01180. eCollection 2019.
• [4069] Rare and frequent promoter methylation, respectively, of TSHZ2 and 3 genes that are both downregulated in expression in breast and prostate cancers.PLoS One. 2011 Mar 14;6(3):e17149. doi: 10.1371/journal.pone.0017149.
• [4070] Identification of metastasis-associated breast cancer genes using a high-resolution whole genome profiling approach.J Cancer Res Clin Oncol. 2011 May;137(5):795-809. doi: 10.1007/s00432-010-0937-1. Epub 2010 Aug 3.
• [4071] Upregulation of TSPAN12 is associated with the colorectal cancer growth and metastasis.Am J Transl Res. 2017 Feb 15;9(2):812-822. eCollection 2017.
• [4072] miR-4732-5p promotes breast cancer progression by targeting TSPAN13.J Cell Mol Med. 2019 Apr;23(4):2549-2557. doi: 10.1111/jcmm.14145. Epub 2019 Jan 31.
• [4073] Tspan8 is expressed in breast cancer and regulates E-cadherin/catenin signalling and metastasis accompanied by increased circulating extracellular vesicles.J Pathol. 2019 Aug;248(4):421-437. doi: 10.1002/path.5281. Epub 2019 Jun 18.
• [4074] Fetal microchimerism in breast from women with and without breast cancer.Breast Cancer Res Treat. 2010 May;121(1):241-4. doi: 10.1007/s10549-009-0548-1. Epub 2009 Sep 19.
• [4075] Network-based inference framework for identifying cancer genes from gene expression data.Biomed Res Int. 2013;2013:401649. doi: 10.1155/2013/401649. Epub 2013 Sep 1.
• [4076] Association between single nucleotide polymorphisms in the TSPYL6 gene and breast cancer susceptibility in the Han Chinese population.Oncotarget. 2016 Aug 23;7(34):54771-54781. doi: 10.18632/oncotarget.10754.
• [4077] HBP21: a novel member of TPR motif family, as a potential chaperone of heat shock protein 70 in proliferative vitreoretinopathy (PVR) and breast cancer.Mol Biotechnol. 2008 Nov;40(3):231-40. doi: 10.1007/s12033-008-9080-5. Epub 2008 Jun 29.
• [4078] GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors.Appl Immunohistochem Mol Morphol. 2009 Dec;17(6):505-11. doi: 10.1097/PAI.0b013e3181a8e809.
• [4079] Knockdown of XB130 restrains cancer stem cell-like phenotype through inhibition of Wnt/-Catenin signaling in breast cancer.Mol Carcinog. 2019 Oct;58(10):1832-1845. doi: 10.1002/mc.23071. Epub 2019 Jun 20.
• [4080] Anterior Gradient 3 Promotes Breast Cancer Development and Chemotherapy Response.Cancer Res Treat. 2020 Jan;52(1):218-245. doi: 10.4143/crt.2019.217. Epub 2019 Jul 8.
• [4081] AMPH-1 is a tumor suppressor of lung cancer by inhibiting Ras-Raf-MEK-ERK signal pathway.Lasers Med Sci. 2019 Apr;34(3):473-478. doi: 10.1007/s10103-018-2616-4. Epub 2018 Aug 24.
• [4082] ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer.Front Oncol. 2019 Jun 26;9:547. doi: 10.3389/fonc.2019.00547. eCollection 2019.
• [4083] ANP32E induces tumorigenesis of triple-negative breast cancer cells by upregulating E2F1.Mol Oncol. 2018 Jun;12(6):896-912. doi: 10.1002/1878-0261.12202. Epub 2018 Apr 18.
• [4084] ARMc8 indicates aggressive colon cancers and promotes invasiveness and migration of colon cancer cells.Tumour Biol. 2015 Nov;36(11):9005-13. doi: 10.1007/s13277-015-3664-z. Epub 2015 Jun 18.
• [4085] ALEX1 Regulates Proliferation and Apoptosis in Breast Cancer Cells.Asian Pac J Cancer Prev. 2015;16(8):3293-9. doi: 10.7314/apjcp.2015.16.8.3293.
• [4086] Associations Among Plasma Stress Markers and Symptoms of Anxiety and Depression in Patients with Breast Cancer Following Surgery.Psychiatry Investig. 2018 Feb;15(2):133-140. doi: 10.30773/pi.2017.07.26. Epub 2017 Oct 30.
• [4087] Inhibition of ezrin causes PKC-mediated internalization of erbb2/HER2 tyrosine kinase in breast cancer cells.J Biol Chem. 2019 Jan 18;294(3):887-901. doi: 10.1074/jbc.RA118.004143. Epub 2018 Nov 21.
• [4088] Ataxin-3 like (ATXN3L), a member of the Josephin family of deubiquitinating enzymes, promotes breast cancer proliferation by deubiquitinating Krppel-like factor 5 (KLF5).Oncotarget. 2015 Aug 28;6(25):21369-78. doi: 10.18632/oncotarget.4128.
• [4089] Internalization of CD239 highly expressed in breast cancer cells: a potential antigen for antibody-drug conjugates.Sci Rep. 2018 Apr 26;8(1):6612. doi: 10.1038/s41598-018-24961-4.
• [4090] BCAS2 Enhances Carcinogenic Effects of Estrogen Receptor Alpha in Breast Cancer Cells.Int J Mol Sci. 2019 Feb 22;20(4):966. doi: 10.3390/ijms20040966.
• [4091] Estrogen receptor (ER)-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression.J Biol Chem. 2015 Feb 27;290(9):5566-81. doi: 10.1074/jbc.M114.606459. Epub 2014 Dec 2.
• [4092] Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.Oncotarget. 2017 Feb 21;8(8):12558-12575. doi: 10.18632/oncotarget.14894.
• [4093] Estrogen and progesterone promote breast cancer cell proliferation by inducing cyclin G1 expression.Braz J Med Biol Res. 2018 Jan 23;51(3):1-7. doi: 10.1590/1414-431X20175612.
• [4094] CRAM-A indicates IFN--associated inflammatory response in breast cancer.Mol Immunol. 2015 Dec;68(2 Pt C):692-8. doi: 10.1016/j.molimm.2015.10.019. Epub 2015 Nov 10.
• [4095] Systems-level Analysis Reveals Multiple Modulators of Epithelial-mesenchymal Transition and Identifies DNAJB4 and CD81 as Novel Metastasis Inducers in Breast Cancer.Mol Cell Proteomics. 2019 Sep;18(9):1756-1771. doi: 10.1074/mcp.RA119.001446. Epub 2019 Jun 20.
• [4096] Down Regulation of CLDND1 Induces Apoptosis in Breast Cancer Cells.PLoS One. 2015 Jun 17;10(6):e0130300. doi: 10.1371/journal.pone.0130300. eCollection 2015.
• [4097] CHM-1, a novel microtubule-destabilizing agent exhibits antitumor activity via inducing the expression of SIRT2 in human breast cancer cells.Chem Biol Interact. 2018 Jun 1;289:98-108. doi: 10.1016/j.cbi.2018.04.007. Epub 2018 Apr 18.
• [4098] Correction to: Elevated expression of CST1 promotes breast cancer progression and predicts a poor prognosis.J Mol Med (Berl). 2019 Aug;97(8):1213-1214. doi: 10.1007/s00109-019-01806-9.
• [4099] Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5.Theranostics. 2019 Jan 30;9(4):1181-1199. doi: 10.7150/thno.29093. eCollection 2019.
• [4100] Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.Histol Histopathol. 2019 Dec;34(12):1365-1375. doi: 10.14670/HH-18-130. Epub 2019 May 31.
• [4101] BRCA1 and CtIP Are Both Required to Recruit Dna2 at Double-Strand Breaks in Homologous Recombination.PLoS One. 2015 Apr 24;10(4):e0124495. doi: 10.1371/journal.pone.0124495. eCollection 2015.
• [4102] Knockdown of eIF3D inhibits breast cancer cell proliferation and invasion through suppressing the Wnt/-catenin signaling pathway.Int J Clin Exp Pathol. 2015 Sep 1;8(9):10420-7. eCollection 2015.
• [4103] Analysis of a FANCE Splice Isoform in Regard to DNA Repair.J Mol Biol. 2015 Sep 25;427(19):3056-73. doi: 10.1016/j.jmb.2015.08.004. Epub 2015 Aug 12.
• [4104] Antitumor Potential of Fibulin-5 in Breast Cancer Cells Depends on Its RGD Cell Adhesion Motif.Cell Physiol Biochem. 2019;53(1):87-100. doi: 10.33594/000000123.
• [4105] Enhanced synaptic plasticity and spatial memory in female but not male FLRT2-haplodeficient mice.Sci Rep. 2018 Feb 27;8(1):3703. doi: 10.1038/s41598-018-22030-4.
• [4106] Recent Advances in Understanding FOXN3 in Breast Cancer, and Other Malignancies.Front Oncol. 2019 May 31;9:234. doi: 10.3389/fonc.2019.00234. eCollection 2019.
• [4107] Fucosyltransferase 8 deficiency suppresses breast cancer cell migration by interference of the FAK/integrin pathway.Cancer Biomark. 2019;25(4):303-311. doi: 10.3233/CBM-190209.
• [4108] miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A.Sci Rep. 2015 Aug 10;5:13170. doi: 10.1038/srep13170.
• [4109] Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.Clin Cancer Res. 2015 May 15;21(10):2359-66. doi: 10.1158/1078-0432.CCR-14-1495. Epub 2014 Dec 30.
• [4110] Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer.BMC Cancer. 2013 Feb 19;13:81. doi: 10.1186/1471-2407-13-81.
• [4111] miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer.Oncol Rep. 2017 Feb;37(2):1093-1099. doi: 10.3892/or.2017.5360. Epub 2017 Jan 9.
• [4112] p62/IMP2 stimulates cell migration and reduces cell adhesion in breast cancer.Oncotarget. 2015 Oct 20;6(32):32656-68. doi: 10.18632/oncotarget.5328.
• [4113] Suppression of motor protein KIF3C expression inhibits tumor growth and metastasis in breast cancer by inhibiting TGF- signaling.Cancer Lett. 2015 Nov 1;368(1):105-114. doi: 10.1016/j.canlet.2015.07.037. Epub 2015 Aug 10.
• [4114] The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis.Cancer Cell. 2015 Aug 10;28(2):155-69. doi: 10.1016/j.ccell.2015.07.003.
• [4115] Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells.BMC Cancer. 2015 Nov 11;15:896. doi: 10.1186/s12885-015-1907-4.
• [4116] ITGBL1 Is a Runx2 Transcriptional Target and Promotes Breast Cancer Bone Metastasis by Activating the TGF Signaling Pathway.Cancer Res. 2015 Aug 15;75(16):3302-13. doi: 10.1158/0008-5472.CAN-15-0240. Epub 2015 Jun 9.
• [4117] Enhanced Photodynamic Therapy by Reduced Levels of Intracellular Glutathione Obtained By Employing a Nano-MOF with Cu(II) as the Active Center.Angew Chem Int Ed Engl. 2018 Apr 23;57(18):4891-4896. doi: 10.1002/anie.201710800. Epub 2018 Mar 23.
• [4118] Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+breast cancer.Breast Cancer Res Treat. 2019 Jan;173(1):93-102. doi: 10.1007/s10549-018-4978-5. Epub 2018 Oct 10.
• [4119] LncRNA RUSC1-AS1 promotes the proliferation of breast cancer cells by epigenetic silence of KLF2 and CDKN1A.Eur Rev Med Pharmacol Sci. 2019 Aug;23(15):6602-6611. doi: 10.26355/eurrev_201908_18548.
• [4120] The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer.Front Immunol. 2019 Jul 11;10:1594. doi: 10.3389/fimmu.2019.01594. eCollection 2019.
• [4121] Self-compassion and hope in the context of body image disturbance and distress in breast cancer survivors.Psychooncology. 2019 Oct;28(10):2025-2032. doi: 10.1002/pon.5187. Epub 2019 Aug 14.
• [4122] MicroRNA-10b and minichromosome maintenance complex component 5 gene as prognostic biomarkers in breast cancer.Tumour Biol. 2015 Jun;36(6):4487-94. doi: 10.1007/s13277-015-3090-2. Epub 2015 Jan 18.
• [4123] MRTF-A mediates the activation of COL1A1 expression stimulated by multiple signaling pathways in human breast cancer cells.Biomed Pharmacother. 2018 Aug;104:718-728. doi: 10.1016/j.biopha.2018.05.092. Epub 2018 May 25.
• [4124] Homeobox protein MSX1 inhibits the growth and metastasis of breast cancer cells and is frequently silenced by promoter methylation.Int J Mol Med. 2018 May;41(5):2986-2996. doi: 10.3892/ijmm.2018.3468. Epub 2018 Feb 7.
• [4125] Lentivirus-Mediated Knockdown of Myosin VI Inhibits Cell Proliferation of Breast Cancer Cell.Cancer Biother Radiopharm. 2015 Oct;30(8):330-5. doi: 10.1089/cbr.2014.1759. Epub 2015 Sep 25.
• [4126] C6ORF66 is an assembly factor of mitochondrial complex I. Am J Hum Genet. 2008 Jan;82(1):32-8. doi: 10.1016/j.ajhg.2007.08.003.
• [4127] Inherited predisposition to breast cancer among African American women.Breast Cancer Res Treat. 2015 Jan;149(1):31-9. doi: 10.1007/s10549-014-3195-0. Epub 2014 Nov 27.
• [4128] Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome.Breast Cancer Res Treat. 2019 Aug;177(1):77-91. doi: 10.1007/s10549-019-05307-8. Epub 2019 Jun 4.
• [4129] TUSC4 functions as a tumor suppressor by regulating BRCA1 stability.Cancer Res. 2015 Jan 15;75(2):378-86. doi: 10.1158/0008-5472.CAN-14-2315. Epub 2014 Dec 5.
• [4130] Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse.Adv Exp Med Biol. 2015;846:201-20. doi: 10.1007/978-3-319-12114-7_9.
• [4131] OGFOD1 is required for breast cancer cell proliferation and is associated with poor prognosis in breast cancer.Oncotarget. 2015 Aug 14;6(23):19528-41. doi: 10.18632/oncotarget.3683.
• [4132] PAQR4 promotes cell proliferation and metastasis through the CDK4-pRB-E2F1 pathway in non-small-cell lung cancer.Onco Targets Ther. 2019 May 13;12:3625-3633. doi: 10.2147/OTT.S181432. eCollection 2019.
• [4133] Genetic variants of PARP4 gene and PARP4P2 pseudogene in patients with multiple primary tumors including thyroid cancer.Mutat Res. 2019 Nov;816-818:111672. doi: 10.1016/j.mrfmmm.2019.111672. Epub 2019 Jun 1.
• [4134] PCDHGB7 Increases Chemosensitivity to Carboplatin by Inhibiting HSPA9 via Inducing Apoptosis in Breast Cancer.Dis Markers. 2019 Jul 8;2019:6131548. doi: 10.1155/2019/6131548. eCollection 2019.
• [4135] Combined Fascin-1 and MAP17 Expression in Breast Cancer Identifies Patients with High Risk for Disease Recurrence.Mol Diagn Ther. 2019 Oct;23(5):635-644. doi: 10.1007/s40291-019-00411-3.
• [4136] Aberrant Expression of PIWIL1 and PIWIL2 and Their Clinical Significance in Ductal Breast Carcinoma.Anticancer Res. 2018 Apr;38(4):2021-2030. doi: 10.21873/anticanres.12441.
• [4137] Hsp-27 induction requires POU4F2/Brn-3b TF in doxorubicin-treated breast cancer cells, whereas phosphorylation alters its cellular localisation following drug treatment.Cell Stress Chaperones. 2011 Jul;16(4):427-39. doi: 10.1007/s12192-011-0256-8. Epub 2011 Jan 29.
• [4138] PPM1B depletion in U2OS cells supresses cell growth through RB1-E2F1 pathway and stimulates bleomycin-induced cell death.Biochem Biophys Res Commun. 2018 Jun 2;500(2):391-397. doi: 10.1016/j.bbrc.2018.04.084. Epub 2018 Apr 19.
• [4139] Effect of Rab23 on the proliferation and apoptosis in breast cancer.Oncol Rep. 2015 Oct;34(4):1835-44. doi: 10.3892/or.2015.4152. Epub 2015 Jul 24.
• [4140] Chemerin Suppresses Breast Cancer Growth by Recruiting Immune Effector Cells Into the Tumor Microenvironment.Front Immunol. 2019 May 8;10:983. doi: 10.3389/fimmu.2019.00983. eCollection 2019.
• [4141] Methylation of RASSF10 promotes cell proliferation and serves as a docetaxel resistant marker in human breast cancer.Discov Med. 2015 Nov;20(111):261-71.
• [4142] Structural basis of the interaction of the breast cancer oncogene LMO4 with the tumour suppressor CtIP/RBBP8.J Mol Biol. 2013 Apr 12;425(7):1101-10. doi: 10.1016/j.jmb.2013.01.017. Epub 2013 Jan 23.
• [4143] Nucleosomes positioning around transcriptional start site of tumor suppressor (Rbl2/p130) gene in breast cancer.Mol Biol Rep. 2018 Apr;45(2):185-194. doi: 10.1007/s11033-018-4151-6. Epub 2018 Feb 7.
• [4144] Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.J Natl Cancer Inst. 2018 Apr 1;110(4). doi: 10.1093/jnci/djx207.
• [4145] The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.Nat Cell Biol. 2015 Jan;17(1):81-94. doi: 10.1038/ncb3082. Epub 2014 Dec 22.
• [4146] The metastasis suppressor NME1 regulates expression of genes linked to metastasis and patient outcome in melanoma and breast carcinoma.Cancer Genomics Proteomics. 2014 Jul-Aug;11(4):175-94.
• [4147] SETD1A protects from senescence through regulation of the mitotic gene expression program.Nat Commun. 2019 Jun 28;10(1):2854. doi: 10.1038/s41467-019-10786-w.
• [4148] SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL-6/STAT3 signal pathway.Cancer Med. 2019 Nov;8(16):7086-7097. doi: 10.1002/cam4.2557. Epub 2019 Oct 1.
• [4149] WISP-2 in human gastric cancer and its potential metastatic suppressor role in gastric cancer cells mediated by JNK and PLC- pathways.Br J Cancer. 2015 Sep 15;113(6):921-33. doi: 10.1038/bjc.2015.285. Epub 2015 Aug 20.
• [4150] Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer.J Pineal Res. 2019 Sep;67(2):e12586. doi: 10.1111/jpi.12586. Epub 2019 Jun 9.
• [4151] The human complement inhibitor Sushi Domain-Containing Protein 4 (SUSD4) expression in tumor cells and infiltrating T cells is associated with better prognosis of breast cancer patients.BMC Cancer. 2015 Oct 19;15:737. doi: 10.1186/s12885-015-1734-7.
• [4152] TARBP2-Enhanced Resistance during Tamoxifen Treatment in Breast Cancer.Cancers (Basel). 2019 Feb 12;11(2):210. doi: 10.3390/cancers11020210.
• [4153] Characterisation of DNA methylation changes in EBF3 and TBC1D16 associated with tumour progression and metastasis in multiple cancer types.Clin Epigenetics. 2019 Aug 5;11(1):114. doi: 10.1186/s13148-019-0710-5.
• [4154] In-silico QTL mapping of postpubertal mammary ductal development in the mouse uncovers potential human breast cancer risk loci.Mamm Genome. 2015 Feb;26(1-2):57-79. doi: 10.1007/s00335-014-9551-x. Epub 2015 Jan 1.
• [4155] Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer.Cell Death Dis. 2019 May 29;10(6):424. doi: 10.1038/s41419-019-1663-5.
• [4156] Glucocorticoid Receptor Signaling Activates TEAD4 to Promote Breast Cancer Progression.Cancer Res. 2019 Sep 1;79(17):4399-4411. doi: 10.1158/0008-5472.CAN-19-0012. Epub 2019 Jul 9.
• [4157] Transcriptome analysis of the cancer/testis genes, DAZ1, AURKC, and TEX101, in breast tumors and six breast cancer cell lines.Tumour Biol. 2015 Sep;36(10):8201-6. doi: 10.1007/s13277-015-3546-4. Epub 2015 May 21.
• [4158] Genome-wide analysis of alternative transcripts in human breast cancer.Breast Cancer Res Treat. 2015 Jun;151(2):295-307. doi: 10.1007/s10549-015-3395-2. Epub 2015 Apr 26.
• [4159] TIPIN depletion leads to apoptosis in breast cancer cells.Mol Oncol. 2015 Oct;9(8):1580-98. doi: 10.1016/j.molonc.2015.04.010. Epub 2015 May 9.
• [4160] Design, synthesis and evaluation of novel sulfonamides as potential anticancer agents.Comput Biol Chem. 2018 Jun;74:294-303. doi: 10.1016/j.compbiolchem.2018.04.006. Epub 2018 Apr 10.
• [4161] A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation.Breast Cancer Res. 2015 Jan 9;17:4. doi: 10.1186/s13058-014-0510-y.
• [4162] Hypoxia-Induced TPM2 Methylation is Associated with Chemoresistance and Poor Prognosis in Breast Cancer.Cell Physiol Biochem. 2018;45(2):692-705. doi: 10.1159/000487162. Epub 2018 Jan 31.
• [4163] Apoptosis inhibitor TRIAP1 is a novel effector of drug resistance.Oncol Rep. 2015 Jul;34(1):415-22. doi: 10.3892/or.2015.3988. Epub 2015 May 19.